@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#>.
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#>.
@prefix xsd: <http://www.w3.org/2001/XMLSchema#>.

<http://nice.org.uk/vcs/commit-0abe8d2ab751f38d5506ebd6005c45d3ab743e8b> a <http://www.w3.org/ns/prov#Activity>;
                                                                         rdfs:label """Actually produces something. something ugly, but something
""";
                                                                         <http://www.w3.org/ns/prov#endedAtTime> "2014-09-02T17:52:00.000000+01:00"^^xsd:dateTime;
                                                                         <http://www.w3.org/ns/prov#qualifiedAssociation> <http://nice.org.uk/vcs/commit-0abe8d2ab751f38d5506ebd6005c45d3ab743e8b-qa>;
                                                                         <http://www.w3.org/ns/prov#startedAtTime> "2014-09-02T17:52:00.000000+01:00"^^xsd:dateTime;
                                                                         <http://www.w3.org/ns/prov#used> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-introduction-Introduction.md-beb4f86b155e8a94e230a0036d627b612f3c6192>;
                                                                         <http://www.w3.org/ns/prov#wasAssociatedWith> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                         <http://www.w3.org/ns/prov#wasInformedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/commit-0abe8d2ab751f38d5506ebd6005c45d3ab743e8b-qa> a <http://www.w3.org/ns/prov#Association>;
                                                                            <http://www.w3.org/ns/prov#Agent> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                            <http://www.w3.org/ns/prov#hadRole> "author, comitter".
<http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230> a <http://www.w3.org/ns/prov#Activity>;
                                                                         rdfs:label """Merge branch 'master' of https://github.com/ryansroberts/markdownpipeline
""";
                                                                         <http://www.w3.org/ns/prov#endedAtTime> "2014-09-08T12:09:05.000000+01:00"^^xsd:dateTime;
                                                                         <http://www.w3.org/ns/prov#qualifiedAssociation> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230-qa>;
                                                                         <http://www.w3.org/ns/prov#startedAtTime> "2014-09-08T12:09:05.000000+01:00"^^xsd:dateTime;
                                                                         <http://www.w3.org/ns/prov#used> <http://nice.org.uk/vcs/file-README.md-fac562d11e047445b7fa0947180813b925fc5613>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-introduction-Introduction.md-ca2458a6779cddbaeb0e986365ad85b7a7a9b38d>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1-CG15AdultES153.md-27dac4afbd0bf4b54a0354ad5f007f02103527d1>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1-CG15AdultES154.md-f2d4fdca9e2ffe1d275c0ce4c35499c2e87d0eb2>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1-CG15AdultES155.md-ecb08b4a3155197c26f19d10f31502b98400d9fb>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1-CG15AdultES156.md-7cfa5bff40f4474fc22ccc7da2f88a84ffa23d42>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1-CG15AdultES157.md-3a01b9b3d48cbbceecd6d7ffafa725894709a2a2>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1-CG15AdultES158.md-19fba74abbeca08dc15a326ca45c044a3da67215>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1-CG15AdultES159.md-8f5f7c12cac45c283ad6c390a83366ef3b5a2aed>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1-CG15AdultES160.md-18226035b6205cf9cbc30b1b870b782d6d62bf8e>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1-CG15AdultES161.md-ca7c1404b3857b3f369cac8a4c7fe592129fd363>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1-CG15AdultES162.md-851fe06475472d5694b09e712d061b8bd9bd8c0b>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1-CG15AdultES163.md-d019d7c6d2409f4fc3467ceaca023b86f9b4c14f>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1-CG15AdultES164.md-fffdd65c1d0dd2ff53242a921d26e3e64cee8488>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1-CG15AdultES165.md-3bcf7ece0d2412814e4765b8065770a00d23b7a6>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1-CG15AdultES166.md-9ba51b2147a8a9e21146e56dfea81499d3e10a33>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1-CG15AdultES167.md-7e67e90ebe31a285cfcc3aa7959232363d3a2214>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1-CG15AdultES168.md-b7bb313f1dc7826619700d3ee93288a12e504451>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1-Discussion.md-b16cde6ab1d98b68e054aac0b160558920cc0d0a>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1-Recommendation.md-fcde5b21d1b635e72404a00b76ddbbab35c4f5d7>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES169.md-3a1111ebf6904052d80dd389201ce74ba4d10bf0>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES170.md-2e2bc10e1c24c8f33e9013afd1c264d513a8c034>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES171.md-cef96ee3235c462a608f269b9686b496a4c8591a>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES172.md-6cc8912b78f6a5e43ca46b7d5ec34e0aff4ffbdb>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES173.md-a148bdc92ffb7c6b86abf8ab560fbe332f8ddad8>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES174.md-5bdd7cf3418db347824486833f53a9bc00695cce>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES175.md-03451b1d5ed8aba03e3195d6dfb38935fea31243>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES176.md-eca207fa58dca49a3b7144965bc90b1ab3ef149b>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES177.md-aa8e1e9877fac96dc0d23cfc638160fdd2d10491>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES178.md-dff4ad7ad8ff2103f892540969a71ba415113e5c>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES179.md-67b407b74519128d2ebe082d4fa2a948e9adfc45>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES180.md-b27a282914ce4fb4e06d8676244d98cff78eb6f0>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES181.md-7f064931e04e87f01a5c3f2c6f41b796d795b28b>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES182.md-a3979c3d173b3131842ac00f904b905eb34f6cac>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES183.md-92bc16e63796cfc543f331a823a0f3a032477eb7>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES184.md-6ef37141afbb2b89792bd6aedb52643da332deed>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES185.md-3066f75c104e7ba4bb5eab8e4ef957fc364498b8>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES186.md-1d5b3d356cde73b07f3f750295c78295496ec007>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES187.md-1c696ab67942026196a9102d249ca1174d6345e9>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES188.md-7914c13da269a04f664930bef9325acc86f3e2bc>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES189.md-e42cf1e85d28e9294a661f7c94f3a89838434d75>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES190.md-408c941e66f6be7af8a6052bafd445b9582faa24>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES191.md-cfdea43f9914ef1bcab5ebe1e26b338e7ce0dc67>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES192.md-f8807be2147799694a132111d667f117160e6192>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES193.md-5b6c577e7c1a48cbe0f3aab275111cb8eeab93f2>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES194.md-1f0c6d62590398f24914419f3f7e605bdbcf0a1b>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES195.md-4609564722562dc9b0b1a9d95ca994d14d82c11f>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-Discussion.md-686dffe806efa0756f878b1bdb1b2756b9667b60>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-Recommendation.md-c5f53202ef6edfeb4c8c6785a941d8d4457da213>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.6.1.1-CG15AdultES1.md-68a9e4beeaa295d3f094ac34ccdf6a820d56d676>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.6.1.1-CG16AdultES2.md-6515ba8bf12cd3c2c63812d0ada0401076ae93e6>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.6.1.1-Discussion.md-5639bb51438d74840c5a1eb63e81cdb103f72815>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.6.1.1-Recommendation.md-6996df0b7886af052727d1b20b189ac40affc574>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.1-CG15AdultES10.md-c1d9be6de7bdb90d705e249c684fabf1377f16c9>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.1-CG15AdultES11.md-bc688a32f82ac2e73fb99646d1ab11550de5c7b4>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.1-CG15AdultES12.md-20fc74793561c4d42bf704351d84b8e69ad99e7d>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.1-CG15AdultES13.md-0d8a002493d1feaaf0fc07d76342414d1900a286>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.1-CG15AdultES14.md-d95b955a4245ff5bece50fc80613d6cb6eaddc97>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.1-CG15AdultES15.md-4668a0eda8d9aa07eedb01155675cd92afd27133>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.1-CG15AdultES16.md-31e997fc7ec6163de5a01152de8c29ffa604cacc>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.1-CG15AdultES17.md-bbf7429d51144faf08612be6ca1bf525efc39a6d>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.1-CG15AdultES18.md-0b4024d7f286febb2f3ffa2c319d40194f5619be>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.1-CG15AdultES4.md-41e1b698fd85a523d929ad9ef003d9cd1f4ac5a3>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.1-CG15AdultES5.md-1da365cc3c8342a21c708f6eb3feee931bdf27f2>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.1-CG15AdultES6.md-636048ca30f97172963e94aaedf3c79dbc458240>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.1-CG15AdultES7.md-3cf289baa1ad5dc9da21f52a579e42fa97c899dd>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.1-CG15AdultES8.md-dbab5dc237586cd37086788d05d6cba7c21ca8a5>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.1-CG15AdultES9.md-3954325a4a615cc4088b6c557e954c0349214450>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.1-CG17AdultES3.md-1d84360487f1d47a2d22e16eb85da527123ca3bc>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.1-Discussion.md-96925e06119c33575335d63fb810d561d67bbeb5>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.1-Recommendation.md-ddb8903e74fe9943dba7c60c8e15c9746e044418>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.2.1-#Set.md%23-8fb3f6db8b1cd10c35592943657bc12bdf18908b>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.2.1-CG15AdultES19.md-a12a6e538be0f70126c1f2f4d406ff3bc0a6428c>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.2.1-CG15AdultES20.md-2f13ba411c939eed671e9e1bb4469732f520117e>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.2.1-CG15AdultES21.md-0af0e8c38217c7a3a94de145bbed31bf7ce6498b>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.2.1-CG15AdultES22.md-d7cf8b2fb44a4efd88675f89008877039612af20>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.2.1-Discussion.md-9f33b4748bfb95407c7ca78484635cd3538cd883>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.2.1-Recommendation.md-c60f0aac4b66bc2491fafc37d1588245d3aad96a>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.1-CG15AdultES23.md-4b38f5f704f196681cd49c1621ed4702818a8899>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.1-CG15AdultES24.md-59f08ee6175f076451d7424af991b982985a051d>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.1-CG15AdultES25.md-c0391ac8b8080581a011f9a468a6d9d3d81bba77>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.1-CG15AdultES26.md-30284b2c3f501060aa0c8def0b9fb924fae539f3>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.1-CG15AdultES27.md-a94a06f3263fd381e60eb66c2513262110750e39>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.1-CG15AdultES28.md-e7e941a9e29cf7ddc7a281e05dd942d09906da4a>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.1-CG15AdultES29.md-b103d6b2b037c2472f83a43a88a2d7a97e95b8e1>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.1-CG15AdultES30.md-51c41577f27e6a7e56a02de53347fe6665f71a5f>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.1-CG15AdultES31.md-938b783740545dff974a3ea37bc04823bbb4835d>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.1-CG15AdultES32.md-59009a7adaf27acf7023566d2a399b0fcf15db99>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.1-CG15AdultES33.md-480578fcec3b1669004c7d54454df188a2c12790>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.1-CG15AdultES34.md-e35d8c604edf73e4ce1736f4694720e804c9af40>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.1-CG15AdultES35.md-77d59950f041564b1682447c8a7f64048bd81cb5>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.1-CG15AdultES36.md-16e1fd68a8ea168ce529acf3373c302236d0e7f9>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.1-CG15AdultES37.md-8d60cc027f8ec51f7b437a5b32ceefbc5cec59d8>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.1-Discussion.md-35006751c398975ccc2a76d2f9d54e88bbd124c7>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.1-Recommendation.md-05a34446b931bfa82ef19894b2a11bca9b8fb17f>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.1-CG15AdultES38.md-bf55232725aba7cec8a49c6e243f92fd20917a56>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.1-CG15AdultES39.md-09fda9808d4c3cd370e82f9ff29e335dff3b96eb>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.1-CG15AdultES40.md-95fd46fa0c20e39f0f6156f83f7aa51a114e0cc7>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.1-CG15AdultES41.md-5016f943358f0de79c58066158e416e5231c5a52>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.1-CG15AdultES42.md-87da028587df8928d5e32d69ec3196d6958bd2ec>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.1-CG15AdultES43.md-81d9b0c2186f658dfc26accf7a09892dad60f0a7>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.1-CG15AdultES44.md-1188462a1a5004556da803d53d5c9ced420970c2>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.1-CG15AdultES45.md-72131b6a886b7c9b510992f47a1680c2f9328a95>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.1-CG15AdultES46.md-bc595d419d1e699f1c55d549d1fa4934ccb99c91>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.1-CG15AdultES47.md-b84495a51778747500445aa8667f1388f4186522>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.1-CG15AdultES48.md-fbc4ac615e9aa6378110870f74aa8a2cca248fd4>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.1-CG15AdultES49.md-09e26aa8497f5acd5110c9a0dfdd2c0b53a314bf>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.1-CG15AdultES50.md-252df9c75a42b66a0dac4258bd768afa3f099806>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.1-CG15AdultES51.md-de6c679fa757cf3c7c5f5618e52ed45651e57f00>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.1-Discussion.md-addfa614caa44f7a38e03ae1e455b5d8d7a9dbbe>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.1-Recommendation.md-dd2990201fde11a267ed20e38417383b4469bf81>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.1-CG15AdultES52.md-d77fb107b703ef06f581be83f6c2e86fad092ede>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.1-CG15AdultES53.md-3b5fc5429e075a9559838d5accb4e0decb82bfdb>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.1-CG15AdultES54.md-608b68de52d4159aacffc6d203d73188512d5e22>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.1-CG15AdultES55.md-69064e304b2789eacb45e3890eef048c46bb3b0d>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.1-CG15AdultES56.md-be37f61fa27cf5010dca8ee3b18aea1bf67db92e>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.1-CG15AdultES57.md-403c50f81f2b73669c9a10e654a32685aa07e992>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.1-CG15AdultES58.md-49e0a5e208ef41c5720451eeb92b9346fb198e5f>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.1-CG15AdultES59.md-10f4321edbaf1efd042a6dab13c833d07096b065>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.1-CG15AdultES60.md-9956dce7fe846c5658518b1a1ba13a86ea05d01f>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.1-CG15AdultES61.md-c01496a0b917df6c09140de09890f6604fddf956>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.1-Discussion.md-0e85609fcf9c6f49a5165cda146ae074bdefee3a>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.1-Recommendation.md-b9eec3096fc2bad6747c8125d41efeda752e8cd3>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.4.1-CG15AdultES62.md-88dd608001c56557ab68bf98ab4904da7e634d06>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.4.1-CG15AdultES63.md-baab09623413d34e0955fc0c50b3bfdc96467698>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.4.1-CG15AdultES64.md-b196bab3966e7b3a35621bcec96992e8c183e610>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.4.1-CG15AdultES65.md-edd2bbeac59b16906eb7a676a76d6bd477132a05>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.4.1-CG15AdultES66.md-c24bb5c7c04a5d7386ab02ea8caf48b33dd99d25>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.4.1-CG15AdultES67.md-9eb49341c956484fe0af28c8cd1811b70c870429>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.4.1-CG15AdultES68.md-92a53bdfd35c52c4e135c9ec16a7a3f76c369907>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.4.1-CG15AdultES69.md-fddd8a561ba78a1c32958957e33f5e2ae956fd57>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.4.1-Discussion.md-fcdffd325dc4d19a62f750046bc1e466c6092343>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.4.1-Recommendation.md-bf59615212af8708e65e9177441f3eebb1d86951>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES70.md-f3a1dc6e99268e1b737f9ac825cee96e85ddd6ab>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES71.md-dac75f2e570afa20f64957e35be778379a69f2d5>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES72.md-ec6eb503049d1522288b858d3421df02de0babd1>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES73.md-6a5adfba2c0c968dffd34e2255d368fa70f56fd2>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES74.md-a06f8fcba321b58d2c0f80a6ee5527c214bc1e91>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES75.md-4ce04d10460984b3337b0eb07371dcbec9b958c3>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES76.md-d494797a2e3d1e1d66e628308e9deee52fd96384>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES77.md-a8702b9ef95c2b540586595fa0356f7482978f4c>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES78.md-9011600731aee6d49222af96f1f4273c79a95159>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES79.md-57d7df8f49b4935c85ab0423060d9d52579995c7>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES80.md-5f7b80a9ff3233d18df834417d7c1e101e895bae>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES81.md-36bdc79f1154c1eb70f3f1ecc6575c31327c9b44>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES82.md-ff9d6c03c0502bc9bfdbeabc79cb64febed25410>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES83.md-14f5b3434507e97bacb08fa30490b52782d2f6b1>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES84.md-5221344f8dd774cf5e5eb8a27095de20b2227d16>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES85.md-de47a69dc005cd87a3690f321cafc5053a4da4a8>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES86.md-2ece7d68927a20c05d5b8fd0c0c8bbb32bafa859>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES87.md-5d38d8a8064bd9beffd9cf8c75ab64759c830ad5>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES88.md-e95b6971cd479ab8cd8da1dc5dfa7fa7b38165b2>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES89.md-1a8466b4c8093041f20c05a0d385cf4002ffe14a>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-Discussion.md-ae280274c679a3adf7e6ad34aa5923d343964e17>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-Recommendation.md-ad6ecfb58583910ada1234823c0aaf320f16d36b>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-CG15AdultES100.md-e93cc18eb69a1ac1e4f0505d23e4450a6d6d1dd7>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-CG15AdultES101.md-8280d795491f45b80569eeca12af40662d4a82cb>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-CG15AdultES102.md-eb662e5442f539ef6aa1fb72fdf48c01ebaa7fe0>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-CG15AdultES103.md-b0df520bcd349d65a02b6081804e207bbe88aed2>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-CG15AdultES104.md-ec91b26d082c61277926325bf5138093b9a434dd>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-CG15AdultES105.md-518cc8a1e1a2c23ddd8626357df014684e0ee56c>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-CG15AdultES90.md-9042dc856af813ec35e94839d2cd4ae60957586d>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-CG15AdultES91.md-95df3bdf77c83abf1c43a2fbf7f6513163a35248>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-CG15AdultES92.md-d649c548b166e9152d623fc821255311dd6bf072>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-CG15AdultES93.md-3483e0115677090c5501121f9ec0da19b773f060>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-CG15AdultES94.md-ea537cff418d792480fa89d30a91937aa226a65a>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-CG15AdultES95.md-9f45a218d203dba2baded3fc995b3315f7364072>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-CG15AdultES96.md-a0e84af4895230aaaf80e10e80ef27d30d8b15d6>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-CG15AdultES97.md-d7580d495e42b0c2ac8af798e61dc408d76f85a1>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-CG15AdultES98.md-791f45352351c3a781693cea38dfa7585fb1c653>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-CG15AdultES99.md-0f5f3a2d5df77a3891af64a40453d7e984e2f901>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-Discussion.md-163f66fded565801f9f79ca5670677e0647fd545>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-Recommendation.md-beae9f3a86f482307cf4adc249322ff6b4a4efeb>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-Set.md-731eec0e60c032d7217b9e3904b70018b34c0763>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES106.md-0d3d9c75f6e8d0c4d8620ed4d4ed4ad767c22720>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES107.md-a616eaf435983c4a9f0917feba1606b4fd910011>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES108.md-92bb5c82e9aa7caaead6890dfd84a7ca06e46d2e>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES109.md-ae4681460b46c6273ff6a7e1ce72d4ee3d400b0c>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES110.md-7d59cddec3398d32974583898034289ef5776be8>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES111.md-5b0f3e465d7ebf97861c344b58aa4fba45b8c663>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES112.md-3e29b76969b2fb1035208859e7ac00c06f4f2a3a>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES113.md-293876a3602fa72974f8382302dc0cd1664c6116>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES114.md-4f9d95e1c3cf1e302442d2d44e8e3e9f5faaa2c2>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES115.md-568b68622ecdb19976b9654e467071f36c112b09>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES116.md-50a59f1e15c381a9df7e96ba5f211bc4b37785fb>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES117.md-37e44a83d533e8b1866791f06cd8a474d86a6795>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES118.md-f25f8d5fdf5d480f78f048651c30e907b402b09a>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES119.md-03826d5ffb3fe76259f7ddc5ced193d76f6cca30>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES120.md-7f25a5463ad1d801b5d4d752d3cd1f6ac27611ff>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES121.md-1c5dc1664f9f9c2b0da22f31910e158b9dbec995>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES122.md-06c5c531cb9badd97d801d385c2f4a6e4f510eab>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES123.md-7c649d323a0decf12ec99846eb4ae8ec3f1793ab>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES124.md-aa0902d8b9b5dfb57642202e4c3853e32f575190>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES125.md-abe5b5726d0b43f509668526b57e6706289a4b1d>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES126.md-2b616ab6f419fa88e983e4cc0126d12f27ad1aa4>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES127.md-6989671a175b34e0a1d3369a253153d462092dad>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES128.md-5582fc2597be125890972fee4c8938baf9e6ac71>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES129.md-38911f13432df85dfe2ffe6f269617094d960dda>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES130.md-49344d9405aea1d5f02cce4ada93332fb23ccdc6>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES131.md-8ac2a234e054bec35c36939d90b7641e235a3a14>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES132.md-2e24961203613fda57fe28f750316e5444e0ac08>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES133.md-a5faf900a078acbfeaa1bd6aa5a2a40eaef19f3f>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-Discussion.md-1b9604fd4a63e94595e0acc331b5f6fabc57a02a>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-Recommendation.md-6210c6bce5a836eff53ebe0ee503624c9c906d42>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.4.1-CG15AdultES134.md-e28105a7ef27937498328c751b8aaf72e0943c34>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.4.1-CG15AdultES135.md-536c7e784794e5b8b2e074b73726e0aba07c5e47>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.4.1-CG15AdultES136.md-e6c5c3f5e50082d1fa23ce5d9e9f10dcc42af3b2>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.4.1-CG15AdultES137.md-e3053e024daa9e824c75b5058ad6856ffcefbd23>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.4.1-CG15AdultES138.md-bb7ba83a63f9930f6af3e6d25f8c43460fac2ef4>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.4.1-CG15AdultES139.md-b3c1a7ffe3072b073fbc1a3b96bfdbb059424108>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.4.1-Discussion.md-21ba304ee2be8ef06740120751a56887a321be0f>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.4.1-Recommendation.md-1aae91d9b48948a2c72513f2d870d2285c584413>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.1-CG15AdultES140.md-3fbad1caca271d0d96521360e55c8fee8933dd3d>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.1-CG15AdultES141.md-64f7126d2bebc2f7ba66179e08856778fd76353d>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.1-CG15AdultES142.md-c37b8a60d4a974fe0649b66727bda0ef687b9354>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.1-CG15AdultES143.md-ce1bc024edb80a9b8f12fd5b92db308fa284defb>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.1-CG15AdultES144.md-7d0545064b2015ce157988b8e8b0a04a2993e626>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.1-CG15AdultES145.md-3db9c2fa76180857c7a439b1397db550cf72df8e>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.1-CG15AdultES146.md-fc640e870a8b6b37411b10b081eabe55a86e8afa>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.1-CG15AdultES147.md-f736540408427b57cd45da5d8548889bfe8bdd10>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.1-CG15AdultES148.md-1383722f649cca2ab3903c3e92136ee040b32b77>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.1-CG15AdultES149.md-63211a4512b13fd5ba0691063a89b3203dba91cf>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.1-CG15AdultES150.md-16694b09c470dd368235bed596bdebd767900fe1>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.1-CG15AdultES151.md-feddd341998ba7d7f869c2e8a228e69273ef16ec>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.1-CG15AdultES152.md-30c9fe2d37839a7f8adaf7cb6c9f47cb62c895da>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.1-Discussion.md-391914d9d80b512779e4d2a70884c12a294e8e5e>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.1-Recommendation.md-df27bdcd536e68f8a45d181515beda9afc45c087>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R__-Discussion.md-8f1b1a58755bce41d402d42b55bdeb69a27f016b>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R__-Recommendation.md-a4d5571fab8b3709eeb79dc48d17f90f65280b2f>;
                                                                         <http://www.w3.org/ns/prov#wasAssociatedWith> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                         <http://www.w3.org/ns/prov#wasInformedBy> <http://nice.org.uk/vcs/commit-f7f5f6b5b95eaa4a561fd2e694cc9d04c02afd97>.
<http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230-qa> a <http://www.w3.org/ns/prov#Association>;
                                                                            <http://www.w3.org/ns/prov#Agent> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                            <http://www.w3.org/ns/prov#hadRole> "author, comitter".
<http://nice.org.uk/vcs/commit-332a35d1000ad9f48052b739c045858dc0b18841> a <http://www.w3.org/ns/prov#Activity>;
                                                                         rdfs:label """Add introduction from web
""";
                                                                         <http://www.w3.org/ns/prov#endedAtTime> "2014-09-02T17:53:29.000000+01:00"^^xsd:dateTime;
                                                                         <http://www.w3.org/ns/prov#qualifiedAssociation> <http://nice.org.uk/vcs/commit-332a35d1000ad9f48052b739c045858dc0b18841-qa>;
                                                                         <http://www.w3.org/ns/prov#startedAtTime> "2014-09-02T17:53:29.000000+01:00"^^xsd:dateTime;
                                                                         <http://www.w3.org/ns/prov#used> <http://nice.org.uk/vcs/file-src-pandoc-CG15-Citations.bibtex-aa7aab08f4333f9e90d619004748c76f172ee25d>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.2.1-Set.md-e9128c752c9f2211a0858764c5e592d9a337c0a5>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-Set.md-9e64a871c32fcc5492cf962f22ed902b9dbd9a8b>;
                                                                         <http://www.w3.org/ns/prov#wasAssociatedWith> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                         <http://www.w3.org/ns/prov#wasInformedBy> <http://nice.org.uk/vcs/commit-0abe8d2ab751f38d5506ebd6005c45d3ab743e8b>.
<http://nice.org.uk/vcs/commit-332a35d1000ad9f48052b739c045858dc0b18841-qa> a <http://www.w3.org/ns/prov#Association>;
                                                                            <http://www.w3.org/ns/prov#Agent> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                            <http://www.w3.org/ns/prov#hadRole> "author, comitter".
<http://nice.org.uk/vcs/commit-b93cb04c455c7c905afbe9bfb41261a2e18254b5> a <http://www.w3.org/ns/prov#Activity>;
                                                                         rdfs:label """Remove various codepoints that tex complains about, a real system would configure TeX correctly
""";
                                                                         <http://www.w3.org/ns/prov#endedAtTime> "2014-09-03T11:38:58.000000+01:00"^^xsd:dateTime;
                                                                         <http://www.w3.org/ns/prov#qualifiedAssociation> <http://nice.org.uk/vcs/commit-b93cb04c455c7c905afbe9bfb41261a2e18254b5-qa>;
                                                                         <http://www.w3.org/ns/prov#startedAtTime> "2014-09-03T11:38:58.000000+01:00"^^xsd:dateTime;
                                                                         <http://www.w3.org/ns/prov#used> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-Recommendation.md-3c04667a9427acb41218787e7aa4995b167008fc>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.2.1-Recommendation.md-81ae768bdad13371835459836a4708e95559d71b>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.1-Recommendation.md-cb19b9915de9ede21d8cd5f459e7e3a9f0c2e96b>;
                                                                         <http://www.w3.org/ns/prov#wasAssociatedWith> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                         <http://www.w3.org/ns/prov#wasInformedBy> <http://nice.org.uk/vcs/commit-332a35d1000ad9f48052b739c045858dc0b18841>.
<http://nice.org.uk/vcs/commit-b93cb04c455c7c905afbe9bfb41261a2e18254b5-qa> a <http://www.w3.org/ns/prov#Association>;
                                                                            <http://www.w3.org/ns/prov#Agent> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                            <http://www.w3.org/ns/prov#hadRole> "author, comitter".
<http://nice.org.uk/vcs/commit-d1f7dbf208197c841e5d3858db1c3dd0f8581842> a <http://www.w3.org/ns/prov#Activity>;
                                                                         rdfs:label "Update README.md";
                                                                         <http://www.w3.org/ns/prov#endedAtTime> "2014-09-08T10:45:51.000000+01:00"^^xsd:dateTime;
                                                                         <http://www.w3.org/ns/prov#qualifiedAssociation> <http://nice.org.uk/vcs/commit-d1f7dbf208197c841e5d3858db1c3dd0f8581842-qa>;
                                                                         <http://www.w3.org/ns/prov#startedAtTime> "2014-09-08T10:45:51.000000+01:00"^^xsd:dateTime;
                                                                         <http://www.w3.org/ns/prov#used> <http://nice.org.uk/vcs/file-#makefile%23-d0d1343afc3661d0444a5883e146ca3cc090f75c>,
                                                                                                          <http://nice.org.uk/vcs/file-README.md-fac562d11e047445b7fa0947180813b925fc5613>,
                                                                                                          <http://nice.org.uk/vcs/file-build-cg15.html-b33a41b6b13709eb1636da7c899be2d859e94b55>,
                                                                                                          <http://nice.org.uk/vcs/file-build-cg15.pdf-6c402fef273b77c394444b38d3c5020c5f45e2f3>,
                                                                                                          <http://nice.org.uk/vcs/file-makefile-1d2f4fca2283b76d3769d9cfa8cc993075f984f6>;
                                                                         <http://www.w3.org/ns/prov#wasAssociatedWith> <http://nice.org.uk/identity/git-username-ryansroberts>;
                                                                         <http://www.w3.org/ns/prov#wasInformedBy> <http://nice.org.uk/vcs/commit-f9b42631df0cecf03e2541dc3bdfd852a575ce87>.
<http://nice.org.uk/vcs/commit-d1f7dbf208197c841e5d3858db1c3dd0f8581842-qa> a <http://www.w3.org/ns/prov#Association>;
                                                                            <http://www.w3.org/ns/prov#Agent> <http://nice.org.uk/identity/git-username-ryansroberts>;
                                                                            <http://www.w3.org/ns/prov#hadRole> "author, comitter".
<http://nice.org.uk/vcs/commit-f7f5f6b5b95eaa4a561fd2e694cc9d04c02afd97> a <http://www.w3.org/ns/prov#Activity>;
                                                                         rdfs:label """Add json output
""";
                                                                         <http://www.w3.org/ns/prov#endedAtTime> "2014-09-08T11:55:54.000000+01:00"^^xsd:dateTime;
                                                                         <http://www.w3.org/ns/prov#qualifiedAssociation> <http://nice.org.uk/vcs/commit-f7f5f6b5b95eaa4a561fd2e694cc9d04c02afd97-qa>;
                                                                         <http://www.w3.org/ns/prov#startedAtTime> "2014-09-08T11:55:54.000000+01:00"^^xsd:dateTime;
                                                                         <http://www.w3.org/ns/prov#used> <http://nice.org.uk/vcs/file-README.md-bb3d9bfbfa29c3ca31b1cc4872c0e095e5887692>;
                                                                         <http://www.w3.org/ns/prov#wasAssociatedWith> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                         <http://www.w3.org/ns/prov#wasInformedBy> <http://nice.org.uk/vcs/commit-f9b42631df0cecf03e2541dc3bdfd852a575ce87>.
<http://nice.org.uk/vcs/commit-f7f5f6b5b95eaa4a561fd2e694cc9d04c02afd97-qa> a <http://www.w3.org/ns/prov#Association>;
                                                                            <http://www.w3.org/ns/prov#Agent> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                            <http://www.w3.org/ns/prov#hadRole> "author, comitter".
<http://nice.org.uk/vcs/commit-f9b42631df0cecf03e2541dc3bdfd852a575ce87> a <http://www.w3.org/ns/prov#Activity>;
                                                                         rdfs:label """Clean up some rec titles
""";
                                                                         <http://www.w3.org/ns/prov#endedAtTime> "2014-09-03T12:50:19.000000+01:00"^^xsd:dateTime;
                                                                         <http://www.w3.org/ns/prov#qualifiedAssociation> <http://nice.org.uk/vcs/commit-f9b42631df0cecf03e2541dc3bdfd852a575ce87-qa>;
                                                                         <http://www.w3.org/ns/prov#startedAtTime> "2014-09-03T12:50:19.000000+01:00"^^xsd:dateTime;
                                                                         <http://www.w3.org/ns/prov#used> <http://nice.org.uk/vcs/file-README.md-bb3d9bfbfa29c3ca31b1cc4872c0e095e5887692>;
                                                                         <http://www.w3.org/ns/prov#wasAssociatedWith> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                         <http://www.w3.org/ns/prov#wasInformedBy> <http://nice.org.uk/vcs/commit-b93cb04c455c7c905afbe9bfb41261a2e18254b5>.
<http://nice.org.uk/vcs/commit-f9b42631df0cecf03e2541dc3bdfd852a575ce87-qa> a <http://www.w3.org/ns/prov#Association>;
                                                                            <http://www.w3.org/ns/prov#Agent> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                            <http://www.w3.org/ns/prov#hadRole> "author, comitter".
<http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963> a <http://www.w3.org/ns/prov#Activity>;
                                                                         rdfs:label """A time before history
""";
                                                                         <http://www.w3.org/ns/prov#endedAtTime> "2014-09-01T20:37:45.000000+01:00"^^xsd:dateTime;
                                                                         <http://www.w3.org/ns/prov#qualifiedAssociation> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963-qa>;
                                                                         <http://www.w3.org/ns/prov#startedAtTime> "2014-09-01T20:37:45.000000+01:00"^^xsd:dateTime;
                                                                         <http://www.w3.org/ns/prov#used> <http://nice.org.uk/vcs/file-makefile-f2975537923f1efd454f7e59d27ee94a88902d44>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-Citations.tex-0d503d623b23c013da25e0ce32bc1f4cc64434b1>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1.md-e721bfd1f0e0f10089e551a77d3e714b580dd8b4>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.2.md-27fe712b5ffb1ec85b7006b96d67287dc54a1728>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.3.md-a09b86a7215459f59901ca27e87a9ade6d4c86dd>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.4.md-71d793dec4b7e35e23232b9d0fc768658b6ad003>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.5.md-096124c41550975b3130ccb9b7d31b093b058a44>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.2.md-b27427f6b03f40589da3450df0d4cf5996628c6b>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.3.md-1b1a490b05932b38795be778517ad12b626dc87e>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.4.md-5243f85cf07647b74caa1d6873a85509cd42df39>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.5.md-50fc1c91478d6a0e41ac974b67181de6d92294f2>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.6.md-7aaf01fe2ca5fd74b488419699808115a7f48cca>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.7.md-b0aa6be5dfe87c8aaf9148519a56f705a1c7dd78>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.8.md-9db206b2a0c173a44cf936dd45c1a888ad56f852>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.6.1.2.md-6ddc6d0fe69ee0038ab39970663df447a0d21112>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.6.1.3.md-7a987b0a9f80c144aba5274849f6bf2e14193352>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.6.1.4.md-d102e4cfa138106b8ee46433e8a7673323b50a69>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.2.md-eccfdc33dd1603d6218fce673b253bdc44034c13>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.3.md-6a736900f7171560a46f466141ea50186a60ef6e>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.4.md-fcfb25056847520c93d96be919c7885c61c95a32>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.5.md-f0545e5fd6b04e723ce922388aa1a6670b512742>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.6.md-57854a49b1ec0df15651b61c064ca124ec0f8d18>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.7.md-f70e761c21bae0df84df9e62bcea5a2e0ebf543f>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.2.md-5d12662d186cef24a9a69b747b7e27d2aca4b410>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.3.md-ba19f42add4f273a54a159ee9d995bc5265af9d2>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.4.md-e48876af6a00a803d48178e7b500c88a5f73a509>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.5.md-82d31a6746626616ee1b8d19146b7c8a535a3f57>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.6.md-0d3182f01560da26290a77417aa47ae0ba1b648d>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.2.md-79badfca49ac920e5e387b2a8df88e1631827756>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.3.md-4b2f3de44bac36bc9ddaae173893d67fb1b20eb0>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.4.md-76e362abeef4847fee1c6ba1e0f15b9c10b0df8f>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.5.md-97f971720af6a3b89f800540172466d221318be2>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.6.md-038696679052075700f91955d9b006b84dcdc15e>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.7.md-a765cab6049ecb28f355cbe483844a8cff221380>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.8.md-ba01f88bc7a2191a23b4d2326ef89e7f81150b19>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.2.md-f422663bb4f6d1d7f09b6c325697b11a766ab239>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.3.md-ad39598d43a812915ee0532cd5f0dc2c38934fab>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.4.md-0551e45941824f8e345508a29811e4622cb8c643>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.5.md-7024a369367895bb71a7d1f664798fd970827e43>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.6.md-e6b824793a559aee65f62b56c01081102062b683>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.7.md-ecb0617d28db3c45d680061036cf52703110c538>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.8.md-e853d97658ceb066bb8d356a9099b1d4d8a7268b>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.9.md-35c2c235b60d752978fd785fb6a86a5bff6f1869>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.4.2.md-53458d0d5490b1c85dd2aaed363517ed812b0ab9>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1.md-0c4528420ec760c97ce7eb4109a47caefece7fa1>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.2.md-64463cd69fda0a320e741e2576dda1444e475bba>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.3.md-5f9cdac9527b4855cddf495a4466506a902ebb79>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.4.md-98761389e214ae7e17242d4b1be379b59267127c>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.5.md-dfb28b39a004f34e0dfceb3e49a60b3e6004c1f4>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.6.md-ace058969ef92544ca15bf1ea9c9128e2849954f>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.2.md-f0948706fb3e67d4e1bd69b7d129aa1b9c94c4f5>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.3.md-a1b13e4e1057be18f96dc53a57415b933ee9a0d6>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.4.md-16f8ad55780b3533095190559385b1408f499dfc>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.5.md-c7bed5231d139d139141579408330728206b33ba>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.6.md-87e6a4d80df8ae2a1d9721e9be72a3995b9e11ce>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.10.md-342a29190553c2fd163b48fc5129b98a38145fd7>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.11.md-0f5fe64b0f0bfcc7267d6e0745dbacd1e74c89e0>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.12.md-648c398b96afd4cd72f096c6fe1a09a642e832d7>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.13.md-163c7e9f2ca96754ade485d4da37d4c836ccd114>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.14.md-568a7e0e088ed0a936ab9e388d431fa6c8b18ec1>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.15.md-0104ff4661006cafe633334728738653fa111985>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.16.md-4fe370ebd7f2c7569155df70ccc0b965eadc5960>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.2.md-ecb35a5bd83b309aba0def6159eb0c1653e5e072>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.3.md-f9cd7f7580f1e560349bd919b1690b88451460b4>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.4.md-9aa179771a2db7f7862fa930b0a3230287ec61c3>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.5.md-3d0c0e4e8a42dfa6fd59270ea5770bf67c987a27>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.6.md-ed1d2a48b0647863e0a043ee45a0e639dc01a772>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.7.md-345d6f822dd279e679db04d12db1d6a063fac52c>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.8.md-e7da9ab1956fc762cdb68e203625aa100d2262ff>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.9.md-ac4450fe75b773b5d67bab97e96024e33bb510d7>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.4.1.md-d5bc5cf38bf4d7dd902e1d112235ef8781c69e64>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.4.2.md-b9bb5737dc77a525e30419bf7bc665ac516490ad>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.4.3.md-c27f5e10a34f3f1c56275998cb5d9fee6bf7eb78>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.4.4.md-bd7b2a367064ac2301dfce5cc2685959c3cc725a>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.4.5.md-6140251524d53ba1ff8d01648bc65cccbe2dc8bc>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.4.6.md-d7429dbfbc61eea01aa5c5495b35282b2bbe2cfc>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.4.7.md-0827ed4609f3e46490aece4ceaabe9681e64e02c>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.4.8.md-cd63c36485b047dddc61da4f5e47677951fe34ce>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.1.md-7b3db7f72c8398c7281e0c3e9acb2c365ae57672>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.10.md-679b8f79b9c755bab5c2da1878a0cdb386eb1e39>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.2.md-0f78174d6895369073aa6045bc3acc6dab1f5be8>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.3.md-5e4ffa4752ce7f736b26ad2920ad04e6006168f5>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.4.md-416ea7ef3d0cd18cde4a8cac5cfda0a0a91bb59c>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.5.md-da76c84b4411e2d3434540ccf2092f8fb784949b>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.6.md-52ae4ffd31db2d111de0c8a8314e39ede13a43f3>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.7.md-828aa3d1efc8447c1e23ef625ce67f86691055e4>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.8.md-20719eda23cf93bb661f2d31e1949751bffa5f01>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.9.md-de4814315d4cec2a0e7c0a29a021ce11d2930e92>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS10-statements-CG15AdultES83.md-5d332540f4b892be122d65d187e9e07e1166ce3f>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS11-statements-CG15AdultES90.md-286d0569bac20f3b24015b7f41c9504789425767>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS11-statements-CG15AdultES91.md-f9587c9c1a41dc5c84ba7fe8626e41a1b7348ab2>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS11-statements-CG15AdultES92.md-d48c87aebe05d87eff40ba1052eaa6b9c149d58a>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS11-statements-CG15AdultES94.md-2b815839478a743d2925ab40549bec89d554a371>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS11-statements-CG15AdultES95.md-11f1323c3f561319e4a627adfe10657eb1ab409e>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS11-statements-CG15AdultES97.md-36264f1555ab5e466240e49ec5b99559742af003>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS11-statements-CG15AdultES99.md-d3732c603fb6e115ce0d28909508218488b28afd>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS12-statements-CG15AdultES106.md-badd0371e8a3aaef09f8219dc34e80a15463b42a>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS12-statements-CG15AdultES112.md-2a2d77f5f2d926659a7b5c2c317d5cbe69454cf7>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS12-statements-CG15AdultES115.md-6dfac822c01eca46e1290f243fd0397c158429da>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS12-statements-CG15AdultES116.md-dbe59b3c5ad20efc595e5c87e78405d2efe438bf>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS12-statements-CG15AdultES119.md-a96aa4a679752bc93871bb35f598e4b32541666a>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS12-statements-CG15AdultES121.md-48fbb83803ab76b4ca1aea38fa6d65d94c0c6abf>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS12-statements-CG15AdultES122.md-622f670e35bab82f6ceb1137eca499115d6e4451>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS12-statements-CG15AdultES127.md-09beb32c0e059b0e17e38aae6b2adaddfdf691ca>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS12-statements-CG15AdultES128.md-344a31e954c67bcd4b0b9d9fb446429b7ab06324>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS12-statements-CG15AdultES129.md-e45d452f36783110199d3aa003f4b2dd33d59967>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS12-statements-CG15AdultES130.md-9c0e650b7331adbd502fc9cc2eff5e43731bbd0f>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS12-statements-CG15AdultES131.md-9ac14387e915a0db67cde6e49fed1ca983045c29>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS12-statements-CG15AdultES132.md-43044804a0b1d7ddc7faa7dd700d431c9dde50e8>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS13-Discussion.md-a2da057674070d6170699dfb766181c3e26c40ab>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS13-statements-CG15AdultES134.md-b71d852a0fcd851555282446f864c3b42602d927>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS13-statements-CG15AdultES135.md-332d559e498efea955140e7e02c26c0459fe2119>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS13-statements-CG15AdultES136.md-a4f23f7a7e8298376c130b60b11f8c7a9d5b9fa4>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS13-statements-CG15AdultES137.md-d5f5ffb6f01dac04e41427b7344f6080249a59ae>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS13-statements-CG15AdultES138.md-3077da5781657b7837a1c186ce41abac334155d6>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS13-statements-CG15AdultES139.md-f1f1e736273c9823a573ebacc0abfdf8534cf400>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS14-Discussion.md-e25b8ac94c3f2a25783ed5a44d4a02cb0cca085d>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS14-statements-CG15AdultES140.md-5717bda0fe4c31fae22f4218e6fd2fb09e658370>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS14-statements-CG15AdultES141.md-30c94a2c1db93e99f3725652b478f45a8f7df0b3>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS14-statements-CG15AdultES142.md-69e5e4e0b9ae6d4064ee97fb156611cb660220a7>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS14-statements-CG15AdultES143.md-f779682d8071b7e89744252e5a877cbb564b156e>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS14-statements-CG15AdultES144.md-adedfb08004b0eeb1e617fb33b971e08179dd814>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS14-statements-CG15AdultES145.md-dda34d1b6714d7dcc3685bb3318f9bf1af38554f>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS14-statements-CG15AdultES146.md-45c5aded02e8aea61a8ee733b9a348e09790fe88>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS14-statements-CG15AdultES147.md-fce31b50b372ec1b12d411ae278e64e99102774f>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS14-statements-CG15AdultES148.md-7df4af9c9d6fe11124303b62494dce522d44b836>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS14-statements-CG15AdultES149.md-b418bb5b60695da97bc07fd73699f10b6d60cc9c>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS14-statements-CG15AdultES150.md-7da755b32e3c0b7e9d77019b877c4d34c1044ebe>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS14-statements-CG15AdultES151.md-0ffc9cd4cd1687ddd780111b0171bac093d3a395>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS14-statements-CG15AdultES152.md-74dbbb2719c45e3975cb54c43be5a9ff2081b442>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS15-statements-CG15AdultES156.md-fcd04126707991f3dfef2bb602c0f81f6f59fb78>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS15-statements-CG15AdultES161.md-afac68967daf0daa6c6e5cf09bbd444f7f62ae5c>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS16-statements-CG15AdultES172.md-9601c86e8e9dcb1a9a421bda2931590cc2ce786e>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS16-statements-CG15AdultES187.md-68a4b662c26e4f6a6361754b33a9fdb4383ea00d>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS16-statements-CG15AdultES195.md-9f74a5c1c975733affcb6037a26067bc20b514fb>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS17-Discussion.md-e69de29bb2d1d6434b8b29ae775ad8c2e48c5391>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS18-Discussion.md-e69de29bb2d1d6434b8b29ae775ad8c2e48c5391>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS19-Discussion.md-e69de29bb2d1d6434b8b29ae775ad8c2e48c5391>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS2-statements-CG15AdultES12.md-56019fb0812b63fbd0a42e7bfd7217c61e184d6c>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS2-statements-CG15AdultES17.md-c2d0681a0f81279d43f0fe8b624f51a7715d2722>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS2-statements-CG15AdultES8.md-9793742c64b5c328bf8e3b7edce6c22b23b29794>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS20-Discussion.md-e69de29bb2d1d6434b8b29ae775ad8c2e48c5391>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS21-Discussion.md-e69de29bb2d1d6434b8b29ae775ad8c2e48c5391>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS22-Discussion.md-e69de29bb2d1d6434b8b29ae775ad8c2e48c5391>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS23-Discussion.md-e69de29bb2d1d6434b8b29ae775ad8c2e48c5391>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS24-Discussion.md-e69de29bb2d1d6434b8b29ae775ad8c2e48c5391>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS25-Discussion.md-e69de29bb2d1d6434b8b29ae775ad8c2e48c5391>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS26-Discussion.md-e69de29bb2d1d6434b8b29ae775ad8c2e48c5391>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS27-Discussion.md-e69de29bb2d1d6434b8b29ae775ad8c2e48c5391>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS28-Discussion.md-e69de29bb2d1d6434b8b29ae775ad8c2e48c5391>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS29-Discussion.md-e69de29bb2d1d6434b8b29ae775ad8c2e48c5391>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS3-Discussion.md-3cf20d57b0b8258463711cedd592007b0b5cdfe8>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS30-Discussion.md-e69de29bb2d1d6434b8b29ae775ad8c2e48c5391>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS31-Discussion.md-e69de29bb2d1d6434b8b29ae775ad8c2e48c5391>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS32-Discussion.md-e69de29bb2d1d6434b8b29ae775ad8c2e48c5391>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS33-Discussion.md-e69de29bb2d1d6434b8b29ae775ad8c2e48c5391>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS4-Discussion.md-3cf20d57b0b8258463711cedd592007b0b5cdfe8>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS5-statements-CG15AdultES26.md-18accec4d2fda88d0e511c4c57de9b273a80f5a8>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS6-statements-CG15AdultES51.md-243b24af86841770042c9ca11ab94b599c5fe03a>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS7-statements-CG15AdultES52.md-315c69a3940b08bba2602d041eb598e276708224>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS7-statements-CG15AdultES61.md-2fca3b4084e419e275246f1a69a4358d15868594>,
                                                                                                          <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS9-Discussion.md-b3e58141dfa0afd78fc8742fda533479d00023b4>,
                                                                                                          <http://nice.org.uk/vcs/file-templates-latex.template-cc964ae12b2b47be075dd37485ebbda2623473a6>;
                                                                         <http://www.w3.org/ns/prov#wasAssociatedWith> <http://nice.org.uk/identity/git-username-Ryan-Roberts>.
<http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963-qa> a <http://www.w3.org/ns/prov#Association>;
                                                                            <http://www.w3.org/ns/prov#Agent> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                            <http://www.w3.org/ns/prov#hadRole> "author, comitter".
<http://nice.org.uk/vcs/file-#makefile%23-d0d1343afc3661d0444a5883e146ca3cc090f75c> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                      <http://www.w3.org/ns/prov#Entity>;
                                                                                    <http://www.w3.org/2011/content#chars> """
GUIDANCE_DIR = src/pandoc/CG15


BUILD = build/

INTRODUCTION_CH = $(GUIDANCE_DIR)/chapters/introduction

RECOMMENDATIONS_CH = $(GUIDANCE_DIR)/chapters/recommendations 

MARKDOWN = $(INTRODUCTION_CH)/Introduction.md

RECS = $(sort $(dir $(wildcard src/pandoc/CG15/chapters/recommendations/*/)))

MARKDOWN += $(foreach rec,$(RECS),					\\
		$(rec)Set.md			  										\\
		$(rec)Discussion.md  										\\
		$(rec)Recommendation.md                 \\
		$(sort $(wildcard $(rec)*ES*.md)))

TEMPLATES = templates/

clean:
	rm -rf build/*

PANDOC_OPT = -r simple_tables+table_captions+yaml_metadata_block -s -S --normalize --smart -f markdown --standalone --toc --bibliography=$(GUIDANCE_DIR)/Citations.bibtex

html: clean 
	    pandoc $(PANDOC_OPT) -template=templates/html.template -t html5 $(MARKDOWN) -o $(BUILD)cg15.html 

pdf: clean
			pandoc $(PANDOC_OPT) --latex-engine=pdflatex $(MARKDOWN)  -o $(BUILD)cg15.pdf

all: html pdf""";
                                                                                    <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-#makefile%23>;
                                                                                    <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-ryansroberts>;
                                                                                    <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-#makefile%23-0000000000000000000000000000000000000000>;
                                                                                    <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-d1f7dbf208197c841e5d3858db1c3dd0f8581842>.
<http://nice.org.uk/vcs/file-README.md-bb3d9bfbfa29c3ca31b1cc4872c0e095e5887692> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                   <http://www.w3.org/ns/prov#Entity>;
                                                                                 <http://www.w3.org/2011/content#chars> """pandoc-seed-project
===================

Seed git repo for [pandoc](https://github.com/jgm/pandoc) based projects. Just clone and pandoc.

Inspired by projects like [ultimate-seed](https://github.com/pilwon/ultimate-seed) and [angular-seed](https://github.com/angular/angular-seed). This seed aims to include necessary tools/scripts to automate pandoc compilation.

With this seed, you should be able to:
1. Write documents in whatever input format [pandoc](https://github.com/jgm/pandoc) supports.
2. Use [gulp.js](https://github.com/gulpjs/gulp) to automatically compile documents.

Repeat as necessary.

Prerequisites
=============

* node.js and npm
* [pandoc](https://github.com/jgm/pandoc) (and the haskell-platform)
* some knowledge of streams:
    * http://nodejs.org/api/stream.html
    * https://github.com/substack/stream-handbook

Included
========

* [gulp](http://gulpjs.com/) - build system (task automation)
    * [gulp-spawn-shim](https://github.com/Dashed/gulp-spawn-shim) - shim node.js child_process.spawn() to gulp.js
    * [gulp-util](https://github.com/gulpjs/gulp-util) - utility belt for gulpfile.js
    * [gulp-plumber](https://github.com/floatdrop/gulp-plumber) - monkey-patch Stream.pipe
    * [gulp-watch](https://github.com/floatdrop/gulp-watch) - watch files
    * [gulp-rename](https://github.com/hparra/gulp-rename) - rename files
    * [gulp-livereload](https://github.com/vohof/gulp-livereload) - automatically [reload](http://livereload.com/) compiled documents (HTML only)
    * [gulp-ignore](https://github.com/robrich/gulp-ignore) - conditionally include/exclude files
* [tiny-lr](https://github.com/mklabs/tiny-lr) - tiny livereload

gulpfile.js
===========

The rules for how to compile pandoc documents are configured from within the gulpfile.js file.

Generally, gulp will take `**/*.md` files (configurable) from `src_docs` folder, compile via pandoc, and then place the resulting files into `dest_docs` folder in the same directory structure as it was placed in `src_docs`.

## Note

I'm currently using this setup for my personal pandoc project; mainly for my markdown documents. It can be set up generally as pandoc allows.

The gulpfile.js file I provided is set up for additional support of [MathJax](http://mathjax.org/) from [mathjax-lazyload](https://github.com/Dashed/mathjax-lazyload). It's supported for HTML generated pages with a lot of math (LaTeX) elements.

In the future, I'll provide variations of gulpfile.js.


This project replaces/deprecates [grunt-pandoc](https://github.com/Dashed/grunt-pandoc); a workflow I used to use.
""";
                                                                                 <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-README.md>;
                                                                                 <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                 <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-README.md-fac562d11e047445b7fa0947180813b925fc5613>;
                                                                                 <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-f7f5f6b5b95eaa4a561fd2e694cc9d04c02afd97>,
                                                                                                                            <http://nice.org.uk/vcs/commit-f9b42631df0cecf03e2541dc3bdfd852a575ce87>.
<http://nice.org.uk/vcs/file-README.md-fac562d11e047445b7fa0947180813b925fc5613> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                   <http://www.w3.org/ns/prov#Entity>;
                                                                                 <http://www.w3.org/2011/content#chars> """Markdown pipeline using pandoc / tex
""";
                                                                                 <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-README.md>;
                                                                                 <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>,
                                                                                                                             <http://nice.org.uk/identity/git-username-ryansroberts>;
                                                                                 <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-README.md-6d6c3102c56599fc9c19f4cb8e31446483f406ee>,
                                                                                                                            <http://nice.org.uk/vcs/file-README.md-bb3d9bfbfa29c3ca31b1cc4872c0e095e5887692>;
                                                                                 <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>,
                                                                                                                            <http://nice.org.uk/vcs/commit-d1f7dbf208197c841e5d3858db1c3dd0f8581842>.
<http://nice.org.uk/vcs/file-build-cg15.html-b33a41b6b13709eb1636da7c899be2d859e94b55> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                         <http://www.w3.org/ns/prov#Entity>;
                                                                                       <http://www.w3.org/2011/content#chars> """<!DOCTYPE html>
<html>
<head>
  <meta charset=\"utf-8\">
  <meta name=\"generator\" content=\"pandoc\">
  <meta name=\"viewport\" content=\"width=device-width, initial-scale=1.0, user-scalable=yes\">
  <title></title>
  <style type=\"text/css\">code{white-space: pre;}</style>
  <!--[if lt IE 9]>
    <script src=\"http://html5shim.googlecode.com/svn/trunk/html5.js\"></script>
  <![endif]-->
</head>
<body>
<nav id=\"TOC\">
<ul>
<li><a href=\"#type-1-diabetes\">Type 1 Diabetes</a><ul>
<li><a href=\"#topic-cg15adults15\">Topic CG15AdultS15</a><ul>
<li><a href=\"#evidence-statement-cg15adultes153\">Evidence Statement CG15AdultES153</a></li>
<li><a href=\"#evidence-statement-cg15adultes154\">Evidence Statement CG15AdultES154</a></li>
<li><a href=\"#evidence-statement-cg15adultes155\">Evidence Statement CG15AdultES155</a></li>
<li><a href=\"#evidence-statement-cg15adultes156\">Evidence Statement CG15AdultES156</a></li>
<li><a href=\"#evidence-statement-cg15adultes157\">Evidence Statement CG15AdultES157</a></li>
<li><a href=\"#evidence-statement-cg15adultes158\">Evidence Statement CG15AdultES158</a></li>
<li><a href=\"#evidence-statement-cg15adultes159\">Evidence Statement CG15AdultES159</a></li>
<li><a href=\"#evidence-statement-cg15adultes160\">Evidence Statement CG15AdultES160</a></li>
<li><a href=\"#evidence-statement-cg15adultes161\">Evidence Statement CG15AdultES161</a></li>
<li><a href=\"#evidence-statement-cg15adultes162\">Evidence Statement CG15AdultES162</a></li>
<li><a href=\"#evidence-statement-cg15adultes163\">Evidence Statement CG15AdultES163</a></li>
<li><a href=\"#evidence-statement-cg15adultes164\">Evidence Statement CG15AdultES164</a></li>
<li><a href=\"#evidence-statement-cg15adultes165\">Evidence Statement CG15AdultES165</a></li>
<li><a href=\"#evidence-statement-cg15adultes166\">Evidence Statement CG15AdultES166</a></li>
<li><a href=\"#evidence-statement-cg15adultes167\">Evidence Statement CG15AdultES167</a></li>
<li><a href=\"#evidence-statement-cg15adultes168\">Evidence Statement CG15AdultES168</a></li>
</ul></li>
<li><a href=\"#topic-cg15adults16\">Topic CG15AdultS16</a><ul>
<li><a href=\"#evidence-statement-cg15adultes169\">Evidence Statement CG15AdultES169</a></li>
<li><a href=\"#evidence-statement-cg15adultes170\">Evidence Statement CG15AdultES170</a></li>
<li><a href=\"#evidence-statement-cg15adultes171\">Evidence Statement CG15AdultES171</a></li>
<li><a href=\"#evidence-statement-cg15adultes172\">Evidence Statement CG15AdultES172</a></li>
<li><a href=\"#evidence-statement-cg15adultes173\">Evidence Statement CG15AdultES173</a></li>
<li><a href=\"#evidence-statement-cg15adultes174\">Evidence Statement CG15AdultES174</a></li>
<li><a href=\"#evidence-statement-cg15adultes175\">Evidence Statement CG15AdultES175</a></li>
<li><a href=\"#evidence-statement-cg15adultes176\">Evidence Statement CG15AdultES176</a></li>
<li><a href=\"#evidence-statement-cg15adultes177\">Evidence Statement CG15AdultES177</a></li>
<li><a href=\"#evidence-statement-cg15adultes178\">Evidence Statement CG15AdultES178</a></li>
<li><a href=\"#evidence-statement-cg15adultes179\">Evidence Statement CG15AdultES179</a></li>
<li><a href=\"#evidence-statement-cg15adultes180\">Evidence Statement CG15AdultES180</a></li>
<li><a href=\"#evidence-statement-cg15adultes181\">Evidence Statement CG15AdultES181</a></li>
<li><a href=\"#evidence-statement-cg15adultes182\">Evidence Statement CG15AdultES182</a></li>
<li><a href=\"#evidence-statement-cg15adultes183\">Evidence Statement CG15AdultES183</a></li>
<li><a href=\"#evidence-statement-cg15adultes184\">Evidence Statement CG15AdultES184</a></li>
<li><a href=\"#evidence-statement-cg15adultes185\">Evidence Statement CG15AdultES185</a></li>
<li><a href=\"#evidence-statement-cg15adultes186\">Evidence Statement CG15AdultES186</a></li>
<li><a href=\"#evidence-statement-cg15adultes187\">Evidence Statement CG15AdultES187</a></li>
<li><a href=\"#evidence-statement-cg15adultes188\">Evidence Statement CG15AdultES188</a></li>
<li><a href=\"#evidence-statement-cg15adultes189\">Evidence Statement CG15AdultES189</a></li>
<li><a href=\"#evidence-statement-cg15adultes190\">Evidence Statement CG15AdultES190</a></li>
<li><a href=\"#evidence-statement-cg15adultes191\">Evidence Statement CG15AdultES191</a></li>
<li><a href=\"#evidence-statement-cg15adultes192\">Evidence Statement CG15AdultES192</a></li>
<li><a href=\"#evidence-statement-cg15adultes193\">Evidence Statement CG15AdultES193</a></li>
<li><a href=\"#evidence-statement-cg15adultes194\">Evidence Statement CG15AdultES194</a></li>
<li><a href=\"#evidence-statement-cg15adultes195\">Evidence Statement CG15AdultES195</a></li>
</ul></li>
<li><a href=\"#topic-cg15adults1\">Topic CG15AdultS1</a><ul>
<li><a href=\"#evidence-statement-cg15adultes1\">Evidence Statement CG15AdultES1</a></li>
<li><a href=\"#evidence-statement-cg16adultes2\">Evidence Statement CG16AdultES2</a></li>
</ul></li>
<li><a href=\"#topic-cg15adults2\">Topic CG15AdultS2</a><ul>
<li><a href=\"#evidence-statement-cg15adultes10\">Evidence Statement CG15AdultES10</a></li>
<li><a href=\"#evidence-statement-cg15adultes11\">Evidence Statement CG15AdultES11</a></li>
<li><a href=\"#evidence-statement-cg15adultes12\">Evidence Statement CG15AdultES12</a></li>
<li><a href=\"#evidence-statement-cg15adultes13\">Evidence Statement CG15AdultES13</a></li>
<li><a href=\"#evidence-statement-cg15adultes14\">Evidence Statement CG15AdultES14</a></li>
<li><a href=\"#evidence-statement-cg15adultes15\">Evidence Statement CG15AdultES15</a></li>
<li><a href=\"#evidence-statement-cg15adultes16\">Evidence Statement CG15AdultES16</a></li>
<li><a href=\"#evidence-statement-cg15adultes17\">Evidence Statement CG15AdultES17</a></li>
<li><a href=\"#evidence-statement-cg15adultes18\">Evidence Statement CG15AdultES18</a></li>
<li><a href=\"#evidence-statement-cg15adultes4\">Evidence Statement CG15AdultES4</a></li>
<li><a href=\"#evidence-statement-cg15adultes5\">Evidence Statement CG15AdultES5</a></li>
<li><a href=\"#evidence-statement-cg15adultes6\">Evidence Statement CG15AdultES6</a></li>
<li><a href=\"#evidence-statement-cg15adultes7\">Evidence Statement CG15AdultES7</a></li>
<li><a href=\"#evidence-statement-cg15adultes8\">Evidence Statement CG15AdultES8</a></li>
<li><a href=\"#evidence-statement-cg15adultes9\">Evidence Statement CG15AdultES9</a></li>
<li><a href=\"#evidence-statement-cg17adultes3\">Evidence Statement CG17AdultES3</a></li>
</ul></li>
<li><a href=\"#topic-cg15adults3\">Topic CG15AdultS3</a><ul>
<li><a href=\"#evidence-statement-cg15adultes19\">Evidence Statement CG15AdultES19</a></li>
<li><a href=\"#evidence-statement-cg15adultes20\">Evidence Statement CG15AdultES20</a></li>
<li><a href=\"#evidence-statement-cg15adultes21\">Evidence Statement CG15AdultES21</a></li>
<li><a href=\"#evidence-statement-cg15adultes22\">Evidence Statement CG15AdultES22</a></li>
</ul></li>
<li><a href=\"#topic-cg15adults5\">Topic CG15AdultS5</a><ul>
<li><a href=\"#evidence-statement-cg15adultes23\">Evidence Statement CG15AdultES23</a></li>
<li><a href=\"#evidence-statement-cg15adultes24\">Evidence Statement CG15AdultES24</a></li>
<li><a href=\"#evidence-statement-cg15adultes25\">Evidence Statement CG15AdultES25</a></li>
<li><a href=\"#evidence-statement-cg15adultes26\">Evidence Statement CG15AdultES26</a></li>
<li><a href=\"#evidence-statement-cg15adultes27\">Evidence Statement CG15AdultES27</a></li>
<li><a href=\"#evidence-statement-cg15adultes28\">Evidence Statement CG15AdultES28</a></li>
<li><a href=\"#evidence-statement-cg15adultes29\">Evidence Statement CG15AdultES29</a></li>
<li><a href=\"#evidence-statement-cg15adultes30\">Evidence Statement CG15AdultES30</a></li>
<li><a href=\"#evidence-statement-cg15adultes31\">Evidence Statement CG15AdultES31</a></li>
<li><a href=\"#evidence-statement-cg15adultes32\">Evidence Statement CG15AdultES32</a></li>
<li><a href=\"#evidence-statement-cg15adultes33\">Evidence Statement CG15AdultES33</a></li>
<li><a href=\"#evidence-statement-cg15adultes34\">Evidence Statement CG15AdultES34</a></li>
<li><a href=\"#evidence-statement-cg15adultes35\">Evidence Statement CG15AdultES35</a></li>
<li><a href=\"#evidence-statement-cg15adultes36\">Evidence Statement CG15AdultES36</a></li>
<li><a href=\"#evidence-statement-cg15adultes37\">Evidence Statement CG15AdultES37</a></li>
</ul></li>
<li><a href=\"#topic-cg15adults6\">Topic CG15AdultS6</a><ul>
<li><a href=\"#evidence-statement-cg15adultes38\">Evidence Statement CG15AdultES38</a></li>
<li><a href=\"#evidence-statement-cg15adultes39\">Evidence Statement CG15AdultES39</a></li>
<li><a href=\"#evidence-statement-cg15adultes40\">Evidence Statement CG15AdultES40</a></li>
<li><a href=\"#evidence-statement-cg15adultes41\">Evidence Statement CG15AdultES41</a></li>
<li><a href=\"#evidence-statement-cg15adultes42\">Evidence Statement CG15AdultES42</a></li>
<li><a href=\"#evidence-statement-cg15adultes43\">Evidence Statement CG15AdultES43</a></li>
<li><a href=\"#evidence-statement-cg15adultes44\">Evidence Statement CG15AdultES44</a></li>
<li><a href=\"#evidence-statement-cg15adultes45\">Evidence Statement CG15AdultES45</a></li>
<li><a href=\"#evidence-statement-cg15adultes46\">Evidence Statement CG15AdultES46</a></li>
<li><a href=\"#evidence-statement-cg15adultes47\">Evidence Statement CG15AdultES47</a></li>
<li><a href=\"#evidence-statement-cg15adultes48\">Evidence Statement CG15AdultES48</a></li>
<li><a href=\"#evidence-statement-cg15adultes49\">Evidence Statement CG15AdultES49</a></li>
<li><a href=\"#evidence-statement-cg15adultes50\">Evidence Statement CG15AdultES50</a></li>
<li><a href=\"#evidence-statement-cg15adultes51\">Evidence Statement CG15AdultES51</a></li>
</ul></li>
<li><a href=\"#topic-cg15adults7\">Topic CG15AdultS7</a><ul>
<li><a href=\"#evidence-statement-cg15adultes52\">Evidence Statement CG15AdultES52</a></li>
<li><a href=\"#evidence-statement-cg15adultes53\">Evidence Statement CG15AdultES53</a></li>
<li><a href=\"#evidence-statement-cg15adultes54\">Evidence Statement CG15AdultES54</a></li>
<li><a href=\"#evidence-statement-cg15adultes55\">Evidence Statement CG15AdultES55</a></li>
<li><a href=\"#evidence-statement-cg15adultes56\">Evidence Statement CG15AdultES56</a></li>
<li><a href=\"#evidence-statement-cg15adultes57\">Evidence Statement CG15AdultES57</a></li>
<li><a href=\"#evidence-statement-cg15adultes58\">Evidence Statement CG15AdultES58</a></li>
<li><a href=\"#evidence-statement-cg15adultes59\">Evidence Statement CG15AdultES59</a></li>
<li><a href=\"#evidence-statement-cg15adultes60\">Evidence Statement CG15AdultES60</a></li>
<li><a href=\"#evidence-statement-cg15adultes61\">Evidence Statement CG15AdultES61</a></li>
</ul></li>
<li><a href=\"#topic-cg15adults8\">Topic CG15AdultS8</a><ul>
<li><a href=\"#evidence-statement-cg15adultes62\">Evidence Statement CG15AdultES62</a></li>
<li><a href=\"#evidence-statement-cg15adultes63\">Evidence Statement CG15AdultES63</a></li>
<li><a href=\"#evidence-statement-cg15adultes64\">Evidence Statement CG15AdultES64</a></li>
<li><a href=\"#evidence-statement-cg15adultes65\">Evidence Statement CG15AdultES65</a></li>
<li><a href=\"#evidence-statement-cg15adultes66\">Evidence Statement CG15AdultES66</a></li>
<li><a href=\"#evidence-statement-cg15adultes67\">Evidence Statement CG15AdultES67</a></li>
<li><a href=\"#evidence-statement-cg15adultes68\">Evidence Statement CG15AdultES68</a></li>
<li><a href=\"#evidence-statement-cg15adultes69\">Evidence Statement CG15AdultES69</a></li>
</ul></li>
<li><a href=\"#topic-cg15adults10\">Topic CG15AdultS10</a><ul>
<li><a href=\"#evidence-statement-cg15adultes70\">Evidence Statement CG15AdultES70</a></li>
<li><a href=\"#evidence-statement-cg15adultes71\">Evidence Statement CG15AdultES71</a></li>
<li><a href=\"#evidence-statement-cg15adultes72\">Evidence Statement CG15AdultES72</a></li>
<li><a href=\"#evidence-statement-cg15adultes73\">Evidence Statement CG15AdultES73</a></li>
<li><a href=\"#evidence-statement-cg15adultes74\">Evidence Statement CG15AdultES74</a></li>
<li><a href=\"#evidence-statement-cg15adultes75\">Evidence Statement CG15AdultES75</a></li>
<li><a href=\"#evidence-statement-cg15adultes76\">Evidence Statement CG15AdultES76</a></li>
<li><a href=\"#evidence-statement-cg15adultes77\">Evidence Statement CG15AdultES77</a></li>
<li><a href=\"#evidence-statement-cg15adultes78\">Evidence Statement CG15AdultES78</a></li>
<li><a href=\"#evidence-statement-cg15adultes79\">Evidence Statement CG15AdultES79</a></li>
<li><a href=\"#evidence-statement-cg15adultes80\">Evidence Statement CG15AdultES80</a></li>
<li><a href=\"#evidence-statement-cg15adultes81\">Evidence Statement CG15AdultES81</a></li>
<li><a href=\"#evidence-statement-cg15adultes82\">Evidence Statement CG15AdultES82</a></li>
<li><a href=\"#evidence-statement-cg15adultes83\">Evidence Statement CG15AdultES83</a></li>
<li><a href=\"#evidence-statement-cg15adultes84\">Evidence Statement CG15AdultES84</a></li>
<li><a href=\"#evidence-statement-cg15adultes85\">Evidence Statement CG15AdultES85</a></li>
<li><a href=\"#evidence-statement-cg15adultes86\">Evidence Statement CG15AdultES86</a></li>
<li><a href=\"#evidence-statement-cg15adultes87\">Evidence Statement CG15AdultES87</a></li>
<li><a href=\"#evidence-statement-cg15adultes88\">Evidence Statement CG15AdultES88</a></li>
<li><a href=\"#evidence-statement-cg15adultes89\">Evidence Statement CG15AdultES89</a></li>
</ul></li>
<li><a href=\"#topic-cg15adults11\">Topic CG15AdultS11</a><ul>
<li><a href=\"#evidence-statement-cg15adultes100\">Evidence Statement CG15AdultES100</a></li>
<li><a href=\"#evidence-statement-cg15adultes101\">Evidence Statement CG15AdultES101</a></li>
<li><a href=\"#evidence-statement-cg15adultes102\">Evidence Statement CG15AdultES102</a></li>
<li><a href=\"#evidence-statement-cg15adultes103\">Evidence Statement CG15AdultES103</a></li>
<li><a href=\"#evidence-statement-cg15adultes104\">Evidence Statement CG15AdultES104</a></li>
<li><a href=\"#evidence-statement-cg15adultes105\">Evidence Statement CG15AdultES105</a></li>
<li><a href=\"#evidence-statement-cg15adultes90\">Evidence Statement CG15AdultES90</a></li>
<li><a href=\"#evidence-statement-cg15adultes91\">Evidence Statement CG15AdultES91</a></li>
<li><a href=\"#evidence-statement-cg15adultes92\">Evidence Statement CG15AdultES92</a></li>
<li><a href=\"#evidence-statement-cg15adultes93\">Evidence Statement CG15AdultES93</a></li>
<li><a href=\"#evidence-statement-cg15adultes94\">Evidence Statement CG15AdultES94</a></li>
<li><a href=\"#evidence-statement-cg15adultes95\">Evidence Statement CG15AdultES95</a></li>
<li><a href=\"#evidence-statement-cg15adultes96\">Evidence Statement CG15AdultES96</a></li>
<li><a href=\"#evidence-statement-cg15adultes97\">Evidence Statement CG15AdultES97</a></li>
<li><a href=\"#evidence-statement-cg15adultes98\">Evidence Statement CG15AdultES98</a></li>
<li><a href=\"#evidence-statement-cg15adultes99\">Evidence Statement CG15AdultES99</a></li>
</ul></li>
<li><a href=\"#topic-cg15adults12\">Topic CG15AdultS12</a><ul>
<li><a href=\"#evidence-statement-cg15adultes106\">Evidence Statement CG15AdultES106</a></li>
<li><a href=\"#evidence-statement-cg15adultes107\">Evidence Statement CG15AdultES107</a></li>
<li><a href=\"#evidence-statement-cg15adultes108\">Evidence Statement CG15AdultES108</a></li>
<li><a href=\"#evidence-statement-cg15adultes109\">Evidence Statement CG15AdultES109</a></li>
<li><a href=\"#evidence-statement-cg15adultes110\">Evidence Statement CG15AdultES110</a></li>
<li><a href=\"#evidence-statement-cg15adultes111\">Evidence Statement CG15AdultES111</a></li>
<li><a href=\"#evidence-statement-cg15adultes112\">Evidence Statement CG15AdultES112</a></li>
<li><a href=\"#evidence-statement-cg15adultes113\">Evidence Statement CG15AdultES113</a></li>
<li><a href=\"#evidence-statement-cg15adultes114\">Evidence Statement CG15AdultES114</a></li>
<li><a href=\"#evidence-statement-cg15adultes115\">Evidence Statement CG15AdultES115</a></li>
<li><a href=\"#evidence-statement-cg15adultes116\">Evidence Statement CG15AdultES116</a></li>
<li><a href=\"#evidence-statement-cg15adultes117\">Evidence Statement CG15AdultES117</a></li>
<li><a href=\"#evidence-statement-cg15adultes118\">Evidence Statement CG15AdultES118</a></li>
<li><a href=\"#evidence-statement-cg15adultes119\">Evidence Statement CG15AdultES119</a></li>
<li><a href=\"#evidence-statement-cg15adultes120\">Evidence Statement CG15AdultES120</a></li>
<li><a href=\"#evidence-statement-cg15adultes121\">Evidence Statement CG15AdultES121</a></li>
<li><a href=\"#evidence-statement-cg15adultes122\">Evidence Statement CG15AdultES122</a></li>
<li><a href=\"#evidence-statement-cg15adultes123\">Evidence Statement CG15AdultES123</a></li>
<li><a href=\"#evidence-statement-cg15adultes124\">Evidence Statement CG15AdultES124</a></li>
<li><a href=\"#evidence-statement-cg15adultes125\">Evidence Statement CG15AdultES125</a></li>
<li><a href=\"#evidence-statement-cg15adultes126\">Evidence Statement CG15AdultES126</a></li>
<li><a href=\"#evidence-statement-cg15adultes127\">Evidence Statement CG15AdultES127</a></li>
<li><a href=\"#evidence-statement-cg15adultes128\">Evidence Statement CG15AdultES128</a></li>
<li><a href=\"#evidence-statement-cg15adultes129\">Evidence Statement CG15AdultES129</a></li>
<li><a href=\"#evidence-statement-cg15adultes130\">Evidence Statement CG15AdultES130</a></li>
<li><a href=\"#evidence-statement-cg15adultes131\">Evidence Statement CG15AdultES131</a></li>
<li><a href=\"#evidence-statement-cg15adultes132\">Evidence Statement CG15AdultES132</a></li>
<li><a href=\"#evidence-statement-cg15adultes133\">Evidence Statement CG15AdultES133</a></li>
</ul></li>
<li><a href=\"#topic-cg15adults13\">Topic CG15AdultS13</a><ul>
<li><a href=\"#evidence-statement-cg15adultes134\">Evidence Statement CG15AdultES134</a></li>
<li><a href=\"#evidence-statement-cg15adultes135\">Evidence Statement CG15AdultES135</a></li>
<li><a href=\"#evidence-statement-cg15adultes136\">Evidence Statement CG15AdultES136</a></li>
<li><a href=\"#evidence-statement-cg15adultes137\">Evidence Statement CG15AdultES137</a></li>
<li><a href=\"#evidence-statement-cg15adultes138\">Evidence Statement CG15AdultES138</a></li>
<li><a href=\"#evidence-statement-cg15adultes139\">Evidence Statement CG15AdultES139</a></li>
</ul></li>
<li><a href=\"#topic-cg15adults14\">Topic CG15AdultS14</a><ul>
<li><a href=\"#evidence-statement-cg15adultes140\">Evidence Statement CG15AdultES140</a></li>
<li><a href=\"#evidence-statement-cg15adultes141\">Evidence Statement CG15AdultES141</a></li>
<li><a href=\"#evidence-statement-cg15adultes142\">Evidence Statement CG15AdultES142</a></li>
<li><a href=\"#evidence-statement-cg15adultes143\">Evidence Statement CG15AdultES143</a></li>
<li><a href=\"#evidence-statement-cg15adultes144\">Evidence Statement CG15AdultES144</a></li>
<li><a href=\"#evidence-statement-cg15adultes145\">Evidence Statement CG15AdultES145</a></li>
<li><a href=\"#evidence-statement-cg15adultes146\">Evidence Statement CG15AdultES146</a></li>
<li><a href=\"#evidence-statement-cg15adultes147\">Evidence Statement CG15AdultES147</a></li>
<li><a href=\"#evidence-statement-cg15adultes148\">Evidence Statement CG15AdultES148</a></li>
<li><a href=\"#evidence-statement-cg15adultes149\">Evidence Statement CG15AdultES149</a></li>
<li><a href=\"#evidence-statement-cg15adultes150\">Evidence Statement CG15AdultES150</a></li>
<li><a href=\"#evidence-statement-cg15adultes151\">Evidence Statement CG15AdultES151</a></li>
<li><a href=\"#evidence-statement-cg15adultes152\">Evidence Statement CG15AdultES152</a></li>
</ul></li>
<li><a href=\"#topic-cg15adults9\">Topic CG15AdultS9</a></li>
</ul></li>
</ul>
</nav>
<h1 id=\"type-1-diabetes\">Type 1 Diabetes</h1>
<p>Diabetes is a group of disorders with a number of features in common, of which raised blood sugar is the most evident. This guideline is concerned only with type 1 diabetes, a condition that aetiologically is a pure hormone-deficiency disease. However, because hormone replacement with insulin therapy is sub-optimal, acute and long-term complications are endemic despite the implementation of lifestyle and other disease management measures.</p>
<h2 id=\"topic-cg15adults15\">Topic CG15AdultS15</h2>
<p>People with Type 1 diabetes are generally recognised to be at greatly increased risk of arterial disease (CVD) in middle age. While the literature on arterial risk factors and markers in the general population is large, it would not appear to follow that the findings can be simply carried ov er to people with Type 1 diabetes. Similarly, the tools used to quantify arterial risk in the general population are known not to work well in people with Type 2 diabetes, and seem even less likely to be valid in Type 1 diabetes.</p>
<p>The group recognised the very considerable difficulties in reaching conclusions from the ev idence in this area. Very little direct information pertaining to people with Type 1 diabetes can be ascertained, whilst the importance of the issue is emphasised by the very high early arterial disease (CVD) risk run by people with Type 1 diabetes. Nevertheless certain sub-groups are known to be at particularly high risk (people with raised albumin excretion rate (micro- albuminuria)), while others combine Type 1 diabetes with combinations of classic risk factors ty pical of the metabolic syndrome and known to be predictors of high arterial risk in people w ith Type 2 diabetes and indeed non-diabetic po pulations. A further group of people will co mbine Type 1 diabetes with a single arterial risk factor or risk marker, while yet others will have Type 1 diabetes but appear low risk otherwise. Ac co r dingly the important factors for surveillance are urinary albumin excretion (most important), other classical risk factors including full lipid profile, and risk markers such as age, family history and some ethnic groups. In accordance with the principle of unified organisation of care, monitoring of these factors annually is to be recommended, but it was recognised that in low risk individuals technology might become capable of programming longer review intervals for serum lipids. The group recognised that different ways of using information from a full lipid profile (calculated LDL and HDL separately, calculation of total: HDL cholesterol ratio, calculation of non-HDL cholesterol) are in use. While the group preferred the first of these as not mixing lipid abnormalities of different pathogenesis, and being a better route to using the treatments for different lipid disorders rationally, it was recog nised that there was not good evidence to suggest supporting one approach over the others. The group could find no confidence in any risk table, engine or equation when applied to people with Type 1 diabetes.</p>
<p>Arterial risk factors should be assessed annually Arterial risk factors should be assessed annually, and the assessment should include:</p>
<ul>
<li><p>albumin excretion rate</p></li>
<li><p>smoking</p></li>
<li><p>blood glucose control</p></li>
<li><p>blood pressure</p></li>
<li><p>full lipid profile (including HDL and LDL cholesterol and triglycerides)</p></li>
<li><p>age</p></li>
<li><p>family history of arterial disease (CVD)</p></li>
<li><p>abdominal adiposity. </p></li>
</ul>
<h3 id=\"evidence-statement-cg15adultes153\">Evidence Statement CG15AdultES153</h3>
<p>The Scottish intercollegiate guidelines 174 identify specific risk factors for arterial disease as cigarette smoking, dyslipidaemia, hypertension, hyperglycaemia, obesity and micro- albuminuria</p>
<p><span class=\"citation\" data-cites=\"Linden_2011\">(Linden 2011)</span></p>
<h3 id=\"evidence-statement-cg15adultes154\">Evidence Statement CG15AdultES154</h3>
<p>The guideline 174 re ports on non-randomised studies showing that smoking is an independent arterial risk factor in people with diabetes. Additional observational studies reported dyslip- idaemia. An increased concentration of LDL cholesterol or total cholesterol has also been identified as an independent risk factor for arterial morbidity and mortality and each 1.0 mmol/l re duction of LDL cholesterol represents a 36% reduction in risk of arterial disease</p>
<p><span class=\"citation\" data-cites=\"Linden_2011\">(Linden 2011)</span></p>
<h3 id=\"evidence-statement-cg15adultes155\">Evidence Statement CG15AdultES155</h3>
<p>Two controlled but not randomised studies reported within the guideline 174 demonstrated the positive relationship between hypertension and risk of arterial death, with a progressive increase in risk with rising systolic pressure. Each 10 mmHg reduction in systolic pressure is associated with a 15% (95% CI: 1218) reduction in risk of arterial death over 10 years</p>
<p><span class=\"citation\" data-cites=\"Linden_2011\">(Linden 2011)</span></p>
<h3 id=\"evidence-statement-cg15adultes156\">Evidence Statement CG15AdultES156</h3>
<p>The link between glycaemia and arterial morbidity and mortality was also reported in two studies reviewed in the SIGN guidelines. 174 In o ne study each 1% reduction in HbA 1c was associated with a 21% (95% CI: 1527) reduction in the risk of diabetes-related death and a 14% reduction for myocardial infarction over 10 years</p>
<p><span class=\"citation\" data-cites=\"Linden_2011\">(Linden 2011)</span></p>
<h3 id=\"evidence-statement-cg15adultes157\">Evidence Statement CG15AdultES157</h3>
<p>Ev idence for the other risk factors is sparse. In the SIGN guidelines, 174 no studies were identified for linking obesity as an indepen dent risk factor in established diabetes. One observational study reported microalbuminuria as an independent marker associated with doubling in arterial risk, however, there is ins ufficient evidence to determine whether reducing albumin excretion rate specifically reduces arterial morbidity or mortality</p>
<p><span class=\"citation\" data-cites=\"Linden_2011\">(Linden 2011)</span></p>
<h3 id=\"evidence-statement-cg15adultes158\">Evidence Statement CG15AdultES158</h3>
<p>A meta-analysis 175 aimed at defining risk factors for arterial disease from studies in people with diabetes, showed that, adjusted for age, both total mortality and death from all vascular causes increased significantly with total cholesterol level and systolic blood pressure, and decreased w ith percentage of women. Duration of diabetes and mean HbA 1c we re not considered to be associated with mortality. However, this meta-analysis did not contain a critical appraisal of included studies or details of approaches used to ensure study quality before inclusions and should therefore not be used as the basis for clinical recommendations</p>
<p><span class=\"citation\" data-cites=\"Kanters_1999\">(Kanters et al. 1999)</span></p>
<h3 id=\"evidence-statement-cg15adultes159\">Evidence Statement CG15AdultES159</h3>
<p>One systematic review 176 e xamined 67 studies, addressing both screening for primary detection of arterial risk factors and treatment of lipid abnormalities in asymptomatic people both with and without diabetes. Reliability and effectiveness of each screening strategy for identifying lipid disorders was investigated, and showed that total cholesterol measurements generally have good reliability, with an analytic variability of less than or equal to 3% and a mean total biologic variability of the order of 6%. A total cholesterol level within 10% of the true value can be determined with two separate measurements, which do not differ significantly between fasting or non-fasting venous blood</p>
<p><span class=\"citation\" data-cites=\"Pignone_2001\">(Pignone et al. 2001)</span></p>
<h3 id=\"evidence-statement-cg15adultes160\">Evidence Statement CG15AdultES160</h3>
<p>Ev idence within this systematic review 176 for HDL cholesterol showed a higher analytical (6%) and biological (7.5%) variation than total cholesterol, however, two or three values were re quired to estimate true HDL cholesterol levels to within 10 to 15%. Variations were also found between non-fasting and fasting blood samples as HDL cholesterol is 5%10% lower in the non-fasting state, suggesting that non-fasting measurement may slightly overestimate coronary heart disease risk, but not enough to make accuracy of screening unacceptable</p>
<p><span class=\"citation\" data-cites=\"Pignone_2001\">(Pignone et al. 2001)</span></p>
<h3 id=\"evidence-statement-cg15adultes161\">Evidence Statement CG15AdultES161</h3>
<p>A dditional studies within this systematic review 176 co nsidered triglyceride screening. Values measured varied by 20%30% between fasting and non-fasting states. LDL cholesterol is calculated from total and HDL cholesterol and triglycerides measurements and application of the Friedewald equation. However, this equation has been found to be inaccurate at triglyceride levels greater than or equal to 4.5 mmol/l when special techniques must be employed (eg ultracentrifugation)</p>
<p><span class=\"citation\" data-cites=\"Pignone_2001\">(Pignone et al. 2001)</span></p>
<h3 id=\"evidence-statement-cg15adultes162\">Evidence Statement CG15AdultES162</h3>
<p>Also considered in this systematic review 176 was the comparable accuracy of total and HDL c holesterol from capillary blood samples. These were found to be less reliable without proper attention to calibration and proper testing techniques. One study found that a Framingham- based coronary risk model was the best predictor of IHD mortality. Guidelines reported in the re vi ew concluded that the LDL:HDL cholesterol and the total:HDL cholesterol ratios performed equally well in determining arterial outcomes, and the least accurate screening test was that of measuring total cholesterol alone</p>
<p><span class=\"citation\" data-cites=\"Pignone_2001\">(Pignone et al. 2001)</span></p>
<h3 id=\"evidence-statement-cg15adultes163\">Evidence Statement CG15AdultES163</h3>
<p>Other studies included in this review 176 assessing characteristics of the screening tests showed that non-fasting total cholesterol alone is the easiest to perform for the patient and provider. T otal:HDL cholesterol ratio is easy for patients to obtain and for providers to interpret and performs equally accurately as the LDL:HDL cholesterol ratio strategy. However, one study in the review demonstrated that risk-based algorithms which directly incorporate age, other risk factors and measures of total and HDL cholesterol are the most accurate approach to screening. These processes are difficult to access and so supplemental tables, such as the Sheffield table, can improve the feasibility of a risk-based strategy</p>
<p><span class=\"citation\" data-cites=\"Pignone_2001\">(Pignone et al. 2001)</span></p>
<h3 id=\"evidence-statement-cg15adultes164\">Evidence Statement CG15AdultES164</h3>
<p>There was no evidence from this systematic review 176 to inform the question of appropriate frequency of screening. National guidelines reco mmend a five-year interval for people with previous normal results and more freque nt screening in those with borderline values</p>
<p><span class=\"citation\" data-cites=\"Pignone_2001\">(Pignone et al. 2001)</span></p>
<h3 id=\"evidence-statement-cg15adultes165\">Evidence Statement CG15AdultES165</h3>
<p>One study 177 co mparing the Sheffield tables to the computer-calculated Framingham equation re v ealed a low sensitivity and specificity for the Sheffield tables (35% (95% CI 28 to 42) and 98% (95% CI 97 to 99) respectively). The old tab les only included patients with systolic blood pressure &lt;160 mmHg, and cholesterol greater than 5.5 mmol/l. Adopting these exclusion criteria led to a substantial reduction in the number of patients eligible for screening without improving detection of risk assessment</p>
<p><span class=\"citation\" data-cites=\"Bayly_1999\">(Bayly et al. 1999)</span></p>
<h3 id=\"evidence-statement-cg15adultes166\">Evidence Statement CG15AdultES166</h3>
<p>A nother evaluation 178 studied all seven guidelines against the calculated Framingham equation in 906 people with diabetes, showing Modified Sheffield tables have higher sensitivity (95% vs 37%) with a slight reduction in specificity (90% vs 97%) compared with the original tables, w ith a slightly better positive predictive value than the original version (80% vs 71%). The Joint Br itish tables have good specificity (99%), but lo w sensitivity (77%) but the tables perform well at the lower CHD risk of greater than or equal to 15% over 10 years (specificity 92%, sensitivity 96%). Canadian tables perform poorly at the = 30% risk, and only slightly better at the greater than or equal to 15% level of risk (specificity 100%, sensitivity 5%, and 85% and 98%, r espectively). The Framingham categorical tables have a lower specificity (83%) for the identification of high-risk individuals (although risk is greater than or equal to 27% not greater than or equal to 30%) and this deteriorates for identification of those at = 15% risk (specificity 77%). New Zealand tables had a sensitivity of 69% and specificity of 88% at a greater than or equal to 20% level of risk, at the = 10% level of risk, specificity deteriorates to 58%. The Joint Eu ro pean tables have a sensitivity of 89% for risk levels greater than or equal to 20% but specificity of only 71%. This means that one in four patients would be incorrectly identified as having a risk above the 20% threshold</p>
<p><span class=\"citation\" data-cites=\"Bayly_1999\">(Bayly et al. 1999)</span></p>
<h3 id=\"evidence-statement-cg15adultes167\">Evidence Statement CG15AdultES167</h3>
<p>A further study from the same investigators 179 assessed the PROCAM program against that of the Framingham equation. Only 56% of the study populat ion were eligible for evaluation with PROCAM. This evaluation also systematically underestimates risk in comparison with the Fr amingham equation at low levels of absolute risk but overestimates at higher risk levels</p>
<p><span class=\"citation\" data-cites=\"Game_2001\">(Game and Jones 2001)</span></p>
<h3 id=\"evidence-statement-cg15adultes168\">Evidence Statement CG15AdultES168</h3>
<p>The sensitivity and specificity of various risk pr ediction tables and charts was also investigated in one comparative study. 180 Co mpared to the Framingham equation the Sheffield tables had a low sensitivity (40% eligible for cholesterol lowering treatment would be identified), but with high specificity and thus low false positive rates. The New Zealand tables had similar sensitivities and specificities to the Sheffield tables, but a 10% level of risk prediction of five- y ear arterial disease risk threshold specificity is significantly lower than the Sheffield tables. The Eu ro pean tables have better sensitivity than Sheffield and New Zealand tables but specificity is significantly worse than other risk assessment levels leading to an equally low sensitivity. The joint British Societies table has significantly better specificities at greater than or equal to 15% and greater than or equal to 30% 10-year CHD risk than the modified Sheffield tables. Sensitivity is generally low, but high at the 15% 10-year CHD/10% five-year CVD risk level. Canadian tables are not reliable at greater than or equal to 30% risk but are comparable with the modified Sheffield tables at 154% risk threshold. The Framingham equation had the best performance with sensitivity and specificity comparable to that of the modified Sheffield and joint British Society methods, respectively</p>
<p><span class=\"citation\" data-cites=\"Jones_2001\">(A. F. Jones 2001)</span></p>
<h2 id=\"topic-cg15adults16\">Topic CG15AdultS16</h2>
<p>Prevention of arterial risk in people with Type 1 diabetes, through attention to blood glucose co ntrol (insulin therapy, patient education, nutrit ion, self-monitoring) is considered elsewhere in this guideline, and blood pressure management in 8.3, below. However, in the general population (at much lower risk) and in people with Type 2 diabetes other therapies are known to re duce the risk of arterial events. The current section therefore deals with these approaches as applied to people with Type 1 diabetes.</p>
<p>The data on arterial risk management in people with Type 1 diabetes are few, though it is noted that studies in people with and without Type 2 diabetes point to clinically effective interventions for those groups. In the absence of quantitative risk assessment and noting the economic evidence placed before the group it seemed clear that interventions in people with Ty pe 1 diabetes must be recommended considering their semi-quantitative arterial disease risk: high, moderate or no risk. Given the high arterial risk of many people with Type 1 diabetes, smoking was considered to be particularly disadvantageous.</p>
<p>advice on smoking cessation Adults with Type 1 diabetes who smoke should be given advice on smoking cessation and use of smoking cessation services, including NICE guidance-recommended therapies. The messages should be reinforced in continuing smokers yearly if pre-contemplative of stopping, and at all clinical contacts if there is a prospect of their stopping. </p>
<h3 id=\"evidence-statement-cg15adultes169\">Evidence Statement CG15AdultES169</h3>
<p>The Scottish intercollegiate guidelines 174 identify a role for lipid-lowering drugs in reducing ischaemic heart disease events but not all cause mortality in people with no known arterial disease, compared with placebo</p>
<p><span class=\"citation\" data-cites=\"Linden_2011\">(Linden 2011)</span></p>
<h3 id=\"evidence-statement-cg15adultes170\">Evidence Statement CG15AdultES170</h3>
<p>SIGN guidelines on lipids 181 and the prevention of ischaemic heart disease detail studies targeted at people with Type 2 diabetes. However, secondary prevention trials of lipids reported 77 Feature Women Men Blood pressure average (mmHg) &gt;135/80 &gt;135/80 Waist circumference (m) (use 0.10m lower &gt;0.90 &gt;1.00 figures for people of South Asian extraction) Serum HDL cholesterol (mmol/l) &lt;1.2 &lt;1.0 Serum triglycerides (mmol/l) &gt;1.8 &gt;1.8 Raised albumin exrection rate is not included because in Type 1 diabetes it is a marker of developing nephropathy and nephropathy alone is associated with extreme risk of ischaemic heart disease. Glucose intolerance cannot be assessed in adults with Type 1 diabetes, but higher insulin doses in adults &gt;20 years (&gt;1.0 U/kg/day) suggest insulin insensitivity. Table 4 Features of the metabolic syndrome suggesting high arterial risk in people with Type 1 diabetes in the guideline have shown significant reduction in arterial disease in both Type 1 and Type 2 diabetes. These guidelines recommend the loss of weight, reduction of intake of saturated fat, increased consumption of fruit and vegetables, regular exercise and the introduction of lipid- lowering drug treatment for primary prevention of arterial problems in high-risk people with diabetes. The guidelines also report a study raising concern about underestimating diabetic ischaemic heart disease risk, particularly in people with Type 1 diabetes</p>
<p><span class=\"citation\" data-cites=\"Miller_2002\">(J. Miller 2002)</span></p>
<h3 id=\"evidence-statement-cg15adultes171\">Evidence Statement CG15AdultES171</h3>
<p>The SIGN guidelines 174 re port on a number of therapeutic studies. The CARE study demonstrated a significant reduction in coronary events with pravastatin vs placebo, although the magnitude of effect was lower than in the 4S study. The LIPID study also showed a trend to re duction in recurrent coronary events but numbers of people with diabetes in this study were to o low to demonstrate statistical significance. The VA-HIT study showed significant secondary prevention of coronary events in men with diabetes aged less than 74 years, taking a fibrate (gemfibrozil) for a mean follow-up of 5.1 years</p>
<p><span class=\"citation\" data-cites=\"Linden_2011\">(Linden 2011)</span></p>
<h3 id=\"evidence-statement-cg15adultes172\">Evidence Statement CG15AdultES172</h3>
<p>Three randomised controlled trials 182184 re ported on the positive effect of pravastatin on arterial outcomes in people with diabetes. One study 182 re ported a significant change in total and LDL cholesterol, HDL cholesterol and triglycerides vs placebo. After 24 weeks the reduction in total cholesterol from baseline was 22%, LDL cholesterol 26%, and triglycerides decreased by 2%, accompanied by an increase in HDL cholesterol of 14%. Pravastatin was well tolerated throughout the study</p>
<p><span class=\"citation\" data-cites=\"Rustemeijer_1997\">(Rustemeijer et al. 1997)</span></p>
<p><span class=\"citation\" data-cites=\"Raskin_1995\">(Raskin et al. 1995)</span></p>
<p><span class=\"citation\" data-cites=\"Goldberg_1998\">(Goldberg et al. 1998)</span></p>
<h3 id=\"evidence-statement-cg15adultes173\">Evidence Statement CG15AdultES173</h3>
<p>Similar results were seen in the further two trials. One study 183 reported re ductions in LDL c holesterol and VLDL cholesterol of 30% and 13% respectively with pravastatin compared with placebo and significant increases in HDL cholesterol at eight and 16 weeks. The final study 184 was in a majority of sulfonylurea treated people with Type 2 diabetes, and pravastatin reduced t otal and LDL cholesterol by 19% and 27% in the diabetes group. Compared with placebo pravastatin caused a 13% decrease in triglycerides and a 4% increase HDL cholesterol in people w ith diabetes. Results were similar to those in people without diabetes, and were unaffected by adjustment for age and sex</p>
<p><span class=\"citation\" data-cites=\"Raskin_1995\">(Raskin et al. 1995)</span></p>
<p><span class=\"citation\" data-cites=\"Goldberg_1998\">(Goldberg et al. 1998)</span></p>
<h3 id=\"evidence-statement-cg15adultes174\">Evidence Statement CG15AdultES174</h3>
<p>The SIGN management of arterial disease in diabetes guidelines 174 cite results from the Scandinavian Simvastan study, which contained 204 people with diabetes (of a study population of 4,444), and demonstrated that cholesterol-lowering therapy was highly effective co mpared with placebo in those undergoing revascularisation procedures, especially in those w ith diabetes (risk reduction 55% v s 32% in non-diabetes)</p>
<p><span class=\"citation\" data-cites=\"Linden_2011\">(Linden 2011)</span></p>
<h3 id=\"evidence-statement-cg15adultes175\">Evidence Statement CG15AdultES175</h3>
<p>Two RCTs reported the effect of simvastatin in people with diabetes. Total and LDL cholesterol levels and the ratio between LDL and HDL cholesterol were decreased following treatment in one study 185 of 25 people with diabetes, whereas no difference was seen following placebo, no between group comparison was made. The second study, containing 26 people with Type 1 diabetes 186 also reported a significant reduction in the plasma concentrations of total c holesterol, LDL cholesterol and apolipoprotein B after 12 weeks simvastatin treatment, wh ereas no changes were observed after placebo treatment</p>
<p><span class=\"citation\" data-cites=\"Sweany_1995\">(Sweany 1995)</span></p>
<p><span class=\"citation\" data-cites=\"Hommel_1992\">(Hommel et al. 1992)</span></p>
<h3 id=\"evidence-statement-cg15adultes176\">Evidence Statement CG15AdultES176</h3>
<p>One study reported the effect of bezafibrate on arterial outcomes in 36 people with Type 1 diabetes. 187 However, there are some potential methodological limitations in this study, which does not make this evidence a reliable basis for a clinical recommendation</p>
<p><span class=\"citation\" data-cites=\"Winocour_1990\">(Winocour et al. 1990)</span></p>
<h3 id=\"evidence-statement-cg15adultes177\">Evidence Statement CG15AdultES177</h3>
<p>The SIGN guidelines 174 re port uncertainty about the role of aspirin in primary prevention. Citing the HOT study (a randomised controlled trial) and the further reduction in arterial risk in well-controlled hypertensive patients with diabetes, they note the importance of balancing this reduction against the risk of bleeding</p>
<p><span class=\"citation\" data-cites=\"Linden_2011\">(Linden 2011)</span></p>
<h3 id=\"evidence-statement-cg15adultes178\">Evidence Statement CG15AdultES178</h3>
<p>The North of England guidelines 188 on aspirin for the secondary prophylaxis of vascular disease in primary care reported a pooled risk ratio by combining he meta-analysis of the Antiplatelet Co llaborative Group with trials published after 1990 to establish the impact of antiplatelet therapy on subsequent myocardial infarction (MI), stroke and vascular death. This provided strong evidence for a general protective effect of aspirin as antiplatelet therapy in patients at r aised vascular risk. Few studies were found containing comparisons of aspirin and alternative antiplatelet agents to enable comparison of their relative effectiveness</p>
<p>[@1994]</p>
<h3 id=\"evidence-statement-cg15adultes179\">Evidence Statement CG15AdultES179</h3>
<p>Fo r evidence relating specifically to people with diabetes the North of England guidelines 188 identified eight trials contributing to an overall estimate of risk difference for arterial morbidity of 1.2% with aspirin compared to placebo or other antiplatelet agent. These trials were homogeneous with a pooled incidence rate differen ce (by random effects model) of a 0.3% re duction in the risk of MI, stroke or vascular death from antiplatelet therapy for one year. This is not a statistically significant difference, and in summary authors state that aspirin given to patients with diabetes appears to have a small and statistically uncertain effect upon the risk of ex periencing a subsequent vascular event. They also suggest that the similar relative risk for MI, stroke and vascular death found in diabetes trials and other trials of patients at raised vascular r isk, indicates that patients with diabetes alongside other indications of vascular risk are likely to benefit from routine aspirin therapy</p>
<p>[@1994]</p>
<h3 id=\"evidence-statement-cg15adultes180\">Evidence Statement CG15AdultES180</h3>
<p>Am erican Diabetes Association guidelines 76 indicate that meta-analysis and large-scale co llaborative trials in men and women with diabetes support the view that low-dose aspirin therapy should be prescribed as a secondary prevention strategy if no contraindications exist. The guidelines also point to substantial evidence suggesting that low-dose aspirin therapy should be used as a primary prevention strategy in men and women with diabetes who are at a high risk for arterial events. The meta-analysis of 145 prospective controlled trials of antiplatelet therapy by the Antiplatelet Tr ialists Group reported in the ADA guidelines 76 showed a trend toward increased risk re ductions with doses of aspirin = 325 mg/day, but the difference was not statistically significant. An estimated 3812 vascular events per 1,000 patients with Type 1 diabetes would have been prevented if they were treated with aspirin as a secondary prevention strategy</p>
<p>[@2003]</p>
<h3 id=\"evidence-statement-cg15adultes181\">Evidence Statement CG15AdultES181</h3>
<p>The ADA guidelines 76 also reported on the HOT study, which showed a reduction in arterial ev ents following aspirin therapy compared to placebo of 15% and a 36% reduction in my ocardial infarction. This study also showed that fatal bleeding including intracerebral bleeding were equal in aspirin and control groups, whereas non-fatal minor bleeding episodes we re more frequent in patients receiving aspirin. The US Physicians Health study reported in the same guideline compared aspirin (325 mg/day) with placebo in male physicians (without diabetes), resulting in a 44% risk reduction in MI among the treated group. In a subgroup of people with diabetes there was a reduction in MI from 10% to 4% yielding a relative risk of 0.39 for men with diabetes randomised to aspirin therapy</p>
<p>[@2003]</p>
<h3 id=\"evidence-statement-cg15adultes182\">Evidence Statement CG15AdultES182</h3>
<p>The ADA guidelines 76 also addressed the safety of aspirin use and reported several prospective r andomised studies in which a trend for an increase in haemorrhagic stroke followed aspirin therapy, although this has not reached statistical significance</p>
<p>[@2003]</p>
<h3 id=\"evidence-statement-cg15adultes183\">Evidence Statement CG15AdultES183</h3>
<p>Co ntraindications reported 76 include allergy, bleeding tendency, anticoagulant therapy, recent gastrointestinal bleeding and c linically active hepatic disease</p>
<p>[@2003]</p>
<h3 id=\"evidence-statement-cg15adultes184\">Evidence Statement CG15AdultES184</h3>
<p>Re lative risk of MI reported by the ETDRS group 189 in which roughly 48% of men and women w ith diabetes had a history of arterial disease was lowered significantly in the first five years in those randomised to aspirin therapy</p>
<p>[@1992]</p>
<h3 id=\"evidence-statement-cg15adultes185\">Evidence Statement CG15AdultES185</h3>
<p>In the management of people with diabetes and new or established vascular disease, the SIGN guidelines 174 re fer to a meta-analysis of platelet inhibitor therapy demonstrating a 31% re duction in non-fatal reinfarction, a 42% reduction in non-fatal stroke and a 13% reduction in arterial mortality</p>
<p><span class=\"citation\" data-cites=\"Linden_2011\">(Linden 2011)</span></p>
<h3 id=\"evidence-statement-cg15adultes186\">Evidence Statement CG15AdultES186</h3>
<p>One meta-analysis 190 of six randomised, double-blind, placebo-controlled trials showed a significant pooled reduction in mortality following treatment with platelet glycoprotein inhibitors. The most marked benefit was seen in patients undergoing percutaneous coronary intervention. A significant reduction in composite death or MI at 30 days was also seen following treatment in people with diabetes. However, potential methodological limitations of the trials included would not permit this analysis to be used as a evidence base to inform re co mmendations in this area</p>
<p><span class=\"citation\" data-cites=\"Roffi_2002\">(Roffi, Chew, and Mukherjee 2002)</span></p>
<h3 id=\"evidence-statement-cg15adultes187\">Evidence Statement CG15AdultES187</h3>
<p>Also reported in the SIGN guideline 174 is a sub-study analysis of a large RCT demonstrating that addition of clopidogrel to aspirin over 312 months reduces the risk of fatal or non-fatal MI or stroke by 20% in patients with a past history of coronary heart disease presenting with acute coronary syndromes (without electrocardiographic ST elevation). This risk reduction was however associated with an additional risk of bleeding</p>
<p><span class=\"citation\" data-cites=\"Linden_2011\">(Linden 2011)</span></p>
<h3 id=\"evidence-statement-cg15adultes188\">Evidence Statement CG15AdultES188</h3>
<p>The ADA guidelines 76 also report from the CAPRIE study which showed that clopidogrel was slightly more effective than aspirin in reducing the combined risk of stroke, MI or vascular death in people with and without diabetes (effect sizes not stated)</p>
<p>[@2003]</p>
<h3 id=\"evidence-statement-cg15adultes189\">Evidence Statement CG15AdultES189</h3>
<p>One randomised controlled study reviewed in the ADA guideline 76 showed that thrombolytic therapy reduced mortality after acute MI in subjects with diabetes by = 42% with no increase in r isk of bleeding or stroke, and should not be withheld due to concern about retinal haemorrhage in patients with retinopathy. This study also demonstrated that the indications and co ntraindications for thrombolysis in patients with diabetes are the same as those without</p>
<p>[@2003]</p>
<h3 id=\"evidence-statement-cg15adultes190\">Evidence Statement CG15AdultES190</h3>
<p>The SIGN guideline 174 re ports on the results of the beta-blocker adrenergic pooling project study, which demonstrated that diabetes is not a contraindication to the use of beta-blockers, and that these reduce mortality, sudden cardiac death and re-infarction when given after acute MI. The guideline also cites the 1995 Collaborative Group on ACE inhibitor trials meta-analysis of nearly 100,000 patients which showed that receiving therapy with an ACE inhibitor within 36 hours of acute MI for = 4 weeks, reduced mortality post MI. The majority of benefits occurred within the first few days when mortality was highest, benefiting patients at a higher r isk to a greater absolute extent</p>
<p><span class=\"citation\" data-cites=\"Linden_2011\">(Linden 2011)</span></p>
<h3 id=\"evidence-statement-cg15adultes191\">Evidence Statement CG15AdultES191</h3>
<p>Three large trials (AIRE, SAVE and TRACE studies) 174 also reviewed within the SIGN guideline have shown consistent reductions in mortality when ACE inhibitor therapy is given to people after acute MI with clinical evidence of heart failure or a reduced ejection fraction. A fourth study (SOLVD) demonstrated an absolute risk reduction for mortality of 4.5% in patients with diabetes and chronic heart failure given an ACE inhibitor compared to placebo over a mean follow-up of 4.5 years</p>
<p><span class=\"citation\" data-cites=\"Linden_2011\">(Linden 2011)</span></p>
<h3 id=\"evidence-statement-cg15adultes192\">Evidence Statement CG15AdultES192</h3>
<p>A predefined subgroup analysis of 3,577 people over 55 with diabetes (the majority of whom had Type 2 diabetes) in the large multinational HOPE randomised controlled trial 191 showed the effect of ramipril on arterial outcomes in people with diabetes. The rate of combined primary outcome of MI, stroke or arterial death was significantly lower in the ramipril groups than in those receiving placebo. Total mortality was reduced by 24%. Adjustment for changes in systolic and diastolic blood pressures did not change the magnitude of the effect</p>
<p>[@2000]</p>
<h3 id=\"evidence-statement-cg15adultes193\">Evidence Statement CG15AdultES193</h3>
<p>Other results from the HOPE study 192 in which patients aged over 55 years, with and without diabetes, who were randomised to receive 400 IU vitamin E for an average follow-up of 4.5 years, showed no effect of antioxidant over placebo. Primary outcomes of MI, stroke or arterial death, or secondary outcomes of hospitalisations for angina or heart failure, were similar following tr eatment with vitamin E and placebo. No differences were observed in the frequency of outcomes in people with diabetes in the two treatment groups</p>
<p><span class=\"citation\" data-cites=\"Lonn_2003\">(Lonn et al. 2003)</span></p>
<h3 id=\"evidence-statement-cg15adultes194\">Evidence Statement CG15AdultES194</h3>
<p>SIGN guidelines 174 state that clinical presentation of stroke in people with diabetes is similar to that in people without diabetes. There is little eviden ce specific to people with diabetes let alone specific to Type 1 diabetes, suggesting that the management of stroke should be similar to that in people without diabetes</p>
<p><span class=\"citation\" data-cites=\"Linden_2011\">(Linden 2011)</span></p>
<h3 id=\"evidence-statement-cg15adultes195\">Evidence Statement CG15AdultES195</h3>
<p>W hilst economic analyses have been conducted on trials of lipid-lowering agents, no evaluation has specifically considered Type 1 diabetes. Three papers were identified within the health economic literature dealing with mixed diabetic populations. 35052 An economic analysis 350 of simvastatin using the 4S trial data suggests that it would provide cost-effective mortality re duction in the UK amongst a similar population. A second cost-effectiveness paper 351 also suggests that the simvastatin may be cost-effective in the UK for those aged 40 to 70 years with elevated cholesterol even if they have not been diagnosed with arterial disease. A third paper based outside the UK suggests that the benefits of simvastatin to diabetics with elevated lipid levels and arterial disease outweigh the benefit to those with elevated lipid levels and no prior arterial disease. 352</p>
<p><span class=\"citation\" data-cites=\"Grover_2000\">(Grover et al. 2000)</span></p>
<p><span class=\"citation\" data-cites=\"Grover_2001\">(Grover et al. 2001)</span></p>
<h2 id=\"topic-cg15adults1\">Topic CG15AdultS1</h2>
<p>The diagnosis of Type 1 diabetes would not appear to present any problems. It is, however, a lifelong condition requiring treatment with a therapy of considerable health and social impact (insulin injections) so it is important that the diagnosis is secure. Considerations also arise over differentiating the types of diabetes.</p>
<p>The group endorsed the commentary discussed above, and concluded that simple recommendations were all that were required. Although in this condition diagnosis of diabetes is rarely in doubt, errors do arise in attribution of diabetes type on occasions, and this is known to result in negative consequences including failure to anticipate ketoacidosis or unnecessary insulin therapy. Accordingly the group felt that cautionary recommendations were in order. The group noted that formal evidence of the utility of tests to distinguish type of diabetes by auto-immune markers or measures of islet B-cell function was not positive, and that these tests were not routinely performed. The group were keen to reiterate the importance of laboratory glucose estimation in line with WHO recommendations to avoid the very rare misdiagnoses with lifelong consequences. The25 role of symptoms and of HbA1c estimation were seen as useful but only supportive, as both lack absolute specificity.</p>
<p>Confirming diabetes Diabetes should be confirmed by a single diagnostic laboratory glucose measurement in the presence of classical symptoms, or by a further laboratory glucose measurement. The diagnosis may be supported by a raised HbA1c </p>
<h3 id=\"evidence-statement-cg15adultes1\">Evidence Statement CG15AdultES1</h3>
<p>Diagnosis, in regard of types of diabetes, is generally not addressed by the WHO report.8 That report notes that children present with severe symptoms, and that diagnosis is simply confirmed by blood glucose measurement (advice that may be regarded as dated)</p>
<p><span class=\"citation\" data-cites=\"Alberti_1998\">(K. Alberti and Zimmet 1998)</span></p>
<h3 id=\"evidence-statement-cg16adultes2\">Evidence Statement CG16AdultES2</h3>
<p>WHO otherwise concentrates mainly on the situation pertaining to Type 2 diabetes, in doing so noting (by reference to the 1985 report) the lack of need for challenge testing when plasma glucose levels are high in the absence of other metabolic stress, and are confirmed by a second laboratory measurement or classic symptoms.</p>
<h2 id=\"topic-cg15adults2\">Topic CG15AdultS2</h2>
<p>The management of diabetes is multidimensional, and each dimension is multifaceted. Notable dimensions include diagnosis and associated management, preventative long-term care, hospital and emergency management, and detection and management of late-developing complications. With each of these dimensions a number of care areas are found (for example in long-term prevention, glucose control, blood pressure control, risk factor surveillance, blood lipid control and smoking), and for each care area a number of deliverables addressed (for example in blood glucose control: knowledge and basis of targets, injection skills, selfmonitoring, dose adjustment, dietary matching, hypoglycaemia management, sick day management) by a number of different members of a multidisciplinary team. This multidimensional care delivery requirement has spawned diverse attempts aimed at ensuring optimal care is available to all those with diabetes. This section of the guideline seeks to examine what evidence is available to support some of these approaches.</p>
<p>The group endorsed the approaches suggested by the evidence, but noted that attempts to implement some of the recommendations in the past had been inhibited by funding difficulties.This however was not felt to be a barrier to reiterating the health gains to be obtained. It was noted that recent publications (beyond the cut-off date of the searches) supported some of the recommendations further, including those relating to specialist nurses. The UKs national service framework for diabetes was noted to have endorsed diabetes registers. The group recognised the lack of any kind of formal evidence relating to walk-in, telephone-request and out-of-hours services.</p>
<p>Multidisciplinary teams provide advice Advice to adults with Type 1 diabetes should be provided by a range of professionals with skills in diabetes care working together in a coordinated approach. A common environment (diabetes centre) is an important resource in allowing a diabetes multidisciplinary team to work and communicate efficiently while providing consistent advice. </p>
<h3 id=\"evidence-statement-cg15adultes10\">Evidence Statement CG15AdultES10</h3>
<p>Most papers in this area are descriptive, and there is inevitable overlap with deployment of multidisciplinary teams and provision of diabetes information and foot care. Using historical controls a study37 suggests improved blood glucose control, while another non-randomised study suggests improved survival (presumably mainly in people with Type 2 diabetes)</p>
<p><span class=\"citation\" data-cites=\"Day_1992\">(Day, Metcalfe, and Johnson 1992)</span></p>
<h3 id=\"evidence-statement-cg15adultes11\">Evidence Statement CG15AdultES11</h3>
<p>Although papers were ascertained addressing these areas,3844 the papers were descriptive with no useful analysis of patient-related outcomes</p>
<p><span class=\"citation\" data-cites=\"Bridgford_2001\">(Bridgford and Davis 2001)</span></p>
<p><span class=\"citation\" data-cites=\"Davis_2001\">(T. M. Davis and Bridgford 2001)</span></p>
<p><span class=\"citation\" data-cites=\"Engelbrecht_1994\">(R. Engelbrecht et al. 1994)</span></p>
<p><span class=\"citation\" data-cites=\"Engelbrecht_1996\">(R. Engelbrecht et al. 1996)</span></p>
<p><span class=\"citation\" data-cites=\"Engelbrecht_1996\">(R. Engelbrecht et al. 1996)</span></p>
<p><span class=\"citation\" data-cites=\"Engelbrecht_2006\">(Rolf Engelbrecht, Ingenerf, and Reiner 2006)</span></p>
<p><span class=\"citation\" data-cites=\"Gupta_2014\">(Gupta, Singla, and Kalra 2014)</span></p>
<h3 id=\"evidence-statement-cg15adultes12\">Evidence Statement CG15AdultES12</h3>
<p>A number of descriptive papers were identified,4548 suggesting such approaches can be feasible and have utility, but not demonstrating comparative advantage to traditional approaches</p>
<p><span class=\"citation\" data-cites=\"Chiarelli_1998\">(Chiarelli et al. 1998)</span></p>
<p><span class=\"citation\" data-cites=\"Gorman_1996\">(C. Gorman et al. 1996)</span></p>
<p><span class=\"citation\" data-cites=\"Kucher_1990\">(Kucher et al. 1990)</span></p>
<p><span class=\"citation\" data-cites=\"Smith_1998\">(S. A. Smith et al. 1998)</span></p>
<h3 id=\"evidence-statement-cg15adultes13\">Evidence Statement CG15AdultES13</h3>
<p>However when such records were used to send judgemental letters to people with diabetes,49 randomising sites of care, intermediate outcomes were significantly improved (probably mainly in people with Type 2 diabetes)</p>
<p><span class=\"citation\" data-cites=\"Chaudhry_2007\">(Chaudhry et al. 2007)</span></p>
<h3 id=\"evidence-statement-cg15adultes14\">Evidence Statement CG15AdultES14</h3>
<p>A number of approaches to medical care without direct patient contact are described in the literature. One RCT of a telecare system for insulin50 provided equivalent control at reduced cost, while another study12 using nurses resulted in improved blood glucose control</p>
<p><span class=\"citation\" data-cites=\"EVANS_2000\">(EVANS 2000)</span></p>
<p><span class=\"citation\" data-cites=\"Biermann_2002\">(Biermann et al. 2002)</span></p>
<h3 id=\"evidence-statement-cg15adultes15\">Evidence Statement CG15AdultES15</h3>
<p>In more rural and remote situations telemedicine can similarly provide apparent time and cost savings where images of foot problems51 and eye photographs52 need to be reviewed by specialists</p>
<p><span class=\"citation\" data-cites=\"McGill_2000\">(McGill, Constantino, and Yue 2000)</span></p>
<p><span class=\"citation\" data-cites=\"Cummings_2001\">(Cummings et al. 2001)</span></p>
<h3 id=\"evidence-statement-cg15adultes16\">Evidence Statement CG15AdultES16</h3>
<p>Three papers using historical controls or randomised controls address the value of multidisciplinary teams with a specialist interest in diabetes management in the care of inpatients on non-diabetes wards.5355 Reduced length of inpatient stay is consistently reported. One study suggests improved glucose control.55 One study, also using historical controls, addresses length of stay in a developing country in newly-diagnosed people with diabetes, showing much reduced stays with multidisciplinary team input</p>
<p><span class=\"citation\" data-cites=\"Levetan_1995\">(Levetan et al. 1995)</span></p>
<p><span class=\"citation\" data-cites=\"Levetan_1995\">(Levetan et al. 1995)</span></p>
<p><span class=\"citation\" data-cites=\"Koproski_1997\">(Koproski, Pretto, and Poretsky 1997)</span></p>
<h3 id=\"evidence-statement-cg15adultes17\">Evidence Statement CG15AdultES17</h3>
<p>No literature on the deployment or impact of diabetes guidelines was identified.</p>
<h3 id=\"evidence-statement-cg15adultes18\">Evidence Statement CG15AdultES18</h3>
<p>Two potentially useful papers consider the type of treatment facility used to deliver care to those with Type 1 diabetes.334,335 One German study334 found that the treatment facility (polyclinics, specialist clinics or general practitioners) makes no difference to diabetes-specific knowledge when this was controlled for age, sex and education. One UK study335 found no difference between hospital- and general practice-based care on a range of outcome measures for metabolic control, satisfaction with treatment or beliefs about diabetic control for a mixed diabetic population. Some differences were observed in the surveillance for complications, with more frequent testing in integrated care. Whilst costly, it is worth noting that fewer patients defaulted from general practice-based care than conventional care. Avoided complications may offset the increased cost of general practice-based care, although this cannot be established on the basis of this study. One UK-based study297 suggested that the provision of a hospital-based diabetes specialist nurse lowered the cost per patient admission without producing a significant difference in readmission, quality of life or patient satisfaction.</p>
<p><span class=\"citation\" data-cites=\"Rose_2000\">(Rose et al. 2000)</span></p>
<p>[@1994]</p>
<p><span class=\"citation\" data-cites=\"Davies_2001\">(M. Davies et al. 2001)</span></p>
<h3 id=\"evidence-statement-cg15adultes4\">Evidence Statement CG15AdultES4</h3>
<p>A nurse specialist approach has been justified by a number of before-and-after studies and case series with such input1317</p>
<p><span class=\"citation\" data-cites=\"Hearnshaw_2001\">(Hearnshaw et al. 2001)</span></p>
<p><span class=\"citation\" data-cites=\"Batista_2010\">(Batista et al. 2010)</span></p>
<p><span class=\"citation\" data-cites=\"Larsson_1995\">(Larsson et al. 1995)</span></p>
<p><span class=\"citation\" data-cites=\"Brink\">(Brink, Miller, and Moltz)</span></p>
<p><span class=\"citation\" data-cites=\"Yokoyama_2001\">(Yokoyama et al. 2001)</span></p>
<h3 id=\"evidence-statement-cg15adultes5\">Evidence Statement CG15AdultES5</h3>
<p>A number of studies of variable quality address the impact of inclusion of podiatrists compared to normal care within what is then usually called a diabetes foot care team. These studies included one RCT showing more patient knowledge and less callosities at one year, and a controlled study18 (it is unclear whether that study is randomised) showing less foot ulceration</p>
<p><span class=\"citation\" data-cites=\"Dargis_1999\">(Dargis et al. 1999)</span></p>
<h3 id=\"evidence-statement-cg15adultes6\">Evidence Statement CG15AdultES6</h3>
<p>A number of historically-controlled or descriptive studies support this approach, mainly reporting on patient preference outcomes15,1921</p>
<p><span class=\"citation\" data-cites=\"Larsson_1995\">(Larsson et al. 1995)</span></p>
<p><span class=\"citation\" data-cites=\"Cox_1995\">(D. Cox et al. 1995)</span></p>
<p><span class=\"citation\" data-cites=\"APELQVIST_1994\">(APELQVIST et al. 1994)</span></p>
<p><span class=\"citation\" data-cites=\"Frykberg_1997\">(Frykberg 1997)</span></p>
<h3 id=\"evidence-statement-cg15adultes7\">Evidence Statement CG15AdultES7</h3>
<p>No RCTs address the concept of integrated annual review. Newly-implemented structured annual review has been subject to a descriptive review,22 suggesting improved satisfaction with care and improved patient motivation. Few full-length descriptions of the review process are available,23 most references being editorials and letters</p>
<p><span class=\"citation\" data-cites=\"Riazi_2000\">(Riazi et al. 2000)</span></p>
<p>[@1992]</p>
<h3 id=\"evidence-statement-cg15adultes8\">Evidence Statement CG15AdultES8</h3>
<p>The current guideline suggests annual surveillance of a number of potentially developing late complications (as do all other guidelines for the most complications). The International Diabetes Federations European guideline recommends integration of these activities into one patient visit.24 Annual review is also the basis of many quality control structures proposed for diabetes care,25 including (implicitly) that of the UK Audit Commission</p>
<p>[@1998]</p>
<p><span class=\"citation\" data-cites=\"Grabert_2002\">(Grabert, Schweiggert, and Holl 2002)</span></p>
<h3 id=\"evidence-statement-cg15adultes9\">Evidence Statement CG15AdultES9</h3>
<p>A series of descriptive papers appear to demonstrate the feasibility of establishing populationbased and clinic-based diabetes registers, with varying densities of information.2636 A system of database-driven recall for complications surveillance is implicit in the recommendations for annual complications surveillance of this and published guidelines. Issues of data security and confidentiality are not reported to have proved to be problematic obstructions to the deployment of diabetes registers</p>
<p><span class=\"citation\" data-cites=\"Azzopardi_1995\">(Azzopardi et al. 1995)</span></p>
<p><span class=\"citation\" data-cites=\"Burnett_1992\">(S. D. Burnett, Woolf, and Yudkin 1992)</span></p>
<p><span class=\"citation\" data-cites=\"Burnett_1993\">(Shirley D. Burnett, Press, and Yudkin 1993)</span></p>
<p><span class=\"citation\" data-cites=\"Unkown_date\">(<span class=\"citeproc-not-found\" data-reference-id=\"Unkown_date\"><strong>???</strong></span>)</span></p>
<p><span class=\"citation\" data-cites=\"Comino_2013\">(Comino et al. 2013)</span></p>
<p><span class=\"citation\" data-cites=\"Howitt_1993\">(Howitt and Cheales 1993)</span></p>
<p><span class=\"citation\" data-cites=\"Kelly_1998\">(Kelly, Bilous, and Murray 1998)</span></p>
<p><span class=\"citation\" data-cites=\"Taylor_2010\">(R. W. Taylor et al. 2010)</span></p>
<p><span class=\"citation\" data-cites=\"Edelman_2001\">(D. Edelman 2001)</span></p>
<p><span class=\"citation\" data-cites=\"Kopelman_1995\">(Kopelman, Michell, and Sanderson 1995)</span></p>
<p><span class=\"citation\" data-cites=\"Vaughan_1996\">(Vaughan et al. 1996)</span></p>
<h3 id=\"evidence-statement-cg17adultes3\">Evidence Statement CG17AdultES3</h3>
<p>The Diabetes Control and Complications Trial (DCCT),9 and smaller RCTs using improved management to judge the effect on patient outcomes, used multidisciplinary team input (in particular from specialist nurses and dietitians) as part of an integrated package to improve metabolic intermediate outcomes. A Cochrane review10 of diabetes specialist nurse input identified six heterogeneous studies unsuitable for meta-analysis, and found little evidence of longer-term impact on intermediate outcomes. An RCT11 of the impact of structured team care as compared to usual care showed improved satisfaction and blood glucose control at six months. An RCT12 of the use of diabetes specialist nurses to adjust insulin doses over the telephone showed improved blood glucose control.</p>
<h2 id=\"topic-cg15adults3\">Topic CG15AdultS3</h2>
<p>As having Type 1 diabetes can have a major impact on lifestyle and self-esteem, it would appear that support groups could have a role in providing for some needs outside the professional environment and even separately from immediate carers. The range of such potential input is large and might stretch from simply fulfilling a need for belonging, through to helping with diabetes-related financial problems (such as insurance), and even providing a further source of diabetes-related information. Coping with diabetes, or any other condition, is influenced not only by psychological characteristics of the individual but also by social relationships (eg support and communication byhealthcare team, family and friends). Informal interpersonal variables, such as social resources and support, have been found to be associated with better diabetes self-management,56 7 family environment,58 60 and marital interaction.61 A medical condition is only one aspect that affects the make-up of an individual s personal identity, and for some may be perceived as a minor factor compared to their environmental and social circumstances. A support group is defined in this guideline as a group of people with Type 1 diabetes that comes together to provide support to themselves and others in their locality. Members are usually unpaid and many will be supported under the auspices of national (or local) voluntary organisations. Support groups have become commonplace throughout health and social care. Patients and carers may choose to contact or be involved with support groups to gain information and support to benefit their own needs, or with a wider altruistic aim of helping other people within the local community. It was not possible to find specific research identifying patient and carer preferences for support groups, or indeed to identify specific groups or types of people who may benefit more than others. Some people attend meetings of groups regularly whilst other individuals are reassured by being aware of a group s existence and the opportunity to contact the group at a later date if problems arise and/or support is required. Preferences are dependent on what stage people are at in their lives and what information is taken (or needs to be taken) on board.</p>
<ul>
<li></li>
</ul>
<p>Support groups At the time of diagnosis and periodically thereafter, adults with Type 1 diabetes should be offered up-to-date information on the existence of and means of contacting diabetes support groups (local and national) and the benefits of membership. </p>
<h3 id=\"evidence-statement-cg15adultes19\">Evidence Statement CG15AdultES19</h3>
<p>The Diabetes Attitudes, Wishes and Needs (DAWN) questionnaire study 62 highlighted that emotional support, along with family support, was a key factor in how well people with diabetes manage their condition, with support networks being considered at least as important as the medication they take in helping them manage their diabetes. Interim results also indicate that people who do not have access to a community of support, especially the young or elderly living alone, may be less likely to be concordant with their medication regimes, putting them at risk of inadequate control of their diabetes</p>
<p>[@2002]</p>
<h3 id=\"evidence-statement-cg15adultes20\">Evidence Statement CG15AdultES20</h3>
<p>There are still significant numbers of people emerging from the confirmation of a diagnosis who are underinformed and unsupported. 63 Qualitative research of various designs examining the views and experiences of people with diabetes and carers has identified that many perceived benefits exist from meeting other people with diabetes. It has helped many to overcome the feelings of isolation and is seen as an opportunity to talk to others going through the same experience 64</p>
<p>[@2008]</p>
<p><span class=\"citation\" data-cites=\"Greenwood_2003\">(Greenwood 2003)</span></p>
<h3 id=\"evidence-statement-cg15adultes21\">Evidence Statement CG15AdultES21</h3>
<p>R esearch evaluating the effectiveness of support groups for patients and carers, across n umerous conditions and groups (not necessarily diabetes), has shown specific benefits including:</p>
<ul>
<li><p>psychological and emotional benefits 65 including lower pain perception and improved ability to cope with stress 63,667</p></li>
<li><p>reduction of carers burdens and stresses 689</p></li>
<li><p>improvement in quality of life 7071</p></li>
<li><p>improved self-care through health promotion strategies which have been helpful in smoking cessation and management of chronic conditions 723</p></li>
<li><p>improved access to health service provision 74</p></li>
<li><p>reduced isolation, overcoming depression and loss of self-esteem 64</p></li>
<li><p>better understanding of conditions, symptoms and healthcare systems through education and information. 67</p></li>
</ul>
<p><span class=\"citation\" data-cites=\"Jessup_2001\">(Jessup 2001)</span></p>
<p><span class=\"citation\" data-cites=\"Knight_1993\">(Knight, Lutzky, and Macofsky-Urban 1993)</span></p>
<p><span class=\"citation\" data-cites=\"Toseland_1992\">(R. W. Toseland et al. 1992)</span></p>
<p><span class=\"citation\" data-cites=\"Labrecque_1992\">(M. S. Labrecque, Peak, and Toseland 1992)</span></p>
<p><span class=\"citation\" data-cites=\"Ostwald_1999\">(Ostwald et al. 1999)</span></p>
<p><span class=\"citation\" data-cites=\"Hanestad_1993\">(Hanestad and Albrektsen 1993)</span></p>
<p><span class=\"citation\" data-cites=\"Maxwell_1992\">(Maxwell, Hunt, and Bush 1992)</span></p>
<p><span class=\"citation\" data-cites=\"Fisher_1998\">(Fisher et al. 1998)</span></p>
<p><span class=\"citation\" data-cites=\"Morris_1998\">(Morris 1998)</span></p>
<p><span class=\"citation\" data-cites=\"Tomlinson_1992\">(Tomlinson 1992)</span></p>
<h3 id=\"evidence-statement-cg15adultes22\">Evidence Statement CG15AdultES22</h3>
<p>The Diabetes UK network of support groups recorded 175,426 members in July 2003, with around 7% under the age of 20 years and around 30% aged 70 years or over. Around 40% had paid for annual adult membership, 50% had a reduced rate membership (including children), and 10% had chosen life membership. The Diabetes UK Careline is, at the time of writing, one of the busiest sources of information for all people with Type 1 diabetes in the UK. In 2002, Careline were contacted 40,747 times (81% telephone, 13% e-mail, 6% post). The five most frequent topics of enquiry recorded were: 67a</p>
<ul>
<li><p>diet</p></li>
<li><p>insulin</p></li>
<li><p>medicines other than insulin</p></li>
<li><p>new diagnosis</p></li>
<li><p>travel.</p></li>
</ul>
<h2 id=\"topic-cg15adults5\">Topic CG15AdultS5</h2>
<p>Having diabetes involves acquiring a great range of new skills and knowledge, including insulin therapy, dietary changes, self-monitoring, hypoglycaemia, jobs, travel, physical exercise, coping w ith concurrent illness, foot care, arterial risk control and avoiding complications. The history of education and information giving in diabetes care goes back to the earliest dietary interventions several centuries ago, and the use of education professionals to impart skills associated with insulin therapy dates from the time of discovery and isolation of insulin. Ac co r dingly patient education is a true corner stone that enables self-management of diabetes, and most diabetes management is self-management. Review of other parts of this NICE guideline will reveal that education and information giving are parts of nearly all of them, from enabling patient choice in determining features of self-management, to acquisition of skills needed to perform tasks and make judgements, to self-care where high risk complications have developed, and to skills in handling healthcare professionals to ensure that issues of importance to the person with Type 1 diabetes are addressed.</p>
<p>The group noted that patient education was a necessary and logical part of most aspects of diabetes self-care, and that self-care was a social, health and economic necessity in the manage- ment of the condition. Specific recommendations related to aspects of care such as self- monitoring, insulin therapy, foot care and nutrition were thought best presented in the individual sections of this guideline. The group noted inap propriateness of the classical clinical trial model when just one feature of an integrated pac kage was varied, and one of many possible outputs monitored as primary outcome. There is also the difficulty of, and lack of funding for, the larger, longer-term trials used for pharmaceutical interventions. Equally, the central role of education in achieving success in blood glucose control and health outcomes (DCCT and other key studies) c ould not be ignored. Such information suggested that educational interventions were likely to be c ost-effective, but it was impossible to make compar ative judgements of different education models, a conclusion seemingly also reached by the NICE Appraisal Committee on the basis of a re port from the University of Southamptons health technology assessment unit. Is sues of information overload at the stressful time of diagnosis, the size of the longer-term educational needs of individuals, the diversity of individual needs, and the retention of the information needed to make informed choices, and the groups experience of these in practice, served to guide recommendations broadly in line with those of Diabetes UK and the International Diabetes Federation (Europe).</p>
<p>Structured diabetes education A programme of structured diabetes education covering all major aspects of diabetes self-care and the reasons for it should be made available to all adults with Type 1 diabetes in the months after diagnosis, and periodically thereafter according to agreed need following yearly assessment. </p>
<h3 id=\"evidence-statement-cg15adultes23\">Evidence Statement CG15AdultES23</h3>
<p>There were no trials located in newly-diagnosed people with Type 1 diabetes specifically, or co ncerned with the initial content of educatio n. The American Diabetes Association (ADA) guidelines 76 suggest that as part of initial visit people should be referred to a diabetes educator if education is not provided by the physician or practice staff, but content of this education is not defined</p>
<p>[@2003]</p>
<h3 id=\"evidence-statement-cg15adultes24\">Evidence Statement CG15AdultES24</h3>
<p>One small randomised controlled trial 77 co mparing the efficacy of classroom teaching of diabetes skills, compared to individualised learning, found that classroom teaching led to a gr eater level of awareness about diabetes self-care. However, there was no significant difference in terms of the level of use of self-care practices. Furthermore, the two education techniques provided no different outcome of levels of technical skill in self-care. However this study made no analysis of comparability of study groups at baseline and was not blinded</p>
<p><span class=\"citation\" data-cites=\"Street_1993\">(Street et al. 1993)</span></p>
<h3 id=\"evidence-statement-cg15adultes25\">Evidence Statement CG15AdultES25</h3>
<p>One randomised controlled study compared two interactive computer schemes to reinforce an educational video. The first gave additional f eedback and information on the correct answers, the second only the correct answers. 78 Pe ople with diabetes in the interactive group scored significantly better in a follow-up test of diabetes knowledge than those following the standard scheme. There were no significant differences in use r ratings for the two software packages, but the people in the additional feedback group had a better diabetes knowledge at baseline, so the re sults may be biased by this confounding factor</p>
<p><span class=\"citation\" data-cites=\"RICCOMINI_2002\">(RICCOMINI 2002)</span></p>
<h3 id=\"evidence-statement-cg15adultes26\">Evidence Statement CG15AdultES26</h3>
<p>An update of the US standards for diabetes self-management education79 based on a literature review covered the organisation of diabetes self-management education, its content and provision. A multiprofessional task force encompassing all the major interested stakeholders agreed the following standards.</p>
<ul>
<li><p>Education and information-giving will involve the interaction of the individual with diabetes with a multifaceted education instructional team, which may include a behaviourist, exercise physiologist, ophthalmologist, optometrist, pharmacist, physician,podiatrist, registered dietitian, registered nurse, other healthcare professionals, and paraprofessionals.</p></li>
<li><p>Instructors will obtain regular continuing education in the areas of diabetes management,behavioural interventions, teaching and learning skills and counselling skills.</p></li>
<li><p>Assessed needs of the individual will determine which of the following content areas are delivered: describing the diabetes disease process and treatment options incorporating appropriate nutritional management incorporating physical activity into lifestyle utilising medications (if applicable) for therapeutic effectiveness monitoring blood glucose and urine ketones (where appropriate) and using results to improve control preventing, detecting and treating acute complications preventing (through risk reduction behaviour), detecting and treating chroniccomplications goal-setting to promote health, and problem-solving for daily living integrating psychosocial adjustment to daily life promoting preconception care, management during pregnancy and gestational diabetes management (if applicable).</p></li>
<li><p>An individualised assessment, development of an education plan and periodic reassessment between participant and instructor will direct the selection of appropriate educational materials and interventions.</p></li>
<li><p>The assessment includes relevant medical history, cultural influences, health beliefs and attitudes, diabetes knowledge, self-management skills and behaviours, readiness to learn,cognitive ability, physical limitations, family support and financial status.</p></li>
<li><p>There shall be documentation of the individuals assessment, education plan,intervention, evaluation and follow-up in the permanent confidential education record.</p></li>
</ul>
<p><span class=\"citation\" data-cites=\"Mensing_2000\">(Mensing et al. 2000)</span></p>
<h3 id=\"evidence-statement-cg15adultes27\">Evidence Statement CG15AdultES27</h3>
<p>Within an overall review of patient education models for diabetes (not type-specific) one health technology assessment80 reviewing four controlled trials of a range of education programmes including items of self-management, self-monitoring, diet and the effects of insulin and exercise, taught by a variety of staff or self-taught, and as an initial intense course or as ongoing programmes, reported a variety of positive outcomes compared to normal care. This review found that one study had demonstrated improvements over 10 years in diabetic control, in ter ms of reduced HbA 1c levels. In another study, an intensive five-day training course was found to be effective in reducing HbA 1c levels. In one study there was no difference in blood gl ucose control with education compared to usual care, while there were no between-group co mparisons made in another other study. Education was also shown to improve blood pressure. There is limited evidence to suggest a reduced rate of ketoacidosis and reduced hospitalisation. However, there was no evidence to indicate that education can reduce body mass index. There is some data to suggest increased incidence of hypoglycaemic episodes. Long-term outcomes of retinopathy or neuro pathy were not found to be significantly affected by education, but there is some limited evidence to suggest nephropathy incidence is improved, although rates were low. Unsurprisingly, diabetes knowledge was significantly improved with education, although this was not true of quality of life. Overall the included trials were of moderate methodological rigour. Three of the trials included were investigating education in the context of intensification of treatment compared to normal care, and it is difficult to be sure that the benefits reported are directl y attributable to the education aspect of the intervention.</p>
<h3 id=\"evidence-statement-cg15adultes28\">Evidence Statement CG15AdultES28</h3>
<p>Metabolic control and quality of life were not found to be significantly affected by a structured outpatient programme of education led by a nurse, dietitian and other people with diabetes over four weeks in a large randomised trial as compared to conventional care81</p>
<p><span class=\"citation\" data-cites=\"Weerdt_1991\">(I. Weerdt et al. 1991)</span></p>
<h3 id=\"evidence-statement-cg15adultes29\">Evidence Statement CG15AdultES29</h3>
<p>A medium-sized randomised controlled trial 82 of a monthly education programme at which different aspects of diabetes treatment and technical skills were considered found that after one year of education HbA 1c levels were reduced compared with normal clinical care in people w ith Type 1 diabetes. However, age differences between the control and intervention groups at baseline mean that this study is possibly methodologically limited</p>
<p><span class=\"citation\" data-cites=\"Lennon_1990\">(Lennon et al. 1990)</span></p>
<h3 id=\"evidence-statement-cg15adultes30\">Evidence Statement CG15AdultES30</h3>
<p>A nother moderate-sized systematic review of eight trials encompassing over 3,000 patients with either Type 1 or Type 2 diabetes, 83 found that intensive vs brief education on foot care provided a significant decrease in incidence of foot ulcers, and in one trial amputations, but no difference in the same outcomes over seven years in another study. This is despite three trials reporting successful uptake of messages regarding foot care behaviour. Another trial reported in this re vi ew found that an intensive educational inter ve ntion including both people with diabetes and doctors improved the prevalence of serious foot lesions compared to usual care, although the composite outcome of all foot lesions and amputations was not significantly improved. Au thors of the review noted methodological limitations of the included studies, and outcome re porting times varied between individual trials</p>
<p><span class=\"citation\" data-cites=\"Valk_2002\">(Valk, Kriegsman, and Assendelft 2002)</span></p>
<h3 id=\"evidence-statement-cg15adultes31\">Evidence Statement CG15AdultES31</h3>
<p>Ev aluation, in a large systematic review, 84 of a range of diabetes self-management education (DSME) programmes compared to normal routine levels in populations of people with diabetes found that interventions based in community gathering places were able to reduce blood glycated haemoglobin (GHb) and fasting blood glucose levels. There is some evidence that they can also improve diabetes knowledge and improve physical activity (minutes of walking). Other trials reviewed that were based in the home setting half of which included c hildren or adolescents showed a significant decrease in GHb after DSME, and a borderline 6 Education programmes and self-care beneficial effect on weight for people undergoing DSME as compared to conventional care. Specific analysis in patients with Type 1 diabetes found no significant change in diabetes knowledge with such programmes</p>
<p><span class=\"citation\" data-cites=\"NORRIS_2002\">(NORRIS et al. 2002)</span></p>
<h3 id=\"evidence-statement-cg15adultes32\">Evidence Statement CG15AdultES32</h3>
<p>A small randomised controlled trial 12 in people with Type 1 diabetes found that an intervention wh ereby patients received regular telephone contact with a diabetes nurse to alter insulin re g imen decreased HbA 1c ov er six months compared to usual care. This difference was not found to be affected by age, sex or type of diabetes</p>
<p><span class=\"citation\" data-cites=\"EVANS_2000\">(EVANS 2000)</span></p>
<h3 id=\"evidence-statement-cg15adultes33\">Evidence Statement CG15AdultES33</h3>
<p>There are no systematic reviews and few prospective randomised studies that report on methods to improve concordance in self-management in people with Type 1 diabetes. One small unblinded study, 85 w hich was methodologically limited owing to high drop-out rates and inequalities in patient characteristics at baseline, found that an intervention of a self-taught study programme to improve self-control behaviour was able to demonstrate improved adherence to goals of self-monitoring of blood glucose level over 12 weeks. The intervention included a wide range of educational and behavioural choice items, and the relative effectiveness of any of these is hard to define. The methodological limitations of the study w ould not form a rigorous basis for recommending such an approach</p>
<p><span class=\"citation\" data-cites=\"Jones_1990\">(P. M. Jones 1990)</span></p>
<h3 id=\"evidence-statement-cg15adultes34\">Evidence Statement CG15AdultES34</h3>
<p>A similar intervention among adolescents (mean age 18 years) in India enrolled in a prospective r andomised trial, 86 w ith an intervention of 15 hours of individualised learning over three months comprising both behavioural and cognitive strategies based on an operant learning model, found improved adherence on a composite three-item scale, compared to usual care. This improved adherence was mirrored in significantly improved blood glucose level compared to pe ople in the control group. However, this study had a small sample size and was unblinded, and it was not possible to determine whether benefits persist after the cessation of the intervention</p>
<p><span class=\"citation\" data-cites=\"Sudhir_2003\">(Sudhir, Kumaraiah, and Munichoodappa 2003)</span></p>
<h3 id=\"evidence-statement-cg15adultes35\">Evidence Statement CG15AdultES35</h3>
<p>One small- to medium-sized randomised trial of a specialist education programme delivered to people with Type 1 diabetes by a team of physicians, dietitians and specialist nurses found there to be no statistically significant differences in diabetes knowledge or adherence to dietary advice co mpared to a control group who received conventional diabetes education. Both groups improved in both measures immediately after the completion of the education intervention but then knowledge and adherence fell away with time. This trial was sited in Finland and there may be differences in content of conventional diabetes education compared to that of the UK care setting 87</p>
<p><span class=\"citation\" data-cites=\"Korhonen_1983\">(Korhonen et al. 1983)</span></p>
<h3 id=\"evidence-statement-cg15adultes36\">Evidence Statement CG15AdultES36</h3>
<p>There were no significant differences in adherence to glucose self-monitoring or in blood gl ucose levels reported at six months between two interventions with novel glucose monitoring devices and control with a standard device from a medium-sized multicentre randomised Type 1 diabetes in adults: national clinical guideline for diagnosis and management tr ial. 88 The trial included a population of people with Type 1 diabetes who had had the co ndition for an average of 14 years. The study was blinded between the two novel monitoring machines, but the people in the control group would have been aware that they were not re ce iv ing the intervention as they continued to use their usual machine. To evaluate adherence all patients were asked to keep diaries of self-monitoring behaviour and this may have stimulated greater adherence even in the control group than under normal everyday self- monitoring conditions</p>
<p><span class=\"citation\" data-cites=\"Davis_2007\">(W. A. Davis, Bruce, and Davis 2007)</span></p>
<h3 id=\"evidence-statement-cg15adultes37\">Evidence Statement CG15AdultES37</h3>
<p>A ssessing the cost-effectiveness of patient education is complicated by the fact that patient education is rarely assessed in isolation. Recent NICE guidance 338 into patient education models considered the health economic evidence for interventions in terms of self-care, quality of life and the long-term complications of diabetes. Interventions improving knowledge of diabetes were excluded from consideration, as improved knowledge of diabetes does not necessarily affect subsequent outcomes. The NICE appraisal found only two published health economic papers suitable for assessing patient education. 339,340 Of these, only one 339 included Type 1 diabetes patients, and this established cost-effectiveness ratios for altering food habits.</p>
<p><span class=\"citation\" data-cites=\"Bryant_2007\">(Bryant et al. 2007)</span></p>
<p><span class=\"citation\" data-cites=\"Glasgow_1997\">(Glasgow et al. 1997)</span></p>
<p><span class=\"citation\" data-cites=\"Kaplan_1987\">(R. M. Kaplan et al. 1987)</span></p>
<h2 id=\"topic-cg15adults6\">Topic CG15AdultS6</h2>
<p>In sulin therapy has to be adjusted with lifesty le, insulin dose requirements vary from individual to individual, and the effects of insulin injections are notoriously erratic. It might seem obvious that being able to keep an hour-to-hour or day-to-day check on actual blood glucose levels w ould be to the advantage of any person using insulin therapy. Potential should exist here to assist with diabetes self-education, dose optimisat ion, reassurance over hypoglycaemia and helping professionals give optimum advice on insulin regimens.</p>
<p>Self-monitoring does not, in itself, appear to improve blood glucose control. However, the gr oup noted that it was an essential component of the markedly improved blood glucose control with improved outcomes demonstrated in the landmark DCCT study, and indeed in the other smaller studies of blood glucose control and complications. Indeed it was difficult for members of the group to conceive how modern flexible insulin dosage regimens could be adopted without it. However, the technique is not easy, painless or convenient, and as a result no one system is found appropriate for use by all individuals. Improved technical facility could be identified from clinical experience. Nevertheless appropriate training and quality of skills re vi ew is agreed as necessary and normal practice. Different individuals are noted to use this te c hnology with different frequencies and for different needs according to personal preferences. Given the nature of the technology it is rarely abused. A newer approach, using smaller blood samples from non-finger-prick sites, was not judged to have adequate evidence of reliability, particularly in the situation of hypoglycaemia, to allow a general recommendation.</p>
<p>Self-monitoring of blood glucose levels Self-monitoring of blood glucose levels should be used as part of an integrated package that includes appropriate insulin regimens and education to help choice and achievement of optimal diabetes outcomes. </p>
<h3 id=\"evidence-statement-cg15adultes38\">Evidence Statement CG15AdultES38</h3>
<p>Pa pe rs contained within a systematic review 89 suggest that the evidence on issues of observer tr aining, interdevice variability, the effects of long-term use and patient acceptability have not been adequately addressed</p>
<p><span class=\"citation\" data-cites=\"Coster_2000\">(Coster et al. 2000)</span></p>
<h3 id=\"evidence-statement-cg15adultes39\">Evidence Statement CG15AdultES39</h3>
<p>One study within the systematic review 89 co mparing self-reported readings against a memory meter showed that inaccuracies in readings were common. This was due to rounding of values, omission of outlying values and reporting of re sults when no test had been performed. These findings were confirmed in another reviewed study of 14 people who recorded lower blood gl ucose values in logbook records than meter memories</p>
<p><span class=\"citation\" data-cites=\"Coster_2000\">(Coster et al. 2000)</span></p>
<h3 id=\"evidence-statement-cg15adultes40\">Evidence Statement CG15AdultES40</h3>
<p>Reported within the systematic review, one trial 89 suggested that patients needed to be informed of the memory capacity of their meters to improve accuracy. A further study reported in the review argued that the true diurnal variability in glycaemia in people with Type 1 diabetes is too great to be measured, even when self-monitoring of blood glucose (SMBG) is repeated seven times daily</p>
<p><span class=\"citation\" data-cites=\"Coster_2000\">(Coster et al. 2000)</span></p>
<h3 id=\"evidence-statement-cg15adultes41\">Evidence Statement CG15AdultES41</h3>
<p>Pa tient factors (as described below) were shown to have an impact (both positive and negative) on the reliability of monitoring in five studies. 89 Re liability can be improved through proper training of patients, and was shown in sub-group analysis to be equally as good in older pe ople, and people with visual impairments (on co ndition that extensive instruction has been provided). One study concluded that impairment of colour vision affects the ability to interpret self-monitoring with visually read strips, suggesting that all patients should be screened for colour vision before self-monitoring begins</p>
<p><span class=\"citation\" data-cites=\"Coster_2000\">(Coster et al. 2000)</span></p>
<h3 id=\"evidence-statement-cg15adultes42\">Evidence Statement CG15AdultES42</h3>
<p>Four trials contained within a systematic review 89 failed to show with sufficient power a demonstrated effect of SMBG on blood glucose control</p>
<p><span class=\"citation\" data-cites=\"Coster_2000\">(Coster et al. 2000)</span></p>
<h3 id=\"evidence-statement-cg15adultes43\">Evidence Statement CG15AdultES43</h3>
<p>Two trials comparing urine and blood testing showed no clinical difference in the two tests89</p>
<p><span class=\"citation\" data-cites=\"Coster_2000\">(Coster et al. 2000)</span></p>
<h3 id=\"evidence-statement-cg15adultes44\">Evidence Statement CG15AdultES44</h3>
<p>A systematic review 89 reported on patient preferences for different monitoring techniques. One trial reported patients preferring blood testing, or a combination of blood and urine testing,compared to urine testing alone. No preference was stated for visual strips or strips with meters</p>
<p><span class=\"citation\" data-cites=\"Coster_2000\">(Coster et al. 2000)</span></p>
<h3 id=\"evidence-statement-cg15adultes45\">Evidence Statement CG15AdultES45</h3>
<p>One methodologically-limited crossover study 90 co mparing blood glucose meters with visual t est strips showed patients found the two techniques equally convenient to use, although overall more patients preferred the blood glucose meter. Preferences were based on: accuracy, confidence in test result, no judgement by patient,inability to cheat with result and use of the built in timer</p>
<p><span class=\"citation\" data-cites=\"Brown_1986\">(E. Brown et al. 1986)</span></p>
<h3 id=\"evidence-statement-cg15adultes46\">Evidence Statement CG15AdultES46</h3>
<p>One methodologically-limited comparative study 91 showed that fructosamine self-test results co rr elated well with laboratory test with very low bias. Imprecision of the self-test was higher than the laboratory test, but could still identify patients with good vs poor glycaemic control</p>
<p><span class=\"citation\" data-cites=\"Edelman_2000\">(S. V. Edelman, Callahan, and Deeb 2000)</span></p>
<h3 id=\"evidence-statement-cg15adultes47\">Evidence Statement CG15AdultES47</h3>
<p>A further methodologically-limited diagnostic study 92 in people with Type 2 diabetes showed self-testing of fructosamine to be comparable in accuracy to laboratory fructosamine and GHb values</p>
<p><span class=\"citation\" data-cites=\"Cefalu_1999\">(Cefalu et al. 1999)</span></p>
<h3 id=\"evidence-statement-cg15adultes48\">Evidence Statement CG15AdultES48</h3>
<p>One trial with 25 patients 93 showed no significant difference in glucose control or patient practice based on frequency of testing. The authors stated that they are unable to identify any optimal frequency for blood glucose self-monitoring in typical diabetic population. There is little or no relationship between the frequency of blood glucose monitoring, the frequency of insulin dose adjustments and the level of metabolic control</p>
<p><span class=\"citation\" data-cites=\"Gordon_1991\">(Gordon, Semple, and Paterson 1991)</span></p>
<h3 id=\"evidence-statement-cg15adultes49\">Evidence Statement CG15AdultES49</h3>
<p>A study of the preferences of 18 patients within a systematic review 89 reported a pr eference for t esting four times daily twice weekly, or four times daily once a week, compared to twice daily ev ery day of the week</p>
<p><span class=\"citation\" data-cites=\"Coster_2000\">(Coster et al. 2000)</span></p>
<h3 id=\"evidence-statement-cg15adultes50\">Evidence Statement CG15AdultES50</h3>
<p>One study from a systematic review reported fasting plasma glucose to be less useful as an accurate mode of monitoring in insulin-treated people with diabetes than in other people 89</p>
<p><span class=\"citation\" data-cites=\"Coster_2000\">(Coster et al. 2000)</span></p>
<h3 id=\"evidence-statement-cg15adultes51\">Evidence Statement CG15AdultES51</h3>
<p>The DCCT included self-monitoring of blood glucose as part of intensive treatment. Self-monitoring is only likely to have an effect on blood glucose control when used to inform the management of diabetes. As such, it is not feasible to analyse its cost-effectiveness in isolation from the requirements of subsequent management strategies. A recent HTA report 89 identifies one paper considering the cost-effectiveness of blood or urine glucose monitoring against conventional dietary control amongst those with Type 1 diabetes. 341 This paper is based on Russian conditions and also includes education in the intervention technologies. The GDG felt that differences in international healthcare systems mean little weight could be placed on its assertions that no significant difference exists between blood and urine glucose monitoring</p>
<p><span class=\"citation\" data-cites=\"Coster_2000\">(Coster et al. 2000)</span></p>
<p><span class=\"citation\" data-cites=\"Starostina_1994\">(Starostina et al. 1994)</span></p>
<h2 id=\"topic-cg15adults7\">Topic CG15AdultS7</h2>
<p>The imperfect nature of insulin replacement the ra py , and in particular the prospective, erratic and inappropriate profiles of insulin absorption, make it necessary to understand the effects of different foods on glucose excursions if these ex cursions are to be appropriately minimised. Fu r thermore, people with Type 1 diabetes are at high arterial risk, which might be ameliorated by appropriate nutritional choices, while some associated conditions can be partly managed through nutritional advice.</p>
<p>The group was impressed by the systematic approach to nutritional recommendations published by the ADA, 76 and the consistency of that approach with the new recommendations from Diabetes UK. 107 Co nsideration of the existing guidelines in the area did not lead the group to any divergent recommendations on nutrition. Furthermore, recent NICE guidance on education models for people with Type 1 diabet es had particularly addressed the relevance of one programme for mealtime insulin dose ad justment (DAFNE) and, after due discussion of some of the issues surrounding that study including the health economic issues, it was felt inappropriate to recommend modification of any of the appraisals conclusions. Accordingly the recommendations agreed by the group are mainly those of emphasis and approach appropriate to people with Type 1 diabetes, but reflecting both management of blood glucose ex cursions and arterial risk</p>
<p>Offer nutritional information at time of diagnosis Nutritional information sensitive to personal needs and culture should be offered from the time of diagnosis of Type 1 diabetes. </p>
<h3 id=\"evidence-statement-cg15adultes52\">Evidence Statement CG15AdultES52</h3>
<p>F our small randomised controlled trials 9497 we re identified examining different diet regimens in people with Type 1 diabetes. One randomised controlled study 94 found that a high fibre diet (50 g/day) for 24 weeks compared to a low fibre diet (15 g/day) improved blood glucose profile, and number of hypoglycaemic events, although HbA 1c , cholesterol, body weight and insulin dose were not affected</p>
<p><span class=\"citation\" data-cites=\"Giacco_2000\">(R. Giacco et al. 2000)</span></p>
<p><span class=\"citation\" data-cites=\"HANSEN_1999\">(HANSEN et al. 1999)</span></p>
<p><span class=\"citation\" data-cites=\"Chantelau_1992\">(Chantelau and Wichmann 1992)</span></p>
<p><span class=\"citation\" data-cites=\"McCulloch_1985\">(McCulloch et al. 1985)</span></p>
<h3 id=\"evidence-statement-cg15adultes53\">Evidence Statement CG15AdultES53</h3>
<p>A high carbohydrate, high fibre and low fat diet, compared to conventional low carbohydrate diet, taught by a dietitian in an unblinded randomised controlled trial 97 was seen at 12 months to improve HbA 1c</p>
<p><span class=\"citation\" data-cites=\"McCulloch_1985\">(McCulloch et al. 1985)</span></p>
<h3 id=\"evidence-statement-cg15adultes54\">Evidence Statement CG15AdultES54</h3>
<p>The addition of vitamin E to the normal diet has been shown to provide no benefit in terms of c holesterol level, HbA 1c , body mass index (BMI), insulin dose or blood pressure over a 12-month period 96</p>
<p><span class=\"citation\" data-cites=\"Chantelau_1992\">(Chantelau and Wichmann 1992)</span></p>
<h3 id=\"evidence-statement-cg15adultes55\">Evidence Statement CG15AdultES55</h3>
<p>There were significant improvements in glomerular filtration rate, and a decline in albuminuria after four weeks of a low protein diet compared to a normal protein diet in a randomised prospective trial in people with overt diabetic nephropathy. 95 Outcomes of urinary sodium ex cretion, blood pressure, BMI and HbA 1c we re not significantly different between the diets</p>
<p><span class=\"citation\" data-cites=\"HANSEN_1999\">(HANSEN et al. 1999)</span></p>
<h3 id=\"evidence-statement-cg15adultes56\">Evidence Statement CG15AdultES56</h3>
<p>Canadian clinical practice guidelines 98 re co mmend that all people with diabetes on fixed-dose insulin regimen should have an individualised meal and activity plan developed. Two studies showed that patients should be taught how to adjust insulin dosage, diet and physical activity in response to blood glucose levels to reduce incidence of hypoglycaemia</p>
<p><span class=\"citation\" data-cites=\"Lau_2007\">(Lau 2007)</span></p>
<h3 id=\"evidence-statement-cg15adultes57\">Evidence Statement CG15AdultES57</h3>
<p>A medium-sized randomised controlled trial 99 of a five-day outpatient programme to enable patients to replace insulin by matching it to desired carbohydrate intake amongst adults with Ty pe 1 diabetes found that the intervention improved HbA 1c com pared to a control of normal care to six months. Positive effects were also seen in weighted quality of life and total well-being. There was no effect on incidence of severe hypoglycaemia, weight or total cholesterol. This trial enrolled people with poorly-controlled diabetes</p>
<p><span class=\"citation\" data-cites=\"DAFNE_Study_Group_2002\">(D. S. Group 2002)</span></p>
<h3 id=\"evidence-statement-cg15adultes58\">Evidence Statement CG15AdultES58</h3>
<p>A similar small trial 96 in which intensified insulin plus simplified diet was compared to co nv entional therapy and diet found HbA 1c to be significantly reduced, although there was no differences between the study groups for outcomes of body weight, BMI, cholesterol or triglyce rides</p>
<p><span class=\"citation\" data-cites=\"Chantelau_1992\">(Chantelau and Wichmann 1992)</span></p>
<h3 id=\"evidence-statement-cg15adultes59\">Evidence Statement CG15AdultES59</h3>
<p>A large cohort study 100 comparing degree of liberalisation of diet away from a specific co ntrolled diet after a treatment and teaching programme with estimation of carbohydrate intake and subsequent insulin self-adjustme nt found that there was no significant relationship between BMI and degree of diet liberalisation. In addition there was no relationship with HbA1c level or severe hypoglycaemia. However there was a relationship between liberalised diet and higher cholesterol levels, and an inverse relationship with tendency to monitor blood gl ucose more than three times a day</p>
<p><span class=\"citation\" data-cites=\"M_HLHAUSER_1995\">(MHAUSER et al. 1995)</span></p>
<h3 id=\"evidence-statement-cg15adultes60\">Evidence Statement CG15AdultES60</h3>
<p>The recent evidence-based guidelines for nutrition principles developed by the ADA, 76 provide a broad overview of research in the area of improved diabetes care for people with Type 1 diabetes through beneficial nutritional therapies. There are recommendations based on well- performed RCTs showing significant effectiveness of interventions for areas such as carbohydrates, dietary fat, energy balance and obesity, nutritional therapy for the treatment or prevention of acute complications, and hypertension. Recommendations in other key areas are based on cohort or uncontrolled studies</p>
<p>[@2003]</p>
<h3 id=\"evidence-statement-cg15adultes61\">Evidence Statement CG15AdultES61</h3>
<p>The recent NICE Technology Appraisal 101 into patient education models ( www.nice. org.uk/cat.asp * c=68326 ) recommends dose adjustment for normal eating (DAFNE), and the intensified treatment required by DAFNE, as cost effective.</p>
<p><span class=\"citation\" data-cites=\"Blinkhorn_2003\">(Blinkhorn 2003)</span></p>
<h2 id=\"topic-cg15adults8\">Topic CG15AdultS8</h2>
<p>Ma ny people wish to perform varying amounts of physical exercise, but this can interact to disturb blood glucose levels in people on insulin therapy. Physical exercise is usually re co mmended to the general population as part of a package of lifestyle measures to improve future health, in particular reduction of arterial risk, which is markedly elevated in people with Ty pe 1 diabetes.</p>
<p>The group noted that the evidence for an improved arterial risk profile in people with Type 1 diabetes was consistent with that for other diabetic and non-diabetic people. Evidence of a co nsistent effect in improving blood glucose control was absent, although by analogy with people with Type 2 diabetes the overweight/insulin-resistant person might benefit from an ex ercise programme as part of a lifestyle improvement initiative. Some people will undertake significant exercise by choice and would benefit from support in so doing.</p>
<p>Advise that physical activity can reduce enhanced arterial risk Adults with Type 1 diabetes should be advised that physical activity can reduce their enhanced arterial risk in the medium and longer term. </p>
<h3 id=\"evidence-statement-cg15adultes62\">Evidence Statement CG15AdultES62</h3>
<p>One small randomised controlled trial 102 was identified that assessed the effect of a 16-week aerobic exercise programme on fitness and lipid profile in young men with Type 1 diabetes. There were significant differences in VO 2max and serum total cholesterol compared to no tr aining. There were no significant changes in outcomes of HbA 1c and plasma glucose. The study was not blinded due to the nature of the intervention</p>
<p><span class=\"citation\" data-cites=\"LAAKSONEN_2000\">(LAAKSONEN et al. 2000)</span></p>
<h3 id=\"evidence-statement-cg15adultes63\">Evidence Statement CG15AdultES63</h3>
<p>A small cross-sectional study 103 ev aluating the effect of three months of individualised aerobic ex ercise in altering blood pressure and lipid profile found that HbA 1c , fructosamine and total blood glucose did not change significantly from baseline levels. The design of the study would not represent a sound basis for supporting a recommendation for advocating exercise as therapy</p>
<p><span class=\"citation\" data-cites=\"Ligtenberg_1999\">(Ligtenberg 1999)</span></p>
<h3 id=\"evidence-statement-cg15adultes64\">Evidence Statement CG15AdultES64</h3>
<p>Another study with a similar intervention 102 found that four months of aerobic training provided no changes in terms of HbA 1c or total cholesterol, although there were benefits of ex ercise compared to control in terms of peak oxygen uptake</p>
<p><span class=\"citation\" data-cites=\"LAAKSONEN_2000\">(LAAKSONEN et al. 2000)</span></p>
<h3 id=\"evidence-statement-cg15adultes65\">Evidence Statement CG15AdultES65</h3>
<p>A prospective non-randomised study 104 w ith a before and after design found that steady-state plasma glucose was significantly decreased compared to baseline as was plasma insulin with supervised exercise program (at least 135 minutes/week) for three months compared to no ex ercise. Also cholesterol decreased significantly, however there were no reported significant c hanges in fasting blood glucose, HbA 1c and microalbuminuria</p>
<p><span class=\"citation\" data-cites=\"Lehmann_1997\">(Lehmann et al. 1997)</span></p>
<h3 id=\"evidence-statement-cg15adultes66\">Evidence Statement CG15AdultES66</h3>
<p>A medium-sized randomised controlled trial 105 of intensive advice and lifestyle programme w ith specified diet and exercise prescriptions compared to conventional care found that HbA 1c decreased from baseline measurements significantly over six months in the control group but re mained relatively stable in the intervention group, but no between-group comparison was made. Also, HDL cholesterol and triglycerides were not significantly different between groups at any phase of the study. However exercise sessions were not standardised in the study and a lack of blinding limited the validity of the trial</p>
<p><span class=\"citation\" data-cites=\"Perry_1997\">(Perry et al. 1997)</span></p>
<h3 id=\"evidence-statement-cg15adultes67\">Evidence Statement CG15AdultES67</h3>
<p>A small before and after study 106 found that an intervention of 10 hours of education and physical training three or four times a week produced no metabolic response at three months w ith fasting plasma glucose levels and serum cholesterol not changing significantly. Without blinding or randomisation this evidence is not sufficient to support the use of a mixed education and exercise intervention for people with Type 1 diabetes</p>
<p><span class=\"citation\" data-cites=\"Schneider_1992\">(S. H. Schneider et al. 1992)</span></p>
<h3 id=\"evidence-statement-cg15adultes68\">Evidence Statement CG15AdultES68</h3>
<p>A non-randomised prospective controlled study 103 to assess whether exercise is related to better diabetes control was reviewed. There was no significant correlation between the exercise ex pe nditure and HbA 1c in all Type 1 diabetes patients, nor was there any relationship to the frequency of mild hypoglycaemic events</p>
<p><span class=\"citation\" data-cites=\"Ligtenberg_1999\">(Ligtenberg 1999)</span></p>
<h3 id=\"evidence-statement-cg15adultes69\">Evidence Statement CG15AdultES69</h3>
<p>The ADA 76 guidelines present recommendations based on a good evidence-based review. They recommend that a thorough evaluation be undertaken of patients before exercise is initiated. General recommendations for how to exercise safely include:</p>
<ul>
<li><p>metabolic control before activity</p></li>
<li><p>blood glucose monitoring before and after physical activity</p></li>
<li><p>food intake to be considered with added carbohydrate as necessary</p></li>
</ul>
<p>[@2003]</p>
<h2 id=\"topic-cg15adults10\">Topic CG15AdultS10</h2>
<p>Ty pe 1 diabetes is for most of the time asymptomatic once effective therapy is instituted. However, it is generally understood that there is a re lationship between blood glucose control and the late complications of the condition. Together these observations suggest that some means of monitoring blood glucose control should help healthcare professionals advise people with diabetes to best effect on insulin doses, regimens and associated lifestyle issues.</p>
<p>The group endorsed the utility of having a frame of reference against which people with diabetes and the professionals advising them could assess risk and risk threshold for micro- and macro-vascular disease in terms of blood glucose control. This was a core component of intensification of therapy in studies showing improved long-term outcomes. HbA 1c is the only measure for which quantitative information linking glucose control to complications is av ailable, and then only when standardised to the assay used in the DCCT study. Near patient t esting was felt to be a core component of making optimal and relevant use of HbA 1c re sults. Co ntinuous glucose monitoring systems were considered to not yet have established their usefulness beyond problem-solving in the occasional person with recurrent blood glucose co ntrol problems at the same time of day.</p>
<p>Clinical monitoring of blood glucose levels Clinical monitoring of blood glucose levels by high precision DCCT-aligned methods of haemoglobin A 1c (HbA 1c ) should be performed every two to six months depending on:</p>
<ul>
<li><p>achieved level of blood glucose control</p></li>
<li><p>stability of blood glucose control</p></li>
<li><p>change in insulin dose or regimen </p></li>
</ul>
<h3 id=\"evidence-statement-cg15adultes70\">Evidence Statement CG15AdultES70</h3>
<p>A Diabetes UK consensus statement recommended that only HbA 1c should be used in the monitoring of blood glucose control. Other studies reported within a systematic review 89 have shown discrepancies in the classification of patients between HbA 1c and HbA 1 assays</p>
<p><span class=\"citation\" data-cites=\"Coster_2000\">(Coster et al. 2000)</span></p>
<h3 id=\"evidence-statement-cg15adultes71\">Evidence Statement CG15AdultES71</h3>
<p>Tw o studies in a systematic review 89 showed high inter-individual variability for GHb assays in non-diabetic and in diabetic subjects with stable or variable control. One of these studies suggested an association between clinical control and sampling interval</p>
<p><span class=\"citation\" data-cites=\"Coster_2000\">(Coster et al. 2000)</span></p>
<h3 id=\"evidence-statement-cg15adultes72\">Evidence Statement CG15AdultES72</h3>
<p>The same systematic review 89 re ported on randomised controlled trial evidence supporting the use of GHb measurements, in particular results cited from the DCCT demonstrated the usefulness of these assays in contributing to improved long-term blood glucose control and a re duction in morbidity</p>
<p><span class=\"citation\" data-cites=\"Coster_2000\">(Coster et al. 2000)</span></p>
<h3 id=\"evidence-statement-cg15adultes73\">Evidence Statement CG15AdultES73</h3>
<p>A Danish systematic review 108 re ported that HbA 1c values allowed clinicians to identify patients with poor glycaemic control, concluding that GHb is the most clinically appropriate t est of long-term glycaemia and should be used in routine management of Type 1 diabetes</p>
<p><span class=\"citation\" data-cites=\"Larsen_1989\">(Larsen and H<span></span>rder 1989)</span></p>
<h3 id=\"evidence-statement-cg15adultes74\">Evidence Statement CG15AdultES74</h3>
<p>One study within a systematic review 89 recommended that no more than six GHb assays were necessary in a given year</p>
<p><span class=\"citation\" data-cites=\"Coster_2000\">(Coster et al. 2000)</span></p>
<h3 id=\"evidence-statement-cg15adultes75\">Evidence Statement CG15AdultES75</h3>
<p>ADA recommendations 76 advise GHb measurements are performed in accordance with clinical judgements. ADA consensus recommends GHb testing at least twice a year in patients with stable glycaemic control who are meeting treatment goals. Testing should be more frequent (quarterly) in patients whose therapy has changed or who are not meeting glycaemic control targets</p>
<p>[@2003]</p>
<h3 id=\"evidence-statement-cg15adultes76\">Evidence Statement CG15AdultES76</h3>
<p>One study within a systematic review 89 re ported fructosamine testing as able to detect shorter or more recent fluctuations in blood glucose compared to GHb. Fructosamine testing does not have the problems of standardisation associated with GHb, thus results are comparable between laboratories</p>
<p><span class=\"citation\" data-cites=\"Coster_2000\">(Coster et al. 2000)</span></p>
<h3 id=\"evidence-statement-cg15adultes77\">Evidence Statement CG15AdultES77</h3>
<p>Two studies within a systematic review 89 described a high correlation between fructosamine and HbA 1c , however later studies debated this claim. One study suggested that although fructosamine correlates with HbA 1c , the value of HbA 1c in an individual cannot routinely be inferred with reliability from the level of fructosamine</p>
<p><span class=\"citation\" data-cites=\"Coster_2000\">(Coster et al. 2000)</span></p>
<h3 id=\"evidence-statement-cg15adultes78\">Evidence Statement CG15AdultES78</h3>
<p>Two studies contained within a systematic review, 89 in patients with renal failure and elderly Ty pe 2 diabetes patients with liver cirrhosis and nephrotic syndrome, suggest the influence of ch ro nic conditions rather than metabolic control on fructosamine levels is the source of unreliability in test result. The systematic review co ncludes that more evidence is needed to r esolve these issues</p>
<p><span class=\"citation\" data-cites=\"Coster_2000\">(Coster et al. 2000)</span></p>
<h3 id=\"evidence-statement-cg15adultes79\">Evidence Statement CG15AdultES79</h3>
<p>One correlation study within a review 89 showed no significant correlation between HbA 1c and fructosamine results over a six month follow-up</p>
<p><span class=\"citation\" data-cites=\"Coster_2000\">(Coster et al. 2000)</span></p>
<h3 id=\"evidence-statement-cg15adultes80\">Evidence Statement CG15AdultES80</h3>
<p>ADA recommendations 76 state that assays of glycated serum protein would have to be performed on a monthly basis to gather the same information as measured in GHb three to four times per year</p>
<p>[@2003]</p>
<h3 id=\"evidence-statement-cg15adultes81\">Evidence Statement CG15AdultES81</h3>
<p>A systematic review 89 urges caution in using fructosamine testing, in light of the fact that fructosamine values can be improved by increased concordance a week or two before testing</p>
<p><span class=\"citation\" data-cites=\"Coster_2000\">(Coster et al. 2000)</span></p>
<h3 id=\"evidence-statement-cg15adultes82\">Evidence Statement CG15AdultES82</h3>
<p>A nother study found that fasting blood glucose level (FBG) and serum fructosamine are not as useful as HbA 1c for monitoring diabetic control, but are additional extras for assessing control ov er short and long periods 89</p>
<p><span class=\"citation\" data-cites=\"Coster_2000\">(Coster et al. 2000)</span></p>
<h3 id=\"evidence-statement-cg15adultes83\">Evidence Statement CG15AdultES83</h3>
<p>Three observational studies 109111 co mpared continuous glucose monitoring systems (CGMS) w ith SMBG. Studies demonstrated good correlation of CGMS with plasma and capillary measures of blood glucose over a range of blood glucose values. Error grid analysis showed the majority of readings fell within a clinically acceptable margin of error across all studies</p>
<p><span class=\"citation\" data-cites=\"Gross_2000\">(Gross et al. 2000)</span></p>
<p><span class=\"citation\" data-cites=\"Gross_2000\">(Gross et al. 2000)</span></p>
<p><span class=\"citation\" data-cites=\"Maran_2002\">(Maran et al. 2002)</span></p>
<h3 id=\"evidence-statement-cg15adultes84\">Evidence Statement CG15AdultES84</h3>
<p>One study 111 re ported acceptable level of comfort with CGMS. However, none of these studies address viable outcomes of glycaemic control or long-term use. Study methodology is not clearly reported</p>
<p><span class=\"citation\" data-cites=\"Maran_2002\">(Maran et al. 2002)</span></p>
<h3 id=\"evidence-statement-cg15adultes85\">Evidence Statement CG15AdultES85</h3>
<p>One controlled trial within a systematic review 112 demonstrated that near patient testing led to an increase in management changes for patients with poor glucose control. Near patient testing for HbA 1c improved the process of care of patients</p>
<p><span class=\"citation\" data-cites=\"Bernstein_2002\">(Bernstein, Jacobs, and Granata 2002)</span></p>
<h3 id=\"evidence-statement-cg15adultes86\">Evidence Statement CG15AdultES86</h3>
<p>In the same review, 112 questionnaires recording patient satisfaction of near patient testing co ncluded that the introduction of near patient testing for HbA 1c improves the likelihood of monitoring and discussion of glycaemic control at patient visits. Patients reported that this was important to them and resulted in greater satisfaction with the test information provided</p>
<p><span class=\"citation\" data-cites=\"Bernstein_2002\">(Bernstein, Jacobs, and Granata 2002)</span></p>
<h3 id=\"evidence-statement-cg15adultes87\">Evidence Statement CG15AdultES87</h3>
<p>W ithin the health technology assessment, 112 a retrospective cohort study showed that, after allowing for confounding factors, mean HbA 1c level was lower following near patient testing and the immediate availability of results. In order to precisely quantify the effect of the testing system on HbA 1c level, further, prospective studies are required</p>
<p><span class=\"citation\" data-cites=\"Bernstein_2002\">(Bernstein, Jacobs, and Granata 2002)</span></p>
<h3 id=\"evidence-statement-cg15adultes88\">Evidence Statement CG15AdultES88</h3>
<p>A systematic review 89 re ported four studies on the effectiveness of benchtop analysers co mpared with traditional laboratory methods. Two studies showed comparable results between the two techniques when operated by non-medical personnel. One study found that the benchtop analyser, although reliable, tended to slightly underestimate HbA 1c , compared w ith high performance liquid chromatography (HPLC)</p>
<p><span class=\"citation\" data-cites=\"Coster_2000\">(Coster et al. 2000)</span></p>
<h3 id=\"evidence-statement-cg15adultes89\">Evidence Statement CG15AdultES89</h3>
<p>An HTA report 112 produced cost estimates for near patient testing conducted by a laboratory or nurse against conventional testing. However, little data was available on the effects of near patient testing on clinical or quality of life outcomes. For health economics to provide guidance in this area, the long-term effects of different types of clinical monitoring on glycaemic control and subsequent complications must be known. A recent HTA report 89 re co mmended further research into the cost-effectiveness of near patient t esting for diabetes, FBG and fructosamine testing. No other paper in the health economics searches specifically addressed the issue of clinical monitoring</p>
<p><span class=\"citation\" data-cites=\"Bernstein_2002\">(Bernstein, Jacobs, and Granata 2002)</span></p>
<p><span class=\"citation\" data-cites=\"Coster_2000\">(Coster et al. 2000)</span></p>
<h2 id=\"topic-cg15adults11\">Topic CG15AdultS11</h2>
<p>The DCCT, and a number of smaller studies which are potentially underpowered, 113 suggest that more intensive management of people with Type 1 diabetes (by themselves, with advice) re duces the rate of development of microvascular complications over a period of years. The primary metabolic improvement in the DCCT was lowering of blood glucose level, and this was the measure used in that study to drive the intensification of therapy. This suggests that using measures of blood glucose control in the routine management of therapy in people with Type 1 diabetes is well founded. A question then arises as to what level of blood glucose control people with diabetes should ch oose to strive for. A closely related question is what level(s) of glucose control should be used in assessing the performance of diabetes services. Targets have been criticised by some as not giving flexibility for individuals with particular problems (eg hypoglycaemia) to be content with higher HbA 1c levels, which allows some longer-term risk for a gain in current well-being. It is clearly useful to be able to identify those in whom newer and more expensive technologies could be tried in an attempt to reduce microvascular risk, and to distinguish them from those who already achieve safe (or safer) levels on their current therapy. People with diabetes need information on what blood glucose level they need to attain if they wish to minimise vascular risk.</p>
<p>There must be a threshold for glucose control and the development of microvascular co mplications, or non-diabetic people would get complications. Indeed, this threshold must be we ll above the normal range as people with impaired glucose tolerance (IGT) do not (by definition) get microvascular complications. As people with IGT have HbA 1c levels of up to 7.0%, this by itself sets a lower limit of microvascular risk. The microvascular thresholds of HbA 1c 7.5% set around 10 years ago have stood the test of all data published since. If anything the DCCT, Krolewski and McCance data suggest a figure closer to 8.0%. Re co mmendations from the ADA (7.0%) and American College of Endocrinologists (6.5%) are not specific to type of diabetes; data does suggest macrovascular protection is gained by lowering blood glucose levels into the normal range, and the NICE (inherited) guidelines for Ty pe 2 diabetes go for HbA 1c 6.5% in these higher arterial risk individuals. Some people with Type 1 diabetes are at higher arterial risk, notably those with developing nephropathy. This can be identified by increased albumin excretion rate. The presence of features of the metabolic syndrome will also predict higher arterial risk. It may be appropriate to co nsider tighter targets for glucose control (if feasible) in people in these categories. Ho we ve r, these levels are better considered as assessment levels , to be used in setting realistic targets for the individual. Major diabetes services in Europe currently only get about 20% of people with Type 1 diabetes into the sub-7.5% bracket. UK composite data (UKDIABS) shows some services doing better, but this may only represent non-standardised GHb estimation. That current technologies of diabetes care markedly limited the proportion of people on insulin w ho were able to manage themselves to ideal levels was not seen as a bar to setting such assessment levels. It was noted that arterial risk would be likely to have a different relationship in this regard from microvascular risk, and that for the former there was little direct information available for people with Type 1 diabetes, but that the understandings gained in Ty pe 2 diabetes and people without diabetes gave strong guidance in this respect. It was felt that as the assessment of the evidence available pointed to target definition in the same range as other published guidelines, and in particular the NICE inherited guidelines for Type 2 diabetes, there was practical utility for practice of care in having matching recommendations. Lastly the problem of hypoglycaemia in limiting was what achievable in any individual should be addressed within any recommendations, to assuage inappropriate attempts to achieve tight co ntrol and counter impressions of failure if targets are not attained.</p>
<p>Maintaining a DCCT-harmonised HbA 1c below 7.5% Adults with Type 1 diabetes should be advised that maintaining a DCCT-harmonised HbA 1c below 7.5% is likely to minimise their risk of developing diabetic eye, kidney or nerve damage in the longer term. </p>
<h3 id=\"evidence-statement-cg15adultes100\">Evidence Statement CG15AdultES100</h3>
<p>One study (1989) 120 studied HbA 1 and retinopathy incidence long term in Belfast. While some clear relationships were established the data showing no proliferative retinopathy below an HbA 1 of 10.0% (HbA 1c 8.5%) are compromised by very small numbers, and only interquartile r anges are given for non-proliferative retinopathy</p>
<p><span class=\"citation\" data-cites=\"MCCANCE_1989\">(MCCANCE 1989)</span></p>
<h3 id=\"evidence-statement-cg15adultes101\">Evidence Statement CG15AdultES101</h3>
<p>Ne ither the Oslo nor Stockholm studies of control and complications in Type 1 diabetes 121 give useful data on targets and thresholds, beyond showing that people with lower levels on average do better</p>
<p><span class=\"citation\" data-cites=\"Reichard_1993\">(Reichard, Nilsson, and Rosenqvist 1993)</span></p>
<h3 id=\"evidence-statement-cg15adultes102\">Evidence Statement CG15AdultES102</h3>
<p>A non-randomised controlled study 122 looked prospectively at glycated Hb and micro- albuminuria risk in people with Type 1 diabetes attending their clinic. Their data did suggest a threshold effect (small and unchanging incidence below threshold, sharp rise above), at 7.98.5% HbA 1c (the authors chose to centre on 8.1%)</p>
<p><span class=\"citation\" data-cites=\"Krolewski_1995\">(A. S. Krolewski et al. 1995)</span></p>
<h3 id=\"evidence-statement-cg15adultes103\">Evidence Statement CG15AdultES103</h3>
<p>A non-randomised controlled study 123 looked at how glycated Hb measurement related to OG TT re sults, performing a meta-analysis on 18 studies. Unfortunately most of these were published before any kind of GHb standardisation, rendering the results uninterpretable</p>
<p><span class=\"citation\" data-cites=\"Peters_1996\">(A. L. Peters 1996)</span></p>
<h3 id=\"evidence-statement-cg15adultes104\">Evidence Statement CG15AdultES104</h3>
<p>A further cohort study 124 looked in more detail at GHb, fasting and 2h glucose as diagnostic methods (and thus mainly Type 2 diabetes), using retinopathy and nephropathy as outcome measures. It may be noted that the Wisconsin data suggested that the microvascular/glucose co ntrol relationships were the same in Type 1 and Type 2 diabetes. The data presentations are strongly reminiscent of previous work, 122 w ith low and unchanging incidence of microvascular disease up to an inflection point, then sharply rising rates. The thresholds for fasting glucose appear to be somewhere above 6.8 mmol/l (consistent with older OGTT data), and HbA 1c somewhere above 7.4% (and below 9.1%)</p>
<p><span class=\"citation\" data-cites=\"Krolewski_1995\">(A. S. Krolewski et al. 1995)</span></p>
<p>[@1994]</p>
<h3 id=\"evidence-statement-cg15adultes105\">Evidence Statement CG15AdultES105</h3>
<p>Tw o non-randomised controlled studies 116,125 re port the relationship between HbA 1c and self- monitored pre- and post-prandial glucose levels. The reports are consistent and can be related to D CCT-harmonised assays. It must be noted that these studies used pre-determined, self- monitored profiles taken from memory meters, and cannot easily be translated into patient- selected estimations, or only pre-prandial monitoring. They also omit the effects of night-time gl ucose profiles between bedtime and pre-breakfast readings. These data give the most robust ev idence of the relationship between HbA 1c and the toxic glucose concentrations which actually cause the microvascular damage</p>
<p><span class=\"citation\" data-cites=\"Rohlfing_2002\">(Rohlfing et al. 2002)</span></p>
<p><span class=\"citation\" data-cites=\"Nathan_1984\">(Nathan et al. 1984)</span></p>
<h3 id=\"evidence-statement-cg15adultes90\">Evidence Statement CG15AdultES90</h3>
<p>In 1989, the European NIDDM Policy Group (Type 2 diabetes) suggested HbA 1 was good &lt;8.5%, acceptable 8.59.5%, poor &gt;9.5% (equivalent to HbA 1c of &lt;6.9, 6.97.7, &gt;7.7%). No ev idence for these limits was given, and it was not clear whether the intent was for micro- or macrovascular protection or both. However, the need to individualise by life expectancy was acknowledged 114</p>
<p><span class=\"citation\" data-cites=\"Alberti_1988\">(K. G. M. M. Alberti and Gries 1988)</span></p>
<h3 id=\"evidence-statement-cg15adultes91\">Evidence Statement CG15AdultES91</h3>
<p>In 1993, the above guidelines were revised to HbA 1c &lt;6.5%, 6.57.5%, and &gt;7.5%. The European IDDM Policy Group (Type 1 diabetes) (WHO, IDF, St Vincent) met concurrently and agreed these, but using the terminology good, borderline and poor to describe the groups. These pre- D CCT recommendations are not justified in the text 115</p>
<p><span class=\"citation\" data-cites=\"Group_1999\">(E. D. P. Group 1999)</span></p>
<h3 id=\"evidence-statement-cg15adultes92\">Evidence Statement CG15AdultES92</h3>
<p>In 1998, the European Diabetes Policy Group revised its terminology to assessment levels, giving advice on how to use assessment levels to set targets for individuals. These were, for HbA 1c : adequate 6.27.5%, inadequate &gt;7.5%. However the relation of this 7.5% to glucose levels was then revised to equivalent to a self-monitored pre-prandial level of 6.5 mmol/l and post-prandial 9.0 mmol/l. These post-DCCT recommendations are not justified in the text 115</p>
<p><span class=\"citation\" data-cites=\"Group_1999\">(E. D. P. Group 1999)</span></p>
<h3 id=\"evidence-statement-cg15adultes93\">Evidence Statement CG15AdultES93</h3>
<p>The NICE Type 2 diabetes guidelines therefore recommended 6.5% to 7.5% as ideal targets, individualised by balance of macrovascular (tend to 6.5%) and microvascular (7.5%) risk</p>
<p><span class=\"citation\" data-cites=\"Boynton_1998\">(Boynton 1998)</span></p>
<h3 id=\"evidence-statement-cg15adultes94\">Evidence Statement CG15AdultES94</h3>
<p>The ADA has republished its recommendations yearly. 76 These choose a glycaemic goal of HbA 1c &lt;7.0% for adults (type of diabetes not specified), equating this to pre-prandial &lt;7.2 mmol/l and peak post-prandial &lt;10.0 mmol/l. However, a table in the same paper suggests that an HbA 1c of 7.0% equates to mean self-monitored plasma glucose of 9.5 mmol/l 116</p>
<p>[@2003]</p>
<p><span class=\"citation\" data-cites=\"Rohlfing_2002\">(Rohlfing et al. 2002)</span></p>
<h3 id=\"evidence-statement-cg15adultes95\">Evidence Statement CG15AdultES95</h3>
<p>Ho we ve r in the same issue (January 2003), 76 the ADA notes in a chapter on Implications of the D CCT that the level of glucose control to be sought under ideal circumstances is an HbA 1c of around 7.2% (average glucose 8.6 mmol/l). This argument is based on that achieved in the D CCT, and is thus not theoretically justified</p>
<p>[@2003]</p>
<h3 id=\"evidence-statement-cg15adultes96\">Evidence Statement CG15AdultES96</h3>
<p>The microvascular risk threshold is what determines the diagnostic threshold for diabetes. In theory, oral glucose tolerance test (OGTT) findings should give some guidance as to this threshold. Unfortunately these are mainly based on non-physiological glucose load findings, and set a top limit of risk for 2h post-prandial levels. Fasting levels have been set as a microvascular threshold of 7.0 mmol/l (based on epidemiological equivalence with 2h OGTT levels), which would map to a DCCT-harmonised HbA 1c of about 7.7%</p>
<h3 id=\"evidence-statement-cg15adultes97\">Evidence Statement CG15AdultES97</h3>
<p>The DCCT data has never been satisfactorily analysed with a view to answering this question. A graph in the original main paper 117 suggests a curvilinear relationship between control and complications, giving the conclusion that lower is always better (ignoring the hypoglycaemia issue for this purpose), down at least to the levels measured in the study (5.5%). This conclusion is called into question because:</p>
<ul>
<li><p>it is based on study averages, and even people at lower levels over nine years may have been at high levels at times</p></li>
<li><p>it takes no account of pre-trial levels</p></li>
<li><p>incident retinopathy is counted only in a forward (worsening) direction, which makes no allowance for false negative retinopathy at baseline</p></li>
<li><p>worsening retinopathy is known to occur in the first two years after improvement of blood glucose control, and this is not discounted</p></li>
</ul>
<p>[@1993]</p>
<h3 id=\"evidence-statement-cg15adultes98\">Evidence Statement CG15AdultES98</h3>
<p>Fu r ther analysis was published in 1995. 118 Un fortunately, this is mostly in the form of a series of fitted curves without the data on which they are based. Curves of risk vs time suggest that r etinopathy progression in the intensively managed group did not increase with time with a mean HbA 1c of 8.0%, and increased little at this level in the conventionally managed group w ith time</p>
<p>[@1995]</p>
<h3 id=\"evidence-statement-cg15adultes99\">Evidence Statement CG15AdultES99</h3>
<p>R eanalysis of the published DCCT curve 118 suggests no worsening of retinopathy rates from normal levels until HbA 1c &gt;8.0%; the low rates (2% per 100 patient years) below that may be artefact for the reasons given above. The UKPDS (epidemiological analysis, Type 2 diabetes, microvascular disease) suffers much the same problems. 119 A similar level is found for r etinopathy of 2% per 100 patient years at an HbA 1c of 7.5% and of 1% per 100 patient years at a level of 6.5%</p>
<p>[@1995]</p>
<p><span class=\"citation\" data-cites=\"Stratton_2001\">(Stratton et al. 2001)</span></p>
<h2 id=\"topic-cg15adults12\">Topic CG15AdultS12</h2>
<p>Ty pe 1 diabetes is an insulin deficiency disease. Physiological insulin delivery is regulated on a minute-to-minute basis, while therapeutic insulin is given a small number of times a day. Fu r thermore subcutaneous depot insulin preparations have, until recently, not come close to providing the physiological plasma insulin profiles occurring at mealtimes or in the inter- prandial basal state. A number of preparations of mealtime and extended-acting insulins are av ailable, and combining these to suit individual needs, while taking account of preferences for n umbers of injections, gives a variety of possib le insulin regimens of differing characteristics. W hile insulin deficiency is the hallmark of Type 1 diabetes, a few people retain some insulin secretion for a short time (and might therefo re benefit from insulin secretagogues). Some gl ucose-lowering drugs work on gut absorption of nutrients or on the insulin effector tissues, and might therefore be expected to be of benefit in some individuals even when completely insulin deficient and managed on insulin replacement therapy.</p>
<p>It was noted that Type 1 diabetes is a hormone deficiency disease. The problems faced by people w ith the condition (injections, hypoglycaemia, hyperglycaemia, consequences of capricious co ntrol, late complications) were noted to be solely a function of the poor state of insulin re placement therapy. The group noted that the use of insulin injections in people with Type 1 diabetes is not RCT- based and never could be. It was also noted that, prior to the introduction of short- and long- acting insulin analogues, the use of insulin regimens based on a combination in various forms of unmodified (soluble) human insulin befo re meals and human isophane (NPH) insulin for basal supply had become widespread, and that, the analogues aside, there was no evidence to ch allenge that conventional practice. Long-acting analogues, or rather insulin glargine, are co ve re d by NICE appraisal guidance, and this recommends their availability for use in people w ith Type 1 diabetes. Rapid-acting insulin analogues are supported by an evidence base for less hy poglycaemia at night and at some other times, reduced hyperglycaemic excursions after meals and small improvements in HbA 1c , suggesting that these too should have an increasing r ole in people with Type 1 diabetes. The group was aware that the evidence for combining the advantages of rapid- and long-acting insulin analogues was evolving as the knowledge base to use these technologies improves. This co mbination would be particularly suitable to matching with active mealtime insulin dose adjustment (AMIDA, see dietary recommendations in 6.3). Some recent NICE technology appraisals provided a health economic basis for supporting this regimen, should appropriate improvements in HbA 1c be demonstrated. Accordingly the recommendations were drafted to allow choice of human or combined analogue regimens including from the time of diagnosis. The group noted the potential usefulness of the new insulins in some special situations, including religious feasts and fasts, and shift work. A need to address insulin starters and people who wished for smaller numbers of injections was identified. A need to caution against using newer, more expensive insulins in people with control problems without proper assessment of underlying causes was felt appropriate. The NICE appraisal of insulin pumps (effectively an insulin regimen rather than a device) was noted, and no elaboration felt to be needed on that. The group found the evidence for the general recommendation of any glucose-lowering drug in combination with insulin to be unconvincing. While there may be a small gain in overall gl ucose control evidenced inconsistently in the acarbose studies, the size of this gain, the prevalence of intolerance, and the suggestion of increased hypoglycaemia, together were taken as indicating that no recommendation for the general use of this drug in this context could be made. The use of metformin and insulin sensitisers in people with Type 1 diabetes and the metabolic syndrome has not been adequately investigated. The group was aware of the concern that arterial complications in people with Type 1 diabetes we re associated with features of the metabolic syndrome as seen in Type 2 diabetes, and that there was evidence of benefit in people with Type 2 diabetes for some drugs, notably metformin (UKPDS study) and PPAR- * agonists (see NICE guidance). While not endorsing the general use of such drugs in people with Type 1 diabetes and features of the metabolic syndrome (see section 8.2, Arterial disease management), the group noted that further investigation might support the high a priori likelihood of benefit in this high-risk situation.</p>
<p>Access to insulin Adults with Type 1 diabetes should have access to the types (preparation and species) of insulin they find allow them optimal well-being. </p>
<h3 id=\"evidence-statement-cg15adultes106\">Evidence Statement CG15AdultES106</h3>
<p>In sulin with the molecular structure of human and animal insulins is currently available. Ev idence from the majority of studies 1268 re ports no significant differences in hypoglycaemic episodes and glycaemic control between the insulin of human and animal chemical structures</p>
<p><span class=\"citation\" data-cites=\"Richter_2002\">(Richter, Neises, and Bergerhoff 2002)</span></p>
<p><span class=\"citation\" data-cites=\"George_1997\">(George et al. 1997)</span></p>
<p><span class=\"citation\" data-cites=\"Karlson_1994\">(Karlson and Agardh 1994)</span></p>
<h3 id=\"evidence-statement-cg15adultes107\">Evidence Statement CG15AdultES107</h3>
<p>Co nv entional two-dose insulin regimens may re sult in a high frequency of nocturnal hy poglycaemia. Intensified three-dose insulin regimens improve glycaemic control, but often do not improve morning blood glucose 129</p>
<p><span class=\"citation\" data-cites=\"Egger_1997\">(Egger et al. 1997)</span></p>
<h3 id=\"evidence-statement-cg15adultes108\">Evidence Statement CG15AdultES108</h3>
<p>Co ntinuous subcutaneous insulin infusion (CSII) improves nocturnal and morning glycaemic co ntrol compared with multiple daily injection (MDI) regimens. With multiple injection re g imens the morning injection must not be delaye d. Total and bolus insulin doses required are lower with CSII compared with MDI 130</p>
<p><span class=\"citation\" data-cites=\"Haakens_1989\">(Haakens et al. 1989)</span></p>
<h3 id=\"evidence-statement-cg15adultes109\">Evidence Statement CG15AdultES109</h3>
<p>Mo r tality from acute metabolic causes (ketoacidosis) was reported as significantly increased w ith intensified treatment; odds ratio 7.20 (pumps) 1.13 (multiple daily injection). 129 The pump data is however based on early pump technologies</p>
<p><span class=\"citation\" data-cites=\"Egger_1997\">(Egger et al. 1997)</span></p>
<h3 id=\"evidence-statement-cg15adultes110\">Evidence Statement CG15AdultES110</h3>
<p>S imilar glycaemic control results from either lente or isophane (NPH) insulin when used as basal insulin for multiple injection regimens toge ther with a short-acting insulin preparation before meals 131</p>
<p><span class=\"citation\" data-cites=\"Tunbridge_1989\">(Tunbridge et al. 1989)</span></p>
<h3 id=\"evidence-statement-cg15adultes111\">Evidence Statement CG15AdultES111</h3>
<p>On the balance of effectiveness and cost-effectiveness evidence, insulin glargine, which has a peakless action profile, is also recommended as a long-acting preparation for people with Ty pe 1 diabetes; 132 some studies in this review show significantly lower fasting blood glucose w ith insulin glargine than isophane (NPH) insulin and others suggest that people on insulin g largine may experience fewer hypoglycaemic ev ents than people receiving once-daily isophane (NPH) insulin 132</p>
<p><span class=\"citation\" data-cites=\"_NA__2008\">(<span>&amp;</span>NA 2008)</span></p>
<h3 id=\"evidence-statement-cg15adultes112\">Evidence Statement CG15AdultES112</h3>
<p>Ev idence from a large multicentred study suggests that people commonl y inject insulin closer to mealtime than the recommended 30 minutes. Due to slow absorption and delayed action, the use of unmodified (soluble) human insulin as pre-meal dose results in high and variable post-breakfast blood glucose concentrations, which together with the incidence of later hy poglycaemia suggests that this regimen does not give satisfactory post-prandial blood glucose contr ol in many patients 133</p>
<p><span class=\"citation\" data-cites=\"Vignati_1997\">(L. Vignati, Anderson, and Iversen 1997)</span></p>
<h3 id=\"evidence-statement-cg15adultes113\">Evidence Statement CG15AdultES113</h3>
<p>Rapid acting insulin analogues allow injection close r to mealtimes due to their pharmacokinetic profile 1346</p>
<p><span class=\"citation\" data-cites=\"Nielsen_1995\">(F. S. Nielsen et al. 1995)</span></p>
<p><span class=\"citation\" data-cites=\"Lindholm_1999\">(Lindholm, McEwen, and Riis 1999)</span></p>
<p><span class=\"citation\" data-cites=\"Sindaco_1998\">(Sindaco et al. 1998)</span></p>
<h3 id=\"evidence-statement-cg15adultes114\">Evidence Statement CG15AdultES114</h3>
<p>A meta-analysis 137 and several open-label trials 133,138145 show that insulin lispro is more effective than unmodified (soluble) human insulin in improving post-prandial glucose co ntrol, without an increase in the rate of hypoglycaemic episodes</p>
<p><span class=\"citation\" data-cites=\"Vignati_1997\">(L. Vignati, Anderson, and Iversen 1997)</span></p>
<p><span class=\"citation\" data-cites=\"Davey_1997\">(Davey et al. 1997)</span></p>
<p><span class=\"citation\" data-cites=\"Lalli_1999\">(Lalli et al. 1999)</span></p>
<p><span class=\"citation\" data-cites=\"Anderson_1997\">(J. H. Anderson et al. 1997)</span></p>
<p><span class=\"citation\" data-cites=\"Pf_tzner_1996\">(Pftzner et al. 1996)</span></p>
<p><span class=\"citation\" data-cites=\"Renner_1999\">(Renner et al. 1999)</span></p>
<p><span class=\"citation\" data-cites=\"Ebeling_1997\">(Ebeling et al. 1997)</span></p>
<p><span class=\"citation\" data-cites=\"Roach_1999\">(Roach et al. 1999)</span></p>
<p><span class=\"citation\" data-cites=\"Group_2000\">(U.K. Trial Group 2000)</span></p>
<p><span class=\"citation\" data-cites=\"Roach_1999\">(Roach et al. 1999)</span></p>
<h3 id=\"evidence-statement-cg15adultes115\">Evidence Statement CG15AdultES115</h3>
<p>Two studies 1467 show reduced frequency of nocturnal hypoglycaemia 148 with insulin lispro compared to unmodified (soluble) human insulin</p>
<p><span class=\"citation\" data-cites=\"Holleman_1997\">(F. Holleman et al. 1997)</span></p>
<p><span class=\"citation\" data-cites=\"Ahmed_1998\">(Ahmed and Home 1998)</span></p>
<p><span class=\"citation\" data-cites=\"Brunelle_1998\">(B. L. Brunelle et al. 1998)</span></p>
<h3 id=\"evidence-statement-cg15adultes116\">Evidence Statement CG15AdultES116</h3>
<p>Two studies 1489 show reduced frequency of severe hypoglycaemia with insulin lispro co mpared to unmodified (soluble) human insulin</p>
<p><span class=\"citation\" data-cites=\"Brunelle_1998\">(B. L. Brunelle et al. 1998)</span></p>
<p><span class=\"citation\" data-cites=\"Battista_1995\">(Battista, Feeny, and Hodge 1995)</span></p>
<h3 id=\"evidence-statement-cg15adultes117\">Evidence Statement CG15AdultES117</h3>
<p>Pa tients perceive an improvement in their well-being and quality of life with rapid-acting insulin analogues due to flexibility of inject ion times and less frequent hypoglycaemic reactions 128,141,146</p>
<p><span class=\"citation\" data-cites=\"Karlson_1994\">(Karlson and Agardh 1994)</span></p>
<p><span class=\"citation\" data-cites=\"Renner_1999\">(Renner et al. 1999)</span></p>
<p><span class=\"citation\" data-cites=\"Holleman_1997\">(F. Holleman et al. 1997)</span></p>
<h3 id=\"evidence-statement-cg15adultes118\">Evidence Statement CG15AdultES118</h3>
<p>The effects of insulin lispro on HbA 1c levels (overall glycaemic control) have not been firmly established. 133,137,149 The long-term safety profile is as yet unknown</p>
<p><span class=\"citation\" data-cites=\"Vignati_1997\">(L. Vignati, Anderson, and Iversen 1997)</span></p>
<p><span class=\"citation\" data-cites=\"Davey_1997\">(Davey et al. 1997)</span></p>
<p><span class=\"citation\" data-cites=\"Battista_1995\">(Battista, Feeny, and Hodge 1995)</span></p>
<h3 id=\"evidence-statement-cg15adultes119\">Evidence Statement CG15AdultES119</h3>
<p>Two multicentre randomised studies 14950 and one RCT 135 showed insulin aspart to improve post-prandial glucose control more effectively than unmodified (soluble) human insulin, without an increase in the rate of hypoglycaemic episodes. Fewer major hypoglycaemic episodes were observed</p>
<p><span class=\"citation\" data-cites=\"Lindholm_1999\">(Lindholm, McEwen, and Riis 1999)</span></p>
<p><span class=\"citation\" data-cites=\"Battista_1995\">(Battista, Feeny, and Hodge 1995)</span></p>
<p><span class=\"citation\" data-cites=\"Home_1998\">(Home et al. 1998)</span></p>
<h3 id=\"evidence-statement-cg15adultes120\">Evidence Statement CG15AdultES120</h3>
<p>A before-and-after study has shown that a lower dose of mealtime insulin can be taken along w ith an increase in basal dose, with no increase in hypoglycaemic episodes when insulin lispro is used as a replacement for human insulin as mealtime injection therapy 142</p>
<p><span class=\"citation\" data-cites=\"Ebeling_1997\">(Ebeling et al. 1997)</span></p>
<h3 id=\"evidence-statement-cg15adultes121\">Evidence Statement CG15AdultES121</h3>
<p>Tw o randomised trials have shown that it is possible to replace mealtime unmodified (soluble) h uman insulin with insulin lispro or insulin aspart without detriment to glycaemic control if care is taken to replace basal insulin delivery more physiologically 1512</p>
<p><span class=\"citation\" data-cites=\"Zinman_1999\">(Zinman et al. 1999)</span></p>
<p><span class=\"citation\" data-cites=\"Hermansen_2001\">(Hermansen et al. 2001)</span></p>
<h3 id=\"evidence-statement-cg15adultes122\">Evidence Statement CG15AdultES122</h3>
<p>A multi-arm randomised trial found that a dding a few units of isophane (NPH) insulin to insulin lispro at each meal, in combination with bedtime NPH insulin improves blood glucose co ncentrations compared to an unmodified (soluble) human insulin regimen in a multidose reg imen 136</p>
<p><span class=\"citation\" data-cites=\"Sindaco_1998\">(Sindaco et al. 1998)</span></p>
<h3 id=\"evidence-statement-cg15adultes123\">Evidence Statement CG15AdultES123</h3>
<p>Splitting the evening administration of insulin to short-acting insulin at dinner and isophane (NPH) insulin at bedtime has a number of advantages over mixed administration of short- acting insulin and isophane (NPH) at dinner. Compared with the mixed mealtime regimen, the ev ening split regimen reduced by more than 60% the risk of nocturnal hypoglycaemia; 1534 improved long-term control of blood glucose levels, decreased variability of blood glucose levels in fasting state and led to improvement in preserved hormonal, symptom and cognitive function responses to hypoglycaemia</p>
<p><span class=\"citation\" data-cites=\"Stades_2002\">(Stades et al. 2002)</span></p>
<p><span class=\"citation\" data-cites=\"Fanelli_2002\">(Fanelli 2002)</span></p>
<h3 id=\"evidence-statement-cg15adultes124\">Evidence Statement CG15AdultES124</h3>
<p>Wh en basal insulin replacement is by either continuous subcutaneous insulin infusion (CSII) or multiple daily administrations of isophane (NPH) insulin, the long term administration of lispro at mealtime reduces HbA 1c ; 130 however, compared with multiple daily injections, patients using continuous subcutaneous administration of insulin (mainly those using older systems) have been at a significantly higher risk of ketoacidosis</p>
<p><span class=\"citation\" data-cites=\"Haakens_1989\">(Haakens et al. 1989)</span></p>
<h3 id=\"evidence-statement-cg15adultes125\">Evidence Statement CG15AdultES125</h3>
<p>Fr equency of hypoglycaemic reactions was found to be similar on patient-mixed and premixed insulins. 143,155 One randomised controlled trial showed premixed preparations of insulin analogues to be well suited for those who wish to limit the number of daily injections; 155 83% of people expressed a preference for premixed insulins throughout the trial</p>
<p><span class=\"citation\" data-cites=\"Roach_1999\">(Roach et al. 1999)</span></p>
<p><span class=\"citation\" data-cites=\"Dunbar_1994\">(Dunbar et al. 1994)</span></p>
<h3 id=\"evidence-statement-cg15adultes126\">Evidence Statement CG15AdultES126</h3>
<p>Fe w studies have addressed the needs of people with diabetes with suboptimal glucose control, and none of suitable design from the evidence hierarchy were found for review. In a group of people with Type 1 diabetes with poor glucose control, the introduction of more intensive insulin regimens may lead to high loss to follow-up. 156 Po or outcome appears to be due to the people refusing the constraints of multiple daily injections, effective blood glucose self-monitoring and regular clinic visits at short time intervals. It was suggested that people should be given clear and concise information on tr eatment goals and the ways in which these goals are to be attained as well as an explanation of the advantages and disadvantages</p>
<p><span class=\"citation\" data-cites=\"Swinnen_2009\">(Swinnen et al. 2009)</span></p>
<h3 id=\"evidence-statement-cg15adultes127\">Evidence Statement CG15AdultES127</h3>
<p>F our randomised controlled trials, two large parallel groups, 1578 and two small crossover designs 15960 we re identified that examined the use of acarbose in conjunction with insulin therapy compared to insulin and placebo in each case, in people with Type 1 diabetes. A m ulticentred study 157 w ith variable doses titrated up to 300 mg three times a day for 24 weeks, found a significant reduction in HbA 1c levels with acarbose compared to placebo, and decreases in fasting and post-prandial glucose levels to two hours. There were no differences between gr oups for daily insulin dose or hypoglycaemic ev ents, although adverse events of abdominal pain, diarrhoea and flatulence were more common with acarbose. This led to more frequent tr eatment discontinuation in the acarbose group than the placebo group. A similar Italian tr ial 158 w ith up to 100 mg acarbose three times daily for 24 weeks found no difference in HbA 1c levels, daily insulin dose, fasting glycaemia and total cholesterol. However, a significant decrease was found in two-hour post-prandial plasma glucose level, and HDL cholesterol levels were lower in people on acarbose than placebo. Again minor adverse events were more common in the acarbose group, but hypoglycaemic episodes were similar in both groups. Although care was taken not to alter baseline insulin doses, this could be adjusted if glucose levels exceeded 11.1 mmol/l or reduced with hypoglycaemic episodes</p>
<p><span class=\"citation\" data-cites=\"Hollander_1997\">(Hollander, Pi-Sunyer, and Coniff 1997)</span></p>
<p><span class=\"citation\" data-cites=\"Riccardi_1999\">(Riccardi et al. 1999)</span></p>
<p><span class=\"citation\" data-cites=\"Viviani_1988\">(Viviani et al. 1988)</span></p>
<p><span class=\"citation\" data-cites=\"Marena_1991\">(Marena et al. 1991)</span></p>
<h3 id=\"evidence-statement-cg15adultes128\">Evidence Statement CG15AdultES128</h3>
<p>The two crossover trials with 100 mg acarbose three times a day over relatively short time periods did not assess requirement for wash ou t periods (although analysis in one found no effect of treatment order) and did not account for study withdrawals. One study found a benefit in terms of HbA 1c w ith acarbose, 160 while the other found no significant differences between gr oups. 159 Po te ntial methodological limitations of these trials would not permit them to be used as an evidence base to inform recommendations in this area</p>
<p><span class=\"citation\" data-cites=\"Viviani_1988\">(Viviani et al. 1988)</span></p>
<p><span class=\"citation\" data-cites=\"Marena_1991\">(Marena et al. 1991)</span></p>
<h3 id=\"evidence-statement-cg15adultes129\">Evidence Statement CG15AdultES129</h3>
<p>Tw o small randomised controlled trials investigat ed the use of glibenclamide (called glyburide as the trials were conducted in the USA) in the therapy for Type 1 diabetics. A study using 5 mg gl yburide (orally) for 12 weeks compared to placebo after a 12-week open-label insulin stabilisation run-in period 161 found fasting blood glucose declined significantly at 12 weeks from baseline, although no comparison was made between groups. No differences were found in daily insulin dose or glycated haemoglobin le ve ls at any stage of the study. A randomised study without comparison between groups at baseline with 5 mg glyburide daily for 24 weeks co mpared to placebo 162 found no differences in plasma C-peptide levels between groups, nor difference in plasma glucose concentrations at any time point. Although HbA 1c levels were re ported to have changed more from baseline in the glyburide treated group at six weeks, potential methodological limitations of these trials would not permit them to be used as an ev idence base to inform recommendations in this area</p>
<p><span class=\"citation\" data-cites=\"Tzefos_2010\">(Tzefos and Olin 2010)</span></p>
<p><span class=\"citation\" data-cites=\"NATHAN_1988\">(NATHAN 1988)</span></p>
<h3 id=\"evidence-statement-cg15adultes130\">Evidence Statement CG15AdultES130</h3>
<p>Co mparison of 15 mg of glibenclamide daily with placebo in addition to insulin therapy in a small sample of people with Type 1 diabetes in a randomised double-blind crossover study 163 found mean blood glucose level, HbA 1c and blood glucose variability to be significantly lower w ith the intervention among people who retained endogenous insulin production. No such differences were found in a subgroup who were C-peptide negative. Although the study had a medium-term intervention period of three months, it did not provide analysis of the cohort as a whole for glibenclamide vs placebo and thus cannot be used for recommendations given the small sample sizes of the subgroups, and the inherent difficulties of extrapolating such findings to a wider population</p>
<p><span class=\"citation\" data-cites=\"Burke_1984\">(Burke, Hartog, and Waterfield 1984)</span></p>
<h3 id=\"evidence-statement-cg15adultes131\">Evidence Statement CG15AdultES131</h3>
<p>A reduced insulin requirement at 18 months was found in patients given 80 mg gliclazide twice a day compared to placebo in a small sample in a long-term study. 164 Although glycated haemoglobin both fasting and one hour post-breakfast were found to be very similar in both gr oups, the gliclazide group had C-peptide levels significantly higher than people on placebo for the same test times of the day, at six-monthly assessment points to 18 months. This study only applies to people with retained endogenous insulin secretion, and thus not the ov erwhelming majority of people with Type 1 diabetes</p>
<p><span class=\"citation\" data-cites=\"Fallucca_1996\">(Fallucca, Sciullo, and Maldonato 1996)</span></p>
<h3 id=\"evidence-statement-cg15adultes132\">Evidence Statement CG15AdultES132</h3>
<p>A medium-sized randomised controlled study found that the addition of metformin to an insulin regimen provided by CSII was able to reduce the total IR required by the person with Ty pe 1 diabetes (including reduced basal therapy) as compared to placebo over a period of six months. This was achieved without significant change to HbA 1c or increased incidence of hy poglycaemia</p>
<h3 id=\"evidence-statement-cg15adultes133\">Evidence Statement CG15AdultES133</h3>
<p>The health economic searches produced no studies giving guidance on appropriate insulin re g imens for those newly-diagnosed with Type 1 diabetes or for the management and prevention of hypoglycaemia, with the exception of the NICE appraisal of insulin glargine. The health economic searches found no published papers dealing with insulin glargine or NPH insulin. A recent NICE technology appraisal 132 re co mmended insulin glargine as a long-acting preparation for people with Type 1 diabet es alongside insulin NPH. The crucial issue for the c ost-effectiveness of insulin glargine is the amount of utility associated with reducing the fear of hypoglycaemia. Tw o cost-benefit studies were identified that considered the role of insulin lispro. 342,380 Ne ither paper was based in the UK (Canada, Australia), and both suggest that the willingness to pay for insulin lispro will outweigh its additional cost. The cost-effectiveness of lispro is unclear and is likely to be most favourable amongst those who require increased flexibility in setting mealtimes, or those for whom mealtimes are often unpredictable. The issue of the cost-effectiveness of intensive insulin therapy is complicated by a shortage of unconfounded data. The DCCT showed that a series of interventions including intensive insulin therapy reduces the rate of diabetic complications and increases life expectancy amongst an unrepresentative sample of adults and adolescents with Type 1 diabetes. Because of the co mplexity of this intervention, health economic analysis of the DCCT data has typically assumed that these reductions are primarily due to intensive insulin regimens. The health economic searches found three models designed to find the cost-effectiveness of intensive treatment, 3434,381 of which two attempted to form QALYs. The health utility values in each of the studies are poor: in one study 343 non-preference-based values are used; in another 381 only a very small sample was used to find health utilities. Both studies considered only a small number of health states and both suggest that intensive therapy is cost-effective. Tw o models analysed intensive treatment in cost-per-life-year terms, and differed in their re sults. One study 343 produced a cost-per-life-year figure of US$28,661 at 1994 prices, whilst another 344 found a figure several times larger. Neither study used UK costs. Note that as several diabetic complications will affect quality of life but will not significantly shorten life expectancy, the cost-per-QALY figure may be lower than the corresponding cost-per-life-year figure. Two c ost analyses also suggest that the DCCT cost estimates may be overestimates. 3456 Few inferences can be drawn because these studies are limited but it appears likely that intensive tr eatment, including intensive insulin regimens, will be cost-effective.</p>
<h2 id=\"topic-cg15adults13\">Topic CG15AdultS13</h2>
<p>As a large protein, insulin cannot be taken orally (it is digested) and is only absorbed across mu c ous membranes (of the nose or inside cheeks for example) very poorly. As a result, it generally has to be injected or infused into the subcutaneous fat. Self-use of injection devices is not something most people adopt happily by choice, and since the late 1970s various solutions to making this easier and more satisfactory have been developed.</p>
<p>In sulin injection pens were noted to be the overwhelming norm in the UK for insulin delivery for reasons of convenience, ease of teaching and portability. Some devices with particular design characteristics can be used by people with disabilities, where otherwise a third party w ould have to give injections. The desirability and often cost-effectiveness of this was noted. In jection into deep subcutaneous fat, and on the basis of many studies into the tissues of the abdominal wall for mealtime unmodified human insulin, are generally advised and logically based. However the needs and beliefs of individuals in giving their own insulin were felt to be of importance. Simple logic also leads to the conclusion that rotation of injection sites should be within one region rather than between regions. Group members (both clinicians and people w ith diabetes) expressed a widespread experience of repeated self-injection with the same needle without problems arising. The group considered the utility of recommending advice on cleanliness for those who choose to re-use needles, but noted the regulatory position from the Me dicines and Healthcare Products Regulatory Agency (MHRA, formerly the Medical Devices Ag ency) in the bulletin DB2000(04). Consequently, the guideline cannot make such a re co mmendation. Other common sense issues included provision for sharps disposal, and ch eck on the condition of injection sites annually or if blood glucose control problems worsen.</p>
<p>access to insulin injection delivery device Adults with Type 1 diabetes who inject insulin should have access to the insulin injection delivery device they find allows them optimal well-being, often using one or more types of insulin injection pen. </p>
<h3 id=\"evidence-statement-cg15adultes134\">Evidence Statement CG15AdultES134</h3>
<p>NICE guidance 165 co ncluded that, compared to optimised MDI therapy, CSII results in a modest but worthwhile improvement in GHb and quality of life (by allowing greater flexibility of lifestyle), and reduction of other problems such as hypoglycaemia and rising blood glucose levels at the end of the night. In routine practi c e, patients who go on to pumps are carefully selected, and to a large degree self-select ed. Overall, insulin pumps appear to be a useful advance for patients having particular problems, rather than a dramatic breakthrough in therapy, and would probably be used only in a small percentage of patients</p>
<p><span class=\"citation\" data-cites=\"Al_Mrayat_2009\">(Al-Mrayat 2009)</span></p>
<h3 id=\"evidence-statement-cg15adultes135\">Evidence Statement CG15AdultES135</h3>
<p>One randomised trial 166 of medium sample size compared a multiple injection regimen from a pen injector with conventional treatment with twice-daily syringe injection. No significant differ- ences were seen in GHb values, blood glucose values or hypoglycaemic episodes. Patient satisfac- tion with pen injectors was high and most patients opted to continue on this delivery system following termination of the trial. However, this study has some methodological limitations</p>
<p><span class=\"citation\" data-cites=\"Murray_1988\">(D. P. Murray et al. 1988)</span></p>
<h3 id=\"evidence-statement-cg15adultes136\">Evidence Statement CG15AdultES136</h3>
<p>One randomised crossover trial 167 co mpared two types of insulin regimen injected in the abdomen with the same regimen injected in the thigh. Regular insulin injections in the abdomen resulted in significantly lower post-prandial plasma glucose values, peak plasma gl ucose and increment in plasma glucose compared to time periods following injection in the thigh. Significantly higher serum free insulin values were also seen following abdominal injection of regular insulin, compared with injections administered at the thigh. No differences we re re co rd ed between injections at either site following injections containing both isophane (NPH) and unmodified (soluble) insulin</p>
<p><span class=\"citation\" data-cites=\"Bantle_1993\">(Bantle, Neal, and Frankamp 1993)</span></p>
<h3 id=\"evidence-statement-cg15adultes137\">Evidence Statement CG15AdultES137</h3>
<p>One prospective study 168 co mparing the absorption of insulin injected superficially and deep subcutaneously at the fat-muscle boundary showed no significant difference between the two te c hniques. A sub-group of 10 participants showed no difference in overall serum free insulin or plasma glucose values following superficial and deep subcutaneous injection</p>
<p><span class=\"citation\" data-cites=\"Meijer_1990\">(Meijer et al. 1990)</span></p>
<h3 id=\"evidence-statement-cg15adultes138\">Evidence Statement CG15AdultES138</h3>
<p>One study 169 re ported benefits associated with injection through clothing, compared with co nv entional injection practice with skin preparat ion over a 20-week trial period. This study had some methodological limitations</p>
<p><span class=\"citation\" data-cites=\"Fleming_1997\">(Fleming et al. 1997)</span></p>
<h3 id=\"evidence-statement-cg15adultes139\">Evidence Statement CG15AdultES139</h3>
<p>The health economic searches produced three published papers 3479 co nsidering the use of insulin pens. None of the three papers compare their benefits (patient satisfaction, or improved HbA 1c ) against their costs.</p>
<p><span class=\"citation\" data-cites=\"Graff_1998\">(Graff and McClanahan 1998)</span></p>
<p><span class=\"citation\" data-cites=\"H_rnquist_1995\">(Hrnquist et al. 1995)</span></p>
<p><span class=\"citation\" data-cites=\"H_rnquist_1990\">(Hrnquist et al. 1990)</span></p>
<h2 id=\"topic-cg15adults14\">Topic CG15AdultS14</h2>
<p>Hy poglycaemia is, for most people using insulin therapy, an inevitable consequence of the erratic absorption of insulin from subcutaneous tissue after depot injection or infusion, c oupled with absence of feedback to insulin need when changes in planned activity or eating occur once the injection has been given. Hypoglycaemia is usually unpleasant, often becomes a source of fear, and can be an embarrassment as well as a safety risk. Accordingly, while careful ch oice of insulin regimen (section 7.3) informed by self-monitoring (section 6.2) is important in ameliorating this problem, other preventative measures are of importance. A higher level of optimised management is needed when hypoglycaemia and its related problems do occur.</p>
<p>The group noted this was an area of considerable importance to people with Type 1 diabetes, but that prevention of hypoglycaemia was considered appropriately under insulin therapy re co mmendations, and secondarily under education and lifestyle issues. The group noted issues re lated to absorption and ingestion of free carbohydrate in people with decreased conscious level. They were concerned that recurrent hypoglycaemia was properly considered in a medical co ntext, and not simply attributed to lifestyle problems secondary to insulin therapy. Hy poglycaemia unawareness was also noted to be an important issue, and be partially reversible and capable of useful management, as now is nocturnal hypoglycaemia (it was noted that the re co mmendations on insulin therapy and clinical monitoring addressed other aspects of such management). No useful hard evidence was available for cognitive decline occurring in people w ith Type 1 diabetes, but the possibility of recurrent severe hypoglycaemia being a contributory factor was felt worth mentioning. The group noted that the ease and safety of administration of glucagon compared to IV glucose (risk of extravasation) meant that in most situations it was the treatment of choice. While it was re co g nised that there were groups of people to whom the identified studies do not apply (starvation, alcohol toxic), and that these people would not be expected to respond well to gl ucagon, it was agreed that the best means of detecting this was by absence of a response to gl ucagon at 10 minutes. Safe follow-up management after either therapy should include oral carbohydrate and awareness of risk of relapse. Users of glucagon injections need appropriate education and training.</p>
<p>management of hypoglycaemic symptoms Adults with Type 1 diabetes should be informed that any available glucose/sucrose containing fluid is suitable for the management of hypoglycaemic symptoms or signs in people who are able to swallow. Glucose containing tablets or gels are also suitable for those able to dissolve or disperse these in the mouth and swallow the products. </p>
<h3 id=\"evidence-statement-cg15adultes140\">Evidence Statement CG15AdultES140</h3>
<p>Canadian clinical practice guidelines 98 re ported four studies supporting the use of 15 g glucose (monosaccharide) (orally) for the treatment of moderate hypoglycaemia. Two studies within the guidelines explored a 20 g oral glucose dose for recovery of blood glucose levels. Recovery was slower following treatment with milk and orange juice. The use of glucose gel also delivered slower recovery in the latter study and required swallowing to have a significant effect. A further study showed no support for buccal administration of glucose</p>
<p><span class=\"citation\" data-cites=\"Lau_2007\">(Lau 2007)</span></p>
<h3 id=\"evidence-statement-cg15adultes141\">Evidence Statement CG15AdultES141</h3>
<p>One study within the Canadian guidelines 98 re ported on the special needs of people taking alpha-glycosidase inhibitors when treating hypoglycaemia, recommending the use of glucose (dextrose) tablets, or milk or honey if these are unavailable</p>
<p><span class=\"citation\" data-cites=\"Lau_2007\">(Lau 2007)</span></p>
<h3 id=\"evidence-statement-cg15adultes142\">Evidence Statement CG15AdultES142</h3>
<p>A bedtime snack may be needed to avoid nocturnal hypoglycaemia. Two studies from a systematic review 98 showed prepared cornstarch snack bars have some benefit in overnight re duction of hypoglycaemia, but the number of events were not significantly reduced</p>
<p><span class=\"citation\" data-cites=\"Lau_2007\">(Lau 2007)</span></p>
<h3 id=\"evidence-statement-cg15adultes143\">Evidence Statement CG15AdultES143</h3>
<p>Canadian clinical practice guidelines 98 re port one paper on the link between incidence of prior hy poglycaemic episodes and worsening in the defect of the hormonal responses to hy poglycaemia, leading to a reduction in the self-detection of hypoglycaemia. Eight papers re port the benefits of strict avoidance of hypoglycaemia in improving recognition of severe hy poglycaemia or the responses of counter-regulatory hormones</p>
<p><span class=\"citation\" data-cites=\"Lau_2007\">(Lau 2007)</span></p>
<h3 id=\"evidence-statement-cg15adultes144\">Evidence Statement CG15AdultES144</h3>
<p>A randomised controlled study 170 co mpared blood glucose awareness training (BGAT) with no tr aining on the increased hypoglycaemia after initiation of more intensive diabetes management. The counter-regulatory hormone epinephrine (adrenaline) response was not impaired following BGAT despite an increase in frequency of hypoglycaemia induced by intensive diabetes management. No difference was seen in awareness of the symptoms of hy poglycaemia following BGAT, compared with controls, although BGAT does lead to a better detection of low blood glucose levels in people starting intensive diabetes management</p>
<p><span class=\"citation\" data-cites=\"Kinsley_1999\">(Kinsley et al. 1999)</span></p>
<h3 id=\"evidence-statement-cg15adultes145\">Evidence Statement CG15AdultES145</h3>
<p>An observational study 171 co mpared blood glucose sensitivity and prediction accuracy in inpatients before and after blood glucose awareness training, showed no additional effect on the improvement of HbA 1c . The decrease in HbA 1c was not however accompanied by a change in the accuracy of blood glucose estimation or sensitivit y of recognition of low blood glucose levels</p>
<p><span class=\"citation\" data-cites=\"Fritsche_1998\">(Fritsche et al. 1998)</span></p>
<h3 id=\"evidence-statement-cg15adultes146\">Evidence Statement CG15AdultES146</h3>
<p>Canadian clinical practice guidelines 98 cite five studies demonstrating a positive effect of BGAT on accurate detection and treatment of hypoglycaemia, and allowing reduced-awareness subjects to detect a greater percentage of low blood glucose levels. These BGAT programmes involve instruction in interpretation of physical symptoms and instruction on food, exercise, insulin dosage and action, and the impact of time of day and last blood glucose measurements on estimations of blood glucose</p>
<p><span class=\"citation\" data-cites=\"Lau_2007\">(Lau 2007)</span></p>
<h3 id=\"evidence-statement-cg15adultes147\">Evidence Statement CG15AdultES147</h3>
<p>Evidence on the impact of hypoglycaemia on cognitive function is not clear. Two prospective studies reported within the Canadian guidelines 98 did not find association between intensive diabetes management and cognitive function. However, six retrospective studies found subjects w ith recurrent hypoglycaemia performed more poorly in a range of intellectual tests</p>
<p><span class=\"citation\" data-cites=\"Lau_2007\">(Lau 2007)</span></p>
<h3 id=\"evidence-statement-cg15adultes148\">Evidence Statement CG15AdultES148</h3>
<p>Tw o randomised studies compared the use of glucagon and dextrose in the treatment of severe hy poglycaemia. One study 172 co mpared intramuscular administration of 1 mg glucagon with 50 ml 50% IV dextrose in people with hypoglycaemic coma. A second study 173 co mpared intravenous administration of 1 mg glucagon vs 50 ml 50% dextrose in people with hypo- gl yc aemic coma. Both studies showed a significantly slower recovery to a normal level of co nsciousness in the glucagon treated group</p>
<p><span class=\"citation\" data-cites=\"Patrick_1990\">(A. W. Patrick et al. 1990)</span></p>
<p><span class=\"citation\" data-cites=\"Collier_1987\">(A. Collier et al. 1987)</span></p>
<h3 id=\"evidence-statement-cg15adultes149\">Evidence Statement CG15AdultES149</h3>
<p>Two glucagon-treated patients in each study (7% and 4% respectively) and two dextrose-treated patients in the second study (4%) required additional administration of 12.5 g IV dextrose following failing to recover consciousness after 15 minutes. In the first study average duration of hypoglycaemic coma was not different between the two treatment groups</p>
<h3 id=\"evidence-statement-cg15adultes150\">Evidence Statement CG15AdultES150</h3>
<p>No co rr elation was seen between time taken to recovery of consciousness and initial plasma gl ucose concentration or duration of hypoglycaemia in either of the studies. Side effects were similar among the treatment groups</p>
<h3 id=\"evidence-statement-cg15adultes151\">Evidence Statement CG15AdultES151</h3>
<p>These two small studies suggest that intravenous glucose gives a clinically non-significant advantage over intramuscular glucagon in time to recovery of consciousness in people with Type 1 diabetes in hypoglycaemic coma</p>
<h3 id=\"evidence-statement-cg15adultes152\">Evidence Statement CG15AdultES152</h3>
<p>No health economic evidence on the prevention or management of hypoglycaemia was identified in the literature review.</p>
<h2 id=\"topic-cg15adults9\">Topic CG15AdultS9</h2>
<p>C ultural and genetic differences between ethnic groups are known to affect health and response to healthcare for many diseases. In regard of Type 1 diabetes this is particularly true of eating habits, while arterial risk is known to differ for the general population and people with Type 2 diabetes. Other care issues seem likely.</p>
<p>The group were aware of a systematic review designed to detect issues of relevance (rather than trials of interventions) and identified papers concerning differences in incidence, attitudes to complications, degree of response to education programmes, blood glucose control, religious fasting and feasting, and hospitalisation. The group noted that cultural and genetic issues affected diabetes healthcare delivery in the areas of:</p>
<ul>
<li><p>patient education and self-care</p></li>
<li><p>nutritional advice</p></li>
<li><p>insulin therapy (including religious feasts and fasts)</p></li>
<li><p>arterial risk</p></li>
<li><p>blood pressure management</p></li>
<li><p>hospitalisation. Insome areas there was overlap with social/deprivation issues. The groups recommendations address cultural/religious issues in the appropriate sections of this guideline, emphasising the primacy of the individual in this regard.</p></li>
</ul>
<p>Manage as an individual Each adult with Type 1 diabetes should be managed as an individual, rather than as a member of any cultural, economic or health-affected group. Attention should be paid to the recommendations given elsewhere in this guideline with respect to the cultural preferences of individual adults with Type 1 diabetes </p>
<div class=\"references\">
<p>Ahmed, A. B., and P. D. Home. 1998. The Effect of the Insulin Analog Lispro on Nighttime Blood Glucose Control in Type 1 Diabetic Patients. <em>Diabetes Care</em> 21 (1). American Diabetes Association: 3237. doi:<a href=\"http://dx.doi.org/10.2337/diacare.21.1.32\">10.2337/diacare.21.1.32</a>.</p>
<p>Al-Mrayat, Ma<span></span>en. 2009. Towards Routine Use of Insulin Pump Therapy in Clinical Practice. <em>Pract Diab Int</em> 26 (2). Wiley-Blackwell: 4949. doi:<a href=\"http://dx.doi.org/10.1002/pdi.1330\">10.1002/pdi.1330</a>.</p>
<p>Alberti, K. G. M. M., and F. A. Gries. 1988. Management of Non-Insulin-Dependent Diabetes Mellitus in Europe: A Concensus View. <em>Diabetic Medicine</em> 5 (3). Wiley-Blackwell: 27581. doi:<a href=\"http://dx.doi.org/10.1111/j.1464-5491.1988.tb00984.x\">10.1111/j.1464-5491.1988.tb00984.x</a>.</p>
<p>Alberti, K.G.M.M., and P.Z. Zimmet. 1998. Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications. Part 1: Diagnosis and Classification of Diabetes Mellitus. Provisional Report of a <span class=\"math\">{</span>WHO<span class=\"math\">}</span> Consultation. <em>Diabet. Med.</em> 15 (7). Wiley-Blackwell: 53953. doi:<a href=\"http://dx.doi.org/10.1002/(sici)1096-9136(199807)15:7&lt;539::aid-dia668&gt;3.0.co;2-s\">10.1002/(sici)1096-9136(199807)15:7&lt;539::aid-dia668&gt;3.0.co;2-s</a>.</p>
<p>Anderson, J. H., R. L. Brunelle, V. A. Koivisto, A. Pfutzner, M. E. Trautmann, L. Vignati, and R. DiMarchi. 1997. Reduction of Postprandial Hyperglycemia and Frequency of Hypoglycemia in <span class=\"math\">{</span>IDDM<span class=\"math\">}</span> Patients on Insulin-Analog Treatment. Multicenter Insulin Lispro Study Group. <em>Diabetes</em> 46 (2). American Diabetes Association: 26570. doi:<a href=\"http://dx.doi.org/10.2337/diabetes.46.2.265\">10.2337/diabetes.46.2.265</a>.</p>
<p>APELQVIST, J., G. RAGNARSON-TENNVALL, J. LARSSON, and U. PERSSON. 1994. Diabetic Foot Ulcers in a Multidisciplinary Setting an Economic Analysis of Primary Healing and Healing with Amputation. <em>Journal of Internal Medicine</em> 235 (5). Wiley-Blackwell: 46371. doi:<a href=\"http://dx.doi.org/10.1111/j.1365-2796.1994.tb01104.x\">10.1111/j.1365-2796.1994.tb01104.x</a>.</p>
<p>Azzopardi, J., F.F. Fenech, Z. Junoussov, A. Mazovetsky, and V. Olchanski. 1995. A Computerized Health Screening and Follow-up System in Diabetes Mellitus. <em>Diabetic Medicine</em> 12 (3). Wiley-Blackwell: 27176. doi:<a href=\"http://dx.doi.org/10.1111/j.1464-5491.1995.tb00471.x\">10.1111/j.1464-5491.1995.tb00471.x</a>.</p>
<p>Bantle, J. P., L. Neal, and L. M. Frankamp. 1993. Effects of the Anatomical Region Used for Insulin Injections on Glycemia in Type I Diabetes Subjects. <em>Diabetes Care</em> 16 (12). American Diabetes Association: 159297. doi:<a href=\"http://dx.doi.org/10.2337/diacare.16.12.1592\">10.2337/diacare.16.12.1592</a>.</p>
<p>Batista, F<span></span>bio, Antonio Augusto Magalh<span></span>es, M<span></span>nica Gamba, Caio Nery, and Cristina Cardoso. 2010. Ten Years of a Multidisciplinary Diabetic Foot Team Approach in Sao Paulo, Brazil. <em>Diabetic Foot &amp; Ankle</em> 1 (0). Co-Action Publishing. doi:<a href=\"http://dx.doi.org/10.3402/dfa.v1i0.5203\">10.3402/dfa.v1i0.5203</a>.</p>
<p>Battista, Renaldo N., David H. Feeny, and Matthew J. Hodge. 1995. Evaluation of the Canadian Coordinating Office for Health Technology Assessment. <em>International Journal of Technology Assessment in Health Care</em> 11 (01). Cambridge University Press (<span class=\"math\">{</span>CUP<span class=\"math\">}</span>): 102. doi:<a href=\"http://dx.doi.org/10.1017/s0266462300005298\">10.1017/s0266462300005298</a>.</p>
<p>Bayly, G. R., W. A. Bartlett, P. H. Davies, D. Husband, A. Haddon, F. L. Game, and A. F. Jones. 1999. Laboratory-Based Calculation of Coronary Heart Disease Risk in a Hospital Diabetic Clinic. <em>Diabet Med</em> 16 (8). Wiley-Blackwell: 697701. doi:<a href=\"http://dx.doi.org/10.1046/j.1464-5491.1999.00091.x\">10.1046/j.1464-5491.1999.00091.x</a>.</p>
<p>Bernstein, Larry H., Ellis Jacobs, and Attilio Granata. 2002. Outcomes for the Assessment of Value. <em>Point of Care: The Journal of Near-Patient Testing &amp; Technology</em> 1 (3). Ovid Technologies (Wolters Kluwer Health): 19298. doi:<a href=\"http://dx.doi.org/10.1097/00134384-200209000-00013\">10.1097/00134384-200209000-00013</a>.</p>
<p>Biermann, Eberhard, Wolfgang Dietrich, Julian Rihl, and Eberhard Standl. 2002. Are There Time and Cost Savings by Using Telemanagement for Patients on Intensified Insulin Therapy? <em>Computer Methods and Programs in Biomedicine</em> 69 (2). Elsevier <span class=\"math\">{</span>BV<span class=\"math\">}</span>: 13746. doi:<a href=\"http://dx.doi.org/10.1016/s0169-2607(02)00037-8\">10.1016/s0169-2607(02)00037-8</a>.</p>
<p>Blinkhorn, A. S. 2003. Reviews : National Institute for Clinical Excellence Compilation - Issue 5 and Changes to the Way <span class=\"math\">{</span>NICE<span class=\"math\">}</span> Issues Guidance. <em>Health Education Journal</em> 62 (1). <span class=\"math\">{</span>SAGE<span class=\"math\">}</span> Publications: 9191. doi:<a href=\"http://dx.doi.org/10.1177/001789690306200113\">10.1177/001789690306200113</a>.</p>
<p>Boynton, Janette. 1998. Are We Agreed? Service Level Agreements for Health Library Services. <span class=\"math\">{</span>IFM<span class=\"math\">}</span> Healthcare Study Day, <span class=\"math\">{</span>ScHARR<span class=\"math\">}</span>, University of Sheffield, 13 June 1997. <em>Health Libraries Review</em> 15 (2). Wiley-Blackwell: 13436. doi:<a href=\"http://dx.doi.org/10.1046/j.1365-2532.1998.15201341.x\">10.1046/j.1365-2532.1998.15201341.x</a>.</p>
<p>Bridgford, Anna, and Timothy M. E. Davis. 2001. A Comprehensive Patient-Held Record for Diabetes. Part One: Initial Development of the Diabetes Databank. <em>Pract Diab Int</em> 18 (7). Wiley-Blackwell: 24145. doi:<a href=\"http://dx.doi.org/10.1002/pdi.236\">10.1002/pdi.236</a>.</p>
<p>Brink, S.J., M. Miller, and K.C. Moltz. Education and Multidisciplinary Team Care Concepts for Pediatric and Adolescent Diabetes Mellitus. <em>Journal of Pediatric Endocrinology and Metabolism</em> 15 (8). Walter de Gruyter <span class=\"math\">{</span>GmbH<span class=\"math\">}</span>. doi:<a href=\"http://dx.doi.org/10.1515/jpem.2002.15.8.1113\">10.1515/jpem.2002.15.8.1113</a>.</p>
<p>Brown, Elizabeth, G S Pal, Heather Jones, P R Hudson, and D F Child. 1986. Routine Ward <span class=\"math\">{</span>BG<span class=\"math\">}</span> Monitoring by Nurses Using <span class=\"math\">{</span>BM<span class=\"math\">}</span>-Test-Glycemie 20-800R Strips. <em>Pract. Diab. Int.</em> 3 (5). Wiley-Blackwell: 25757. doi:<a href=\"http://dx.doi.org/10.1002/pdi.1960030514\">10.1002/pdi.1960030514</a>.</p>
<p>Brunelle, B. L., J. Llewelyn, J. H. Anderson, E. A. Gale, and V. A. Koivisto. 1998. Meta-Analysis of the Effect of Insulin Lispro on Severe Hypoglycemia in Patients with Type 1 Diabetes. <em>Diabetes Care</em> 21 (10). American Diabetes Association: 172631. doi:<a href=\"http://dx.doi.org/10.2337/diacare.21.10.1726\">10.2337/diacare.21.10.1726</a>.</p>
<p>Bryant, Jackie, Hakan Brodin, Emma Loveman, and Andrew Clegg. 2007. Clinical Effectiveness and Cost-Effectiveness of Implantable Cardioverter Defibrillators for Arrhythmias: A Systematic Review and Economic Evaluation. <em>International Journal of Technology Assessment in Health Care</em> 23 (01). Cambridge University Press (<span class=\"math\">{</span>CUP<span class=\"math\">}</span>). doi:<a href=\"http://dx.doi.org/10.1017/s0266462307051586\">10.1017/s0266462307051586</a>.</p>
<p>Burke, B. J., M. Hartog, and M. R. Waterfield. 1984. Improved Diabetic Control in Insulin-Dependent Diabetics Treated with Insulin and Glibenclamide. <em>European Journal of Endocrinology</em> 107 (1). <span class=\"math\">{</span>BioScientifica<span class=\"math\">}</span>: 7077. doi:<a href=\"http://dx.doi.org/10.1530/acta.0.1070070\">10.1530/acta.0.1070070</a>.</p>
<p>Burnett, S. D., C. M. Woolf, and J. S. Yudkin. 1992. Developing a District Diabetic Register. <em><span class=\"math\">{</span>BMJ<span class=\"math\">}</span></em> 305 (6854). <span class=\"math\">{</span>BMJ<span class=\"math\">}</span>: 62730. doi:<a href=\"http://dx.doi.org/10.1136/bmj.305.6854.627\">10.1136/bmj.305.6854.627</a>.</p>
<p>Burnett, Shirley D., Martin Press, and John S. Yudkin. 1993. Compiling a District Diabetic Register: Theoretical and Practical Considerations. <em>Diabetic Medicine</em> 10 (3). Wiley-Blackwell: 199200. doi:<a href=\"http://dx.doi.org/10.1111/j.1464-5491.1993.tb00047.x\">10.1111/j.1464-5491.1993.tb00047.x</a>.</p>
<p>Cefalu, William T., Zhong Q. Wang, Eric Redmon, Audrey D. Bell-Farrow, Debra McBride, and Telle King. 1999. Clinical Validity of a Self-Test Fructosamine in Outpatient Diabetic Management. <em>Diabetes Technology &amp; Therapeutics</em> 1 (4). Mary Ann Liebert Inc: 43541. doi:<a href=\"http://dx.doi.org/10.1089/152091599316964\">10.1089/152091599316964</a>.</p>
<p>Chantelau, E., and P. Wichmann. 1992. Pathological Proteinuria in Patients with Insulin-Dependent Diabetes Mellitus: Relation to Intensive Insulin Therapy 1. <em>Exp Clin Endocrinol Diabetes</em> 99 (03). Thieme Publishing Group: 16468. doi:<a href=\"http://dx.doi.org/10.1055/s-0029-1211161\">10.1055/s-0029-1211161</a>.</p>
<p>Chaudhry, Rajeev, Sidna M. Scheitel, Erin K. McMurtry, Dorinda J. Leutink, Rosa L. Cabanela, James M. Naessens, Ahmed S. Rahman, Lynn A. Davis, and Robert J. Stroebel. 2007. Web-Based Proactive System to Improve Breast Cancer Screening. <em>Archives of Internal Medicine</em> 167 (6). American Medical Association (<span class=\"math\">{</span>AMA<span class=\"math\">}</span>): 606. doi:<a href=\"http://dx.doi.org/10.1001/archinte.167.6.606\">10.1001/archinte.167.6.606</a>.</p>
<p>Chiarelli, F., A. Verrotti, L. di Ricco, M. de Martino, and G. Morgese. 1998. Approaches to Quality of Control in Diabetes Care. <em>Hormone Research</em> 50 (Suppl. 1). S. Karger <span class=\"math\">{</span>AG<span class=\"math\">}</span>: 4147. doi:<a href=\"http://dx.doi.org/10.1159/000053102\">10.1159/000053102</a>.</p>
<p>Collier, A., D. J. Steedman, A. W. Patrick, G. R. Nimmo, D. M. Matthews, C. C. MacIntyre, K. Little, and B. F. Clarke. 1987. Comparison of Intravenous Glucagon and Dextrose in Treatment of Severe Hypoglycemia in an Accident and Emergency Department. <em>Diabetes Care</em> 10 (6). American Diabetes Association: 71215. doi:<a href=\"http://dx.doi.org/10.2337/diacare.10.6.712\">10.2337/diacare.10.6.712</a>.</p>
<p>Comino, Elizabeth J., Elizabeth J. Comino, Duong Thuy Tran, Duong Thuy Tran, Jane R. Taggart, Jane R. Taggart, Siaw-Teng Liaw, et al. 2013. A Preliminary Study of the Relationship Between General Practice Care and Hospitalisation Using a Diabetes Register, <span class=\"math\">{</span>CARDIAB<span class=\"math\">}</span>. <em>Australian Health Review</em>. <span class=\"math\">{</span>CSIRO<span class=\"math\">}</span> Publishing. doi:<a href=\"http://dx.doi.org/10.1071/ah12175\">10.1071/ah12175</a>.</p>
<p>Coster, S., M. C. Gulliford, P. T. Seed, J. K. Powrie, and R. Swaminathan. 2000. Self-Monitoring in Type 2 Diabetes Mellitus: A Meta-Analysis. <em>Diabet Med</em> 17 (11). Wiley-Blackwell: 75561. doi:<a href=\"http://dx.doi.org/10.1046/j.1464-5491.2000.00390.x\">10.1046/j.1464-5491.2000.00390.x</a>.</p>
<p>Cox, D., L. Gonder-Frederick, W. Polonsky, D. Schlundt, D. Julian, and W. Clarke. 1995. A Multicenter Evaluation of Blood Glucose Awareness Training-<span class=\"math\">{</span>II<span class=\"math\">}</span>. <em>Diabetes Care</em> 18 (4). American Diabetes Association: 52328. doi:<a href=\"http://dx.doi.org/10.2337/diacare.18.4.523\">10.2337/diacare.18.4.523</a>.</p>
<p>Cummings, Doyle M., Susan Morrissey, Michael J. Barondes, Lance Rogers, and Susan Gustke. 2001. Screening for Diabetic Retinopathy in Rural Areas: The Potential of Telemedicine. <em>The Journal of Rural Health</em> 17 (1). Wiley-Blackwell: 2531. doi:<a href=\"http://dx.doi.org/10.1111/j.1748-0361.2001.tb00251.x\">10.1111/j.1748-0361.2001.tb00251.x</a>.</p>
<p>Dargis, V., O. Pantelejeva, A. Jonushaite, L. Vileikyte, and A. J. Boulton. 1999. Benefits of a Multidisciplinary Approach in the Management of Recurrent Diabetic Foot Ulceration in Lithuania: A Prospective Study. <em>Diabetes Care</em> 22 (9). American Diabetes Association: 142831. doi:<a href=\"http://dx.doi.org/10.2337/diacare.22.9.1428\">10.2337/diacare.22.9.1428</a>.</p>
<p>Davey, Peter, David Grainger, Jamie MacMillan, Narayan Rajan, Michael Aristides, and Michael Gliksman. 1997. Clinical Outcomes with Insulin Lispro Compared with Human Regular Insulin: A Meta-Analysis. <em>Clinical Therapeutics</em> 19 (4). Elsevier <span class=\"math\">{</span>BV<span class=\"math\">}</span>: 65674. doi:<a href=\"http://dx.doi.org/10.1016/s0149-2918(97)80091-4\">10.1016/s0149-2918(97)80091-4</a>.</p>
<p>Davies, M., S. Dixon, C. J. Currie, R. E. Davis, and J. R. Peters. 2001. Evaluation of a Hospital Diabetes Specialist Nursing Service: A Randomized Controlled Trial. <em>Diabet Med</em> 18 (4). Wiley-Blackwell: 3017. doi:<a href=\"http://dx.doi.org/10.1046/j.1464-5491.2001.00470.x\">10.1046/j.1464-5491.2001.00470.x</a>.</p>
<p>Davis, Timothy M.E., and Anna Bridgford. 2001. A Comprehensive Patient-Held Record for Diabetes. Part Two: Large-Scale Assessment of the Diabetes Databank by Patients and Health Care Workers. <em>Pract Diab Int</em> 18 (9). Wiley-Blackwell: 31114. doi:<a href=\"http://dx.doi.org/10.1002/pdi.237\">10.1002/pdi.237</a>.</p>
<p>Davis, W. A., D. G. Bruce, and T. M.E. Davis. 2007. Is Self-Monitoring of Blood Glucose Appropriate for All Type 2 Diabetic Patients? The Fremantle Diabetes Study: Response to Kolb et Al. <em>Diabetes Care</em> 30 (1). American Diabetes Association: 18485. doi:<a href=\"http://dx.doi.org/10.2337/dc06-1992\">10.2337/dc06-1992</a>.</p>
<p>Day, J.L, J. Metcalfe, and P. Johnson. 1992. Benefits Provided by an Integrated Education and Clinical Diabetes Centre: A Follow-up Study. <em>Diabetic Medicine</em> 9 (9). Wiley-Blackwell: 85559. doi:<a href=\"http://dx.doi.org/10.1111/j.1464-5491.1992.tb01905.x\">10.1111/j.1464-5491.1992.tb01905.x</a>.</p>
<p>Dunbar, J. M., P. M. Madden, D. T. Gleeson, T. M. Fiad, and T. J. McKenna. 1994. Premixed Insulin Preparations in Pen Syringes Maintain Glycemic Control and Are Preferred by Patients. <em>Diabetes Care</em> 17 (8). American Diabetes Association: 87478. doi:<a href=\"http://dx.doi.org/10.2337/diacare.17.8.874\">10.2337/diacare.17.8.874</a>.</p>
<p>Ebeling, P., P. A. Jansson, U. Smith, C. Lalli, G. B. Bolli, and V. A. Koivisto. 1997. Strategies Toward Improved Control During Insulin Lispro Therapy in <span class=\"math\">{</span>IDDM<span class=\"math\">}</span>. Importance of Basal Insulin. <em>Diabetes Care</em> 20 (8). American Diabetes Association: 128789. doi:<a href=\"http://dx.doi.org/10.2337/diacare.20.8.1287\">10.2337/diacare.20.8.1287</a>.</p>
<p>Edelman, D. 2001. Rate and Predictors of Glycemic Testing of Nondiabetic Patients in a Managed Care Population. <em>Diabetes Care</em> 24 (5). American Diabetes Association: 95759. doi:<a href=\"http://dx.doi.org/10.2337/diacare.24.5.957\">10.2337/diacare.24.5.957</a>.</p>
<p>Edelman, Steven V., Patricia Callahan, and Larry C. Deeb. 2000. Multisite Evaluation of a New Diabetes Self-Test for Glucose and Glycated Protein (Fructosamine). <em>Diabetes Technology &amp; Therapeutics</em> 2 (2). Mary Ann Liebert Inc: 23338. doi:<a href=\"http://dx.doi.org/10.1089/15209150050025195\">10.1089/15209150050025195</a>.</p>
<p>Egger, M., G. Davey Smith, C. Stettler, and P. Diem. 1997. Risk of Adverse Effects of Intensified Treatment in Insulin-Dependent Diabetes Mellitus: A Meta-Analysis. <em>Diabet. Med.</em> 14 (11). Wiley-Blackwell: 91928. doi:<a href=\"http://dx.doi.org/10.1002/(sici)1096-9136(199711)14:11&lt;919::aid-dia456&gt;3.3.co;2-1\">10.1002/(sici)1096-9136(199711)14:11&lt;919::aid-dia456&gt;3.3.co;2-1</a>.</p>
<p>Engelbrecht, R., C. Hildebrand, E. Brugu<span></span>s, A. De Leiva, and R. Corcoy. 1996. <span class=\"math\">{</span>DIABCARD<span class=\"math\">}</span>an Application of a Portable Medical Record for Persons with Diabetes. <em>Informatics for Health and Social Care</em> 21 (4). Informa Healthcare: 27382. doi:<a href=\"http://dx.doi.org/10.3109/14639239608999289\">10.3109/14639239608999289</a>.</p>
<p>Engelbrecht, R., C. Hildebrand, E. Khnel, G. Brenner, R. Corcoy, G. Eberhard, C. Gapp, et al. 1994. A Chip Card for Patients with Diabetes. <em>Computer Methods and Programs in Biomedicine</em> 45 (1-2). Elsevier <span class=\"math\">{</span>BV<span class=\"math\">}</span>: 3335. doi:<a href=\"http://dx.doi.org/10.1016/0169-2607(94)90010-8\">10.1016/0169-2607(94)90010-8</a>.</p>
<p>Engelbrecht, Rolf, Josef Ingenerf, and Jrg Reiner. 2006. Relevance of Terminological Standards and Services in Telemedicine. In <em>Information Technology Solutions for Healthcare</em>, 11034. Springer Science + Business Media. doi:<a href=\"http://dx.doi.org/10.1007/1-84628-141-5_6\">10.1007/1-84628-141-5_6</a>.</p>
<p>EVANS, D. 2000. Insulin Adjustment by a Diabetes Nurse Educator Improves Glucose Control in Insulin-Requiring Diabetic Patients. <em>Evidence-Based Healthcare</em> 4 (3). Elsevier <span class=\"math\">{</span>BV<span class=\"math\">}</span>: 72. doi:<a href=\"http://dx.doi.org/10.1016/s1462-9410(00)90324-3\">10.1016/s1462-9410(00)90324-3</a>.</p>
<p>Fallucca, F., E. Sciullo, and A. Maldonato. 1996. Combined Therapy with Insulin and Sulfonylurea for the Treatment of New-Onset Insulin-Dependent Diabetes Mellitus. <em>Hormone and Metabolic Research</em> 28 (02). Thieme Publishing Group: 8688. doi:<a href=\"http://dx.doi.org/10.1055/s-2007-979134\">10.1055/s-2007-979134</a>.</p>
<p>Fanelli, Carmine G. 2002. Administration of Neutral Protamine Hagedorn Insulin at Bedtime Versus with Dinner in Type 1 Diabetes Mellitus to Avoid Nocturnal Hypoglycemia and Improve Control. <em>Annals of Internal Medicine</em> 136 (7). American College of Physicians: 504. doi:<a href=\"http://dx.doi.org/10.7326/0003-4819-136-7-200204020-00007\">10.7326/0003-4819-136-7-200204020-00007</a>.</p>
<p>Fisher, E B, W F Auslander, J F Munro, C L Arfken, R C Brownson, and N W Owens. 1998. Neighbors for a Smoke Free North Side: Evaluation of a Community Organization Approach to Promoting Smoking Cessation Among African Americans. <em>Am J Public Health</em> 88 (11). American Public Health Association: 165863. doi:<a href=\"http://dx.doi.org/10.2105/ajph.88.11.1658\">10.2105/ajph.88.11.1658</a>.</p>
<p>Fleming, D. R., S. J. Jacober, M. A. Vandenberg, J. T. Fitzgerald, and G. Grunberger. 1997. The Safety of Injecting Insulin Through Clothing. <em>Diabetes Care</em> 20 (3). American Diabetes Association: 24447. doi:<a href=\"http://dx.doi.org/10.2337/diacare.20.3.244\">10.2337/diacare.20.3.244</a>.</p>
<p>Fritsche, A, M Stumvoll, W Renn, and R.-M Schmlling. 1998. Diabetes Teaching Program Improves Glycemic Control and Preserves Perception of Hypoglycemia. <em>Diabetes Research and Clinical Practice</em> 40 (2). Elsevier <span class=\"math\">{</span>BV<span class=\"math\">}</span>: 12935. doi:<a href=\"http://dx.doi.org/10.1016/s0168-8227(98)00047-3\">10.1016/s0168-8227(98)00047-3</a>.</p>
<p>Frykberg, RG. 1997. Team Approach Toward Lower Extremity Amputation Prevention in Diabetes. <em>Journal of the American Podiatric Medical Association</em> 87 (7). American Podiatric Medical Association: 30512. doi:<a href=\"http://dx.doi.org/10.7547/87507315-87-7-305\">10.7547/87507315-87-7-305</a>.</p>
<p>Game, F. L., and A. F. Jones. 2001. Coronary Heart Disease Risk Assessment in Diabetes Mellitusa Comparison of <span class=\"math\">{</span>PROCAM<span class=\"math\">}</span> and Framingham Risk Assessment Functions. <em>Diabet Med</em> 18 (5). Wiley-Blackwell: 35559. doi:<a href=\"http://dx.doi.org/10.1046/j.1464-5491.2001.00438.x\">10.1046/j.1464-5491.2001.00438.x</a>.</p>
<p>George, E., C. Bedford, S.R. Peacey, C.A. Hardisty, and S.R. Heller. 1997. Further Evidence for a High Incidence of Nocturnal Hypoglycaemia in <span class=\"math\">{</span>IDDM<span class=\"math\">}</span>: No Effect of Dose for Dose Transfer Between Human and Porcine Insulins. <em>Diabet. Med.</em> 14 (6). Wiley-Blackwell: 44248. doi:<a href=\"http://dx.doi.org/10.1002/(sici)1096-9136(199706)14:6&lt;442::aid-did386&gt;3.0.co;2-w\">10.1002/(sici)1096-9136(199706)14:6&lt;442::aid-did386&gt;3.0.co;2-w</a>.</p>
<p>Giacco, R., M. Parillo, A. A. Rivellese, G. Lasorella, A. Giacco, L. D<span></span>Episcopo, and G. Riccardi. 2000. Long-Term Dietary Treatment with Increased Amounts of Fiber-Rich Low-Glycemic Index Natural Foods Improves Blood Glucose Control and Reduces the Number of Hypoglycemic Events in Type 1 Diabetic Patients. <em>Diabetes Care</em> 23 (10). American Diabetes Association: 146166. doi:<a href=\"http://dx.doi.org/10.2337/diacare.23.10.1461\">10.2337/diacare.23.10.1461</a>.</p>
<p>Glasgow, Russell E, Pierre-Andre La Chance, Deborah J Toobert, Jane Brown, Sarah E Hampson, and Matthew C Riddle. 1997. Long Term Effects and Costs of Brief Behavioural Dietary Intervention for Patients with Diabetes Delivered from the Medical Office. <em>Patient Education and Counseling</em> 32 (3). Elsevier <span class=\"math\">{</span>BV<span class=\"math\">}</span>: 17584. doi:<a href=\"http://dx.doi.org/10.1016/s0738-3991(97)00039-6\">10.1016/s0738-3991(97)00039-6</a>.</p>
<p>Goldberg, R. B., M. J. Mellies, F. M. Sacks, L. A. Moye, B. V. Howard, W. J. Howard, B. R. Davis, T. G. Cole, M. A. Pfeffer, and E. Braunwald. 1998. Cardiovascular Events and Their Reduction with Pravastatin in Diabetic and Glucose-Intolerant Myocardial Infarction Survivors with Average Cholesterol Levels : Subgroup Analyses in the Cholesterol and Recurrent Events (<span class=\"math\">{</span>CARE<span class=\"math\">}</span>) Trial. <em>Circulation</em> 98 (23). Ovid Technologies (Wolters Kluwer Health): 251319. doi:<a href=\"http://dx.doi.org/10.1161/01.cir.98.23.2513\">10.1161/01.cir.98.23.2513</a>.</p>
<p>Gordon, D., C.G. Semple, and K.R. Paterson. 1991. Do Different Frequencies of Self-Monitoring of Blood Glucose Influence Control in Type 1 Diabetic Patients? <em>Diabetic Medicine</em> 8 (7). Wiley-Blackwell: 67982. doi:<a href=\"http://dx.doi.org/10.1111/j.1464-5491.1991.tb01677.x\">10.1111/j.1464-5491.1991.tb01677.x</a>.</p>
<p>Gorman, C., J. Looker, T. Fisk, W. Oelke, D. Erickson, S. Smith, and B. Zimmerman. 1996. A Clinically Useful Diabetes Electronic Medical Record: Lessons from the Past Pointers Toward the Future. <em>European Journal of Endocrinology</em> 134 (1). <span class=\"math\">{</span>BioScientifica<span class=\"math\">}</span>: 3142. doi:<a href=\"http://dx.doi.org/10.1530/eje.0.1340031\">10.1530/eje.0.1340031</a>.</p>
<p>Grabert, Matthias, Franz Schweiggert, and Reinhard W. Holl. 2002. A Framework for Diabetes Documentation and Quality Management in Germany: 10 Years of Experience with <span class=\"math\">{</span>DPV<span class=\"math\">}</span>. <em>Computer Methods and Programs in Biomedicine</em> 69 (2). Elsevier <span class=\"math\">{</span>BV<span class=\"math\">}</span>: 11521. doi:<a href=\"http://dx.doi.org/10.1016/s0169-2607(02)00035-4\">10.1016/s0169-2607(02)00035-4</a>.</p>
<p>Graff, Marilyn R., and Mark A. McClanahan. 1998. Assessment by Patients with Diabetes Mellitus of Two Insulin Pen Delivery Systems Versus a Vial and Syringe. <em>Clinical Therapeutics</em> 20 (3). Elsevier <span class=\"math\">{</span>BV<span class=\"math\">}</span>: 48696. doi:<a href=\"http://dx.doi.org/10.1016/s0149-2918(98)80058-1\">10.1016/s0149-2918(98)80058-1</a>.</p>
<p>Greenwood, R. H. 2003. National Service Framework for Diabetes Leaves Questions Open. <em><span class=\"math\">{</span>BMJ<span class=\"math\">}</span></em> 326 (7394). <span class=\"math\">{</span>BMJ<span class=\"math\">}</span>: 881aa881. doi:<a href=\"http://dx.doi.org/10.1136/bmj.326.7394.881/a\">10.1136/bmj.326.7394.881/a</a>.</p>
<p>Gross, Todd M., Bruce W. Bode, Daniel Einhorn, David M. Kayne, John H. Reed, Neil H. White, and John J. Mastrototaro. 2000. Performance Evaluation of the <span class=\"math\">{</span>MiniMed<span class=\"math\">}</span> Continuous Glucose Monitoring System During Patient Home Use. <em>Diabetes Technology &amp; Therapeutics</em> 2 (1). Mary Ann Liebert Inc: 4956. doi:<a href=\"http://dx.doi.org/10.1089/152091500316737\">10.1089/152091500316737</a>.</p>
<p>Group, DAFNE Study. 2002. Training in Flexible, Intensive Insulin Management to Enable Dietary Freedom in People with Type 1 Diabetes: Dose Adjustment for Normal Eating (<span class=\"math\">{</span>DAFNE<span class=\"math\">}</span>) Randomised Controlled Trial. <em><span class=\"math\">{</span>BMJ<span class=\"math\">}</span></em> 325 (7367). <span class=\"math\">{</span>BMJ<span class=\"math\">}</span>: 74646. doi:<a href=\"http://dx.doi.org/10.1136/bmj.325.7367.746\">10.1136/bmj.325.7367.746</a>.</p>
<p>Group, European Diabetes Policy. 1999. A Desktop Guide to Type 1 (Insulin-Dependent) Diabetes Mellitus. <em>Diabet Med</em> 16 (3). Wiley-Blackwell: 25366. doi:<a href=\"http://dx.doi.org/10.1046/j.1464-5491.1999.00062.x\">10.1046/j.1464-5491.1999.00062.x</a>.</p>
<p>Grover, S. A., L. Coupal, H. Zowall, C. M. Alexander, T. W. Weiss, and D. R.J. Gomes. 2001. How Cost-Effective Is the Treatment of Dyslipidemia in Patients with Diabetes but Without Cardiovascular Disease? <em>Diabetes Care</em> 24 (1). American Diabetes Association: 4550. doi:<a href=\"http://dx.doi.org/10.2337/diacare.24.1.45\">10.2337/diacare.24.1.45</a>.</p>
<p>Grover, S. A., L. Coupal, H. Zowall, and M. Dorais. 2000. Cost-Effectiveness of Treating Hyperlipidemia in the Presence of Diabetes : Who Should Be Treated? <em>Circulation</em> 102 (7). Ovid Technologies (Wolters Kluwer Health): 72227. doi:<a href=\"http://dx.doi.org/10.1161/01.cir.102.7.722\">10.1161/01.cir.102.7.722</a>.</p>
<p>Gupta, Yashdeep, Rajiv Singla, and Sanjay Kalra. 2014. Comment on A Primary Care Based Healthy-Eating and Active Living Education Session for Weight Reduction in the Pre-Diabetic Population by Daniala et Al. <em>Primary Care Diabetes</em>, April. Elsevier <span class=\"math\">{</span>BV<span class=\"math\">}</span>. doi:<a href=\"http://dx.doi.org/10.1016/j.pcd.2014.03.002\">10.1016/j.pcd.2014.03.002</a>.</p>
<p>Haakens, K., K. F. Hanssen, K Dahl-J<span></span>rgensen, S. Vaaler, P. Torjesen, and K. Try. 1989. Early Morning Glycaemia and the Metabolic Consequences of Delaying Breakfast/morning Insulin. a Comparison of Continuous Subcutaneous Insulin Infusion and Multiple Injection Therapy with Human Isophane or Human Ultralente Insulin at Bedtime in Insulin-Dependent Diabetics. <em>Scandinavian Journal of Clinical &amp; Laboratory Investigation</em> 49 (7). Informa Healthcare: 65359. doi:<a href=\"http://dx.doi.org/10.3109/00365518909091541\">10.3109/00365518909091541</a>.</p>
<p>Hanestad, Berit Rokne, and Grethe Albrektsen. 1993. The Effects of Participation in a Support Group on Self-Assessed Quality of Life in People with Insulin-Dependent Diabetes Mellitus. <em>Diabetes Research and Clinical Practice</em> 19 (2). Elsevier <span class=\"math\">{</span>BV<span class=\"math\">}</span>: 16373. doi:<a href=\"http://dx.doi.org/10.1016/0168-8227(93)90109-i\">10.1016/0168-8227(93)90109-i</a>.</p>
<p>HANSEN, HENRIK P., PER K. CHRISTENSEN, ELLIS TAUBER-LASSEN, ANNALISE KLAUSEN, BERIT R. JENSEN, and HANS-HENRIK PARVING. 1999. Low-Protein Diet and Kidney Function in Insulin-Dependent Diabetic Patients with Diabetic Nephropathy. <em>Kidney International</em> 55 (2). Nature Publishing Group: 62128. doi:<a href=\"http://dx.doi.org/10.1046/j.1523-1755.1999.00274.x\">10.1046/j.1523-1755.1999.00274.x</a>.</p>
<p>Hrnquist, Jan Olof, Anders Wikby, Per-Olof Andersson, and Ann-Mari Dufva. 1990. Insulin-Pen Treatment, Quality of Life and Metabolic Control: Retrospective Intra-Group Evaluations. <em>Diabetes Research and Clinical Practice</em> 10 (3). Elsevier <span class=\"math\">{</span>BV<span class=\"math\">}</span>: 22130. doi:<a href=\"http://dx.doi.org/10.1016/0168-8227(90)90065-2\">10.1016/0168-8227(90)90065-2</a>.</p>
<p>Hrnquist, Jan Olof, Anders Wikby, Ulf Stenstrm, and Per-Olof Andersson. 1995. Change in Quality of Life Along with Type 1 Diabetes. <em>Diabetes Research and Clinical Practice</em> 28 (1). Elsevier <span class=\"math\">{</span>BV<span class=\"math\">}</span>: 6372. doi:<a href=\"http://dx.doi.org/10.1016/0168-8227(95)01054-h\">10.1016/0168-8227(95)01054-h</a>.</p>
<p>Hearnshaw, Hilary, Jan Hopkins, Andrea Wild, Mary MacKinnon, Roger Gadsby, and Jeremy Dale. 2001. Mandatory, Multidisciplinary Education in Diabetes Care. Can It Meet the Needs of Primary Care Organisations? <em>Pract Diab Int</em> 18 (8). Wiley-Blackwell: 27480. doi:<a href=\"http://dx.doi.org/10.1002/pdi.262\">10.1002/pdi.262</a>.</p>
<p>Hermansen, K., S. Madsbad, H. Perrild, A. Kristensen, and M. Axelsen. 2001. Comparison of the Soluble Basal Insulin Analog Insulin Detemir with <span class=\"math\">{</span>NPH<span class=\"math\">}</span> Insulin: A Randomized Open Crossover Trial in Type 1 Diabetic Subjects on Basal-Bolus Therapy. <em>Diabetes Care</em> 24 (2). American Diabetes Association: 296301. doi:<a href=\"http://dx.doi.org/10.2337/diacare.24.2.296\">10.2337/diacare.24.2.296</a>.</p>
<p>Hollander, P., X. Pi-Sunyer, and R. F. Coniff. 1997. Acarbose in the Treatment of Type I Diabetes. <em>Diabetes Care</em> 20 (3). American Diabetes Association: 24853. doi:<a href=\"http://dx.doi.org/10.2337/diacare.20.3.248\">10.2337/diacare.20.3.248</a>.</p>
<p>Holleman, F., H. Schmitt, R. Rottiers, A. Rees, S. Symanowski, and J. H. Anderson. 1997. Reduced Frequency of Severe Hypoglycemia and Coma in Well-Controlled <span class=\"math\">{</span>IDDM<span class=\"math\">}</span> Patients Treated with Insulin Lispro. the Benelux-<span class=\"math\">{</span>UK<span class=\"math\">}</span> Insulin Lispro Study Group. <em>Diabetes Care</em> 20 (12). American Diabetes Association: 182732. doi:<a href=\"http://dx.doi.org/10.2337/diacare.20.12.1827\">10.2337/diacare.20.12.1827</a>.</p>
<p>Home, P. D., A. Lindholm, B. Hylleberg, and P. Round. 1998. Improved Glycemic Control with Insulin Aspart: A Multicenter Randomized Double-Blind Crossover Trial in Type 1 Diabetic Patients. <span class=\"math\">{</span>UK<span class=\"math\">}</span> Insulin Aspart Study Group. <em>Diabetes Care</em> 21 (11). American Diabetes Association: 19049. doi:<a href=\"http://dx.doi.org/10.2337/diacare.21.11.1904\">10.2337/diacare.21.11.1904</a>.</p>
<p>Hommel, E., P. Andersen, M. -A. Gall, F. Nielsen, B. Jensen, P. Rossing, J. Dyerberg, and H. -H. Parving. 1992. Plasma Lipoproteins and Renal Function During Simvastatin Treatment in Diabetic Nephropathy. <em>Diabetologia</em> 35 (5). Springer Science + Business Media: 44751. doi:<a href=\"http://dx.doi.org/10.1007/bf02342442\">10.1007/bf02342442</a>.</p>
<p>Howitt, A J, and N A Cheales. 1993. Diabetes Registers: A Grassroots Approach. <em><span class=\"math\">{</span>BMJ<span class=\"math\">}</span></em> 307 (6911). <span class=\"math\">{</span>BMJ<span class=\"math\">}</span>: 104648. doi:<a href=\"http://dx.doi.org/10.1136/bmj.307.6911.1046\">10.1136/bmj.307.6911.1046</a>.</p>
<p>Jessup, Mariell. 2001. Mechanical Cardiac-Support Devices Dreams and Devilish Details. <em>New England Journal of Medicine</em> 345 (20). New England Journal of Medicine (<span class=\"math\">{</span>NEJM<span class=\"math\">}</span>/<span class=\"math\">{</span>MMS<span class=\"math\">}</span>): 149093. doi:<a href=\"http://dx.doi.org/10.1056/nejmed010109\">10.1056/nejmed010109</a>.</p>
<p>Jones, A F. 2001. Comparative Accuracy of Cardiovascular Risk Prediction Methods in Primary Care Patients. <em>Heart</em> 85 (1). <span class=\"math\">{</span>BMJ<span class=\"math\">}</span>: 3743. doi:<a href=\"http://dx.doi.org/10.1136/heart.85.1.37\">10.1136/heart.85.1.37</a>.</p>
<p>Jones, P. M. 1990. Use of a Course on Self-Control Behavior Techniques to Increase Adherence to Prescribed Frequency for Self-Monitoring Blood Glucose. <em>The Diabetes Educator</em> 16 (4). <span class=\"math\">{</span>SAGE<span class=\"math\">}</span> Publications: 296303. doi:<a href=\"http://dx.doi.org/10.1177/014572179001600409\">10.1177/014572179001600409</a>.</p>
<p>Kanters, S. D., J.-D. Banga, R. P Stolk, and A. Algra. 1999. Incidence and Determinants of Mortality and Cardiovascular Events in Diabetes Mellitus: A Meta-Analysis. <em>Vascular Medicine</em> 4 (2). <span class=\"math\">{</span>SAGE<span class=\"math\">}</span> Publications: 6775. doi:<a href=\"http://dx.doi.org/10.1177/1358836x9900400203\">10.1177/1358836x9900400203</a>.</p>
<p>Kaplan, Robert M., Sherry L. Hartwell, Dawn K. Wilson, and Janet P. Wallace. 1987. Effects of Diet and Exercise Interventions on Control and Quality of Life in Non-Insulin-Dependent Diabetes Mellitus. <em>J Gen Intern Med</em> 2 (4). Springer Science + Business Media: 22028. doi:<a href=\"http://dx.doi.org/10.1007/bf02596443\">10.1007/bf02596443</a>.</p>
<p>Karlson, Bjrn, and Carl-David Agardh. 1994. Influence of Intensified Insulin Regimen on Quality of Life and Metabolic Control in Insulin-Dependent Diabetes Mellitus. <em>Diabetes Research and Clinical Practice</em> 25 (2). Elsevier <span class=\"math\">{</span>BV<span class=\"math\">}</span>: 11115. doi:<a href=\"http://dx.doi.org/10.1016/0168-8227(94)90036-1\">10.1016/0168-8227(94)90036-1</a>.</p>
<p>Kelly, William, Rudolf Bilous, and Gordon Murray. 1998. A Comprehensive Register for Diabetic Outpatients: Experience with Desktop Computing from 19871996. <em>Computer Methods and Programs in Biomedicine</em> 56 (2). Elsevier <span class=\"math\">{</span>BV<span class=\"math\">}</span>: 20510. doi:<a href=\"http://dx.doi.org/10.1016/s0169-2607(98)00026-1\">10.1016/s0169-2607(98)00026-1</a>.</p>
<p>Kinsley, B. T., K. Weinger, M. Bajaj, C. J. Levy, D. C. Simonson, M. Quigley, D. J. Cox, and A. M. Jacobson. 1999. Blood Glucose Awareness Training and Epinephrine Responses to Hypoglycemia During Intensive Treatment in Type 1 Diabetes. <em>Diabetes Care</em> 22 (7). American Diabetes Association: 102228. doi:<a href=\"http://dx.doi.org/10.2337/diacare.22.7.1022\">10.2337/diacare.22.7.1022</a>.</p>
<p>Knight, B. G., S. M. Lutzky, and F. Macofsky-Urban. 1993. A Meta-Analytic Review of Interventions for Caregiver Distress: Recommendations for Future Research. <em>The Gerontologist</em> 33 (2). Oxford University Press (<span class=\"math\">{</span>OUP<span class=\"math\">}</span>): 24048. doi:<a href=\"http://dx.doi.org/10.1093/geront/33.2.240\">10.1093/geront/33.2.240</a>.</p>
<p>Kopelman, P. G., J. C. Michell, and A. J. Sanderson. 1995. <span class=\"math\">{</span>DIAMOND<span class=\"math\">}</span>: A Computerized System for the Management and Evaluation of District-Wide Diabetes Care. <em>Diabetic Medicine</em> 12 (1). Wiley-Blackwell: 8387. doi:<a href=\"http://dx.doi.org/10.1111/j.1464-5491.1995.tb02068.x\">10.1111/j.1464-5491.1995.tb02068.x</a>.</p>
<p>Koproski, J., Z. Pretto, and L. Poretsky. 1997. Effects of an Intervention by a Diabetes Team in Hospitalized Patients with Diabetes. <em>Diabetes Care</em> 20 (10). American Diabetes Association: 155355. doi:<a href=\"http://dx.doi.org/10.2337/diacare.20.10.1553\">10.2337/diacare.20.10.1553</a>.</p>
<p>Korhonen, T., J. K. Huttunen, A. Aro, M. Hentinen, O. Ihalainen, H. Majander, O. Siitonen, M. Uusitupa, and K. Pyorala. 1983. A Controlled Trial on the Effects of Patient Education in the Treatment of Insulin-Dependent Diabetes. <em>Diabetes Care</em> 6 (3). American Diabetes Association: 25661. doi:<a href=\"http://dx.doi.org/10.2337/diacare.6.3.256\">10.2337/diacare.6.3.256</a>.</p>
<p>Krolewski, Andrzej S., Lori M.B. Laffel, Martin Krolewski, Maryanne Quinn, and James H. Warram. 1995. Glycosylated Hemoglobin and the Risk of Microalbuminuria in Patients with Insulin-Dependent Diabetes Mellitus. <em>New England Journal of Medicine</em> 332 (19). New England Journal of Medicine (<span class=\"math\">{</span>NEJM<span class=\"math\">}</span>/<span class=\"math\">{</span>MMS<span class=\"math\">}</span>): 125155. doi:<a href=\"http://dx.doi.org/10.1056/nejm199505113321902\">10.1056/nejm199505113321902</a>.</p>
<p>Kucher, M., J. Schneider, K. Piwernetz, R. Engelbrecht, H. Zock, and R. Renner. 1990. Integration of a Data Driven Blood Glucose Simulation into a Rule Based Expert System. In <em>Medical Informatics Europe 90</em>, 74447. Springer Science + Business Media. doi:<a href=\"http://dx.doi.org/10.1007/978-3-642-51659-7_139\">10.1007/978-3-642-51659-7_139</a>.</p>
<p>LAAKSONEN, DAVID E., MUSTAFA ATALAY, LEO K. NISKANEN, JUHA MUSTONEN, CHANDAN K. <span>&amp;</span>NA: TIMO A. LAKKA, and MATTI I. J. UUSITUPA. 2000. Aerobic Exercise and the Lipid Profile in Type 1 Diabetic Men: A Randomized Controlled Trial. <em>Medicine &amp; Science in Sports &amp; Exercise</em>, September. Ovid Technologies (Wolters Kluwer Health), 154148. doi:<a href=\"http://dx.doi.org/10.1097/00005768-200009000-00003\">10.1097/00005768-200009000-00003</a>.</p>
<p>Labrecque, Mark S., Terry Peak, and Ronald W. Toseland. 1992. Long-Term Effectiveness of a Group Program for Caregivers of Frail Elderly Veterans. <em>American Journal of Orthopsychiatry</em> 62 (4). American Psychological Association (<span class=\"math\">{</span>APA<span class=\"math\">}</span>): 57588. doi:<a href=\"http://dx.doi.org/10.1037/h0079385\">10.1037/h0079385</a>.</p>
<p>Lalli, C., M. Ciofetta, P. Del Sindaco, E. Torlone, S. Pampanelli, P. Compagnucci, M. G. Cartechini, L. Bartocci, P. Brunetti, and G. B. Bolli. 1999. Long-Term Intensive Treatment of Type 1 Diabetes with the Short-Acting Insulin Analog Lispro in Variable Combination with <span class=\"math\">{</span>NPH<span class=\"math\">}</span> Insulin at Mealtime. <em>Diabetes Care</em> 22 (3). American Diabetes Association: 46877. doi:<a href=\"http://dx.doi.org/10.2337/diacare.22.3.468\">10.2337/diacare.22.3.468</a>.</p>
<p>Larsen, Mogens Lytken, and Mogens H<span></span>rder. 1989. Metabolic Evaluation of Non-Insulin-Dependent Diabetes in Primary Health Care - the Clinical Usefulness of Glycated Haemoglobin Measurements. <em>Scandinavian Journal of Primary Health Care</em> 7 (3). Informa Healthcare: 16771. doi:<a href=\"http://dx.doi.org/10.3109/02813438909087235\">10.3109/02813438909087235</a>.</p>
<p>Larsson, J., A. Stenstrm, J. Apelqvist, and C-D Agardh. 1995. Decreasing Incidence of Major Amputation in Diabetic Patients: A Consequence of a Multidisciplinary Foot Care Team Approach? <em>Diabetic Medicine</em> 12 (9). Wiley-Blackwell: 77076. doi:<a href=\"http://dx.doi.org/10.1111/j.1464-5491.1995.tb02078.x\">10.1111/j.1464-5491.1995.tb02078.x</a>.</p>
<p>Lau, David C.W. 2007. Evidence-Based Canadian Obesity Clinical Practice Guidelines: Relevance to Diabetes Management. <em>Canadian Journal of Diabetes</em> 31 (2). Elsevier <span class=\"math\">{</span>BV<span class=\"math\">}</span>: 14852. doi:<a href=\"http://dx.doi.org/10.1016/s1499-2671(07)12010-4\">10.1016/s1499-2671(07)12010-4</a>.</p>
<p>Lehmann, R., V. Kaplan, R. Bingisser, K. E. Bloch, and G. A. Spinas. 1997. Impact of Physical Activity on Cardiovascular Risk Factors in <span class=\"math\">{</span>IDDM<span class=\"math\">}</span>. <em>Diabetes Care</em> 20 (10). American Diabetes Association: 160311. doi:<a href=\"http://dx.doi.org/10.2337/diacare.20.10.1603\">10.2337/diacare.20.10.1603</a>.</p>
<p>Lennon, G.M., K.G. Taylor, L. Debney, and C.J. Bailey. 1990. Knowledge, Attitudes, Technical Competence, and Blood Glucose Control of Type 1 Diabetic Patients During and After an Education Programme. <em>Diabetic Medicine</em> 7 (9). Wiley-Blackwell: 82532. doi:<a href=\"http://dx.doi.org/10.1111/j.1464-5491.1990.tb01500.x\">10.1111/j.1464-5491.1990.tb01500.x</a>.</p>
<p>Levetan, Claresa S., Jacqueline R. Salas, Ilene F. Wilets, and Barnett Zumoff. 1995. Impact of Endocrine and Diabetes Team Consultation on Hospital Length of Stay for Patients with Diabetes. <em>The American Journal of Medicine</em> 99 (1). Elsevier <span class=\"math\">{</span>BV<span class=\"math\">}</span>: 2228. doi:<a href=\"http://dx.doi.org/10.1016/s0002-9343(99)80100-4\">10.1016/s0002-9343(99)80100-4</a>.</p>
<p>Ligtenberg, P. 1999. No Effect of Long-Term Physical Activity on the Glycemic Control in Type 1 Diabetes Patients: A Cross-Sectional Study. <em>The Netherlands Journal of Medicine</em> 55 (2). Elsevier <span class=\"math\">{</span>BV<span class=\"math\">}</span>: 5963. doi:<a href=\"http://dx.doi.org/10.1016/s0300-2977(99)00039-x\">10.1016/s0300-2977(99)00039-x</a>.</p>
<p>Linden, Belinda. 2011. Non-Pharmacological Management of Depression Scottish Intercollegiate Guidelines Network ( 2010 ) Non-Pharmaceutical Management of Depression in Adults: A National Clinical Guideline . [<span class=\"math\">{</span>SIGN<span class=\"math\">}</span> 114. January. <span class=\"math\">{</span>SIGN<span class=\"math\">}</span> , Edinburgh. <em>Br J Cardiac Nursing</em> 6 (3). Mark Allen Group: 14243. doi:<a href=\"http://dx.doi.org/10.12968/bjca.2011.6.3.142\">10.12968/bjca.2011.6.3.142</a>.</p>
<p>Lindholm, A., J. McEwen, and A. P. Riis. 1999. Improved Postprandial Glycemic Control with Insulin Aspart. a Randomized Double-Blind Cross-over Trial in Type 1 Diabetes. <em>Diabetes Care</em> 22 (5). American Diabetes Association: 8015. doi:<a href=\"http://dx.doi.org/10.2337/diacare.22.5.801\">10.2337/diacare.22.5.801</a>.</p>
<p>Lonn, E., J. Mathew, J. Pogue, D. Johnstone, K. Danisa, J. Bosch, M. Baird, G. Dagenais, P. Sleight, and S. Yusuf. 2003. Relationship of Electrocardiographic Left Ventricular Hypertrophy to Mortality and Cardiovascular Morbidity in High-Risk Patients. <em>European Journal of Cardiovascular Prevention &amp; Rehabilitation</em> 10 (6). Ovid Technologies (Wolters Kluwer Health): 42028. doi:<a href=\"http://dx.doi.org/10.1097/01.hjr.0000106836.977722.cf\">10.1097/01.hjr.0000106836.977722.cf</a>.</p>
<p>Maran, A., C. Crepaldi, A. Tiengo, G. Grassi, E. Vitali, G. Pagano, S. Bistoni, et al. 2002. Continuous Subcutaneous Glucose Monitoring in Diabetic Patients: A Multicenter Analysis. <em>Diabetes Care</em> 25 (2). American Diabetes Association: 34752. doi:<a href=\"http://dx.doi.org/10.2337/diacare.25.2.347\">10.2337/diacare.25.2.347</a>.</p>
<p>Marena, S., V. Tagliaferro, G. Cavallero, A. Paganiy, G. Montegrosso, W. Bianchi, P. Zaccarini, and G. Pagano. 1991. Double-Blind Crossover Study of Acarbose in Type 1 Diabetic Patients. <em>Diabetic Medicine</em> 8 (7). Wiley-Blackwell: 67478. doi:<a href=\"http://dx.doi.org/10.1111/j.1464-5491.1991.tb01676.x\">10.1111/j.1464-5491.1991.tb01676.x</a>.</p>
<p>Maxwell, A. E., I. F. Hunt, and M. A. Bush. 1992. Effects of a Social Support Group, as an Adjunct to Diabetes Training, on Metabolic Control and Psychosocial Outcomes. <em>The Diabetes Educator</em> 18 (4). <span class=\"math\">{</span>SAGE<span class=\"math\">}</span> Publications: 3039. doi:<a href=\"http://dx.doi.org/10.1177/014572179201800408\">10.1177/014572179201800408</a>.</p>
<p>MHAUSER, I., U. BOTT, H. OVERMANN, W. WAGENER, R. BENDER, V. JRGENS, and M. BERGER. 1995. Liberalized Diet in Patients with Type 1 Diabetes. <em>Journal of Internal Medicine</em> 237 (6). Wiley-Blackwell: 59197. doi:<a href=\"http://dx.doi.org/10.1111/j.1365-2796.1995.tb00890.x\">10.1111/j.1365-2796.1995.tb00890.x</a>.</p>
<p>MCCANCE, D. 1989. <span class=\"math\">{</span>LONG<span class=\"math\">}</span>-<span class=\"math\">{</span>TERM<span class=\"math\">}</span> <span class=\"math\">{</span>GLYCAEMIC<span class=\"math\">}</span> <span class=\"math\">{</span>CONTROL<span class=\"math\">}</span> <span class=\"math\">{</span>aND<span class=\"math\">}</span> <span class=\"math\">{</span>DIABETIC<span class=\"math\">}</span> <span class=\"math\">{</span>RETINOPATHY<span class=\"math\">}</span>. <em>The Lancet</em> 334 (8667). Elsevier <span class=\"math\">{</span>BV<span class=\"math\">}</span>: 82428. doi:<a href=\"http://dx.doi.org/10.1016/s0140-6736(89)92996-6\">10.1016/s0140-6736(89)92996-6</a>.</p>
<p>McCulloch, D.K., R.D. Mitchell, J. Ambler, and R.B. Tattersall. 1985. A Prospective Comparison of ?Conventional? And High Carbohydrate / High Fibre / Low Fat Diets in Adults with Established Type 1 (Insulin-Dependent) Diabetes. <em>Diabetologia</em> 28 (4). Springer Science + Business Media. doi:<a href=\"http://dx.doi.org/10.1007/bf00282234\">10.1007/bf00282234</a>.</p>
<p>McGill, Marg, Maria Constantino, and Dennis K. Yue. 2000. Integrating Telemedicine into a National Diabetes Footcare Network. <em>Pract Diab Int</em> 17 (7). Wiley-Blackwell: 23538. doi:<a href=\"http://dx.doi.org/10.1002/1528-252x(200010)17:7&lt;235::aid-pdi101&gt;3.0.co;2-h\">10.1002/1528-252x(200010)17:7&lt;235::aid-pdi101&gt;3.0.co;2-h</a>.</p>
<p>Meijer, P.H.E.M., J.A. Lutterman, H.J.J. Lier, and A. van<span></span>t Laar. 1990. The Variability of the Absorption of Subcutaneously Injected Insulin: Effect of Injection Technique and Relation with Brittleness. <em>Diabetic Medicine</em> 7 (6). Wiley-Blackwell: 499505. doi:<a href=\"http://dx.doi.org/10.1111/j.1464-5491.1990.tb01431.x\">10.1111/j.1464-5491.1990.tb01431.x</a>.</p>
<p>Mensing, C., J. Boucher, M. Cypress, K. Weinger, K. Mulcahy, P. Barta, G. Hosey, et al. 2000. National Standards for Diabetes Self-Management Education. Task Force to Review and Revise the National Standards for Diabetes Self-Management Education Programs. <em>Diabetes Care</em> 23 (5). American Diabetes Association: 68289. doi:<a href=\"http://dx.doi.org/10.2337/diacare.23.5.682\">10.2337/diacare.23.5.682</a>.</p>
<p>Miller, J. 2002. The Scottish Intercollegiate Guidelines Network (<span class=\"math\">{</span>SIGN<span class=\"math\">}</span>). <em>The British Journal of Diabetes &amp; Vascular Disease</em> 2 (1). <span class=\"math\">{</span>SAGE<span class=\"math\">}</span> Publications: 4749. doi:<a href=\"http://dx.doi.org/10.1177/14746514020020010401\">10.1177/14746514020020010401</a>.</p>
<p>Morris, D. B. 1998. A Rural Diabetes Support Group. <em>The Diabetes Educator</em> 24 (4). <span class=\"math\">{</span>SAGE<span class=\"math\">}</span> Publications: 49397. doi:<a href=\"http://dx.doi.org/10.1177/014572179802400408\">10.1177/014572179802400408</a>.</p>
<p>Murray, D. P., P. Keenan, E. Gayer, P. Salmon, G. H. Tomkin, M. I. Drury, and D. J. O<span></span>Sullivan. 1988. A Randomized Trial of the Efficacy and Acceptability of a Pen Injector. <em>Diabetic Medicine</em> 5 (8). Wiley-Blackwell: 75054. doi:<a href=\"http://dx.doi.org/10.1111/j.1464-5491.1988.tb01102.x\">10.1111/j.1464-5491.1988.tb01102.x</a>.</p>
<p><span>&amp;</span>NA. 2008. Novartis Has Announced That the Final National Institute for Health and Clinical Excellence (<span class=\"math\">{</span>NICE<span class=\"math\">}</span>) Technology Appraisal Guidance. <em><span class=\"math\">{</span>PharmacoEconomics<span class=\"math\">}</span> &amp; Outcomes News</em> &amp;<span class=\"math\">{</span>NA<span class=\"math\">}</span> (561). Springer Science + Business Media: 10. doi:<a href=\"http://dx.doi.org/10.2165/00151234-200805610-00029\">10.2165/00151234-200805610-00029</a>.</p>
<p>NATHAN, DAVID M. 1988. Glyburide or Insulin for Metabolic Control in Non-Insulin-Dependent Diabetes Mellitus. <em>Annals of Internal Medicine</em> 108 (3). American College of Physicians: 334. doi:<a href=\"http://dx.doi.org/10.7326/0003-4819-108-3-334\">10.7326/0003-4819-108-3-334</a>.</p>
<p>Nathan, David M., Daniel E. Singer, Katherine Hurxthal, and John D. Goodson. 1984. The Clinical Information Value of the Glycosylated Hemoglobin Assay. <em>New England Journal of Medicine</em> 310 (6). New England Journal of Medicine (<span class=\"math\">{</span>NEJM<span class=\"math\">}</span>/<span class=\"math\">{</span>MMS<span class=\"math\">}</span>): 34146. doi:<a href=\"http://dx.doi.org/10.1056/nejm198402093100602\">10.1056/nejm198402093100602</a>.</p>
<p>Nielsen, F. S., L. N. Jrgensen, M. Ipsen, A. I. Voldsgaard, and H. -H. Parving. 1995. Long-Term Comparison of Human Insulin Analogue B10Asp and Soluble Human Insulin in <span class=\"math\">{</span>IDDM<span class=\"math\">}</span> Patients on a Basal/bolus Insulin Regimen. <em>Diabetologia</em> 38 (5). Springer Science + Business Media: 59298. doi:<a href=\"http://dx.doi.org/10.1007/bf00400729\">10.1007/bf00400729</a>.</p>
<p>NORRIS, S, P NICHOLS, C CASPERSEN, R GLASGOW, M ENGELGAU, L JACKJR, S SNYDER, V CARANDEKULIS, G ISHAM, and S GARFIELD. 2002. Increasing Diabetes Self-Management Education in Community <span class=\"math\">{</span>SettingsA<span class=\"math\">}</span> Systematic Review. <em>American Journal of Preventive Medicine</em> 22 (4). Elsevier <span class=\"math\">{</span>BV<span class=\"math\">}</span>: 3966. doi:<a href=\"http://dx.doi.org/10.1016/s0749-3797(02)00424-5\">10.1016/s0749-3797(02)00424-5</a>.</p>
<p>Ostwald, S. K., K. W. Hepburn, W. Caron, T. Burns, and R. Mantell. 1999. Reducing Caregiver Burden: A Randomized Psychoeducational Intervention for Caregivers of Persons with Dementia. <em>The Gerontologist</em> 39 (3). Oxford University Press (<span class=\"math\">{</span>OUP<span class=\"math\">}</span>): 299309. doi:<a href=\"http://dx.doi.org/10.1093/geront/39.3.299\">10.1093/geront/39.3.299</a>.</p>
<p>Patrick, A W, A Collier, D A Hepburn, D J Steedman, B F Clarke, and C Robertson. 1990. Comparison of Intramuscular Glucagon and Intravenous Dextrose in the Treatment of Hypoglycaemic Coma in an Accident and Emergency Department. <em>Emergency Medicine Journal</em> 7 (2). <span class=\"math\">{</span>BMJ<span class=\"math\">}</span>: 7377. doi:<a href=\"http://dx.doi.org/10.1136/emj.7.2.73\">10.1136/emj.7.2.73</a>.</p>
<p>Perry, T L, J I Mann, N J Lewis-Barned, A W Duncan, M A Waldron, and C Thompson. 1997. Lifestyle Intervention in People with Insulin-Dependent Diabetes Mellitus (<span class=\"math\">{</span>IDDM<span class=\"math\">}</span>). <em>Eur J Clin Nutr</em> 51 (11). Nature Publishing Group: 75763. doi:<a href=\"http://dx.doi.org/10.1038/sj.ejcn.1600478\">10.1038/sj.ejcn.1600478</a>.</p>
<p>Peters, A. L. 1996. A Clinical Approach for the Diagnosis of Diabetes Mellitus: An Analysis Using Glycosylated Hemoglobin Levels. Meta-Analysis Research Group on the Diagnosis of Diabetes Using Glycated Hemoglobin Levels. <em><span class=\"math\">{</span>JAMA<span class=\"math\">}</span>: The Journal of the American Medical Association</em> 276 (15). American Medical Association (<span class=\"math\">{</span>AMA<span class=\"math\">}</span>): 124652. doi:<a href=\"http://dx.doi.org/10.1001/jama.276.15.1246\">10.1001/jama.276.15.1246</a>.</p>
<p>Pftzner, A., E. Kstner, T. Forst, B. Schulze-Schleppinghoff, M. E. Trautmann, M. Haslbeck, H. Schatz, and J. Beyer. 1996. Intensive Insulin Therapy with Insulin Lispro in Patients with Type 1 Diabetes Reduces the Frequency of Hypoglycemic Episodes. <em>Exp Clin Endocrinol Diabetes</em> 104 (01). Thieme Publishing Group: 2530. doi:<a href=\"http://dx.doi.org/10.1055/s-0029-1211418\">10.1055/s-0029-1211418</a>.</p>
<p>Pignone, Michael P, Christopher J Phillips, David Atkins, Steven M Teutsch, Cynthia D Mulrow, and Kathleen N Lohr. 2001. Screening and Treating Adults for Lipid Disorders21Reprints Are Available from the <span class=\"math\">{</span>AHRQ<span class=\"math\">}</span> Web Site at Www.ahrq.gov/clinic/uspstfix.htm, Through the National Guideline Clearinghouse (Www.guideline/gov), or in Print Through the <span class=\"math\">{</span>AHRQ<span class=\"math\">}</span> Publications Clearinghouse (1-800-358-9295).22The <span class=\"math\">{</span>USPSTF<span class=\"math\">}</span> Recommendations Based on This Evidence Review Can Be Found in Screening Adults for Lipid Disorders: Recommendations and Rationale, Available Elsewhere in This Supplement and from the <span class=\"math\">{</span>AHRQ<span class=\"math\">}</span> Web Site and Clearinghouse. <em>American Journal of Preventive Medicine</em> 20 (3). Elsevier <span class=\"math\">{</span>BV<span class=\"math\">}</span>: 7789. doi:<a href=\"http://dx.doi.org/10.1016/s0749-3797(01)00255-0\">10.1016/s0749-3797(01)00255-0</a>.</p>
<p>Raskin, Philip, Om P. Ganda, Sherwyn Schwartz, David Willard, Julio Rosenstock, Peter A. Lodewick, Michael D. Cressman, et al. 1995. Efficacy and Safety of Pravastatin in the Treatment of Patients with Type I or Type <span class=\"math\">{</span>II<span class=\"math\">}</span> Diabetes Mellitus and Hypercholesterolemia. <em>The American Journal of Medicine</em> 99 (4). Elsevier <span class=\"math\">{</span>BV<span class=\"math\">}</span>: 36269. doi:<a href=\"http://dx.doi.org/10.1016/s0002-9343(99)80182-x\">10.1016/s0002-9343(99)80182-x</a>.</p>
<p>Reichard, Per, Bengt-Yngve Nilsson, and Urban Rosenqvist. 1993. The Effect of Long-Term Intensified Insulin Treatment on the Development of Microvascular Complications of Diabetes Mellitus. <em>New England Journal of Medicine</em> 329 (5). New England Journal of Medicine (<span class=\"math\">{</span>NEJM<span class=\"math\">}</span>/<span class=\"math\">{</span>MMS<span class=\"math\">}</span>): 3049. doi:<a href=\"http://dx.doi.org/10.1056/nejm199307293290502\">10.1056/nejm199307293290502</a>.</p>
<p>Renner, R., A. Pfutzner, M. Trautmann, O. Harzer, K. Sauter, and R. Landgraf. 1999. Use of Insulin Lispro in Continuous Subcutaneous Insulin Infusion Treatment. Results of a Multicenter Trial. German Humalog-<span class=\"math\">{</span>CSII<span class=\"math\">}</span> Study Group. <em>Diabetes Care</em> 22 (5). American Diabetes Association: 78488. doi:<a href=\"http://dx.doi.org/10.2337/diacare.22.5.784\">10.2337/diacare.22.5.784</a>.</p>
<p>Riazi, A., S. Hammersley, C. Eiser, J.R. Eiser, and J.E. Tooke. 2000. Patients Experiences of the Diabetes Annual Review. <em>Pract Diab Int</em> 17 (7). Wiley-Blackwell: 22630. doi:<a href=\"http://dx.doi.org/10.1002/1528-252x(200010)17:7&lt;226::aid-pdi71&gt;3.0.co;2-x\">10.1002/1528-252x(200010)17:7&lt;226::aid-pdi71&gt;3.0.co;2-x</a>.</p>
<p>Riccardi, G., R. Giacco, M. Parillo, S. Turco, A. A. Rivellese, M. R. Ventura, S. Contadini, et al. 1999. Efficacy and Safety of Acarbose in the Treatment of Type 1 Diabetes Mellitus: A Placebo-Controlled,double-Blind, Multicentre Study. <em>Diabet Med</em> 16 (3). Wiley-Blackwell: 22832. doi:<a href=\"http://dx.doi.org/10.1046/j.1464-5491.1999.00047.x\">10.1046/j.1464-5491.1999.00047.x</a>.</p>
<p>RICCOMINI, PAUL. 2002. <span class=\"math\">{</span>THE<span class=\"math\">}</span> <span class=\"math\">{</span>COMPARATIVE<span class=\"math\">}</span> <span class=\"math\">{</span>EFFECTIVENESS<span class=\"math\">}</span> <span class=\"math\">{</span>oF<span class=\"math\">}</span> <span class=\"math\">{</span>TWO<span class=\"math\">}</span> <span class=\"math\">{</span>FORMS<span class=\"math\">}</span> <span class=\"math\">{</span>oF<span class=\"math\">}</span> <span class=\"math\">{</span>FEEDBACK<span class=\"math\">}</span>: <span class=\"math\">{</span>WEB<span class=\"math\">}</span>-<span class=\"math\">{</span>BASED<span class=\"math\">}</span> <span class=\"math\">{</span>MODEL<span class=\"math\">}</span> <span class=\"math\">{</span>COMPARISON<span class=\"math\">}</span> <span class=\"math\">{</span>aND<span class=\"math\">}</span> <span class=\"math\">{</span>INSTRUCTOR<span class=\"math\">}</span> <span class=\"math\">{</span>DELIVERED<span class=\"math\">}</span> <span class=\"math\">{</span>CORRECTIVE<span class=\"math\">}</span> <span class=\"math\">{</span>FEEDBACK<span class=\"math\">}</span>. <em>Journal of Educational Computing Research</em> 27 (3). Baywood Publishing Company, Inc.: 21328. doi:<a href=\"http://dx.doi.org/10.2190/hf6d-axqx-axff-m760\">10.2190/hf6d-axqx-axff-m760</a>.</p>
<p>Richter, Bernd, Gudrun Neises, and Karla Bergerhoff. 2002. Human Versus Animal Insulin in People with Diabetes Mellitus. <em>Endocrinology and Metabolism Clinics of North America</em> 31 (3). Elsevier <span class=\"math\">{</span>BV<span class=\"math\">}</span>: 72349. doi:<a href=\"http://dx.doi.org/10.1016/s0889-8529(02)00020-8\">10.1016/s0889-8529(02)00020-8</a>.</p>
<p>Roach, Paris, Michael Trautmann, Vipin Arora, Bin Sun, and James H. Anderson. 1999. Improved Postprandial Blood Glucose Control and Reduced Nocturnal Hypoglycemia During Treatment with Two Novel Insulin Lispro-Protamine Formulations, Insulin Lispro Mix25 and Insulin Lispro Mix50. <em>Clinical Therapeutics</em> 21 (3). Elsevier <span class=\"math\">{</span>BV<span class=\"math\">}</span>: 52334. doi:<a href=\"http://dx.doi.org/10.1016/s0149-2918(00)88307-1\">10.1016/s0149-2918(00)88307-1</a>.</p>
<p>Roffi, M., D.P. Chew, and D. Mukherjee. 2002. Platelet Glycoprotein <span class=\"math\">{</span>IIb<span class=\"math\">}</span>/<span class=\"math\">{</span>IIIa<span class=\"math\">}</span> Inhibitors Reduce Mortality in Diabetic Patients with Non<span class=\"math\">{</span>ST<span class=\"math\">}</span>-Segment Elevation Acute Coronary Syndromes. <em><span class=\"math\">{</span>ACC<span class=\"math\">}</span> Current Journal Review</em> 11 (3). Elsevier <span class=\"math\">{</span>BV<span class=\"math\">}</span>: 11. doi:<a href=\"http://dx.doi.org/10.1016/s1062-1458(02)00618-9\">10.1016/s1062-1458(02)00618-9</a>.</p>
<p>Rohlfing, C. L., H.-M. Wiedmeyer, R. R. Little, J. D. England, A. Tennill, and D. E. Goldstein. 2002. Defining the Relationship Between Plasma Glucose and <span class=\"math\">{</span>HbA<span class=\"math\">}</span>1c: Analysis of Glucose Profiles and <span class=\"math\">{</span>HbA<span class=\"math\">}</span>1c in the Diabetes Control and Complications Trial. <em>Diabetes Care</em> 25 (2). American Diabetes Association: 27578. doi:<a href=\"http://dx.doi.org/10.2337/diacare.25.2.275\">10.2337/diacare.25.2.275</a>.</p>
<p>Rose, M., M. Hildebrandt, H. Fliege, B. Seidlitz, L. Cotta, T. Schirop, and B. F. Klapp. 2000. Relevance of the Treatment Facility for Disease-Related Knowledge of Diabetic Patients. <em>Diabetes Care</em> 23 (11). American Diabetes Association: 17089. doi:<a href=\"http://dx.doi.org/10.2337/diacare.23.11.1708\">10.2337/diacare.23.11.1708</a>.</p>
<p>Rustemeijer, C., J. A. Schouten, E. N. W. Janssens, P. F. M. J. Spooren, and J. J. van Doormaal. 1997. Pravastatin in Diabetes-Associated Hypercholesterolemia. <em>Acta Diabetologica</em> 34 (4). Springer Science + Business Media: 294300. doi:<a href=\"http://dx.doi.org/10.1007/s005920050091\">10.1007/s005920050091</a>.</p>
<p>Schneider, S. H., A. K. Khachadurian, L. F. Amorosa, L. Clemow, and N. B. Ruderman. 1992. Ten-Year Experience with an Exercise-Based Outpatient Life-Style Modification Program in the Treatment of Diabetes Mellitus. <em>Diabetes Care</em> 15 (11). American Diabetes Association: 18001810. doi:<a href=\"http://dx.doi.org/10.2337/diacare.15.11.1800\">10.2337/diacare.15.11.1800</a>.</p>
<p>Sindaco, P. Del, M. Ciofetta, C. Lalli, G. Perriello, S. Pampanelli, E. Torlone, P. Brunetti, and G.B. Bolli. 1998. Use of the Short-Acting Insulin Analogue Lispro in Intensive Treatment of Type 1 Diabetes Mellitus: Importance of Appropriate Replacement of Basal Insulin and Time-Interval Injection-Meal. <em>Diabet. Med.</em> 15 (7). Wiley-Blackwell: 592600. doi:<a href=\"http://dx.doi.org/10.1002/(sici)1096-9136(199807)15:7&lt;592::aid-dia625&gt;3.0.co;2-j\">10.1002/(sici)1096-9136(199807)15:7&lt;592::aid-dia625&gt;3.0.co;2-j</a>.</p>
<p>Smith, S. A., M. E. Murphy, T. R. Huschka, S. F. Dinneen, C. A. Gorman, B. R. Zimmerman, R. A. Rizza, and J. M. Naessens. 1998. Impact of a Diabetes Electronic Management System on the Care of Patients Seen in a Subspecialty Diabetes Clinic. <em>Diabetes Care</em> 21 (6). American Diabetes Association: 97276. doi:<a href=\"http://dx.doi.org/10.2337/diacare.21.6.972\">10.2337/diacare.21.6.972</a>.</p>
<p>Stades, A. M.E., J. B.L. Hoekstra, I. van den Tweel, D. W. Erkelens, and F. Holleman. 2002. Additional Lunchtime Basal Insulin During Insulin Lispro Intensive Therapy in a Randomized, Multicenter, Crossover Study in Adults : A Real-Life Design. <em>Diabetes Care</em> 25 (4). American Diabetes Association: 71217. doi:<a href=\"http://dx.doi.org/10.2337/diacare.25.4.712\">10.2337/diacare.25.4.712</a>.</p>
<p>Starostina, E. G., M. Antsiferov, G. R. Galstyan, Ch. Trautner, V. Jrgens, U. Bott, I. Mhlhauser, M. Berger, and I. I. Dedov. 1994. Effectiveness and Cost-Benefit Analysis of Intensive Treatment and Teaching Programmes for Type 1 (Insulin-Dependent) Diabetes Mellitus in Moscowblood Glucose Versus Urine Glucose Self-Monitoring. <em>Diabetologia</em> 37 (2). Springer Science + Business Media: 17076. doi:<a href=\"http://dx.doi.org/10.1007/s001250050089\">10.1007/s001250050089</a>.</p>
<p>Stratton, I. M., E. M. Kohner, S. J. Aldington, R. C. Turner, R. R. Holman, S. E. Manley, and D. R. Matthews. 2001. <span class=\"math\">{</span>UKPDS<span class=\"math\">}</span> 50: Risk Factors for Incidence and Progression of Retinopathy in Type <span class=\"math\">{</span>II<span class=\"math\">}</span> Diabetes over 6 Years from Diagnosis. <em>Diabetologia</em> 44 (2). Springer Science + Business Media: 15663. doi:<a href=\"http://dx.doi.org/10.1007/s001250051594\">10.1007/s001250051594</a>.</p>
<p>Street, R. L., V. K. Piziak, W. S. Carpentier, J. Herzog, J. Hejl, G. Skinner, and L. McLellan. 1993. Provider-Patient Communication and Metabolic Control. <em>Diabetes Care</em> 16 (5). American Diabetes Association: 71421. doi:<a href=\"http://dx.doi.org/10.2337/diacare.16.5.714\">10.2337/diacare.16.5.714</a>.</p>
<p>Sudhir, Paulomi Matam, V. Kumaraiah, and C. Munichoodappa. 2003. Role of Family in the Management of Type-I Diabetes: An Indian Experience. <em>J. Clin. Psychol.</em> 59 (6). Wiley-Blackwell: 71522. doi:<a href=\"http://dx.doi.org/10.1002/jclp.10151\">10.1002/jclp.10151</a>.</p>
<p>Sweany, A. 1995. Effects of Simvastatin Versus Gemfibrozil on Lipids and Glucose Control in Patients with Non Insulin-Dependent Diabetes Mellitus. <em>Clinical Therapeutics</em> 17 (2). Elsevier <span class=\"math\">{</span>BV<span class=\"math\">}</span>: 186203. doi:<a href=\"http://dx.doi.org/10.1016/0149-2918(95)80018-2\">10.1016/0149-2918(95)80018-2</a>.</p>
<p>Swinnen, SG, T Hajos, F Holleman, MP Dain, JH DeVries, JB Hoekstra, and FJ Snoek. 2009. <span class=\"math\">{</span>PDB<span class=\"math\">}</span>56 <span class=\"math\">{</span>tHE<span class=\"math\">}</span> <span class=\"math\">{</span>IMPACT<span class=\"math\">}</span> <span class=\"math\">{</span>oF<span class=\"math\">}</span> <span class=\"math\">{</span>STARTING<span class=\"math\">}</span> <span class=\"math\">{</span>INSULIN<span class=\"math\">}</span> <span class=\"math\">{</span>GLARGINE<span class=\"math\">}</span> <span class=\"math\">{</span>VERSUS<span class=\"math\">}</span> <span class=\"math\">{</span>INSULIN<span class=\"math\">}</span> <span class=\"math\">{</span>DETEMIR<span class=\"math\">}</span> <span class=\"math\">{</span>oN<span class=\"math\">}</span> <span class=\"math\">{</span>QUALITY<span class=\"math\">}</span> <span class=\"math\">{</span>oF<span class=\"math\">}</span> <span class=\"math\">{</span>LIFE<span class=\"math\">}</span> (<span class=\"math\">{</span>QOL<span class=\"math\">}</span>) <span class=\"math\">{</span>aND<span class=\"math\">}</span> <span class=\"math\">{</span>TREATMENT<span class=\"math\">}</span> <span class=\"math\">{</span>SATISFACTION<span class=\"math\">}</span> (<span class=\"math\">{</span>TS<span class=\"math\">}</span>) <span class=\"math\">{</span>iN<span class=\"math\">}</span> <span class=\"math\">{</span>PATIENTS<span class=\"math\">}</span> <span class=\"math\">{</span>wITH<span class=\"math\">}</span> <span class=\"math\">{</span>TYPE<span class=\"math\">}</span> 2 <span class=\"math\">{</span>DIABETES<span class=\"math\">}</span> <span class=\"math\">{</span>INADEQUATELY<span class=\"math\">}</span> <span class=\"math\">{</span>CONTROLLED<span class=\"math\">}</span> <span class=\"math\">{</span>oN<span class=\"math\">}</span> <span class=\"math\">{</span>ORAL<span class=\"math\">}</span> <span class=\"math\">{</span>GLUCOSE<span class=\"math\">}</span>-<span class=\"math\">{</span>LOWERING<span class=\"math\">}</span> <span class=\"math\">{</span>DRUGS<span class=\"math\">}</span> (<span class=\"math\">{</span>OGLDS<span class=\"math\">}</span>). <em>Value in Health</em> 12 (7). Elsevier <span class=\"math\">{</span>BV<span class=\"math\">}</span>: A412. doi:<a href=\"http://dx.doi.org/10.1016/s1098-3015(10)75034-8\">10.1016/s1098-3015(10)75034-8</a>.</p>
<p>Taylor, R. W., L. Brooking, S. M. Williams, P. J. Manning, W. H. Sutherland, K. J. Coppell, D. Tipene-Leach, K. S. Dale, K. A. McAuley, and J. I. Mann. 2010. Body Mass Index and Waist Circumference Cutoffs to Define Obesity in Indigenous New Zealanders. <em>American Journal of Clinical Nutrition</em> 92 (2). American Society for Nutrition: 39097. doi:<a href=\"http://dx.doi.org/10.3945/ajcn.2010.29317\">10.3945/ajcn.2010.29317</a>.</p>
<p>Tomlinson, Sally. 1992. Disadvantaging the Disadvantaged: Bangladeshis and Education in Tower Hamlets. <em>British Journal of Sociology of Education</em> 13 (4). Informa <span class=\"math\">{</span>UK<span class=\"math\">}</span> Limited: 43746. doi:<a href=\"http://dx.doi.org/10.1080/0142569920130403\">10.1080/0142569920130403</a>.</p>
<p>Toseland, R. W., M. S. Labrecque, S. T. Coebel, and M. H. Whitney. 1992. An Evaluation of a Group Program for Spouses of Frail Elderly Veterans. <em>The Gerontologist</em> 32 (3). Oxford University Press (<span class=\"math\">{</span>OUP<span class=\"math\">}</span>): 38290. doi:<a href=\"http://dx.doi.org/10.1093/geront/32.3.382\">10.1093/geront/32.3.382</a>.</p>
<p>Tunbridge, F. K., A. Newens, P. D. Home, S. N. Davis, M. Murphy, J. M. Burrin, K. G. Alberti, and I. Jensen. 1989. Double-Blind Crossover Trial of Isophane (<span class=\"math\">{</span>NPH<span class=\"math\">}</span>)- and Lente-Based Insulin Regimens. <em>Diabetes Care</em> 12 (2). American Diabetes Association: 11519. doi:<a href=\"http://dx.doi.org/10.2337/diacare.12.2.115\">10.2337/diacare.12.2.115</a>.</p>
<p>Tzefos, M., and J. L. Olin. 2010. Glucagon-Like Peptide-1 Analog and Insulin Combination Therapy in the Management of Adults with Type 2 Diabetes Mellitus. <em>Annals of Pharmacotherapy</em> 44 (7). <span class=\"math\">{</span>SAGE<span class=\"math\">}</span> Publications: 12941300. doi:<a href=\"http://dx.doi.org/10.1345/aph.1p047\">10.1345/aph.1p047</a>.</p>
<p>U.K. Trial Group, E. A. M. Gale for the. 2000. A Randomized, Controlled Trial Comparing Insulin Lispro with Human Soluble Insulin in Patients with Type 1 Diabetes on Intensified Insulin Therapy. <em>Diabet Med</em> 17 (3). Wiley-Blackwell: 20914. doi:<a href=\"http://dx.doi.org/10.1046/j.1464-5491.2000.00258.x\">10.1046/j.1464-5491.2000.00258.x</a>.</p>
<p>Valk, Gerlof D, Didi M.W Kriegsman, and Willem J.J Assendelft. 2002. Patient Education for Preventing Diabetic Foot Ulceration. <em>Endocrinology and Metabolism Clinics of North America</em> 31 (3). Elsevier <span class=\"math\">{</span>BV<span class=\"math\">}</span>: 63358. doi:<a href=\"http://dx.doi.org/10.1016/s0889-8529(02)00021-x\">10.1016/s0889-8529(02)00021-x</a>.</p>
<p>Vaughan, N.J.A., M. Shaw, F. Boer, D. Billett, and C. Martin. 1996. Creation of a District Diabetes Register Using the <span class=\"math\">{</span>DIALOG<span class=\"math\">}</span> System. <em>Diabet. Med.</em> 13 (2). Wiley-Blackwell: 17581. doi:<a href=\"http://dx.doi.org/10.1002/(sici)1096-9136(199602)13:2&lt;175::aid-dia18&gt;3.0.co;2-w\">10.1002/(sici)1096-9136(199602)13:2&lt;175::aid-dia18&gt;3.0.co;2-w</a>.</p>
<p>Vignati, Louis, James H. Anderson, and Philip W. Iversen. 1997. Efficacy of Insulin Lispro in Combination with <span class=\"math\">{</span>NPH<span class=\"math\">}</span> Human Insulin Twice Per Day in Patients with Insulin-Dependent or Noninsulin-Dependent Diabetes Mellitus. <em>Clinical Therapeutics</em> 19 (6). Elsevier <span class=\"math\">{</span>BV<span class=\"math\">}</span>: 140821. doi:<a href=\"http://dx.doi.org/10.1016/s0149-2918(97)80014-8\">10.1016/s0149-2918(97)80014-8</a>.</p>
<p>Viviani, G. L., L. Camogliano, M. G. Borgoglio, P. Salvini, H. Ohnmeiss, and L. Adezati. 1988. Acarbose Treatment in Insulin-Dependent Diabetics. In <em>Acarbose for the Treatment of Diabetes Mellitus</em>, 18282. Springer Berlin Heidelberg. doi:<a href=\"http://dx.doi.org/10.1007/978-3-642-73583-7_61\">10.1007/978-3-642-73583-7_61</a>.</p>
<p>Weerdt, I., A. P. Visser, G. J. Kok, O. Weerdt, and E. A. Veen. 1991. Randomized Controlled Multicentre Evaluation of an Education Programme for Insulin-Treated Diabetic Patients: Effects on Metabolic Control, Quality of Life, and Costs of Therapy. <em>Diabetic Medicine</em> 8 (4). Wiley-Blackwell: 33845. doi:<a href=\"http://dx.doi.org/10.1111/j.1464-5491.1991.tb01607.x\">10.1111/j.1464-5491.1991.tb01607.x</a>.</p>
<p>Winocour, P.H., P.N. Durrington, D. Bhatnagar, M. Ishola, S. Arrol, B.C. Lalor, and D.C. Anderson. 1990. Double-Blind Placebo-Controlled Study of the Effects of Bezafibrate on Blood Lipids, Lipoproteins, and Fibrinogen in Hyperlipidaemic Type 1 Diabetes Mellitus. <em>Diabetic Medicine</em> 7 (8). Wiley-Blackwell: 73643. doi:<a href=\"http://dx.doi.org/10.1111/j.1464-5491.1990.tb01479.x\">10.1111/j.1464-5491.1990.tb01479.x</a>.</p>
<p>Yokoyama, KK, KC Griffin, PJ Godley, AK Cryar, and BW Woodward. 2001. <span class=\"math\">{</span>PDB<span class=\"math\">}</span>9: <span class=\"math\">{</span>COST<span class=\"math\">}</span>-<span class=\"math\">{</span>EFFECTIVENESS<span class=\"math\">}</span> <span class=\"math\">{</span>ANALYSIS<span class=\"math\">}</span> <span class=\"math\">{</span>oF<span class=\"math\">}</span> a <span class=\"math\">{</span>MULTIDISCIPLINARY<span class=\"math\">}</span> <span class=\"math\">{</span>DIABETES<span class=\"math\">}</span> <span class=\"math\">{</span>CARE<span class=\"math\">}</span> <span class=\"math\">{</span>CLINIC<span class=\"math\">}</span>. <em>Value in Health</em> 4 (2). Elsevier <span class=\"math\">{</span>BV<span class=\"math\">}</span>: 115. doi:<a href=\"http://dx.doi.org/10.1046/j.1524-4733.2001.40202-126.x\">10.1046/j.1524-4733.2001.40202-126.x</a>.</p>
<p>Zinman, B., S. Ross, R. V. Campos, and T. Strack. 1999. Effectiveness of Human Ultralente Versus <span class=\"math\">{</span>NPH<span class=\"math\">}</span> Insulin in Providing Basal Insulin Replacement for an Insulin Lispro Multiple Daily Injection Regimen. a Double-Blind Randomized Prospective Trial. the Canadian Lispro Study Group. <em>Diabetes Care</em> 22 (4). American Diabetes Association: 6038. doi:<a href=\"http://dx.doi.org/10.2337/diacare.22.4.603\">10.2337/diacare.22.4.603</a>.</p>
</div>
</body>
</html>
""";
                                                                                       <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-build-cg15.html>;
                                                                                       <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-ryansroberts>;
                                                                                       <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-build-cg15.html-0000000000000000000000000000000000000000>;
                                                                                       <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-d1f7dbf208197c841e5d3858db1c3dd0f8581842>.
<http://nice.org.uk/vcs/file-build-cg15.pdf-6c402fef273b77c394444b38d3c5020c5f45e2f3> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                        <http://www.w3.org/ns/prov#Entity>;
                                                                                      <http://www.w3.org/2011/content#chars> """%PDF-1.5
%
2 0 obj
<<
/Type /ObjStm
/N 100
/First 834
/Length 903       
/Filter /FlateDecode
>>
stream
xnUG)$,?3B 2
,ZR)i%YNETKg?G_4h29L$YxEIl\"_Jl'Z;p,$72:'VHmiV_4Q#lf%'E(gX:\"$8*sSQBJd=AXMN.hE5EA1Zh)-E-2TOKH aEEF56PM?DJupbBcB&c6@#`$9$@P0t8{j2q	!+I@^k>RcHz0dFO!P!S:BP	pXbab'`p@M\\22Ca% hWV$ T[[Q
lev&cy#3z2)A0x;0?|;8%q b|z/5g7>~WgWc5_>e:ro2|>cwsw?/:e-g9:x|9z0>?',+Pz+P+TP+*xt7T\\QTRQiWVu|{WXptT2/n8cGfWv<XWw<DWJU_T+Uq&w-cbTRUbzW[JUyRUbT]*o~[JUyTPJUyTJU~h=N,/''y47h
endstream
endobj
203 0 obj
<<
/Type /ObjStm
/N 100
/First 888
/Length 905       
/Filter /FlateDecode
>>
stream
xWGShn1^CdO6`h*U5gZtWx$Mw!Q<Jv3%s(,sC@
^HX IYicy
#P:+ 0\"0> kH k== +.K $W. %cf{=91W|!>&:.HTWb*8j8Hr]'da-+'9nU	/j{U.L $IC+	.*Sh5	TTuNEQS	
S'iKPVQ1CA;2>M^Mlty!(hN-58gH(
:P#
VcF$A0Ic(b(d4\"60P*cg3IC)GCp-0vs.cH vJ`(P0;p*e(
 CVP0=IRv~^k'z^Kzzqn7TX
*|pyd]
?>~~-Aon|!Hhwd #d	IGP$dHBE{0
l?6/a3qx\\:f`Wx%L<H?	uo=K	um v@B{H	u>6&Yag;?gV$:2PBB@BSHs
	uN!|t=5Yg{gVr.:2PgVRJ@BYIH3+	k$@F2+	
endstream
endobj
404 0 obj
<<
/Type /ObjStm
/N 100
/First 888
/Length 888       
/Filter /FlateDecode
>>
stream
xX\\GWhmV7CH?>}08@6Tm`Hh FWJ5v|b[RUZuD #\\\\c'.>]N:E-16E	QDDCtq1$P8\\\"	N$$%xACkhLbs IEc@ \\'$r=fdf8fc\"(G ?t,KH*D'+x%&f\\7q``|N$$[`/Csp2$DR>ppaR8}U;Dr\\1TrR383 g8Ap0`yy3G	'lqnpp9MMpp	Iw48D1?8xw/'9cuPuyF>r?co/-^y?x'W,_X<\\/=/;g,,?]ow<+EP><v<C4,Tyh7TPh[P.u|RQ[**sN-EwCEenPQ[h-S**sg|[/7l}V**2wCEex2h/fCEex1k/e}33jvCEefPQ|4TTf235TTfr_xFo+	UVetU]e&,D o
endstream
endobj
605 0 obj
<<
/Type /ObjStm
/N 100
/First 891
/Length 900       
/Filter /FlateDecode
>>
stream
xj\\G~m RxaH@<bp @ZLOuNl7Rt.Ys=kJ:2B *R2 s:WL\\qXL)3+*3q%0WE[ \"1q,3h$zTVs1;GR&,a,0_p}4n.);q\"q1d	HM&pDm@64HEF3]@SB\\:K	AMQy#0MGOV6u\\(5PtMg}
YL;*>;*cR^GZQA04|e@ 8vT0av *&QA*+BT&$&%YaIG
fp; Q9'1pu&i^{I>?<>}ykya#9|+/qxNsx5zozpz_~nx=&9nH4K\"mHJhDHK\"oHtJhHd%Q6$FC(fC,gWUWXyWvo+V}{Cy+V`|X|b|l2\\b]Xe2cnv].+VeUv1b]FXe+Vev*8].#+VeD.c2\"b]FdW2rNXelwt*Xemq_wW_rw1bkvBY
endstream
endobj
885 0 obj
<<
/Length 431       
/Filter /FlateDecode
>>
stream
xMO098NcL&c+hl(H{26&VMcR*ZI6}WwJ25)V=1@#cBzU ?$	yI6dUn2:ro>24wB@
Z?Bf9pP/_	vTEQ)?niIjRCa^]&_eQwG8lW%tS4sN#=M&
'N>8d2aDQR(>F;P'R.5awO e%>Lgh	V
IYtQ(DI\\@O1Mgu} ae%ZGpj
endstream
endobj
925 0 obj
<<
/Length 382       
/Filter /FlateDecode
>>
stream
xN0Ob|uT*6[*Aa<?J[H<9o[Q)]eAGkD2o7nof'vzRvqWFbRTFaC ^@x:d*t@)'hLFuR0]EM)P[
/!%(AXJEyR&h(~Rkn=-[G{Oa-X1XF,43Vc1XJ$87pB@j\\z2.eUU,'v\\(It^> %'
endstream
endobj
960 0 obj
<<
/Length 387       
/Filter /FlateDecode
>>
stream
x?O0|
Plj!)T-OH.=3:o,2X}b@~_Z$asvND^@@7/xhURF1xdu 8b58Gii4K4GE2oRL[# zp+<z!lGcw.mK'(Sb% qR%5W\"kN5R<%-t5ep]>5\\hpIb1J&w	3.dU(q'xnrU7_vl|2 d;^]2igA Yw@
endstream
endobj
806 0 obj
<<
/Type /ObjStm
/N 100
/First 908
/Length 2252      
/Filter /FlateDecode
>>
stream
xZM`l9tH\"eVjvz}A_bzI$u*QkRkjIdL3nxx6dF\"*hM !C4Q].DF	mAF92o3p7 *%G]9U77< @\".4ywrH`vt	'-0	JZcf =paI#4nn=Z7J1Iq7IMS55:|2[KVTw5>tW%3dX5,`\\`R#yl+mU64FMcp`xc$Yy==1-kL?4h^x7kCa0&`'ih.(yP{yZ$4}\\_m\"A LH1NsI+!+n`qub*V\\!CZ=ziC?d.m7~U)G/;/zqWE9 /}aZPjCUU>TZPjgjU~VPgPCrN-*U-:=TZe_]|5^z_cxh_.7\\_\\^|DO..?\\}_X~AmWW10unQmm%j:Yg!B<yZk!Zk!Zk!{lJ?pwWa?yI[ndlY3i!,q}::8XJ)a<YG+g%#	 ,\"zi`.XaT4*amY
Rhl<>#l<:
hCCr	 VaG~#U:r;-Op8rUyX*I&GTFE,-KlZZ\".TR}+=XRdnN;Sa}HtmIy{M:Nps&nw\\)u6<NY$w^[)eaEH47Wb&^K.xuQX?:7%UyPEy$Ag2rV _~[95k8+=#p%jWGki/9/hG?d_I;z=qW1A{=FV[9jZQ[-uG!B<
y(QG!en-x,;x1I9l,!\\X6{3O?Y6$K|X lRm!A-6dwm'<R	\"Bcrdfv='l]O*d9dB7ewGW3pDN*}-o!.zU8V'86|rUML1
wS8\"$@M3Y7|whGHMHjEphu1	o){SIe18m.HgL$j#sHHzbdLz$26H\"mQ4pk8Ds+^\\ZvV[[D8^{?Mz%j;}EDU3,N^6quHpe\"WS.^)6Md~/jV n?8+# P	Bp \\8	GD{	G p$	y$i!OC<y4iWC^|#K]F|qt/x;}#;!L#p8q8EmGqdU%sd}3(N{1Gv<:I
endstream
endobj
996 0 obj
<<
/Length 360       
/Filter /FlateDecode
>>
stream
xKK0+rLI&f*uk{[<n]=TB(	s7>j0b1xl.n,
E li'R;9oU =)ew^p\\)oO]U++UwmFjUDDn!	4X(l	t\\!.L^n 7UyR{7VYUc4Y?nTz7bc2Eo	JR!/9 Cp/\\I(VXwzbr2jifF2GQtf@2V>Cpn2nwFu)#\\VS~jz8kf7~
endstream
endobj
1031 0 obj
<<
/Length 374       
/Filter /FlateDecode
>>
stream
xMK@{73;yTx6Vok60d	<3ya/b']9y@'N;Qn<jW(b),|m\\BT>?)9i'U[DWNDqZFU$Tl]WUjVjj8/2dfR.j^\\J{p]3AZ^\\ye7u7	rg7h^Mq0	rdMn
FZ'6Vw|awdMQGa34VTO	@KGM2PCxP\\n; kH,UA7[0
endstream
endobj
1066 0 obj
<<
/Length 363       
/Filter /FlateDecode
>>
stream
xj0=OQu[P%pbh\"tl~s@<nvuV,Y=	tqn#Vrufq_\"/\"'7/|PVa#j1p'G#BA4t`:.kq]rr+6D:`;Fw|{GDK\\\"^\\Nkp#/yTG@C%PEB:(mKddKd4RZT4\"t4AM-P[4&LFmu EFm8f_
endstream
endobj
962 0 obj
<<
/Type /ObjStm
/N 100
/First 954
/Length 1881      
/Filter /FlateDecode
>>
stream
x[]}BItU_R5N	?8!,3a<QO+FjttTJ3=!J
DRZk[2j,RJT!MbPd,Q4%{\"y$$:+08y9	H&vmWvd*JJjk(TI'&	 '{`T:y`u5VG Qnh40J3JM}ZMV;6p2<R-0|xIN	+T#j_)&n:NM#`GjZ0(.Rba*eS'$bih3*$>)r(zvi_5['j7Qn&r@T^I[;:F@rMz[^
$Q]It-u+>mZ r[* 3u7Foxo[9An},E[YZ3mYejo9`g1=;_?7?|7o
wy{op:w!V2:5,E,a	XPY:J?Kwr+O_}ua<,c\".<gj.P--w7r[ei;Dx(G=Kxexv<$.<H3vz8!Q3v<Yq/<g~<,m\\%8HC9K_{SLI6fi;p_yu)5s>F\\mxocb;<8\\}lZ?2`7-vM`;Nw8\\}sqGKA^8i7=*g~GMq9m[RCPxo)lWgyz]:bv/nXn+_>o~|Ho>us:7R?\"n=g~X#zkh~LiMyMWxmk+^[|W<_|W<_|/Vo]M*BmU%{CbHaTwx(V.Xrd(?kaH[R2iB`%?VI[L|oWSG++ithRpHo4$mKS#*4tDpgD<sGTlJC?
CB\"*ShHD4*v2\"7l%!%)$\\@im1&r'R/(!V_()***|fhdxdddtdld4i @L2d4i @2d\\U#b	LgrDsM6D\\P,}8H$$<cB.D&N\":IDtDtDt24<2O%pNuR{WNZNtD=4\\%:?4x\\%:i<Ntt rd4d<d2do:SYE!fd32Vri5$GYd:u @ld6m @l:wNd6du$$$Sw.s
endstream
endobj
1096 0 obj
<<
/Length 372       
/Filter /FlateDecode
>>
stream
x?O0|
Plj!)T&i$O{wOV)6^;,`iHUK6jYcSk7k/?^xw'yns)rT~; [Zm+|PR9J@!P
JS e vj%<Jp(oq;KRlh %`rN	tH,T:SQcI+BZ/M!PL:(I:Q(Q@x@Ou[Qb`Ha+Y;y*%/`7
endstream
endobj
1101 0 obj
<<
/Length 2948      
/Filter /FlateDecode
>>
stream
xuYr6+z)W(9L$wRSSWf1,YWv9 @Iv/l	p~.8:$Iug!K09/x~*x<<c?O/zL?PegD.
\"Y8c#asL .e`[41,|yDA=	M5/z`z-s0)bgdK;?xi9U#7I800<k^mc s(x>bKcZ>7}m0;52^P*l'U(XtDy(c;\\2o0'[W-BYD.sF<5H'5kj2g:DZ03uxg9}eITS3K[Gwt9.RPg>w;-/Oe]>zUrrXe{ Up;<+OIV`b=AIJtFVzd&o0N[{4OQ{*^U}uZ1LB*,Pt2?%_\\VHs)?H`I,b
!9Rin*GdzxSP@yFZe4;m_ts=#OJgn*%St~xm18R A4ZS gRyw<jo20+hs56\\5mV['(c3r\\?xuC{:tD:8-  --q@OOUI<:@WD#/\\5-s6|LYT7<\"Wy+Y\\),T@x!cZQ|X*V{|j:gi3Vyn>EFIg}e[l{V62FL\"	&ck931U>'cO8@ReyzL'eaH>z>6&Zp
kCq\\O+v^S}5#*gSLe5P2 G7LT5>uLQQ#gIj`7 . 1+O*xGeoE2rnZc!IrM|w+;#=uElF3oh33WCj-<
y
R[
5u7EQU$)(Evr'i`:$Wzv;YcC*>HAuZy05.=7^8'J2T)u%+,>mFPq6X,jM?=<)xZp6YhCw BBt3	Y[w/:s\\]15DUBKxH[/Kg% 5\"Sf w:B<UQJ	{R0= u9T\"q6l\"	nG%
\"CvwQfjz]|Ea_LLD3i=O3r|o|iX;cQiA|qXd1H.Po|o2?r/KN7HZw+f]RI2Q.a~@8dOFr
qZ_o770<8jcX3V+T%TVV\\g](\\P$w77n6jXrhxr[\\yY5E5x{}gSbF\\>oo	RImuQk@Ra=w\\*PG6 p}=M0t y=x$s	^qNXwDw,P'Z\"5{qq)qutNY<< h	 cGwYO2A4	u)>3{tO	LFB\"v9QV1ts7m2Exx+vCo!4}1.mSl)oD\\mt;nED8b#vL:*MUBgwV mEH!s-=I\\SHDu0Xu='UVEJ{
Xyx-2z|0?qx9-rjQ8HMN	(\\N+OHy Qd-h~]#`
%|E2#RVHx
:x3s;V\"n(ghy|$S\\
'x5)\\?ZIAT\"E^t-)PJ\\>Gw*Ye6]R8%	3TD;3[(Y~/=`0_5@ k^7$_@@ZI[7Ui\"69SY Nk*WWZvz\\7Ndo+8\"ogSIe0J,O0|'^0H~NfmrYc(TPe<Em\"}B$,uTm$EUnZRm\"zWZ_ ?qMx?7g%:aQkZ\\acPo|mR	BWK_
endstream
endobj
1105 0 obj
<<
/Length 1496      
/Filter /FlateDecode
>>
stream
xWKo6WTdi34qA+\"Zvw3\\u0
^q7h%7	zJTM$EH%BWQB,EL=Zx2~xS7]oCKZqGZJ~p 3g1]-/2L_Z2Kb7<ehu~Lohb]%dQDkU`w%5#DA'~gF:XNki-A^rf$/u]zN`x]Wo@aN{1=L;~tu i0z;tf2;0pv84m`{zgUt{/Fq]@3Vk!!ukn	yu4uf/g%VTT	w }*`_d~/LOZi*TIL=3q='vnc3vfX\"E-sp-p> PN\\X k*`zRTtZ?*m%88u3;Zl:X2:]I:(V&<WtU\\x;Lv\"^K!~
QiH_P'`K\"+G m#$(|,fy>|zOA+3;ecv$ukx@NC%!)T=1a)Ae)x0?7sOxS!MTEk[S \\7 KHU*^w'x#t,+Ck{vCXq*!;$h9pqs}Pg)\\tl 0|Rd?@groIi\\.PF]A,\\l%;;\\MC6'pcL(^;%57n{1e*)9?9B'	OyR@b-o[#d7LG,-Y')\"$O2Yx	<><gDhngGyOJ`oh
:O!QtT|>BCp`(T.Q=xX	 /Z}$5B3i#L6wy:)HI9M v_qk2y`-s'4s;(bEML*>J!L!$;Q8<lrc$[V$2Q=Q{'\"_\"M~_p
endstream
endobj
1110 0 obj
<<
/Length 2202      
/Filter /FlateDecode
>>
stream
xXKo 2`kEd3;;\"2es%$vHv;E$z~UTOuiWq\"mvWWM~-l3h3IeU}oo~~RiN-Eu'8dw]&F=yl?{m&yko;	8=\\d=cTQ7b3pvQ4_u(Uq{lyo_{Z2!.<QM3_egs82&krZK}=e,kX7J'<,	}\\h'YM5_'Ty3=v,IL6|{V%m	w'V7^i~o@l?j}uz[Y)px39]-t}CT
&53<StI1:yw)os|*[*32h4UF-\"=lB$>~q> 1MRX q;c	{KN@k2
'2[#gg<sc7<Bi_${Xmp{;tA6*yX	Ma.j$]f\\m[EC0/.4D70z37b|xlG(-w@hd89hd;LH/h
pn0\"sN)[t&yrp3$3p\"?	 O\\PiV\"B
R$*hi 6B!<rD%mr0@fP7'#\\@hTV E'*|=u1#]J Ps9q2-Dd$E+D@B*41q;N|]*r&C{ E6nFx7q/{kT\"NJbYweFABZJ-nQghq-1A^Tg1GyKy*)%vYp5RMV_G5;:, ;J%%)i%n 5	}D 4\\iaqJuuTzg^R8IcyF;@.*#%vu(eaE[rMKU&uaqC2&7$QE(pK;;nn\"
H_nO'W~VIdFJ9G2u	O1_o``x JDHv=9maj-1G:Ld?RE 5D
&@mc:fw&m%WUg]iw.. z=#xq*V{9;qJ(RZU4M`s>fz7A`rY
I8C:(\\Ixc&j&4E\"0 :qs 	^Ly>xpn1. .VbR0/ t*av~B>q8ME-*$SGFk\"ul,uoZ@u1jm5j}yIF\\~$@sSpRr<y@OQxGcEkOV #n,T (UoKEb&\"cml<G>]RwPcl)^
KdX'@}.@C	}9s[&xNX~un
mlRpDXYw8uI=S|1zC7L=vRJsHez)_STisq%=*aWPjl)4M2ZLGp$HZb_*Gw-j~zkI!h;BbvkmwO BW>'
endstream
endobj
1114 0 obj
<<
/Length 1912      
/Filter /FlateDecode
>>
stream
xXK6e x-G-A/mGu=%HQ\")#h[Eo\"IWEX6]?aUdu~#3J_]~q~l&F.w<14i8?[VtXr<hoio&+UaE2YZfLeK=VBN4(NjE&Kec?Z\"wt5BmJ9a_'KNV>0E-)T^ c0vF0Yi$A0k4V8KV,OlSveaGa'%iK2\\{/SQ kWiy{$	w2B;~6 Ut	n45u%6$MB%f j\"seU7MlFl}&~E6^ps7&xNOi%q4dP=BBFv%MJLt'Sl7]MJ[	)a,xe7aq#T'Y2R84N]['QVK[6UW}+Nnz(x7gWw74to	h~
Pa_US_V'Yu2Zl|h<+Q$6YX8 yo8I0oqTnk4\"~mHq+gy1:aLu]s|\"{S
12s# \"^[!@MhG?	FwR9-d'B:*9^Iir3g N /jj cd6BD!g\"mSO :i-rzIy\\T9dJA$S:O~K>f
Kr~Dr_2FizWRl>QVRZ\\Pb,V`a5A\"o\\\\AZz5]e[F)A&B82JGA/9?X( ([Q:pmhEt$sv}9yqH},M|.*4JaB4+gH#%3nDz2.r }kX0HLrxSu$@{c4Ty!6<xsmg$u%)ydf!^d$-p 5 P}cq;^8j\"P;C?DQ9r=W\"LC<8(L|s=t^c+w`XB@}ymV,+cyIi465c9S3ireyDOcqG 
y2|M)y`CRr/nO3g~IZU3m\\[LSU[<D+VKq9>#Rn]IweC5:\"hAF]/Pt!~x+K[fK@iPGe%6	7}vIYV__C/sA1	r_Fbc]^TV4RD>b.Ma $Ki)~D(
 SXi;F/o
W.s3u>u|-K#>2|b#
g\\\\Y0-o&;#rzC?\"vKYI+`IfK(
r<B1W{EGe

endstream
endobj
1118 0 obj
<<
/Length 2322      
/Filter /FlateDecode
>>
stream
xXKhkDR/a;YL-,m!R$,b=*2ZWwj}jT2+\\*Mduw\\#&YmnE}Kwk4!MFUQHzoqi&x/yw?)v6W,}.$9tM$Iwgunp,G{\\pk$Z y$#VYzI(]uZJr(4S4$12}U8m+}u+WukM2-Ip_c2`RXSXl*zd0zJ#FUZ:Mjn8*\"X0YQgW<7K~OL?;NMuZqE8U?.P
Y(gv4qH%h^heg!G}Y6\"S.'ar9h&Mdwvu_${o9sA5J[4d8	l2Wk^s&X}!jKbo~2`/?LxSY%!
i z;Jo<rx<%&xhTw(%(_ke#~E<ZA |@]+XS-c$Xi?MJ:	V=eALYoE?s|)}Z	<#DyN)!5'<:RA)<yM<DA2{v%?{@B\"nP_W]J\"k`I7`-Lh3'~0h3>MSjt4Edqnsohsj8\\@qZE|]	#PP9ALCdpnF[e0p8X?mfJ@OYAS.e!L&Knh >Y6 PD`}~Of3O,fx7ahhE(e@R(nxt?9?yG'Qs `mIpw2Go[|.AR@NWp~[!Jx&@#=5co-pA#9@\\lvZ^N\\lv)kS$Kp5L-:|3o	N:h'dbPa=|!;o>LRV@9++TtXMBXk])T.,8bstu^cdW6I^{ SHQ#rrd5y&t`g.MR5Oj	.hcg|$v>JBs.$ (.uQ(`	^Icv@{e qe7
YT>JA\\IVx5^s{:sa50enxzP,l RV.jF#?h23_h4Kahy^kjT+St}l. jIQr_se&Cg?egtt
 rVfF_
KM~E{iqp'aj.3w?P
w'Af %%FGLIrY8 Ew\\];Z4xB\"a]@ 4r~;N3=hQ6N 2sikNv2e8&sz&zmLf,RsM\"}B!]FVkYVV&@_0irh7O^1X')\\\")E-9jU$k LUnpS,4W[TZ0Z@\\lEb$\\l<>]lK
meke1u%a>=]^s,jm a%RBs!4[HC,B	iS0Sqgz(T3Z%_;ua/d}t#aaP4T;BY,5^}K^{QFV~kUEa]AS}4/w(
endstream
endobj
1122 0 obj
<<
/Length 2199      
/Filter /FlateDecode
>>
stream
xXKlkH03;3FHr7U\"H^WU.6Mrs_r)r+6b#m6Tfp3NSfmGph8)p9SPUW]*^yLNl/n'Mm_0lwzpk5#-NZEcU{ P(+nQQ|wRz*4Q=i?T_/xC<ZF}n(eSNJ$BMOWBS=UGKhpo?V@D^O\\YR/Z.,cy[HZmH8aWzv|?FFp
x*Z	&W[vj%Z>b5UdoDv=g#2,=6%$~\\c\"4l`+)>Zl.Ig]`Khup!$_;zxG=6 `1''2=#7+grS9U(@_n$Pl\\+]Z(<l<VQW\\g1tiT3L
|&R%rg5]4Nedwa>pmt:E>%Bfh+wFd|3Od~ah^	iz<R}ti.G'K?T91
n(93!0E	F@rK;?]CXtmG11^H;dkDCuUSk E,3`c hh)[FrZgK<;;yC}h)=O=h=?X~+,te\\r|DA\\*S/ohN2j>,f74FP#|'uT4iP> \\+W`\\(8_e=Xq;sFd2	 ;COSFi\"F!l<1[J	%1'2Q9e F0\"_x&]g<R%Or}4OXbJmR+qL6	ZxV~3f1!?(S&)J?}#Z&*0l\"FpB&T@@#K.c_0kS/-eRG2.89DZR[b1G<o 4P0s'PrSY=E1f7e0\"Aahs	p +'wip@?07;zJh,eNn2;QrrVEsq\\fYaO}pKiRi$]OI_XVt&/@&v3<Y1=.0`[z00'6Fm.RBzK5Z302B'\"[t}5V\\\"{Tj\\N,4,E;@'yYT0kk4R$:p[P\\ }`e}}xK&MPuedIWr
{S*kC^\".-T,*wDq]x?B
IP	\";S,0)oo \\j{\"7PTH*,S2SHB\"FFEu-G&w!3.	Z|xzFElm
H{chAyB7U-6hmFwRNbo`2EL#%0x' * LeF`e >J	Vz %
2Nf;V`M{g#3;(z	X}A~%K*T9s5i&wyaKkOL%A]X-89BWSO9;<:noroVsoy.w$b0
endstream
endobj
1127 0 obj
<<
/Length 2619      
/Filter /FlateDecode
>>
stream
xYK-2VA0f^\"HwC6!*VQm!,Nv]C(qerJE^vJ*O\"{W\"jnz??\\~8pl}Qc;o{YDf2q<dl;}V!v:Qw|	eHH'\"Of/\"w<iB
	.UdWBUREO\\QCN$j,i7w@N3/eV2:eiiZ#<my2L|Wb{#(N8hlT56Hs;kx&@fzOUG#1lss1bYUIGMR6 '~4-#.?hk PhMGfS:*T3= 't,oX]VfqH {@`7\"@$I=iDoH0-:p`f#hPqRT<( J@`WUH!\"gkyAt<Z9jhq}>QI[sU*f
u-\"t #+9H}Up6,UL2\\7z5q'XvfyWb6$olSD,*9M@~BF0q77Th qn-A8I<us/4r}[U,-h]bOoh^o~KBHD^ibI'
0<B,; /CQPsg&E={UrYurA01oXx4DIwpg?8pXZe*Y^[ SwF[j.Mc[E8S,w_M`QMr6+%{Cw!D3}{xe5Ja?cT=nztZ8-RP|91x0^@)}?AI</`xN]?@@?%}\"}hzm) jT!=( qDW2OE9G[=*P kC(
LYHE*VkerV3vMeJ\\6
[VH\\'QF],a@ 86pQy1\".M_ZjD6)o1
|/qz,:		$YiMq9zh%uY#=)!cswq4p9*o9\"H^%Fd]OzO2=&0;:z\"xY`\"3Q(D6 Q)EK*U (s)@I<LC,_}jz\\`@Vq&34zijz-[ce`M/(R^pn_e(]{nRTK$G-^AzX9_@GAc/?ODHXc#G;b5DPq.X}Ojl/Uw`{@PR5 F>I\\& R)62,%iYP)nDM,U)COH+>,r2(+JA<Pu:wz|%WI\\W\"NC\\jFD+uY`W/^!@q-'$SoH@:Mue-IL/ie?!pY7j|_pCBZ-6-?wH 8a*/X%Us[7Qnh[37-X$I(U\"ixH}Tz9E%\\NbsJ5GO|Z=P>Y58Bq \"Icw]*(Vb\"3R) =v/5 _cZUIBKD ]jEwOs]_ n,^dpFg`o$h_
w`$~HdtR$rY~KW=Qw`$9X'gL	f9A$P	'n0gK&l|TZ YFtN`XVJ\"DZhRF7BEUX.hd[2`Q	z6L%Op'.;1<=;yxxt|	Fn>B?WB@mvk HcKGO52?x,ac#`O-vD *p%9T*VH?mg
endstream
endobj
1131 0 obj
<<
/Length 2167      
/Filter /FlateDecode
>>
stream
xXQ~f(R&f|;yixiJ{Pe) ~ >@lM_oQ;2/w]
	)S%ve\\yN7{pf%!OZWx7\"i4N'>-:7y|gx-{|Dbo_'wuwKH.#5/p tuQ$hvQH\"TUW.H4gC7(spoS74	-0! *sz}=u<GZo~aD:+w(2+sJMW@8B\\_7`4p2p-!xeEJ]{IH{&	X{4$~ ceQ&k&n<I'6u #B	n|`%;KUxju4}	*6z}/P$43hk7:IS{i}k' lb'u^T\"N=^JlfJz yxGGsYD[0rv3 `e DM>UT:52Z~Ni_]YOy&pw?b|i+xoH	#V2!(8onp+4|Q6q! =XEri%8ZgU&
N1qi0@wO#c H!ZXUYWR/`'zllbC	`10)84R
J\\O}Hv]H7lKS+H~\\	3\"O]XlxGN|;5&m3qDj>L|O|tl[|#^	Lh_>V7A=F Wi jY2SE4kUP;Xp5Iv73\\%Uw%HDh+@
;C\"RBEC(DZUA@M(M*HboK\"TFd&yd<c\\=)zk4);BKkBUVpa\\$#M/_ UzX#&*luL<j?rB:&brn\";3I.TDqu$Hyb
(@>+FAcmO&O&YX7h<v8c<(I_T=!D.WulMWC}0zEzC*Z 'XhLu/zAp%u)gH/.MZ%L5O7xKH9%|S<>y	xi\\-t,k|c 
TYxk,@&tHOKVMn*+z!qp;YYVHb!IT(zU+^MToAAQk>5l} 4uqXZA^^wEO$,PRFz
Ozu~aHNB^s=\\<]84vWACNpH`bR1^\\CNx=>YRp.% %_f#|T;FvT	3V3tQW
D0l\\Q+E$8]d4az[+^&u\"$K D ~}P:'>Q^}uq>BbYZ:K	qZhHo@x4f)IB2Zf*Jpoh2{7
:\\~+*\"iUKGS78Y+D3s.Z`,dLDu+hYk\"Y({poeA{,w|%B 
endstream
endobj
1068 0 obj
<<
/Type /ObjStm
/N 100
/First 949
/Length 1736      
/Filter /FlateDecode
>>
stream
xZ~BM\"%`Hb-FgQn3ql<N0|HRJR-DX;VR#Ro18j2Zn!$WA*T:bsRML6F[17s%wt:F-TKRR TReQTAG?<TEPKh4PP@9>8&o&TRj\\K w
,VRs* RK%XORcIcTQKM)6))IyQMeB@Es%Q	F {b*[	H(rxR>.`BHvAuy\"a*xsfaq4|	=&''g^^~5IpYocX'z<?)R@r12x	l5\\j={i~n{p`?iXHo43zMz,_i<?oI; HXyg	7g%$!GJ$bD	9-[k3R.hP8'o[vl-4q4^x	nkpwR)Yb)N@Re	oWwf$q, =\\q=)Wo.Ex>B u]^KWm)qYe)q
\"#UnimY>2l}\\[uEAI#-w>\"ns|'7HK9+plU	0nU9$-w>Y>wbnVP}PDQ|e1c@/HOw0qYb~vo?A )W|wh;x3hg<
(hIY'em'A&A'&ale,d&6YMmle,d'>Yo7&tivk8/TC4I}	pA4-$rE2$	|)uR4QMES_idU_@703XUz%]%oWU~%]%+*nx|3Z]Vruh+qh+qh+qWV_E[\\G[^G[]G[_G[\\E[|$\"pvJ[Vb'=_3*U8\\ ](_aK#v	])kr5G=~}7E?1a|T0m_qLOwWjnTGN{G38=[A[V V)!+RK_uD69vf'3vB/	=u&WjGEO\\\\TysZcK?--98P|;RjE+Y.M3ab!W
endstream
endobj
1136 0 obj
<<
/Length 1810      
/Filter /FlateDecode
>>
stream
xXK6W@(Rc-+d_yI~7
b!5oMobIeAYu88P:\"<JtvR~NZ$E[G7->,<|*2|6xg:&}X,gfh4E~w{;,Tj>?W\\QRVo.`QEjBG;,+{t=0Y~{gctbM\\Ih \\trGeq)3:[cs@1+i !? }kZ02-/TxON1*uAG%aXLJMxXkW$,r6xn7M.`:X 8?[ np)sb<|6l^xSOei**rUW!Rj0[\\^/V^w{V&ov`;2lBZmyU7h9&e26mijF9=e~)Z%<5B#	L+pxq7N>{b7je  ~LIlx<7P)HbKK{;&2{cjP]q#DIekdJ RhH\"6(Av/fym6V6uDQEMIP0O:t(AKm
YIHT`uSOV>P!B8`-jt0LC3 d>\".qDR-NPf5IzdKg`a62-]B(E`qU/3?3ep}G80S2	F?isPoa<R8;
T#`+ ftveZ,p @l'Oy=t8` tJ'~d>g'd(/C.-o93agYwtK>C TY_a(.H!&% 
h$Bl $[fe9k<SgJ1tTQxxFMevzP\\Pj}aj`J50T-=KF4LRszSd<_+;Pb`R9)3,8f{}G e##%HR+@JKJycQ378UvA8bj6 D	5iG&qEv9\"Y~FoVT%RNn.^wcvMp,M\\uql7?
.kOs3t8?\\v2JiP~c$1S!+|$1'gMq(?227;'aasg3^OY2?_$4+@|g9D?G}ROyczfji9;dgi+67Me\"WQzdJ3y6sL}m\"

dygyf#wQK10hyYeZ!>X?q
,Xax:@t2?y)QleQr
endstream
endobj
1140 0 obj
<<
/Length 2234      
/Filter /FlateDecode
>>
stream
xXKW*j[ERx}%g) 3 $= \\Vyql>KdtbUefI<fSufw}fcQlmE#|Oum?$V^M6H7UM634~3'<O>1k<LE/_?I6-L:'a8{Z,o>Fwmw#UdSq:Ih^v;g;/{|6:[INxSH'Mw0i{Z=3g_AZ<mn!^>5mv<h{/U'r<27H<f[2_,pa%Q@KefFQGkiUnqS-LeKi3T }>v!_d5{K,t yur'JltM&PMl9 WzkAPdgqjrXr>O@>'-N</C]Lw|P@iu5z|gDK7h=mB\"H+]?]ao%KGLJ ^MT+AT{0jOlTsW:RR>B>_x0=Zg|f#`cB;PprD|<egYzP@*p!=\"?'`xQ4 uINlrp/XN/+qJ Au/<NE9'G_fkM!)4JInHA_'S`(ATkZ,m wS> e-CKTKhBv}70kU#8L\\i!--'QVc
?J51MIo~oGuLrBD,4e\\FRJ$$'X\\D=fhT\"z'[_uGR
K_Z9JuI\"NkNbZeHL\"# K]9;KUDqmG	!S ($`g9@YKpTr9	wO`AOb_b :8^'y0@{r%DTe_\\1-Z*x2hh6*vr=C>C*D$DN^tOi\"c<R\\aYWrA46NYr )K22NURT *iZ>;/O\\gLNVlF4s]K)TD!UQHHILfdg^BCNO\\.i<n>K(*X[J\"V.:iJ@s!Z{@@&Om};\"Q7p'h\\ZEq>I/I]9?x1R% e1kY|epRP*)>YvR5uZ:ka:oH}Jb+4pR`RhCI@WN<3jgoe7&)J4*UrU5H^LfN<:+yCCI	bW^H!Jo>	BCxIA$p`\\t+_,DrNkl!]#|#'BwO_EPo#UMFrI%Rsw0X~?&ZiVuZ4d,'C$0U%F!8oq@;WZ@?I/f6tSD,moof EVBXzzdS?	Bl=vw6RPQ>6$| ea~J)
endstream
endobj
1144 0 obj
<<
/Length 1968      
/Filter /FlateDecode
>>
stream
xXK6e 5!@&d ]`$#_^4bd_ld]\"v>MEZlv',M8fwMhffiGVQ?0HuO<ermvs!Mn~e43o0Or})O8oLaND|03tmIdtr#A;0ejW<OVf<hx,FD*Y@#*r=Z3-<jyF7?MY=Zcn/G7F,kl9$(t.a{GRfi&cq: f:z1U<\\oN_>F%J^'y1,EXh1BZLL|Z@~|.YQGeA^L(z}F3_(<75'|J%#NrO!=>?]SGVkoIQ  >/A, p^xnrVXYCevGnL(T;Asfdmb0$\"RI(EDVg`1Ndt$urBiekF:@[
/<g( \",W1Pk:,%HY-]P^EV
fINS~LU`O*Se%A<no.	M^j$I?>2,'e9}h+zB9w<sJ+2y@V#;q){I'%O$w%9PZXNFi5^~OC}2(+dn )2<0K+xiY.}o\"o )ejGId /ylE[ JKO9t=LNL< p+GeT`#bj!G0z	@0wu.\".ZBlDhs}gz'k:RV6=@WYhObhv#@oN<CT3[UV>jh:9t}i3-&DMIjt;u#]& x#q]lgZ]ueq*i>KMu\\~G7EN5
r/>t%7a8K_JI {E/=RA?qITfEW!U^Ls_.hBMvO)&FI!VW.~}iN^dz%kUe7/EHVV\\]Y\\Z\"n_	jBEBHWL)_H~$\\+5V$2*>YAaq-qPi/psU~+*YYz[`8UzWA$jc<ebN0OefifSHuk5YDFACP/;`8WV*hu4hG<=sBQe~	U+]gSw ;xzo(?_rhK
bMdi6GtPo\"-R\"{{qnNcjHPU72v[
endstream
endobj
1148 0 obj
<<
/Length 1871      
/Filter /FlateDecode
>>
stream
xXMse y3L*la	P8F7(JT*h~|?bmWJHU:ev_N7W^yT$G'Q-N3JyTj{epNz5TZ$7jg*iA#}?$wv:aJDTxv;=U4XxL\\$VH:H# :&
Tz4z$APm3z^RpxgTg3=/Z'-n!C;@,0YeC~0eG ,b0`'7s{XB%#p=;di~5;NpluJILOm}RM-SJ)_aW\"ns*G5}X	IpP/vEyFJAeVA^=f< :}] nspF0qHB7Sm?~-+mxP}[*G_Gp&kOv3P.>m\\0C$&UF@\\=j\\)>Ri*ia?a<:5r#tE>O'dENf#k BVIrP$B~d2*zK'-+<G	6qxYZEMco&fXaVa4Yc>QNO<!l=jIfgI{&p]tt:xx0)J+}F=MJCC3lLGwZ)Kg	2p%Y	 H8&oS-EpEAy QSTs\"/&mAno	&g\\M^N#wAaH2ZPH`^Tg|wHoGQJt
[(yK.3jw*xH-Qi L@C4}HZ [Do +.8]i#A(ZlCg{77Gp$bpF7bb%K	Q/%N=*AU5&8A!AD	NUq5Y8q
yb7-U|Gn\"\"nWh~5r5Ag#8e**Ng?HYy9bJ[|LsC(!#uJGwt	sjv}y	n%9\\e2))VNIv=29yvJr)rvB=}dS1:3G'$dNv*J_eyUCGJZ<H=b](De%O.bA-\\^ KA[C8wU@;[ECfA@wuX9	_a-	@OmJ/2E$3[1x~Y
@/0B'<x/LVs<6,N~D(5%CO/0S,m-1ID 8w<|9V	ev42=47S-l_&k?R7P]e+XFb<,\\		(!
j,^}w 
endstream
endobj
1153 0 obj
<<
/Length 2033      
/Filter /FlateDecode
>>
stream
xXK6%t+|y, m@,~%{XbDl3S]].L1[g*LiYT\"/Scb7-a<6O5sS%(y^$nhqdY#g\"yFUZ?;\\$SSE/gF7]ub(eo0fGFaQU|7&TYp:jVzyi<:N\"T:pM:!:;A'q\\BnAUrcA6;$ar<Gt{\\S\"~u586G#0zR,np	!2,JHUR@2w={73\\&z7xe:?3MKU6+9JW =Z9ad-dz2-*q	yI!<=#?j|)|Ec\\[E#m<l1x9S~@$<@vZi:0f7s(JLn8HNQAWkp-5C bLMcX.z&$o! F7LK |V7|KgfIUf&gR?1%(]fLDa)-z08${\\=:SRm}e`0U|jR&JYBpD.Dnwm#{{.c7pF-0 pwT[H&|1Mg)<'U	{8J*jE7`:PC#KSGk\\+4<BpCREK'91tklPJQ cNZr I We0=1	[g1P!hDE!=tp3OB0R)z.NLwiRj:=[)T.LT\\i5@e#'\\\"=u;kRVk>?`f-j-f*D|g_= tk>XdS*#?xw'm^6/F9Cl-=s*FJ:#q3pVAR tJH;6l GL:OxbsH3oQ O#i!q{[x@C%|NS]!?zFi=(
[V~<@}Qa
lt\"'F# xO_ZgHZA,nK.b'(0i 8\"\"LG o29P)%Hwr
F>9i}a LU|4BgR >b\"p0Tg]0#4- x_]Viv=D)Xt0
kxZimt,D.>!`y#s%cmt?i54R?}2q1Ko8
 szTYitV#d;z#y|SEaq5&{*by\".r>ZC[\"[vu7A(cy}#(jeiwq?AWQc	Brz|\"Q9pXn=0,Eyh~9kH^&qj}@ZJ*4  <b:zdAZfx|B~7&RLodFduB3D~C_/81 gvV-zu!xo^t4
endstream
endobj
1157 0 obj
<<
/Length 2240      
/Filter /FlateDecode
>>
stream
xXW0bHvI
$@5	h l/{ry
	7w|kM/(<>o}QX1q|&>iSP6i][tfl<4WyI08v$YCyjCJh9LevGmy,fdbtqP7hCI[^CM<5T:M[|z/>7CMD>GkW6JYPC*;Oj{JAwYew2Woj}:z8:q(6	S?L&3RD#:+?eNN`*3hl:8f}~|X 7u1eWKYl20dy~FEN,AT\".j9.Y5#pcARD~c/4o!\\f<-65&>4*:#G8?K;=|6E,`[}@0 7i_AZ#*MSD@Ht{.I**$`2D>&W-H)\"E(\"]UB^gn;3n5/0~K3!;<A6l@\\Cj2]JblKJ]2O	>3^?Ox1<@6h5.}u0}]P@Ih6p0,/Bu\"ZkXc6B1VX]f`%,s%k=
k/d|ZD}/*8}GS	,uhR^vE!NljIws-UM	ehJ,~	srl2T7(\"N~2crJv-y{h>uxB$xE.X	q/WYu`iP<G\\Rpg&MZIzQI9L& 4s$@m1)Vx{
_h(8\\p^4JdV$ZhL\"08S]I 9],J!CMUEHMd5s&4\\t$-3;+7M	4GYBZ\\9kXI)f\\kE
p}z#8!Cul

I=/Hl
Z>'4Iq\\q?]ZhuF9&$8]^Hh/	o	tmN;}} 2w|DgLplq&]z/udR  -DK5qM~\\6&Bjnz.]tP (*(5@S*05!BMl/@v,t{;f8|S3>p-As=r2@(IGaItt giPJNoY[]AH.vK+`I0/J Cq,p5BiX
$/B2
<\"ek?u91J|bRf y;24<0rK\"!mCJ12-Asoz=aTM}v#4cpxaKf; 6xJ)vV+$>W,D *5I @L~XOk)}+kuL|p>?Lhp6 Ef0L:1hAn[e2yf';F'~9qh3kd`/@fk\\$S9zGJeXndH$\"\\i|{QP9
ESDdG+FI\"e:2jZ]#zPN)JBiDBs8&z^B({(/G7X1=dy I22,AUBq<VplG.3d[r $'\"<eh=.
endstream
endobj
1161 0 obj
<<
/Length 2201      
/Filter /FlateDecode
>>
stream
xXK-TM<:*UsHHB gk}|@V;_2|/2	y.wP*-jWe*U{mwN^Nk~^]w~E:Y ,+8Z
%w=;,u4y4e_JxX`V'v|>ksgT03<x^1]HCg{R_yO(j.H%*wwoNO9%U';nNCf7g[	nraP3L|u;w-,igW	*Z1q#/iGgnK^k
S2KkS_}i63<((4\"02YOQ3t(R:1o-L),[}H8;o]/	A.hUg:M(%i\\.8q[L:,$^%Ksi-`qfyL+P=]CZb&lr]l(ChN^Ut`s]yzn I-UEvLf;>.m&0O\\qux
`h'wX	H
R[ Ux1/QmY@hDq6'O\"\"`\"=%R`<a4v7Gmqqo
@e,?+oR&/q^5>&@?<2iSk ;%K\"Q0g'\\D`!#ge
_UFs3v'RY$Og^.,*|#}
u ]eG f8aw|gg K|\\&,od=J>8R=*!tX/oA^U
G:j~=eW?JdGJ:2ofLK]TQ}$'1z niF@jVWHDDyBcZu-bQy\\1	wsc4\"9\\2.oH*TWeXP/!Zai*%t x{\\:CX:.pV^L<j>@fTrQsc\\Qyk07*N2-JN)Pw2|hfW2&1*cu#sh#Fc<-%}o+uD~oJBM2t{'qCXYG
v\\&L1\\8Xqk[ b}XsX:{f}Hk2|oc{l6tdiH7Q_bJRQ7+>pH)hpUe6:<HiX}=
d>Du#/Ok'; w!Ep01mND}PWU rKLvEM.kyS / ^HX ](~o]bcALE^<(]@E	(MIM{[h^3UE'7,mh)Lk%OiK,!%$$X]\"B`?X&'uWQ
+&$;}2t,<mYw`2EZ@	pOurC=aH_oa\\+ mVO2IbIIN_88b1+M:&QVjlrf5\\3mVelcL;M9*sW/zs(kL;&K>b\\9n}e<`'-*
	!5b4JqDQ`sb@	YV7~?Ol5
endstream
endobj
1165 0 obj
<<
/Length 2491      
/Filter /FlateDecode
>>
stream
xYK-T&]qrsE(5(J3\\D<e&%6y6E6OMuZ,Tbo<m;]:O0W?OyiT%QI3' e\"hMUZ(:9c{';nU<]*<{0z{+<iHr?~JnNPYy>
P>(OnKL:2&K;Ov~*wH}]Vj<W%njwb%N'vdQg93vDXL;v.{PL70[4UeJ7hp (dT ~8xO`n>,Il7=ufF	I9/(5;oI44Q${a-\"{m@]k4W8hY~/GwOFy$	apXf[I'/bf1L;E7YY>t2V< #?*4N|TQjtB9CM =6jiq0QWV]gD>4i^+Uf,&NjH]U2zdmL2d04s6p4^xq.aC,4$%p`2:8NC]|E4^,pNvR83?]kOoGH0GPHU%:[N;SwnY\\!Wi \"ovZ788Wq&B FQNf4[:<i\\NyZ/X6%M?7Yd5
p&2 Dy'L.sx?YR@d2?c7(.CN_@&4^Vy>78xSz@^)KZ	`&50p

7j?k_EX[} s B9uM+\\gif0Ov8[yME~[a2~\"0a>D18U]F|_nhLe,Nmg(T(!_CXcF4fDc40YP`u
\"$!ul{p@\"/{v,ev*PkP`
zy&wbQ1xRAZht(Ske&	plNB4?YdSgx<Q}p(*+R7F%ylect;s 
?_2
7.Qe#/#Bey<bYbq:uT[!x%:ci!	LMe(dh-- 8e[.<Isb,+f'dSHG*jQ~jOO/x-4yFl6){eC=xVpOBI_i%FoY8 q{5uqQ9qlO`feZf~>tc=hwX9X6WrHt/!vTP)>O\"T(7!{PwtP l7U5@WpO)yPAId0P/\"w][IU$S;d=6$7'y-[;LUwc	.H\"L)f#R|qQ>\\_FyUA PQ` tIiyxuWD@N:Q&+E;pmgiV5!S8,I29faM9#8JrO5u+o'>hl%uD;qoG7
M? x]-ZLV$G?\\
?~[N52Q3yIb<ALAu^&2gK_q/=%Ynrgz)xlWX%+#)^]|>L\"^)PIy 
+7Ww%Bc?y\\(}HR8FgUT';	/X*FLr_``'H|ucRV
y*F2h|b&~60VnB$0-i	T1 J}3yc,A	rg	J'BHlU!-)SLxQ_A&)qC{kAEG %W;MaOI~xcQ&/43]]o|{??
endstream
endobj
1169 0 obj
<<
/Length 1272      
/Filter /FlateDecode
>>
stream
xWn6WHV(J:&i6mK-RR}gv^\"sH3ah%?	qi\"RY4U+{|iWfv)z0[R4I;Wc3<9'N=I$T*R![8n1MNf\"g:L~emk*0rm	)SwDQcI\\!+gw};pw^P_m_&t}o0L[8lXu[hnyU<.25{gst
Nf/y\"I8,u[7\"~8n?=;c1zu9fX)d,Qf}MpPbd9 !=As 3dur{Ny%e-e
DzL1q@I$!Ndup[LhbOT72E]4QHv`)YMD:)8*+/.sV:k6-L8h H l;Bae]NOK*h8&T2HH\\5U(*#yebCB`tAN`P[P2dPONi4Ld();()!+:(XqSwW	\\pti/F U =-:	F,	C`6\"mko*V*k5Ax#K,`m}LFAFp,lXcZ;RSIA	@fYB8O{D 1%8Kp[x)^	o2S$'0xXnomy(v^&qgP\";v|]&=(ybU
[>VA~EMy:}CR)`@Gg`_ZySZ\\v#HJ@sa6KdP(]5]7P*.?FzLCs5M8SpU[B
`Rsa\\EE$
<*jrN)SRl:_ciFkS=^=N=2lwui?8<Adt+w&5)M
endstream
endobj
1173 0 obj
<<
/Length 2060      
/Filter /FlateDecode
>>
stream
xXK6&$bNQm[ITw_J3XoQdao}x|o)EyoxUYoJEVloOScm&}?W'96rK&l6<U=6DNO'`n<#-jW?cdV]q:I<1X;xOz{Fk-'p,-<(6{vm5h&stt@2:me&g<U<$ z1Zo<NALjk7p,SM!h~g}w;M`=<+O~fC0 NgtvfLv5QuGx)M.hUx\\$dvA6@ufMO3vh*XvUp(A_S<
%Gdt]O=#Y`08GIE#NvZ&$c`7CO69)R+
z<(87qyy(ri;YQO`
j<EzUua5'JR=_|t92X6vRwI~nJ| 8=*>C?EP:%HlR^^ux@1W~A}`X(A*
zN@9k#G@c53y|9sP! 1nGT#pCz&>#XHDot//@wA',x.R.s;zT#	|y7~VMF)a}?0eEjJ\"7H:l#xJkSshype=YLfprCHhrtegWT~ .:sIHT
2!3SsKUP(V!:4*7\")t`j/C	Vv,F(!M)=TAI|..<*p'9
 x _2{/c0 Wj\"V^M*4ms-cCC(@tUA
<YKL|/r\"cC)Cd amQ*KnG^urcF:+S^Q~P]U<)XP4y-
LB 8 uH6F*<f '=~f-;$wkk2fvO-[K27OqfOyj@nhbJP@C<RE+=bI_CCm{GkAv_n.Do$~^
>y$B=}DLUCed 6, K^}3HxP)^rO3hOC3_	?8.?)H,x@949$)>DBwx*~D1v -	mdS{Vq:FpbqI\\4hz*T!@Ty,i|N>r:,CR@xHk~==WroVF\\`$<de@>`hK^	*c</BR!jR6%%ZTF$ueJqh*a')DQB#~iz/w5	*SXt 3HI8Cly(UE<RuUW';5c,-!4?C7k=
endstream
endobj
1178 0 obj
<<
/Length 1153      
/Filter /FlateDecode
>>
stream
xVo6_GUQ464D\\d#_;^Dx_h%$oonyq]EXFI\\WpD<BSGM=kF7g[3c$-Vz9Y#YZ \"M(FE%V%P=N <tZ;_//(**<N+z^K9,e\\-Z!SnY<gY$I)iYw1'gi4hWLI&,h<IdQ	vSH1{_;ws#(8IH:2K)W	BzLFCA?$arpsM$@
{kG^O~Cd@jr0j.v.XN#O qc)M#	%DaE_^' qYIDov\"w:\"|U'?HcJQ3ptz`t)sy #F`ju( +y(~] qY3i|Lm	mA	z7tO!?wQqSb'?Kg L_Pf +kOy@'$&*o@}^KG;mwv;\"7rj(x(z9L2%[{ pgO|ZrQ4&#cOjW*$}A,zs;`h>
tp?A@N
3\\wJu02B8@%
}m!n-CzT~{x[ qe$-4+m_g=[4}/STL3iV5`4b7gBOn2m:1B6qDwdOd}PO4^B)YD<uf!P}	x~|v[f8Il,Wiy&%iqsMs
endstream
endobj
1182 0 obj
<<
/Length 1705      
/Filter /FlateDecode
>>
stream
xXKsHW8<eyljS[R[I\"]IX!_8\\l/^T\"R*|&Y UXorr%[.=b}\\zhlcwQz8\"\":Q2bRx^ZGvG\";Mv=njh2OkVx(mrlw{w{akKf'YK^+\\tf{IH/nlM~yP$9B2qeEgUi5W%m'(Q/n'@nY5'H,CNub@f1xb+$EiTd~Tu-zf sE6}gM8B4?O0$*D^[zcQ%
I?\" E72C8*A]yb 5z~ G\".dP^3Qr sY|1o[?iJr	4]-eBs;/zMkglDn/$djSu$pJ'J J]= dgo;~@wb\\Mm=O TPPoD5%3V{kmjLmS,#HnwN10LiCPI 8uBFr\"82_'7hdd!mDj>_A	`ymsG{gA	8-04UK<_Ge[!82A
4C(QR^ff1YtG#J]/}F@qk9+yDWgy ^ o?ts
iS9_85U,T|2N.y
kkh<hjl4lw-. %{U(i	XJoa8d>0ry% 

iu74%4o*O* NpouMC^P	pQntE7A[TdR JzI[A*/!5\\ y{x3(YE=VUnkAE- <tg@^9GVh!{9 CJg.YtJa'\"	'D#$drPa(<
dAm/?^b=$9,Q=@U(j65n5|!q>_$lj\\?]ieDiok_V`Gz23wo|:3c
m>
cL)h-Fk5yvf(??B:sr
xfLdG14m7aE|_;]6#z=R%zmnpRi.W/ )h9|Hk[0 	qZu
endstream
endobj
1186 0 obj
<<
/Length 2811      
/Filter /FlateDecode
>>
stream
xuYK6Qt+>v&Av`imNd_=h\"bE'&)?^>KZn)MymemMVl^\"9~x,21Ib1}?A)&3Mz0u4mw{CG<@)]e\\Yi9P
?b},6OYuvZs;2:M4~5b^M
fqnSp	/&D?zHWm\"<i4VQYO/tf?}:MY7We),N\\X^fQExF~l'P({#}:%Yf`	zHL&8 n<MG20uo	4hQFn8-I|n%vI@i=^-z;u-gEbD];[MR1@1`		W	@M4DVG;A*EKv:@Dj`*woUv r&&i\"3B\\bMbiP;+;VB1yd 7B#~\"Z82HO;4~Zw6K@i Io,1TnH6VZUx}b}V?%Mq'_vUmct%MSw85mIbY`Bt6*6#<@#v\"*dbTaXw#/8kuF+Q1$2)DX6MX 1XJw%5k9Qr{\"SUktiFdC=$;	DMatzMZ>MR@~kE)
CY T$<q0
Jti,M,[I'k6pXEYe9e9%]+AIe#OcX!wlY8`~qFBW|(Sv	F|8JN IC/>Vk4.'/i2\"[/Hw,dqld`m^*H}|/D:JK&t)@I  (Y4R rA \"R!o2empY#Qf%>Y	Mc\"$=S sV~#BP,_n2m%KLDHeSb{R=5\"F\\%@ %L`G`18`:8?brd{a+u1z$)_Y\\UU,TnJr}M	!YA!O-@|vD&]~\\&hL&ZW|{\"7e(-'y\",:'|+ a~7JOq]]9v^,TtY 
gE\\Znrp}obc?Ba-~Bs[R)t:8Wo{?*huUh,zjOD5$0~-? %(t~el)zJ#Y<%v{VD%WIF+FoGpa-L
2% q^u{j9!<JAeC]Cemf&&XSHp?aou:7RTIZ]`R+!TD2cQJYUZ)+Q=P{5)pD,fS1N+arMYYj}HN)n&6E }ZN_-U9|k7KQ^$.,kL#:i{-QnIjsbH=G:J^D
8E oZMDt.G?SNGL$2
fR$,8<r.EE9!(THEp9UTUOzW)jJq%y0:8-? '-w\"*&a(%l/G\"'A\\xzTe1%:)3ynt^r}q\"8srj]+\",l
e@de).^%&8Lra~98y$D_-rDOZ0jXUZqTB}-	o#93QH vb})fPfSj=W3&v#)}1dF_@\\U9<=o%~uz/e*aT~O
Yk+Z]6K>J(Z$ps~k]gYy\\u5 T`VXXexUJFf%eH#i;y,_`^=]26emP^t#/65b)&u*rXF*Q4v<sY*'X)ZpXj=BaMk<+?c tj5 3?{_$qgJp|?aaB
endstream
endobj
1190 0 obj
<<
/Length 2074      
/Filter /FlateDecode
>>
stream
xXKWj&@dmS\"$LZF7(!9h4F?lwe2~O5iSrt40NyZTU*s{w$_\\oyQqH +=Mfhi7fI4NlFm;}.K&ZTdhhL~GY%g`p
`7z0X)0$9(7N`#&G7t)eYEUOG'tJoH~Lyh=+/e>[j,dk4G3\"+\\,5CCk$YOXl-/?^;75CV_lA&-D%y|T1H+:XB9=`RmTT9
`W)UR

_E>3.-?!<=Q4IkipZ^Q\"Q Z@@B1Ek<-BTR6t=j2A7
mcBN?k%Y=RUVQ*z b_*p+Oa[ * !Yfd Rb@+,&mH|w'^(k$C3 E')nv,-u| =8!3\"g>Ae\"XtWx\"?yS]%?1]F^dMOV}{rbB_JD0owQ[ 9YuocubEf5O.PMn+_hEUgG97L, \"A>N!h PEE<P;n7H q,D8m,|Cm{1,K{Rp'lod'Ao J&^r*96E0jg*|=.DM^*V2dP =3ctExpJjji];	<<{.AL0xk!`b`	R#/}7TFz5cTrty##^-u1SI0f) Y[6jRZbuPz&i/4-)=GPY!\"bm1[`$0yt	Qq)|GwjI~2-GoGfw:Yu9rM@oO^zRu7rHa0'qt=)-~Jmh7N6E
S@b|,^-mFQ%eN 'rBJZZ\"a~y|xl8nbGxf-) 6jkRYeiQ+nD{F!sByz*5C?9Dpi>&R|8TuZ45CTggBBdLi\"HZ^r:L~`j^tFuTo,TLBldU\"J4K4eSAo&JgygI7` R{C\"J&A\"4rx=0R~40~VQvCd %PrbE}5 p[<L\\6$uT.1:: \"kp)C_c99Y2<p3@?\"~_E. 19Tp7b_ShtM%@O:~L
rG6i]<Y)}|z'lV|i
endstream
endobj
1194 0 obj
<<
/Length 1576      
/Filter /FlateDecode
>>
stream
xWK6W H[f6mG3dfHya(x,_=V:,I<Va Q:Rm'\"xkt5OH =
xU&zvYlv,/+)#[mS{:,o+8oj%q!1Q8zS[[qY6;'H:0Jg(z.-Ruz<o7#7n9}5]D.D_8,+.B-a  +nvxKf&oMKZ {QOL$T!HpKsA1+ EG4WYR(4!5)Oyrre_/pQiw1Z[C~WXD'A@`aNge-Ly%4y[D\\.&0Pu?5)[Pfi!47d.rga:~zvM=$Nu4)N[s KxO 5Ge]a`CuEv9>K!pGRCTS4hn;pA4D<L9U	|*SwM[aV\"	#-`aTm8mEh$\"+LOCqJ(sue1	iHl^z=KqX~$u0|Iyoeg67=\\1.o?^im1eIjCW<b+|r
..*N=J[wM}_'*XI&&Yh|Nzxk sjCZzeNDa2y Tar]RmN[=fVmh[$b\"1k){@9ek6<[\\qHpQAy$%NP`x8ZK<~	A|DRA
Z 7\\SZjetu22]'	:I!E(F>Gl>'b'8<8Wxlmt5`$cv-qla2AawB1uy|w{(@[\\?^An8|@8
[n[S;8kqtjkJ|m0N(=!N0@|LHr[%PZ=]hj:zy3tAq=N!0K365U@xf{$!N~`TxOP)-IR|7rXX&\\4K0*iv'z`gaQ'fx995chm5/+081*P^_JCPQwC|cSx
d-^?'Q`
endstream
endobj
1198 0 obj
<<
/Length 2777      
/Filter /FlateDecode
>>
stream
xYKs#U%	'U9SEBXr u~$g!UhhtCH\\7Puy\\Pef;+[{Q`6Lg[;eY4Gx8Gv`+<0c4|Xg~fU!|LRq)NHWE=:a<ze*a3S$CAy^
8e=^_Pm@LKL+i/034/vqs^sH*X%_t\"E&upj(*Y37;OZ\\=e4v~B=3gmcNgAIv-qo/|m)Z=+3|kc8gF+_y0xXrYoX7n6Y>gK.ihNFgOuZ9N9i=/gF\\vayr'^i@;h #HQBOzGy|``	n|,8$\"x;:B/6_e,e~' +g<AM#{:`y1=tnAWeS+XdDtZwh$[B0%:a*4+>Bu?ovE@%:`*!H0GjN 5{gr?[H0i'7RV1eFYb@>){
EXe@4<.NA;Ym ~y.yw)tE4,H\\Z_8EK|
}QO_<r|>D\\G*@#`:Y)
BI#a]6 +E7xl
Yr,A$-<8Q!@kbT.xU.pw&84\"*>5/d[ m2DB)@ _2<{(G\"f=\\(tf:9v}}~3~1Id@z2(r!]<VfB^  ~1rD03D~.!$YI4Y2]}eKVei&	]xo
ZKwr!4 |U]ElE5TaXx2	B;N3CnQBU-cEE,hrB&/`U?(M
FbZrp:3dbtF h/_d.bP9/sPd<A >aH4H!$bOD_ z#N<;Jo^[~v=nN#[AevV@J	i ^gAfzY0l B/P\\A2Tizw4Bpxvg6\" .*ZXB\\g4K0<AVAyu!*{}SeI+U\\}E*2M9$sq3ls(C[cdV3@OCgoY!XbA!VoOd_FnM#}5P[QJhaY3BBljlpXGXZ)x[&uQX9>s@L[|0|W`+HfCO]XI	Y~*Hz`dkelSxGa!](l}l3xvAIDPtNs\\dM6?g_<y#
8OaB;O@CtBAxbMq)>/4tx5:H8
y@(/A[`nBQPcz78 /BUiICAE\"*<q<nuZ3(2df}	}nXgr}sr63+hkX }#B(E+zC3'zvkbIi|va))b]AbPhG=5[n-agrxTm,PG<Kc\\cH:tda	@'9D\"'G3qSfA*BIjwo##ZoK.Lq$`_c>[I\\$N,qY#Q\";t%Q19][_R}K\\:vU#r<kf_Q	%:OT_'b5L|3C)]E]:_W} ;Q)8MGI5m_\\rI|iZLe!:xWehB5bI

bq57+S><'0
endstream
endobj
1133 0 obj
<<
/Type /ObjStm
/N 100
/First 922
/Length 1202      
/Filter /FlateDecode
>>
stream
xX\\7WT!.`//{wZCtM{J\"N%yKjDD.0hO'HR-^wxFO)Rsn%:GTz@HJxO@G_O2 YNeUm4
W-;5UxMbPi`:UXAy`, 4BP-zLrbdA\\rx///`V1@.
$!\\'< \"_b]w`
3cJq(rPYBff
1$!4fc(T\"_GBkP%5f$G=jQ@BJZTG`#;#:9Q,
1mC\"5qX=rE0?SpjdUZP>n^_Qmrw^)0jauQ4tw( sc=txLy?xn?~mox7?|N\"HE<m!&VhkZ&-sj9Vhkh-\"?%Wrz.R`S^\\B,oOZ9'm!m8Z	E4J7[&]N_t+ @\"Z[Mx-T&/{ k%
%%lMkbVnnhhkoFn	rrN\"ZxE4>,9j=1mLWinbzK|!:Cky-.K7;\\lb3)s)fh3M%Vd9^!=,rgh%;As7Fsr\\NrOU3E1btrnYq5Xy\\i7)y1w}rq~w[.N|v{hQ:fhjhU.}r1r>>%}ry7}v~7 
endstream
endobj
1204 0 obj
<<
/Length 2103      
/Filter /FlateDecode
>>
stream
xXK6-20VDR[z'3	bsJr`K=:[*\"gR9l2nqO4iSrs4eJUYoJ*6N|r,Nd6UbSg;n:8=f#g<iTvO18C{:\\%<Z~L)o|d3O#;-QtRJ*t.Memz&Mdug;w_a!hR4 +#/eaHaYNx9vrbAg8r}0eV6.^7hjY^/T4opr\\S}|[\\ul3nL<(pE*:wBJh(!8-h4jq\"=)28RPcAomGAD]wacX ]V	}(SHkB1@n l5Jf2_E;Y6\"\"P{t'0qkUbqvgG=
+cJ
Z;Fad=OSN`5hU/h J!N$=1Z=\"9X^?N3u p,OA[9*X!l c-a*rm{=fL|+mN3hhA!~'LdZEr&g<d8dK (Pis[Uq*cq%(I\"i{@g000s[|1\\yQ9N!`\\t!8YIBEC#i|!9MA_bb\\L&GqSF%!B`F2k'||j4X~:T(@cjB0YS1`SV2y+J(k*5J?ysMjoavQi5c(T	!{cFKL\\o6-'q\"7BsE0KrETRQ@`AxK_Ow686P7I iDKY~*Xy|\"a&Ou9%RR1= crb`{;S{p1:gTQbVv;-<L4*p*k |if}}3[H[,2 Bj$^h8\"@5H)xHDq]0a]gg4@+`n=ScRRG=*M,j,HA5m0M]W8'B,WKAVgGeXIF@\"a	\"#bBUH=@3n`gTX:p
?1f,? |	dv[[boL|U&c]#X*?)TVU'(cc@vp*DF$8;#%:y=tj_507HQJZ(KJTDY] /I{c?kODeroUN$PMT;kT; %<U%kH8A
?]*qk0}q(``5CefoUD=>OZDSFxBjH8QB-j:TfT/D52]\\y !<'HhA7S&4{.Bq& <YLv<#b
;;zv] iLEw^eiMr9
endstream
endobj
1208 0 obj
<<
/Length 2393      
/Filter /FlateDecode
>>
stream
xXRu%Qn{	4E&D%CSv02XuTQfI6?}IO_HM7eVnv$nj%t*We)*Ty:nnilaidgFYF8<du4c:jT!F^agMi`g{q4A<4k[8{fhIcyg5+{F5_VM_HjcT'fv*}UV:z(sYVuw,MnuQQeUlU-.\\DW,vt}*~Mdx+ARJC,4.oUN8W1YLl6;q[sF(wpyZ#$z;nt`Ivi8rV	n3g,s^L8*Lut[?OY>t9UN\"mXy<Y+^o/d:Z=<G_Y3}
UE)Z&g9BFE VO}e'<q=iOP\"*?=K%<Fb.C U4>^O<%%1I.-% ew<v$WzoDXky(T CNT[,{Iy0Iog'7 >~ wd#	< F:8f:QqHHi?sQXu7));
?
o\\;gqX-I-@^#p3O&?va+~xu&&	g&PB $vFMoVKN FW;{1K[PEl{=$Ebw=F{rUYSawkZs[b'i10J$:D9NaTkrmp&sjqVCIA>+Vn=eq<<or_M8aP8.Fxb30b7O{*k?YqRe>l~,!&.a/|Dr&2cQBV%*or+Z'r	O]Wq<a?~|	 hnL8-qFRet'<uK :mwuPdh:F7|[TDlRb&cb%?1po'nZsBh,iTugX[5[b^Rt%p1\\YIY?*XOb*I!r9g(U~@NDu	n*XU):YL\"nYTQ(|b/9'}^y/k}<
 @SYb[\\&aS.	V3>5b1^VO+WUEy	 7+>RN=wxC]D,*dd yCdb1n'()8.rE\"Q[3$> \"Ha]dmt{#6ir9wTXgW[*d,(xl`}QsUth&^?PA2vh>zxe&&u)Tu/Y9x&\\ Z!xWfN'#<kfH_7W!dh>7%xb[B~gBgrZi' \")_]8>x+)W_@lm-%92/,IPW~MbUx ~<?]E?Q>$9U](CQCv>x3CK_y	&|a5=J2L,Fh&J6/y;Zrm~@C(D:S.s|wVT
fzl$vOeE1 v,4Mzn	z)FFQ.$]`]Q|lXU$4wWW#3L.H9S5ST?R&K/q%u$.sXB@J]?)A
endstream
endobj
1212 0 obj
<<
/Length 2436      
/Filter /FlateDecode
>>
stream
xYGCuL)z=4=p%M<Yr%m}g8CYz\"@NP)6?~*~JVKFlRy]MUTW6[vT\"]r8nfY82/0;\"lD}&pp4&{:vmgB4a~,5e7_f7KhG<>{S6t\",VMtD)kdcVIxdAfG7:stxw8;wR,1F#E%heQP'~3<j2p&vPaFZ4Sd|i{-[3jDe;DAM'kjEkzD,njh12Y-WVb9;t=t8Be
Q(5	nuE|:]Wy\\eJ>@%&=v>ZVGp2jFsb,t+&B{/?::G;&L\\jG@0La/gt?vSY;b8H]]FPj}^)W=y|q8`3d]@WX~BMYlXOI%aqsC&HEe6_7XZ[<aF=C7nJ|~BE!2al=Ztk3D|l#Yk[2:7dB%| 9j`-uAX^g]X+ig]y-c8{ZN;!~L`D$Hf'CxbwF\"
lZkE7] a!?%d!/*]Z<#j{=XI6`L+5k8W9E5Nv4mp1O#t^,F}u	S^Mu Xt|4*'u ]w`\\dXA1AG6PCEIEu,3R.tq# r,(ctK!9m*d`\\Bc0Hc? z?@W,8&]Y]\\\\pF@=xRAJ&XA)'q)q$b1?$sHl	5<	Fj )F1I-BKrW^`>#ju#`e;URB9`\"(v2Kq5	o@ Wp3TK1bDBA!d+'MdT\\\"Rb
 &0jTQFgQ/74)u.5mw,scD[*+X,dYUcS) ^J
9EYX8LCLdgjY5,JB7XyB$yY
\"sLdn<,}$Y#XE3LR=!C7'Ou	GT O{E.:7EI[Q_r\"'FTqk{3i| 8o<p;B.+W KAo|'X-\\%i]#A$_mp5}%H&(R5a@P34\\JBvfkmqH6UQ>I'c(H=L.%gX0/Y'qAb@	0MO4`AcAZzI)M^7;GI7wg9<W~'H| Ve.^E,73#RF R,bSr16G?	| >VsPIKI,=E,N&	<v
GWy!SYQs3G5MOh<a!o3 1?S%BsbhX.[W
h A_S,)n>i4?
~RdpQ>|S_?-7b(J*#oh??}t
endstream
endobj
1216 0 obj
<<
/Length 2335      
/Filter /FlateDecode
>>
stream
xXKokEQ$$6[b<ri5dr_>E~T4NO
H\\tPu!5Yksxqqs3<p`yX8aQu`ynj.=#ur3NN})9>C^q,m3T*=)JD	$vZfV%yZxN2C&FLE\"{Fu9<+mFT<uT7~|Dzt/*C,it^%U31uH`lIJ&{!ht;V|
ofx;\\meD!UyU<J{+xTo_0\\cW\\/tO\\xv-s$e`$:Xc,LRJpmy/*-r3&9Zp-Q(SMGoZ1x@8_GpZ p<&\"hW&JX+xw~uLI3I=zX.5}cH@Ds~8pC|ab^PV=+Cf }	?B&K@\\DUa!@IUh
x-9C5)@U\"RB&G0{S`/
CXk8T! 34[Q}@\"\"}1	w(=,,><UDstoy?^kb8b?MV9aIk*AKC:Dvy28v~xwdAB%8:=`m+h[	3+d>u[`e@nvJCAm`0Pq+^HQe]'fR?yF4kwB'1:FtEMhM\\	=B_;=:sF\"Bd	*j]L$Uh(of\\we)0rmmW^quLvj%3dT[v8fJG+:7Cl'?v).JlM%ejNZU8:#8T+J*` fN`G.zV8\"Gd*6\\k$;euAN,JX4T}Xk<W@O4Tj6&7sgT`B4uV#[BtS)fw	gCQ&1ryF3>W9XE0{\"}!Xed^0y0-G%%4>r=JKn N0am 1b#F|EVTS56l5a_'mn;	%q,N$	% =8qU\\\"2/u#f	LcHlTp}_~#r8%ITqZ H^4Q@45X0%~6CzZ}pa;R<@'}VFc'[qmg_jy7iM5\"|[HTD#fk3$=Aw6>0UI<@xBK5}Z`rl	x^^1.`ZXT-b13)\"U[T)X=KVp_ Mw8A
ILhP?{u/~=*~+/ \"!B9D 4$3#Hb_A%F.H-P
#N2[n29}xW4  )|PbXqhArxmtC@-W.Q+zRQ(&w ,YlJ~+Jrk(E\">Py @%
endstream
endobj
1220 0 obj
<<
/Length 2288      
/Filter /FlateDecode
>>
stream
xXKjZD=}SNJs}H!L~} T{EA@&!9!>2+C'Ic!=BUY3QG=x\"1W=];j{}z24rVKIguW		w:vn(s9/&%L,z>tj%YP{b( l;}EXm&2/%fI^O5+Q&{[WkPQkIh@	YzY,_/uS!n'vjj&41rL^xRlO*h2,-(8EAdE%hWo:AM}OIi0K\"Khi%n!7lX*t*ny9y]pRM%	m /<oI9G^Ga;hG$(RHp|RH8>'B`.INQqd)bSEf:\"LfcGX}1,tU kk r6[(W\".Og\"W*uJ,F\"QLf(i`Kq>e]4+^WK
ZXhP9H?a[w iEsb}',h['.AVGDTaEOZSWyuxfeL%&HD`H(k#6g;jdJieM|LC8IXKu2$asLT3 wr4zA!Nu^	* iIyth@{5> &	Ca6oFp& ZE)/) C @c$6Q7W(\" x +	4.
6 joj&MH']z
UPoy-^1esjYjPsgiyz YMPDaQ
z0\"fu=1HEN^yhv+\"\"e*$x[/*.p@R:J5q@_CxU'Gq-Z{4#.S/3hR=RQd:9 yZAP)D#T<u}v,~4'{6NuOpZo0r`^F4h?r62iN	`-'K'm>AeF'+KrWHU` szCll%P&fSs]1bM-\\^R>l=XE7 MHaIHp3/{s6}T+_@~x	D^r%*Kc $NS|j<A|gD.o|4KWb_P9MS4h?&uP,RH^z}#jbJ5kmf,Jb/yU2S*4,KSio\"Xo2uZ3^NKJz.7+BgRwbBL8c&7M{!]7+e^}=:{ON\\@!cMMLfA\"+zt\\n>iXicks/}yjpdjivoHX;MVE_nP*nP5#Q\"bg<=\\EY 5l73|,wdw9?q|-V29:rzVO3}kkWq0[q]\\0W714e31G}fwT(%]y6y-*M-MoH0is!S5nWD :u

_'q]f_fnHxSr[6Ks_ar]Wo=@AS6p?OEGSxN5$+8M,J)V6M
endstream
endobj
1224 0 obj
<<
/Length 2600      
/Filter /FlateDecode
>>
stream
x}YK6Wa~mzvO6{\">_? QLN`hwEO?D]ER8b,ExiX0Ii`{H883~d0eNwI,B[CAU	h+F~kw;wIo;{-tWe @',qd`aU@iu,/NNM{&;	6kQ
V3&L3Y6X{_G3	'|!&A:+mee/r.dp`$Rt;5-18Ez\\\\hM%-6e*k*)WliZq4^nxWD5~}RT\"!AYa1^`Bb.fIE=v#Z{_G8+-ow?NRpsS.2
QpA._E:U89#:UY__e%`6+.02D(qfuo\\?Jz#PH?.dM\"&<Kz5rHyV\"SrAF+OIk^:El>aB0'eySA<O(Ob'+5:V?4b:tiq)~|F}Vie	WOq/*xN]V&w<yP8`~fY/U epRwKyYom	2,3EPJ
)P68i	Z\\vb>@DC#.(Yr*2d& 5B<F+19$+4= ]..?)y%4R#**zI(EmYfXkaq
8$.7{{72!Gpx'y>qX9WEV7ZV7Z{:OD	`o s`?7]>E4'zYo53>utXwr
kK''Q;$T'Mo
HCjy}+.n]|3<(qe\"~B8 N	qbL<MN.,
&d\".hDH	=/{G~9j0eE(yWl9T#!P;W\\b!m g/k>0R][cpfE}l2YO/U[LCPaR]| Qcqb*;1~U0Oh67`VmQ,u'[ CFa>1c/*
B3gx9!0\\aYW( BlYj>fbe|
eRAxs`7kB mpRG>!Q-=(rTKw+O;o2n<Hl~'*]
:3u/:|'u^Eqa&}\"
>/
]PPd2>I93^6Y$%zlPGtpvms?$'G|ZsBa$[?~`_avxuH,\"Atp	?$i^^oTXB5\\Jpq7;/2<*pj btTQIe{<Z3E;\"B8|i6575j</mcNWP?ocnJU f^^IRDXOygEd24~$U1)2LZ{)AVW Sm>@97%7^e4im/ewM9
'Lj2iRtsf9r=?+GO?6)U8	Ly5EF+9u.c|aStPWf;w\"%Q<X#c:\"T~@MMU?_52epjOM4@A<pK6r6.,^I}+e?Pt	,l[XT%z]t2L{l^i(Jqh& ^aui'7d,}Rn*|f(JI+edL_oJetW{:Luhoc1:Xp* {9PKxOmF~&-8RSEa[aZ<?Xj
endstream
endobj
1229 0 obj
<<
/Length 2063      
/Filter /FlateDecode
>>
stream
xXM4qexwNG$3{$K*jdE=].w_/]WyO;'BZ;!e\\.8dZF4Ud';PW_.n8g	/ixQ})zO{X765[nhzzk$O7*k{`6f@HeXuGjFgRF3O{?9MgdNA*oMVinoe$01Hbln3dilwu5*\"0Wozdzq-!RzQ>o/2Nd0ty4egjj`0vcBg;z89&fPB	.49W'u=gHLN}gN604  6z^gsV9Xd'+Si5}7kQEIn 0a,:zX0pg[P0n zC:pM8Gr,QtI#_Bz80H>dg3=P[oKR$7hE4@1 6/djs ~pW*e]Z:GI;6|<OQz&ScXs5(C@EU|c&wd|2G<yt~z!'NWuxs]i,k]qp Mg9<+\"kpe9P|-+zu4^Q<-_Tqpet$4K8R\"eRd!FV,{7SQl{59go-Nc-3SR*
w|}*6%J;01B M?K}Qdq,,ImW~m g.+`&j\\	D,c#MwPbQYQ;-mk	
P<l#*8f94;ai	-Sd=| -l$`E.yRDk.pyk]/L_\\0wiu3h{%p+,V;,J$!YB Wo2*R|Wi4KB{-Ra\"#=pq1nDv*yTnF };}Y2A~@nh /x$?\"+C7l{X6r9po~P-% ]k@ DW0g{Y7Svkhk;|(Tn#L*#v m3
-LR
N)_lJ5sHrp8}	_WQw72L8@#`s>)#$l&&cP|P)$9GMiKL?c
.[[E&TS!9B~?O8>Z	+*K[*Ge)7Y*^sJTRs	&L2q5#71)/Tpa)T5YMjR%=`8^_kua\\tAKQ|6!ugtI9v8/	0 )W)*d%'$#.n!nKH8Bqs@>$)0} v	 ykm]zqm8?
igiPO[z$
|_]rGOIz27}LPoJI\\|y;*VTUaC%
endstream
endobj
1233 0 obj
<<
/Length 1751      
/Filter /FlateDecode
>>
stream
xXK6W(\"D oMZk%Gvy:^zpHoH'*Y}|7tec[djJ3m\\_F}\\VY4HG?[7s7}o>qGU|De)j{|ZgeT7:W0p$O*N~LVYn3`COkT{}GReI%_6U};f7&tYmovBO,0-Dw_MX#`)=ILls\\@1~'p-U0#PbHhQd$pbDN(Jg<m'XsRu'z!0]Ln WRlXF)kE1BsQGipiS:ODK
MKRETC	5 mqvy%>D7GimiTqbC^ `k_ws ZL,d7u<\"wvP|8L|&8){^^qJugTH$T FW5<G9L|O#]E>B!1dztwayQ]Q=t[;89U7ON>>j(Kz46Y7xCPak$_
M0VTuXJa)\"8!df[kYop
\"?:fuApYBVH*wy-X/ 06ro_|;NW#]cYJ#B`n= qItc- n3%%N/;ui)aa\"!:!#`oP x 1}pWJF%	U.T IRyy:=|f,AtA/c2?7p3J2 SYy#A=l6kAFVHy}^.+t$Q*\\`0R,D[xr.0
uCIJlP_T	Sl!cAG
a+oB}9KtoKCY;mR Qytq%{!N<rtU\\{@]	zvJO<_RjO2C*Xl 33M ]e +Y#/<C
+.O6o4?D;^k2,G}@GNFIo:%_r6m/XI}j'{}_yBk<Vim3$_RolxDF<TmPo_z9ZJ|$@FD WMDNX4Um''ps^i7B7?w1sHG)D&P'B& s8,t
endstream
endobj
1237 0 obj
<<
/Length 1514      
/Filter /FlateDecode
>>
stream
xXK6WHkEiX#Ym6Jrx\"@Ng<;^VMLO7o?$|UFe~\\OjRg[Y~-f)exik<_Jb+>?\"Hj#N~RNYo55]Wm{V5x6*_dtoSs	/kw%\"w?L5cix^Q)	P@G7VNlP#;6DpU
U^GkijJf38?1DShI3~N\\5&QI46yTH4qqsxz[>MfjdVk8slzvfMVQSDNt~Dc);`My'Tt=uFJmP`ZG<`)R,Oq?G(cr:V'u~Vj_I c\\$>*x$YR\\e	T$bY7L{$eNBX[3F	fC'	cLZ;)3 X A)U +`kF\"kY@z|z/J1ATUb5O0^vK]eIX#/&xLm$XAB~%Rnk?c@Oz)i#qdNqip DEpDDRQU#2D@3Fg\"q1H	s mh?izKC%C)SOI`iOq,m7]{@D_3p
)#)9jV@xN@O@B2<I<:PZFW
GOx1<6O!*vTui@AXur: \\5h\"R0x!9P\"h]wLiTLnR/Y}-6]:\\A#ph N^wfam>92K	. JIHX\"Zr0Mz<Z?TE/emiB-Ki^o,bdPXAX{i7v0IT=['sv<^X#YRqJ$BfBUqCRt~N54
8(Ka	NCd$K<j93cLKvrHCHM%lYoK&qrc*x1R.3%[50Pf9rkO]dm}|=^afD{\\|}p&<S;<0@x\\P3h /u69@Qi|uq_&T
endstream
endobj
1241 0 obj
<<
/Length 2501      
/Filter /FlateDecode
>>
stream
xYIWN '3T9Ur#BbT7,U. F/_CI6_>$yq]f(6E^7fnguov:F$e?a\\=g>b9N&EdjS4z=&#/[r`OES\\w)xLevs{6xufw?K5#eWJvP,<#-1~xt}ET`P w;SZW{nAcL1Dk^q* +I+>\"{EMn'd:s  +:g^I>;\";R?p7h~y{k{m,\\QzuCy]X;)\"SzY/* K@5#uy?'`7AX90ATrWydrSp^;W*3{ U-6-rzuv>Vi;vqR:rl2b7|a[K~qpvQ[9zC&qWZ^M{:
+]IgG3'.[?zs[\\.JAMEjt\\E`<<=_KRfoKAp7:VU''3y:qt;z)<4L!.C6GJ2w}apjO)CG_^pVx482X.SY>jdhhM;wfM'Yd0h8B,#ni)~#[wrjP6	)2.ps(p!Ux;=!O[9H!Bb:t1O7n_,GZ|lVT?GGp\"k3w\"-E<J$Im ZX:s,0 L*P	ynjp2 H V?W:NPNgao)348gL-';c:n{,D$(s  aar'f	xc!A
{11LAue%V;suABctd[+8S=;_v8hxOb]N$v/pkrrY1H'-@@	t_DvrW9:n[tWS=E`]Gv18h@Xs;9!EE4x v8]-@U].U)9jsHC:S<\"8$( x)F(S 28
@glywyG`Q/*:,rm(MF,J@@V4+gD \\~R|AmorqV] &dH!3,Co~+9</R3{`|OF
9~,KI#6.'w]
E! 8YeCP#[Izypo+[1JM('wNl]A4{r>@UGmSU!&{*)s/|	egbiTwDr$bg2i\\#bpWF5pkW]xZqCZ%UM08YNq)hc\\mk!(||	c`=C8( u\\:.E*#R0z?LH1Mt;dCTe?nyW \\	vt5zi8$2h+D/_? 5]~]u\"I86&B@s\\E+|~c)?8!LqFjPz#LTgGQ	uav~xQRW jq/IQ\"!RrX@8
HT-WpfP!Bu7}RopC$\\
>CIPTMg%F=TQeN+qUv>`
iZqlD_[]8i_=BJW4&PuWs ~<{ +x._1j^b{w$VJ ?p!&#yR(av_Iw1@qKUTP-ge@Tx%h]
IX $tzf,Oe&K9R/IHE& ^i~V`
eh(S*<Ss>m?
endstream
endobj
1245 0 obj
<<
/Length 1672      
/Filter /FlateDecode
>>
stream
xXK6WH\">:nhk	e>y|a>HE=Q4\"!ZYoe.LY$)v'w8>|Iot9.W|	|<[:z+
yd3WCLr\"gv6vqFx_To
W5}hZ4#n-@SP)\\k!x -Md65#ckh5-P9TXXhU`~H%TI&O\\e
yL\\D<.)I0tl-5}Pr	$m@qiMe;JpsDQ;UI/]Q>N	0[[xhrMejI;;s<Hq[KMA9q[D\"MI7C y^;J<Yx~|vwiJhf%g\"~e2{K`,-n!>YqEi
{<%tHQoi[y|32O/9kM77b{Zn{>sR2B$0d0#f?^dR*r.DJ=&K5]!){hRFgp;WTC`rbzC%U)=u!`]tiJ|v!*3. (RBDp%0Yd'\"NxHj/64Mi}p-/Z2{J\"J
o]LWUhb3A90v@s|UpT3P5mTy$Mo0}HD.t2rkT(.] _DD\\z{f#-EI1QGru~4c=|^[{bLaj+\"O{Jxdr5g4zF7|v3YR)r*y0XN ZC$T/T1<#q	.!zE?pDmkBqaGN@Sk8:\"a.H)o3{j4NM;BP?H+,y&AIp{6d>7s?CS4Ro8+-1m`03QsLY'fXF'jgGpiA>{B4(gnf(	(yoRz g2$cK:}L	7IVpqu+A^MDq ^A$O DENt;\"WH& 	u|eO&E$kR$Sr#@+P?k}=D<0rg\\ B:h\"7k>scW\"f'{vo0
endstream
endobj
1249 0 obj
<<
/Length 2005      
/Filter /FlateDecode
>>
stream
xXK6WY+H6Mig:;=4=mDWM f2| 	jJV^%zWU\\iV\"NR%+RE^S6n5.-\";M|\"i	e4inypp(rs'w5=e-?xMOA*e.\"p=7A;It{?->.-Mj35~44$[F};4	VPU`fkHrG=}E,\"\\mc%?IR@\"R)opRF&=,St,U;=~.:e*YJw E,s:;8jG16:8*jpD*u} Y7$*bQtd/[{<6(=6N`dQmFtzqxU'
6fj=l)4(NQuHf  \"9~16';Y|AsL;7{\\\"<t<,43(cp,\"9JD5	DTGG=% 4AWyCn<,')hN#g<-0m1)IXJA6cij
t	z1=l(5ghG{->mW:X[/*ENvHl/EPdXQ@$~b3Nz5#kq	g4\"V)k,}FBck.QCi,96bpCGA6Hb6(((U)_FV< nS%_-H-~YnWy\\<T=o8z !8$ O|Di>LP@p%20HDgtvRqIo6l^PY%lNP\\i&Au mc=vEu\"C~H3&}{#/!4.F,b%T=17?}O+$D.9e(7oP17N=nX`)T=Skn`daW$I#1Rr}fPxN+ fU[` %$3 z]jc5J6b$8$EY(*`<geR[y;g<wEi:/=thwkwda%U[pJ`E xH3IG _X{+>w(DPLMH|&+kP>1yqHCO;t[;_\"tT nQ_Pq:$@bLUQ={S&gOZ_P@||7 - n;*GG/tmG&E\\,Gp--Y0d_pK8yr%deq6^^86z)`n? 5EHu?
o}o\"	`]fIj8<|<*rl(C$4nh&<T,|\"\"2z-JT\"75j*g)PfYx%['PKI7>		t.&Hfd/J&I+Z6g(yv?
endstream
endobj
1254 0 obj
<<
/Length 2326      
/Filter /FlateDecode
>>
stream
xXK-K|Rz<*_l #!C
@}JGB4~}`n|Y:XmWI\\X	)LS6f[KG*V7Vf1.\"ukn}<QKq]E{3f5xeQ,nah^5^;<!Lh LpY\"@z<75lmz	=nsjaFi5zTvw)2e[lU[\":U;3s<\"M5(hUG$\"0MAL)M*bY0B4Bx_QL\"'t8\"G;,~#2S;DxlH$xamRC8%\\{?XH'f u(
d	LH@6iqT\\j-8yi5f7DDvBW!.$\\qa\"%5Z{Yi3tc~f<VV#A!;.n'2=`s4['Uy\\|z{{{h5dO/aX#LM/
`NO\"W3$QP{2:P.$ H^Q<MObI:<0eQ)dlp
ZQ]$XXghu(AW&o3D\\yJwiW5+w~g5/^E}<9N=QeS|\"]aOdG`0g8bx_#mc'4^+e\\D+jm!l;*-ba(dF	A7uaVH$fyDd$A;#Tq<^;LDD9d8NNsy*,$vt/u[j$Bdh}|1Y=u;$,t]	}EVS!F{#AYJ7p4Or/{6#iJx h0'$V$ |)#gfnEU]:,h(O 4)nxNV2,=K@*> Bt7aoQpb)\\__YgsQi84Hzs$/5_%f >6N-J8/PN)u{f@nOmH48e7K	X0R$Rq241`1M2)jt2Gu*8U8Gd{r7nvY(N]n
((,#.WoAf=^a7uDMy^6t	i-R!Iy0y80LqY8n:on` \\./
kxpJOZ9wJ<3o=>d[^4):x+9Zr*-su\"(DP-ts!z[@YtDgX\"g--yr..4c6sntXxN7;8G?@%\\(L|9V>]14md{Ce>'\\FU9SH_g8o%tQeL/C4Xk;l}b?b  b8|ClV[@ 'tExW._VIB* $
z3<2bmc-#|%:=oD)Ri\"C]X|#pK12gOgMS{nGK|As]IWEV(/~Z.KUq' !.
,Sw];mu	<:uUp!F?}0	pEScM-tvb
z/<8f`?></,$I88HCi#fJ
endstream
endobj
1258 0 obj
<<
/Length 1873      
/Filter /FlateDecode
>>
stream
xXK7W8I>nM6hdoMl!fK{x\"@/Dq$R$?J<;%WU\\*_=V2I\"/WyV*V6zIiLNT4\")~~/{\\7S;>|}'PpXpIRDe^;~I3N-NeT7zt?NJ4ODG0g$p3tCVPX*Q@	nM4\"qJDj HHhDz::7u|no>_q$xh>lqRF&-wn6Hev3070^A{v[=nDuCVl:<1i=59r&Najba4!)>( /Xl?t<|gk44MQFP#~A3J
\"~$dXYU0HKE(;2h`l4!
! Mq_P	`X!:$u* lz
i8=x\"^C~Q`7NT<M`1phMafef1cN+tXFXGJ!r#]e=V,<4GP?a6r$jH	!C?#+e$OI3Yip:NeJ3B&4Pl1Q`i07Y)R^)l<+j(hwqy\"\\Fcjg4+X9fU^PR@((~9`,,bUkGh=K8w-Jz!iO,{Z9i\\hgr
]np5Nlxq=
3G|F\"\"YFs!	8E&#o/`L[a%za3H*@:_SI pBjHF{!)n!TvNw	|znvlmrV?C~l-L+?5 3N/R@=Gx.bhB:U_ eh wj	+#,\\sw6z:I=Ye6ew#\\d~.^*1Zj)5_BP3:`Vt|#~P<%G- *p4. Li$c
;VY6dv,oFd 0[!l5-v-lN	\\!i`tVI9s(RBl/O.n(b)T7MbCOs}Rtp-(aEMn6{q}:qoAXf\\z;57s3>\\f2|q9nRyXqgCk+5#xQ2J)$znHz O,668'?8r]W.oKW(+u]<<)3
endstream
endobj
1262 0 obj
<<
/Length 1887      
/Filter /FlateDecode
>>
stream
xXK6W(\"zm@I\\+Rg!EldMo}H\"-6FHE)2NeGdt'=leyeE~v~('I
M6\"|DBqU	q'eNiev$PC#S{H
446\"xqU{gg-K`&jeFU
B!N2%RD{qQ=-QGZ5-`9iGI4<ZTF$,?iud{jBRu^	vpUz0<YdhD;dLOcd+>TcDP67v?c 1y]I,& `;5R(q8/E-weY_~./b9Bt87|g0_di(fn@-o82 	gg8tAHhhz21ApJTRq;cl|b5o(eCp$x
i=rZ']&$.5m'bQ(ZJ/ID4E`$K!NuA`u!)?	 (5
f5^`[!\\ w.X1~=\"E\"i9:93\"?60<Vz*Lg4dI5H4!XAPM	ZXQVttXA.+n=	TI^B/-P%|E%b4;@$!%\"*>*ThZ~k[%gduo11F,'B33gi7pPGQ3]HB=-Q_On!$!j^Q/s4&2%T.U{t]Zdcw4)z' Nhd4'Aa#-Q b	$;zsMU/,K1,K\\!!MxH;iiB8 W8Jf6*<W0k#=4 GdlW6NG!79E_`-rg2/fhMcQ ;(K@aL+\"Z@7d<vDi=F->*@B#1uH8rKb _Fm\"V):fU LTj>Q#!ye)burNMJelpOq.psv!|FIP!$C4j0C7PD5	urNE\".'$vi`2m ]xdu&%_KhF*3]`O1 ,BD1>W\": t*dU'sk/Sh4],R+,-?bQV%\\svpX*	Bf\"3 qKd
LTYo[wXn{?8?
R73n6b{NZ|AGhM8_`y	Y(fzKs;i;Hzn[}\\z\\04k_lfP$u/`z>Td9G(Qjk w\\u7Tnb&+\\4.!Wa
endstream
endobj
1266 0 obj
<<
/Length 2103      
/Filter /FlateDecode
>>
stream
xXK-2\"m;3s@K,9[*;b ,U_dC?=~E*4=v\"NRJvb'Y2=^w/fU~a3L34#vEB#.O;]f99s2j}s#u/et|yU%q\\ZK/QcFGt%hd}0ynCsx+`ry	08^.~C6D}jXg3l+rV$~ RDmhN3T C}CC$1
vzMLh]otzgh#sD4j=ZS@1yqj,h:?  ,|7nEzO}ByCH~,.ju'/~&*7gU8;<VhF;\"CBkA~}k$(wCxgiOD <Qeg`{BS &;9$N id<C~9G\"!2:/2PoJE5n`wE,j{B
h
LdzGzCDM42j6{Uo:`5P^t{EUFb4+<n^U*~rD+}g~ q7I^npegV\\f^Ptf$12
!Ab\"]@NSK>x>x { }_Zc,teZE{$L=kV/$IwXE_xtU<PFB!MT`HZ$+Iz 'Bb7:&@\"(|}4^FRLc}:}n+,>8Ezw~,?h7I~K:D(( =I_uvax5w?\"sKV,4E;i*0df&5RkQ0z]BAqIo%}2gLtuwfJ)F~3g9sK**Lbq \"t5nUHy>z.pC_E	)xutRp+
@G?n<_	r.15h<ls6|aliYqqYOqj4 mi\"R*d\\fw6~@2NC $`5&yeueDK#!wtW[,ELW-$@XM{J5 s- m2'QGd$8{,w3`zIGY&IxcMkBe(uQRPH5C 8-\\!Uan8QJ \"*tQa\\(b,|Tp{a`*!)9SztOpn|F\\I|Qw]&8E^iM3!UAqQ0m0$)f% gjb^Y8WYBeP0WJHwT7dND$\\xHruomtMq8FRt~AE{X;w
.@TEK2_Pn 8hF{*l]J4z~8(=N09wS98eB
*d$,	4Ouf5k?m,I(}U\\BRjb
endstream
endobj
1201 0 obj
<<
/Type /ObjStm
/N 100
/First 928
/Length 1213      
/Filter /FlateDecode
>>
stream
xYn7W(HFi] 
E.lH\\ucqfsnR8T_@8W;oEN56-9\"\"Kjl1VPsIpToz
3Zk`yc [ 3lpUFNA7f]bvu
9(7M/h5wIM Rtb-KX
LaWxR=1dLuMQmZCG3	bO+YE=fI3{:Y 
h
Z\\JP ^ YG\\90cDYvZ+:HFY-.+H\\kWe5$BzjZCA'_sE9*<S`^YR
i)<(J^(P]!#Rk}as>Pg)|#?yl}a|rm7nw}|*|>}}_>^pitG7<WO?cpR,$n~r`^Z[lpbBch&1Qt	{\"/))C@_AGC:r:'?ZNQX=c{	j\\pQs,9Yiz=:m3ZDc {a6n;.WdrEqDc'KY^g]v&Zb-u!w/'~8Wa2xr&02RC14/W/qhiL7*pzp6#M	A!8$<jIMn	5*,]r'|w2Lq'ubDsX(jbh!_}g	%\\p3KtYm ZE-`_6ikVwFTx%tf#hLch1xLl9?V\\V\" ZhhN)m3J~Tap+uMk{W/19Ai!E? (
endstream
endobj
1271 0 obj
<<
/Length 1587      
/Filter /FlateDecode
>>
stream
xXK6W(
)Jtk'=$Zmz8[9CW@/9|7}$C}z!I5U^%}dU'U)\\KLVoE-G^n|ffYS*KxXE4I%d;\"o`*h`%5O[4Y`#9}^uf,}&z2UUOI70Ef4Q%<crta`XM.h9dshy4`2hh;VXm'kD#/ \\O;-9utk?X5e~q 9c]Nv:Yi~V?;,Thi27pHp21Fu	
m-n|zZI?QYcy>2k@&|e%]YQH?}N[\\7u}99pVZWq_UH90#y|8}CZ#ZYnV B<H52Nh<q(q]TCT7VC{!z*cdBcMg(1|A2+f!LbN0HTV40h\\i4!R?Ovq6sm')i,xRE&[%k .~V/ vU5?[V/R=x'(`\\Wh+x=&G9{d|ZH2F=QBBj$^|@H4h`^c^:{y~&{Yyz`O]8x4VO
	6{z|_?s,7/:k?*k=L <
<(D2XP?30+{3j=#1_~o7OMf	Zr[[R-j)/<95K~L/gQ_	y^4-_(aSysL]OWa_KL G(@.5hy@
\"puM%b	ysO v( qp)|E#8/\\%pTV]\\ob!RY ?E(bAz1Y5OTp6+XUtHXc|3R@ ZCv{4#vv\"U&wT@@2eLYX ? 2plIT8:r8 JY^$&<5x8pBc3!V@	. 0+<
9~\\;	ep@.gI)tV:kkc4zx{;%0=	
TAuC/,9NUmZ
endstream
endobj
1275 0 obj
<<
/Length 1400      
/Filter /FlateDecode
>>
stream
xWK6W(Hofz!%9p%TwHj7u6N3!!W9ow|\"u'(nj2YTnH>^oE[
zi@Ve?57D}9%\\'\"^R.d]F6l\\>,6SPfM8hLT0=~05ld13 I?k$ENoD:=2:Q{ew
0e#hla'$-Qw(&DHau3eS51yuUKO_<=Yvi8j\"%/1'=4KA9`SL;k 2 NL-}^M<7z^uuz@z9z 5x|& O5  *b|@~C[eyyrmH>QE>*KZ8(XE{;>`4>/p]vn2!*K^,X iU#:R9	kN&*\"k+N-rmQZb
I<,?OD*MJ54O-qM0HWwL$$1'Zt->2=?p6P>p-|#%sc<][hphRYS6;Go)vA
MMG$DJy3O,kjLDCY~ b[G2kV(s^[/h) 2i*PCN:*8R +Wp/9,jzH5wpt1[QL&SL2,%op/N8!#FVn]77-.@rl@9!Z
`X7,8\\cOwB@xg+NeG VY~\\hc&H
60Ud@bFt(^8|=6bs C\\X-188$R$`{=)lLg1r+J){	p9T-ke8.Am8oo7\"zVy.xhQ\\Q
H'rkSm`uzy?}PM1lfO%xjn<jXo);&8y^^+`&qj\"b-&NO3Q0&[kq=y{7
endstream
endobj
1280 0 obj
<<
/Length 1596      
/Filter /FlateDecode
>>
stream
xXK6W1	6H[`AkkfTb}IQWw4H(R&+E^~/xrU:[3.emVWM.dWv}o{3vl%l3^IfdW~x'KKJRm w`]0WdzI-y8DwN{#7^6iqn
a<y;nPU{gt &hx`>w7naD5xH`-iso0{pgO7`P[nZ4I>1zhsUCE9t;{*B#!
.]B0*TV&/ i7[~keQ=QlY
L+!\":e f\\Hm=@[cvh	@SVyQ]gvsW8O!
 \"$\\}x
&WRR#No(\"b8;4r[^Ddy']6\"EJD?xO$OSai|JiX.P`\"!4_e4Rh@&-KjUI&pb;&9) Fa~o Br9i;m4~riMl@}01PV`JMFyRMqJ%7 w F0V_.BeQ*x!7{%!i:u7< Cz&jR.sprBfq\\R1zJMt-MLkOoI\"3 xxr7)$`?W;#v~)J&W5%&!ko./o;AwI`umAJ~lZ`EG #}%M-lj kI-HB*0~)d01==_)&iu*@MU 7V&o<39'z8>;6:?G^oC!YvpVeYg_+b3u#yZ^)*hl6uZ(363LpM8\\AY:U7<+Os06gr\"&/U}]HThL_cTC6U[ 4  (Yct?Dgjg%S?l?`D#_4rb#a`3o!\") (;QGv`=YL-(;`zHIP|N:}g~w4)B{2! /K*hFU^?B
endstream
endobj
1284 0 obj
<<
/Length 2308      
/Filter /FlateDecode
>>
stream
xXKQ\"> 	0esP[MD)M>,{A`Od\"YL6M!/_Tfw80lFi\\XfoM9Mz]ucn..<a:45'G&O~s>?wg7YW4Zhp1[gZbUq]OqOf?z!W E:I4,U(/Z6IU\\5TaUZeWDbfUJ5iK,)Y5bPig~ZfvFM&20N,-[ClUF Kn_L0ikl8I;;y\\m@G}Fns	{EvpL5UnL07DE#9tU8xrGXbm^;:	Q$Rkv1(t(Gi?f#rNNG\\ bqxMk<~SLtqLJo\\8.(h/LX*B&F.fah(X	MV':
)5.)@F|gA\"Apfa.t-3QI|}FV'\"hTc:m\\MF8xt3#5}I```;~W5/2#<V&3!\\Cyg`%/U=qg0 pDf2J@{74DM 0g,96v#@+MS!x^zyidVbdi#0DO&Fi 9,#`Jj|zQ6rnYpPU$d/rpBAlm	 ?@,Qd_#Kdvo coIDl@a,08[BodAVh@$}\"3f/-{p _,j--s6fRp^'/e~,8%{{]|(eC*l/ef\\bg@o)0]{ O/	o< +L*	BL6T>4A	Z4hwgH<l`^0IrsD$0a:42A:mB5rfqV.EV]E@7a)Uu*(L+H5qI,QuT:hI1T+QRgPHRlJ#,]~PH)0yK4/A3*sY:`ym|CNV+~J^6L{UEj&X| 3}u\\+pJ1&!</<k=xWo_G4S#u>aDGBp#	`#U>1es'}N,r} JC9'btuu~+-#p#ysUyy ~rn Fr(+0u]8d<cNM}2Vx)}iJ
G )<P(.ZEa5wRudh{6.&UO-5(n-wC!YNop^:iex-5w^V1kegb`B%I.N^4\\n	u_2j]<!Rhz/2~B\\3wpYpTp(xR2+B~04E8mAd6F$s]0Y>x 4(`rXe5YC+k qk`NUTyqZ2yeh>\\hV%(cv+C^k)+fC,:DG@^<j-)O]}Uvod>=JP_?sj}a\"`i	bA_@;;/WORTIB@B>Z~}7
endstream
endobj
1288 0 obj
<<
/Length 3279      
/Filter /FlateDecode
>>
stream
xZKsWUTdVMbCtCNh M\\oE.CO/?oqHauC.iE+2L|r;!h*3JsMg04-ngYx5\\8fOggG79/_[sJI^(=O|=|45:xP;ITe27\\;{%;{N4OuWKp]?aOFc5w22MXi(*Ts%O3+Nw_D=dY<cl:FQ !@^4t.aZfL^W*OSCG+@/&M2n8mfFsFI9M%vee:|rn|owy(+@7On6c'tcUufX5xAIu`kh};:sMgdCO%
Q<@;fX$,ibiMw5 UQ&sVeQHzR`c77Up7cP@%3Mv#wL<gqMSS4sz!3wyER~ww_ }uY)*ip
C_'uKJa8to<d&.>>@uMfiX1H(MT/i>c+UBhhB6\\0#&4'jS$x[OX!o;SCw&@kA]hST{V]0KaBG.	YYNW:,s|i ?n$A\"f3	4Az,2XKxbky.Y)NDrReDC*\"(+P<P9_ *0^0p)[=[ZyXe,d\"huG\"p/,9tvCk@G?R$:Jba&T)8	@M xxN	*P`)Hu]}y5IUrr~,:WloUa
0<~z{{j
H_Wsuy{@-Pfgd@ZsJ %qp \"\"U<~x7*r,X{~NY@s(kxIXDs
G;g<:`el>\\CBoAa4te&@QGYR)MI0*X0%JtAi)zuAr
\"8r9j\"rq1Pw.^[da<?}'-I<0dR	T^PxRSAB}Woo^A<a'ag2}(	uz2T	d6oRR]n
]_77u5Hq,-X
$o/QTPk~xi.
uU	FyA4`*BP\"0@!^YFV3n?#SlMMAc5rX&@^Fiu={YI%|_ON0o};6 #!hjz-6hCyfpV6h`OEB
zKPBHc@}#QE:x$:d|oQ>h\"Un!;-P5]eJOi he2Psp?{Y[F-0O Ao^+-UjkWQ|C Ydta!3Z6yaa+G 8 (s_2],;L\\ETaVTd83(:r]%\"axK#*D?^RRk_Yy(cbL#f:E9m,xHB\"d+
(w3^	,sJ*@ke&AgJ.7Fe%t	[C	3_ e(~=I-!HK8RJb@MFMKR9i\"ccQZdJn@REa>kNw|0tV)E4)j|gn1CP%o
O.XvX#-ast+NQ)EL
fPD*i\\N$vgH7Eg['	o>_2%q};*,Db9H^8Y9r889O68sfe.JX,/1vLmfNp^u+Cec;%egc?oNIU[t=*zibJR+]CJ#fO*XMvDUX,Y3'jVCC%6.QSc3qUFg_o|\\a-i\"$i*K]=-e<B'<	n*|9W9X:g?<awv]yN| G33Sd:)>
s~14$m<b&KzFiIf1MI<yN
Owi2Jq>vb^ rUN=n3	4||u@-2J*l?(.{cI*o~&f$?QK`IS:/.@%@R~%FP=2+gb3XCs\"+ hfs
LRPM0~QJP:}_	pRycKSeETs(Gm#`mc4B
:L%'Ws??
endstream
endobj
1292 0 obj
<<
/Length 1615      
/Filter /FlateDecode
>>
stream
xWK6WTbEDY:nH&VRb}g8#i_.y|8Q]Jy|}(:7QlD'JI\\F.;n^*u?c{4Q755)cWY04|~]z|z%3nyu;
[^TB&YEox[sCOczu<q$:oIohlUEG/-j~v|&YQGk!ZXv&^ev]ZE}aHMN7_|3;Avg1*K!ppq%.}&I+'eal@{}Ie*QRd~>U>,o8pwbcwY694.e\"rR88;(??e^LiKV+GLoJG[@1k?C8, HhC!N)+Dl
|ov),;Jp/:)K#A>L$}M\"Fo9q86OP$v}wL\\j{3E1-n)e<?48 @eGrg/g&IVrnf*v81<E\"J	&s$LljP?2IkAV:	 |mHp]awho;Z'{Pn-GZp(XK6x8!x]_Q {QaL a?	g7#lEYA!hVT~:0'C|	y[T6?;W9	-Ursi*NM/TGz[Ss5ZD]?	?m^G9t<i}Bi/)xi;-#,h(?AGjd)QLHh`vf7 vmO*uf5~;J3F2d@fA$_!\"tR%X;G/DAaob(~7/iAN?A2v.X<	i-'Q<D-2dV*Dfs/TD>zv\"Bjj=Ov~z1am$4VrRzph;khE3Um+#SA] $(T  BQy D%}!wtEMlQ$Oe\"UhJ3tIF
{{plTwtE:=*RZr!
=UZirWxD:s>p\\r C0fqai	}e{/%%dl Pv/&5=];?5u9ewJ\"&Gg.=
endstream
endobj
1296 0 obj
<<
/Length 2200      
/Filter /FlateDecode
>>
stream
xXnF}K`Y7 h'{ta.s^\"g-hq.W>|jya	$[$qj/V/Sqm&3]HC6N7?>|VQg5Z(aUKnpwN~06/Tr:%~M;nmXT5WJbvE+Gk1P`S%7H,_8
%VC5niQ	NaUwP|H***Qqnes7;e84*6/KWi {n29/d9+6Xe8O(rN-*S!;{*;w5w{Wcv~gw;f(iA[8&1p]hH$>		V,KH[,Yn}j	k>+RFW=UiWTHg}4+-6mi#$a	l/]<Yj@))Q2)kp3:~d@jZ.XaW{oTtJ'0[]W{ |@V.<Tf' [Rx\"w\"%aF8hP Ygq~[J->)\"lp57V%OKM}+fFG$ M k$'sc,	7!/?\\=Q$y|<X7q}U0<RWr28TX)EP<(j^0] 6<OhYOcT+'eMJgz)f\\T<2AkD $a>RDJ4Q~k|Af _2q\\,_yIEAT,qx[By:,l4	dx|?

`G0,6I=ozK(u,^o-Gf*}P0L po\\Zb$d0mk>7+[	}	X\\ABvN4
C7^R
.x&Vt<Ucy
jX1-(Opp1(k)Z=H2`'psjO6dc>5ir	z;V
ovSQ#3xwVCPl`vd+g%({KOAIzBveIw!|%N19<\\<?#
%?RQ5`}?M(g gJ.~&xUL-a:B2`cG*)O]M8Q4z]Fxxl<nsa3;?HO6?s[%/</A'09YO?rdJ!w}I,d/-)z2yy>U|M3X%>SbW>a]Pd.qtRBy#st> ?cA8Oi|*%yt:+(v%#V DG4=KM	g=z#X]bn3r+'98WgT|\"3eo +M92 z'}Iyt-/c}7&Z:'~zTH_ V5zg+Av%EhKmM QeIv}J?p'?}oj~^=yg&M/<2Vdj-#z+~Ltc>,h ,gv_\\	_HLd&TzvZGnU0\"MgU3h/umy?]M|7la(LYdyh!)}v?:`
endstream
endobj
1300 0 obj
<<
/Length 1746      
/Filter /FlateDecode
>>
stream
xXK6W dnv7CQ4F/IG)z9<:gPWg/^dybaT83mm`Yl}TuIU)Lm}D.]in?:j9+4/oeTsJj|y~yv|d$K|[57y\\$0oxwE[~/SHu._G6U\\Nvfw<.xEz/wq']Ea%XU7dH9MEbJ =SZtt
_,y)2[yNa ^6$HAr!|`of?FVpja'	.3qmns& G+{;YyW:lUYsn2q/z9jukvizQhiy*_&|SVpcIq_Tq}AA|Ie,[$(\\sHsl	`e	]l OWBI` ep?tp	bcob&WhTEm <%#yWSxG%+Y\\7S3u#Apqiu`kv~8zexN!8Z@UO'nNmSIFN3ay|lEy4a;#D1b6uP?`adaBB9_h'sgjYQI	Z$Vn2^!Q;JV6<u #h89K$A`.#>(=h)!}r-/AI/J|%}MS8
u`r1<-[IBjeIs7GFWttVDpVmWmWJ35`)zZ3EJ`@un.1t^Wypl
c 1xk2,yTpCu(:M<p7u{!:ALK\"
c8p@vI)\"RtXR@:|n{hr,u!'z<s[vNlefX}G	mp0Fv,RV'39d|>hNyMUn8kj XN=A)6@\\	C{0d*|DGVv`d=*n&yph7kXr\"	+S7y1p8PCF%v[&E Do	x`>K~,%>j1	o*m#`\\N>:|j2.'X
 =Tg-mcdsK5W^SCjU[<q%|dA2jvvBOrRdCc13,7FSh$vnS
~rZ<\\SzC_[lR*yNm_7{	9	Bie,_<2
endstream
endobj
1305 0 obj
<<
/Length 2025      
/Filter /FlateDecode
>>
stream
xXK6W*jD0D~&@]v_E/aSZYR6isUW{3We>t_T=9b4)$QTacw<>1AqY7&SvMqsWXMxM)jpriv_'r1(,fA&Q)?pYy> <FR.0U7h4GD&_):O'U(9,sqihzq'0$;1<q&~C,RMreYG;Uoh!60A?sp@N7CJ$I;6Rd~8U3,,]dixo(s0Jp&BpB.-Kb>A{7@+{iHgWU6k^mHo(eT3Bnh?F)q_[A @2d4MOgj0d[	u-&UKl-ED\\tO;HzdEnbG,3 jjVa?	+pzrym4NH)Q'z.F)
.Nvv-at}gWK0_7  )HbV@'K_@E72&LG{nxz2g2BxJe<KBr]Or$(8$:~@a+`yZ&0Fr- \"y]&GG\\T2\\ozZ3/Vhd> `;W.biI\"0X( X^v'C+:QWZ{w2J[2TmZ[brY$7yRM!XutrH
t@#QUevm;8T`$r*ff0.Q
*)@\\Ce1'gIx3$Es[	reFR'a.}3850h.B[8AqKD
|Gqu]x .K@Z,DU;YBpmXQz%p;	=%4 +4HfQgBPsAQCv<1(8U/Ps'7V%&oHV@MkG\"a>Z1	J`l;IGW5m5b;JWbvYk9VTcWL)4,~^A-HdS4c7$MbB/o5{ln+E*9!6R(tqrIB{f=o~bI\"wx`\"72-a}29/j-Tdm|o0 sgP=C =y=G9J*(3l )[e~.9WOs^Q+\\1(J-DRd0,O~BUG&l8D4^ 7zI8F]I}|a1B'0)6,O$0 
[QB
x#z4*}^6[H41CuB+47
endstream
endobj
1309 0 obj
<<
/Length 2856      
/Filter /FlateDecode
>>
stream
xYI(kDB - 9dfFRy%UFN~)YVw|}Z5qSj_,^EYVE[du=z4'4q(>MilU^M&+\\q]6	.Gudto=w=~h<8OOSqs*UsO}:rfpc$<vTuZE/ hNw/W\\n:Y5Hh;_]\"5q@+O$}qO%]f:n9nBm|!=ppdb='$YF4~=wE^>i12/-F0$E3J9Yz=h(yk%zh!NEQ\\SM4,GI2PqrNx#Zjhx}V9jx,'K`X^W^~4S6ED0ZU'rHn=cA<hhy*.0@@<4RF6L'W,Tx9/T*f[x3! i#}6,eoi?hjg<F8C'#m
Du @.Rv>OP/pQsKpLP|;E^/:+JlK8Y.M|vq7, sxh2b{ p48lWc=i\\|:-F=.b D_ZFbIo[,V	\"xZ2bwUX&#?43a2  '.5XEe5*\"D
	3x]DHv #ovvg2{egF=45AtQTJw:gOq==,Y$6@9; D++2I\"R@P@d'vbaQHwf\\ Q:} 6~<auYSY\"=)+;HOv)L$>7?~h$H	io0in	8+f9r!wLK
 _HfX	V
\"W:Z6ws0^iR1$Ha=$3Io>T$|/^s ~Cd	6-}{QKE\"G}!yt3sg\\ahA,\" 2iY2H2h	{tNpY]>gfn[n*kQd=,^Nj}iQE'c4'fhIizt{eE\\`'?8/e|Bew<6c10IY
UWY\\T\"yLfMD0
1}Y':4D5|[Ip19Bb D_[V -SQhI,[*4Z>l^!TX;iEdqYK7't}wm5C0cyie?a,9-(cnfVqI/kkL};`l<r_
t
@&CjxDq9i&y[Vo{o;882HVRK=8<Civ\"^J0 g	f\"&wp[hL*S~[\\S.*XR 9PLxZ5)&o~*34/r}Q-7Q2T3d^Al'0%H%lyX*x^!_we:; %U!bN+P,a\"'	v~e1{VAda`Yn Nwl7dR4UKV)u$Q70hh_^wa$drESA:{wU[3iEDRS|vy8y?T3G*pQRnZ[%4apvDowj4G0!@|C~TSJZqZyaO3FN skVg3z&z.*\\,&qpM:3+][b'>eT{<VY(]kC\">0[?a^%40HtS=Nl7gYr yCs;{ijI~'z& H|YNybaNiqNw1Ul;^v8KI^yP6t,wT\\c:	l>g~u++)8[:N4$a[FZa LxxyAoE$bQH\"EO>'i-wc G1znZBF(O20oa#W+9erPUXs%I\\cnb&~p
endstream
endobj
1313 0 obj
<<
/Length 2959      
/Filter /FlateDecode
>>
stream
xuYIsW-TJIr(C+>oF&v<{~&wO|cZ.|JR<3OOQ=du=$|334GV2.]Z3K#kla	ta/z_pA_{^u#:){s8by/xc<e)s[4TDkp37[LN8{6ozI{FYT*1Wkm8LR7LKe2$n3L-4>#1Y>Iv:KcU2'T!j.+0qQ_QKF?$.]j	ZGf`8!_p#$vQe$^]tw/o>!<OGDUh~Qg( vf[DS8iXnyD'>Pru]y!ZQ
og_-#&d\"VpQ*Va	X]%+L7}*J':
mDIT?@0N|xnGq9RDx:Geu^3L8!GK}|VnZ*m}/^x 4,Bt[\\
nni1\\j4.#}v; k\\f.y9n^.M=`u\\(aT6E|y'8(J\\;,F~+&xt{}tUE%,p4//>aODfF-&6t;ya90xUgiqMz3ZbI	gnPE2zZYjm%FAgz0A3OA=dc<]vn@+*[T<HK3$HT![{rD-dUB<+9C!i\":4e
Z9&i\\;dnK
SQ9FA(,#~r\":
&~!2/N&B 	\"fn\\uVFSd!uGR2K=@5s	'*@2jpl,F^o:W7_/t\\kucU4(>\"& H@fFqx:~/X FaLLVIK\"k`v1	\"29wKFOaZysGa[=-IqgGQUA!zZed*Cz;^^9;nM:
T!$N*As(5i`=.h,Mhxvv ETQo'?irS5I' k:G-k\"Sl,C!1!+f_h<^+/* 5$4))\\.l>Ts15<i*-TDye>) P}
:eyMC3-9y]K
zgogxEYs`zGUYktv#5t!tR-z>,_h8P6 F{A
dd35
1*X)Dn%@dOyGrbP3&FP~S XB@7Wzl/xZK1*IWPyb2e,,\\Im/_@-E1sF2lw3ce|%UyIz**Hvrm-TA)k<CZ[#3ZW_e9IKNh	HJWx%,.uRY?p#&^^e!dtU(Ek8-X-QgixS
)Mbboztp*,\\q.H%5Z$hKmiF)DM~F.qNx6X|mFl0aUqvo'$LrBos^7(%P;xPIV4or[w?I+iy7z1Hf'|2&lDHw']RWvjZ#q12IIq!xit&

TJl;gr\"A4
	Deyo=,qZoy5[OrPXr@e lhQzV|{v#/,SiO
)YxQJ#QD>IzEu g]\\*8| S^~i*W^=6s -!E0pKV$	*Zm)fAR?~0I*Gte!d~#&o)8l9<,x/T.;_FK	ki>+Zm7@t]P:EuP;z -dQ(653ZoN**WKh_kleDH_mvN1Ry$YI~Wn{5#-
endstream
endobj
1317 0 obj
<<
/Length 1659      
/Filter /FlateDecode
>>
stream
xXK6W(\")M7H`h,zv}g8C[z3o:(>J\"<#!$Oeo$h[G_M2}M*U@R}&&\"Dk)M3's0JfC*~AlbFmX$4L4M
4?)nV*+;j)YOh=uFCr;S0G4n;eX`p^hsvl*In*6q>PW=9Xe)kuJej\\S;!4m=[4~nQ$iJv4-DmIv <m~lyG*(1!%*AX%g`./fI%@\\W eG[ya~hKxws[K+%=X9>`GJ
@;Tm
BN>`N-#_A7cN5=PdCC?Lr8E)o|nvqnrZB-Xb9?Nbr0M$!DrT!`M]#v$cAkey{4V2&obe9Y&I:o)xyqB#,g$>9M}Ov
y!1+@?6\\vz_KFqw(	Q`0yshK$&lbvX Y{}CF8g&X6XQ	IdHr&~G6	P);^;G9o7E!=sVhCg|c{fHdF,7&_	\\MsOQx$Y&%vHIuuOBd`60@-:Cd;@471Ld@6K-@
`.)*4QEQxD1Qorx%[]rEE-}/@B&+P9oFw@@}p;1/iUD%E=q3=t/|jEUVoXpi`d^CA=qAP(r#%-	VsO/u|<<qN
LStG@fJ6\\l JY @1B9quG9+6Gqm5hrtfO<2=/#!${	k5Eq#t?`,=}2O@$PodB!4=L*3e~Y1Yw<0gwrCf>'szc0o)H%#xsz${} z{
endstream
endobj
1321 0 obj
<<
/Length 1370      
/Filter /FlateDecode
>>
stream
xWMo6WT@I}n6X$A/MDR!J	_873o8h8t7,x<L^	Ydiq]Gra7mKLwu%;U=h7Z7UO[hf%	TOoIbZ.J+k`/i0_#4yz;i72E,KaRE<+Rq\\^Tj$xj#O,u31N=$8\\	O.AWC:DS5lhSm
b4UPP3`?pZF,3! Z+PdvK)Y.W@RMb\"89+=V'ZY3l!%Gez/4RW+/af2J'+C3F=\"S=tIp'QY?A@'8,,A.W\\A AyJFRtE\";.W&V#j7pPcC,KH
 (Oyv1q0hYD\\$F`4?=AEB0r
GtB!XM
iBEZZf$V=-[:g5@
d	v(O3p 
>IYF\"<\"#H-IL*2~WmtU%#j%k+0X9suY?	
81<,]UJ+*mBKR R!\\P'I'uaePZ<wj8~;d!W.Iv67>]X+
I`} ITl.%A>9N)>NR>r(Em=>e bg cYz*x8 5[XAK]i[[2/(X$';],.BA:uK'f'!4C4Cx;ts3m3/(	=}Ikl<f<Nz1i]+G6%`cJ=SE<IB-|K?RXY\\~T=[_?G?zmuJ,H.g}HH[td\\!]:,wGgW3`Y	pj;-_\\?\\`Z
endstream
endobj
1325 0 obj
<<
/Length 1069      
/Filter /FlateDecode
>>
stream
xKs6<R3C(&N HYQ;ns }|`M7$,XmB(iy4XUsGRf
qqde+_<*irYR{=Yhf,aHJ\"gIVBo(>ZnE-&[.HH'QY&`lpFiA8k8eqak	+)Z'FTFT{w5!eX9</:l%+PY}h2> !XqKvJjipiGn8vvv<]}Nv5UzbSQJw^B!r_s]*kj`wb[ooM=&C'MZ4Od4)1EFY]K.\\&+kL(	s4+#B?'&gL&)29E|]~@7	G_`JE
HL0`	{<P./kE!^HB$TjFR|Wd>Jn4S($Nu	hoJegSl7A^m{v(.}:|H/jtJ9a~xj}FrM?Yv>cW?ZhII

yoqtK9AH_{^lQ^W
LCkELL>	_`RA3>$|PR~Zg<OO99VJz8V3!.NdOHi.~!w[9G:ROZwd+uy;:|z^/rH,2<-n$
endstream
endobj
1330 0 obj
<<
/Length 1541      
/Filter /FlateDecode
>>
stream
xXKFW(kE,(>aVaHnR
 9irH?vl8&HeP*<H,*	VUwx*vT
G3%Y:I$x(Dg\"b	hJFyZ.Y-r,dv4p7aWHdEkY3\"BDm|v-Q,7G4^kv}V?/dZbKt$e7kQdMsk-GmwnMK} ]98e*H<*'.H(25#*gru<RDw2U]w4v!mwn`oyO3$E1?$}!J1W~_{u9^G,e?$3)K4OJZ0vusGeg2QK8a4%dT
=O.v$L-Zk'zA+j!+ttnBTI>y f=WW:5/- N1U[6oc%/P3
UyXG4}u h>9\\z5bx2/-bU-n1=H9H	yC80aH\"nI#0]mJH
F\\5Z	8SpgP%*Xov3w&lRDTR?(CWe(FCh5&\\=gj-Bmn$cB^K8<>R y(g@|)[1i+g SJ@v@S\\	4+iH [vWrTx3Y\"
D|;_\\KOr5mq,~%>&N8|8~]!QSY3 qC01*\"B}v}?nC%.*#g/|OS7![w$mkkTC+|s-hb`yn4.)j~}Al%f-a=K lQ,_v(&qXbXc>)vf-zt.(^E~5	KGyR]4	v0TO]TSS53	?0\"X_[1KS1q<i8H[P^<s5%'\\284EwtrU$l7oD	8J
\"R@7vN
endstream
endobj
1268 0 obj
<<
/Type /ObjStm
/N 100
/First 922
/Length 1225      
/Filter /FlateDecode
>>
stream
xXMo[7WP~9o4FA\"p }J
>)iRSIZ4J&+>[IqU <q%)=)U|\"<I*RHzA
nRHMeRb 'ZTcQU1HzKZAC10=%SOU(Ru HV( TzQ[xUsT_dQY9'2T:1F10/(#J$j@U$ a!b~BpHVc~=q35c$r\"qAK[0X2 UKsRF1-4`@QEI<7pOf@40V`vT&<[l`@Y%hpY	+b#
0-{6ZM7
#.A9@zjahUQuoj(\"al_tC_or3<E_>~utS`(Z,`_w&m_N7/o{/lF%fz]<g>/&&19D1@~\\a++V4c:{:<W<J9v94C2iLR;=#$=]7==9[kdnJqPG`!>CP^.'\\/|p4;Z94Lk tcp2[$:#0rc:yItmgwrNUx9o|O.hE)m-^3wgx t%lQBl#`I4.:|v%RC><H5gN3,M&W94NhMYcO\".R<+h8}7Z]Tv}}\"5'\"}]sWiwo}jz [U=$Zj4Fe*4WnTUs]=hCWe4{Q;zQFz.hq4p7{Ic!b2PQboC,sgJ9tm@
endstream
endobj
1335 0 obj
<<
/Length 2129      
/Filter /FlateDecode
>>
stream
xXK#\"ws 9>%v7mO^rig$VXNpwVJRy]5B_nt>&i/ZMl9t[/fiagFK_D)h$n52{?w>m%s!jt=REv;2?`ol_O$c;(tBt]d/|4*X[QdSTj(2fH^0Kg8fTap>d4n4$]\\YZgUgp;,qfQn[^tWY;T6,E]j
5o%A|0F-,L2C HvP7D~Ea_V7_=l\\W2vJ)pH0zIFV(kG\\V%45hG{8!>cfeVQ~zcKO+#>=y@1RQ?>=B@Zh!T (|m|9ag{LGpM[   ;<vY2wK M3Aj|_yxAQ0X/xz%n:%N4B`_hY?+!ccAq||4P{E:nB<h`u`t)3I*V6%edQ<+`\\\".S'AR@}AxA+	O!BN]^tzt1Ipng( v!w7aO`v;Cz!_s[
@C3~p&~}1LM_ Z\"ZnsUb vlf022Q g=@B&3}%in7SW}O\\Fh
`nA02{VeYOYBgZ3$Y 1P!	c2js#gIR8*874ZI#@A	f:c/2]<Q- JLUu&1jv h~C$AF}w@r\"TIQ@^69R& x^	DX$e9xo? +PA]| mi= oh#hr1wMZehJ1BgB' m%T.Nd|sN)9DOUXA+U2FYWCL]l[w[v6sG3|HB]?^>.?VO>}Ihe)uV&?UDW(Y|_9! kQK3pr(qTBvGobBF^RyI$)Ao(Vl7aba|yaE?TK i	ef:)O`c>YdMZ.d$6G~MncB`8BQ}`zUO r{]o.r3J,twA?eEDY%g:DFQ!+c(>/7]:47DV ^}a;S)D&4BqLmi5!V-&l'Q.N^bEt?osR7yq8sTs=Zt_Da3	B%e-Q7bL'X +}%IXyL4Z&Z>/_(xOo xh\"oU5F
endstream
endobj
1339 0 obj
<<
/Length 2328      
/Filter /FlateDecode
>>
stream
xYKs$T2\\v@Ktva}-O!D$HJv]C\"?>|LgNYlkcwzs}_)Luv|7:F??}U:z*be&;u(vveFCLj\"myptuly8y`[&(NUlaqqaYx*5QOi%L}<Gx`n~ILJu>?\\,_&Y?<1Un|!5=	:)I\\RoK_1i'lY`M}tgVCN,Ia:/1i]leM.yj33qLRd,xPn~iZF<PE`u\"gMR
#vY7},r#lTfULL427O%t7I4z/s OD]84L)$;4,}AVGFYNV+u/P[~>hmMHWfK&3AgpZnh|<inMd*6g:0gL?KIUT/pLdLxPQ 2Fm-%_M8KD)G.gY`c
}e:6L.y ,N1;wMp426?PDZ+`nJf8KE[1(]q7L;Y#h(n-0ATk|-;KjgpjHmQPgb6g9#n|T$TIdmharEp9T69V|
Fnd
{%L@,_f6,Dv3h([pEVN
}'|>Qq^ ,U u|E2kB@]|)WJm[;W_E<$)WBk8$Z3];4+4~=hXIe)\"Q}@r+pd&w3Jyh%\\*@jHOeFjJNn7^8o|.crifR*DQ;\\/	o``*(
' I\"-RmUd 
LN#pDnZ?7 p>
Ip&i.Y
=-b 

,)
[`2E;!,A
*'t+JSM}p\\nJa8(`:=,mxQ-?)o2T!dR(rbTa6EE:RN~[fgdu',|rH3$6$-C)PL@e26=6hnXV[E[UXf[_|/8K|Fj^#T.h M%Ey[H/:DkKUH u-i9.,tY*3cIe=IH0@t'N!=yn5At+HCC {'9\"RTL~/TrC#8%(u]`Ce MPYl+#AGV*FXqAKPr+2nn%?aRdT}TRm)*RzI8f[(X=hF,$6GA`j>q1JjY_<}t~>	pl*jCiBO1i!i*,Q )%Lj|l,6xib;\\[i`J1w=G/12q@xR~# n@.:c9M%u%l[jy\\TW/s `P	;$OplAu LYbvJb)xrHU =^9\"__ra7# ay$q&|-Kt_oQ
endstream
endobj
1343 0 obj
<<
/Length 2404      
/Filter /FlateDecode
>>
stream
xYI8W(e(j=VIL0=ZbHGK+~FYv>|}]v}/U+2.
>E;SZei:=O^v:	:[sqpHR<ri^WL4fq2L{Fn4]
5g7rOn7
\\6~NQ9R,I#@$yTPq133<vknL9];u\"?$cRb(u,6yvC<x6s@\"M{]Z?8vhtR:w\\qI]/\\8 
u7|rKsq08,uP		r2rvdWyiFLWck<*;q8$}HT)@r2=DTBjvZgAMF1-23'c{tec,:U4\"j{f|: Uw*-0@jmbq?Z+CA[`FxX39,) {[-0+FX%HT	s)xA]g HTs5JrXZ:akx:SoAw6Ma~=&0b]m>SaZ+1Bkh.Bcn{5>kgp4#WT%d|F409p]w8IfZlq28#d#%a;ll?LIOb\\l5v0<
~PBj95m?tmd9AgWt577sE{!4qaaNX<Gc%g<v.JdUh{,\"KwO5
iOL1\"dq\"*d|}i<~SXmCeO/ao`<8@I7>b^7#5Bek6GR& ;@0Z1Pu//7ZkfeyiN8'@)Y'4\\ uTMu<
nFB0\"3wVT9zcSNMlF;Y&)
e=Qbbd><wdbE y*+6\"prRyjwBu-?-o\"0YCnD8U000.;(@'?9hgZ
k(p\" +
m(GWwXR\\h9b.YETjl+R`jf_~6(E?c1?[!r>rG07<M,<#qAhNDHsL:+n	Fo;bD
0\"(xH  RrC\\5CStRnor&Xe2Uh?$J+J&}Xq`''2X*H4q0 h!l#a7l#_;b57H&4Y' \"\"BO+@VIU<zJ@/=Veiuo1V'>^7?fC	SzfOQw<>%Po-O6?H $4Ae(X:X%b	9 YQ gHZ{ADC~z0;+0%pZ#89T]e#u!9Jhb2h+&  y)J~`obS/2=DIio(^|0391`0og'!r-;GPeFpkPyx=Ptz^Xy%9nq		-3'S$EXxXRNzf-&<ptvH Ox5W0+)t;_/82ikq]/J_YNLKwo9SToUt{{vSA*k[A!\"+y, Ox
endstream
endobj
1347 0 obj
<<
/Length 3047      
/Filter /FlateDecode
>>
stream
xYIWUeqg&{Lh-ECnw~}[sE~)w7|xT.bSYE+2N|}Z;4v,<vgi4cwHK7t?}Q$SSzWdi\\CVz?x_rdvgqU4Oc9~^~AzCi[7`/L=i*>Sp5^0>CVqF82G_OL>cgl4pT>y}LM|rs4hbv4xv	[U/Piyz%74]
9JT&ag#qUtLcJSG,}ZTy!EO>t3j0R'gp/dz8\"'%tc<\\EOf83~||81akbr5n uYtZe4+R#{a7jU\\%T4/5c o`+; -{Q'qVd\\\\kYH1aTE\\)|8B7	@>w/0a\\%*ar~s]7Ht\\%?79@jpO9pWG-b|jRoy0<=:^5]q(#|pAI _vYtttEC5EpFWAl<v]|Pg\\~noYltQ% bs/\\zZEF'l375x|	vQI
\"B =@g E&q8L33/e$e1x
J)lANo1y X6>x3q*\"Cl?:8`zjb	Y`|2
_{A@Q*&>:7 ly6q\",O]r\"
=*@}Qdb&^p\"pD5 g|q3qjx0(X~5VHU*#B<.z6Pc'>,OmV%8,+\"bG5G=s'%uA%J\\{%'u'pIaZrdM_GgH,ioeUqalZU2Y\"ba^c,+'`d:$4k.Ump- ^ /\"bjBy G7Jn7.)7+$dK| G{do A}}m(JJ%8g@_LZt|UL6brT.Gf(s(}3\"Sl|.C,
1
8)sVXs4hZxMN4T/8Z5Y$`q|'F(5`	hwpg2<f[x'4Hb3wyZlyZD
,Y`6Upgrbdiv1)${$~94/i
-I2 Hz3YST]x{PeBBD4J!|qPeJ,YT<\"bF;_f@o*P\"sAxw%@-Dd#g%]\"C-KnVu\\&zXv@gfr|E)fUvl(RrE*A\"PNL,
UeZ|R}(dfkb,nn7 ZQZqYg09o_405.p'
)dDe_?VW=zY\\etKp:+Jv cK<=jpYM`7q8xpxh+^U\\Uz}E	 =mN_Ck11\"<\"sM/g$d'aP73^5')bANwOqJf1{A	!Cqa;@H8ed6_K&YF|!!vgUu)T/G^7<a<`|qZq8;xNv`}?9Kjr=,3nQe)\"XP9`>bL1QS%+ =17q)3ty:TKKr$&pI	k<|^E-HX](	mQ(lkNtvi*U
jxLH-r av\"?ZB.'~a%9L$V0qPYJMP>#!cHV
B](eZ2X\"	,1SA|rEe@V4BIUeC!(hF@&rXG.
|(]i(8L%tAE[@n;\\t*Ao\"|I78rm<w5Li(L%bP|A@ $Es>mP|-sMig9
82& $Ji<;'e9 $8RsqiafZq)'B$q`(~xx?>
endstream
endobj
1351 0 obj
<<
/Length 2834      
/Filter /FlateDecode
>>
stream
x}YIwW=	N3y#44pe|UB1=R]ZEvD~Q
<wJ]adv{>.n$I`[Z3tWFwaM&}4`d:=\\4Qf&f	yON@y|Wi0M6ED*a/\\T(Jv=)
jHW,Tp8k3(	qE2LSSu?xGEFnkD lU6`a';NrbAL<Iq<5uOS=hY&Oh5o@3x*=04v4W\"XY	KU	kc::eap_Y1UY'K)6Q$VNey'f/|H3H`n_^*OBjf#qp zLyj ^n7h9Xc`L{<:`myL[xIOd&G~%Wh&b?ZW\"<8f|4M}ryRq,!G|$J&A$[frI&poEmxS
*k}a@x<}yzKu:	VO? G/.KDU I(m N`}X&X	\\gDF@KYl<lb H1{IZ]VEbm86hzM Rx2kN7|(0X:e57`;/0l:Sw3.HG>xp/k$ }NvI3$%)ACjWrIktu]Zo=4WafIe:?:,<.OK}=hfgdZH$% BWoZ
|@d9f|t9JI{8pX!ZOrbOhfRzRy$JgLx4yO2r'M%`\"VP3 [N?ZKYxktzqY6t4c~x)M1;n3=?9SA0p!DeQN*	\\E N	Q2XazZb5lrh|B# TsF*,Rd;:5X<4.guOrrf^]R+'SB`6s\\o5DNj,g]b=#INk`z,%0uuEX&O
 V;r:q<O-o!!Dy$+-=p=A&w$kee!eH=*Y k\\XXb!Ar\"R\">X/1?EONkIBf\\#G$+>-%$aS_5r9V|\"?5k_e}.Zms4F|O^Ol
TgaK8>Wc^KM95RN.qEt(%jTZ9
1Hb('4[e;va/Y$?6qUQ:&S{0E!6D.lR?Z>c/N3
?,Z9K./&|''R91n'Qo
Th*'~O070@dS'f^<vK#uSi^->Q*+l@r]@-EgaMP%5+*)M7%Q$E%S&L#8	09v)Kq&)6iXbAc#KAHsZURr:%Z#^(qIt^\":#u)r!p	/Z2\"[Z3Na`_ N_lb=SuK+]QbIUh}S~@+	$slgN\\;^,yuU%L$Q}` !%#)gQ(=*XB]3Gk,Hr>;-~C7joSoXxyH]u|29 s)g?=@r	hTA\"QsTGE*BU'J	'.w`i6{wuilw}y)fBRlqEc6j<v?ZJP9$TKHl%*=D9dsmb9K9:R5of+*AzNG)tf#G18c+,WNLQ	|uaQ3gO\"B/Zj~yJ_jTX}/g) |r#z(VTE4<Co?
endstream
endobj
1356 0 obj
<<
/Length 2044      
/Filter /FlateDecode
>>
stream
xXK6W(zQ&foM\\k+JhL3X|>| ldU7^_bSU!Fd#6\"MP\"/cngt5V4Ac?qp]aF=OMSK'QwpAMaFl7m%aRx>n*4tPZ?ymHl5mCiN-5uQ?*xRwE_<y> ?z+eT0-pk).J8mL_/Lv_}iN_!*];/X%2YVYM-M1DusGclckk,4D7`M=UV[TJEwQKMda;U\\VJ	;u	GlmvXx{[\"x?u<ObUO\\$]DY	j4Xj93@k/yms@~cUtT^ws=g_'&OU\\lC,S*<=}Xk!;snn%>/lwx,8FzdzpUWdbKp[x7;zp2Q7(bPtr!`VX7WGvGN-#%9(;k,wZ2osTD|t\\!rz7#5:?M L4e5C;m	&ZV/\"I7Y$OIpd_c8L=c@ERgj> JrA	K`z(y@&(.
2:- dN8,yU.	-8l
H\"Mfx|q ;^~m:;GcVDOE^L&q 1|GPC,<mel'd![Z;7h},'*.kjHGY:%2lKlk}OKHcDb0fz4s}O uVE\\eO@6%-Gv6V0M1\"<yDZzewf4\\[F YZ.xj+Z=~eVId(n	+Bgo+O\\1,PpN9] !r4d/gZ@S!u-@}()~U+.^}/40ksve01pykh	G' sn B9#TA\\)`F%d6%VRb1*m \"W7^@
,CNjBD!Kg2B$C \\
)/yE[Dhf7D`kx18[E.<} 0v/%_(s 3Gr3'0;Z@9KwzQj_($#o=>w#|+;q$L!^?#E-N9);eZ-ynC3T?JvqDB_35h7-D>2lkz( =SpJF	dj`+':\\st#
u\\/|fX/Gc&]9RF3slc9uJ`8X<HP4BU~7htW/Q@*}5A@|{osOPwN0u5/sn4p'6+\\%Id)+T@Lvi\\R>F/&=JPL2V(&u1<uk:Nr|phRtV.y66
endstream
endobj
1360 0 obj
<<
/Length 2713      
/Filter /FlateDecode
>>
stream
xYKW(UyIU!\"!	1Ejrf_Y)2 -1I7_>2Odj$MFiTe)*ty6~~qZ{~dvl;!)Ep_UNE_YRy>i=YO'vm`owY\\)?4.yps!~ W!}xrv2 *O$88!=yu/EW7F<Or|i^XMQIS| `G8Cytg4-i_x@:O*LJ@YT*ifgCxro?f0'30I5MM_$CAujuR+*sfeya$?>x+Q,r<ey&@|+]oCVEgEMwQIs)&QME^_mc{v.sr6/x-[

vuC>X!pGlVe.
O)<qb0iyaa[ngcy`9\\|&J[$Uum[HJ$sTdA3:B^ v{0e2@vy	RzX:H['\"&MNDpZ		H!m;{YM1>pOF>g`?`wRv1m:<'8=J-c `?2}bx#GW{)!r> ]%P|\"D{Fmx}J%J)o`v1+ k>R
#Ea'+r&l;:c92*.=:q F[%O	{r
\"{$I$+eh<KxD};^)cmwF\\@e5%^9{Gr*j7#M>SC'w$9pG <C?R'5^&Z|B%qYuK
*o{C(E40[7J0TzUfU!t a@^7H|EM`2%A)6@S!hfFdLFdy`>
^MRK9#5Ys)\"R]`Du~'$5;0XKUby#uy0`	`]W)N>|
+,+&\\C5DERh;X(P$F,5j(=SW^&{DmJUUt4t04,*Ig ?Fct)-AYtEZK`-=CoHQ!or]~Z?)RC\\fYlo+MrJrVS)o=y*fBb-`t/ Gd&)K>.x H i
 *qZ=O1M<Je!Vyd<V-&/}#d	$NBZ\\7e[J7U'Bk\"UTZQi0_ E>Rt.YR|aKT01h\"'inVBot)}!F*F}GP+q!0&=PIrA[i6]u
,H R1PIc
WZ4PI#quMTE[^We3 &<o#Z YKc!u%l}#;D+LeXZU	T+)~ zwm!RbH-a7HQ{Q1(m#\" R+L' <qA,m$xf@`d^vf0tg0X=-H#;\"V@c9^C+O$HiM:$J9\"WFR'A1]$Q#>vw+}Do`3 $bj\\o3_9q\\D^`yn}-U?	<>KEt'/NSYNj=L	<,C4 qW)
O7\\8UX7/R@]s		[a@W.l\\b=p|d\"#9bu4Ca\"ED:Q'Y_'|WdWZ\">gWHGD4*AtA.X*MLS) -!(8e)0:KFq'jm kVAHt^w50u;m?wGO%C4-m/H[^t&%Pes 9:
endstream
endobj
1364 0 obj
<<
/Length 1949      
/Filter /FlateDecode
>>
stream
xXK-T qZoU*US$zIB 9d%!9|~<AI`-92.gEp>e?#(;hR2y4(nzjh0&9{s;U%)mRp6hr8oE,UAbz=VO \"Hmx^va/hokZm=Zi5s7K;]+^L\"	iZ0rv~^dRyzGA'r(?f*m;C<$;O\\;x~D>%/hhs;@oBWe!wPT>@*X mp^(
phO|Zt'Jr>@VX2(+$)}kFz#`Iw%u=*UG}G9O
y	D)Cd'Z;\\uE<;T`Wrx\".u85mc2i|RE?|gJP		$\"2 nps@)X7#VeF~n
 wq,s[XRGY(DHT/U/X~Iu]cV^*u r@lU pMk9 9bgX9n}kn*#e_K=C@<
.nuK!b0?7,< l|Y*e7i^w&AO'\"RxY D[ l1T 9g|f!>l{XAYr3 1lRb*git2^MFHc8dl8ln)[,1YF$0\"^B%U#lu,2NXzhjt:X\"D=TtbDe3`+'ok2&'Pe\\37= :aQx3xq%%a4LR{\"o.D|%JI`V hEtEm#x#O#ZO u`f_X\"J1mn<P_IyW(j#s}n'`.K~z8\\c_y%4L+&Pc~p
LLPSv0wzmar
I!LO4h5wr~w:9rLQ3=;ct ^_MKZp< )4<%3Bu{J3vvq\\\\mn!\\ VvP[7v5r]1J`v\\uXmp|H^z5 r#v
mh/j3d~fH;g>)0@k$1<e_M)*8Fftwj*\\QcA_vf, 6sk7$k7	38P>[]XB,@2;avR:PP\\2&s$z?<\\Uod..
h7M -pK WI3G&m[PPChP#1y\\Sbl%IC4=YKRTtMw~z\"a`hd RwW*/`	7KlCUEHQ.3C=.kk|1Qd|9H^~9}/di
endstream
endobj
1368 0 obj
<<
/Length 1896      
/Filter /FlateDecode
>>
stream
xXK6v\\:N[E/Ac+Nme%Ev-KdQ/J4.o>\".\"\"IYTQI&h~I\">2r=A3/Xs{{m#F[us~}eUlG2;oA*OTOv'i$K)zxhaBca<O\"EMh)}{J4-A p72qcYT*y}Wvw2T\\;gm|4zuwhf8m_tq bQan kVk=L`\\K}?VhhR\"QD,`lzT7[q=Z&W71spl!o~<$*p:~j	`,x[gB7G\\ '^&\\a%&K\\4GP2HQ+{<f:XCR`F(RD~poZF;E2Slhz'?^~Ny&!qBH3\"hOx#o5:xDoPDV\"iqq	n_S)
df-)P0\\'v1ZJ/n8o $7`@[(Ytq ]CsCxiyBzqvnO4$D_.}>*%!hNmhNFDG#`rftr.j0@ ZDW3m?usu)DZ)RH=e*EI;?<=.<$B&, K}G}mz,`v#\"$fg03 w#1
YF/W4[_ '?N_HGp4T8y0eA+0)qig =#FZb^*;4@w/!jZy.k=s,W>,@IXRWOh3t1p#Sz@~D5N?Z{t0m %+@0\"f'2<MY=q&oceEfw$-$	'6Tmeq1LC ~ T
fJTik xw>XMR F\\D[mX&P|>[G32T+,3L^,I4H}Cr]oL@3*W[K,7u<B/{4^~}YAoCNc1>la\") ;`[(i	7`Y
0\"|= hPSn~ seg-&+|y )=':J.Pi: bC0_`sxUr_4; R'fSvb=[IccC3#A0RLql~~\\JfB'RtK_w?jP@D\\9/4e/bhOk?l<{cF@p#e EV
rO2k0|tT=T<(7>h\\o
+g#*<3M\"r'd9?jlAky$9bd&7s?RgR
endstream
endobj
1372 0 obj
<<
/Length 1679      
/Filter /FlateDecode
>>
stream
xXK6WtIhpF z1!97#^!/^y\"o `+'
$8mmd?mdG?/8~o{-F0N5uS[;7\\'a={SL}oZ6GzcMcO Qt`]7Poo_j[5o-htM
u/0A-Aa':*0/Ir_U\"R-PLMQ'7E
ToD3 +cESx,LXM&QQpu[vv^k4mcUOVm{bz.+:6@{GL@7k
^g7UUj|<;Jk|jM49[Ym WG6Q\"l*O'!i'wOm;#|
bYW Q+1\\M
SIer2)$m7tj->JQqF>DES#*JF2%98c@9I\\|X@)AZ, %Z1TQ)QNa@|rNahH	BK58<Pi2kCfA*>^wY}?biFuL1_3~u;c@`{G!Ta;$p&_0C8>.H+4NzGsBx17	gmhr#UJpO2 XsC,/u FR0@-	pDw,[M?|VES8:SJn >`|D4h!8,W'5/RJR	9 +w#]il\\g6$advD]ad@fO._X)YKCezOT9)lJt5R
 /NPhJFzjGLv;2^u\\@YE c!dhspQj*0T-!,)\"Y>k'<y_PP<@P((
}aX0\\hg8o*@0fl5QYrtRw@TUtg^q:6dei4QN[[eG
2fh{)2r?nbqQF1(v(1usFJ*}Eglje9N1F!;	cDWd	!%0]8I+e{!]Pqa0x-D)+]OF+oF8.\"Gn,&BJR@vk|n	Hq7Ryv7
endstream
endobj
1380 0 obj
<<
/Length 2484      
/Filter /FlateDecode
>>
stream
xXr}BU Aq&o6NR<\",!C*^t5;p!}l5w\"]~Tb&%/Q2nbUff_~^jmra\\3V}2UFB0~@HEY70|EWn.a_DK7P|,s[mQ2_.j8v{](hkW5r[(kEReX	2C*~p([U}{~
,* Upf6$J.hq2-XJU?z<*~rE`+aV8\\PysGccRy:JY@e:n[}ReabmNG] Z1l@M<La2;0A1h93rWF`Ta%<B)at*!{3k7Uj jG~m=_Rx.1|FU:JC0P!S80*FRhkh[ 0b&FW%CcJ
|xFg<5m%t8q\"r#Lfe ip&<&a862(	Pd[O}Wyk[5gpBi&S<Vv%ZGOWl[?V[%F >xdfrtI)\\~1Oa\\Cr[lKD[0N9{FZ3 }npEIq8:+n3o'#ki`c9a%87 vU?k~=#  Sxn3C<\"#!v\\qi\\D@D$UVn\"	,Omp}9d6TbCChA rNv9O,Y.N:XGn>p5jP56}!(0iIBK'L[jP`\\(!<R[Bf?$j	_^~MkIO~(w3PJ.@
=-		`fR^LREu755!>@a~A;-zYA*{$/]0VnC!z*=!C*Hk @jEP;00C5{pF)V<&Q&l9R@K0~49P@Tx3^IMM<o^od'p)rLDjqI+N{~tW]aMLnQ*d'x
gDO)(? \\Wk7I\\FQl(Y[GZr8G$`0BK\\u0g7)Hei~s^|UI\"vNP0bWP*Kbv\\e0M*tld6Sw>b\\BkL.K /*V/7<SGzy@KuWuy<Ar,@J|8o)TCbs lyH`k|@7X3rQ9P\\rOu4c6Xs_BX(b{Dha->?S9FC7ehnWzEl@R1]\"tRpM(J!%qkC2@VBG4
	6g*=@(g\"f]w{nzCpN6Y ],!o\\0mr9PkBl8fAKZb5x+x+UbPw_{b-e#D ,\"LY ,R.B@ne+Q:?[~	c&\"t~ Fw	\"[.qP8U(?'HM5,K#Zv6|1%|'|c5
b\"r?R#	2J86vt	<VQ,owx
endstream
endobj
1396 0 obj
<<
/Length 3272      
/Filter /FlateDecode
>>
stream
xY[s~zA2#c'$6}%ZfC.I%u~}L`,^](	TVHP*#9Z&#Bht+8,-ViPn*.oted1a0m=L^X2wu%_?S):P[^L1r}Jfd>Hn^_]r&*tbOj|=n*xF1p2xv{VJY!S=`%#F!H'/E?lFOJ<[tN!yi?{^oi7Q;^=B!Pm1Skl{2MQFo@ob>_^0p2
E<F#+#|2yHY=l	\"$ap&8}~G5tNoW*o0G.sDAeVU~	0Pwc:9uIwW8U.6M<jxW3k=rmwggdi(fxmm!R_^&*f#w;M>arQ`j5LFX]o84!pW{yOSn]w\"R^;._G3ohU?0W|zoB8kI!oiB=\\o,KE@yWe&)fYH]`-EfY7c\"8)9o`;73lz|(S	>Iz	1sz L_^x\\M>;aLy'fa;&}*gdqihg=t1kx*Z/9\"+U$i4)YC[siS,^9qY>_xBQtw~e$C|_KHAG0W`$1L0|/fE4t5Lb^,+C 3V;#z\\Uk$, \" \\u7!nJJ 2I>kM%qB& vW:w~?UUMK)k't'Ubk03?N	ZIz33W&+uBPE]5c._r,S8}-P<xy,3H9/*#=(Spr1b;+f;EzBd0;gMqx ;FIO%`=v+;MG^i$ eK@Vec:9Aw3i#x('ZRp8~hSU\"~#dD_pMW)iy#Wb$DsFXa:OG`t5COE1`&-JOoH
kHd*2JV?i5]	`gJt2B86}wQWZ$9+eLYyU:o
73N%-8zf4'=&GR$am-8PIoh	:Yr%dr/8F(]SWA=!nu\\fC+zT}'#gfjnLi0[gQ2uL&(gB[Q5FBoBI\"}Nl5
|nC<5r?wYvVJ 
.GzQZ3bvu
{wz	1pS5 waS>E0roUD}u<=**GAeg9;.~%ji1*jdL1&|N[n\"-l4!_Si\"\"v+w.
F:%@'xS9a	uz;Bh]`[VsFn\\tK/Gc	ESU|wi516[m~K%Cl'~na3LT?k 2T	P~*kEos,S6/DdLPo
.'|J,j d	,8PuOX70jteO=*;_3&{ | H]OB8JY9[g
\"9QtJlQ`OI.b}3\"|3=;yc+*Hzi$RlC!9i O9 r\"(HB%kN.qpo[PSZ45|>3TP?(iDzu7r4
Mp5&jOpi1P8Y#)r([$@bSnV/0;+x. *Ggx|DBCkN 1u&66v`|ehON hin ~P#8D`7$Nz,EE%V*N}!whG[h\\4O%psGZ{\"z0A(O=1T`i04#1c0C@7{.2T8*oO}gU9X\"}/:2#iR\\!}W,}k]1j2Ke$&Wl8&KPyH
x=P*U*ebdMvpvhM_cvww[&1mfl@BYh2yU$<|aBrgvyomP|[v? , XY#sqx=b)Tp\"f0
endstream
endobj
1414 0 obj
<<
/Length 3379      
/Filter /FlateDecode
>>
stream
xZv6+ICx7slx$%>3YPT1!v[ FDYTgoN(cY*#D?GB)fSw2G&gUYyjI+\\rsP'soeq,og[q%0CeiC_oQ&]qZTUQO1lr,*&]]L,4?BmSZ?;&/$;__L#Cm3]h!=RFC^t[_%_-YeBt\",#rY2}qlxWDK\\S_NeKS'O%f.G{IYS,ja)GkrkO
^A%4IMW'(gM:	]y{{Z!=\\XW<K @5QjlE$y]=hJDX$8mk:M-?BZNctIQ(]#D!y92&0mvr0`Jc.kZ'<q5CjRa>Njx|:6eb8Ku;Ce9-Li$s@]p'%Z\"|OA_2XN}PvQ1#Q7nf4_x	lr$K/=-,uxh	fkUoI1x~a:2 H|.erVS//B XqwF*DZ =20c*=\\,O[|<
\\s_!S}h},^2E*&OEE
?Q@M`~2`sr+W^:SO a'H_PC]%'?py%
S{V|Dsdct0+?l+(EOI5~)G+#7\\W:o.F}DN.O67#ZN@B95Eop-A[XT_$4E4qrVv9/T;b E-S626|`0+-@SYS4PFx<\"XwqR@GsRA%\\*8Kh
ZC4U-Hz[jyEmh/pU 2x,R0LLss 2C'XL)?BYQ npSYQk0eU2XyEg7|7Ul.6|
U~9a<wsTV]:C4\"e_E rnT9JcAgWA[ Tk4muBC}e_;:~LoATk$PB wVA{:'WX&6\"H]$yO0=sGk!O)0iOw=\"UCYSf{Q*.
,B
3#i,tHXJ+CwErFs,knLry|d*I\"RnEi=C4~BdogZ)Aif
Zs+=S$'xo (\\\"1Ru?PZ-AKe}bTlAgzW3B.n_A\"$oPsQ#P*>WYhH?XnF	f'Y!1H\\x2)vH/NwQQ1_w	$HHWROg)+SC99&NPLs18jptYD&Y,b)G	geaER
jhXy{pU18|p
de]N*4:~q-AorCt-yL_w7r!~X<y*h*)ZGR]REm]J0L%m	G mP|x3Wtr9mf1tzl+-B^aKc$#L6h33<^wdXm0.2rF~%tkrI7f!BJxm}wmvm%BiUjzb{i$tL}[&C	{q`^[5.=8$Kd__|)`'d9998y8,dn0FrrG\\bxn,B|s
3pmY/}R60dc7Hc)vt}:(bVDwh.pO
H[H*$5UXA2_UelnZr_qT[r/;GASd^[
AqbJV3MgY1gxYMReMw x1.I&G,\"Aui	r[T~9^Vs`YA}]pQjY=:f7^N39_]r . $m1G/6gD7ll.38?rvsG{xR;QJLbv[8LE?%]SOXEJfe*=yX}vaG88O1:{*[$?|p?)60v4 3MT\",+oI_\\6{?MKE[*|j=#|vDcdC~x _S}iD^Ec;5\\ 0M8E6t%GKzw#tx48 	yH |
_rO(,SCw{P*8_Sm1[4u>%nD>/3lm}-(|0d+UU?YpWHo7/OU&k=7z5>Ty=Z{@6wt(+4DJca:
endstream
endobj
1429 0 obj
<<
/Length 3349      
/Filter /FlateDecode
>>
stream
xZv8+Ccxl'N,	HJ(l+YP 
@U[Eb$Godx9yQ&X#%R'GjIbmv5Oy]#F,:/oGcbMi4|W(D8R&Z}jYRgZd.I;fw6=JclYe}dx>K@~~	tJ$'Gd)bL4*|U7|@Gck]dq&6[\\/,joP#)L2,a _,EN	k{*}yDx9|9JH_a+U^U\"+lD~[%l^4u5t5EE/IXy?n	e
g{jhedH2,ui.HxHW\\-~~\"@k:7:ESlLXGuv3^UsrYSOp~Zap,Ccd-Lw,SE_]/z}[;N{iv,J+b'K%F8ml~=_::xurS<3g}5li)Mg 8]7`a z;XU<Ve[oetoy&{LzHih#m*rzC,9s4E$r^}VN*&U|i;MX2W<Bm|50:<g{h;wrZx~\\i{Vu8}W3 :Y=l;?qV\"sNre*Q
I%N=YQ b$.uG{Mt4Yb21SuP@HtItQ q87fnRu;hou/0NL xm[X#QE, o Llyb9`Ic\"CA\\8zh6E8C	,G3P 6o=r*E|NhlD
JM8!4{f2QY/t||4P\\ I(~G& (nVuY/y=8LljDY8S,yHVLv '9~.
5oL7\\#\"9n1l
0EUf8m 3nal.A{F>*	BUu3MxOZ_5S}-W#gXq,YUdB.,_:MY5BPsoRFvwf!L0~0+ `^B=Zj`#D$SkCS3I}tF'jXAf 4dvQw7Ao@H*xDiti&d^3;0g%'+mbRY5w.)O|1AtWnM
m'jG!$/`\\!sS_SGP*4)qs	LWzU;` -|bQQ:pI_:*>!KBv-it)(D1_0b5OGs{_t@*f:-@/W]j M~Q o_y:F
G<s6>89}iT+K94k0dO2avm\\1X%Lyn$Xh%}&F5G{`0=>sQ|yLFA3/\\Qpxy,NTZ%npplc4B\\BZf/6<o(m%.C$^S#2l
<H84OeNE71O{vh-lEo|}<2:! &txU3lg,X\\:|<-Zd$D+f#\"c)\\pJ^l]%{)=ZW<F_?O&4:qTZk;LIi2)~XG}N`\\\"!VE]}3~Oh]N[w}Nu5v.B3 S6pi\\rHS$6]A\\	26qm^\"hAi%%H1F'UShAA}90@B%V(@	xc>>LboFkegs302YF]4l*}+lg>>WoyV?SWI_M
+`AFT'ItN7:mbq({g2%qVg6^aM_^olWio mwG EIWV (es!4]{,fu%Gmk\"s?{/3v?4'	C+CR/PC-<pw}[o&qK%=1K)^		IKT :}lGI80'Ac\\.TmmN |gh[GKc$\\/teHySxJhG
*w}bmrKfd_~q$FY,gxj;@|5B:4%z]_B2M$2XX	]Oz`kJ9RlE@@i<w.'-Q2N<&S4>g]K6h$DrJEKRgek,[!9SO'ai)2 <(`\\pc|r`qBEWU nVqWoT$_3J3aj$JnG=~
endstream
endobj
1332 0 obj
<<
/Type /ObjStm
/N 100
/First 947
/Length 2175      
/Filter /FlateDecode
>>
stream
xZo~b=]U]]:It\"%~0p6S=_w0evgcX`TW*Q)kGv1:++@t)	DS3*uIJkv]s:wsa20L:(T1\"jNSBT\"9,PY[08 8cU>X#8SLQHJ ZX@3Jye!)uZU
A`l%,BnPvERqQPpTnt
q2.
1J|W*P%X>0`|rT1+Si0KL/91\\itZ~*H;f86#b
(P9Q.H#AXrTJ#X0\"T2#[$GDE8\\aB
ZxYr@Jf`o(OfpF}-lrM@.-;<g0	z
n|uyb^u?>xB_/HVM<;?c*f[
wC~^e0k$C	\\|x7  $Di6O[l?cmm_[(\"dT-}
-o:wl4in-t\\u6IZ+ByRODK=4o]5ZR!(6i*|>v*3mQNT}`HoKm,&Rh38IMZ49?OH}$+d-[ yWxz'J&(n\":rH? m+W6A~'wS>Qp',	-<qWybHIe4|hIS4%qm`SO/..y@37C[WgA>S,fDIRt,UB+p~0Ctu~y'}1]7= S,)1%Jl%ii8YhV=9z9R?;-yw#)q#EbU5?DR@Sa-^MImhm)	o\\deF.:6fW[gW
W[Qy^bwlU(
XK
7IG=>?=?zLc;zD-.;:zIGG+(K''gv+jyZ^HzFGS+Ed	*\\RFpKqzVS=:	4'2)4t#o`Uh2TK6.QQnVcLs.a4}f
!!}B[*J~:c{&m27kxp;['	dKD3jYp:$CXlTo't\\&Ek En4x<
=w:sRd(p~k?zuR]OjU.->e>xRf9p`niuaAGaq%_i%K<,G6lHpy|\"-mq&u=[	iA)l\\k^=\\4'fasP8,BAQQ9RoV}(q`\\4avLb5lMm	Mi%_~c8
)u}(cuo^Qi/l8X.R%e$2t>)BZ$wm2bV|lU!j Qwl%'[=px[ Z6*`P	<sx<3=A%@@'&{39M~1hh$ #IHRx$)<
Hx?<[\"~Jo
endstream
endobj
1445 0 obj
<<
/Length 3095      
/Filter /FlateDecode
>>
stream
xZKs8WEUE0$-8h
II%F(K&> _h>w<<O}2xt0Gb$bIb0i~z7OdE%cSVQ/]Eu<h)U^.L\\EB.w>j:*MjK]c#VDw]$xNHbmLIR
T2\\`6yHpXy7;Uwi.dj&3J5w4Q]).&s+&:&!+FqB&L6,4i-uN=?b,)\\h	X^8fC/\\-TcLo-L-Q@u\\thxvVd`	R3UEVmGM<tr\"wx\"B&fS'Oj+U8%8QTd5N2X# 6QE5KRi(rrRf9x,Uq<t>u|?&tmm4s/(XY)~T%]s	&XSVUFU'M1?/4YJN=-}/Xkunamnb+gt$7.I%*VzxUSmJGm	uK&!8nd^}/\\[w}V}C=|IeR-m:.]VbR ShTuny$^Mn
>:,]Ul\"d(cGvl{c*aqN{`i0Jx	
#qyX@<NbFn#,K`^B&Wt A,T\\I\"wB;J}DB5 R$Nk5up7Dr6}~ng] aKYR;oc
va.7 ECw,d:5,b:%HZ
iuoSyW\"O,<^)bwY	)N:!|DOkzrM>BNKS3@
b'
\"
FHPHIYVzcQ4l^=a%}<d{Xu}P%_TF6hb{|_Rg \\7d|{xE {At3+M
~B3U{+hK[Wx&R%	.2/*F%:<n!/(5gB{.,7k]j6b>k\">-hj:ZURu6C^,E\\uux~(Ydg5}38Ad>-i[!hiK5*vq.YA9;_zjpDF5cadM:!i2ThW
zs3&Rm?W#%$kr Z@nk
r.X=/<4{NC,PwNgnaiDTWC2)BD{ymDF?(Q65SfjAYAZ(xtML&RJ<9\\TeS-[`R }c_&v,1OYlp8BOouK{$k}b	*x	L;&9)pM6pLWL/ 3!%bf+# zP UP
&g z=?Hq	dgPgFcl,c$CMJ&L$[sVgM9H^(r:u{OXB[8jXQ)1	fxs![hh+slC
^&VV`Ac*L'wH*J@:fEA-{$|A\"L6f^u=<a	w)&p=D6/ObP 0_?=G+G6V-RW/WwZU1T@mp}U/ dpFPQ=Fr+2a;	y|0oP$NdIU=nm_C>=yI/4q>ig]q$y
gM*69MUJ^eGQ\"z09sG5Fa}/8nsLOQ/) ^G
L(b`o
aYd	MB)M	z2HqM &4mDhU a@U;\">0qV&>byw9d[8a<I}M$Ki/r@Ah8'bC:@}~0Ku
H,?f;IR4sA+W*1':+4q7&r,xsY2?d>+GR\\5Y_y`_~F+&b(IPU<e>A|3A;(\\8yS/72U4	S
>QFtmwx{CAr
YA,AR?
!<{LI
endstream
endobj
1460 0 obj
<<
/Length 3198      
/Filter /FlateDecode
>>
stream
xYMs8WH` 97dc'ef-F%&%d<~_AYTd[{~G8wo/=Df=?\"5#y$G6qBnu^MT-_dnLp__t'p|:6\"N_3<YTBuQ/mQE5I)_'Std]-D4&a\"ZW6E2K>[v\\L}Y:nYK- t_tb\"_Zz|iLb5ORp ~L8w -}WUR\\$2.? Vdc1Lu&*WHb?:~F,QZX5rKT#Mfg4&:P'w0ze,d,1Ka2a.Fi]wfItT{TH(:Q2_Q,xGvA[PTHC4|V~0(0Y\"Q2prVPU
a1(\\XU}Cyih$.F^s ;J\\&na9b	e1hZ3Uy+WN	ix_=&Z-dR`8?8]w_Wt2:8u0bw,*J#@JL{ 1q\\.
.1a|]W$}B[w_	\\0c=+x9]z>8Xd^;aS<D~?_<eEvhmSqJvtMuIo9sX/gmF o)3G9LRi9QJeGJ`{SZz{!Ew<j]M`a>OepF9 Ycv ?0I `Bf}e=!vebUr{]xIf.%	75t8B&!|aE2_Sg55I!Kj92C_#3_ Sl|us<L,or=p? uWT4bTSS|UTU~OyN/~\"SGy~TLl(,3kUvK2*qRdlCIQ$M3Im{e\" aEdyj$G-Fz@ 
Q +
Qy]^mOKig3JF*:\"H<i1KojP!l%fKh>#(2wI.v|5AOo<g\"J\\7~Ynk z kt3-vh(F@@'DjBgC}ED4yup! J`F'O_5UU,
@g;lP$JbVx N+e6(S7G,\\p-1Hd<** gq2:?[
 ~{&qG9i{f7F>a@P.];	^U;x=?Pf]>AW!^'p<<3pv|LEMK[%zssB`3~!<ral,QZ]u7F@xl~	b|{4p'F*E`+
5b$`8`I3\\~J(
9^?MYZ<	wq_GabaT']x.k6I9Z-U+x/a	.~80Z)a.	AJ0I4d)nCgM<mrNB	D2ByQ#1sF\\zYp#[,]Xgpo}AK}=$n	VX
S<K3~uH;]P%`C[H]JMOzI|R$'4`2m!T,49Jca6ski[S~P0O):NQsq\\^|ZY .#oK\"J2MUI5m!<R!p|t_	DvM~vV<ZgI5P@>Opr*Nqf#Gl@h\">Z(ass?rS(c&rBB.b`za0&FG`Fk,x5enHJI</Jq*=kG5y(eEjm}\"%=R+%d2uJF|LJLg58_N H@?1\\V!;>4CF~cOe>hUMNE>'@X-\\F
dh?:R1p''7hLfDdF3aZ:-pPWM$8wQ\\Gm5>@,dG\"<m4M}weqH;n-;B	QC]f5/7<*hxWD\"\\2Og'W/m'M|dr2j)D0?]*tegGC)
\\G)5]-7	MbN^kdnLY<q2DW)[Yw1o`4fRoi@HxXTOaD
i~7a${
endstream
endobj
1475 0 obj
<<
/Length 3533      
/Filter /FlateDecode
>>
stream
xZ[w~[sV0q! =-vq6>0,sC.)9LY/\"13|3T:4>ov*;I*JGr$P:GNCOccLMN<LiZ\\\\%KLIx<2-NQlqQlMQOypBD0JEWkWBgfdM&eXK=POtgqrvoI	{`|2Y,=U\"e=|Gl.w5r=1pE.tyzz,N
Y2S.oi<gc(aCi~s*2@[!VRNyQs}'M;)8[Ve={[U
QRh9-oYLK.b=`A_,#qH3ZV8>	;W1
By8+2M!in|x)[XE9OZbYU0 +y\\
ULxMr%E'tE[VUHWA\\gbX*Aw=cl|6jpn>mE&1tv_vV!\\d*i2nK'ME%)JM= vN(G.PU,	j qy.;$3w>yW~]
cX0*W|l w~T \"0;b}PVcj9AT,k4APiir	K?-8WV<;+xRAa!/`]WZ{![,~&DA
z-0HghI
\\l80B49([h	:T]mMowR 2@ i) xSiE La8%hq*):@'zI6iz F'wOi;n+uo2ECQnuB^F]4@rq`pl&P{Y,8~p]idW	h,<t<j[#Qj6l<hk(
a\\ \"c	-.q-SEim[\\~jtaUW-6<y`id&MT,Nv2epc9>&8Mq w~Ye7oD+^1ZU]x }Nfz!Pa\\6&xZj2o&i]<S|l6e \\6H(T-UUj]V|MbKGWqX%6hV }'8ED1\"H8_iM.Dy|4-I@Qhb`6Cn#PDH5OE^ZteUL}9k/.)vbx2561MsMO#dgp		T!_*AC-~z>IT@ [[ /P%e\"dfmg]M|`RD
&Kk=!tU!4t:9:{i\"lL4{m\"gW!RmFB.I1jy:('JLH{^I(@p+7F=#;&C9*Y
wMJ@B\\-#x(ErbJC P>pJi!Ivr{{
y#v|-%mrU/^g@HS#`~ti}NKh,]z
&9)qELB2a*kX];;\"2CDA	kE<a^R`0\\*BPSO:
)MBfR]7*)Imb]NG{ad'Ro3x\\o@52RyjD|A-XGW)=-#mjc\\q^;7r%lI9+7hq6:BtDGK.>QX2**Z	ab*
k|s!)c|oO[J ^Qz9o8rlm
olI	`fCXhn)!]=m[L qBB%6QgW`jp\\6>D5b<ChJw0j ZmaR\"31P{)O)E:{,v1]BYAlMe4Ul#c`1?9|Dr/X\"4EU.8\"eQA+o5^FJY`yI'
2GP|{~mSY_yn_:La_^&;JBrh'YoOrA_LkCP9x?3z-		|g\">F>_!|.t>#Iqa){$\\T^Y5xNZ 35w&%iCMH,!J0MN(O62b:cKI5\"SrrR1 e:Yt	Co}J?]y0'=8>#9&tHe,!^*?\\L$2>YrA<3r(*/` A={WI,.! m|8r-L`,hZ=%0n@k1JYa=Sk8pW5lN/*31{muj)91P?# +c\\zilD@ytVmNHgerAOJ?oG>PK13lC}r)DJY6`A@%BO~t;9D|^p9_wlvyk I.RTg[7sfl*26heVT${~&H}e[.4:y>
endstream
endobj
1492 0 obj
<<
/Length 3375      
/Filter /FlateDecode
>>
stream
xY[W8~_sn_HsgX`>D7Vd'	D.ITEli|bn01?	b{|KF&3:
{'UY?dXHlHW;E
wQ&8N=yY~q/%G~-v^q|I)I[kg8,Nu_Yc}oZWvMU6eV%Js8z,EZc}m4oaiNy&#--?\"muS|]_P+1s`:dZ=2|ccGp pJM?ImM=iY[e5eO}Z7vAvEApxk-;lHjs8m%2a_V77c(
t^yO2Hnjdz1kKB&%Hi!hJ=ef!Y1LU[bIY}QhL|^89Zk$7kD\\l3(8F]^p2FJAIE +KnrE8%?+j06Y1g>Y z6%a	'+MI>l/	UP6\"u\\419u.Rs5$f1Y{[7]MolF P*Fx=VNC%C%pPq9FFXUcE2EP.<: <'B*Ks+[T\"	W&uB*Bole
Bx7`B/C?/I&
Mg;E7`Yip`HD;eV aW
vHC~i2pV4uneM_$B2f$krwc?y'm6DY% Cuj|E6%dlgM[=5E&k:?-05,~\\'	!#nH*&_tG1izcvxI5>a/wtujUCwF]n^J0W-3;aTf58KG`\\2=1 #y'
*V]__6sbq{7Co@3k:%b^X76&zj 5 |l6):`>,%JDq:7mC}_aT},+	fIkpR1Ye!D'$Dw8!xP[$1!\"T{d`Z0N3.yV- fY:M+@s`f\\hec 1KOm?N=@LS9QW))Uw!s?l3 pMek\"X.vu^({>&Q~,
}SvBFaCx1
s}x32RR\"Q$)s:qXj~:4og93}FBM#@@c 4ea je\"(7,3kt:-*

*U,Yw i^Xr[b#[;)w7USdZKwRX/pnTRh\\`2kdCuzeTKz'4Tbz@Tro Y`6dR.;wCjc5.S~qRSHWz9 WVjX(uodYeKf-8G*j		!t:g`eU4M.&f_iZ-^\"|tMFz}4H|YBvwKnaB$/j=%?>UJ5*I:MQ	(fU&Mm`E4cl-6_,wUKeF`BhT$ZM9X{|ubvVRZ}Z*m$3|<PN
WmdK=~b3]*(iH;uX CoySv:FJrKvd?*[ f$blGK}wx^Ue4L1]dD:.edD7C[7\"8pPO&5+}In[`:(I !<NXd?z6z7NQemqB{?Tq i \\+/wcOwM7C@e{O|.IwKWk\"HnG5/O4SLzQUzI_l=YsmV+ae jPJ~a	|[	_w)tN=:;706D+6yz}KAR_#@s2.bD1@``+%u	Et|}74tr}{vES&Z9p}gwaryyvGM|tvt9sz~/HU(/ $.~ {jUOnx;]lE1+P]Wy}sIMU6w$zM\\d.<!Eh1Qp@r^ ~sB(9`.p>o_I|<p
OT,	!/\\Gu9UEo<}.m?nT3BxH1
_;&s6Sv,9 L?nT sU#$XAM
K$#Bh4H2]_1(zA$/`Amm$(zTWE:C+}X]
(T}]4GEZyA<Hv|c'
endstream
endobj
1507 0 obj
<<
/Length 3281      
/Filter /FlateDecode
>>
stream
xZ[w~#ubY;Pu}g0,!! h>w<~|vJ;q9h#1J5)'7kq<.>xI>VkYS/&&MrwE]l,Lp)8p\":62oav@-y5N\")PiZRu>Z>Lk!IGNK}+ODk^fS|m4)f04?!43p2|P:R5wakLpa8)ScqLdKz#VlU2S:/+NY;\"	aMhxI2+,s	zPjZ~/}E~;vVSmkv@n,EL>uoN_08
T&fw6 ?~9YRTu?yYtc!\\	u5E@0a!Mhy8x e_h6r N -[p\\1!@uc5Yr\\4]VXX_XZKG#VpsxVz2&NyC5h!+uut8bkP&V!2n'@x;L&vW0d8 ;<C&uaM>hP?d!oz\"N&jc5]}}N,\\xP~*bM=Mg]h<
fDrTE4R:KN\\$sh0,j!rYvh#h~tMDUYO8o|2*`{Tu,s5X,`*LG<)#+	t(CU2L O2=XRY8h&'|1I}y3\"c7j=*bU3X{os9-~mFRS)8]AdVJsdx
F^^<
*Rk-q;	.|^yBiQ4;x1.,@m=m8]]o_g58z}H}U/yok\"U?t7?VL4T.@;s}8#d]H0bb0]L=SW\\2`n&d(74^O	jZg,Sq'D*|H-5j .i(0Ae)v&<?q]_8R\\7C	d<A#a<Gb
4>W5MKuU3ZCu2s`.IVSJ#w=O8o	'{6Akb/aQt]l-7unca_}_u~+bcPXlE``\"8	0^DI70C*c s+FF;/|ES5Yb+n):P
tefug%e9~pc>\\D*)J~w0QE
Kt@}ljE#_r{mV$ /poZZnZ8(wMamE~}y22)1\\0P^1eX^>yfh 50!{FzaP
W0J[yOOF@!$ <$^]1{{
b'0yF0T7A9!PT*4!*'d=K%(Pk @oLQ]h
*Zg0ahv<#X!L8L0DaYqlYseA x8J_L1oU1Ynlk~(3}v bt?V jb,ZQ)}F<
n1O`0$xS(bK4mSi+ OBMz|gmW/G>XQQcsla7%U7>)n2P!y|CU2R:k6\"ym2 En,p+v2,iIeS`\\Ip@@v15IEj{lPu1<w%BlQWQH]Xjy0!y!Y6>{cv
8h	!eDkWC_yzK!ven?JY+T\\|4*f2E*15y6=u>JNMp1F9)R#0l_V(k)Un
CE`_j)]1c/3  ^/KML9){~s|OzDt(c)S@eTWA8n?29,Z|j^!)t8nC&$c!4v1GS |( 8`%It<pO2@K/^Q24'zV[t b[,e-S:mb(71c I2bAX7l2WWT)}`E?2koyJ eO&d3EWyr7Ez]7'Bg:@~f[74l^O|P*eQC9EvY7@Vd0j8|`vZSg]xKgpQ@VQs&@ c+Kh!Aw
endstream
endobj
1522 0 obj
<<
/Length 3202      
/Filter /FlateDecode
>>
stream
xZ[w8~rf4m349Vl_lKcw_\"
$A|fxt\"90gxG\\Jc72:aBbmUfr29\"b6qtVs,OMrSzUwA*yx@$Q[Wuf%&mwGGHh^,woO:kirRg).o'z:Q7IaH6%k\\`Qn9yBpk}'\\WeVu^HxZT^,<'}Y,'U#.%Yq[n+[rIwp	WhItxSGP af<X[We4sb0ogDD,|yU6	\\pAX2	dBU
!,x/f'qNO\\s*vaFPjRLV#6J[O x^&A1nqVS1'OV#o*u@U>%Ld4v)+h`\"/GjCC'uUiD]~gwH(m&\"lCg%)p&<2Y,W,H'i^gm:>)C*ZYWQ2u/X
w(=>^|*>rLs>q%f` $I &)~\\jk1	6.rp@&HKUh{`u3BM
`woE^X;F!BmZf-5!d(hiQ 'K6T&X	b^K%U!+%FH I1J=~QzJL%=/#KW\"p%_GTlE^Gr4&:wG{R0LoA@2+qU6_U cCq=vxt|zINtbw/z.EMCo4O_1\"OX\\JqnTfVTug1P/%Nxn10nr-J1a[d'3Ns$+!Xr#sa!+lJWxyNwP@kHHx6 72
|-<&]$
9Aw!={EXF+8\"x@9T||.(L'-mF*zy E}bzD[CjfMYCL;Hs>45l
9 &K3f lQl	,!pyo,U$yQ-bP]V\"NXM	?u6L32fMn B3N)&rP:Qf^x$[w^<mHb9_(q)jSF?4<nH@w {|7EC<<Ojq0VE6L| xWr7zU`^wXU~m7dO+\"1X}8~pKkP9 0b;bc$c;`w:OSo_Ro_BY}oq76_ Lye>[1D(_\"&kn1xIoUyO'=2ihjoPA!- 3dh?<nGasbRKx|<kDw :7OkV<ME0$De;=`.	~r@$vxp.	2	Y!4<2!hs$P<YKaM'4U'Ot F _!bJ\\L	 ?;)`r'/gN/Y~4 S}n@Fn@$]d X/rEp TwOhbti_T0iRa*|1y.u:M$BnMds9ZN|@Z.3Om@))F_=RR~0%TGP7.}J{S77aCn)H#7g\"Sax$IZ\\b'!81zD`6,eul
XP
#!}# :dB5 CmvT
0r=BX&4HWR*e?[
R`3Y{j
Xf9jBu-YkbOCHn/~aFuZl@QT/>'xkdW%]uo+T!i_Z,0N @Sm)_EwIJ&6bS
fp~qey*rtujQ`u|_v34\"%xq*+P]GR_U4`!w<*_ea*;b[VAL6KFZ)\"dFmPZ9(=guQi9ewD4R\\7xKMa,wi)lF)=oSA7s!J2<>i3+~|u)e.N)`!W\\hM	dZw<gT99%OBEni@?W]y$tmQdA:OV|O8sJPQdnh].
cI86HT'L.qfvj0,uv},oZfUV<8K 2Jy.NL-K\\'@l=q1]]1@\\FS	b
endstream
endobj
1535 0 obj
<<
/Length 3450      
/Filter /FlateDecode
>>
stream
xZ[s~)5`Fy*d%XfB:$_],(k:M ^]8za]G?$QY(xKL\"mw?+g<O^	^UF]#vu~gUDZM#$	_fEqN!f\"&b(.yR(_1JK$IYic$v^wj,ewj|?O).IUr8XVY
_	--vMfW?Ebpb0b$KF6fY>	~/Gy?+7c\"E3iY.eU9H&9}l!;A^EaB'31!|y9d^\"Du,
e/
j\\F)<
X7p5Yxpc2o0w5p&*!9(hIJ`Zfq;j7!m\"KnN8Ni9A{An1D`L<2eS]ym*l4*I8+L36!rgU;J6	7LS8tAmgxVAA2}H'i/p~wJg\\)9$pY'Epeni*}Xa:$w'9!P:|gz,9| Se T._po.)A%twVa`BPET''^l&,&=ZjsR)#[Bsx #j\\I-4,r=^?4'>|qB}GXaHCkh#5b|5\\u|ZB31N2bd9>7{j_>bO!\"zU8<$>}_
Ckc\"gCD9|1A:?l5h\\glJSV VR)t`!g1(7N.0-`t:@r' m=~9G\"dWN(!Y!xe+O61=',1F>u''Cfz6X wBM\\nwKe^2`R|8E6'rXlQ$3I!(la U7Lw+@,1G]I'/-ZZ wYS]hrB~!gj	0z]!&Rhse1
/l\\];A9,8L6{g*jV%k?50?InMW, Vz$iQor@'z~,A1meQQ2HX5O~<ei0`2\" b+	-,aT\\eKvu#Vb)k8x,DzotqcZ /qV>I= 9bN0xS?GYeacOSL7'?.8w2VPdSd lG	g~}>4+W0JxUgG~1-g$3q=EmGw0liQ;qAZJ;*u; 
HY%|U,1~8f+f
XI^S,	yl:UIT
!	I2<dO)a,C,_,#q22PN71{8ic-ibB&}-d4c&W:!H7=E#}1sv(Fof @fqxoipz=q0*g}|wq%QoqmbpYv'v=72GN|fK?j,\"X&\\!om>v99D]'>\" =;
,P|#-0@q;%Q*yQPzYa{#}aDc[<g*T;_vGvR +bZ?TpQK!6AB 0DEMPJ<2PE>E!kSKgRcJUvh=$\\A]Y&ph;WlwrfRZ\"d*d@*6K;K{l	DC+*.bi$R]Fkxu|[<$d <elogHTkODK+E\"BSY=`#HH\\k{uc1.vJoJ )!!R+:,9EZ aKTVhHYN<!Y^w~1\"5
p$+te$8IQC /zLcY3i*8-s8:k*<+<U
8obWTd-ay&0<^v/]!^T\\Hg
T>	qfk/.2EC\"Y#Cb}l6.3	.	D${,--OytXs$mJ.Bj:(Rc4Ov	1Ri8tk*u/`?uO$3!p^S`07nKVW(hSCs1tA>9hUd2,_4+;,XO9	C]3#`nEjb_d$m\"F98hC.NNFZ&Bd2{c	1b=+fLzBC,[fK\".8	 y;Mo!Z|wkb:j7Adf(qaQ#0+[E%Pi^&btpb
@(OpbE%F3q{Ng`ICk4Yt9WKCj$\\B2\"m$LsDe&Q0Qe#d9 
C)lQ{y
endstream
endobj
1431 0 obj
<<
/Type /ObjStm
/N 100
/First 1032
/Length 3288      
/Filter /FlateDecode
>>
stream
x[[o~a4(QR,]d]>Mf>A(Qg4:@a 97EQp`hiJ)4i3=<dl('Q8>p_)x'!M>H='WFd89}wIbzLhA(s:zN@c,F*vO8)xGRaxxVCPULU1LJl2(1xCyd1W1ZMSlW1$bjR,vT:+(B&+C	raR<.H)zA3%I#\\N0AEK^*!(1PKqLT'dL[L|$&@$<fco1kU	,g`$D6s]Y[,/hz5Ng,Fe q,$\"L	HG\\h5Iuc*u	w8U:fM]@/5Q*\\lq	1+pV_>GqWoq _-/vG-
<Fq)d=\\t~OO//GoO;<wWo&b3(`kBQFv%vr=2C|wN}v{a@3S#qI/'Wo/;:%;B+6AG8JvG/X/
H4ppqaBva+H b3)lX%MMF%.{){#|!'kS @6F UWYxX'N-{W1agx*`v_{D,-EsZ`T @TF@E|l}/ymg8*Qtn~vy>ggX#sR#f:-{6-?>W7[_;?0o.?MU
c75+j6~*h> iDhDlvsnDiP#xug\\.5p>~TL	s@9 p?61vb`Le3i gl& d1c /a-Ro0\\!+v<) \"bK!F%7fK0CM e-RPO;zA%B0- 4 <sV6M<[@H$r/%Wr>C6%G,!4#LE3N's~w)\\<99?,!-ov'.D~by[-#@x
*``krBxhNKl] ]gYvsb?.ik@b>{gY0eh As xd!+V)-<gF9I n$[P'r6#\"0wCl2	m15@4B}5?\"ed=' {-~	3 I90Um\"`$P0F<5=&_T,pMl9[<y@x	a BV})kkPy%SHVcZ))9A\\:.VJ& 38Ej:JKW2 8-.f()jKKcFn[J-5Bn77^jX/mg2rrCm[zkj/[n^$~B_[Y:#*7az8@V`)o
@n$y@CO_b[5)#0rWxt76DN7y kVVXS W'Y;MCCZbg5NyalGen3jl	jdP
p<
Ta|(Ty6Zm+20yn ~QFypvo>QD%/rrZ6vZ%,twhZj/_^n`37l<&'7xrh^`nw1;a9 apE~p;hCqg[*Xk2h2_f`xeQd}M44MIKAsYg !a{
Vj:!8BlC	)	au I-Kc
yO'(\"fESF_#\"ubv)kL|liyRSnonbkb::i}NC[GDL1oWqRX0i86
oQ`o8oWPlFfk>j0@*:{-}V b[8hL%z#AV7[%b\"~m\\ay3XU 	$*a}v?mO2a}r>qOK#c#ylSrPS8Y;]hLq!TJzZfbs:FXX_5u f4<#h;[njh?s:WDr6~ `a; i%\\dy]D+l7=0LXiJ9Y,[hHk(#pbrl#g$jBHF
eM7X|C+
X/{79e:l#+]EB\"LC>PBXV [RegXTieJ
endstream
endobj
1550 0 obj
<<
/Length 3263      
/Filter /FlateDecode
>>
stream
xZVJ}WiX+[j)o	'p5d[J-fxTjW&,&EG7/^$i$i.\"ad+Td&7wYWt4tp7EKvy3deS/.2J/9{6)Z(t\\d_AIrwGr,t&L#	A@PP	w\\f-o^Z Qk3y]&/X^N_@oBXONik(M_/\"zPSVD$??68do*K~9f}_	n}Y/'mCz(=*:3N\"U;QxX=sgwrT'`R^fPe-$&;zSWm_v^'\\|WE!r00:L3#2R;?wogcbcs2*$,	wyguTHp	lM(B3?0n(.Y8	i(}!CjaT:4Y<%5T)BJi2~ai#g=HBS[p[c#{uD IM*\"R.j*	A-'P#wx~ ,K/N][hC*u; z.sZ>;Q+0tdvi6iL2]v4uN-u  &XjXV7Qe\"4]Npp. K%]j;S+axc0%,N1%A0}|pBeC'\"e(&iI	qh&NMCVkQ:O<a@\\9FcgWJ_r5w.E1s^Y-O668:16yz]( =QLE\\ws	ZMpdns!aaL.}aq	Vst rne&(wkLNi98ofDT:_Mv7\\'Jm4tTF}OIC^Y%_$uk; >O,SJ6Y<5[<N{Y,auX2FS;xD.=@ /8F6c,'
 \\Q!@jGRtdil,i8y~,2%7v,v-.p*v(K|vR+y4UQOxAS%g>%v@`,ZP{6b3:ta{5']aOcZ!JfR<ftu0h=)El&P(*e%h<vpQ
{AX%#aJICdh+(i[ M( Q<7RF4buhA]U>0>XB<Yu}}Y$
vu5Th-Gu;#Z<+}s'gB1|t.O0#Q}RomW`T8 _;vYsG<)A:k$E9@,~I(V)E9Hz<]P_Wn O>~]-JVUn@790?,Y;$+zb]'PDq|v,naf#J\\k6X+R?vSDFcrG@
DhKQM$&6>(\\sC3(\"tl35.o\\aQ7]MaY]QhlU([#p@IY3}LKFs3bp7}VU=?oN&'%!W9A8*Tq}{] vBW#H`Vs:.(~5 e??1nh>.c-}qE4(0MFTDOy}	Z\"1%Z;j9L)c)5DX5~>B-LySX|#mV6BQF4'p`PPkNv0lQm4ovj(fk.?W (\\,km W?GEV'|eba<*W6 }Y	zx^	> +v 1#n27i>}H}0kX?l]y6o5\\I@])F*;NnG+B^h$1
Nl!j&=>EEJ$>K.)Yl6 =~[,Kh0Z-o]Ws0%^38%uiL:u::$[n	q3)xt!^q`tOd-elDwZp\\ECN<| 309mdM@f^wO\\m ;:G+uWI{\\NAOFe&kY6	t>5*;GmZ`~'g~n(m
y(L[bKlQ G2	C&v2'WWlK~}'GW}?H03^j$xUi1!6I0_>yyF\"Km/nMZ,gg)#xs	-W@xb,2Lnhs7	khi?6opS
sUzsRb&Tdy<3J&ua\\?0fYwpaawuc^3Il8HJ'7/OdW
endstream
endobj
1566 0 obj
<<
/Length 3504      
/Filter /FlateDecode
>>
stream
xZ[S8~S-teev*SS;`xIvo3<`HG:;GGytHFD&`\\H(L0xItSj%?w/:e2A=&AdLm	<)Vy&?0v32/fdtJK!TFO[<fKjY?]\\H}mV#JQhXQc(,<2-bE49Qf/qO7[YJb%kSJ80tws6)WR2
'79kA\"B	KV	;L
9b&S-e-fO%Xf6%9}Y7$R.]cLxKo|<zuL3Err81*qh+MI`:/b.~v(`C>WW~C4z24MG-&4dobGhuyfe	bpW
''6x?7u(uW	z%OYSuEiT{O(w]QWYdiBY1Ce~wMYW+n{%3Fb:kGk \"\"ZVT9wQth;tI?HkvQbTOrDqG[bw=)2[L~$OG0pXnXbyaE2La5`dIOMQazV,zwhz9\\Rkgq\"X6\"kV-,+:'yU-_9L\"9dL~|TQ-K[4+*HVjCG Obh,[n5ywO82(JKoR20dp=X4IcpB?e<>*3Bw+Ok4G@l!o440o?1Yq7*+>f?as:7$hq^<B{\"v{6acV}VT^zp= wtYb,C~\\/QV!SXd{uXYc2Pma:n/.o1FC@Lny\"v^xW;[xW!k_yCPWTNF44(dPcUw{?\\eGz;j+*'m3dC|K
Fm7X3'Vj&FS7u%h%y\"noLD_s[o}k0F2lm_0FCItYAtT/fqQEh9~~jC|#wsbQ5]vVyi5HO0(' T.2C^#z7w;/Y<M37n7J8isR0} Uam!X-aI6,u]M. Tc%,aR%,jn ;8.@v>L*/kpc,z N~-y9&$svEY*e	 roea @~\\]<DDluWY1`.m.GXp*1J3P]e!yw<]X:xevV21,$.W\"!]zx|xk6<og2kyt|{b\"P&In/kS1/v8I
K,O*I2oJP`C[*BrPT1B`!	2KVNMSZWQx\"M,CQh/W ]lz!ytr	zPTCI

 ]3 gZ,r%-&Sl+!0T&\"*Rk hS.5;wbEdRD-D|(4|IhiJ8.l^gB cYw~;\\<iMsF.piK&rq#fxeY0i^{4W~,i6 1+S^(JfrB?OxH~{3?H?S+%x|vY6)q=p1QZYAuUiL:21wfkQL9Kt83)gG6IHh]8<*c0^2'UU/d8#U\"CNN{pHhwE^?9!fLF,J]\"ur~`][rl`#L<Iec%3K}]&wWCB*]2?t!dVq!ka0z\\vH'\"<h+,]!iUi]vSqpe-'Kv6Yb[qXz!#0(^uA5SP>wJ7N$>19#9PYa^N.]W	@p}9?!qm!^;wZ>.{r	/0z}OPKq}Hj#6	zYW0MJn6 2 t*7Z{e)[`}^!_Krs@]zI#2 <1\\b~KEw!W?E#]d2w_X!X{%Eb79 =x*vnZ8EBDq%#|wEo<SH*?I
|}e_QjP ^zc_HE\\:lVe*D9yY:mk]`Z1G@GT>^Kq /Sf>@^4x	W!w[T(,5zr~odbwtC1~bz?JW!IIVoPx	__|% @PT^4?Ko
endstream
endobj
1580 0 obj
<<
/Length 3670      
/Filter /FlateDecode
>>
stream
xZ[w~#udd[v+)`%); RV/9 `Eg5b<<1B9t3v :B	l4?g4bapM:]`H<}{C(KuI$y{Qgx\\)B-bjk5Wlu\"&IaA=C@'$xMSd2`q}vGwB2/\"-8_jx\\e{$+.A+?X<[=gedA:uk:\"Ea2qtezx%Rmw-UjU&H$;tahC>}g-40tnDcd$QZS\\sGTy4M$tkzD1:r0 p0cU.LY3IO`!Tac*Ald'y	G}pc< F>~TXO0-AIoB!BJ_Gm>aKO7_QCtxa7r_KmHh|\"JDdw pyU,7=^|{Ap;{$k3+rJRLb\\.z
^LTo^d/dLfTd5%-`lVK.	-<&\\6TZLs\"Z.8k^Vf[2H>gr*dk^G`n
UB
 ||k,8A$akqV/wv+lsHR	8vM	32=6'ZEVju
Z]cHeW&U7m	`	_<mY,7eR5mi048wZ4Y G\"*p qypg8)	V6 1yLS>FYF	p9	$Fw%	Z+[A{K{$s\"Z53ec1_]6hacqkB;	Q7BT'l{~[4Z~*03& c/ygI f [0	NXOsA`mWj	BDD_0< \\waemy~,)]={7r3@1C4jTCRaFRYd8]W rNII#z[We-,*JTIL[s6ITs	8f;~eF>2 nT)|=oYEeD1FSaL'F,8(	Bpk'3 ws b) n\\<ZF(G<)x K\"Z h;CrWvjDN8\\ T,6;GS0s-60qc[Zv/Gsc1W.jlzA GklD5`3  b^ m#WH_L\\PfMo{;_:m[~w,-+'yH Vn*jAbX^s.nLfq}\"iEBu^QW* `[Pl}5	jUzja.o|V& BD}a!D::On680KVD9WsT<tlCcY#)ny&P@LK{D$1
+<0!mo| o{T6g3/?&HX	jtqNZO;0B?$hwBEy#^}@#p$ hvU`]BVm!/[<#@TZ<hC*)e,{~@t^GRP1J59d96t.`TQ*bI`A+j[n`&Xf'
z1Nz@\"&>.	I!e'AEph!2 CPqk?kTL~-l#O\\$\\$pH#||edD*OzUC'ef?5YdUQ1K'd6CsRf4{GI_`qa]XecWY6>R	\"Y#}:Oi,r|AMu+s=.HtU~w ,%ayQJPa;7)$eZ'gsBth1q.&H
VHYSp)~\\
7_Dm@7^V\"6\\t(SR.IvzZ=.JuXi~N*_\\Df)2Y1l*^g)IaeIxUN>/m0I/t**qR-dGgO8O~I~{X\\L,%d	~X0H_;`I%K6x)6|2 (N[2
C&7P6w ng4/T>r$O2mqB]x%Qq8u:s/q]U:1Le:(2b m%ble9}{y|4e! S*<,
!dU:0|UNgmJD
zRuS=oam4]ZJjw7\\cKff1gtn*|lR	f9_hFZXue@0&?5W	>D}o w[Ol\\w84&@?]\\3YLaf>J2A+65rB/n|Gi?	BfPpST ?	b>o>/s:ot3b#M?G<?>]?Am00tg`&	b	[%
endstream
endobj
1593 0 obj
<<
/Length 3741      
/Filter /FlateDecode
>>
stream
xZKs8WHUE0*[Vgb%)#2g$CI_ (DE\"A4_'zr,><>0Bo0!I4B',
Al=1<\"2'I>O<;DG|J\"fI9	?fY\">PbMsRnK &_4%]%8:#:IZkz.MLy7'3.=i*1@Kd5siw\"-RQX&,}2u4YIy=;e>.|cQ?^JZ8(Hfl}=w&  Vi6V[7=JX]deXQ<\":mU1K 7a0?G#sr+I;ieb<-Ap!}bUSLq{b)%ZKkJamknD\"<62HG=\"!ArXDq[uh9-jT> ;rV4|DFY|RX;`(3=IBycoE{Ml4=KZE,.&-EAm<p3[,ah''/A;_mac	s@/E>7]8e/2?N@z_E@o\"|v OQu1;=.gl<nW`i` ^1ec@\"_`cckW}5K\"%&}34;7iwU)Eb9[yMI:}V^R	?CfQD@;.8P>lUY\\hJtinXC8cui;IajUL)^[mZLyR$@vX>+`k:U|[
\\ ?t4
pk:|xSRZw%\\j~g'Q&w@slxDp@	o ^d$\\
p,=
t'phZ&yny2e$Z8\")N`&F/8Gz3P<aA|S'bmstc;}k}z+WD6	8ps/`3.b!n8<>39# {`885P9K/He\"G A1CjM,5GbBNd) 83}*\\_1C?%sXb>cP>~H `?`/S?tr1/8F<E=*%uTa<4OrT CvY :LGy	0gy@CXhLyX 1U H7qjnB>%>j!qET@	)n\\'85?>$CIq}@*	&@0+^LLxQ%7qC-}RfnKhU\"-G3RbC 2yo5bVel\\2,_LPg<7iC!6UEG0\"WRz(c@7:k2~Zf*FNxob 7GuPR &pp')[4L[mMYOOY=Gb5[{fQ	7Q.Ww0'gl}iPH$?#Fol4I\"l1tYT#T[&ci2DpJBp_jt-\\z_n8l/7O(-
ad#6DHSSL}7]-_FWO`oc>NC7OeXg0Q'EG2Bp+g`nXt;b6A&fM8ZX.4B@bSyj$Q+)!$VNCHoVrh@c>g[yj&6lhSuHl&RHl^9[^lb*6 2nR~1g.E[6vCXoW7 5[ou&P0Y8BZeK`STRh`1VZM(:c
M;= d`Ql#($c.{'+_,3.S2>`R.]X*SvB5N[0&4-OU7Ep|LB32 .qzzOOQuL_9&|u%|c](q+&}-oI9K#NI_\\Pr	G*=U,(MB[Jr,H=BgCM[\"Zx]1S)IB8.K2Vj <Nu!16t%+L:2_`eM*k>~!~k$+[nhNo Rp;.Qa	Edc`\\p')3i3c9%*8
,{+:2[wXjUS}N@j@d4	dE\"_#N@$q . chX>:s+:m`VGl5I!A}>oN004VMuaH L!Q(1	UcwqBj`M./-e2YajQI7_B]XP'|?|hY'EFHWX5n xtu;{;SiVm,aQ 0y&-%3\\\\Aum_&V	&41#Z	N_3	:<xBa).A
e
VxsBk45\\F7=K!N:QA^\"XPq\\BV69lY!!
$5yw5e$uIb7-9cTH-%{J]F4Ffn$# +k 7u_> c,'.o{w
b^kdM6mgwymlQoURz.\\*6]1x~;%F L@22_3;M@!?k}w
endstream
endobj
1608 0 obj
<<
/Length 3204      
/Filter /FlateDecode
>>
stream
xZYs8~#]Bpnm|IYLjwKP&F7%Qlg^4@_7,G+*>DH,O#eH(v-4xdNW\"R<i+Uuxy5/jSL;NM(UTTvtw	U9orvuq3>K-|lQixq+
$hO|{6+\"yyr5[h/h;	SBT$n8U\\&bUb+b8XE*/+y7Mg[:=Sa00j3aF:3{ PG`]SP&D]SY+ap,Ay+45E^cZHm_@v?tI@0	=G()@/HIT0+XhI0n:Ep2Pe&S$5fuf9'}w$yO! 7	-mdt%.Sw-z2CEej4psw^bs&N|1+;|Zw]~UgQ4}\"'p$A [e N?;fag[PT[{q
nZvPG|_7qV>o(8UX8.P[gs\\<$
ybZZ1x95\\LCz
;!K!6bp6#EwdG94&?M#kaRyIDZ6<D%:w i?cnYUp?_j[_.&PHp#qG`.;7]9,KgpL.\"}kWC]>V|gVMmu_j*gLh.GnI]1[&FtLg,+eI M@f]	NVmQ_yb3b|().MHS`xMhbd#H\".-
buSP<>S{~=,uDf6a)&>LIQW&3t[--e+P}'1fD;]>lB I@'5@xJ:npzK:!G:Z<,MzqR_c\\c$~]/i+dpd?l7R,T*%ZJ~p&2[\\[Qay:[LfiQ{g)H`[Dw%C^snk!N3+QowI@bh;GrYF'U{mEt1i3RUs#/@Y57f|hBYB/H=m Zmc@s{ XGP&!f1J6tHX?^ da(py4?@M0q;nf6L\"!U$Ip01` @8\\{9=Hq C)UboA.d{~u^d\\* &2paIyxX!~3ZRXu @i|&c*IFb'q-\\2;/xYQU0:QoV<D\"	VlbFTT3wOs{[|pm53>ce
5v4,
XQt*V1 BOB*iltW|f'V4='Ro78h	aceq$][6]Sd<I1z22q{nCy8h;ICjPme_$x$<KWVDIg>$IJcBz.I'*|%%GQ\\3BN'1O<J 8X]:19~lV\"3/\"q.v[q3UCeaG Cr:	- 47R 	hn8eDx+,BM!u\"0I='Q E3\"\\-	tP,Y
y9lm1Y&pBVw2E^kI:-+7~L
e%X.$*XJj\"LE6vw62L;\\[C* 
;/[bdCB	/^M*eo<g#]K<gXpOd0q@}U1f ,d]vCIARk>+}&U4Oz8mQ.UKUE 4,>R.P1\\`3Pg:xR@)h&b#	,dMo=}DbM9KK`5~,4	`XIh} 'z3##t:_=i8o_J.RY]qjnd|!x86N']j>/~?XPy;h3APPD$Gf`hTc_\\T}f/I(nMuup+)b.)8|CTzL=KpZumTqOzT2@	UW[`] oIML'7S&b<6nl:I\"yq<%x0I_.h`{-?fet.u~EYS
endstream
endobj
1623 0 obj
<<
/Length 4026      
/Filter /FlateDecode
>>
stream
x[Yw~#}fDc_r=DPSH[y1( T'llSjy9PR?ft30}U-oxHYQ>'C+ir^P3>ds:a*\\)':d,6k14h_2K5oFiRFV${crc+\\EYg5T5d02/c%o,zsEcadk! 0Ceu<<U  _y3RQ`IRn=g'h$$I+Bw/)p	22yFe4zUrEQ*
,I-TCyTA
D2K0u*)JafYQ 

-`Xf:J<)	O_U	
g-K?iX` tJ
{}Z6oc`=G8	()?<]nbwDAp%2 D*:^Uu]iv@4rF6L	r>&U
j)1x\\\\fO#=uE+nejTI<`\"lt\"@agh<?'Fn#FOPV+n|u
5Yd,)7IE9_`)[g	Nv;p8PHt_
Mb)U{M]LX} 	tg(B~>FR FFZ1V2$Ox?pB RC*Qi_TqvEwXK02B|q}%qJY@r<.kq6X ozhX
),9H$:VLhVSm5^eF2t
~p@l-y3[j|m/1*bv H'8yZfww[]8Nq1=./G&9DXX`
E0a{UG
Nu&cl v0+-1oQO6tT+?:te!gIT]_e+s}1Q/$4{mA-;Qx{+436|;VBc.T{iN0QI;R)8- YWH.$!DlG%m}h4Zt1:qk|@f2a-Z0ka=o8Xt<(&]H0+(rx-jEE
KL=Eaek;*&Q$=;z>dc%p%	
o(x4v_cWp!J)>SZ)8!tb Rv3Et vFX0
440w-Trhi^g9`N5By&=c4X2
p6/)a=ZwRv*q}.rgvMVA-,,mb^i4&Iw4pe)n&
n0I|JFEl;c0_U=1C9&^WXH;Sd	gK90#0w
|#Jx|w;qht)*dB.m^qK!?L	&{85\\-\">j$^{-zma`E3t&6C|;qSc.#(Z]g_.$w;Qf(j<b$Phtrt$a/m\\KLWK(o{?`ehP(W.BFW]>SkZ(7x<s
\\mydxpFU&gcA}(AYidBP#P%\\fk7ZLyKG}Q8BTGVC84DYQ%:GE3c
x|J<)f[#.'
!,&,d`&>b`P%yi:]Vy=ohtEw',:\\=	Bz{l`x.zdftxL=NWHaeBEtbutA7NB3t01g(}	|/ 60HMOpiKP-^vQiQJ]Hr=:Cv2F9I+m%mDjB
1fIBe![cQ@cCQVP&gQrX.e4N6
Q{!lm.9_VGIN;\\>qNb'~jO8o&;P~>[5 LaW_%<]!3|m-'	ElPQB(.h<$_|gLXnGX9ZmTM2*Vl[$oEuD-s>M/eZ%ul7F\"[/xC0: 
={%A	rN(CMTz7$%+DWi2]&inNscfS,iysL|&) &qHL h
\"!qyYg_rvP.\\NJ`.r_WCMJzgz D{(G>_` A?oGf5Q_Yt7n/Eg.6%5#Dx)bA4w_{(sHEMwf|slQ8p2{xiUzq_p_&kZU6;G\"UHa:).8Bh<Uh7tMy~oVFH1'$,MEyH_8jZf;;P^D8N]R`4hy:8CO3.w*sf;fOI-h-Et{p/D6|W_|RNg9NC:i	'&7.=	@=}~}Ky1J7:S4 RG^n;!,!{0U0W?(#
W*olyYFP<aw>/Y:<r@cE4%'&7s<WV&A}J>(XSW6%IMQm\"M}YTSNs:Y?u067 |x{b.5<|2u|}\\@:S[t;?9.N2r)nZx7>uWUa!alg
endstream
endobj
1636 0 obj
<<
/Length 3419      
/Filter /FlateDecode
>>
stream
xZS8>E>:U%qWW+0@^]y0-6!a=ZV?~6:s);Ck`vX	Atl:;FQQ%94YY~I+$y{7V)JGRQN~6YLyg:a]Yy:mp_*gP2[=!x4\\,y?.SY`[D?=_0aTox7KSD7]ndl~u\\(KPox
~%UXo.oTH 	1-'5<\"]&~pjDMf[XQ8JFWiWh)5AI3bAioTQS gy;	
d<7=AN-J1E}KYX{{	QNeOISC
4#IuW  bA_O,*~)tM3\"h i/ot1MQo@|%uMYDA*t=>YY)6nd@M+:pTE58!8zL&'P&`EmB(m	Ht6m]r}*d7Df2SLlWPibhr 3suY =zy@ikv\\]f{v]=,mi[V&J`I=E!RRsb4M[#'1<+[UQ=:FIqG>G\\Vi6a*)WIQJE840%-;Il?* wq\\dUrj6qD8_! ;4D0A3Z<_vmjCc\\5U6{8dy:	I5LubBd?0:k;i!VNZywA1c\":Tjc	M2Q,gG0q&A34x<oY?	I70
\\``DXgKE2wg\"!XI`1'Nx%DP'ak
g' I2[bT5?6hRQ7]Yw q-57c$i96{ /8o s[$ uTnp8t@s F{oY8v~80XdS=:)m^[HMK?vy% 9W&a
BoLOWb^2W`k7)39`&KpAa@Fvb!A%m\\s$5/9x 5':jgG(QSes,bx>#yI~9H,E\"GE9Mh%s<~y\\l-VH/h8ON'b9fIRzxR,C>NBDA^,LraZMZa|*j.D}(2 HtmJLt.!Zg$t^-Az\\l8Bd8px4zHZ#z< b-g=V{C*tL	4-}+Ihv&g{Fl=q@nR2 ]A\\!Qz,z;P+!ae^_wA.dI@\\n|obV&yGQYOAA%Q6e_eUvX?u%	qnrBH/dpOxxv=r0S<C,AU/}NJ5g2{>jZ@sEe|`\"nB\"kQ4K9rF`\\7)C3G3|QGsQ2yjgbTp4_syM|x]Z, ]Fu,)AU.<	@_z#2S/ >pej&[-LQ0?j7sjD,Ue4^qh&j)8{H)x=	V`e(86)\"FIAuH\\@JM~oX4YfyB8D s0,^gC%g]N?PT\\}olWR..n DP0 =shfS 7[
5f`baY5p./Uu_])4>7Yto0? F@p_UMKO]$)[`3|N4iHdRg
!h6Jbl.sj]Xcw\"0v:*k_F] tsk]{hF?w u/''d4	buto@[:_:e[_!56lCimK.|W*|wy~\\rxx<7-vKi$'5	<BW
_4G'R%xt=YVv1#Xs;pkC$qc5#\\2#3Cy3*6C@'!M^z*oE+b;*Nj$oh_L?z\\q1:C	Q@q>.'e[R 5GD:mA2pXE\\8L&>bX_22 D2|a<sW5w<$T&}.E\\ Z5+\\dq.A5lxySxl^bQZ=|>!w^XZK3i\"FYtdzU$_w\"EePqF5	S/7~_n64,t!3%3BJ00H4K';#*j;a<iZ~pR{q{$2O_$7X
Z+!G*P~iLGey.> M2%5H^;PKwn*
endstream
endobj
1537 0 obj
<<
/Type /ObjStm
/N 100
/First 1032
/Length 3327      
/Filter /FlateDecode
>>
stream
x[[o~h$R4X`/@-v}M.~n(\"?RTH&?D2G1L):2S4)D=9cL!}d|FJ4Q }DqhE1b{_p(cWd0gT$*X;J)hcwSbf{#50HyJ/	B:	~JB	yI\\`FEPjfH$1H4^rPW[Su\\'	;a)r[$rVY)R1T(v4JTlHP[9 kE>K-^X6
TcuPc}2Vs0RjB<^j/ZC9@JS%CH&m@>!00ADgdk\"jOlmihDFCFmIC2}j]J@mbT\\cC,`4k{j6Y7>Ui]lUqf5d~L%bgq3-_]-_m0|@W{#trtlC\\NM,hO/._={VGX:<>;]_;rt%xdl{ afH	ge[*2of\\d!GX3W1%H<v2I&7R:M@Xp`W>x*#
+8z ^~,':X4Dw]up]&DJV3;(ZY.`it&a_%s|8:l933U%7`!Ad~z9-;)C0?5~~vz9={6-alk}y1s?df/^go0iyiasu9-o7{7lszyaDvqb]o0*eBY	b{)[w}.xpk%t%R*FFFFFH%^=Ta $8G!]cyvk%tv;1!8hV'_ <m99XglY1	,m9<N3o>XJY^Ohf -MEa
38& |+8Ep^s!2w'$be7=\"'P/)@1Dy+rr m1;:#dMo>aC	3e*G6m!jDQc4} >I$2K)J%
~& `#rHO}bn@@40I[60IIpPZ\\BqLBDnhY9%U#p.[Q7>/ B\\ae vgX:tDWO:Hi!_Bo..a1/O*Mo.7Voh~7 8yexRcy)W$vE(DSX	B?X'2ZZ#3Zp h1GI0XP,2=	3b[#9q(:  t@A54Ap)Ut'\"<ka	~}8$-,[<ov6Xy%8;Pzd:3%y%|y.wg[Mjt 6I=ezt2JeYD,Hi17-AwmRY	+!~DXZJ y=[v6Yak3A6G9kR5`z?:(@G pedAR`H+Jxa_81ees_[>\\.G[?*\\%=|X(`/FWHm=pfE$V,5-7 |(z50X>
 g74~*6n_ZSvRyRi^IW*(;[h_#a#C6_jA|M
'l=Jt0C\\'OZzA);)\\z,6ej%L5,.K5I1TZ8d.Vp0\"w8+V[m5QfNrbv,_hw,$g4Z +BZNw~yF]7,X4Twu	\\i_+X:)<J[P8l#IC08p>=;$-!CdBs41K(J)PhwU>:jlhCzvYuJI]P#/rY|xrO`$'1H>!(v|}w]ie+gZ9Xz+mH#zc6B
[}TxKCP5 sO.pJ-LuX-Li[v-yPEq
Z5o2V\"4Z14wkt9POFY5hL[2] {dj]/-HO9=@|svw4\"74B1vi@h[LK,bMx]cK70G' ;t#CA&KzD {k).5-Zf?8+'qD8k7^2INQ\"bNXemqp\"NT-\\3Av/4`2kxX/zo2B,|{BaTm[8.+wQlb.~y{I@]'>iYjvUJ$3&SN[Ih}f1`ejTHR\\2\"/Yo\\lB)}*aE }@ozL8hqc-)Wrq[ <:y5usx<W#%`D`<R\"\"#n Upw=.{?_7
endstream
endobj
1650 0 obj
<<
/Length1 2121
/Length2 24685
/Length3 0
/Length 25974     
/Filter /FlateDecode
>>
stream
xePk6]wow XpKp`yg)
k$UVe1 %A.L,| y=+(@I)4v  . %SwG' /%@
htzWL<
@c5O +/rva41v~W-.b O'+K?1D-56;X L
L E
@ -m sP*
RQRWVez r?.bjR qE5	 P @Q]'w	55me	V?5 Xn@'g?i;3]@v% X8133Y:0,lfip9 _joNK	@h$	Nr{o28/_yeey`hF/@
V9'+5v:{7])_ s+[ffeLADQFRBUQ}@grpO<qy> fb ;w'n''l=Vfnno
?w2 t =L-kSY[ r :}/n@+F 3+S%?(E7x%~goCJ~B@ 39\"}h9cKVH_+c;+[M4g+gI+/['H9}_K`d.\\r7[ ,_F 3+{ '}89lkI L w/g\\ f?!n ,70Kqx# {L{L{L V ?{{yMo{Vs+@N^?{vvC{m>8A;y'w?G^9[yK'?j|';Ol<.]t/[K_X	d2{DC`}?J@oQQ7#^;I~L\\  h 2Ni\\'?UMt[HK6j9} W<g 9  $/h_EeT1ycIxO EBd,[I=(Ca)P6;Oc&5>v$+^Y\\h9&L'[%4pGh^eYc0=]h:)yjf0U=v4HUwXK2_E\\\"'BK2mW-`f4\\}
,a5	Tciy:MHp~MB*~]A|wK/(~r?{.0A**GGa#1
EE
I}?trL|pBb_q2W	}+*0Hw\\*oMJn(<^oK	Md m^{oG.9|>)%/%'N{ydBk2J&.>=6K.})
AM\"-dpg8Q<9xIO:'A!\\d_H
/L[Tu{z)}6#p:fzo!WBQXWl4ZO[VHE~c] `r%n,q'[4/[d8(WRsjaRKGm\"9e^SSPs/2@wP\\k)C'vu%nC:WW/[-YHz(OXyB`v%wF[XOXULu1x.SDezaY_@i}H7jgHnu7)nWS!_=bt9!R4d0Bs3UcU%%N3|>EKE5^*JEx tI~$r>yr,dH?6U1~T'{w8VDkS]U^:lnKt$Y>6iK^_u}dIv;$VL q
>6CW!T<'pqT8@=i1d;Ft=2qV]i)xI#m[I$ZS;iS~G}fFxi:Yp	,*2W.S0,==alF3JSN0$J:_XajV7nc}ps8	-$
CK	q?,J^7}<C&+<AEWdl.s_*c=6.2=C[n{?kWe$'sPx%TVS.HU)bxL(4c4&>R{D+dzD1Y+bv4~;$3q>V	G1
5jX*Z$m#CEFs#+796M1SN}s\\,!oSs_c'|2t~Y;?C\"&1~$u?79
4,4L/mj8i9v+t.I&.M2J[XGcc0j{WU\\/d!+s`JakV5_b`u33QWjqt%8WM/9l9&xpqcF[[(A2}}P|l)

Wd#C!?z=Uqb<L7`e&WQKe0'	ixNQ<9DfF5w6v.G6O\"I0vk7/X4AJ45%,QcdO\">w^GOeZJ&<G*]`sE~&}nvw]yf#45\\KC5|f,:Z 	^}H]iLu&V
89FxnEt|3T]ju-wmiZMRh\"l8d!F{16[Q-29V:)*o:E0J^qB
6P v!OV@i^	<tvxs\"[N.8Np_{!EEb F0p[%K4%G\\I%<R	|AN~T,1hz/e%F:Nx(Kf8gLoC5y\"-QZAxyEt@^7`e2^+)~37HD}'(`n`2..6ad]H,}
$Xi~u%cM?~5hQ3ql~[iE4A]]|.~'?	)*Ws-CSs,}RJSodwpM IK\\;Z)Y$s}C8ol@^7)9-!L,Y#56sn#[A<eF &&%!f$I7>/sV@TcwJGl=NX`Siy8UhEc+8j3}|9J@@3vZ}@+[`X*A1q }S9j;aNLARe)LJ+x
IY~!$/i!(R9;O'bm$jQLvI{:Z_gXXDm6/}%IW[hcrm:\"PyCP7*&<e+9Mb
kXCKI~x^2DTh\"b2x#:VU}}n=:WT=(@.jG{xhin^
]xq;KbH.qxj9.|!r)c%&4H5HOl{LSirlV-&.Bfj@w/>h L<ksoG2{b~d*_Tz|=SEM*ajN6@^Qb6'bVN6!
j@zJ[B1o@e9s{L?;f%+xu)
\"0%VtB~z93hrHNY,H33h
{hMMkgpd:Wxp+ ZbRBXrC7K%L-S!PV'G+^_p&#:yvYa.qhmui3f{F	HDt2+Vl\\eOn4Bo\"3=eCF~\\3NpEvxF%YRcvH>(}APKL.8@\\/O~|zYZzX)r~vw+7_u .<cuOpLV,\"J?H8%+R1 ;*	Q5h!pmi\\`62'UV\"y>,8mCJrw;fZ|*OrVT!h77mf^6
'3Z)l.|f>YLr=Z3GOQ_`@$Ou>bYwq7\"dr:uTy= b95ih3S?S_euoH	
S<2NWhUufAmC0TP)'\\'\"UVLy0hQk ^b<;{uB{S_T*,e_Bz.n3>/2
b,y![s<E=^p5Np!!/QjDU6B34.rH`jxF[+vVhbMWkMTcZXg41_z~X<3{]m?$n%\\L^-Y.+y,|ZH\\yl%cY<b{\\7E24SAn,w*k7n+#nSN$+v]>Pl^4/X5_}Jcb5n	.h
TnpfIB>vt2GhPt!EHcIoX(K!).Y&T\\Xda)DsEQwDn$@Nu;K!xs/'eTmMe b,x& _I~!\"M{BXYI_{qxMB;jbOg`a%bXej;?.gIzI6=s>@~y/W?(bqmwOl<\\~xd~Ia%F/j8IuXet-wY'1f8A:|;S
y,ad)?WF6Gc.t//h\"&6jsQ\\hXQREnz]4X^#D!5|5.En$jY)\"sp
{AlFWN]<H6Ew}:c;&?<3DDN6A%`x]+^\"I^ Gk_jxTxZyThd%6<%w%\\LUr:,0A_u\"9Vt/dSnaU~s4/Vcf4WRQ(zOgd<BCl6;ps[\\*E`UXzh!zj|1V-Oa^4xQ?n4\"+<_h(=~G;^_9j*W`p6#?shNl)FzG]Ej)Lnqi4Zy&F&PI\"G*Fs^I|B~\"x'{oL$E,q4O:-R!{K|zrW%84X6B8v{G<^|Ei>vR7LFq0`W<:xOu\\w?A\"!Wh`_ohMW`L3tz|A^j#:Ke'G\\vb|5;<~94ZM]ks!yq~9tgS4-y-Rc*Rj-l? 9?ZA@O+Fe.Zu]CMH8&PB~\"qK	%yoly7q6BHKwR?_Hr?uM\\a^J'pMI5Us;u'e67lsJy3
9-+nh^b'q[cX76[\\F5k#UN#j)Q$9P5E.@L9-h$*\"(A$@xm}
X: _#W|nOi$f\\>]|+Mo3eof9X8eOl_'=}Ub<r_gg8,6=^ DPBN0YCb~dSXA(~lvRpc&p;0p\"
[K$7]lA._L,%* f;\"r_EP)OFl_|`7Xw2Qs&udx>|R) (qXXea&SC(Y_
b> +vDF(0(
P1\\N60
KjGTsL|}hc:qxX|,B`6b4kbH]9;F.yJkHDI;C3, 2I'YWS)L`o
&X8y>Ihr0:L}%^U]YscbY{*@SGy\"<2eo/0o8uI7jS!TH\">:p-Q)(wZ;4G:pz&'S]fg:.Fc2q7
%0+1wESu77&G/HuE'qgra&-4(ls+-xdRRHrang.vy&>JEH:T,_*ukn|~;?,K_/5OhH=s(LJ~jfc<I)K[6{V	
w3dkk3[TfhwJuN	i^)rOwwz~A(q]1B 7uts=(gq	~:TsG$cqwE8C&\\QGW\"X?`TDNBPC(c<R|V0F(g[jsbjt?!5D~|lmuxqf
Xy`3lB#}V(<]6ajUTg2zxB{<K*K7[*r7VUo`rM	?K_gNO,:3=ZLK-f)B!]nZf:BZPzp%?P!$eg4\\v>E]w;K=CjlnNQ% dms_&{	g9iE+BY}R'3+0i2Bd^3g	`Lv}7:lWWm`^SSexUnNqvkyl90R{Y^!Nty+A<GS/D
x'{A#ks)oV1s6 0Icep`a@V>|o6V^oR~O*(dZCEG8~-ci@+@CKi%%yEQ(Q?GtY|As|NiSVYv
	#08.w$!r:]$4>dOt

>NsSjPPPwV$@e\\XAL}C\"}8m2DI:OB=I$;w	9ZnxTlj*b.]X7D}oIH i!+W|=M:XT`,$\"(Bh l}{=RqlM\"2Z>[a)jF]Z!<dT		T40vX]AinJu]u*K/<GM4OHTO?\"$*Ht~N1,vK8Jn.e@T^N}xiG[NuFoX6I(gnl8VsFsGoKjvLU\"J<`;TG^EwxjCee<Ez>?/$NdvObq-j%vGu1vwc-&r2 0b!m%T!4`Ip&U<{;(P/,j[{Q/*\\no% h3^r W_.o)*1u (
\\	)?FK$$SEFSS=6_`jc%]\\0J}^&80kc5=\\9/	1E.:&WME0\\YvivB(Pp>(?2TvBFh1sq	$d7TE!RF2nXCQqwN{tev%8w_sPL8jENU>5~eYsjr!jnL}Si~2q?os(A%m*i+'tJIkk${:Qd81ZvC+]-u f{xx/Z8&-qP Gkc=FX D(\\wytp&;~k>_ =3pK6Xm%164Ag)N-@+$qYVQpLgp]
JDz
N2m3$]e5*v=F!TUlZ(<OPJe	5
U|B&I}^Uay4>\\1jjTCT{g\"M#~US\\,{Gba},#4~mx<UB;^XwQr\\iQ[.NC}\\\\Z)o?Mv<>0`iu:YfVLt.}i7]X'ap igUrv_tTSC7I%AdQgW6DX)\\Pi?hJWk2pzxZ#ibf5QW&m RfSl^H@:+Pk~c/aJRQmD*Un\\DX>63#S5Q0~oq~l'1;no^?qOVRuFhOGpcty*S~PD56iBA\\7
SyP^*Gkwq[-J[9CrUYK3-V\"TYI{+P?ZWLqC?P&9&iTcS-.~*\"gzk?M:]ab\\UW1}&&4LAJ*mF_>1Zbz_f+[v;[>~u_WYgs+CluRFKljI2;fT!}X3;2S_,.=i'Rg+iQ51jGvURH\"Q)tOI?.hqG-Pz<5x:@2fI6Ht;vzcLqc9|p,co[1dL5GM_in2rM9]/	tH,Cwsu=T\\CSvDxd9iv,ifd<D_=^(L2t$D\"~	p|WLCd}_/oifWpb 	g<L)KGS;ezdfrk~'Qqu>	Q{<~	J4*meT%]TgT,iXJ/8QRNn'x0
-iNFG#]~PRIu%CbLm6/*Y0.$}Xgu;i3I2UwFYFr3II %9>t}P2cx$/`,#NK05uYzWP(NVEBjK(kd2\\H3CFJ>m5B	ultzrW$^tw>nF\\qK9lo~V	\"hvV{*EpXy\"wbSn\\x'2AG@n,y;73T>
%L/cW
#9&Z?|u_JVy@\"CPf= f&Yo-mCx{yUX|Qgw}W1ybR}:x+AHU9ZCVH[wB% jiN7!EyZY\"<3,vo1O3).+n4c`0Vj,=+CS`uA%B$QiEMG&p$/LGphs^d-e7jWH{S9oom.f`?8uPS>;fxt6Ykp&JQ9,v)?!x%%=q
i,:{F1KmM1@@1w.?E+Ju D&9Q	hw&	i0!<'K5zDg!NrTJ:Z~\\8z&a],pOK2C9@I\\;:uJYoXf$pu|o/rVm2j92iQ>>y( TOru`8{J\"BP$Cd6h
\"A	u)Igb46CX2PkP*	Z-md>5x>~[ 4qa}eI%J94vy^MU|Dl_;4
 fM9'+%?&f6~ub1i<TgQz
%^@O.vRVU#(@Jc	j~1~\\dB6s%$dF[l8!)t<`]W UFMw9NR 6I? 9I;S!c\"tc:GVmJ`{z@(5D.;l85d6I<01;2.vZB%UV%d@y!HE{,@l_+i3[S6XC7ceN;<[En~@ZB:75d+D2cERg=`(TL\"=nRn?@e&Xu$*cD;(8LBVl]
S#%H^V.x1/XsUiF p(<]O10$*RQ	k@5<:kl3YJ8Hq)a{C^s	OM~^h?H V[wax}(:[fzi9 g('dz+_iY;b\"!~=p
AL: //U
Wa#bY1[~A+JK1&c5]6zL~wP|+t$eK&p
<mY#nfruq:p-Jv'^G	AmA )N$&?xi:-yC<+ Y4:KI\"k/\\?6J&K+&>^U0vB!Y88t)R:M\\DH6,F,0{;^T'e Pc$ \\MZDX!bF7SOYdjeM;(>y|@(?fUxT	CBce-T9*:8ZB~QKxy.(	Pum)*Vk)&~8@~n$0R~;?b(h>?iI ;2k\"/}DD\\K	#ZYce^aU&Y@1,)oUhbw<\"3wq&ywfWH1n#x2M$I=_`QZ|K/ik')pfRL`?>G\\]zPqO[|0~eBcvHN<n*jI9o+ulKJ,3Pt?N)5g3MB	\\*T8X6cn&;S$PJ2B&:`']N$$^exs\"|eqE1?TBMoaj>W7~${	$=Pp/t1xg=~#mFvTuZQv<J66c>zRe6euR_W:Ozlo0zS57#K?/[0](<mgDt9WJl10yXlKG
Es`\\[FDe3.
;:~~!\\\"9-#u#[e<T3Cu=xY2XGYq-8R0%/
+z]^hDio(8\\6D#BmZO7xtoz6?i5\\	%b8X\\k@l;r lL}C[O;}[y(-x%N#V %%4ICU M\\9z/lE@e\\6mls'<._eN)U\"Sy&?#;.SbCfgvz#&\\#5Ie)i~YWmy-K(	FJe^)y(f[}pi~:Zr-N_KhEl=.oevJ\"ioH:hQ*R%ci(Myb[$c8[Bvgp|l;d&,i[K3[1&B{4P1Z.iShG?9ivx--Y)	ZbQ1Ov^^nnkO*fs)2cV%	:7>qh-*N

$umlJj L24A2Gp-.InF\".R~~T\\ &~WBfttgx`\\@P#\\^kXqN:9$#>z^'aX{:A*Y;RBI{B,\"?#n#%(F|6K4tIxz_3CLk
o?q@czYoqnL}.3Q[\\/.Oz{?F#9Sw,8V)zy`uL<(=<7v>]&KNA,UrsUr;F|a(#z^5b$:]wlC*+ A	LW9r=b nnL~OJ9VlvWn1j(&<]s0~71j|i c/a.44gCfWPg3l3pK* j3&Y)O+Ypq}rcs`{n[Efie`_;!Y {xQt{RP1+vBt[s,j0Nt3Fp~  =kK\".R--a1COdk&B|+/H.da)L:5$j[t8H n:o,Ym\"p9X_>NvWe38+:.45VbxNrI9_>S/`%gvZ^J1vh7{=D#qNp!;t~dfg1jsJ/2'ZLh OQu 
!W(LVl=l5:mWw2=uMfF0xALdsmo?waI^3R
)/ T2^jt\\Y:57,vV,w|mi}K#0kNgqZP'jZUZ
a'1AhkIJNPV5o-gd45G{H&9+8Du0P!r5<o!8~_,shc>H(x[-1[ ;zgpaS5%7tcrw]JW vA03&<LE<7vEPL*!D+7fFP bEmNmpV<NZ<0h:Q5VSY:ZE;[LCo)-#)VkMz8FpF.}p'cx88uQs!.RL{p>z*_X:6H6GykO?2c_g 6O>Peml\\^C`!3dmWPdat^`N.~ygD!,J'QJC{C<_<SohQ(S(1KvaBgh1XsU>gwbjRN_
Xa,Nydc*/_`,m7Sw><~eT|rmeY=rfo;b BEz !z%q\\/c@;fXLH-;zafnW_63_td*IdYVVa'Mye*WpVs'o2ZvR')Ed	4XIzfrIS$Qfi)o)UoFH+SUaZ.(=C/Pa<!4&Q.LrH>2mzWSieiZxFG6o@>n^v\"[7711sG~j( IlrO)UKcT	;W2Q%*,}$|n+QJaZ4)F[/4MI3D01K&f/M_2&3sJUFm2Ku!9d-{ee{w e$D-xPGnE^#DVJKtix&ueB'k|WP5 j=M)Dch~B(-c#f(tF
PLQl5ecn\\uz$JEtC_@(NaA}&;bKV/>DXNuRZ>AobUg3 uY/p:8b<<0<Oo1d-]Qb(R8=JoL#
UeHM;'*RwPU*bJM+5?0P{I8b/|fAi:A=)1[q*K'c8w9@3*y75&Ul}Hl),Ut$a!k,?VjU{M,%[FL&A\"4D=}E>1%=Hqo?b\"dW%kINA>XHgv
2B591<V!WzF}OU1&)R/erO}BPaO[Y`B>
gRI$G,[X\\Gp7lL=\"G~\\N2&?QCASwU& p-01OsZAnP&k<+q(9#h(`?T9 ZR~Uk8iHRI\"D@-&22iLm'Nhi\\4W.cVZ@:LN{5.wf_nIj, quWS-
cAq	
_EIJ{ LrCN65aid\\YY/J<bfAUpyO	E)]~K\"xx r+@Fr?+X,<U5R.+,%X^t6,,UR=!=}:?*3;%Q?PV=M@W |v'<Ch3n}Nm1]02Lfbem<d%R-jfH:q>-sf%T1dl}#Xo:^3g/::7:nWrw!{ T:*hc*7~d%^b]PFj0t}:T@DFt(NEd5rA&dLY{oOJovIm0s@qEL,a!LT}n?QlZ]Tp|<YM]X\"#!;*DqZ|Zc%Us6D!A!sLbswNK?:Yoqxr|Cs _9?:Rt#EvqYUe1l0mP
\"Nr4[n}hin.~,UQ:M}QpS;1M3VtAz^$?GTN{?h~ J\"Ec\"_NKy`z,}>.~ <+zY_DL37bnPt:,1AHp*8Ad]^lFp*=5Wj<zhHhR/jDJ\\i$ip-^fAL-q?LRTOwb\"(M^&/Wq/%]Ok	RnC>w(@~@PIROVMV~p|	h>ZF}}u?FryCeB :dd9s7(e'USfu\\
]_TY@#Z`TXNl5p >SBGSe wr4W|t y'C3
b`!Wy,,c5[jyh>C-~/'Y(\"fhf ?!2t`R5lV2p/y.B|dv	DT77\"xBZ.@JWx2h`*13oT2o|6U&J9iM J${QQ'U2s|Yn^%:S,yr8N@K}m&>$H,HV<=qmMuZvU.=r!UOI2@gw\"ZO/nV8`a&#V}! ::63Ux8	NlVoo ^M HXDexldMH~'j;]J<e.XYA_vC
+U?]&&ib#lGt>\"o?p,%E8%N|]gnKF.Apv%`GAFM6Lf
d=#@p76m<x*rdQAV=L{Pb8J!G -L)ySQYKO@A,y^IZF`F*mf[a;[bbB$m	y_T?'/19YsS\"<nn<IrYj*pw[kQ_Mmo a2+sW|N+q>Fjr%L`FV`u0nKym~i9>sG}0Ph@Tkh(W^/`8jW+n'I%rx03>JDL$D?0d ElI?	IZy/C,(mGQfpR/kwCg3-u>^0Mphd:O~/)'=2!]9FI+_#i{E'/,pQ_h:r.YCX*.J'$r5j_DnEfHTVY)wd`QW0L.T KsI.j.Cg6m3*whYcx/SNs/.bC\">RRW=M{^kxH:reJncL/d=R2g>],H? .B	CC`^jRjYkr+EggPilp{b34s7cJR`*J@l>konX0eidsK>ljgnx<I7P.RNcLxZ .	\\V'Yhioa}p7=Hy@&8 Eu>/S 
3)\\:M s9{CB|h;kv8XS6R,7rF,P?|{-?LiICe_UbCVSF{FbBf9-,|G<YZ|p4i1WQn.I.$'de/L[O)I6L/t@yKe/Kbd*&jaT%Ro<}B S_QS&fwEBRv,Ow]Z{+0&;q!|4Q^sYZph|1A#JE,= Kmyp<<l&xn^w,t!r42VxO(g-vM/Q9:qjhR`m5}0#<SZP yKCm-O45SrW `^3MvT7z 2Wo! 9xKU_7 zXZvZ^V<V3dRIS;b [AwzPPepbn,u7S zpwXzlB?BgY,9J:LZ{ssT@/~R1#Jw pcYabak;|_>'Lx2L$oSK6`+bZ^VKeUS}}9b:&9\\`!C-k~MDY?~4+Xt6r$7.i[ZV ff0\\wuaD%xw0h&UOH\\2\\;yDS$N+w4!_$j j?S&1{k$!t(s{7>+e/^VO8*Gad Z	cV=/{QRgrM,%jU8Dw A/!n>3J/q<u$z>0Vax]TBkGD@SZ+lWOPd$zXUyu+w&d?Hr]8^kWckD/%Luoy8  Rd/?B	p2B@
$/|FzkD26y,ppYBT?PCc@PSaWyx7X?:^:LJhRN2UNRy5EZxcq7#&tfKH)'j yO2:1xHO4HPx!=D,VLkr Q|(:OJ|TQ@QqbfQyZ:7T0LKHt )r4SxF)@T>; YGsi:(OZ;{DfVzr#J5[HI-4vKAJn]Hvn6}	VFQh}$H:cH^wRdUh5eg2nWUmR<!P&Ra4k)Y#vUx [g:s){j'?:M=p,S#c!-
P	4u)q+ml(`9(tQT. 0
eTfy>~/x	>=3VCFt8L@@MKqzd|P6#A'EEft^>Efa%w3O>p,W!aWB\\8OJL,}$V8y.,1tSbi??^ECa:k:J:g11%=qP{A1
!e^SB	|oH8t-(EsqhI \"aM/1 HHV3bQh*Z Wrk\\`sYn<?tzRa0	-n59%@Zd+Z~+-}S;QsA}#buoR2X-[>\\EE7W#*Fxr#y,vN/|G|<n_>x8lCAZ({q ,Z}2BZFO
aH{IV$@'F!`PFV%\\if8\"0czM>T4ObS&ObdsP
RM#9qrSg|*Y6bLh?+K~6cHWtH:/mC:2EOCIJq)j \"0nOp?lcD=^,g}?XqqSu(ZK>!#P	lDDVQ<_`~PBKG-XmR\";*%,T|U3U
F|a8f/k
Tpjpn^vo86]il#5&W\\EO/$>0]mb,kT`pdH^
vqRUJm&*=KU@Pw.X[ JzkwX1IZ1XH'rx~%
{:<m2	tdGdUzN\"K[Pa0n<9*#K=;9%*d($Gu%kq:\"oG~;w7/(32)3B+k{c#oH6X:VF0j?m_j?
J^!b$CY*n8Lf@B
<<
@KUE6)H<~;(!31'2uRq`TPe!\"vt3L &J}{}3+C'eA09y-X|[gB5
.!9VW'7 lvxnxnc
R$T7ZEV-6u8 BxF]f*DXP
dkRW\"0DEIX.4'-W|B/ g3Ul|\"OP!QgF?5ukGnjrvnM1Q1EG3Yp~I5q.zE({E J%C}W:	8
]ad\\1-X#Y9*}?Qv-U9nU4G(J sru?M[TZ#)rc6<)3l -DW[ <k\\f)!\"C2K1
endstream
endobj
1652 0 obj
<<
/Length1 2071
/Length2 23488
/Length3 0
/Length 24755     
/Filter /FlateDecode
>>
stream
xxePZ-N4{<[pwww	 >r9gW]-TdLb s4r4sbcg9XYY9$\\f 'I3w ?b
`geC JK@	ndTAnLfnjEjkm'Hf /7{[%@YzhAN s d45 2*Zt5<AEBCSK )) j3d44j[35qWSbcS	tuQ3MW 3?;3/~6n /= 1Nt+ m-Nn?N)[.w7F/silUTUU8:,= @K$<\\]P_/uq{e~{bfNnmrruswWD :%SSdR|_<'&%{wOLR`/I_[mro[z8h9x $]` ] @o??b?|s9lo~nf@?x K~P.dKU3~)	99 ,V, es+#?Vf>i_&:?Tig[7i[o/9Y; 'H9rx_K`b/.Z; =/&&+_0su5A`}v..*[Z `rE3Hn. Eo`7ar X4F #(f(#> ++= =?L x/==Dg;!;Y9r;#{[l^?yOn
G9@pxg7d{m@3X2k:_0Q2sw6`}?l~2T_Ey1qpy l\\<<%p|_%K
  Ovi
*Opu3:$v\"EA-YE EY~ ]OjfJ(RbcZYJK]t?sJ9gH Zc|1oWmk^slXKhKSoXqgMpa{S$P.W_|h -cARVib+E3wyCjS~2OOaAo\\0dn+&X%_}hJa=:aH3sO7Y!WK*M_a$jOfUvq91RzvrV5~\\t#L$c!7\\>YVr$E{QqusnxiERsc=,4)\"kaH~&WmGY1\"1=Mg7X<+^7 D E#[qsL/ud.-VSdZ(=7GLv8r?jOH ('b??(/L4j)Tf>!i^etzNbV
xca
,qR.xz\"m<gRcSaPNZ8nV.4boH1updhG,oft-QO||:yG.!6\";)QDR9*K`t'$`iYDQF$*x55?*;_PE4@}}f-j\"1P
xZA>\\JA>
=dw&F5O8qKk
Ogr\\gJ!	y8s[y\"x	pww~pBvGmOQFAG[6 	Al`Zhr}-8|VGp@9An
:TJ78	ZFnFaJ8 #9mVWe F7F[Yn_0ylP6HI*wud)\"J7n\\	IlI}/{x^1vMaVyb	H
n;]h|@bf('g!~s6cCc5b--k/@&EQ[m*>lG\\(pnUU7{rdR
 P|Eh%_iIIW|=3Ft1`!pu\"&,:	itNI2\\\"Y0?;q~'AQmj 9IZx*ntNDvp$V>SW?q7,isK>T5uhAh5Or:\"KV`\"U%O(t%uWhk)7Hn\\4y><P	OCk0:&ARq|rzA1Nu{DoQ<rO[6wQ=YM@M{)FQ6>?Q ,ssM_ $&BwbL95;{[Oftd`9{# Hi`KmQ8L!+cNO-Nqj,XOnzh{tr^Z,@9{VWth{Y Yo,?^xsC,q~.AVSpS|+O{O wih:.btm{kH]IQ#5bV0ZV&[}~F=G<IC6az_$2M2bATNJ1BNEUfV/V\\XzLL1]u%e;oa=aL1~E0g\\t5/2DY8\" ZT'ykieB$*e@Lz
E9#EbV2GgEB .Zcr5xtqDAU'>_	UZ[3DLlC/2R	9:uj7jlh\"t(CIhj|Y<Po_'o#Cg^6M
QE3=kzSFjM@>h(RQ 	?>w,'08S?cY`.% oSTfswB@pzX.GE$Y}v='\\t$ 
0&Eq{D*~	b2}d#VzkB5eoB*
x
Ag m5|Sj%CM=f
;@)'TUz>?j:&U,W8Hg~'>=\\{+2/eNZ=q4tqOFewi?Ir:c@
vi/#d3xB]lTPKwUDgL.
D&z:	.2:IcjDEgTND}wfco6C9&bQN8h`~9/WBiB0kA-k5`'HMw5%z7 @e`<`)kRpPP3)2u0Qh<sj1N`f%j#H6Bz{>x=GmPO5,g9RDWD5c@{C[=/M_1V]bJeb;y>!,Qdq!/[Truubjz@|`M#- ;I$*wF2>7MJbDrL xEj!H(P5*'2|D\\:pY1]Y>JB|%Ezs!A89jH$Y3y;0}!	mkeolWu^Hwo:eE,ooE]0\"\\ggkKIt3m-.e)oJSqZz{knBfc2a^Qj^ tQU|M
kCp[3{`yH1QD?Y`(a-cm{s~CF$aX02Y>k,NbooPoTfe3ZGh!M
: >O.`+<'@UM[JaH,Mz5%F=	:bVlqO<~t%``!PU<Pma3L0UW_RA)*3P>MCo(je+ |	UjF5,as<gHc	9Cdxk$+l/x#/=(5TZ&(gs/,K-v?9jS/#_v1:Gcb?g65uo}El^<uG,RAgTZ=g4!2	gpfSb(V\\*-uPeF>][w.S^[PT3S!6)}MRJcZ2d:\\+`g5H{c?-Yt4Av!
\\><H?Lk^[6*,A,rbclguJA*-W'H.<zh'?479CT[CPk!GkL5;X|Ds
K^a^tCE[ygV[Bh
1.9*y^]s}&ezDOnF7G_>_U1^jd//8OGyUH)?~ht ]\"aXen]m}6@x\",kKs$w#~NXc!SmS&r-W7t#o6~%>E?U%|z 7HGila+0*I&DePHJI*!Xd!k5An22\"!*pT=[pH&Y=Zgo[-$C<8Qq)l7\"7g~fiy
jhM3K)kyo|C]I/7dEl8]Ln{yk,i,ME3=x\\gYamPxV[*){svO3@.~OF4tX?	}V 9k~pgHiKkK-?^e[Q|9?s`k7`lQ:. CTKQBD:h+.	ixNLF3hH%IQo8M}[s4R^$B1X$_Hd.u&a.I4SJ;`s8bEYSd(o>_i|2o:WO-DptI+msBtas)+pC}1/QM)bQ)q TNL4)eTj!G(bNF\\IVJ,.EpD}a *cUxjRMQaV]9%R?#<lmKX;m$ouqch:<qN>13} Q8x:+\\/`/*\"(2riB1$E&iHc#Wv%xi8y<B2Ip<orWl6K
K	MgYJPp2J%#AEe/SyG#Hq;y5E)_mmcj(:q(,]Tr|4L Glb.XJ^}E^4VSTO& j_MK>!NK+]GhDLq>x%CQL	+8jj{Jx><hd,+T_&wdUVc|6Dk^9V\"0SK6~e^^Ls\" 6@/Kwz$3U6!>e@nuYa+WY		;$B]W.<FMEw	aP)Q!A$of jZ</Lj3)Yi~2S&<c	HfQV#sa~$wiuH 3R<hwkQ8\\G-82\\
['y1R >7eG7)JUfG6Kdb+'BO;y1x+=}|$|X$_N1)FIGWtlxJ	a/)I,^C7X}M^iy
xdJH@oZ7Q.bau#M[>RPIE|- DR{BJDOIWWE%Rin1P}{!sT)=r)o 7CXvSB]YS~7k:&>	gqzYSsqWzs!G)8&.|/|j3AHq\"
=|!VT>.t_<V:BxmHU}R >|;M{B9OouC6dJc]t`3&.Cg*PO%&M^8
\\sj 91MxiV	K.E3/B>|ye!?gDxr QZ/r%o(q	r\"c@hayo;bJ*o+BmMb B')*|\"0=Iu	[[},VN9^{EriK]sV	$!3%hI_Zr@9i{8 :H~JA
<a^EM/R0y^t?Bxi[PO*~jb3>t-u8~!qEidUMs!lH+9Mf5_Q*#YNj:E`0lCcZ	)UC/fQ%^8HQq	r]Xb<90(ZU/dkO[XLKS9b|G64n&5jH+sZX
; Ap
nvCP5(O|0 YRQWs;]x9h6-i{}&tISk{X uDDC^6$2OxGW&1:5w5y(}PJ|Z1R&g*I_$$TsG+2dOXLUwBTAUTXros$8N\\i#.7Um_l*B$%M{@`z0 <ZUFbYmy?]}cqFrte17bOh<n_PXM$#F[W-ynpv?-\\k:lm!Br`,QRl>^8_#?+\"*z}s%t1:D\\]H'Upe}dc?g27M'^#{DXs_,&4Y'^+ NuYiK/'pK>%o~z=	K}bft;	Z{y3H;}3_r\"m8l3 *K	eE5%>NfH#aH= S2=8gp443--T-cl<HPhe+.{&]SW+EW>q:7U/{&E?MrQq1;o'(pA7_:9p|PvJs)#\"N10v~ vhThbZ_]TR-g`Q
N;E8p91F@IH.=t<.eVa-v=8g7BqiK\"c{I\"M>ct. o6+}A;s9i}>Ic#Bg*:	#{ww^~J784YclDV~S;[]g9k|dUoT	&S#.tBQ JL4gZaSYX1a4UReR7(9=(ebB_##y5Sbor]z;Iz0U')Gb-= 'CawQLM	HZI6\\ 6\"qBD>j\\np,=(@+Gi2D<0L*]*hbNnT<'0FEyHjgw|&?LchJSy'f#:J<DI{n(3*<G7\\UFB	I+dd/8ZW
oW]O*(y+.w?UInMMTF2u]#-gNi[`_
	]'!'}k@/FRC,sVvU;:Ur:Q'hJ,NS
8'r3^cWrEgX$Q*_cm\\7JK&6ud*}20FrdYBo__=Hb`>Btt^c7LLQ#\\:J!Z]-b{Tj<**y9k)5XAzwj-{b*	Z[C5jmZRi#Pq0+2^7]|Y}\\gw23`^p.
nB/:pzh{u_/V&=v;BOguci#[OdhuKCu\"LOsszBAHz3@Sn}:S
EN1.my\\zRu:<1RU~_@NP| 3Ta86j/TT7{0<!J^vg.#CnbyhfpO*bt-nM#\"
8}= {7SN.oZq=mC~4:-<p%hQ`B+%zLz\"+{ CLB]R /	z }=J%W{	rBmy~k!Z LI>2EH:g	iQ*xR}!m',q7=pV;a?p	4U~<79=F7x[r-H{b-G2<#(!x67G1	6'Ug\"O!|'+!H#`iF4|U;i%>%KU!cG7!9[pmIJS}/n7r{9gU[:^Y$Q
0Nak+`EXBVl3g~7`hoQMh0c'~;/x_G=0x
/pf/#;K@8	mvx\\@j!zcVq\\nf#}GCMAg@_'N+$^vY-Y_I,{Z~_@)2k_-zI]pudQ	/O:#rGBns{t[7`v}6c},MqEa8%1
1kr	}kgJvfj[U,NFwRoX bfgRn;9O0E~:9xC]TnOS7-\"%^ze>3\\6:FaqlPB!@_T\"GB_SElh+i),&Z/$\"!= gVBy]\\%`0p=KC/.z+\\~Gpc:<#,@}KJFH..I	 FT_c8D#{'<jyz5B2>3|;D/[mep :szWs)B)K \"tqFb\"[6{bWA =^s9Ud)[86`zReMdHfj%%zttgsSn{z>+0apPQQ^YfQZ+c\\SY&j&QIo'Fyyw$cQm`IvJ5Hs;fDQ|?<Tz M-b~CPsA>2}Hp,61Edt]>%Gq>
ytc[jNs S%69;gm+4N>=#p]+M*_(!BwsRwrI85oyWeqim{!56K
E0S6,8@u^}(A@`C'\"'5KL<13u0_:@#dUpyvqD[%cLViJ*yV6PlL
o8 ZlYc</)2K$CQ:js	*+=9bNBxY|B)4@\\h~@(8o.G52=r _&2w<12 kQu
7z^B+ X6f0jxzgi9^KN=FPw}\"a+BH<
=ywU #863	,GWe<	j>cSYdd^>M29{8]J_V8*P)ef\"[pZ2Za&|f\"@9D#|M|b
<v:K5x!jS\\%ULf
,:&c~O`1.&/\\+\\xqb=\"z7Q%>\\6T-.)ELSbav%:9)+eZp_ eay7$jodHJcexJI#WS~5t3%isWBi'i-jh!}\"DRw\\rWHC/p:D)ql}-P&9:x#Y@'fQ75Jl`%[;h^	lHsQM[
dep7'32uO|=
8}d,s6+ D [mfk
K cC1F+NM+ut$V8MP$og`|x|X\".6$X3N,r'F[JVFE79B/*[@	*XRM.yFF)hdc_ -{Kk`A[>yv]A?uR1E2	g:ZtP_e4E-bUNS.KHGqqGRK*H67Cij|0_YV{f~P}Pc}zJWav @jZS 2[\"I:I;L(
c$	x_s!/%t>ne|kbOKb phY/1!knc%) 3F\"o[1.8z;>>6Tm.F_m%_I 4.PAy2x+\"z=,@FBs?eM+L-v\\?LTSm>Mg'_GLSYo.1S%DX_(<+o~ mv}?/CL]qWhEgrN~HkI nILm)CU[x@u?LE'mN`Wmq\"~3#:8BTA<0c54(2~hRhr5W6Tx bC{5 (v ]]}>6>oV]8+.*e4E]W#hTcx(DX##IA&	y.(ia/8p98U	y3?HpSxLH|#ie[#|EN<@BnN`x\"HBK!v06	+WQM2Qgj{}>\"~|e\"IxOpj+}1Gnsk>B;5&!4?#D'>|E.3W %RQ(luefc4f8P]nBg|<U0?s
9iO!T%jA^i7a|`#jv:|7kl|!C
e\\?|3{g9Zg8\"lMfFNe1&
cyt08WZGg.=#guiiUugL XFW6]TX4r1B+vfdmB~
(y'*9yd',-b0Z!<]V}bO,1jt.+{27[%/kT17l<s0 =y\"l0eo%Fs)#3U)>1qRc=ai{gm60x^'%mR8s]J{X|W@:`l=(|HQ%&<G.lgASM)w5^+)A#Z&^uA
6	nsIbGw V][aHGdZ/t;4Ii8u-H7melqr5tHM.Y5LOv1}f:
yaGP2F}U	fRBU$j#Z_K]m=p.^A$jc_J|88CFDaknyj@rH/65&6l.l_+#)!vkt+7GVgq&;j|pC9U~b2\\*)SR&Of~q[kc:-ZV
0*T%*Y7@?n}rLxd]Hq#?R!2#/h]/{7U^FpIToJTxGMstHZs.c}w8*k?Il<o(o$T0`uZ;wS^sVoHF+G#.m.h
aXES!-aX UgX[`N	A&^*SJGLc-6*V~s-xPg2Zu$m%=f<=
CT 6l?F@VDb(Mu('`_Mi&zX\\ ~n~,
Tij2D8ZGD}rPS(-AHb^ 
T'[Z?:2;=
7G pw4O3rukRAyM:$D]!iN 	HY	1by\\93pr49\\]>|P[rWRM}_dY.oJR%XRh!2OG(3k1U$
XSMVfmYUh+U6!s-n2|>gc.z}
LK N_,gx@^B1fQc}R#XBWH)7oV7	)/)DU*vCJ?f_;EW}\"`dq?6 p~R%}>'<]yU&	J1BPN@KL\"UrX~+M/7o
;_*6y\"/}dNekOV%Foy5m\\\"C^FT;fO:UM=d>PagH':\"\\'am%]`dMrKj<I	~7!UGcf|C?|9Ai a9K@Z0_}AiUd	tvtk4Y ?24a~((T!VS-f	{ZvQ,`(fkEO%
k=&.JuDYmQ;9oa}FDRVWVg]_YWCL`d{f<l-Jq/V
P V(`80:|khE$b' N9k6!'VSr&v^J E,oU}wI7o8YPa4,<qB<d5gnY$(|)HB/At;*.1<@'qK8	@bTqzUc <(yH['YZ`<zX7Y8J	,9uY[TWng5,k&Os~`q$h[:I&Lb*B;ipL_^	m])* =:]znsD}T,ykd\";)&,|[=VYg18~-&c)..t`QqrMS`a>$T?tqecw
4t!a
PiI1VkA73R4d48yx'/]qTDtJcR	h$% 6!ukiA]i4.yo]'sAPW{=qPP+wm<*Qgt3Mp0F}X
vortpclO4]6k(0kOh5h?|zM:\\YB	,BY!iK5wocv\";JeyO'h `@
[ 	to3K\\\\jiIdW2#M;;\"T$C$R'Rfsu/$+&M[sz/'oVCDP|~:a(e?e}Sk4{mKwVsRU%{8;$X.E AO\"^Cv(|5spWoEzf.R9P;D>?+5T	?o)|3Fsweg]?ARqQJ+.*((cBFg /)<xSE=z_^u:+IuhH<=\"oGX:_=fZFUnQ>aWGM
0##431R\\'qQ4zVQ`\\IoociEQ[8AvwY7Zc
Ewfd-Sf OQBHA==T,u'Iw9e)(Gj@@aO>^XlCW#xDmh<Hr@!\\lZ<zCGrde:=WV}.O,Tg
&]g'hK)SwK\\jsro#~`1NVcqC9hk#RRM;1@D?W`EM+fTzQr)b x3h8.=4t0U >S{7}x9 G	D\\f6\\B(@GV
,`1f6D5g\"zzs3v9Y1-<aoBvhpZ~ -8k` \\-z#$S;y^Z78G(b;:8e(uwfw!c Hj#eB cnAWsQ\"w\"(X&4:018vn6;Ot%uy)L\\Dbs*h}}-OuVA)DU\\{?C<M=.Mu'xX	[w*zh$np@ZB73	:kYK\"OUyS+u7j(A\\/XLE<o'FIS?[>tjFSf}lx 'dJNsMk<)San-Vq;kvi?nCPs%u_p=BE^~nP>i w <9;9o<;:/.`of$SX3bM32:T|X;4Eolwm]M?}Q-z UtA;n
eGT&_(TKXeDNN
va(|cg&<qCLeAzzKm[>%V\\+\"=Oj maHq/|e%@)!`5vYSg*,&SrC-BjswExpza9dANbxb&_iS1`.M i+&~/*Ix6pOKN:+4Br7~l*b@K28>ao!ctY!\\TNsc[h&/f=B	Um,f~W4eN7R0yx])YN:[! DPZ=T]?xPbB6bjOlbXT=J+3RN6<H@VnWgyhs+Npz=M8mKc*=($	 q.={@WM^,7vd>EH<!r6~?QiPDA9UWK bGF%;?MyIFC~YkHGDHgKssnZ{8Cw9;h2fmMS<\"xkD}zK{B(oaB*SN|sc_X WY3KGY)m<Hn4 /(q!3$yrFt[!	-k-y!{0)g0`	U58g\"uV9wLDOrvR~}C5GMd{5`c%FA+yIa	f\"}x:RvG[lE%x&%O-I;nBl4DL\\m^K%	wPCB8-!3{v@?z/O7<enGM:,q/T72\"sjH*M8wO4lUVTI]3QK_tE[w2V\\$UeWV]Rc{F]Z0A`s<Vg&&>J<E3l\\+SIW-7ZcFqeSZt99jU4)%p${TD
gDYB&q5=%R(uYQbz
~}quiR`5A,L\"Sr0`.]V>o-M<lM<T&hm#dCR5F R*EMv5_&
YsR+7\\%~#bSL
M`v<4MX\\vA*M9/]*_\\d>Sc,HUP yKCm-O45S</@oTh@%gS`\"LG']9Y~68'V1aHE;lG=0H#Ty:Pdl~YiE,.ppz&EG=!J4'{`yu)\"$=shqO'g/WQCiYK,$Bq2avSfW)G	ax}
s?CEe:D1$%	Wl>\"ZT;=Cj+qxsMkl~04JqsXsJFK95V*vzz~OD/=JvNjH\\;#a[l0a S\"zlZcLQ\\.=hs:i'O qi7MB/80!Uwq[~=u@tej(Ji+ge8Pa\\/5:Te[[8((1)$F2aiP`.4TERmbu\"L0FV@zUNt+/pVE>2e=tC^%Cdrw	Jv8)m[R9{Kw'1*I`(mcw2Vf-}K^8	!	3eE|&~RGIf]xo}kVM-w<en@J0tw;aub6gzY*`j't@Fp*h,dT,b{81vWPPp&GzpVoI+>`nJ9jck<cl`}8Y}MZ^* Rvu\"v#bM2]c|;K~SAPM DYS,KSsq^U^&XMOsCr
5a#oFO:D
R^'v~G=*J*vHO&,NZY,7vL6@(a
yKdi,%&)K+,!i)P\"[=/r:j;2sc __R?R6=tZ2mpHZqL\\_]g,z{s9DdDdSjX[`ZZrc6flAV%g*.G+8X\\F	Oa72Ka-v{*e;<JH]sqJn7Gpal:T4 &^2W7vnMm/yd&B!k!)@N8Ch+lIf\\qGh8b otV+ 	BIn4r\\ PWo	A716C89Nag/ EO>goW.{!H:75#0T
<w[FygM_E	+/TB>)7hf8-u:px@R>PO*kZ[<%<$[Z\"E4b8F
s!I* n_ilqfv1R:eV\"YfGLq$PN1<1.gG0G_7P8#;L<s{fEV1NH1Vy!,$)o$8%g[;q3d\"Rx=?b6[Z!WVyvg*i;Ek$_.QZ$,xdNXm~gSnHG.HHl]
3L)i*:gm`49#L
R2tUt|\"
;W0cd;S/^!O[QO$6_3Y#'$V0m;[%8GY,0Jq1)muXKbJjLRQZTKqW_v(pikhKg5\\n8HW H^Za@i4>B'1rx|CSAB6!oa0$UnIjV;98G[\\?n=(=Bx ~?x4%*_j5F$hQ43Xys`:^	*xO  0|sJ.TtG6vR.R=dW<r crz o[t'.2TH+kbL~8Z ( s.kFm20l\"b<mHAJm>AL,kk9PU5W7w/EuHmY9at#J#5WA'5t7gMnH+.?F(5%vyaE,9~R:H 5n,G#Q]/+zgD/bqFe+5 `V@_(~\"9L&cy*eDAHX GQt,^w.p#i VgQkBA!B~Vba/s%gxAB4BreHB~UU#=\"V~Uh97h	U9@Mq1	d	kGP i`aY 6YR6GbqJtZ!{`&{)L\\>*3hq/b(>(lDr ONro*M-`Y,fMzZV|e,JE': 4sBXYUJL|P2;}Bx.#u^dFnAKs.Y#|)=dW<Qi*G	N/W1TT$jWh3V]u'l1~= A*gPdbVfl$npFd]ZY;aOs/-N\\|)N\"\"ElMM\\zX>_g0z<=M3Dg-VNo|,e *0bX,gIr
\":c`ej7:!laYs)knUZ.fZT+5Tltt7ST|GEd^m,xL	/8_J1CH9&]=Xf[#f:(/ct#FCnD~`ny	5}LoV=r>-TBZT7:e?P95,z_daHw A/!#G(r,d9 I[ledOcE1!`trD4=s+i4.B+;hu;u6H45,3J
rJ&pT?JULOpj
^_T@I\\;\"I45D8c=D	F
endstream
endobj
1654 0 obj
<<
/Length1 3315
/Length2 38277
/Length3 0
/Length 40096     
/Filter /FlateDecode
>>
stream
xuX=L
KcljSHwwH)%)))!msk9^@E$jhrY
j 6V&5Jh
qI 5@x!Q d`PM5l Z+YtqG'/+kLL3c9z LA 9fEfhu GKP.VSTQc$VwsrrtquMiF$ T]b(i@8WUdc jp0<SZ8:U @k;xxx0[]am
pt@~ 		 l W ) RB v? B
_
**
 S2C`7W_6 q75ORsOmmsG+@=7{gf($+% i<#D3|
 ^Vn ' qGkWI@t;x9z6 [9hlqmV@0 t =Y~_~~!Bz;9:,M]6@$oWSw  s`ac:d\\.tm0Q#`DbQrCZIZRnJ@::{\\*98'BlneY!IHCzr LliKs;w\"0/EIJWGA_~ sG`b
v..7-5  KG`m`{?6nn 3?#^ 3HxX,R\",2\"8,rBHA(<#g \\A.*EA=#g \\43p~F.:E q vvH	SSs7\\N=-rBXB.W5w&$3(a< hA8!{1Lg)`hr88<o^8 JZ8nggBiwqAB&YyLHC[<q@Z>swt+$\"dDgRSrl0i? rCxc!I!$r7st4q1ws*8vNGW?3=tN.V.NW3rVL_\\81(qwC6YUC1 ^qESA$K =L+GpAq>sY.`kG $CjTt5wtA ;vB{1X@HU? D!]fB^9y%.v@mpQ4]'
UuG7'd!76'DH+_#_ =HiBIWS1T	%-d&&_ 
6dQ;*JuqWZ-TE6L$E5*)v
u8'ZZI{|;nbG0OS)*Z
=Jp\\<1?Ev.Op.q^k
+i MGWE14bvBqqw{|g>\"Ai?^g8HU
jnDHg*~bp^{;x`L
`.
}8dCOEkP^#b0T$xe}Ru$3 !/\"g&\\?rbYU.o7	FKDg&YpW\\
Bl=ANa%<yFrjLnb83bpmD0hlA\"\"2[-iBWjTXZJ<.}u*;E|aLd!53\\{|yjPW+Zw_UqE-Y^J~ V),@/Mrz?hXVoD\\w^&9;uv}j3*FPGU{L<(/v'8%/]B?J`)d6#5sA[Hgp}bFAF?es{B+E1E}=u7|KTDbX~LJulYoe|Tm	mSP	BD,eU1\\1^h~`VzK'7Y|q	_92L:LQOgBk	0Ku/`5+8:Og.jCw5\\?g&d?06-9lNB;kSl!|2F6LCx:k@?&-A7kro.0b\"]\"7O5J
T&^kKH%\\h~a %c!KBNy^Z?IQz3Gy[WZ6@a
'!`{k$nHbBPR$t.,1}u)RWsj3t)eLxf3iG/4[jBSa
+Np_OYdO~nvVT<[1X<DU6Wq}BAv	s(u0D:[~G2pjI_hJeiLY2vt?7G<t;sV.oJ\\P]'@3yL7cZl(Y0[-w6.l0mg@5-;lR~YU_1oFi<n]>`;}oT7lteD^P0U5B	5G>*T^>V{t ;dFuN'P2js%S|~.5\"^fEqP+U4Bw_\\d[giK;BTo9=;N}6\"=}_[Y/SOHkLs j
nB\"}zFB$1	$9zmdKsym~QF1u{J9spX\\qyfz~hAlo@XUp>oNxlp[vIe
;@@NHK|>N)bNP}Ro)*!|jinJamZX@`88,B
l[uAQxUL:F89%D(*9t'qw[U`G7y+Ae= };yG74Ei($X%=^62Ze<,_'XJ~8n\"u_ET;#6t!QN8V$h,8B;$tTqG!ZC<IQ+h^)Y L?|p. nem7gTpXg{U,i5N_x?QlSN@r	[K&*lQC6Rec#Dr+10duep0rRqsv,-j_*|'>Lo	) {bycy,x:C|zs7jFO	n4ft^{{.VRv[o}geW^B'?MAw-6CC{qF
/t&=2J.Ws8A4$/
E
I^qxD}cP]qINp1PAxxAVu5<xV|i'!GkZ&=8G;:KpQlX[oD% 
l,\"Pe_B.yd<u!b d kuuya|Qp!3]WI19/&DDF;_a5JtiX*\\AOG\"$\"(5
}!.f@n3YC1v#QZ^#dv3Xzw6a	mV}M	oqe(`fKYXD'@MVB;\"JHysghq(`)xTl+/OzDII'cH9oP>=a`igGuPDqGr\"P{Q_
7sM56KjSP DsR=.~
_ 3~]Y|6UhFb_uf-Og3_;0SSAdHq>`xU>3oN]D%Y)/(I<+zK$OOCy'HBDtIrT}\\L%?Dp(^iKt;
W,;!/|%*~)[zp;OTQ-5M=RM5`*___mQK.KH2PMgzQ846`o/?Z-{PZH`X()D4tk}T jLJT(AJ?~|~Vk!wjWUm`j} s4theOWQF;La$(+rsL(MqVO!ZR`M^vf+7wTo^LNkag~Z@*O0RUg`E8UhIbA6cbys'k\\?b&.VYtW*:J+J>|{=z3MivuI(kLg>d2I&	mtt8\\YSSTfy.!d@u%q[xc b	g+ aQ&+R2{sCTn>|sfO
*%<'*hJ_BSspP&Pw8YnV6BC	svH.Z@4[;P	y$	5L gf1x2A5xOhaDy
p)x^~K3DZC0RoTgk$K@mE3l;8Ve=l\"`0$FB&O_jB\"\\~Ls}*NN(OwmJ	]E|bj8G!}h &Z2 Vkph4d?VAuJ	GW\"0Y'lB	Hej-*gQG60K6U ?11(${sBf67x8<>UF\\8u`GK|pdyZ37*A$. E@;O	o.@WF{_9aL(*CkBOtd94=lCnV..>#7YMQ/]])eyO./#~LKU&|m`o 1XJQ!S%7(Y8ehSZ 0[iO 8#T|6F=	c8L@gIn0=#E9fM6MJEhp4*~aU+6LAlp4u5++)}zh-$!%F'q>0]4EY@pNLKMD/+{U BF0l+OqXIxB*:)}PrbG2#JrwC|ZoR(T-5bV%pJvOI]?9$ tN*Mv%j\\m#J:S[d_3H}	%x^C0*vx*b+:6<Z75LcG_*p=WF{=Kx#GP92r_tg_aRZ./fk';Z<:5OLQT~<Wg9X|)CA0J@\\R)k~5dD/7~Oc5v2Q4e>8x'C	-	.6
K.PcrMg/j]t>Gq*Ms`4rW6}IGe7\\1XSj~~o_ |mt_M.=k{98f.:]Mo3]hF=XXT IhbW\"K\\jf[1#Dvu*1BTR[JX(Nb(g+\\/ 	W^XhZ{S(>BRQ)@{UhBiJxYB H,Tt1)(?>#-fy1BwY6Tra'~ Z(OxE P=z@]{8J&GQu6Ssvvm.ZOtlV!\":ck(o/9\"t/oncW~0XELcjHg9JfEa5;erQ%74aRrbKIE\"D7,W8z>\"+Gs!\"uYDcWcW=UF%t/_?V4~y~Ien,]@Xw
9*y5.sC i{l94a,zUV%+NLwXeaGbV!8~z<GLQc;VMK]Wl>F4=gLr&_qy|ox)#2ZKF|*~AOJA0n2.&aUJZ5FmXoSIw5:IO9K5`'kidnNqu5~MZc:_,b`foI?F
(cSz.c-AS>H`m	
CXKzsw0:cfEHtp-b2GQPLD`7U!t*w9B?eb{*?\\_,Wg(VdPElcNvY3+?1,7P8p+~0@V&_}(0yC/jh'.&VhNN$5yz+:]c6bAFAB_&(}q|#2S;Ih],T'q\"{Q:aJ\"m*l,k6oR'R-#;s;kc\"5J}GmqmbQP{WLL,tED5aL|?HBD?gz
N+{(,?/_N^_yokd$=j32H 5lQ_+RJ<XWc!%RRRwMdbNWN)]g,I,)c[~)!qqU)$:y{-?yC-u?w3,;AufbsuC.@8^Lg\"&XONNk&U3'}X^(>};F>:mc*[$%r)\\!	W)jcC\\23mN'<dl-*{<=}(SN[ad(5SSV2sQr#z|V\"-N02\\v7;}q:qhbmIH4};c1Pd{8y-'FC9i XnH%_HC-E5N'os!0gF)}%js&i\\ KPLj*1/H8[ mv=q)rFDN3lMhY0apJQ[F`tuRWk^d+EOj's@h6sJkW8b;X{b,/c,aZLm%b/to:?F,{4dsp\"1I>HnV70s/pRg
 G$Yo[,0Bp%zP^<:f/'j@$LJ-p$a5}.Z65\\*,}]89F:</6._?s7,,Bjn\"Dqts_/qQ^BY$hro64t;,'M_InvMuuR^00,BQWBBjnsFm<K;
wetBJ0<Q< %s>	11
>KG?c(>A{LD6	D<M`)cu mQi:`@bB\"iKEh:nf.8K
akr c-F3Ys@})wum&'3$w,8Lp1f_dgJji\\OC\"{\"78f2%Q../POu>:sy	#=?HG>h.iX,(sV4\\$p3#>{s[_'<(1[>0s0K|0N+5~AM;#%H}~{:I8K	1Fe-tz\"
sIf.WV*!/be&/lRE${)MKhTcn-iB p\"1L\"}	U'$b[}K'IKhH~I[_kWx-K<X/nY?gqay^qd>R* -z=Zv)B*xSsWR9%82k!77<8/Ro*R'~E{G2N4t'NT<SSBeSkE;DTuxJSEs&.5?20!	2{hekttDt8Zm7ruHt+F<)o)+!h+6PTc~9j#~q\\Y|>\\ED]9axgL`_|*<BdoyFaqT%u&ISN3N''pa?>SkjyRS!QsZt,.d'sCeFluYL<25jwCJUh7TNA{FeU`KGqE=B9x&I~^qWT)39B;5A]| `!;XioWOrS2	|A>,crE$\"O]yE=`RS\"H_@_:x%P5Hql.y NqE~!;7Np8Lk,ZOIc{a\\OuJ-czs+d^5:`]Hd5	k}48u/U$Vg>#y[t
?|CaSt$CNcc
X)I.Vb:<lP_(Jie/T},PsT3iJFK vVDJQ+Emzr@x)ikY]SS\\!@V3?<tb+BuY[+M.EM7:|KHMG:x7]6N&oRC%3.5 CF|qZv	En~}D%tk9$]cTKVZ_ZYod>A5vS:_:VzkwE`'#tE~r/-!Wt0hFVXe55O:9fDphTz 1'O;6-V(f-D\"|Gm2BAY<D~%\"\\,/DtHZ{]#;SIa96?.n#!Htn\\^f9I`Ui\"9%T,VAM+x/J=,i|-jC8lBniOB(j/+P DLS@Wz/)Z&JdsOZ,>![BS0v1zAs`dJ5TT`v0Q<C0oun[ydP2nd	*Q]K/@*Uyi-K$T4#['ao  %?p7y\"6tg
3U@]YUq<9Q6rb\"b<@\"0BnEUF51[UNJc\"pVfz=hr
M)t3 $m8RcQ5^p|_*\"bI.	9+7f\"P`DzdJr
/uJ @a? $jMHbD(F2\"\":{/tp-S<}KjI3_3Xs:<	m2[w zC.,~5qrR>oo`^_*NS1{(L}[1%n\\ooGUisvjEv/dx#v	v;Cxxco^6a=e/q0RsBF-0VBU|}O>s(KS{,k!%&I*O naG$4;h@8Z
W&8KN)%s85r>6#|gJzv))){x 
SPC\"e +&:>A-1qd^2=\\Iwvh|JJhY\"fuH6gu4dcN>v_3T T|D-WF`][oyA<uRR2+iKY$ U'6vvzS~']6:AEk?qkwd?DEfNTxZ02fpO~f.^JV>g}B}n%rH,*ivtA4Q
tV#!7P\\Y$Yi4|XqE1kV6J&)4K .`	 TD;'g(nk]Ip/p~o }pD75J68|jIKo&?
=<NxXr<kxM2&CEOk5k)}L[J2YvW44|hq	A`	q3hZ-^JWb6v<>)r+}tkLK-Z9O
mFH\\#7`r#ywkF7g(um9se,#8wIf\"4Hf(mIvn<~ip7=*02W_
g]JW\\Bvp}S:YYN{VxgYd$opL1?|
s&YxKIJ Ovq{jo$
-uO[9%t~+cO1p))kB}^EN35@}tW0?^faH[x$52U?rf+Lz7v)VOlNJLwh>|13#W,
TXnss>2*^0<do1>b=HW1k |ER|f0N1i(=1!iui7k%O'3,_Ak,I7 _01dDvful-%_k Tp4Xyy<JsFW?9J{':^asj-?! UvcJa$?7%k.C}TtO!-d^++A!4e 0n*P#>b'ViaDd{v~~naBMRy\\|_rhDM+.gjgL%kUt&dWOoDf5wBY%u\"M[fxSTJ;c-J49L*:^S6 {!)s'3w_PVb}%aX	30	Gdb9O(;wrU,;f79?)](1rjveJO#@cw~{+_uiFG&#?#%Advg\\i2fG\\<ZWcycwP\"r=M,|4ayTpqkai,7U
-\"7Z/ICG%5\\1H-\"&?Uk8d_TZkRy_%C,f'ms{$!7=tE8*b\\p%~fS(aQ3{$N|v?	W|'/APh'Oh?+F_4
unu}UW|^LcQN`$'ML;,brlCWGa+X=Sg<A<<%=]cORJ;snQWEFvaj[|RF3;,H^}&h\"IiDI<-rp~5vB[2h.pB}-$K<f6I}S2bJkE:b&Pj~	\\y$C|?=%CC_?]`xt^m 6ti 1uP$G15!+fPWzMuNPk(aUvRtNLWzX]y)'(	L<w=c4A-E,idK$0jlB[)R\\}4
;kIGz:q.xw>C[7|2N Sa(f}:\"WM/#F+OFa*5\"-qsr#W3!x[esRuKY1zKAeO@u>#>YK uqQ`_D'#xDd+gR}(gd9{Ig5LFs#P~nV(|mh_Z$q#zoF4{	%
_ZZhvP9
kG&8%~8NJ#+l~nW[V^k(XNn  GQ|>>\"=THy6=;wt?!Xu -60.|W=xU.x&pI-9'yXDN:E!43i	0XO?C:39LvD38D_E$``dO>,OtWK?cQw L<4C@[b	pWz!	>U_?r-f)1iw|k	3~w6\\qf(Tf*1Q;,aNqW
WFsTZ\\A_Ew*>l	YdYd>8{wL?`C[,*Z4t5F;_#]_UJS<$gv~<o'@>?6[,zdKdT1OLi{;ib_*	qQnJ^j '2t6bURqw4wfw~z[R#@#iG%)R(KlnOHcEi&\\jg~6Z+y
2(i\\#OT=jr66W1N9bg6	RJU#<xveJrKi`%ORsS=a (~m'$UbX>aIdibPzU !vJ,4|25pxqUcJa
84FR_ }TR82F(<7toU
PzW8=K5zjIYmO &s\\6`<)nRvD%BVC+#Pn?9UU%2DveNR9cP: /Z1kY,{q4LgA=k9QH=7_N&[hX>/r84J`W`f^tl|^4t{=CVRAQV).i):_	Og5O0Cyy+@sq-n;@%6\\<s88EZ\"BG]%AkvE{'-57r5m_:BHXW)	
2M.L6yb.;^Ja!*![sY2O,vP\\+?Az)Qdy0REmH\"_rzHxy
Dx:vR$
jd*Oo*N2}AM5Rl~9i\")]T`zFZF.HkI) Zg)T:a,H4=]7@M0#FIj[K
%MB^d2d#PRZZd&cRunT4iWYz<k[~p3 o9GI.d;yF#UAk\"rMt]8y8?7K{U\"n1
^Z6S(
pGtjqoaVvT~5{rV\"G7-yKRa1P'{8<[haZ#WD~NXxvjy2n5\\!^Pn >8'9h]}@	mv,GpFjE[](z!93	$~${ST\\^w#c h[HWgjW@V` )Myc,8MZ
Zfw89N
Ja=*MT;9>HULOmJt}^(:tz%r7N!bJ>%MM&Zfc_Scj+LiTt3(nB&Yx/V.n%/@\\MTD2'rDk%ey.j;mp _Mx`gv'S0#C84qM3=Y>AyCCuwxSuc7c~m]Bu/7&t+u=a-Cfz=_j>u>b$+:Zlzs x[*Z[hBs$_Mi])2%92l|y8]D}7q#P@QF .'YYk$B=CQ|o@g5(SBLIm`F++IeJSA7694XK2x;8xNe [3)a4{d$/_;nDKUUt+3DZin){$Gv9GE
haC5Z<&hNm-hy_LM~,>X@/[<\"f0M^<yL23iK_%|)19^aEQB!t2m 3hL
^PD!{v\"P}dGC3~e1JI-J3t`$gttH2?]g$e\\PT{TFBdTo_#1'et=`A2sppmd2$vW?$ZqM
;-PBSS7 -.A$2{Y:/I?F&O*n='!N&jO?Q~\\*7fm#a[V7'[v<Im5)~pve{hH d;y/!L~V%432{R=	b=	)S[iI0pKuX@RRJhn--;\\~7*;_-9 eG	f+2${S}rl!PLT835J#;Of+<4>*X(z?z> %(o*U2	sa7=YhRI9`fvxz (5;[xya>=
@rtVPSvpdFUCqk`1v?NaG
eePa*h@t
x_#v~DhiB-4\"\"$LCbE&^>^S
G{Ku,sa\"w gv%:8DE>|cR]6V~A\\,=QG(e5mH!OH1^OuA.>vnzWh\"YR`;~a_t 6nxuj/e&<xcFeO-.dXeO 2KL$H5ZjlJ ?rYH2':{i5MDM\"pM20DN[b(Qa|?UsH3^N=e@f6/xKA4B!-S[+gW^bCT_f
&F}4A-
h;skil~h_d3i4:Qt7]\\\"*%Taxy*X^.r3:qylwnJ{?,rh9K'6Y`~F Ij6b7w&)WK\\<Yoo
;hR]b5E-t\\;5]>dE'3P:|B,MoU]m3YP~8a&5Iu_q6b<
5#tcWwS_v7Y7:mYj7S;@:0$@nQ W%/
KFzBoF,r4#|o+gJ9z>U.3F|!CFrA+ApJDjP|	R>p;Pu
UV hxgK_V#	YsdC6Jo={!IxV&3b4vL$ /$=2JY*sTc8c%d{#/0o=Ym]l|I?g*0gCJ,6b!?D{.y1H0-soPi(JQ)a@]s+DrpXvli.qU>A$O@ )[Kvh)$1):K/ewrxJw$L>4/W(6>S;+UyC<SWV:e8cyqT4K;Xhz< 1y4Vt8*@CRg\\|G~P}y[=T #A'uNT
O	`.D<r)g@D(Z!V6g`	[.Y~yvPTYcGf'TaUBoE7hYwa/w>m]pBRWy^VI+
n*D>|lT5?C6vB!IP69Tm?;,\\9{H;?kpR{f3rd^B8y9N| .,dhI*@;6K24PPD.p'U@s6YrfJs1WLjcW6JT.tXv-\\-kkZjY_)4ej)+u'	vqi&g8x,xN| #++~xF}1.L5XL,t4ew.9&b	7'?@'\"Ld_6Yd$,#E$|9Zv	/X\"'[3+CZi!.aY?pzLTIG*D3Vc'W;E/a
I/Cv7{BbF.L2|-Udx.z)
G~{SE=g@Ayh9\"Y<ws$7$S;J?If0vOLlEf{\"tju0',FSN[d	d$_@^(Qv4E)3	z7m`wvPotW;SP
H]6'GR.+A\"BC}i67J>|ZXc.VsCFKcBQ|C?U-,9c1o}vQwL\\wmOU:zL)F6,ZUHd/W-,1ql<_q0k<N2k)X5<f ]dp=% :	~eRy:A>WU(?h1-P>fw\"Tq<6Hk!J8`){Q,Xr^A gR9<Pbes*;7Kb!K{qW^)e<h`=LI/0o8h&\"PdtMazTl:|I($[6|\"Lx(*$2]n{e H#wkpxWon	iy-
0ogkuNx[9
<Du0e'pljWRe&rpL7 {^r5\"&}>nX4892;G8bP>)%T})*,8~2DCuLs-UB^bS\\e+D:&]>aa7+;3?DR&4w7P3%9C?<YWR#&`LYa _&#=
wUPv\"\\{SJKReXupl*X;>n<_9w3{% D
^U\"An.WO
wXu
A8p1<n?3C\"2h(hK!	Hj6P|T
'V&`9/!#ZPv_yK,({7)w$)T:4v.=-?Y	:WGxC|k}r4T~@}( pE3H1 +>;O>D
;zz,UNv'Qz-iuI(4e;g??6v5b-XKm}! CO|e9|k	h%&+W{%)`4d
P-34V7F7'34#q>TV*FZS|6uN]\"JlVB?MA[Q^!m9U!KCtG=nhq`x= YQc7kX=W1ZArh4e89RrAeJX-118[\"#3Wp+?o?R~ D-OjgKeho /%_,o<CR>^04$BNyp`bc_](,/oF8A#Vbe=fd*Z=	9R?E/[#O)8t,R8:hgsf=&o|a?$D&zeq-n*q1?RcwwPGi`k\"Ps5g?D.}A2ar[<UjK]1Mn$]BO-OM%Bh7by;mgl?'zq|pPXi|GXal1+BWAT]!vbyk?![w2/:b;zw	CA\":^RR<gZX<)*]coGBZ%k/;
ws[2K$ofrRe_<c-=[nw'1^=\\E2~wj~$\\Gegf9\\+M*	(oTq1s*xgS/l|B<.1t:`:Up}-6	|@>RePsPVIqEuo*M<m^$Mc5r
'HC.	-3m4s}U<SH6,a}`6x![T-(bYITO-,09u,5'v3
Q%V0EC9o|Jz}d}:
fKtf\\N+oE[2c5\"ll3 -][	CIy^(bnlho'>,yYP6Rts;4::roOkjc5$|A&/HP72hpBS(oOjfG*?`FoiC1L;01 LNsrP(8Vn'[d:\"xAqR` .DL{P7EY#guz]e]!>L$ra/m~	#T6@lls$	d>W{ @(a
yKdi-401<Nd:/|d)T=CkuwS??t/Tuw-dCw-Jsh|M|&F{}-3$/ox'<5Y{?](lWvMG	y/AXsS%sGj7*Ek`2]J(']UjLPuBSsIb-u>N|TfKw^nZ$Rd|_'U|x2qq >	fe(D5%--/ciZAR-]nsIw2BX8xIbvP9Uw+TI+\"bum_+5 +v4@5QmP\"@ry~qU/h>'x$w{%)1Y#L8( :{mILiG/Uu6l+1}s,b	z$61U`{k\"jY-_@u?9vT^1R>'C0Jl>'s7V
cf!D S%dc\\N?Sw=c\\tR^[nBa13m.mHx-<qkIw Fqt|efvp&lQ ,bn]
tW,Pb5CjhzA(A\\]z $K#^`hFEKwl2Hq!>*KheMNd0+UkD\",_FfCZ:h)Q_4{[+\"bh5j@H.EdT\"EQBbZPd851RBwd|`0k!B%;	 ,]`~+ ooF'ZO$gG%yVHmf`ot!0V\"g>A[!)<97|-:Oe |mr-p/lfnGaEd	Vz	5{<<	w*-mY0M4zAVKKS{ iXf<G?_$<zW`DxgGY,-@HZ[^dKSElQg<
=.t
]HZ/3hb*a^waTsD
U%.vE7H[X>qtDw`yEY 8M,!-,paX|~WFQ#g-\".ck#BFa2yD2AszY-6K^[-@wet.`\\Y3A6B4vg\"nK7m>WZs
WrxY_w2lZ=DKf'lGh[F[H}d7A8I>-Y/EOP\\k5{P8+a1l32nJbtKxzUg
pj{{>V=W?kVgx
44hIbG'O)Y0nc-vNR;tZ9lXNS//r8t:	YhAab;z$<sCm:25L_5#$=kb^r*/i|[TZv[b`>l7_7A]
S'_im7b_EH#* AEl3-`~gWhD \\?:lJ*06rYID}XpKD nR;rxIQ%A`*ho}I!^8O`U0\"d2O#v/vz'F,]zZ<B:A?F-(H[uiav:J~dg++4l]gFlsCPT{[
xpy32f.+h=@F_>P<Nm1JJ<a4V6J	f=Z]}vo_SE Qzr_)hFn`:%_[SvtAfowTUa.=_<E75/B$U6m4xFMMC2CBk4w@+KZZznRSqNpL4to39##fC\\k?1!|xvs_ytO'b;$SWG 19q{fNCap}o0%)o	fH,47ZlU&6%q#7&b(muJvV}`!gn(1=|O16'.~g.$c=1)?:=OY0G:=r9ZFi*Iz\\*b?8|RL=IZ<0h:Q5VSY9g\"nd'yOO^SF3b\\fsR=%>?naW$\\WH;$5O)Wq#[<v\"JB\"
Q=$wWX\"Vf:\"l.8\\;=o.Qv5W*3	#dI)#Y~ivNe^iWE~N7FQ c(	_k3z~\\}}_$!C$o,R=t,v4sGB*q\\}:9\"/=[+B)z=rK|(;ZK Z4BTk<MY&>7x!+>H/f@>fI?kbAl.XO :$/8CyH\"QS|]H*mNwaP^]]dUc @sLKV$2s6>0={t?zs>-Esig8}]wM]kVWvL6?B_B*80Ln}m0 Uivw&fy5g>m\\*P]$	2?bJI)u;P\\rq
nz`#\"@xCkx
95]!JYe. :suPWp\\Itkq9E:Aq}h#<tek\"+#RM4zX-ltmk]%q6=4<q!,ST&_4yR4myDD)Uyw8w;+1Demvqjk5	_(CER~7,34|EpNWVfL{Ev5sN0\"QQi<Mr-'IY<J@YmNB`uO WZBQeSzb_1_GKa8fYq mpH^<OtbI}EuVCtuJS6$Ax(0lH6rZ7P5<1su)ygsRX<8(#@g,dEunNC4NVJ {Nqa^h%}uUp*n%_c[C<~7-83McB@,F\"d{v_kL$j~TO*PUK#{s;;<?{fjcS5VMO w
(_JR/6|xMhRwIn@p3k[b_{vM8&9L'K!ogdUpttwc|+o&o5u8}lR[?AV,0Ho ? =S80jr1. tMfX.Q\\x^w9/zawGj3ba#py5 E5uYJqSDm/`F+% cAO4st:xmOWNZ679PiC;3JY#R}1AJA`ireLQ-Tfc,)[C(pW?2i\"y~y9r?NL\"E6
]Gw`/s-b}G=k!V+8#3ZrYat7MT!w$ME=/k5:kdWM4%W06MqbERwD*
BJ>b}>vm	HK0KI,\\6MIuJ[K6\"R=P4X(K13(*!gp0^3DRq~lo#K#OHD#HN jfT=!4b'r,CG'4EWO.dMS)t&FV2&%->9xu/-7VTiT 1#w31Ezz{b*pQOr.zh/SUC\"=LF^Jw)9HUS1|_w2N.dcowhA, 3dcb`]3*do&xv'![5\"v0r>1;\":anttzN?tmVN 0`d*[Vxzb;Y0:iGY!g9x+t`J4.s&S(l?,?FBQ4~q|6KcY*]X4tl07`5Q>mht>%_dnNOUd80\"ik;H2c'|F+] )a`MNKJTC[jj7+#aX.}2%<QlO5mm? bd(7KOjXJ?CII\"_ Hr+?M{t2i41zMZ)JCq-07iH l\"qh!5
vICp@K/?]a#Z,wo:[K7t(D`&bP5;d(+lJV^'sE `MRCN;rFqD}UW=h;Z>Jr+ `#x<HZbozEB](@uAK`4.=EoEZ%h0DsuYh*6FX\"p(6oHb|@`NRZeM <TetmLj(q\\1KXe1yIPFVoPwB(qn]pf09Xw'Sp;^ca'1*|p'ZO7U/n+H~YTy`>.<,kE(pxLUF25kRKS * 2. <E DK-sy[~977KNgrw^ra	F0c{IAv5T3w 6o,*^J=?ZG\\ql=@G'_C`7)	Mk/%/ lN`EjF=~e2)\"V8Y\"W3(e@xM6;Gp5DMd;_d,A`exW6K[QU=`q:kF OWc_,fbo-F'e]T=Q*0J>Grz5n}z,|[g`v>lT|$n<fh$Rz1`m/}$+&!yXhAh^$Y'1[wfy[4
Sd,&+$wR]-p|8WWuA	  (10E]!]sY>)v>v	K\"\"*992))C^-.
jkp=^\\F=,nUi46	YDI|l,AWxDDN)VeR^Tvm4aciU4uo0YH\\\\Qw=u>uskc<8(o9	e?u,
{UAAIl\\:33nZktv(!9rscxtTd-el{Tb@zh%4_wn0]$`\\EI!%A7vanK5w=e!:,?Wq{3`9bi+8[q@DSkx:Q=t\" :`jlQRh#2!7wC6D+ v]d*x9ONLgb=Zn[+x\"u\"+T>r;]XaV T^\\\\A&7OFS
l%l]mJ`g7uPjR4 W{P3*S6nU}1lXV :!5VqZ_>'j	s`;7(Y^AlOP/Ef+[j61~hO-(Y IE^ts3h_&E>j~Jp[T(#E4w-Z|LLaU3bT]e&8#~cm\\>5@E`8506CF4smDy8?3:#f<:1[TW3'ugl!@C\\ 6N{5DNO+%\"n+V0(Iv{+Z+L|F]Ms{aB	@k)%^#oKTj5?J:.hr,s[~~
pYI\\>Q2Hk.yd9;{v><*m/#_m?9~1WgRF`<\\}m 'F^>JqoRnAsuT,}#NPL&*X/iCex$Ghbel]T}o iA;?][x\\^;a}4%l]nHe0$3f?v\\
K_q3W<LY7/,P/X2,{\"!/e~{?=Ui~K(oEm75?FfFWwVxm\\{IRwgT APJuzNhs%.BO|gAdC)dw7;b3	rk\"KWOV n<QH@]t> *PkL7ao Gn,+`4b;97jl3Fzysd=5cY.\"X(Ua`Ko
Q|1]L>G\"mT'xvN8K\"&ZIq#>r 9SmR.+ `{F&]1&^fw`\"QjcnAjZSHPWIUDv_I(M6i$od15FE]&F^b	x~HJB^	%7J?g2HF9+6puB/@O0Vm7V-EPa&hR+~p#bg4k~;)~:${=f$2H0OOKB7%$:CUE*%8	zux7eCLM
;d	GgrO[g)WzkT >z(ty,dy5x0>VoDKv8q!#W=.-FdQ)s7i='lRMG3@L?#qZ7nU^|/Su|g{W<X*.%f;wxRR9E'}w~Ng3F(l,alU)<[:06&c]^)P:BRhZ|#w61b\"HPm1/j'*J/1W~b /z,g&nDHKMm]+0)Ag|DW*n<p~93m$Aim%oZf/4124sc=\\#}JEhnoj|xTcGQQ9n;Vq1~u8Y`K[=$t]g!z\\+`*45|~JQuxb/{Sg`IJW!V /Miir2x*WzhPtu.q9z4,waM 1Y;7*R
bqH-/BL7Ha\"8GOIWX	f7VLw
NLu5arDi[u,JsM
s{twmw(hIPiQ0cW';<*SKgJt&99fAEof]I|=I;0h:SA6 bPh*DlVHb	Fyb7*G[@\\Zyb4 2Z}]Pzus}(H:y;S~._?zCu E}
i}<]	5-<Y5hWP>7:E2y(`VP>LQ=FoaYK`w%fx>eCl_Vp[b7K8>9f*VA[o[7,djQ]`IJ ZVTNh
e`{.n-6R{[37dX/5{5;7Veq[1b8_^ OP:z0u%w\\O4i;1Umn>bS
7k}a1Yi4;#r'/ ofJq@wL5:t='_|UsL8\\\"z(&
Y#m5o>N&YT. Lp)ez*?8mET^|FQs+u]w}&\"6r.eB\\0Vm\"H>OBszB)m_ONz hgX|eM!fm}.$UF8oXN-R}<j4d]h8=4pc +#80LNKwJieziny+L]Ys1|wi>$`TbUe,@(r,xMx$L2n2S;:r&3Vk?`5K4oZ%	rK_	PV{
bt1G6l+=*/' Avc_wrFsSd;~/7/U7&	C!A-Rxr%y/Z[(%aEJsf`7$+7F$KF;?N-OOi:|_Y[9Q+		2'3MRW6r2wJ\\mZV'hSGt\\Hno lhNiU-q,@cO<	J.I9RDQ{k\\J 8	<'uOe[# hK2g_%6&q =aSA^T33jj5$f+`,~S\"-I=3y'ADfA .XM^M%3<aMkb/l%{'hM(rN5A&1UYY%{{.b
r [9J7NB-#Yb ckHqdr<6nXC0wAfKeEm;>pZ:1gOA&`r!i(UBX~;v y`|g\";xXoPnx} 5SqI<GbbIV[/OSY0O`~2!T-kJCbYp)aEm)1N6vmm`0 3,sphM(4x{+-!M`79IMtCq'xsD `EE?EXK,9N=U+qqvMbHfSuz}sD@qMfA	_Nwvq|o5 T3'X@A&5OkhZ
v>p4}{mY+#38LiVK^YDnGl=[UY3>]6R{j2Xo^xD2zmr?uk[}]J!LpKVB5z|Hj;5WX[EF~}/kTHw(`tM_U=8|BG!#WC-]\"t'O-kDwpf?DM>m]Ysa?_yubktcBk)v`ei/8q\\=^WCVb}1+=MXsCj3H)'FLh[i0.gc,35Fd:u9g~2=Ka:f\\bJgZD;>3Xh?&N-(Qus\\hYT(HcT45AH&~t?cZB/%RacC?lG}]%lxmU4N4,(+GuX	Fh1AwksWhci>fTsyp4oKqD-7]*reT?SNy`{f=rIER-*;$E]d/y?)*)=|EA&EbVu05<P[!H-^^LNN**x!Eg 1 _u~P6lL)wUVC*dP!3kg#^aQF\"Zg;h@|GHMp.}bmoRiDLS5
Q{$67~(V \"swoLlZ\\|:s;@Cd\"{i8W`_sRLn[j\\\"Xa&Yr+ctyFM0',[mA~UqwmrruGY*b%s\"8CIf>]O0&PCrSk+bN@
	r(IiNfP^]/ !jEQ afG/Jm8\"l=i#	PaF;&-E#2G;->,/\\D\\)o_W0(YyzFxIr1u|FH!+;Nqty~
OBzw]h 5DEguiF#
 N~/(+RDy|p\\L\\\\lT /n>/@}D4ER?{oksJR#+1A;NF7|h3V7~2wg
9P<F1oji^VFh?inEDfPv*pF6%[	tv~W^3	m#=7(yvC$<r-sg)T!7Qk~|m4\"24)cWa|\\C{Kd!_W9BxCDWl>xPRs`4sW_+yA8K
AvxEP*j__#Y8>b|_%
(9qsw2xoos@^kR5H5NN
=9=7Lo-j2fnB[Y3D7etW]9:&}M4^]C ?_sdK[3?P}6~|6kY($uPSbCKtR2LMW~
 kt&F*/pZwxfVjuZ2F8q$eh1/NPE--c!\\BtIG*SnY&w&,C5SQNSyT]K<rL;#~!@&D`@
JF39-`9b>1-o9r$3I)2ZMN%,a{-e0^3f9n8;>Hgt@)z{sCT\"F_9o@^;h;`\\-H^nd`\\'}r!M;6p'$rZ67A*7^t?-(.MKC%U.bu:-% *N G7MiVxt1bfCK\\[E's#o&!@ !d&j
gm}2r,A'ow|rytak\"bqAt8i[x>>CjIjxPS5Krf3]5>%Rv<!4.jk77^SnBwW	A ~))e_%h(|._gz\"?2*5k; sKQy/pqqe,a{w9J3[<b>S26i'C#I:*v=P_XgYp|)U2rECgF Sa-<>X_(wC DJOj9{Y>V!Y65\"ZaozAwsC:,OYc.'.GGb=T\\\" U6\"+4 qKB~<P|[m_~/oaePqG0%L9l(ADo;> Gmp ,\">eoU9j	:z/#l~O9tGV7N,(y7Am'[MWC$O^dF=N-^-e7|_{`1`y`jD9Tb6zxR:7^qtDA9.>\\VHid\"XB3cQKS
P9wg|hqbu+c&pY?+jjKS@MF\\n0HHQWkGhkr?{mn\\`p	Y0?v(Wj:6E:-\\2'!F|TmXxV[NZpMy-Ee]'{PwE N2s22-O:Y}{'u* 	\"-$XF]-[@2Q>N{$BH'S0B:Dv]M,~Zq0QpG]84`{k0Zw'-`(*MWV6.o]=+T1}k8Ey	&Itk`
endstream
endobj
1656 0 obj
<<
/Length1 2387
/Length2 20328
/Length3 0
/Length 21719     
/Filter /FlateDecode
>>
stream
xuTCAaww	.%;	9X0<U]]]ITMA ;0=3@N^dklD/64001: ;1c0	 (_C,LL Ii
 *@	h[_CDAsw@dm	0303 @FK halc Z uUqU*5 \".IVP 5 j^^./&${ fwFGk# *0	 r4gKhxt *k9') 9Kwok)_^{-68X9%%9hglg:lvve{R-uvtC_.tl<]{<Q\\		@z{fiM^XAZB\\U^Ac {>a19 v [WN'fZ'0,L~WQ(-?_Ml@0	 t  L,[~_i8-N.@ O<3'@ JRRS;h 6s_$mlmT]glki#k&X*,$,J`+\\v6@ =3+_ Wo?^[`c|-	2rw&ng23s ^@:`  3#]`0
6M F?	`C\\ F?`7q2%3Q +QjCZ?EjQ7qjQCUkv?]7q373mm1UgyY^_
5*5J7_mWW96WU_C^{WT?b^ZK?D.:Kp..PKSiEc/V; \"ovtez__M?-\"rg{mz|eeX MfA&K|K~chB-l~ 
7Sx}
?a<6%T]*4G`PH+m@/]6LP>nmdvAy94s<*w;.)`av-/T[L{oh0j #te5zS)o`
_6py\\U&VLl-|XQhe>09dYM'$LgKV/oW2=e	z)|,U@cqIg3=Ic]'AK%PAjYK#2hCumAc~da| bqyUy3O\"Ns3_J1Kk*mY&x|B4y`BGHaMJfK(|'tp^hJi;128@K'@ sxZ83q.[2!.1M(1\"0)dZvO+=5\\d_$4YR]L )Q@E:U~W\\WMmd.l4[*##CvZ@OhHyy%Off6[$\\+i=*!B[\"j>\"Ev=T<hKu#gU&[MjBee#J.^QwLxS=Rfvv]/~Y4IVI93e[%	->R{-+%1jFVO#*6n}77jI\\'('UA;%c4H	4S.-ySq]u\"'C\\(*]`n kJX'`:mFr?,o%[~F{x/+Jz#Hd92yZ@CZ%d8p^f\"|D~.4]So4Em[3sMGx QE UrT ~GV^$A2\\PF!;WWd?[~]1im5AHuLV=C>w1t^_~>`raCP\\Myc<_4!Z0{b3s(LKq>c w-zXsvnE|Lt=q'#u]Mf\"Jh!O4/(@bA1Pp9{LTq`;GdGv(6;J1S XK_eb	A%U}\\]x$eJKS3qm@ :|)vE$ufyb#YC[4}MWwNozdR\"q(\"ql9~RkOQ|;]rt#?vlu5T+XdnF2Bd#=d]uYMo-YSZGS?OI|ZPR-73$g{y x[S3~
[+9naxs'iGXpqs`<6K'P1+xaswBO<	)g2.M.L(YZ.W\\+x)MJK{eK>9JW_|5UhPUmB0 i;5enc[(&YP:%/$kB7Od}xs>rgN't[<gAy?K{\"V-),|*m3<~bC<j%/]
l^A24KOFH5-YB*;Uz *<xq>Mz?jOiB|Ctxz?mfA_-y4 2(}Gp2.Mi	Yk=*WCVx0y*B
 8G4}SDm`e\\H:PQ]_`F4,j=S#}Q9'QT0sLI&SHow]M3uALWyG\\v\\f1_laz	2>6{~	iS'QAxbNsPeBg5<t@rkOse!G\\DA%RSCS	Z 1 d\\S+V8wZ%qS	nT}%-:c:~D^;W6U>_&:s	f'XM#3{.GU5{pUjU	\\w\".023![RpYzWw,pKQ@/Z[E
/$q\\*d7%2?gvW+YM2l~?REq\\H;|{ni4X`_,x*&F'Mcu &Vj']	p5Ca<4:A^]U=lM\\b4wT1z@=M`x7xK}`QZALb.+F1duIRy}hceva Am)3.3-B)&y#2x<}Agvn^*R?uX~5Ap**5 ({ 1ozu``8o!-Ud1Mfr&5]O&8'T#;aS!r!YlMv/:ZQo?9SsDY2e`lH4~lgV4(\\n>^LF\"]<wkny6 zpf5o{|m4ZK	\\DZZiZX'M9gtc/a\"A~
JoS{6`]_]G'HK ^
!!z	K]iOZg{7qAA!;y 5YQ`}V$U## o}qub7#d9IBz%4{))1}A8G[*_3kVa8WG0JR|]&B83e	g3pR[nA}3	cnnIU2fHqS\"|A4jlx3/^T#`5)_BliM^0e\":i.}I7x\"p#k3AeCu&t5A&M9Q\\15yJe#C*Yh'5v8,3kEmy>yq;rcw-O6\\cb2I41^~_d	4{2$>VB})-	y(Ale1s>_(>KWqyV9z1
sA,=3[,
y8#fcd0`#';?
~9bvBkwSp~Z=jj8%{`^n%T.&3[nBwQL;&g(aPEJgkk
)9,N`U1JUGQ.g`	WK[m+J
/%.H]1~v\\tPe^9.V^Q7K/0o<[k\\V=?28	!a+~Zkg9lu`g-+6PS><{	y?HDG&1oH+1<<bt?!A|!3g#X3
/[?H<T@`D#.g.#$/2C.u#%Yazf<r%;gi#0^?`uEiA:u3RH4au9pD,-S5TYb;V{[hCi~c*{mSl^]-5A2BB4]o-y/H^g/t/XD@Ae/szCq8uV[F9Z _w'}qQ&I	eh4#PO~
<pl_'iw&Ym-lFKF=5P]tIe5thg)p,!BKJWzkyYn+Q
[?,Qu=B,	@=|44kd-s6Y$L[qrbiB:k6%k>g7hUBQU65Dfe1>5Y@<3~_p\"oEUVRnb.p% !a2H7FZP:8{E>1$:CsB	VYczwWrA30=R- K?[,FDLVcv#N\";aJYT?\" =-e|\"r2k~h-i	tu$bIfTz	X
Eg~)7FmeMmDdDBJ	#B*qq*U	kF@'R+{ 02Mb)^tor.}mixg{zu
70-,	}?U0_fd+i\"Zy++DC'VS]l-&(*)~a2S {#nk<t \\
Y6Z,%M^a]yIr8P8^!0n\"k	e!29ZWdv]{]+0uf^t}	xD- Y^QIXY\"(:i*L2|dsOexCA(W{vwF3-G;=}duuN.R
sI6[6V+T;*XI%5;\\=$$M#i>oN}}S;W0	xTyB#1? X+|>hAK9g
1aWgLTg`h>^MJRFuIE_!')U`Kl/r BLb-.u$S5~!Sh:.S&Ug25/F%&vZWKam7t#g^_y}HSt
hi$J{>ek=N8;(_(Ay747CE~jZ7kO_thC;[fmLD-b9[/kI'pYb\"&L$*Ax~C(aNVF<a3> 9.d5vD7.O^qlB;VR`a[,~Fb|))e6)ob>w1[Y[;45*QwpI|U:\"6ZH8rD!|1*2)2iVvdP'w<?[r&q+'Efu}v&(:^X=W@x'
2(eP+- jQ[GC0Rv%QtAY.#'oDX;l{-/YYHQd{];?b3.jC&ys;lh24+um&-Nf]x $(gD*s&/OHumz>}2_ q3!rB6Z1DD-vZW\"djL9HHbr%UFOS!/d5	EBn78lJ7APO:h9N_ kb+fuqxZ%S,3tdiC0L|N }*ss-K-/7&FT7a<{PX8%_vJNs[/pTqYUv+ys<GG&ZwAX-$)xjh??RQs$X?Adu51HcU72<4L52Wkcn1ulh:or\\jTVDn+sf32G
0M*W&K]3OeU08U]LQ@tIOwp)a,`9$ hcU*xL(+8FQ{!y(9^ [!RrUTF|*!NS }9stk~Ct@,J$^Xk+S|;-
tnc%VHQ%ybmb3w4;[gw7[CBe/.u\")5dl	9a 2:@:B{\"*b;Vvl1>[\"tI\\4h-`\\>NjV +>V*=fc7k;w*-`-c\\6@m%&}:o;hV}2Y2c&E-+mi-6,UVQBvE|dm'u)De>&L:eYz7m4:{>pCle OK#sH?DAvqFo0'k>Dl!MUq<KJ];wIX6$@)aDL~h>i&\\Q3!pD;1o{VL1iw FS}B8(q>ySDr_LYfnQ01	pJ#Zm54ovp8Yx~Kiy(	6	$kRZuU]!2A1?tTa~#TrV56pU_3kxc~=8w ~9Q.
grGf2CPP>w54pQ$eIO.tRujGOI1_85g /:~Q;|-W'|TvSXYy~I.msnC?CCvTguy}CS'~&z02oe9|rt>4g+{S?_?B
m#GCuSL!s	bb}vBorhPz/C?g7Pw1%UNI+P!>gh e|yg8on5ftw@y(7\\2io$T.8??|wH5'D3;7_BbCD$:XQ2LaHH%J4	:AY;jFdD9pt>.$?PpqQD\"N!rAV
/*nA7_ncCCj	e(;bgA^\\iAYdEc	{5AtJb[adQ$Xg{2_(e=(r*H\\\\E&<T0d:c=OLA8c0<rizoHt|61+m6s2CLnR%:^\"#;~m}|]s9{..[bzg/fO>#_V')XBLtWESs._g MP\"]WgrR\\]yPU0j;j
zT;@k:'si+Cuk]/|\\OTB1R0(0&v?v*J?8O}sj$M/XB>;ABYnBhUN4zmRj`]EBBK',,kj'$2j(Z6[Y4_w6]<k.K	;Yu lG<+e:Smtg8Dx(L3p^Qxe;|CVh;y:.dnk3
69E5x5[$A.}B!mk|t{,LYE?:BMfHKS8='@_{;zgm  Ixmc5p!+LxiOD%u9J?_?M}dq?#pD~\"S3,4Kmp=W?$'gJy?4o Z#]th33zh
um#YWj%}o0_1Id%0cG1T`L/'?	-<ZM(Warx]\\bhp2U|H0y.ZH#a=GWL!V.2vsb0?wdK14qsJ'}<oky6Ffkji<)~i oMwM*so{.e1&1n s\"yr9u
,rKpdv9`M-*wj0QKAm: q%0wH	Q[GXeM]AlJn*TR;_M[s`w/
BbI?<~Vezw61'tiEUqa6|AV~%,ejN<g=MWT74s61@cA8'F(dnkL|O8,a1-HtffuRN}N<y5vb0*bD;{<>3qt$v?9A?t|;l3m5jdUS8&_O)Cb#/=}u_fD?~V)~[Q) t9SG61?RC1t,ZwwrtbYPgy4UyZy o!4-%lBN,Tg_tmu.FV&|v`ql\\zGm\"3BR/*'RR<4i,*F|jv{{k(?#(YRx3[|$I/e7/A4}A!q6P\\||I$&U<BA!OVxReI!!Y0hnfn58c'{8[QTQ	3},`EYq>EiRO~1_JS)TC&+M|(Uy+v*}9h'f7IYl2~n9
;;Nn802FayY0CWiT{1a<FO]*8v?)g7zsk+8s.>]
,:}_)J#8(Jq(<|i-0[I6i
O*ad\\ga@_9 3vGSYd)4PI1n&g +#fj2Dn	P>O\\Zi_#zhBcpbizX)ws =[(:4TMDOw/j<q_1Jvq3nw8eBCg`lM^]x >_+oJKO)?bXI9d	3G0A5|#&LhH 	!LGqU3#}<>tuv]/NF	*.3kt#S==})v YuO<:6a1_#qZ|f\"\"\\S>x8GsRD;@O\\>SeZ#S&?E Trh>J1K<7(J;a1Yh#KE8:fd.ZPKZrvj%42AhIG
U[FU6R,F *vHo%7.oXk'Sj(w?`:xuF<:pI*kAV,@*TM}/eGXk9%G7jLj2@):@V`5fH,HqHO_._vDdpIF9:\"1S5Qj7}o4j$Hbl_z'hEiz0v0>XUU[`}7.`0`t~eMWpl,.hFbK:/cf/;\\u%#y\\7=*jY-aqZIrrUyU9a6(\\:=Wh_h6\" CN4
g
ugJoFu1_4n,nH0UUqe
'z>{_YkIGiQK.BJ/wX5}|[P^$Koh-Ud'hTWwaM7'};2TRe5%c$m%=62*T(q(o[
i
F6iWuS
yCm.a#K:u%E)8#F X;3z{J'(	1YQrglK	V4'@5%{SuOs\\2zvse{I
,63\"% >.!<]xMuU8wWV94{JvMfbyT}YgD+y--#}=j3y0Axz=i^47=siP{1BM4i\"iw.B-'}.Sa/c2xkw1	<LTA*|p[(uoLz|3Yp{8P:RYz:V?=)cB~}[$
*8SlLG<~')hZyAg0rkR&o-,?4RYa[J~.(YLX~_z, ) %9qI3GkSRrY4	n2`Ti)/^:+S./Jj16<]p
V\"]f'9 G><N7_E pY]:K
Cy&[J1P+nn:b+78[dvau'=UxA@!FhcWfdR}_\\ OtLqdPm}dnS[4aPwQ=?|9Cb7M|xI,w.<<TaxH:_LXLt.p	l=K.F/B%M2_W8}OrG~q2ll=R8%Tgw\\LK I^E%-X1CRV3%'[p1UGy~vt_Q@vq/	L&OoRzP#A
Kgn(s:'mNf^RT}4qG0bpT.|//[n**?Gs2=uQNQgI02<Dp2\":NV$y9>{YpO_6ZB'c<DH[,OtXLg;XHQMDrIf.& T`{U%F/Z/vkICnRM>E]*H*hM
,VIn+8]\"taY>x'ERi-1M262=C}sbgW8OSw->?=*j],yCg8;.w-WT@'#W0^My5 o#_Z.E4s/ zVLc_PB.SFA~7o}6nJ]{z:z7kv3IQ4_iS)BA~XgyJ8r#oD3|[i/DoX\\JPg(6+f}5jjHC}n>7ob-54M^>F[b>7D)+SPF
G$%9Tg(MuiQ*\\MqCC44i9A5Y:&]V=ku?),rgpsgh;q,hr^Es&U}.79Gf -L0qaP!B{WHAQDzm^]y^oS^&tmtog{Q.sARn}b`_G_c$qP#06@i'*	rL\\N[j0k	MSrWdcFD!Pb.4Q%`!Pz#=P8NEQ{wW;f+2l
wX<5e0%= D[D T3Zqs(F4/95V%+sz`K8KwW,gR[Ftws9+Sf$\\
;gvvx(,t5X=T7 3*w106/ifQ?S]@@KeQq.=o(XfcA8iE\"mG-KL@0V,4r5p/%.nzLg6WOsm:T./	r{p[dzg[jB,ip.{\\Z
ewN?/r\\
/6=#Ri~1|i5!&u	d2~n_sR	FPTT-'YZlG,XYy8pD=tsg7hp\"c4{)nwrfr'Wf5Nsw%(m.V|&p85,?)?;:5m)OqJ|@N<-fjSyQ%N Ks7`r>d(yh;d&O~< A=V~E_Mlbo!?&9,h[wEUJH;mgmFz~'Vfv  ~h/NI6R ::]G='!lT[LMOp#$NcGpU[&w>s6g;%Vpq*H.LAj?xP-V[ii{-|?Goz;%1&Wu9C>;~8
xm,kcS?/R9g$~;{.}jA>4y-:F{AR-wl(!E#:!aP4%Uk_'NyT0_[IqnIj687D+H\"^Y1F~v-Q<Gg/,03=vW'W+NQ\\\"(T'|EV8Xm|KLAc'bc \\yDb]D`JSOLz*A_g
0u*e
e.b
nz&7GDb.(wmB_w}&z|>'OW:|o7*<B5'LG!:F~8KZP
@CmG#g:6q75}`L@(wNL$p+m}-
>Fz*chz.p'd+Y30N<xS!qaUUlaTh jrLg^0riC<}x69gwJcaWX.w%E27CD3Dx31)*1g5
rfs\"-,R]v(+TQh~RP#AJp^J5% 5@d  `7Gay],G)BH>L~bsL~lJA0M.YpW~d!S2
ld;[i0n	,=	,U~$fz)G6$I>
\"ybYx7?S$Fy] cjl.jr\\%5ro/l5/I+s (@\\]|hg!X.^<:2z%5mA4qTytx)C0ND+o[X)9ZHmJm>nAr4ogA&$jx{h2UjomGD:r\\c[p O*rtattpjQBYQGR)Idf:`5F8r'T \\3fr2LL~h9m6h&))?wq M_P	^ii=V/B9\\]y$$D\\|q,>Xs5 v)ek1&O4@&~Gj\\&)W$s$N2cXRTR)&BJ1aYiy@ [rA)ET]n/ex6bA`UNT9iGn(npOmk}DP%I`]3 rbM )F]]G@J S,/oGC(.4hD^AN1-d%`QVQX}:#l/}61'.a}A0?b5R]Q266Q9( -{vD!mt2^X l,=$M_M:r-J$i1U'wbR
9roq`u\\B 9
i1TD86[fqIOlPcJRP&U/vxA.<Cr!\"X=/'wl:yKKS^{<yi!g5XW-:,~uLZ2O3&X1V WWnF#'X6/5y?eG_&wvn'h2@QQ	.:((^|:{6u ~Rc597iG=+P9-+&>\"V{8aOm~I kx2rAM	J*B;Q^&'.N3/Ja%6#AtcZ.
wSUthsu]gZ;6g*t\";N6:n)50:=c8!/?[N~|*'S'\\4OM7##kQ9&bM[yZ?Xg@
		oft>IA\"/qS XWS:,L~	iJi
WY:t8P  H&u?5L[	)hfI%R[trJft
;b)\\Mdh}iW Ormo=iq_3sOfA~F4Yj
sSqaSlO!./Z(z2$v%B]y*(}_>/eTB\"~R(27&9#V.w[O! 9xlXtd\\^c^	jwVbJ?%0p\"mtpi.jAqpXo
=.
Z/V,&O4@7'CD(W
Q8[
ZD+sO3CB\\=R)+,VQydk@Cz_.>S`/B-/ciZ:~Y)N%rjP-VW
D_Ru9\\BB{#0GYrBy6BcMxhe[!^0?Z_#cAGfRBCTevil.U	N?L3DS?'GE;<93<_&F
d\\\\U_9Pm.zu}/'-UsU&<?>uD%FS[~J>g^?SqG:$.1Y=oqjDDB	,qC AQ&]s<zn{T<.wO&P.9[f^t~^FMJh=\\Dxq!sW(i_gsMlasyF&n5X<U43|lY\"a~v'%UKC\\)4{J@HkxWCM%*,Q~\\Li_a!?G4}o GjB0Zdo!{-E*0[?v!o9u`EO.Z]T.JxJnKS&?l}O]0bF2	f0{Md?)r?Uy	8so*NICj&s	2o 814<Z9=JI~>iUgmCJ.=fvo!OEf76%xN=:|&1pqBM%<VV\"dNT(dzBlsU9SqPgI3'>fS:-7 ;xh-
%;jwL,0f^.FQv-H\\\"Nr>:>tiOR ~O#Fx5$GkIm}<BSk*@|<9[$PqZD4	XYbW_GrujthnI2=^ZN;g(g/^1*
KJ7pmm
(XBH%}e53ws9`@lrd;_:?%&$7IEaDpW,lvBJU:zl:$So&UjLdeFzn$g0F}	~w`\\iz4r2\"F_?xPH0u f)dwm}'.@
h7	>OJ	Z$G)VA<PkRNU7tRI1@?7ZWMM~tfq}fX1I|{D:Y=	e(WHx5ya_\\; ?{AHvxvKmtCj )U+D RJ/\"f{;)f?dTY? 2}Qwaf5$2KlJt>xwAg-s4,uU@?khYbe6T%0Z	^(j*).DnhK$=Q8|w$A
?^H^^=v*S\".V<-^7GI@l%zJV_qeU3p1PLR!a![q]W{Ss9Ddok7c?BLeB
endstream
endobj
1658 0 obj
<<
/Length1 1718
/Length2 1523
/Length3 0
/Length 2576      
/Filter /FlateDecode
>>
stream
xTiXEEE*\" = k!,A$9ILLR)dQ(EEK[;KP,u sy<~{~
q>13}ATt4BHZ*YLZ,nL}\"c!} .P
@0AiDCi+	QfQ:!\\@NQ :@Zz4jD> RE@aK8\\g:qk.\\^\\+	\\
<1H;Ut@2 X`T(Q8n$3*R2]$!/Vb
1].IP%PT@P
uQaB%D)!ed+ '&F6rJH.62!t$B:|q *A8$iF&bR-1%$c!RHWRgb:,:0fq(Eh8Nh7/0$xx P:ec`\\&#Y+d\\e|H2>hPDP%gah
.yDBo11$ 4 5	*(lJf\"ULTqYPwY1e_p3L^NN39Bj18A3ujD>jW8xH1w2D:*CQrPB k@Rh,:mGM6y=GH
R1TOE0	q.	p!@
Dk$E	2XPS`1 C\\Ed0N|\" A^YrAN
<B~$2IIHZ^NtP M^`55 BobZghC, !IKmpaMlv}Wd`sgI_u+O.C,MUKqo?zYG%A\\`]s`mR7XGg*347M--o^#|6 9<#S\"S]g+g&MYx86kxzC)i^ISmWm.~ywB}vaT.uI$t<3ZmGle*I#m=%a/1[GFW)Wjl[o]lqQ,,kekX>VDgOO-yVl<(I_w:FYv;5FYV&Lktsm__pv_N{NG)}soxH9<Gk.E~l^QWSG9m^FToGFUl} ^82[:Z'>}h?)5H}O)K60{~dF%v~uK/{@Uo~{jT^AVV)7c]s}JW?bu\"hs8m4%WevlZ%Qy>JW_z@5lON{j~H~fYnluO;5'mL7x,agtT1n;u9	?WnoXv fkY/:PN%?J7t=:'|O
4~6JVck-Wj)s}ZJLZjqp'=>`_;wtC?of,l_=K-v01O|eUcGs{PPwJNvv^b~u1.Q$;S|oHh[&on0&=v,n&#XGEHHj$md`S?Llq	*.hkSpCDvL@Yyt)_p|-iM?Mvj3[ELamKm;-.,8?h0O|1Ql{P9x6<`}#_>u0x@nCKcU~M.@j&6inZuoMLv/cqywy:Z~A[rmnr0b}9S3qhx6:/_0[.v|cl`YTA~dFqY.y=f[6gt'zl`m`YfrZWpYtO|;h%
endstream
endobj
1640 0 obj
<<
/Type /ObjStm
/N 100
/First 977
/Length 4004      
/Filter /FlateDecode
>>
stream
xZYs7~cD`UrZ'qGa49SBR~qr4>a@LLzCu41&X&QgG:V 'd>-H\"n\"n4 feD`>Zj}`B@F+31'GB%MJ0gI+D*eTsOR\\(B5^HdKPi
4Vo pf`Q4Ye >XP,$fAFLpJqP(rgA5: HWpYPGcBABH(4i>q	:FhyBH?q 0Ydr(wrCEaX#)z0,cO#DaRh _:p(@!I:D0Ehu(Fd9C,W#rRT( !JS0 R)d9R
S1z0(%)rrJ1QF>B,m \\krm@O=?Y&z6fxo&k~3%a:K7wow?]Et[ojz9]o. u*2'!kXNuLgejQO3 SI)hyJk|JMn
?tsnzS6ov#0lE3 *]IT	zCC?vw,|m@CbG+#yy}y9dy+wY/N!f;Vk\\iZ0Yp ;0XB)rMY
D
wf	igC >
H\"gR(,OZ*K6xZE~Ju5|\\&_\"^VU%gMF	).>#.SHKAUeLw>`v-o_NZS5+!:fH2\"R0&BGHajYe[VCw/b3:
h[!#v]ox2E>n +I]|j[F@y#L@2J&x,IaoF>Jy[@1h:v4Dwcf5R	4Z!A_ev!0	 [N~qW=FQ.9<^6cA\\K[;zR
v$7%4&<Yq_Jb]6UJ=e=]dg;7mH1#z9I%8 m6x[^AZ1!p<&43f&XJ[-DZ1/-tFg,+@K^FR,)'3KT@gbeL-@16+ 1E`E]xrQVBf(yQQG\\?`Tf^zq4t%h/I4F-jIi[-Ej,:'E<mzwNvJwVpx'aJ
`i>:yHUP3O2QH;!fU]PMsQKWvYty6w}oF7f[fRk'nyyI w\"2z7[-7	7/3Vq5M~_G>o/xf~_7fy5now6^|{Mk~vgKTKy{?v/8}dvOk=~v\"| AA4v]f{;6F$Th-qT\"erng}?g{#?/%f]gf;Yvmw|-uUw+Ms|}}=CG-+D'u7wV__*_n*W%_..W}&ez/V./JvEol3nhD,@'r-c,z-\"f]CY`?fnzaS0W?<m8=Ql}by~fPLla$8E}@*CMUW
C],cS ~f^]* mjW GY$F2eqdw[hr$9~sbR)JU6L}	
OvyoJ're,	O)b5'f]Tb,	kM*Z2M=RIz\\R`/sp8|Wp6\"Z41mygkQuraZ
~ovY=g.~l~i,~H
tB,m2n.F/nt[Kt9gHKi#D#%BZ
jgGg{>wt:`n;\\`)3YP&MXgr@\\yYbF
Q&LBH]&02yRlh+*}\"\"	N_ B.\"e2	$JD)U$('ZIFRQ&!L`L[bx(g
L_d\"3
Y.ESKU&IbVE*2uYE)2S\\Q6\\[[&E&2Hj'?I*.BRLIc2%,L3,[ !l	d[!{J.*+{t\"D\\Kt%x/_9uKjHAK?P%.	bO@.IVxgetK'S o?Lk+1D-Q3o /*/3Kxu%x)0KUt2=^jWE[DK!^{9a{9a{9a/{aGy!/BKa/De{1/\"uZ}?OW:W2VH} *'EJR1jz!Fy!\\z>qC>q'xuE EGQ2FGqD8X]b.I!cmu='!'xT';;S]b/K 3 G0C	+z{^a+j{^a*j{^a*j{^a*r{^a/+r{^a/+b{^a/*b^-Z1~Cpz_bCj3?=x5=6=^rF5]jP.Q{M.n^bk0t6]Q{-Z00aC
u9r5}0kkaBp_Ch
=X^tH+)|HQPbAKIu7]!uC]j{Aj{uaBpuy2v
endstream
endobj
1665 0 obj
<<
/Type /ObjStm
/N 100
/First 883
/Length 1719      
/Filter /FlateDecode
>>
stream
x}47)B#X{tWejG>>>3= [F?9a[7o67iOl}Sos2km7N11pl
2X`Gc0xpsOj%i>uqF	S,B)+t,a2\\E	$OQ(Vn1LLNa%2Zc24P Y,Pm*Y*`sqYPe3'+`>q3xF8`1l@&DJUjTVQa$8`vmpC,.Qcpc1Ci<x!'Ns?X
XB 4aJ#p1HL3(q\\9SdgOf+<,pb?Sk|mDx8~?}T^|c_
=~cO?geAK-{kI_Y.ZQi,jki3-qVhVKe(4h!2B^,~k{>]KK-ikaX+N{FFL}'_:?KXw{G3vz^3.-BwaJBOF(4he7- n9{-k`o{uZ2d/fK^{g={d^2p({wgK=[=c}+\\}kp+za\\ljw]p;OE.=3S_]w]WuE+qnhiz>.Z7rr\\W3Uw]%x:YuU+	}vs{(Yno\\W3U_]w
MHr~V_W~uE+4%_uU)i~WQdW3U_E>fnhjo)Z@H-<jOX_-qZ7G/ZY^reV z+++EJDYjYJ}Z,-g?Ks+~td?~G`?3G~8{+[`?29mo_s~jNh]'{r]jR]]4/.Z'D'+- 6d{8^=2}[`3}{9V{ehqT\\2h]Z}pjd>Y,>^x$?__2[vt7.3.\"_bUKV/9.q1.8Bk.,ve,|ol|V1#^V#Ffp#bVhB2[^4b5EVZ~)Efp\"_BJ~/~}_d_dnp
endstream
endobj
1666 0 obj
<<
/Type /ObjStm
/N 100
/First 914
/Length 2837      
/Filter /FlateDecode
>>
stream
x}M+)FD} AEWEPY\\MRLESfM|$(naXZW\"FoDM~BaKl- iL[lm+}lyEE$NuKbb(Q$
nY|GO,-
#bGTK	2C>ARAN$$&7$F(m6IXDKbT+\"vID}$-oU
E~bBmK*)%[rP?xM* ^I.J<I%5'nm(x=*l3|\"Uc8DDyX>IiK;pqz%pJ$Diq+d7&r-m~KSAwGA>L]?rO
cIErYe,3`U	V-Q,w
P7haM[|aM>C*\"+b{(yGQ(:cQ5aG	.u|L7m/|'cvedbY|X*/+VXlbI,AEXO]qu\\x3?)/Wy_#Q'<;fs]{vzcOa~jS_Vn`c=.Gtks7KSb#]'WUjjs5JY&l[tY.cE/N{a;^f+`|b+`|b+`3Vg='={Za'=V`O3tbv2iNq=4Oq=4Oq=q=
{0{8vvP/}Aal}aBl}tY=k[n#Y?ksP>M`=]c{}J8C1$^/ufi.az:/DYOX_Y<_(n5W=P(g}lyv|OYw<ck:1}15Mq~8kg7{:&8{N7m}g}'g9c9ty>(#$!o??~O_>VxW#e4)GS\"?.~9p5B2Lv<LEM&
S6~m.OR4\"E?=1RTeLU14)9q8n)j(:.)Fr2[Siw/I1Q[dn0TrNPoUN?SW\\>A}\\\\ynsq('+<nx)d#4{n)b2VP(VPuT)5+6.k6WJ	a%eV!/S,jVn5~?4>>p`J4+QMS-nr+I7!A*q%&%F&_n7T7	f*cT%U=QTDnrJjlhl)IdSd3?@*h a\\RLl^Plv|(6PV1TK[k^vGS9/v5obgg9g&O@hNmBZfed)sg`vdW	Ft _'9;esv1||fW
+)XM	k	 	8W'SpnN>&|L9O|z\\W{ZaB^pf_C.z/ce_#&iiD0UsZO3oWlYW
E_|L8r41s&sdW	 <+:wB]{	+q_0]Kt=}90&`0>~fS.+0;Xz(Kr1c/y%=.;8R.^)@8:j :84PCiN>.K{
G<jt1G3HMvcASII^(8	RvxX1r/Xm/G:8+sJA${R\\fp@8UW^sJ8PY90ZT_% 6*^o+0;|W-_se'Vy]b^#_-<W(ijC;`?__o`N4suK>IvZm}w%TWCM/ jI$+L}Ly5?\\M\\Qd+l ^8lP>qx}Ap v&4	9}e3j!U\"VJGJW8aPU6rf-b'dI$lqA\\VSL9pg)}
endstream
endobj
1733 0 obj
<<
/Author()/Title()/Subject()/Creator(LaTeX with hyperref package)/Producer(pdfTeX-1.40.15)/Keywords()
/CreationDate (D:20140903113951+01'00')
/ModDate (D:20140903113951+01'00')
/Trapped /False
/PTEX.Fullbanner (This is pdfTeX, Version 3.14159265-2.6-1.40.15 (TeX Live 2014) kpathsea version 6.2.0)
>>
endobj
1713 0 obj
<<
/Type /ObjStm
/N 20
/First 192
/Length 680       
/Filter /FlateDecode
>>
stream
xMo0:.V	Oti!h\"@Kvi],F/E2dUDSP\\\"[X.D$
e.
(c( $PZa8S\\^6Swf}{WN*wx9.K]tTA\\onis(Y&o+Ui|Wfu+BR\"dq%c:&cKj\\=-IrYn^ `C
QK!vZMGc&JldSl*Y&[q\\i&5P&[*ON~)qs/#v2G;`t{}:\"tum~0M$1VAK]	MmUAYe#C`Z+6xx@<<l`wUNK!B-LDD6A&'*R=QRJFFg3p4p4p4p1,?-z,_N7kN2p~=479{Qf;Za~:|:o{.Q|z1
endstream
endobj
1734 0 obj
<<
/Type /XRef
/Index [0 1735]
/Size 1735
/W [1 3 1]
/Root 1732 0 R
/Info 1733 0 R
/ID [<5D4772BAFF28DE565FBAAD7EEC8D4B3C> <5D4772BAFF28DE565FBAAD7EEC8D4B3C>]
/Length 4066      
/Filter /FlateDecode
>>
stream
x%[lWg_Nb;;8oI/s;-HU} @\\UBR- C7!R+OSK
!U|_xfk	 ,0 hSUI4!	B;vmhnhshum(av	mDv	4]C&lw=h7[AM`/
 ava'B[E E'=h>h}!BD!U*64^7SBj tih5h]cht[hjO5iHNqh{	'iF4$BF8fvi*fh{sh{4h/94<2Y Wv^zz7M^`	MiVhhJ5p0Z-pmMvm#\\hGd!(Z5&B;&> |P3Fc-
!!g0{EA+0{<rfY]<1BEe=>5gxh	,
	1fYB$4*#2($	,
	fY\"1Be8*1Br7f=f891BJ3($F3($+=Wf0!f0B#'3avWDI3g]'fw;f0UBav|a;\\!fw;f0%Bava;b;(1;vPn4JL1Gehp0@;Cs&M
fw%BM(fwh}%fwGHaDC$n4hv%?fw;'q09k>D3NN fw;9NXOk fw21 ;{`v'c%l # ;aN&l% !V}`v'cv vd ;I?a7n a/6Z>>bvCnMZj dv-
4\"f.BM f)$-Mf(#c\\9;d/9;D9	0{N!i#=gh*ff!<0{Ex`\\. MhJys-(f(} f[v^=oCS =oGA0{N!Q.SH	oGSkA%0{Ev0{~m:9;DV{ 0{p`\\lZpb1{U
 f.$BZUB\"Vs*vsH`%\"l =gA6	f)D	 fYP- ,(nsh`E!O0{# =v`!C`Bt`|	m`|m 9; 9BB80{N!Z&=g-S	G$2;Ctpu@fBFx
,(U	P1{8hpLN42,8]\"<	huhsBP_] .#tWXsh;ehpnj`0v[ahP.#+nHweD:%}44x +	e-4v2[w?+Ct@F ,*ch	F4FX(DZqQ:P6v@|FN4-
G@3aBT\"V^N^~0 Ap]]T{Mk44L`Lq	8k*:fd}L08.`K2Up\\7M2X*X}	>;`< &{! | |5 6@\"Z@z@T;	iwHVz?iIOZx'-<iIOZx'-<iIOZx'-<i}S` 9$o] <yOx<'<yOx<'<yOx<'<yt{R39{<'#:TjP \",5ku@_#P	kj7	*{:Rn?P-; j!4x&F O([<uK' RCZ(s4*~>`w]:f,6umK,\"XS7J[1K-4m:dYw:JGf)Z. 1Gq|G',q ,>`fb53,xQr>'MS`*M=K5+kOK U<k_*B6RgYz>i|7+P21:rkC[e8iuitWwPA+TWmf1Ei1iH3*4mgT5:UT}QD	ISqv3f6k3{1i#r,V>;_e'?w{T5LfK<I
f?*oTW=z@{-f?Tk_-MkDmcThg4U 2$^^cf{WvZx2~o@5g/}48.}i-pK#seIMJUX%7lQHm=
6iw,]lZ@hpK%w.c^CQ 8F,xQQ0NZ@YBE}O5T> *J*.ZRP1T&Y *u:-:,|q 5>-&/Q4:#JkPylS-e+L
>[s:K;hLcN!Nf:Lha_n) f:=qpP~C\"44\"I@!4)kJJJ)/?LmJoJLrJKJKJ2;:9p) )	 )	 )	 )	`ft*%3~@z7u>7:|FnJMQc'tD-n,F(UQagf<`&g<hm46@FmT63*fk:Dl4Q1%Q
3*\\eVYhQ`WbhI=(ceV|O'4\"fWV]<.6JFX:m*e46
btp6nd~SQ2ZRFs&]!cl5LM2isKSE=5aa#'#*s^~K|gYuToUSuDJELr4FLcW?Lq.3=eGoF#@?3`>G(g]~H_0e&L'_m~T2Q_2c_f>zBY(3e}g>:&]_j`	+:v	+:K8+~J1?X
endstream
endobj
startxref
355845
%%EOF
""";
                                                                                      <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-build-cg15.pdf>;
                                                                                      <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-ryansroberts>;
                                                                                      <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-build-cg15.pdf-0000000000000000000000000000000000000000>;
                                                                                      <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-d1f7dbf208197c841e5d3858db1c3dd0f8581842>.
<http://nice.org.uk/vcs/file-makefile-1d2f4fca2283b76d3769d9cfa8cc993075f984f6> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                <http://www.w3.org/2011/content#chars> """
GUIDANCE_DIR = src/pandoc/CG15


BUILD = build/

INTRODUCTION_CH = $(GUIDANCE_DIR)/chapters/introduction

RECOMMENDATIONS_CH = $(GUIDANCE_DIR)/chapters/recommendations 

MARKDOWN = $(INTRODUCTION_CH)/Introduction.md

RECS = $(sort $(dir $(wildcard src/pandoc/CG15/chapters/recommendations/*/)))

MARKDOWN += $(foreach rec,$(RECS),					\\
		$(rec)Set.md			  										\\
		$(rec)Discussion.md  										\\
		$(rec)Recommendation.md                 \\
		$(sort $(wildcard $(rec)*ES*.md)))

TEMPLATES = templates/

clean:
	rm -rf build/*

PANDOC_OPT = -r simple_tables+table_captions+yaml_metadata_block -s -S --normalize --smart -f markdown --standalone --toc --bibliography=$(GUIDANCE_DIR)/Citations.bibtex

html: clean 
	    pandoc $(PANDOC_OPT) -template=templates/html.template -t html5 $(MARKDOWN) -o $(BUILD)cg15.html 

pdf: clean
			pandoc $(PANDOC_OPT) --latex-engine=pdflatex $(MARKDOWN)  -o $(BUILD)cg15.pdf

all: html pdf
""";
                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-makefile>;
                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-ryansroberts>;
                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-makefile-dbf388eb52d5447c7acb44d0534799d8cf91a975>;
                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-d1f7dbf208197c841e5d3858db1c3dd0f8581842>.
<http://nice.org.uk/vcs/file-makefile-f2975537923f1efd454f7e59d27ee94a88902d44> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                <http://www.w3.org/2011/content#chars> """GUIDANCE_DIR = src/pandoc/CG15

MARKDOWN = $(shell find $(GUIDANCE_DIR) -type f -name '*.md')

BUILD = build/

MERGED = $(BUILD)/merged.md


PANDOC_PDF_OPTS := --toc --chapters --base-header-level=1 --number-sections --template=virsto_doc.tex --variable mainfont=\"Liberation Serif\" --variable sansfont=\"Liberation Sans\" --variable monofont=\"Liberation Mono\" --variable fontsize=12pt --variable documentclass=book 
PANDOC_EBOOK_OPTS := --toc --epub-stylesheet=epub.css --epub-cover-image=cover.jpg --base-header-level=1


clean:
	rm -rf build/*

concat: clean
	$(MARKDOWN)
		cat $^ >$(MERGED)

html: concat
	    pandoc -c --normalize --smart -f markdown -t html --bibliography=$(GUIDANCE_DIR)/Citations.tex --standalone --include-in-header=style.css $(MERGED) -o build/$(@F) $<

all: html
""";
                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-makefile>;
                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-makefile-1d2f4fca2283b76d3769d9cfa8cc993075f984f6>;
                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-Citations.bibtex-aa7aab08f4333f9e90d619004748c76f172ee25d> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                          <http://www.w3.org/ns/prov#Entity>;
                                                                                                        <http://www.w3.org/2011/content#chars> """@article{Alberti_1998,
	doi = {10.1002/(sici)1096-9136(199807)15:7<539::aid-dia668>3.0.co;2-s},
	url = {http://dx.doi.org/10.1002/(sici)1096-9136(199807)15:7<539::aid-dia668>3.0.co;2-s},
	year = 1998,
	month = {jul},
	publisher = {Wiley-Blackwell},
	volume = {15},
	number = {7},
	pages = {539--553},
	author = {K.G.M.M. Alberti and P.Z. Zimmet},
	title = {Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a $\\lbrace$WHO$\\rbrace$ Consultation},
	journal = {Diabet. Med.}
}
@article{Hearnshaw_2001,
	doi = {10.1002/pdi.262},
	url = {http://dx.doi.org/10.1002/pdi.262},
	year = 2001,
	publisher = {Wiley-Blackwell},
	volume = {18},
	number = {8},
	pages = {274--280},
	author = {Hilary Hearnshaw and Jan Hopkins and Andrea Wild and Mary MacKinnon and Roger Gadsby and Jeremy Dale},
	title = {Mandatory, multidisciplinary education in diabetes care. Can it meet the needs of primary care organisations?},
	journal = {Pract Diab Int}
}
@article{Batista_2010,
	doi = {10.3402/dfa.v1i0.5203},
	url = {http://dx.doi.org/10.3402/dfa.v1i0.5203},
	year = 2010,
	month = {jun},
	publisher = {Co-Action Publishing},
	volume = {1},
	number = {0},
	author = {F{\\'{a}}bio Batista and Antonio Augusto Magalh{\\~{a}}es and M{\\^{o}}nica Gamba and Caio Nery and Cristina Cardoso},
	title = {Ten years of a multidisciplinary diabetic foot team approach in Sao Paulo, Brazil},
	journal = {Diabetic Foot {\\&} Ankle}
}
@article{Larsson_1995,
	doi = {10.1111/j.1464-5491.1995.tb02078.x},
	url = {http://dx.doi.org/10.1111/j.1464-5491.1995.tb02078.x},
	year = 1995,
	month = {sep},
	publisher = {Wiley-Blackwell},
	volume = {12},
	number = {9},
	pages = {770--776},
	author = {J. Larsson and A. Stenstrm and J. Apelqvist and C-D Agardh},
	title = {Decreasing Incidence of Major Amputation in Diabetic Patients: a Consequence of a Multidisciplinary Foot Care Team Approach?},
	journal = {Diabetic Medicine}
}
@article{Brink,
	doi = {10.1515/jpem.2002.15.8.1113},
	url = {http://dx.doi.org/10.1515/jpem.2002.15.8.1113},
	publisher = {Walter de Gruyter $\\lbrace$GmbH$\\rbrace$},
	volume = {15},
	number = {8},
	author = {S.J. Brink and M. Miller and K.C. Moltz},
	title = {Education and Multidisciplinary Team Care Concepts for Pediatric and Adolescent Diabetes Mellitus},
	journal = {Journal of Pediatric Endocrinology and Metabolism}
}
@article{Yokoyama_2001,
	doi = {10.1046/j.1524-4733.2001.40202-126.x},
	url = {http://dx.doi.org/10.1046/j.1524-4733.2001.40202-126.x},
	year = 2001,
	month = {sep},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {4},
	number = {2},
	pages = {115},
	author = {KK Yokoyama and KC Griffin and PJ Godley and AK Cryar and BW Woodward},
	title = {$\\lbrace$PDB$\\rbrace$9: $\\lbrace$COST$\\rbrace$-$\\lbrace$EFFECTIVENESS$\\rbrace$ $\\lbrace$ANALYSIS$\\rbrace$ $\\lbrace$OF$\\rbrace$ A $\\lbrace$MULTIDISCIPLINARY$\\rbrace$ $\\lbrace$DIABETES$\\rbrace$ $\\lbrace$CARE$\\rbrace$ $\\lbrace$CLINIC$\\rbrace$},
	journal = {Value in Health}
}
@article{Dargis_1999,
	doi = {10.2337/diacare.22.9.1428},
	url = {http://dx.doi.org/10.2337/diacare.22.9.1428},
	year = 1999,
	month = {sep},
	publisher = {American Diabetes Association},
	volume = {22},
	number = {9},
	pages = {1428--1431},
	author = {V. Dargis and O. Pantelejeva and A. Jonushaite and L. Vileikyte and A. J. Boulton},
	title = {Benefits of a multidisciplinary approach in the management of recurrent diabetic foot ulceration in Lithuania: a prospective study},
	journal = {Diabetes Care}
}
@article{Cox_1995,
	doi = {10.2337/diacare.18.4.523},
	url = {http://dx.doi.org/10.2337/diacare.18.4.523},
	year = 1995,
	month = {apr},
	publisher = {American Diabetes Association},
	volume = {18},
	number = {4},
	pages = {523--528},
	author = {D. Cox and L. Gonder-Frederick and W. Polonsky and D. Schlundt and D. Julian and W. Clarke},
	title = {A multicenter evaluation of blood glucose awareness training-$\\lbrace$II$\\rbrace$},
	journal = {Diabetes Care}
}
@article{APELQVIST_1994,
	doi = {10.1111/j.1365-2796.1994.tb01104.x},
	url = {http://dx.doi.org/10.1111/j.1365-2796.1994.tb01104.x},
	year = 1994,
	month = {may},
	publisher = {Wiley-Blackwell},
	volume = {235},
	number = {5},
	pages = {463--471},
	author = {J. APELQVIST and G. RAGNARSON-TENNVALL and J. LARSSON and U. PERSSON},
	title = {Diabetic foot ulcers in a multidisciplinary setting An economic analysis of primary healing and healing with amputation},
	journal = {Journal of Internal Medicine}
}
@article{Frykberg_1997,
	doi = {10.7547/87507315-87-7-305},
	url = {http://dx.doi.org/10.7547/87507315-87-7-305},
	year = 1997,
	month = {jul},
	publisher = {American Podiatric Medical Association},
	volume = {87},
	number = {7},
	pages = {305--312},
	author = {RG Frykberg},
	title = {Team approach toward lower extremity amputation prevention in diabetes},
	journal = {Journal of the American Podiatric Medical Association}
}
@article{Riazi_2000,
	doi = {10.1002/1528-252x(200010)17:7<226::aid-pdi71>3.0.co;2-x},
	url = {http://dx.doi.org/10.1002/1528-252x(200010)17:7<226::aid-pdi71>3.0.co;2-x},
	year = 2000,
	publisher = {Wiley-Blackwell},
	volume = {17},
	number = {7},
	pages = {226--230},
	author = {A. Riazi and S. Hammersley and C. Eiser and J.R. Eiser and J.E. Tooke},
	title = {Patients{\\textquotesingle} experiences of the diabetes annual review},
	journal = {Pract Diab Int}
}
@article{1992,
	doi = {10.1111/j.1464-5491.1992.tb01803.x},
	url = {http://dx.doi.org/10.1111/j.1464-5491.1992.tb01803.x},
	year = 1992,
	month = {may},
	publisher = {Wiley-Blackwell},
	volume = {9},
	number = {4},
	pages = {389--394},
	title = {The Diabetes Annual Review as an Educational Tool: Assessment and Learning Integrated with Care, Screening, and Audit},
	journal = {Diabetic Medicine}
}
@article{1998,
	doi = {10.1055/s-0029-1211985},
	url = {http://dx.doi.org/10.1055/s-0029-1211985},
	year = 1998,
	publisher = {Thieme Publishing Group},
	volume = {106},
	number = {03},
	pages = {240--269},
	title = {A Desktop Guide to Type 1 (Insulin-dependent) Diabetes Mellitus},
	journal = {Exp Clin Endocrinol Diabetes}
}
@article{Grabert_2002,
	doi = {10.1016/s0169-2607(02)00035-4},
	url = {http://dx.doi.org/10.1016/s0169-2607(02)00035-4},
	year = 2002,
	month = {aug},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {69},
	number = {2},
	pages = {115--121},
	author = {Matthias Grabert and Franz Schweiggert and Reinhard W. Holl},
	title = {A framework for diabetes documentation and quality management in Germany: 10 years of experience with $\\lbrace$DPV$\\rbrace$},
	journal = {Computer Methods and Programs in Biomedicine}
}
@article{Azzopardi_1995,
	doi = {10.1111/j.1464-5491.1995.tb00471.x},
	url = {http://dx.doi.org/10.1111/j.1464-5491.1995.tb00471.x},
	year = 1995,
	month = {mar},
	publisher = {Wiley-Blackwell},
	volume = {12},
	number = {3},
	pages = {271--276},
	author = {J. Azzopardi and F.F. Fenech and Z. Junoussov and A. Mazovetsky and V. Olchanski},
	title = {A Computerized Health Screening and Follow-up System in Diabetes Mellitus},
	journal = {Diabetic Medicine}
}
@article{Burnett_1992,
	doi = {10.1136/bmj.305.6854.627},
	url = {http://dx.doi.org/10.1136/bmj.305.6854.627},
	year = 1992,
	month = {sep},
	publisher = {$\\lbrace$BMJ$\\rbrace$},
	volume = {305},
	number = {6854},
	pages = {627--630},
	author = {S. D. Burnett and C. M. Woolf and J. S. Yudkin},
	title = {Developing a district diabetic register.},
	journal = {$\\lbrace$BMJ$\\rbrace$}
}
@article{Burnett_1993,
	doi = {10.1111/j.1464-5491.1993.tb00047.x},
	url = {http://dx.doi.org/10.1111/j.1464-5491.1993.tb00047.x},
	year = 1993,
	month = {apr},
	publisher = {Wiley-Blackwell},
	volume = {10},
	number = {3},
	pages = {199--200},
	author = {Shirley D. Burnett and Martin Press and John S. Yudkin},
	title = {Compiling A District Diabetic Register: Theoretical and Practical Considerations},
	journal = {Diabetic Medicine}
}
@article{Comino_2013,
	doi = {10.1071/ah12175},
	url = {http://dx.doi.org/10.1071/ah12175},
	year = 2013,
	publisher = {$\\lbrace$CSIRO$\\rbrace$ Publishing},
	author = {Elizabeth J. Comino and Elizabeth J. Comino and Duong Thuy Tran and Duong Thuy Tran and Jane R. Taggart and Jane R. Taggart and Siaw-Teng Liaw and Siaw-Teng Liaw and Warwick Ruscoe and Warwick Ruscoe and Jill M. Snow and Jill M. Snow and Mark F. Harris and Mark F. Harris},
	title = {A preliminary study of the relationship between general practice care and hospitalisation using a diabetes register, $\\lbrace$CARDIAB$\\rbrace$},
	journal = {Australian Health Review}
}
@article{Howitt_1993,
	doi = {10.1136/bmj.307.6911.1046},
	url = {http://dx.doi.org/10.1136/bmj.307.6911.1046},
	year = 1993,
	month = {oct},
	publisher = {$\\lbrace$BMJ$\\rbrace$},
	volume = {307},
	number = {6911},
	pages = {1046--1048},
	author = {A J Howitt and N A Cheales},
	title = {Diabetes registers: a grassroots approach.},
	journal = {$\\lbrace$BMJ$\\rbrace$}
}
@article{Kelly_1998,
	doi = {10.1016/s0169-2607(98)00026-1},
	url = {http://dx.doi.org/10.1016/s0169-2607(98)00026-1},
	year = 1998,
	month = {may},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {56},
	number = {2},
	pages = {205--210},
	author = {William Kelly and Rudolf Bilous and Gordon Murray},
	title = {A comprehensive register for diabetic outpatients: experience with desktop computing from 1987{\\textendash}1996},
	journal = {Computer Methods and Programs in Biomedicine}
}
@article{Taylor_2010,
	doi = {10.3945/ajcn.2010.29317},
	url = {http://dx.doi.org/10.3945/ajcn.2010.29317},
	year = 2010,
	month = {may},
	publisher = {American Society for Nutrition},
	volume = {92},
	number = {2},
	pages = {390--397},
	author = {R. W. Taylor and L. Brooking and S. M. Williams and P. J. Manning and W. H. Sutherland and K. J. Coppell and D. Tipene-Leach and K. S. Dale and K. A. McAuley and J. I. Mann},
	title = {Body mass index and waist circumference cutoffs to define obesity in indigenous New Zealanders},
	journal = {American Journal of Clinical Nutrition}
}
@article{Edelman_2001,
	doi = {10.2337/diacare.24.5.957},
	url = {http://dx.doi.org/10.2337/diacare.24.5.957},
	year = 2001,
	month = {may},
	publisher = {American Diabetes Association},
	volume = {24},
	number = {5},
	pages = {957--959},
	author = {D. Edelman},
	title = {Rate and Predictors of Glycemic Testing of Nondiabetic Patients in a Managed Care Population},
	journal = {Diabetes Care}
}
@article{Kopelman_1995,
	doi = {10.1111/j.1464-5491.1995.tb02068.x},
	url = {http://dx.doi.org/10.1111/j.1464-5491.1995.tb02068.x},
	year = 1995,
	month = {jan},
	publisher = {Wiley-Blackwell},
	volume = {12},
	number = {1},
	pages = {83--87},
	author = {P. G. Kopelman and J. C. Michell and A. J. Sanderson},
	title = {$\\lbrace$DIAMOND$\\rbrace$: a Computerized System for the Management and Evaluation of District-wide Diabetes Care},
	journal = {Diabetic Medicine}
}
@article{Vaughan_1996,
	doi = {10.1002/(sici)1096-9136(199602)13:2<175::aid-dia18>3.0.co;2-w},
	url = {http://dx.doi.org/10.1002/(sici)1096-9136(199602)13:2<175::aid-dia18>3.0.co;2-w},
	year = 1996,
	month = {feb},
	publisher = {Wiley-Blackwell},
	volume = {13},
	number = {2},
	pages = {175--181},
	author = {N.J.A. Vaughan and M. Shaw and F. Boer and D. Billett and C. Martin},
	title = {Creation of a District Diabetes Register using the $\\lbrace$DIALOG$\\rbrace$ system},
	journal = {Diabet. Med.}
}
@article{Day_1992,
	doi = {10.1111/j.1464-5491.1992.tb01905.x},
	url = {http://dx.doi.org/10.1111/j.1464-5491.1992.tb01905.x},
	year = 1992,
	month = {nov},
	publisher = {Wiley-Blackwell},
	volume = {9},
	number = {9},
	pages = {855--859},
	author = {J.L Day and J. Metcalfe and P. Johnson},
	title = {Benefits Provided by an Integrated Education and Clinical Diabetes Centre: A Follow-up Study},
	journal = {Diabetic Medicine}
}
@article{Bridgford_2001,
	doi = {10.1002/pdi.236},
	url = {http://dx.doi.org/10.1002/pdi.236},
	year = 2001,
	publisher = {Wiley-Blackwell},
	volume = {18},
	number = {7},
	pages = {241--245},
	author = {Anna Bridgford and Timothy M. E. Davis},
	title = {A comprehensive patient-held record for diabetes. Part one: initial development of the Diabetes Databank},
	journal = {Pract Diab Int}
}
@article{Davis_2001,
	doi = {10.1002/pdi.237},
	url = {http://dx.doi.org/10.1002/pdi.237},
	year = 2001,
	month = {nov},
	publisher = {Wiley-Blackwell},
	volume = {18},
	number = {9},
	pages = {311--314},
	author = {Timothy M.E. Davis and Anna Bridgford},
	title = {A comprehensive patient-held record for diabetes. Part two: Large-scale assessment of the Diabetes Databank by patients and health care workers},
	journal = {Pract Diab Int}
}
@article{Engelbrecht_1994,
	doi = {10.1016/0169-2607(94)90010-8},
	url = {http://dx.doi.org/10.1016/0169-2607(94)90010-8},
	year = 1994,
	month = {oct},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {45},
	number = {1-2},
	pages = {33--35},
	author = {R. Engelbrecht and C. Hildebrand and E. Khnel and G. Brenner and R. Corcoy and G. Eberhard and C. Gapp and G. Klepser and A. de Leiva and M. Massi-Benedetti and R. Mechtler and K. Piwernetz and J. Sembritzki and J. Thiery},
	title = {A chip card for patients with diabetes},
	journal = {Computer Methods and Programs in Biomedicine}
}
@article{Engelbrecht_1996,
	doi = {10.3109/14639239608999289},
	url = {http://dx.doi.org/10.3109/14639239608999289},
	year = 1996,
	month = {jan},
	publisher = {Informa Healthcare},
	volume = {21},
	number = {4},
	pages = {273--282},
	author = {R. Engelbrecht and C. Hildebrand and E. Brugu{\\'{e}}s and A. De Leiva and R. Corcoy},
	title = {$\\lbrace$DIABCARD$\\rbrace${\\textemdash}an application of a portable medical record for persons with diabetes},
	journal = {Informatics for Health and Social Care}
}
@incollection{Engelbrecht_2006,
	doi = {10.1007/1-84628-141-5_6},
	url = {http://dx.doi.org/10.1007/1-84628-141-5_6},
	year = 2006,
	publisher = {Springer Science $\\mathplus$ Business Media},
	pages = {110--134},
	author = {Rolf Engelbrecht and Josef Ingenerf and Jrg Reiner},
	title = {Relevance of Terminological Standards and Services in Telemedicine},
	booktitle = {Information Technology Solutions for Healthcare}
}
@article{Gupta_2014,
	doi = {10.1016/j.pcd.2014.03.002},
	url = {http://dx.doi.org/10.1016/j.pcd.2014.03.002},
	year = 2014,
	month = {apr},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	author = {Yashdeep Gupta and Rajiv Singla and Sanjay Kalra},
	title = {Comment on {\\textquotedblleft}A primary care based healthy-eating and active living education session for weight reduction in the pre-diabetic population{\\textquotedblright} by Daniala et al.},
	journal = {Primary Care Diabetes}
}
@article{Chiarelli_1998,
	doi = {10.1159/000053102},
	url = {http://dx.doi.org/10.1159/000053102},
	year = 1998,
	publisher = {S. Karger $\\lbrace$AG$\\rbrace$},
	volume = {50},
	number = {Suppl. 1},
	pages = {41--47},
	author = {F. Chiarelli and A. Verrotti and L. di Ricco and M. de Martino and G. Morgese},
	title = {Approaches to Quality of Control in Diabetes Care},
	journal = {Hormone Research}
}
@article{Gorman_1996,
	doi = {10.1530/eje.0.1340031},
	url = {http://dx.doi.org/10.1530/eje.0.1340031},
	year = 1996,
	month = {jan},
	publisher = {$\\lbrace$BioScientifica$\\rbrace$},
	volume = {134},
	number = {1},
	pages = {31--42},
	author = {C. Gorman and J. Looker and T. Fisk and W. Oelke and D. Erickson and S. Smith and B. Zimmerman},
	title = {A clinically useful diabetes electronic medical record: Lessons from the past$\\mathsemicolon$ pointers toward the future},
	journal = {European Journal of Endocrinology}
}
@incollection{Kucher_1990,
	doi = {10.1007/978-3-642-51659-7_139},
	url = {http://dx.doi.org/10.1007/978-3-642-51659-7_139},
	year = 1990,
	publisher = {Springer Science $\\mathplus$ Business Media},
	pages = {744--747},
	author = {M. Kucher and J. Schneider and K. Piwernetz and R. Engelbrecht and H. Zock and R. Renner},
	title = {Integration of a data driven blood glucose simulation into a rule based expert system},
	booktitle = {Medical Informatics Europe '90}
}
@article{Smith_1998,
	doi = {10.2337/diacare.21.6.972},
	url = {http://dx.doi.org/10.2337/diacare.21.6.972},
	year = 1998,
	month = {jun},
	publisher = {American Diabetes Association},
	volume = {21},
	number = {6},
	pages = {972--976},
	author = {S. A. Smith and M. E. Murphy and T. R. Huschka and S. F. Dinneen and C. A. Gorman and B. R. Zimmerman and R. A. Rizza and J. M. Naessens},
	title = {Impact of a diabetes electronic management system on the care of patients seen in a subspecialty diabetes clinic},
	journal = {Diabetes Care}
}
@article{Chaudhry_2007,
	doi = {10.1001/archinte.167.6.606},
	url = {http://dx.doi.org/10.1001/archinte.167.6.606},
	year = 2007,
	month = {mar},
	publisher = {American Medical Association ($\\lbrace$AMA$\\rbrace$)},
	volume = {167},
	number = {6},
	pages = {606},
	author = {Rajeev Chaudhry and Sidna M. Scheitel and Erin K. McMurtry and Dorinda J. Leutink and Rosa L. Cabanela and James M. Naessens and Ahmed S. Rahman and Lynn A. Davis and Robert J. Stroebel},
	title = {Web-Based Proactive System to Improve Breast Cancer Screening},
	journal = {Archives of Internal Medicine}
}
@article{EVANS_2000,
	doi = {10.1016/s1462-9410(00)90324-3},
	url = {http://dx.doi.org/10.1016/s1462-9410(00)90324-3},
	year = 2000,
	month = {sep},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {4},
	number = {3},
	pages = {72},
	author = {D EVANS},
	title = {Insulin adjustment by a diabetes nurse educator improves glucose control in insulin-requiring diabetic patients},
	journal = {Evidence-based Healthcare}
}
@article{Biermann_2002,
	doi = {10.1016/s0169-2607(02)00037-8},
	url = {http://dx.doi.org/10.1016/s0169-2607(02)00037-8},
	year = 2002,
	month = {aug},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {69},
	number = {2},
	pages = {137--146},
	author = {Eberhard Biermann and Wolfgang Dietrich and Julian Rihl and Eberhard Standl},
	title = {Are there time and cost savings by using telemanagement for patients on intensified insulin therapy?},
	journal = {Computer Methods and Programs in Biomedicine}
}
@article{McGill_2000,
	doi = {10.1002/1528-252x(200010)17:7<235::aid-pdi101>3.0.co;2-h},
	url = {http://dx.doi.org/10.1002/1528-252x(200010)17:7<235::aid-pdi101>3.0.co;2-h},
	year = 2000,
	month = {oct},
	publisher = {Wiley-Blackwell},
	volume = {17},
	number = {7},
	pages = {235--238},
	author = {Marg McGill and Maria Constantino and Dennis K. Yue},
	title = {Integrating Telemedicine into a National Diabetes Footcare Network},
	journal = {Pract Diab Int}
}
@article{Cummings_2001,
	doi = {10.1111/j.1748-0361.2001.tb00251.x},
	url = {http://dx.doi.org/10.1111/j.1748-0361.2001.tb00251.x},
	year = 2001,
	month = {dec},
	publisher = {Wiley-Blackwell},
	volume = {17},
	number = {1},
	pages = {25--31},
	author = {Doyle M. Cummings and Susan Morrissey and Michael J. Barondes and Lance Rogers and Susan Gustke},
	title = {Screening for Diabetic Retinopathy in Rural Areas: The Potential of Telemedicine},
	journal = {The Journal of Rural Health}
}
@article{Levetan_1995,
	doi = {10.1016/s0002-9343(99)80100-4},
	url = {http://dx.doi.org/10.1016/s0002-9343(99)80100-4},
	year = 1995,
	month = {jul},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {99},
	number = {1},
	pages = {22--28},
	author = {Claresa S. Levetan and Jacqueline R. Salas and Ilene F. Wilets and Barnett Zumoff},
	title = {Impact of endocrine and diabetes team consultation on hospital length of stay for patients with diabetes},
	journal = {The American Journal of Medicine}
}
@article{Koproski_1997,
	doi = {10.2337/diacare.20.10.1553},
	url = {http://dx.doi.org/10.2337/diacare.20.10.1553},
	year = 1997,
	month = {oct},
	publisher = {American Diabetes Association},
	volume = {20},
	number = {10},
	pages = {1553--1555},
	author = {J. Koproski and Z. Pretto and L. Poretsky},
	title = {Effects of an intervention by a diabetes team in hospitalized patients with diabetes},
	journal = {Diabetes Care}
}
@article{Rose_2000,
	doi = {10.2337/diacare.23.11.1708},
	url = {http://dx.doi.org/10.2337/diacare.23.11.1708},
	year = 2000,
	month = {nov},
	publisher = {American Diabetes Association},
	volume = {23},
	number = {11},
	pages = {1708--1709},
	author = {M. Rose and M. Hildebrandt and H. Fliege and B. Seidlitz and L. Cotta and T. Schirop and B. F. Klapp},
	title = {Relevance of the treatment facility for disease-related knowledge of diabetic patients},
	journal = {Diabetes Care}
}
@article{1994,
	doi = {10.1136/bmj.308.6938.1208},
	url = {http://dx.doi.org/10.1136/bmj.308.6938.1208},
	year = 1994,
	month = {may},
	publisher = {$\\lbrace$BMJ$\\rbrace$},
	volume = {308},
	number = {6938},
	pages = {1208--1212},
	title = {Integrated care for diabetes: clinical, psychosocial, and economic evaluation},
	journal = {$\\lbrace$BMJ$\\rbrace$}
}
@article{Davies_2001,
	doi = {10.1046/j.1464-5491.2001.00470.x},
	url = {http://dx.doi.org/10.1046/j.1464-5491.2001.00470.x},
	year = 2001,
	month = {apr},
	publisher = {Wiley-Blackwell},
	volume = {18},
	number = {4},
	pages = {301--307},
	author = {M. Davies and S. Dixon and C. J. Currie and R. E. Davis and J. R. Peters},
	title = {Evaluation of a hospital diabetes specialist nursing service: a randomized controlled trial},
	journal = {Diabet Med}
}
@article{2002,
	doi = {10.1002/pdi.305},
	url = {http://dx.doi.org/10.1002/pdi.305},
	year = 2002,
	month = {jan},
	publisher = {Wiley-Blackwell},
	volume = {19},
	number = {1},
	pages = {22--24a},
	title = {The $\\lbrace$DAWN$\\rbrace$ (Diabetes Attitudes, Wishes and Needs) study},
	journal = {Pract Diab Int}
}
@article{2008,
	doi = {10.2337/dc08-s061},
	url = {http://dx.doi.org/10.2337/dc08-s061},
	year = 2008,
	month = {jan},
	publisher = {American Diabetes Association},
	volume = {31},
	number = {Supplement{\\_}1},
	pages = {S61--S78},
	title = {Nutrition Recommendations and Interventions for Diabetes: A position statement of the American Diabetes Association},
	journal = {Diabetes Care}
}
@article{Greenwood_2003,
	doi = {10.1136/bmj.326.7394.881/a},
	url = {http://dx.doi.org/10.1136/bmj.326.7394.881/a},
	year = 2003,
	month = {apr},
	publisher = {$\\lbrace$BMJ$\\rbrace$},
	volume = {326},
	number = {7394},
	pages = {881a--881},
	author = {R. H Greenwood},
	title = {National service framework for diabetes leaves questions open},
	journal = {$\\lbrace$BMJ$\\rbrace$}
}
@article{Jessup_2001,
	doi = {10.1056/nejmed010109},
	url = {http://dx.doi.org/10.1056/nejmed010109},
	year = 2001,
	month = {nov},
	publisher = {New England Journal of Medicine ($\\lbrace$NEJM$\\rbrace$/$\\lbrace$MMS$\\rbrace$)},
	volume = {345},
	number = {20},
	pages = {1490--1493},
	author = {Mariell Jessup},
	title = {Mechanical Cardiac-Support Devices {\\textemdash} Dreams and Devilish Details},
	journal = {New England Journal of Medicine}
}
@article{Knight_1993,
	doi = {10.1093/geront/33.2.240},
	url = {http://dx.doi.org/10.1093/geront/33.2.240},
	year = 1993,
	month = {apr},
	publisher = {Oxford University Press ($\\lbrace$OUP$\\rbrace$)},
	volume = {33},
	number = {2},
	pages = {240--248},
	author = {B. G. Knight and S. M. Lutzky and F. Macofsky-Urban},
	title = {A Meta-analytic Review of Interventions for Caregiver Distress: Recommendations for Future Research},
	journal = {The Gerontologist}
}
@article{Toseland_1992,
	doi = {10.1093/geront/32.3.382},
	url = {http://dx.doi.org/10.1093/geront/32.3.382},
	year = 1992,
	month = {jun},
	publisher = {Oxford University Press ($\\lbrace$OUP$\\rbrace$)},
	volume = {32},
	number = {3},
	pages = {382--390},
	author = {R. W. Toseland and M. S. Labrecque and S. T. Coebel and M. H. Whitney},
	title = {An Evaluation of a Group Program for Spouses of Frail Elderly Veterans},
	journal = {The Gerontologist}
}
@article{Labrecque_1992,
	doi = {10.1037/h0079385},
	url = {http://dx.doi.org/10.1037/h0079385},
	year = 1992,
	publisher = {American Psychological Association ($\\lbrace$APA$\\rbrace$)},
	volume = {62},
	number = {4},
	pages = {575--588},
	author = {Mark S. Labrecque and Terry Peak and Ronald W. Toseland},
	title = {Long-term effectiveness of a group program for caregivers of frail elderly veterans.},
	journal = {American Journal of Orthopsychiatry}
}
@article{Ostwald_1999,
	doi = {10.1093/geront/39.3.299},
	url = {http://dx.doi.org/10.1093/geront/39.3.299},
	year = 1999,
	month = {jun},
	publisher = {Oxford University Press ($\\lbrace$OUP$\\rbrace$)},
	volume = {39},
	number = {3},
	pages = {299--309},
	author = {S. K. Ostwald and K. W. Hepburn and W. Caron and T. Burns and R. Mantell},
	title = {Reducing Caregiver Burden: A Randomized Psychoeducational Intervention for Caregivers of Persons With Dementia},
	journal = {The Gerontologist}
}
@article{Hanestad_1993,
	doi = {10.1016/0168-8227(93)90109-i},
	url = {http://dx.doi.org/10.1016/0168-8227(93)90109-i},
	year = 1993,
	month = {feb},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {19},
	number = {2},
	pages = {163--173},
	author = {Berit Rokne Hanestad and Grethe Albrektsen},
	title = {The effects of participation in a support group on self-assessed quality of life in people with insulin-dependent diabetes mellitus},
	journal = {Diabetes Research and Clinical Practice}
}
@article{Maxwell_1992,
	doi = {10.1177/014572179201800408},
	url = {http://dx.doi.org/10.1177/014572179201800408},
	year = 1992,
	month = {jan},
	publisher = {$\\lbrace$SAGE$\\rbrace$ Publications},
	volume = {18},
	number = {4},
	pages = {303--309},
	author = {A. E. Maxwell and I. F. Hunt and M. A. Bush},
	title = {Effects of a Social Support Group, as an Adjunct to Diabetes Training, on Metabolic Control and Psychosocial Outcomes},
	journal = {The Diabetes Educator}
}
@article{Fisher_1998,
	doi = {10.2105/ajph.88.11.1658},
	url = {http://dx.doi.org/10.2105/ajph.88.11.1658},
	year = 1998,
	month = {nov},
	publisher = {American Public Health Association},
	volume = {88},
	number = {11},
	pages = {1658--1663},
	author = {E B Fisher and W F Auslander and J F Munro and C L Arfken and R C Brownson and N W Owens},
	title = {Neighbors for a smoke free north side: evaluation of a community organization approach to promoting smoking cessation among African Americans.},
	journal = {Am J Public Health}
}
@article{Morris_1998,
	doi = {10.1177/014572179802400408},
	url = {http://dx.doi.org/10.1177/014572179802400408},
	year = 1998,
	month = {jan},
	publisher = {$\\lbrace$SAGE$\\rbrace$ Publications},
	volume = {24},
	number = {4},
	pages = {493--497},
	author = {D. B. Morris},
	title = {A Rural Diabetes Support Group},
	journal = {The Diabetes Educator}
}
@article{Tomlinson_1992,
	doi = {10.1080/0142569920130403},
	url = {http://dx.doi.org/10.1080/0142569920130403},
	year = 1992,
	month = {jan},
	publisher = {Informa $\\lbrace$UK$\\rbrace$ Limited},
	volume = {13},
	number = {4},
	pages = {437--446},
	author = {Sally Tomlinson},
	title = {Disadvantaging the Disadvantaged: Bangladeshis and education in Tower Hamlets},
	journal = {British Journal of Sociology of Education}
}
@article{2003,
	doi = {10.2337/diacare.26.2007.s33},
	url = {http://dx.doi.org/10.2337/diacare.26.2007.s33},
	year = 2003,
	month = {jan},
	publisher = {American Diabetes Association},
	volume = {26},
	number = {90001},
	pages = {33S--50},
	title = {Standards of Medical Care for Patients With Diabetes Mellitus},
	journal = {Diabetes Care}
}
@article{Street_1993,
	doi = {10.2337/diacare.16.5.714},
	url = {http://dx.doi.org/10.2337/diacare.16.5.714},
	year = 1993,
	month = {may},
	publisher = {American Diabetes Association},
	volume = {16},
	number = {5},
	pages = {714--721},
	author = {R. L. Street and V. K. Piziak and W. S. Carpentier and J. Herzog and J. Hejl and G. Skinner and L. McLellan},
	title = {Provider-patient communication and metabolic control},
	journal = {Diabetes Care}
}
@article{RICCOMINI_2002,
	doi = {10.2190/hf6d-axqx-axff-m760},
	url = {http://dx.doi.org/10.2190/hf6d-axqx-axff-m760},
	year = 2002,
	month = {dec},
	publisher = {Baywood Publishing Company, Inc.},
	volume = {27},
	number = {3},
	pages = {213--228},
	author = {PAUL RICCOMINI},
	title = {$\\lbrace$THE$\\rbrace$ $\\lbrace$COMPARATIVE$\\rbrace$ $\\lbrace$EFFECTIVENESS$\\rbrace$ $\\lbrace$OF$\\rbrace$ $\\lbrace$TWO$\\rbrace$ $\\lbrace$FORMS$\\rbrace$ $\\lbrace$OF$\\rbrace$ $\\lbrace$FEEDBACK$\\rbrace$: $\\lbrace$WEB$\\rbrace$-$\\lbrace$BASED$\\rbrace$ $\\lbrace$MODEL$\\rbrace$ $\\lbrace$COMPARISON$\\rbrace$ $\\lbrace$AND$\\rbrace$ $\\lbrace$INSTRUCTOR$\\rbrace$ $\\lbrace$DELIVERED$\\rbrace$ $\\lbrace$CORRECTIVE$\\rbrace$ $\\lbrace$FEEDBACK$\\rbrace$},
	journal = {Journal of Educational Computing Research}
}
@article{Mensing_2000,
	doi = {10.2337/diacare.23.5.682},
	url = {http://dx.doi.org/10.2337/diacare.23.5.682},
	year = 2000,
	month = {may},
	publisher = {American Diabetes Association},
	volume = {23},
	number = {5},
	pages = {682--689},
	author = {C. Mensing and J. Boucher and M. Cypress and K. Weinger and K. Mulcahy and P. Barta and G. Hosey and W. Kopher and A. Lasichak and B. Lamb and M. Mangan and J. Norman and J. Tanja and L. Yauk and K. Wisdom and C. Adams},
	title = {National standards for diabetes self-management education. Task Force to Review and Revise the National Standards for Diabetes Self-Management Education Programs},
	journal = {Diabetes Care}
}
@article{Weerdt_1991,
	doi = {10.1111/j.1464-5491.1991.tb01607.x},
	url = {http://dx.doi.org/10.1111/j.1464-5491.1991.tb01607.x},
	year = 1991,
	month = {may},
	publisher = {Wiley-Blackwell},
	volume = {8},
	number = {4},
	pages = {338--345},
	author = {I. Weerdt and A. P. Visser and G. J. Kok and O. Weerdt and E. A. Veen},
	title = {Randomized Controlled Multicentre Evaluation of an Education Programme for Insulin-treated Diabetic Patients: Effects on Metabolic Control, Quality of Life, and Costs of Therapy},
	journal = {Diabetic Medicine}
}
@article{Lennon_1990,
	doi = {10.1111/j.1464-5491.1990.tb01500.x},
	url = {http://dx.doi.org/10.1111/j.1464-5491.1990.tb01500.x},
	year = 1990,
	month = {nov},
	publisher = {Wiley-Blackwell},
	volume = {7},
	number = {9},
	pages = {825--832},
	author = {G.M. Lennon and K.G. Taylor and L. Debney and C.J. Bailey},
	title = {Knowledge, Attitudes, Technical Competence, and Blood Glucose Control of Type 1 Diabetic Patients During and After an Education Programme},
	journal = {Diabetic Medicine}
}
@article{Valk_2002,
	doi = {10.1016/s0889-8529(02)00021-x},
	url = {http://dx.doi.org/10.1016/s0889-8529(02)00021-x},
	year = 2002,
	month = {sep},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {31},
	number = {3},
	pages = {633--658},
	author = {Gerlof D Valk and Didi M.W Kriegsman and Willem J.J Assendelft},
	title = {Patient education for preventing diabetic foot ulceration},
	journal = {Endocrinology and Metabolism Clinics of North America}
}
@article{NORRIS_2002,
	doi = {10.1016/s0749-3797(02)00424-5},
	url = {http://dx.doi.org/10.1016/s0749-3797(02)00424-5},
	year = 2002,
	month = {may},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {22},
	number = {4},
	pages = {39--66},
	author = {S NORRIS and P NICHOLS and C CASPERSEN and R GLASGOW and M ENGELGAU and L JACKJR and S SNYDER and V CARANDEKULIS and G ISHAM and S GARFIELD},
	title = {Increasing diabetes self-management education in community $\\lbrace$settingsA$\\rbrace$ systematic review},
	journal = {American Journal of Preventive Medicine}
}
@article{Jones_1990,
	doi = {10.1177/014572179001600409},
	url = {http://dx.doi.org/10.1177/014572179001600409},
	year = 1990,
	month = {jan},
	publisher = {$\\lbrace$SAGE$\\rbrace$ Publications},
	volume = {16},
	number = {4},
	pages = {296--303},
	author = {P. M. Jones},
	title = {Use of a Course on Self-Control Behavior Techniques to Increase Adherence to Prescribed Frequency for Self-Monitoring Blood Glucose},
	journal = {The Diabetes Educator}
}
@article{Sudhir_2003,
	doi = {10.1002/jclp.10151},
	url = {http://dx.doi.org/10.1002/jclp.10151},
	year = 2003,
	publisher = {Wiley-Blackwell},
	volume = {59},
	number = {6},
	pages = {715--722},
	author = {Paulomi Matam Sudhir and V. Kumaraiah and C. Munichoodappa},
	title = {Role of family in the management of Type-I diabetes: An Indian experience},
	journal = {J. Clin. Psychol.}
}
@article{Korhonen_1983,
	doi = {10.2337/diacare.6.3.256},
	url = {http://dx.doi.org/10.2337/diacare.6.3.256},
	year = 1983,
	month = {may},
	publisher = {American Diabetes Association},
	volume = {6},
	number = {3},
	pages = {256--261},
	author = {T. Korhonen and J. K. Huttunen and A. Aro and M. Hentinen and O. Ihalainen and H. Majander and O. Siitonen and M. Uusitupa and K. Pyorala},
	title = {A controlled trial on the effects of patient education in the treatment of insulin-dependent diabetes},
	journal = {Diabetes Care}
}
@article{Davis_2007,
	doi = {10.2337/dc06-1992},
	url = {http://dx.doi.org/10.2337/dc06-1992},
	year = 2007,
	month = {jan},
	publisher = {American Diabetes Association},
	volume = {30},
	number = {1},
	pages = {184--185},
	author = {W. A. Davis and D. G. Bruce and T. M.E. Davis},
	title = {Is Self-Monitoring of Blood Glucose Appropriate for All Type 2 Diabetic Patients? The Fremantle Diabetes Study: Response to Kolb et al.},
	journal = {Diabetes Care}
}
@article{Bryant_2007,
	doi = {10.1017/s0266462307051586},
	url = {http://dx.doi.org/10.1017/s0266462307051586},
	year = 2007,
	month = {jan},
	publisher = {Cambridge University Press ($\\lbrace$CUP$\\rbrace$)},
	volume = {23},
	number = {01},
	author = {Jackie Bryant and Hakan Brodin and Emma Loveman and Andrew Clegg},
	title = {Clinical effectiveness and cost-effectiveness of implantable cardioverter defibrillators for arrhythmias: A systematic review and economic evaluation},
	journal = {International Journal of Technology Assessment in Health Care}
}
@article{Glasgow_1997,
	doi = {10.1016/s0738-3991(97)00039-6},
	url = {http://dx.doi.org/10.1016/s0738-3991(97)00039-6},
	year = 1997,
	month = {nov},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {32},
	number = {3},
	pages = {175--184},
	author = {Russell E Glasgow and Pierre-Andre La Chance and Deborah J Toobert and Jane Brown and Sarah E Hampson and Matthew C Riddle},
	title = {Long term effects and costs of brief behavioural dietary intervention for patients with diabetes delivered from the medical office},
	journal = {Patient Education and Counseling}
}
@article{Kaplan_1987,
	doi = {10.1007/bf02596443},
	url = {http://dx.doi.org/10.1007/bf02596443},
	year = 1987,
	month = {jul},
	publisher = {Springer Science $\\mathplus$ Business Media},
	volume = {2},
	number = {4},
	pages = {220--228},
	author = {Robert M. Kaplan and Sherry L. Hartwell and Dawn K. Wilson and Janet P. Wallace},
	title = {Effects of diet and exercise interventions on control and quality of life in non-insulin-dependent diabetes mellitus},
	journal = {J Gen Intern Med}
}
@article{Coster_2000,
	doi = {10.1046/j.1464-5491.2000.00390.x},
	url = {http://dx.doi.org/10.1046/j.1464-5491.2000.00390.x},
	year = 2000,
	month = {nov},
	publisher = {Wiley-Blackwell},
	volume = {17},
	number = {11},
	pages = {755--761},
	author = {S. Coster and M. C. Gulliford and P. T. Seed and J. K. Powrie and R. Swaminathan},
	title = {Self-monitoring in Type 2 diabetes mellitus: a meta-analysis},
	journal = {Diabet Med}
}
@article{Brown_1986,
	doi = {10.1002/pdi.1960030514},
	url = {http://dx.doi.org/10.1002/pdi.1960030514},
	year = 1986,
	month = {sep},
	publisher = {Wiley-Blackwell},
	volume = {3},
	number = {5},
	pages = {257--257},
	author = {Elizabeth Brown and G S Pal and Heather Jones and P R Hudson and D F Child},
	title = {Routine ward $\\lbrace$BG$\\rbrace$ monitoring by nurses using $\\lbrace$BM$\\rbrace$-test-glycemie 20-800R strips},
	journal = {Pract. Diab. Int.}
}
@article{Edelman_2000,
	doi = {10.1089/15209150050025195},
	url = {http://dx.doi.org/10.1089/15209150050025195},
	year = 2000,
	month = {jun},
	publisher = {Mary Ann Liebert Inc},
	volume = {2},
	number = {2},
	pages = {233--238},
	author = {Steven V. Edelman and Patricia Callahan and Larry C. Deeb},
	title = {Multisite Evaluation of a New Diabetes Self-Test for Glucose and Glycated Protein (Fructosamine)},
	journal = {Diabetes Technology {\\&} Therapeutics}
}
@article{Cefalu_1999,
	doi = {10.1089/152091599316964},
	url = {http://dx.doi.org/10.1089/152091599316964},
	year = 1999,
	month = {dec},
	publisher = {Mary Ann Liebert Inc},
	volume = {1},
	number = {4},
	pages = {435--441},
	author = {William T. Cefalu and Zhong Q. Wang and Eric Redmon and Audrey D. Bell-Farrow and Debra McBride and Telle King},
	title = {Clinical Validity of a Self-Test Fructosamine in Outpatient Diabetic Management},
	journal = {Diabetes Technology {\\&} Therapeutics}
}
@article{Gordon_1991,
	doi = {10.1111/j.1464-5491.1991.tb01677.x},
	url = {http://dx.doi.org/10.1111/j.1464-5491.1991.tb01677.x},
	year = 1991,
	month = {aug},
	publisher = {Wiley-Blackwell},
	volume = {8},
	number = {7},
	pages = {679--682},
	author = {D. Gordon and C.G. Semple and K.R. Paterson},
	title = {Do Different Frequencies of Self-monitoring of Blood Glucose Influence Control in Type 1 Diabetic Patients?},
	journal = {Diabetic Medicine}
}
@article{Starostina_1994,
	doi = {10.1007/s001250050089},
	url = {http://dx.doi.org/10.1007/s001250050089},
	year = 1994,
	month = {feb},
	publisher = {Springer Science $\\mathplus$ Business Media},
	volume = {37},
	number = {2},
	pages = {170--176},
	author = {E. G. Starostina and M. Antsiferov and G. R. Galstyan and Ch. Trautner and V. Jrgens and U. Bott and I. Mhlhauser and M. Berger and I. I. Dedov},
	title = {Effectiveness and cost-benefit analysis of intensive treatment and teaching programmes for Type 1 (insulin-dependent) diabetes mellitus in Moscow{\\textemdash}blood glucose versus urine glucose self-monitoring},
	journal = {Diabetologia}
}
@article{Giacco_2000,
	doi = {10.2337/diacare.23.10.1461},
	url = {http://dx.doi.org/10.2337/diacare.23.10.1461},
	year = 2000,
	month = {oct},
	publisher = {American Diabetes Association},
	volume = {23},
	number = {10},
	pages = {1461--1466},
	author = {R. Giacco and M. Parillo and A. A. Rivellese and G. Lasorella and A. Giacco and L. D{\\textquotesingle}Episcopo and G. Riccardi},
	title = {Long-term dietary treatment with increased amounts of fiber-rich low-glycemic index natural foods improves blood glucose control and reduces the number of hypoglycemic events in type 1 diabetic patients},
	journal = {Diabetes Care}
}
@article{HANSEN_1999,
	doi = {10.1046/j.1523-1755.1999.00274.x},
	url = {http://dx.doi.org/10.1046/j.1523-1755.1999.00274.x},
	year = 1999,
	month = {feb},
	publisher = {Nature Publishing Group},
	volume = {55},
	number = {2},
	pages = {621--628},
	author = {HENRIK P. HANSEN and PER K. CHRISTENSEN and ELLIS TAUBER-LASSEN and ANNALISE KLAUSEN and BERIT R. JENSEN and HANS-HENRIK PARVING},
	title = {Low-protein diet and kidney function in insulin-dependent diabetic patients with diabetic nephropathy},
	journal = {Kidney International}
}
@article{Chantelau_1992,
	doi = {10.1055/s-0029-1211161},
	url = {http://dx.doi.org/10.1055/s-0029-1211161},
	year = 1992,
	publisher = {Thieme Publishing Group},
	volume = {99},
	number = {03},
	pages = {164--168},
	author = {E. Chantelau and P. Wichmann},
	title = { Pathological Proteinuria in Patients with Insulin-Dependent Diabetes Mellitus: Relation to Intensive Insulin Therapy 1 },
	journal = {Exp Clin Endocrinol Diabetes}
}
@article{McCulloch_1985,
	doi = {10.1007/bf00282234},
	url = {http://dx.doi.org/10.1007/bf00282234},
	year = 1985,
	month = {apr},
	publisher = {Springer Science $\\mathplus$ Business Media},
	volume = {28},
	number = {4},
	author = {D.K. McCulloch and R.D. Mitchell and J. Ambler and R.B. Tattersall},
	title = {A prospective comparison of ?conventional? and high carbohydrate / high fibre / low fat diets in adults with established Type 1 (insulin-dependent) diabetes},
	journal = {Diabetologia}
}
@article{Lau_2007,
	doi = {10.1016/s1499-2671(07)12010-4},
	url = {http://dx.doi.org/10.1016/s1499-2671(07)12010-4},
	year = 2007,
	month = {jan},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {31},
	number = {2},
	pages = {148--152},
	author = {David C.W. Lau},
	title = {Evidence-based Canadian Obesity Clinical Practice Guidelines: Relevance to Diabetes Management},
	journal = {Canadian Journal of Diabetes}
}
@article{DAFNE_Study_Group_2002,
	doi = {10.1136/bmj.325.7367.746},
	url = {http://dx.doi.org/10.1136/bmj.325.7367.746},
	year = 2002,
	month = {oct},
	publisher = {$\\lbrace$BMJ$\\rbrace$},
	volume = {325},
	number = {7367},
	pages = {746--746},
	author = {DAFNE Study Group},
	title = {Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating ($\\lbrace$DAFNE$\\rbrace$) randomised controlled trial},
	journal = {$\\lbrace$BMJ$\\rbrace$}
}
@article{M_HLHAUSER_1995,
	doi = {10.1111/j.1365-2796.1995.tb00890.x},
	url = {http://dx.doi.org/10.1111/j.1365-2796.1995.tb00890.x},
	year = 1995,
	month = {jun},
	publisher = {Wiley-Blackwell},
	volume = {237},
	number = {6},
	pages = {591--597},
	author = {I. MHLHAUSER and U. BOTT and H. OVERMANN and W. WAGENER and R. BENDER and V. JRGENS and M. BERGER},
	title = {Liberalized diet in patients with type 1 diabetes},
	journal = {Journal of Internal Medicine}
}
@article{Blinkhorn_2003,
	doi = {10.1177/001789690306200113},
	url = {http://dx.doi.org/10.1177/001789690306200113},
	year = 2003,
	month = {jan},
	publisher = {$\\lbrace$SAGE$\\rbrace$ Publications},
	volume = {62},
	number = {1},
	pages = {91--91},
	author = {A. S Blinkhorn},
	title = {Reviews : National Institute for Clinical Excellence Compilation - Issue 5 and changes to the way $\\lbrace$NICE$\\rbrace$ issues guidance},
	journal = {Health Education Journal}
}
@article{LAAKSONEN_2000,
	doi = {10.1097/00005768-200009000-00003},
	url = {http://dx.doi.org/10.1097/00005768-200009000-00003},
	year = 2000,
	month = {sep},
	publisher = {Ovid Technologies (Wolters Kluwer Health)},
	pages = {1541--1548},
	author = {DAVID E. LAAKSONEN and MUSTAFA ATALAY and LEO K. NISKANEN and JUHA MUSTONEN and CHANDAN K. {\\&}NA$\\mathsemicolon$ and TIMO A. LAKKA and MATTI I. J. UUSITUPA},
	title = {Aerobic exercise and the lipid profile in type 1 diabetic men: a randomized controlled trial},
	journal = {Medicine {\\&} Science in Sports {\\&} Exercise}
}
@article{Ligtenberg_1999,
	doi = {10.1016/s0300-2977(99)00039-x},
	url = {http://dx.doi.org/10.1016/s0300-2977(99)00039-x},
	year = 1999,
	month = {aug},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {55},
	number = {2},
	pages = {59--63},
	author = {P Ligtenberg},
	title = {No effect of long-term physical activity on the glycemic control in type 1 diabetes patients: a cross-sectional study},
	journal = {The Netherlands Journal of Medicine}
}
@article{Lehmann_1997,
	doi = {10.2337/diacare.20.10.1603},
	url = {http://dx.doi.org/10.2337/diacare.20.10.1603},
	year = 1997,
	month = {oct},
	publisher = {American Diabetes Association},
	volume = {20},
	number = {10},
	pages = {1603--1611},
	author = {R. Lehmann and V. Kaplan and R. Bingisser and K. E. Bloch and G. A. Spinas},
	title = {Impact of physical activity on cardiovascular risk factors in $\\lbrace$IDDM$\\rbrace$},
	journal = {Diabetes Care}
}
@article{Perry_1997,
	doi = {10.1038/sj.ejcn.1600478},
	url = {http://dx.doi.org/10.1038/sj.ejcn.1600478},
	year = 1997,
	month = {dec},
	publisher = {Nature Publishing Group},
	volume = {51},
	number = {11},
	pages = {757--763},
	author = {T L Perry and J I Mann and N J Lewis-Barned and A W Duncan and M A Waldron and C Thompson},
	title = {Lifestyle intervention in people with insulin-dependent diabetes mellitus ($\\lbrace$IDDM$\\rbrace$)},
	journal = {Eur J Clin Nutr}
}
@article{Schneider_1992,
	doi = {10.2337/diacare.15.11.1800},
	url = {http://dx.doi.org/10.2337/diacare.15.11.1800},
	year = 1992,
	month = {nov},
	publisher = {American Diabetes Association},
	volume = {15},
	number = {11},
	pages = {1800--1810},
	author = {S. H. Schneider and A. K. Khachadurian and L. F. Amorosa and L. Clemow and N. B. Ruderman},
	title = {Ten-year experience with an exercise-based outpatient life-style modification program in the treatment of diabetes mellitus},
	journal = {Diabetes Care}
}
@article{Larsen_1989,
	doi = {10.3109/02813438909087235},
	url = {http://dx.doi.org/10.3109/02813438909087235},
	year = 1989,
	month = {jan},
	publisher = {Informa Healthcare},
	volume = {7},
	number = {3},
	pages = {167--171},
	author = {Mogens Lytken Larsen and Mogens H{\\o}rder},
	title = {Metabolic Evaluation of Non-insulin-dependent Diabetes in Primary Health Care - the Clinical Usefulness of Glycated Haemoglobin Measurements},
	journal = {Scandinavian Journal of Primary Health Care}
}
@article{Gross_2000,
	doi = {10.1089/152091500316737},
	url = {http://dx.doi.org/10.1089/152091500316737},
	year = 2000,
	month = {may},
	publisher = {Mary Ann Liebert Inc},
	volume = {2},
	number = {1},
	pages = {49--56},
	author = {Todd M. Gross and Bruce W. Bode and Daniel Einhorn and David M. Kayne and John H. Reed and Neil H. White and John J. Mastrototaro},
	title = {Performance Evaluation of the $\\lbrace$MiniMed$\\rbrace${\\textregistered} Continuous Glucose Monitoring System During Patient Home Use},
	journal = {Diabetes Technology {\\&} Therapeutics}
}
@article{Gross_2000,
	doi = {10.1089/15209150050214096},
	url = {http://dx.doi.org/10.1089/15209150050214096},
	year = 2000,
	month = {dec},
	publisher = {Mary Ann Liebert Inc},
	volume = {2},
	number = {supplement 1},
	pages = {27--34},
	author = {Todd M. Gross and Anna ter Veer},
	title = {Continuous Glucose Monitoring in Previously Unstudied Population Subgroups},
	journal = {Diabetes Technology {\\&} Therapeutics}
}
@article{Maran_2002,
	doi = {10.2337/diacare.25.2.347},
	url = {http://dx.doi.org/10.2337/diacare.25.2.347},
	year = 2002,
	month = {feb},
	publisher = {American Diabetes Association},
	volume = {25},
	number = {2},
	pages = {347--352},
	author = {A. Maran and C. Crepaldi and A. Tiengo and G. Grassi and E. Vitali and G. Pagano and S. Bistoni and G. Calabrese and F. Santeusanio and F. Leonetti and M. Ribaudo and U. Di Mario and G. Annuzzi and S. Genovese and G. Riccardi and M. Previti and D. Cucinotta and F. Giorgino and A. Bellomo and R. Giorgino and A. Poscia and M. Varalli},
	title = {Continuous Subcutaneous Glucose Monitoring in Diabetic Patients: A multicenter analysis},
	journal = {Diabetes Care}
}
@article{Bernstein_2002,
	doi = {10.1097/00134384-200209000-00013},
	url = {http://dx.doi.org/10.1097/00134384-200209000-00013},
	year = 2002,
	publisher = {Ovid Technologies (Wolters Kluwer Health)},
	volume = {1},
	number = {3},
	pages = {192--198},
	author = {Larry H. Bernstein and Ellis Jacobs and Attilio Granata},
	title = {Outcomes for the Assessment of Value},
	journal = {Point of Care: The Journal of Near-Patient Testing {\\&} Technology}
}
@article{Alberti_1988,
	doi = {10.1111/j.1464-5491.1988.tb00984.x},
	url = {http://dx.doi.org/10.1111/j.1464-5491.1988.tb00984.x},
	year = 1988,
	month = {apr},
	publisher = {Wiley-Blackwell},
	volume = {5},
	number = {3},
	pages = {275--281},
	author = {K. G. M. M. Alberti and F. A. Gries},
	title = {Management of Non-insulin-dependent Diabetes Mellitus in Europe: A Concensus View},
	journal = {Diabetic Medicine}
}
@article{Group_1999,
	doi = {10.1046/j.1464-5491.1999.00062.x},
	url = {http://dx.doi.org/10.1046/j.1464-5491.1999.00062.x},
	year = 1999,
	month = {mar},
	publisher = {Wiley-Blackwell},
	volume = {16},
	number = {3},
	pages = {253--266},
	author = {European Diabetes Policy Group},
	title = {A desktop guide to Type 1 (insulin-dependent) diabetes mellitus},
	journal = {Diabet Med}
}
@article{Boynton_1998,
	doi = {10.1046/j.1365-2532.1998.15201341.x},
	url = {http://dx.doi.org/10.1046/j.1365-2532.1998.15201341.x},
	year = 1998,
	month = {jun},
	publisher = {Wiley-Blackwell},
	volume = {15},
	number = {2},
	pages = {134--136},
	author = {Janette Boynton},
	title = {Are We Agreed? Service Level Agreements for Health Library Services. $\\lbrace$IFM$\\rbrace$ Healthcare study day, $\\lbrace$ScHARR$\\rbrace$, University of Sheffield, 13 June 1997},
	journal = {Health Libraries Review}
}
@article{Rohlfing_2002,
	doi = {10.2337/diacare.25.2.275},
	url = {http://dx.doi.org/10.2337/diacare.25.2.275},
	year = 2002,
	month = {feb},
	publisher = {American Diabetes Association},
	volume = {25},
	number = {2},
	pages = {275--278},
	author = {C. L. Rohlfing and H.-M. Wiedmeyer and R. R. Little and J. D. England and A. Tennill and D. E. Goldstein},
	title = {Defining the Relationship Between Plasma Glucose and $\\lbrace$HbA$\\rbrace$1c: Analysis of glucose profiles and $\\lbrace$HbA$\\rbrace$1c in the Diabetes Control and Complications Trial},
	journal = {Diabetes Care}
}
@article{1993,
	doi = {10.1056/nejm199309303291401},
	url = {http://dx.doi.org/10.1056/nejm199309303291401},
	year = 1993,
	month = {sep},
	publisher = {New England Journal of Medicine ($\\lbrace$NEJM$\\rbrace$/$\\lbrace$MMS$\\rbrace$)},
	volume = {329},
	number = {14},
	pages = {977--986},
	title = {The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus},
	journal = {New England Journal of Medicine}
}
@article{1995,
	doi = {10.2337/diab.44.8.968},
	url = {http://dx.doi.org/10.2337/diab.44.8.968},
	year = 1995,
	month = {aug},
	publisher = {American Diabetes Association},
	volume = {44},
	number = {8},
	pages = {968--983},
	title = {The Relationship of Glycemic Exposure ($\\lbrace$HbA$\\rbrace$1c) to the Risk of Development and Progression of Retinopathy in the Diabetes Control and Complications Trial},
	journal = {Diabetes}
}
@article{Stratton_2001,
	doi = {10.1007/s001250051594},
	url = {http://dx.doi.org/10.1007/s001250051594},
	year = 2001,
	month = {feb},
	publisher = {Springer Science $\\mathplus$ Business Media},
	volume = {44},
	number = {2},
	pages = {156--163},
	author = {I. M. Stratton and E. M. Kohner and S. J. Aldington and R. C. Turner and R. R. Holman and S. E. Manley and D. R. Matthews},
	title = {$\\lbrace$UKPDS$\\rbrace$ 50: Risk factors for incidence and progression of retinopathy in Type $\\lbrace$II$\\rbrace$ diabetes over 6 years from diagnosis},
	journal = {Diabetologia}
}
@article{MCCANCE_1989,
	doi = {10.1016/s0140-6736(89)92996-6},
	url = {http://dx.doi.org/10.1016/s0140-6736(89)92996-6},
	year = 1989,
	month = {oct},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {334},
	number = {8667},
	pages = {824--828},
	author = {D MCCANCE},
	title = {$\\lbrace$LONG$\\rbrace$-$\\lbrace$TERM$\\rbrace$ $\\lbrace$GLYCAEMIC$\\rbrace$ $\\lbrace$CONTROL$\\rbrace$ $\\lbrace$AND$\\rbrace$ $\\lbrace$DIABETIC$\\rbrace$ $\\lbrace$RETINOPATHY$\\rbrace$},
	journal = {The Lancet}
}
@article{Reichard_1993,
	doi = {10.1056/nejm199307293290502},
	url = {http://dx.doi.org/10.1056/nejm199307293290502},
	year = 1993,
	month = {jul},
	publisher = {New England Journal of Medicine ($\\lbrace$NEJM$\\rbrace$/$\\lbrace$MMS$\\rbrace$)},
	volume = {329},
	number = {5},
	pages = {304--309},
	author = {Per Reichard and Bengt-Yngve Nilsson and Urban Rosenqvist},
	title = {The Effect of Long-Term Intensified Insulin Treatment on the Development of Microvascular Complications of Diabetes Mellitus},
	journal = {New England Journal of Medicine}
}
@article{Krolewski_1995,
	doi = {10.1056/nejm199505113321902},
	url = {http://dx.doi.org/10.1056/nejm199505113321902},
	year = 1995,
	month = {may},
	publisher = {New England Journal of Medicine ($\\lbrace$NEJM$\\rbrace$/$\\lbrace$MMS$\\rbrace$)},
	volume = {332},
	number = {19},
	pages = {1251--1255},
	author = {Andrzej S. Krolewski and Lori M.B. Laffel and Martin Krolewski and Maryanne Quinn and James H. Warram},
	title = {Glycosylated Hemoglobin and the Risk of Microalbuminuria in Patients with Insulin-Dependent Diabetes Mellitus},
	journal = {New England Journal of Medicine}
}
@article{Peters_1996,
	doi = {10.1001/jama.276.15.1246},
	url = {http://dx.doi.org/10.1001/jama.276.15.1246},
	year = 1996,
	month = {oct},
	publisher = {American Medical Association ($\\lbrace$AMA$\\rbrace$)},
	volume = {276},
	number = {15},
	pages = {1246--1252},
	author = {A. L. Peters},
	title = {A clinical approach for the diagnosis of diabetes mellitus: an analysis using glycosylated hemoglobin levels. Meta-analysis Research Group on the Diagnosis of Diabetes Using Glycated Hemoglobin Levels},
	journal = {$\\lbrace$JAMA$\\rbrace$: The Journal of the American Medical Association}
}
@article{1994,
	doi = {10.1136/bmj.309.6958.841},
	url = {http://dx.doi.org/10.1136/bmj.309.6958.841},
	year = 1994,
	month = {oct},
	publisher = {$\\lbrace$BMJ$\\rbrace$},
	volume = {309},
	number = {6958},
	pages = {841--841},
	title = {Correction: Comparison of tests for glycated haemoglobin and fasting and two hour plasma glucose concentrations as diagnostic methods for diabetes},
	journal = {$\\lbrace$BMJ$\\rbrace$}
}
@article{Nathan_1984,
	doi = {10.1056/nejm198402093100602},
	url = {http://dx.doi.org/10.1056/nejm198402093100602},
	year = 1984,
	month = {feb},
	publisher = {New England Journal of Medicine ($\\lbrace$NEJM$\\rbrace$/$\\lbrace$MMS$\\rbrace$)},
	volume = {310},
	number = {6},
	pages = {341--346},
	author = {David M. Nathan and Daniel E. Singer and Katherine Hurxthal and John D. Goodson},
	title = {The Clinical Information Value of the Glycosylated Hemoglobin Assay},
	journal = {New England Journal of Medicine}
}
@article{Richter_2002,
	doi = {10.1016/s0889-8529(02)00020-8},
	url = {http://dx.doi.org/10.1016/s0889-8529(02)00020-8},
	year = 2002,
	month = {sep},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {31},
	number = {3},
	pages = {723--749},
	author = {Bernd Richter and Gudrun Neises and Karla Bergerhoff},
	title = {Human versus animal insulin in people with diabetes mellitus},
	journal = {Endocrinology and Metabolism Clinics of North America}
}
@article{George_1997,
	doi = {10.1002/(sici)1096-9136(199706)14:6<442::aid-did386>3.0.co;2-w},
	url = {http://dx.doi.org/10.1002/(sici)1096-9136(199706)14:6<442::aid-did386>3.0.co;2-w},
	year = 1997,
	month = {jun},
	publisher = {Wiley-Blackwell},
	volume = {14},
	number = {6},
	pages = {442--448},
	author = {E. George and C. Bedford and S.R. Peacey and C.A. Hardisty and S.R. Heller},
	title = {Further evidence for a high incidence of nocturnal hypoglycaemia in $\\lbrace$IDDM$\\rbrace$: no effect of dose for dose transfer between human and porcine insulins},
	journal = {Diabet. Med.}
}
@article{Karlson_1994,
	doi = {10.1016/0168-8227(94)90036-1},
	url = {http://dx.doi.org/10.1016/0168-8227(94)90036-1},
	year = 1994,
	month = {sep},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {25},
	number = {2},
	pages = {111--115},
	author = {Bjrn Karlson and Carl-David Agardh},
	title = {Influence of intensified insulin regimen on quality of life and metabolic control in insulin-dependent diabetes mellitus},
	journal = {Diabetes Research and Clinical Practice}
}
@article{Egger_1997,
	doi = {10.1002/(sici)1096-9136(199711)14:11<919::aid-dia456>3.3.co;2-1},
	url = {http://dx.doi.org/10.1002/(sici)1096-9136(199711)14:11<919::aid-dia456>3.3.co;2-1},
	year = 1997,
	month = {nov},
	publisher = {Wiley-Blackwell},
	volume = {14},
	number = {11},
	pages = {919--928},
	author = {M. Egger and G. Davey Smith and C. Stettler and P. Diem},
	title = {Risk of adverse effects of intensified treatment in insulin-dependent diabetes mellitus: a meta-analysis},
	journal = {Diabet. Med.}
}
@article{Haakens_1989,
	doi = {10.3109/00365518909091541},
	url = {http://dx.doi.org/10.3109/00365518909091541},
	year = 1989,
	month = {jan},
	publisher = {Informa Healthcare},
	volume = {49},
	number = {7},
	pages = {653--659},
	author = {K. Haakens and K. F. Hanssen and K Dahl-J{\\o}rgensen and S. Vaaler and P. Torjesen and K. Try},
	title = {Early morning glycaemia and the metabolic consequences of delaying breakfast/morning insulin. A comparison of continuous subcutaneous insulin infusion and multiple injection therapy with human isophane or human ultralente insulin at bedtime in insulin-dependent diabetics},
	journal = {Scandinavian Journal of Clinical {\\&} Laboratory Investigation}
}
@article{Tunbridge_1989,
	doi = {10.2337/diacare.12.2.115},
	url = {http://dx.doi.org/10.2337/diacare.12.2.115},
	year = 1989,
	month = {feb},
	publisher = {American Diabetes Association},
	volume = {12},
	number = {2},
	pages = {115--119},
	author = {F. K. Tunbridge and A. Newens and P. D. Home and S. N. Davis and M. Murphy and J. M. Burrin and K. G. Alberti and I. Jensen},
	title = {Double-blind crossover trial of isophane ($\\lbrace$NPH$\\rbrace$)- and lente-based insulin regimens},
	journal = {Diabetes Care}
}
@article{_NA__2008,
	doi = {10.2165/00151234-200805610-00029},
	url = {http://dx.doi.org/10.2165/00151234-200805610-00029},
	year = 2008,
	publisher = {Springer Science $\\mathplus$ Business Media},
	volume = {{\\&}$\\lbrace$NA$\\rbrace$$\\mathsemicolon$},
	number = {561},
	pages = {10},
	author = {{\\&}NA$\\mathsemicolon$},
	title = {Novartis has announced that the final National Institute for Health and Clinical Excellence ($\\lbrace$NICE$\\rbrace$) Technology Appraisal Guidance},
	journal = {$\\lbrace$PharmacoEconomics$\\rbrace$ {\\&} Outcomes News}
}
@article{Vignati_1997,
	doi = {10.1016/s0149-2918(97)80014-8},
	url = {http://dx.doi.org/10.1016/s0149-2918(97)80014-8},
	year = 1997,
	month = {nov},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {19},
	number = {6},
	pages = {1408--1421},
	author = {Louis Vignati and James H. Anderson and Philip W. Iversen},
	title = {Efficacy of insulin lispro in combination with $\\lbrace$NPH$\\rbrace$ human insulin twice per day in patients with insulin-dependent or non{\\textemdash}insulin-dependent diabetes mellitus},
	journal = {Clinical Therapeutics}
}
@article{Nielsen_1995,
	doi = {10.1007/bf00400729},
	url = {http://dx.doi.org/10.1007/bf00400729},
	year = 1995,
	month = {may},
	publisher = {Springer Science $\\mathplus$ Business Media},
	volume = {38},
	number = {5},
	pages = {592--598},
	author = {F. S. Nielsen and L. N. Jrgensen and M. Ipsen and A. I. Voldsgaard and H. -H. Parving},
	title = {Long-term comparison of human insulin analogue B10Asp and soluble human insulin in $\\lbrace$IDDM$\\rbrace$ patients on a basal/bolus insulin regimen},
	journal = {Diabetologia}
}
@article{Lindholm_1999,
	doi = {10.2337/diacare.22.5.801},
	url = {http://dx.doi.org/10.2337/diacare.22.5.801},
	year = 1999,
	month = {may},
	publisher = {American Diabetes Association},
	volume = {22},
	number = {5},
	pages = {801--805},
	author = {A. Lindholm and J. McEwen and A. P. Riis},
	title = {Improved postprandial glycemic control with insulin aspart. A randomized double-blind cross-over trial in type 1 diabetes},
	journal = {Diabetes Care}
}
@article{Sindaco_1998,
	doi = {10.1002/(sici)1096-9136(199807)15:7<592::aid-dia625>3.0.co;2-j},
	url = {http://dx.doi.org/10.1002/(sici)1096-9136(199807)15:7<592::aid-dia625>3.0.co;2-j},
	year = 1998,
	month = {jul},
	publisher = {Wiley-Blackwell},
	volume = {15},
	number = {7},
	pages = {592--600},
	author = {P. Del Sindaco and M. Ciofetta and C. Lalli and G. Perriello and S. Pampanelli and E. Torlone and P. Brunetti and G.B. Bolli},
	title = {Use of the short-acting insulin analogue lispro in intensive treatment of Type 1 diabetes mellitus: importance of appropriate replacement of basal insulin and time-interval injection-meal},
	journal = {Diabet. Med.}
}
@article{Davey_1997,
	doi = {10.1016/s0149-2918(97)80091-4},
	url = {http://dx.doi.org/10.1016/s0149-2918(97)80091-4},
	year = 1997,
	month = {jul},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {19},
	number = {4},
	pages = {656--674},
	author = {Peter Davey and David Grainger and Jamie MacMillan and Narayan Rajan and Michael Aristides and Michael Gliksman},
	title = {Clinical outcomes with insulin lispro compared with human regular insulin: a meta-analysis},
	journal = {Clinical Therapeutics}
}
@article{Lalli_1999,
	doi = {10.2337/diacare.22.3.468},
	url = {http://dx.doi.org/10.2337/diacare.22.3.468},
	year = 1999,
	month = {mar},
	publisher = {American Diabetes Association},
	volume = {22},
	number = {3},
	pages = {468--477},
	author = {C. Lalli and M. Ciofetta and P. Del Sindaco and E. Torlone and S. Pampanelli and P. Compagnucci and M. G. Cartechini and L. Bartocci and P. Brunetti and G. B. Bolli},
	title = {Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with $\\lbrace$NPH$\\rbrace$ insulin at mealtime},
	journal = {Diabetes Care}
}
@article{Anderson_1997,
	doi = {10.2337/diabetes.46.2.265},
	url = {http://dx.doi.org/10.2337/diabetes.46.2.265},
	year = 1997,
	month = {feb},
	publisher = {American Diabetes Association},
	volume = {46},
	number = {2},
	pages = {265--270},
	author = {J. H. Anderson and R. L. Brunelle and V. A. Koivisto and A. Pfutzner and M. E. Trautmann and L. Vignati and R. DiMarchi},
	title = {Reduction of postprandial hyperglycemia and frequency of hypoglycemia in $\\lbrace$IDDM$\\rbrace$ patients on insulin-analog treatment. Multicenter Insulin Lispro Study Group},
	journal = {Diabetes}
}
@article{Pf_tzner_1996,
	doi = {10.1055/s-0029-1211418},
	url = {http://dx.doi.org/10.1055/s-0029-1211418},
	year = 1996,
	publisher = {Thieme Publishing Group},
	volume = {104},
	number = {01},
	pages = {25--30},
	author = {A. Pftzner and E. Kstner and T. Forst and B. Schulze-Schleppinghoff and M. E. Trautmann and M. Haslbeck and H. Schatz and J. Beyer},
	title = {Intensive insulin therapy with insulin lispro in patients with type 1 diabetes reduces the frequency of hypoglycemic episodes},
	journal = {Exp Clin Endocrinol Diabetes}
}
@article{Renner_1999,
	doi = {10.2337/diacare.22.5.784},
	url = {http://dx.doi.org/10.2337/diacare.22.5.784},
	year = 1999,
	month = {may},
	publisher = {American Diabetes Association},
	volume = {22},
	number = {5},
	pages = {784--788},
	author = {R. Renner and A. Pfutzner and M. Trautmann and O. Harzer and K. Sauter and R. Landgraf},
	title = {Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Results of a multicenter trial. German Humalog-$\\lbrace$CSII$\\rbrace$ Study Group},
	journal = {Diabetes Care}
}
@article{Ebeling_1997,
	doi = {10.2337/diacare.20.8.1287},
	url = {http://dx.doi.org/10.2337/diacare.20.8.1287},
	year = 1997,
	month = {aug},
	publisher = {American Diabetes Association},
	volume = {20},
	number = {8},
	pages = {1287--1289},
	author = {P. Ebeling and P. A. Jansson and U. Smith and C. Lalli and G. B. Bolli and V. A. Koivisto},
	title = {Strategies toward improved control during insulin lispro therapy in $\\lbrace$IDDM$\\rbrace$. Importance of basal insulin},
	journal = {Diabetes Care}
}
@article{Roach_1999,
	doi = {10.1016/s0149-2918(00)88307-1},
	url = {http://dx.doi.org/10.1016/s0149-2918(00)88307-1},
	year = 1999,
	month = {mar},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {21},
	number = {3},
	pages = {523--534},
	author = {Paris Roach and Michael Trautmann and Vipin Arora and Bin Sun and James H. Anderson},
	title = {Improved postprandial blood glucose control and reduced nocturnal hypoglycemia during treatment with two novel insulin lispro-protamine formulations, insulin lispro Mix25 and insulin lispro Mix50},
	journal = {Clinical Therapeutics}
}
@article{Group_2000,
	doi = {10.1046/j.1464-5491.2000.00258.x},
	url = {http://dx.doi.org/10.1046/j.1464-5491.2000.00258.x},
	year = 2000,
	month = {mar},
	publisher = {Wiley-Blackwell},
	volume = {17},
	number = {3},
	pages = {209--214},
	author = {E. A. M. Gale for the U.K. Trial Group},
	title = {A randomized, controlled trial comparing insulin lispro with human soluble insulin in patients with Type 1 diabetes on intensified insulin therapy},
	journal = {Diabet Med}
}
@article{Holleman_1997,
	doi = {10.2337/diacare.20.12.1827},
	url = {http://dx.doi.org/10.2337/diacare.20.12.1827},
	year = 1997,
	month = {dec},
	publisher = {American Diabetes Association},
	volume = {20},
	number = {12},
	pages = {1827--1832},
	author = {F. Holleman and H. Schmitt and R. Rottiers and A. Rees and S. Symanowski and J. H. Anderson},
	title = {Reduced frequency of severe hypoglycemia and coma in well-controlled $\\lbrace$IDDM$\\rbrace$ patients treated with insulin lispro. The Benelux-$\\lbrace$UK$\\rbrace$ Insulin Lispro Study Group},
	journal = {Diabetes Care}
}
@article{Ahmed_1998,
	doi = {10.2337/diacare.21.1.32},
	url = {http://dx.doi.org/10.2337/diacare.21.1.32},
	year = 1998,
	month = {jan},
	publisher = {American Diabetes Association},
	volume = {21},
	number = {1},
	pages = {32--37},
	author = {A. B. Ahmed and P. D. Home},
	title = {The effect of the insulin analog lispro on nighttime blood glucose control in type 1 diabetic patients},
	journal = {Diabetes Care}
}
@article{Brunelle_1998,
	doi = {10.2337/diacare.21.10.1726},
	url = {http://dx.doi.org/10.2337/diacare.21.10.1726},
	year = 1998,
	month = {oct},
	publisher = {American Diabetes Association},
	volume = {21},
	number = {10},
	pages = {1726--1731},
	author = {B. L. Brunelle and J. Llewelyn and J. H. Anderson and E. A. Gale and V. A. Koivisto},
	title = {Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetes},
	journal = {Diabetes Care}
}
@article{Battista_1995,
	doi = {10.1017/s0266462300005298},
	url = {http://dx.doi.org/10.1017/s0266462300005298},
	year = 1995,
	month = {dec},
	publisher = {Cambridge University Press ($\\lbrace$CUP$\\rbrace$)},
	volume = {11},
	number = {01},
	pages = {102},
	author = {Renaldo N. Battista and David H. Feeny and Matthew J. Hodge},
	title = {Evaluation of the Canadian Coordinating Office for Health Technology Assessment},
	journal = {International Journal of Technology Assessment in Health Care}
}
@article{Home_1998,
	doi = {10.2337/diacare.21.11.1904},
	url = {http://dx.doi.org/10.2337/diacare.21.11.1904},
	year = 1998,
	month = {nov},
	publisher = {American Diabetes Association},
	volume = {21},
	number = {11},
	pages = {1904--1909},
	author = {P. D. Home and A. Lindholm and B. Hylleberg and P. Round},
	title = {Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients. $\\lbrace$UK$\\rbrace$ Insulin Aspart Study Group},
	journal = {Diabetes Care}
}
@article{Zinman_1999,
	doi = {10.2337/diacare.22.4.603},
	url = {http://dx.doi.org/10.2337/diacare.22.4.603},
	year = 1999,
	month = {apr},
	publisher = {American Diabetes Association},
	volume = {22},
	number = {4},
	pages = {603--608},
	author = {B. Zinman and S. Ross and R. V. Campos and T. Strack},
	title = {Effectiveness of human ultralente versus $\\lbrace$NPH$\\rbrace$ insulin in providing basal insulin replacement for an insulin lispro multiple daily injection regimen. A double-blind randomized prospective trial. The Canadian Lispro Study Group},
	journal = {Diabetes Care}
}
@article{Hermansen_2001,
	doi = {10.2337/diacare.24.2.296},
	url = {http://dx.doi.org/10.2337/diacare.24.2.296},
	year = 2001,
	month = {feb},
	publisher = {American Diabetes Association},
	volume = {24},
	number = {2},
	pages = {296--301},
	author = {K. Hermansen and S. Madsbad and H. Perrild and A. Kristensen and M. Axelsen},
	title = {Comparison of the Soluble Basal Insulin Analog Insulin Detemir With $\\lbrace$NPH$\\rbrace$ Insulin: A randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy},
	journal = {Diabetes Care}
}
@article{Stades_2002,
	doi = {10.2337/diacare.25.4.712},
	url = {http://dx.doi.org/10.2337/diacare.25.4.712},
	year = 2002,
	month = {apr},
	publisher = {American Diabetes Association},
	volume = {25},
	number = {4},
	pages = {712--717},
	author = {A. M.E. Stades and J. B.L. Hoekstra and I. van den Tweel and D. W. Erkelens and F. Holleman},
	title = {Additional Lunchtime Basal Insulin During Insulin Lispro Intensive Therapy in a Randomized, Multicenter, Crossover Study in Adults : A real-life design},
	journal = {Diabetes Care}
}
@article{Fanelli_2002,
	doi = {10.7326/0003-4819-136-7-200204020-00007},
	url = {http://dx.doi.org/10.7326/0003-4819-136-7-200204020-00007},
	year = 2002,
	month = {apr},
	publisher = {American College of Physicians},
	volume = {136},
	number = {7},
	pages = {504},
	author = {Carmine G. Fanelli},
	title = {Administration of Neutral Protamine Hagedorn Insulin at Bedtime versus with Dinner in Type 1 Diabetes Mellitus To Avoid Nocturnal Hypoglycemia and Improve Control},
	journal = {Annals of Internal Medicine}
}
@article{Dunbar_1994,
	doi = {10.2337/diacare.17.8.874},
	url = {http://dx.doi.org/10.2337/diacare.17.8.874},
	year = 1994,
	month = {aug},
	publisher = {American Diabetes Association},
	volume = {17},
	number = {8},
	pages = {874--878},
	author = {J. M. Dunbar and P. M. Madden and D. T. Gleeson and T. M. Fiad and T. J. McKenna},
	title = {Premixed insulin preparations in pen syringes maintain glycemic control and are preferred by patients},
	journal = {Diabetes Care}
}
@article{Swinnen_2009,
	doi = {10.1016/s1098-3015(10)75034-8},
	url = {http://dx.doi.org/10.1016/s1098-3015(10)75034-8},
	year = 2009,
	month = {oct},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {12},
	number = {7},
	pages = {A412},
	author = {SG Swinnen and T Hajos and F Holleman and MP Dain and JH DeVries and JB Hoekstra and FJ Snoek},
	title = {$\\lbrace$PDB$\\rbrace$56 $\\lbrace$THE$\\rbrace$ $\\lbrace$IMPACT$\\rbrace$ $\\lbrace$OF$\\rbrace$ $\\lbrace$STARTING$\\rbrace$ $\\lbrace$INSULIN$\\rbrace$ $\\lbrace$GLARGINE$\\rbrace$ $\\lbrace$VERSUS$\\rbrace$ $\\lbrace$INSULIN$\\rbrace$ $\\lbrace$DETEMIR$\\rbrace$ $\\lbrace$ON$\\rbrace$ $\\lbrace$QUALITY$\\rbrace$ $\\lbrace$OF$\\rbrace$ $\\lbrace$LIFE$\\rbrace$ ($\\lbrace$QOL$\\rbrace$) $\\lbrace$AND$\\rbrace$ $\\lbrace$TREATMENT$\\rbrace$ $\\lbrace$SATISFACTION$\\rbrace$ ($\\lbrace$TS$\\rbrace$) $\\lbrace$IN$\\rbrace$ $\\lbrace$PATIENTS$\\rbrace$ $\\lbrace$WITH$\\rbrace$ $\\lbrace$TYPE$\\rbrace$ 2 $\\lbrace$DIABETES$\\rbrace$ $\\lbrace$INADEQUATELY$\\rbrace$ $\\lbrace$CONTROLLED$\\rbrace$ $\\lbrace$ON$\\rbrace$ $\\lbrace$ORAL$\\rbrace$ $\\lbrace$GLUCOSE$\\rbrace$-$\\lbrace$LOWERING$\\rbrace$ $\\lbrace$DRUGS$\\rbrace$ ($\\lbrace$OGLDS$\\rbrace$)},
	journal = {Value in Health}
}
@article{Hollander_1997,
	doi = {10.2337/diacare.20.3.248},
	url = {http://dx.doi.org/10.2337/diacare.20.3.248},
	year = 1997,
	month = {mar},
	publisher = {American Diabetes Association},
	volume = {20},
	number = {3},
	pages = {248--253},
	author = {P. Hollander and X. Pi-Sunyer and R. F. Coniff},
	title = {Acarbose in the treatment of type I diabetes},
	journal = {Diabetes Care}
}
@article{Riccardi_1999,
	doi = {10.1046/j.1464-5491.1999.00047.x},
	url = {http://dx.doi.org/10.1046/j.1464-5491.1999.00047.x},
	year = 1999,
	month = {mar},
	publisher = {Wiley-Blackwell},
	volume = {16},
	number = {3},
	pages = {228--232},
	author = {G. Riccardi and R. Giacco and M. Parillo and S. Turco and A. A. Rivellese and M. R. Ventura and S. Contadini and G. Marra and M. Monteduro and F. Santeusanio and P. Brunetti and M. C. Librenti and A. E. Pontiroli and P. Vedani and G. Pozza and L. Bergamini and C. Bianchi},
	title = {Efficacy and safety of acarbose in the treatment of Type 1 diabetes mellitus: a placebo-controlled,double-blind, multicentre study},
	journal = {Diabet Med}
}
@incollection{Viviani_1988,
	doi = {10.1007/978-3-642-73583-7_61},
	url = {http://dx.doi.org/10.1007/978-3-642-73583-7_61},
	year = 1988,
	publisher = {Springer Berlin Heidelberg},
	pages = {182--182},
	author = {G. L. Viviani and L. Camogliano and M. G. Borgoglio and P. Salvini and H. Ohnmeiss and L. Adezati},
	title = {Acarbose Treatment in Insulin-Dependent Diabetics},
	booktitle = {Acarbose for the Treatment of Diabetes Mellitus}
}
@article{Marena_1991,
	doi = {10.1111/j.1464-5491.1991.tb01676.x},
	url = {http://dx.doi.org/10.1111/j.1464-5491.1991.tb01676.x},
	year = 1991,
	month = {aug},
	publisher = {Wiley-Blackwell},
	volume = {8},
	number = {7},
	pages = {674--678},
	author = {S. Marena and V. Tagliaferro and G. Cavallero and A. Paganiy and G. Montegrosso and W. Bianchi and P. Zaccarini and G. Pagano},
	title = {Double-blind Crossover Study of Acarbose in Type 1 Diabetic Patients},
	journal = {Diabetic Medicine}
}
@article{Tzefos_2010,
	doi = {10.1345/aph.1p047},
	url = {http://dx.doi.org/10.1345/aph.1p047},
	year = 2010,
	month = {jul},
	publisher = {$\\lbrace$SAGE$\\rbrace$ Publications},
	volume = {44},
	number = {7},
	pages = {1294--1300},
	author = {M. Tzefos and J. L. Olin},
	title = {Glucagon-Like Peptide-1 Analog and Insulin Combination Therapy in the Management of Adults with Type 2 Diabetes Mellitus},
	journal = {Annals of Pharmacotherapy}
}
@article{NATHAN_1988,
	doi = {10.7326/0003-4819-108-3-334},
	url = {http://dx.doi.org/10.7326/0003-4819-108-3-334},
	year = 1988,
	month = {mar},
	publisher = {American College of Physicians},
	volume = {108},
	number = {3},
	pages = {334},
	author = {DAVID M. NATHAN},
	title = {Glyburide or Insulin for Metabolic Control in Non-Insulin-Dependent Diabetes Mellitus},
	journal = {Annals of Internal Medicine}
}
@article{Burke_1984,
	doi = {10.1530/acta.0.1070070},
	url = {http://dx.doi.org/10.1530/acta.0.1070070},
	year = 1984,
	month = {sep},
	publisher = {$\\lbrace$BioScientifica$\\rbrace$},
	volume = {107},
	number = {1},
	pages = {70--77},
	author = {B. J. Burke and M. Hartog and M. R. Waterfield},
	title = {Improved diabetic control in insulin-dependent diabetics treated with insulin and glibenclamide},
	journal = {European Journal of Endocrinology}
}
@article{Fallucca_1996,
	doi = {10.1055/s-2007-979134},
	url = {http://dx.doi.org/10.1055/s-2007-979134},
	year = 1996,
	month = {feb},
	publisher = {Thieme Publishing Group},
	volume = {28},
	number = {02},
	pages = {86--88},
	author = {F. Fallucca and E. Sciullo and A. Maldonato},
	title = {Combined Therapy with Insulin and Sulfonylurea for the Treatment of New-Onset Insulin-Dependent Diabetes Mellitus},
	journal = {Hormone and Metabolic Research}
}
@article{Al_Mrayat_2009,
	doi = {10.1002/pdi.1330},
	url = {http://dx.doi.org/10.1002/pdi.1330},
	year = 2009,
	month = {mar},
	publisher = {Wiley-Blackwell},
	volume = {26},
	number = {2},
	pages = {49--49},
	author = {Ma{\\textquotesingle}en Al-Mrayat},
	title = {Towards routine use of insulin pump therapy in clinical practice},
	journal = {Pract Diab Int}
}
@article{Murray_1988,
	doi = {10.1111/j.1464-5491.1988.tb01102.x},
	url = {http://dx.doi.org/10.1111/j.1464-5491.1988.tb01102.x},
	year = 1988,
	month = {nov},
	publisher = {Wiley-Blackwell},
	volume = {5},
	number = {8},
	pages = {750--754},
	author = {D. P. Murray and P. Keenan and E. Gayer and P. Salmon and G. H. Tomkin and M. I. Drury and D. J. O{\\textquotesingle}Sullivan},
	title = {A Randomized Trial of the Efficacy and Acceptability of a Pen Injector},
	journal = {Diabetic Medicine}
}
@article{Bantle_1993,
	doi = {10.2337/diacare.16.12.1592},
	url = {http://dx.doi.org/10.2337/diacare.16.12.1592},
	year = 1993,
	month = {dec},
	publisher = {American Diabetes Association},
	volume = {16},
	number = {12},
	pages = {1592--1597},
	author = {J. P. Bantle and L. Neal and L. M. Frankamp},
	title = {Effects of the anatomical region used for insulin injections on glycemia in type I diabetes subjects},
	journal = {Diabetes Care}
}
@article{Meijer_1990,
	doi = {10.1111/j.1464-5491.1990.tb01431.x},
	url = {http://dx.doi.org/10.1111/j.1464-5491.1990.tb01431.x},
	year = 1990,
	month = {jul},
	publisher = {Wiley-Blackwell},
	volume = {7},
	number = {6},
	pages = {499--505},
	author = {P.H.E.M. Meijer and J.A. Lutterman and H.J.J. Lier and A. van{\\textquotesingle}t Laar},
	title = {The Variability of the Absorption of Subcutaneously Injected Insulin: Effect of Injection Technique and Relation with Brittleness},
	journal = {Diabetic Medicine}
}
@article{Fleming_1997,
	doi = {10.2337/diacare.20.3.244},
	url = {http://dx.doi.org/10.2337/diacare.20.3.244},
	year = 1997,
	month = {mar},
	publisher = {American Diabetes Association},
	volume = {20},
	number = {3},
	pages = {244--247},
	author = {D. R. Fleming and S. J. Jacober and M. A. Vandenberg and J. T. Fitzgerald and G. Grunberger},
	title = {The safety of injecting insulin through clothing},
	journal = {Diabetes Care}
}
@article{Graff_1998,
	doi = {10.1016/s0149-2918(98)80058-1},
	url = {http://dx.doi.org/10.1016/s0149-2918(98)80058-1},
	year = 1998,
	month = {may},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {20},
	number = {3},
	pages = {486--496},
	author = {Marilyn R. Graff and Mark A. McClanahan},
	title = {Assessment by patients with diabetes mellitus of two insulin pen delivery systems versus a vial and syringe},
	journal = {Clinical Therapeutics}
}
@article{H_rnquist_1995,
	doi = {10.1016/0168-8227(95)01054-h},
	url = {http://dx.doi.org/10.1016/0168-8227(95)01054-h},
	year = 1995,
	month = {apr},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {28},
	number = {1},
	pages = {63--72},
	author = {Jan Olof Hrnquist and Anders Wikby and Ulf Stenstrm and Per-Olof Andersson},
	title = {Change in quality of life along with type 1 diabetes},
	journal = {Diabetes Research and Clinical Practice}
}
@article{H_rnquist_1990,
	doi = {10.1016/0168-8227(90)90065-2},
	url = {http://dx.doi.org/10.1016/0168-8227(90)90065-2},
	year = 1990,
	month = {nov},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {10},
	number = {3},
	pages = {221--230},
	author = {Jan Olof Hrnquist and Anders Wikby and Per-Olof Andersson and Ann-Mari Dufva},
	title = {Insulin-pen treatment, quality of life and metabolic control: retrospective intra-group evaluations},
	journal = {Diabetes Research and Clinical Practice}
}
@article{Kinsley_1999,
	doi = {10.2337/diacare.22.7.1022},
	url = {http://dx.doi.org/10.2337/diacare.22.7.1022},
	year = 1999,
	month = {jul},
	publisher = {American Diabetes Association},
	volume = {22},
	number = {7},
	pages = {1022--1028},
	author = {B. T. Kinsley and K. Weinger and M. Bajaj and C. J. Levy and D. C. Simonson and M. Quigley and D. J. Cox and A. M. Jacobson},
	title = {Blood glucose awareness training and epinephrine responses to hypoglycemia during intensive treatment in type 1 diabetes},
	journal = {Diabetes Care}
}
@article{Fritsche_1998,
	doi = {10.1016/s0168-8227(98)00047-3},
	url = {http://dx.doi.org/10.1016/s0168-8227(98)00047-3},
	year = 1998,
	month = {may},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {40},
	number = {2},
	pages = {129--135},
	author = {A Fritsche and M Stumvoll and W Renn and R.-M Schmlling},
	title = {Diabetes teaching program improves glycemic control and preserves perception of hypoglycemia},
	journal = {Diabetes Research and Clinical Practice}
}
@article{Patrick_1990,
	doi = {10.1136/emj.7.2.73},
	url = {http://dx.doi.org/10.1136/emj.7.2.73},
	year = 1990,
	month = {jun},
	publisher = {$\\lbrace$BMJ$\\rbrace$},
	volume = {7},
	number = {2},
	pages = {73--77},
	author = {A W Patrick and A Collier and D A Hepburn and D J Steedman and B F Clarke and C Robertson},
	title = {Comparison of intramuscular glucagon and intravenous dextrose in the treatment of hypoglycaemic coma in an accident and emergency department.},
	journal = {Emergency Medicine Journal}
}
@article{Collier_1987,
	doi = {10.2337/diacare.10.6.712},
	url = {http://dx.doi.org/10.2337/diacare.10.6.712},
	year = 1987,
	month = {nov},
	publisher = {American Diabetes Association},
	volume = {10},
	number = {6},
	pages = {712--715},
	author = {A. Collier and D. J. Steedman and A. W. Patrick and G. R. Nimmo and D. M. Matthews and C. C. MacIntyre and K. Little and B. F. Clarke},
	title = {Comparison of intravenous glucagon and dextrose in treatment of severe hypoglycemia in an accident and emergency department},
	journal = {Diabetes Care}
}
@article{Linden_2011,
	doi = {10.12968/bjca.2011.6.3.142},
	url = {http://dx.doi.org/10.12968/bjca.2011.6.3.142},
	year = 2011,
	month = {mar},
	publisher = {Mark Allen Group},
	volume = {6},
	number = {3},
	pages = {142--143},
	author = {Belinda Linden},
	title = {Non-pharmacological management of depression Scottish Intercollegiate Guidelines Network ( 2010 ) Non-Pharmaceutical Management of Depression in Adults: A National Clinical Guideline . [$\\lbrace$SIGN$\\rbrace$ 114. January. $\\lbrace$SIGN$\\rbrace$ , Edinburgh},
	journal = {Br J Cardiac Nursing}
}
@article{Kanters_1999,
	doi = {10.1177/1358836x9900400203},
	url = {http://dx.doi.org/10.1177/1358836x9900400203},
	year = 1999,
	month = {may},
	publisher = {$\\lbrace$SAGE$\\rbrace$ Publications},
	volume = {4},
	number = {2},
	pages = {67--75},
	author = {S. D. Kanters and J.-D. Banga and R. P Stolk and A. Algra},
	title = {Incidence and determinants of mortality and cardiovascular events in diabetes mellitus: a meta-analysis},
	journal = {Vascular Medicine}
}
@article{Pignone_2001,
	doi = {10.1016/s0749-3797(01)00255-0},
	url = {http://dx.doi.org/10.1016/s0749-3797(01)00255-0},
	year = 2001,
	month = {apr},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {20},
	number = {3},
	pages = {77--89},
	author = {Michael P Pignone and Christopher J Phillips and David Atkins and Steven M Teutsch and Cynthia D Mulrow and Kathleen N Lohr},
	title = {Screening and treating adults for lipid disorders21Reprints are available from the $\\lbrace$AHRQ$\\rbrace$ Web site at www.ahrq.gov/clinic/uspstfix.htm, through the National Guideline Clearinghouse (www.guideline/gov), or in print through the $\\lbrace$AHRQ$\\rbrace$ Publications Clearinghouse (1-800-358-9295).22The $\\lbrace$USPSTF$\\rbrace$ recommendations based on this evidence review can be found in Screening Adults for Lipid Disorders: Recommendations and Rationale, available elsewhere in this supplement and from the $\\lbrace$AHRQ$\\rbrace$ Web site and clearinghouse.},
	journal = {American Journal of Preventive Medicine}
}
@article{Bayly_1999,
	doi = {10.1046/j.1464-5491.1999.00091.x},
	url = {http://dx.doi.org/10.1046/j.1464-5491.1999.00091.x},
	year = 1999,
	month = {aug},
	publisher = {Wiley-Blackwell},
	volume = {16},
	number = {8},
	pages = {697--701},
	author = {G. R. Bayly and W. A. Bartlett and P. H. Davies and D. Husband and A. Haddon and F. L. Game and A. F. Jones},
	title = {Laboratory-based calculation of coronary heart disease risk in a hospital diabetic clinic},
	journal = {Diabet Med}
}
@article{Game_2001,
	doi = {10.1046/j.1464-5491.2001.00438.x},
	url = {http://dx.doi.org/10.1046/j.1464-5491.2001.00438.x},
	year = 2001,
	month = {may},
	publisher = {Wiley-Blackwell},
	volume = {18},
	number = {5},
	pages = {355--359},
	author = {F. L. Game and A. F. Jones},
	title = {Coronary heart disease risk assessment in diabetes mellitus--a comparison of $\\lbrace$PROCAM$\\rbrace$ and Framingham risk assessment functions},
	journal = {Diabet Med}
}
@article{Jones_2001,
	doi = {10.1136/heart.85.1.37},
	url = {http://dx.doi.org/10.1136/heart.85.1.37},
	year = 2001,
	month = {jan},
	publisher = {$\\lbrace$BMJ$\\rbrace$},
	volume = {85},
	number = {1},
	pages = {37--43},
	author = {A F Jones},
	title = {Comparative accuracy of cardiovascular risk prediction methods in primary care patients},
	journal = {Heart}
}
@article{Miller_2002,
	doi = {10.1177/14746514020020010401},
	url = {http://dx.doi.org/10.1177/14746514020020010401},
	year = 2002,
	month = {jan},
	publisher = {$\\lbrace$SAGE$\\rbrace$ Publications},
	volume = {2},
	number = {1},
	pages = {47--49},
	author = {J. Miller},
	title = {The Scottish Intercollegiate Guidelines Network ($\\lbrace$SIGN$\\rbrace$)},
	journal = {The British Journal of Diabetes {\\&} Vascular Disease}
}
@article{Rustemeijer_1997,
	doi = {10.1007/s005920050091},
	url = {http://dx.doi.org/10.1007/s005920050091},
	year = 1997,
	month = {dec},
	publisher = {Springer Science $\\mathplus$ Business Media},
	volume = {34},
	number = {4},
	pages = {294--300},
	author = {C. Rustemeijer and J. A. Schouten and E. N. W. Janssens and P. F. M. J. Spooren and J. J. van Doormaal},
	title = {Pravastatin in diabetes-associated hypercholesterolemia},
	journal = {Acta Diabetologica}
}
@article{Raskin_1995,
	doi = {10.1016/s0002-9343(99)80182-x},
	url = {http://dx.doi.org/10.1016/s0002-9343(99)80182-x},
	year = 1995,
	month = {oct},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {99},
	number = {4},
	pages = {362--369},
	author = {Philip Raskin and Om P. Ganda and Sherwyn Schwartz and David Willard and Julio Rosenstock and Peter A. Lodewick and Michael D. Cressman and Beverly Phillipson and Bonnie Weiner and Mark E. McGovern and Jean M. Norton and Gabriella G. Cucinotta and Bruce D. Behounek},
	title = {Efficacy and safety of pravastatin in the treatment of patients with type I or type $\\lbrace$II$\\rbrace$ diabetes mellitus and hypercholesterolemia},
	journal = {The American Journal of Medicine}
}
@article{Goldberg_1998,
	doi = {10.1161/01.cir.98.23.2513},
	url = {http://dx.doi.org/10.1161/01.cir.98.23.2513},
	year = 1998,
	month = {dec},
	publisher = {Ovid Technologies (Wolters Kluwer Health)},
	volume = {98},
	number = {23},
	pages = {2513--2519},
	author = {R. B. Goldberg and M. J. Mellies and F. M. Sacks and L. A. Moye and B. V. Howard and W. J. Howard and B. R. Davis and T. G. Cole and M. A. Pfeffer and E. Braunwald},
	title = {Cardiovascular Events and Their Reduction With Pravastatin in Diabetic and Glucose-Intolerant Myocardial Infarction Survivors With Average Cholesterol Levels : Subgroup Analyses in the Cholesterol And Recurrent Events ($\\lbrace$CARE$\\rbrace$) Trial},
	journal = {Circulation}
}
@article{Sweany_1995,
	doi = {10.1016/0149-2918(95)80018-2},
	url = {http://dx.doi.org/10.1016/0149-2918(95)80018-2},
	year = 1995,
	month = {apr},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {17},
	number = {2},
	pages = {186--203},
	author = {A Sweany},
	title = {Effects of simvastatin versus gemfibrozil on lipids and glucose control in patients with non{\\^{a}}insulin-dependent diabetes mellitus},
	journal = {Clinical Therapeutics}
}
@article{Hommel_1992,
	doi = {10.1007/bf02342442},
	url = {http://dx.doi.org/10.1007/bf02342442},
	year = 1992,
	month = {may},
	publisher = {Springer Science $\\mathplus$ Business Media},
	volume = {35},
	number = {5},
	pages = {447--451},
	author = {E. Hommel and P. Andersen and M. -A. Gall and F. Nielsen and B. Jensen and P. Rossing and J. Dyerberg and H. -H. Parving},
	title = {Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy},
	journal = {Diabetologia}
}
@article{Winocour_1990,
	doi = {10.1111/j.1464-5491.1990.tb01479.x},
	url = {http://dx.doi.org/10.1111/j.1464-5491.1990.tb01479.x},
	year = 1990,
	month = {sep},
	publisher = {Wiley-Blackwell},
	volume = {7},
	number = {8},
	pages = {736--743},
	author = {P.H. Winocour and P.N. Durrington and D. Bhatnagar and M. Ishola and S. Arrol and B.C. Lalor and D.C. Anderson},
	title = {Double-blind Placebo-controlled Study of the Effects of Bezafibrate on Blood Lipids, Lipoproteins, and Fibrinogen in Hyperlipidaemic Type 1 Diabetes Mellitus},
	journal = {Diabetic Medicine}
}
@article{1994,
	doi = {10.1111/j.1464-5491.1994.tb00297.x},
	url = {http://dx.doi.org/10.1111/j.1464-5491.1994.tb00297.x},
	year = 1994,
	month = {may},
	publisher = {Wiley-Blackwell},
	volume = {11},
	number = {4},
	pages = {418--423},
	title = {Measuring the Outcomes of Diabetes Care},
	journal = {Diabetic Medicine}
}
@article{1992,
	doi = {10.1001/jama.268.10.1292},
	url = {http://dx.doi.org/10.1001/jama.268.10.1292},
	year = 1992,
	month = {sep},
	publisher = {American Medical Association ($\\lbrace$AMA$\\rbrace$)},
	volume = {268},
	number = {10},
	pages = {1292--1300},
	title = {Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. $\\lbrace$ETDRS$\\rbrace$ Investigators},
	journal = {$\\lbrace$JAMA$\\rbrace$: The Journal of the American Medical Association}
}
@article{Roffi_2002,
	doi = {10.1016/s1062-1458(02)00618-9},
	url = {http://dx.doi.org/10.1016/s1062-1458(02)00618-9},
	year = 2002,
	month = {may},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {11},
	number = {3},
	pages = {11},
	author = {M. Roffi and D.P. Chew and D. Mukherjee},
	title = {Platelet glycoprotein $\\lbrace$IIb$\\rbrace$/$\\lbrace$IIIa$\\rbrace$ inhibitors reduce mortality in diabetic patients with non{\\textendash}$\\lbrace$ST$\\rbrace$-segment elevation acute coronary syndromes},
	journal = {$\\lbrace$ACC$\\rbrace$ Current Journal Review}
}
@article{2000,
	doi = {10.1016/s1053-0770(00)70021-8},
	url = {http://dx.doi.org/10.1016/s1053-0770(00)70021-8},
	year = 2000,
	month = {aug},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {14},
	number = {4},
	pages = {488},
	title = {Heart Outcomes Prevention Evaluation ($\\lbrace$HOPE$\\rbrace$) Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the $\\lbrace$HOPE$\\rbrace$ study and $\\lbrace$MICRO$\\rbrace$-$\\lbrace$HOPE$\\rbrace$ substudy},
	journal = {Journal of Cardiothoracic and Vascular Anesthesia}
}
@article{Lonn_2003,
	doi = {10.1097/01.hjr.0000106836.977722.cf},
	url = {http://dx.doi.org/10.1097/01.hjr.0000106836.977722.cf},
	year = 2003,
	month = {dec},
	publisher = {Ovid Technologies (Wolters Kluwer Health)},
	volume = {10},
	number = {6},
	pages = {420--428},
	author = {E. Lonn and J. Mathew and J. Pogue and D. Johnstone and K. Danisa and J. Bosch and M. Baird and G. Dagenais and P. Sleight and S. Yusuf},
	title = {Relationship of electrocardiographic left ventricular hypertrophy to mortality and cardiovascular morbidity in high-risk patients},
	journal = {European Journal of Cardiovascular Prevention {\\&} Rehabilitation}
}
@article{Grover_2000,
	doi = {10.1161/01.cir.102.7.722},
	url = {http://dx.doi.org/10.1161/01.cir.102.7.722},
	year = 2000,
	month = {aug},
	publisher = {Ovid Technologies (Wolters Kluwer Health)},
	volume = {102},
	number = {7},
	pages = {722--727},
	author = {S. A. Grover and L. Coupal and H. Zowall and M. Dorais},
	title = {Cost-Effectiveness of Treating Hyperlipidemia in the Presence of Diabetes : Who Should Be Treated?},
	journal = {Circulation}
}
@article{Grover_2001,
	doi = {10.2337/diacare.24.1.45},
	url = {http://dx.doi.org/10.2337/diacare.24.1.45},
	year = 2001,
	month = {jan},
	publisher = {American Diabetes Association},
	volume = {24},
	number = {1},
	pages = {45--50},
	author = {S. A. Grover and L. Coupal and H. Zowall and C. M. Alexander and T. W. Weiss and D. R.J. Gomes},
	title = {How Cost-Effective Is the Treatment of Dyslipidemia in Patients With Diabetes but Without Cardiovascular Disease?},
	journal = {Diabetes Care}
}
""";
                                                                                                        <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-Citations.bibtex>;
                                                                                                        <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                        <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-Citations.bibtex-965ab483ac8dc09ca7d27c3c1666c5e5e2fd00f0>;
                                                                                                        <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-332a35d1000ad9f48052b739c045858dc0b18841>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-Citations.tex-0d503d623b23c013da25e0ce32bc1f4cc64434b1> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                       <http://www.w3.org/ns/prov#Entity>;
                                                                                                     <http://www.w3.org/2011/content#chars> """@article{H_rnquist_1995,
	doi = {10.1016/0168-8227(95)01054-h},
	url = {http://dx.doi.org/10.1016/0168-8227(95)01054-h},
	year = 1995,
	month = {apr},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {28},
	number = {1},
	pages = {63--72},
	author = {Jan Olof Hrnquist and Anders Wikby and Ulf Stenstrm and Per-Olof Andersson},
	title = {Change in quality of life along with type 1 diabetes},
	journal = {Diabetes Research and Clinical Practice}
}
@article{H_rnquist_1990,
	doi = {10.1016/0168-8227(90)90065-2},
	url = {http://dx.doi.org/10.1016/0168-8227(90)90065-2},
	year = 1990,
	month = {nov},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {10},
	number = {3},
	pages = {221--230},
	author = {Jan Olof Hrnquist and Anders Wikby and Per-Olof Andersson and Ann-Mari Dufva},
	title = {Insulin-pen treatment, quality of life and metabolic control: retrospective intra-group evaluations},
	journal = {Diabetes Research and Clinical Practice}
}
@article{Kinsley_1999,
	doi = {10.2337/diacare.22.7.1022},
	url = {http://dx.doi.org/10.2337/diacare.22.7.1022},
	year = 1999,
	month = {jul},
	publisher = {American Diabetes Association},
	volume = {22},
	number = {7},
	pages = {1022--1028},
	author = {B. T. Kinsley and K. Weinger and M. Bajaj and C. J. Levy and D. C. Simonson and M. Quigley and D. J. Cox and A. M. Jacobson},
	title = {Blood glucose awareness training and epinephrine responses to hypoglycemia during intensive treatment in type 1 diabetes},
	journal = {Diabetes Care}
}
@article{Fritsche_1998,
	doi = {10.1016/s0168-8227(98)00047-3},
	url = {http://dx.doi.org/10.1016/s0168-8227(98)00047-3},
	year = 1998,
	month = {may},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {40},
	number = {2},
	pages = {129--135},
	author = {A Fritsche and M Stumvoll and W Renn and R.-M Schmlling},
	title = {Diabetes teaching program improves glycemic control and preserves perception of hypoglycemia},
	journal = {Diabetes Research and Clinical Practice}
}
@article{Patrick_1990,
	doi = {10.1136/emj.7.2.73},
	url = {http://dx.doi.org/10.1136/emj.7.2.73},
	year = 1990,
	month = {jun},
	publisher = {$\\lbrace$BMJ$\\rbrace$},
	volume = {7},
	number = {2},
	pages = {73--77},
	author = {A W Patrick and A Collier and D A Hepburn and D J Steedman and B F Clarke and C Robertson},
	title = {Comparison of intramuscular glucagon and intravenous dextrose in the treatment of hypoglycaemic coma in an accident and emergency department.},
	journal = {Emergency Medicine Journal}
}
@article{Collier_1987,
	doi = {10.2337/diacare.10.6.712},
	url = {http://dx.doi.org/10.2337/diacare.10.6.712},
	year = 1987,
	month = {nov},
	publisher = {American Diabetes Association},
	volume = {10},
	number = {6},
	pages = {712--715},
	author = {A. Collier and D. J. Steedman and A. W. Patrick and G. R. Nimmo and D. M. Matthews and C. C. MacIntyre and K. Little and B. F. Clarke},
	title = {Comparison of intravenous glucagon and dextrose in treatment of severe hypoglycemia in an accident and emergency department},
	journal = {Diabetes Care}
}
@article{Linden_2011,
	doi = {10.12968/bjca.2011.6.3.142},
	url = {http://dx.doi.org/10.12968/bjca.2011.6.3.142},
	year = 2011,
	month = {mar},
	publisher = {Mark Allen Group},
	volume = {6},
	number = {3},
	pages = {142--143},
	author = {Belinda Linden},
	title = {Non-pharmacological management of depression Scottish Intercollegiate Guidelines Network ( 2010 ) Non-Pharmaceutical Management of Depression in Adults: A National Clinical Guideline . [$\\lbrace$SIGN$\\rbrace$ 114. January. $\\lbrace$SIGN$\\rbrace$ , Edinburgh},
	journal = {Br J Cardiac Nursing}
}
@article{Kanters_1999,
	doi = {10.1177/1358836x9900400203},
	url = {http://dx.doi.org/10.1177/1358836x9900400203},
	year = 1999,
	month = {may},
	publisher = {$\\lbrace$SAGE$\\rbrace$ Publications},
	volume = {4},
	number = {2},
	pages = {67--75},
	author = {S. D. Kanters and J.-D. Banga and R. P Stolk and A. Algra},
	title = {Incidence and determinants of mortality and cardiovascular events in diabetes mellitus: a meta-analysis},
	journal = {Vascular Medicine}
}
@article{Pignone_2001,
	doi = {10.1016/s0749-3797(01)00255-0},
	url = {http://dx.doi.org/10.1016/s0749-3797(01)00255-0},
	year = 2001,
	month = {apr},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {20},
	number = {3},
	pages = {77--89},
	author = {Michael P Pignone and Christopher J Phillips and David Atkins and Steven M Teutsch and Cynthia D Mulrow and Kathleen N Lohr},
	title = {Screening and treating adults for lipid disorders21Reprints are available from the $\\lbrace$AHRQ$\\rbrace$ Web site at www.ahrq.gov/clinic/uspstfix.htm, through the National Guideline Clearinghouse (www.guideline/gov), or in print through the $\\lbrace$AHRQ$\\rbrace$ Publications Clearinghouse (1-800-358-9295).22The $\\lbrace$USPSTF$\\rbrace$ recommendations based on this evidence review can be found in Screening Adults for Lipid Disorders: Recommendations and Rationale, available elsewhere in this supplement and from the $\\lbrace$AHRQ$\\rbrace$ Web site and clearinghouse.},
	journal = {American Journal of Preventive Medicine}
}
@article{Bayly_1999,
	doi = {10.1046/j.1464-5491.1999.00091.x},
	url = {http://dx.doi.org/10.1046/j.1464-5491.1999.00091.x},
	year = 1999,
	month = {aug},
	publisher = {Wiley-Blackwell},
	volume = {16},
	number = {8},
	pages = {697--701},
	author = {G. R. Bayly and W. A. Bartlett and P. H. Davies and D. Husband and A. Haddon and F. L. Game and A. F. Jones},
	title = {Laboratory-based calculation of coronary heart disease risk in a hospital diabetic clinic},
	journal = {Diabet Med}
}
@article{Game_2001,
	doi = {10.1046/j.1464-5491.2001.00438.x},
	url = {http://dx.doi.org/10.1046/j.1464-5491.2001.00438.x},
	year = 2001,
	month = {may},
	publisher = {Wiley-Blackwell},
	volume = {18},
	number = {5},
	pages = {355--359},
	author = {F. L. Game and A. F. Jones},
	title = {Coronary heart disease risk assessment in diabetes mellitus--a comparison of $\\lbrace$PROCAM$\\rbrace$ and Framingham risk assessment functions},
	journal = {Diabet Med}
}
@article{Jones_2001,
	doi = {10.1136/heart.85.1.37},
	url = {http://dx.doi.org/10.1136/heart.85.1.37},
	year = 2001,
	month = {jan},
	publisher = {$\\lbrace$BMJ$\\rbrace$},
	volume = {85},
	number = {1},
	pages = {37--43},
	author = {A F Jones},
	title = {Comparative accuracy of cardiovascular risk prediction methods in primary care patients},
	journal = {Heart}
}
@article{Miller_2002,
	doi = {10.1177/14746514020020010401},
	url = {http://dx.doi.org/10.1177/14746514020020010401},
	year = 2002,
	month = {jan},
	publisher = {$\\lbrace$SAGE$\\rbrace$ Publications},
	volume = {2},
	number = {1},
	pages = {47--49},
	author = {J. Miller},
	title = {The Scottish Intercollegiate Guidelines Network ($\\lbrace$SIGN$\\rbrace$)},
	journal = {The British Journal of Diabetes {\\&} Vascular Disease}
}
@article{Rustemeijer_1997,
	doi = {10.1007/s005920050091},
	url = {http://dx.doi.org/10.1007/s005920050091},
	year = 1997,
	month = {dec},
	publisher = {Springer Science $\\mathplus$ Business Media},
	volume = {34},
	number = {4},
	pages = {294--300},
	author = {C. Rustemeijer and J. A. Schouten and E. N. W. Janssens and P. F. M. J. Spooren and J. J. van Doormaal},
	title = {Pravastatin in diabetes-associated hypercholesterolemia},
	journal = {Acta Diabetologica}
}
@article{Raskin_1995,
	doi = {10.1016/s0002-9343(99)80182-x},
	url = {http://dx.doi.org/10.1016/s0002-9343(99)80182-x},
	year = 1995,
	month = {oct},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {99},
	number = {4},
	pages = {362--369},
	author = {Philip Raskin and Om P. Ganda and Sherwyn Schwartz and David Willard and Julio Rosenstock and Peter A. Lodewick and Michael D. Cressman and Beverly Phillipson and Bonnie Weiner and Mark E. McGovern and Jean M. Norton and Gabriella G. Cucinotta and Bruce D. Behounek},
	title = {Efficacy and safety of pravastatin in the treatment of patients with type I or type $\\lbrace$II$\\rbrace$ diabetes mellitus and hypercholesterolemia},
	journal = {The American Journal of Medicine}
}
@article{Goldberg_1998,
	doi = {10.1161/01.cir.98.23.2513},
	url = {http://dx.doi.org/10.1161/01.cir.98.23.2513},
	year = 1998,
	month = {dec},
	publisher = {Ovid Technologies (Wolters Kluwer Health)},
	volume = {98},
	number = {23},
	pages = {2513--2519},
	author = {R. B. Goldberg and M. J. Mellies and F. M. Sacks and L. A. Moye and B. V. Howard and W. J. Howard and B. R. Davis and T. G. Cole and M. A. Pfeffer and E. Braunwald},
	title = {Cardiovascular Events and Their Reduction With Pravastatin in Diabetic and Glucose-Intolerant Myocardial Infarction Survivors With Average Cholesterol Levels : Subgroup Analyses in the Cholesterol And Recurrent Events ($\\lbrace$CARE$\\rbrace$) Trial},
	journal = {Circulation}
}
@article{Sweany_1995,
	doi = {10.1016/0149-2918(95)80018-2},
	url = {http://dx.doi.org/10.1016/0149-2918(95)80018-2},
	year = 1995,
	month = {apr},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {17},
	number = {2},
	pages = {186--203},
	author = {A Sweany},
	title = {Effects of simvastatin versus gemfibrozil on lipids and glucose control in patients with non{\\^{a}}insulin-dependent diabetes mellitus},
	journal = {Clinical Therapeutics}
}
@article{Hommel_1992,
	doi = {10.1007/bf02342442},
	url = {http://dx.doi.org/10.1007/bf02342442},
	year = 1992,
	month = {may},
	publisher = {Springer Science $\\mathplus$ Business Media},
	volume = {35},
	number = {5},
	pages = {447--451},
	author = {E. Hommel and P. Andersen and M. -A. Gall and F. Nielsen and B. Jensen and P. Rossing and J. Dyerberg and H. -H. Parving},
	title = {Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy},
	journal = {Diabetologia}
}
@article{Winocour_1990,
	doi = {10.1111/j.1464-5491.1990.tb01479.x},
	url = {http://dx.doi.org/10.1111/j.1464-5491.1990.tb01479.x},
	year = 1990,
	month = {sep},
	publisher = {Wiley-Blackwell},
	volume = {7},
	number = {8},
	pages = {736--743},
	author = {P.H. Winocour and P.N. Durrington and D. Bhatnagar and M. Ishola and S. Arrol and B.C. Lalor and D.C. Anderson},
	title = {Double-blind Placebo-controlled Study of the Effects of Bezafibrate on Blood Lipids, Lipoproteins, and Fibrinogen in Hyperlipidaemic Type 1 Diabetes Mellitus},
	journal = {Diabetic Medicine}
}
@article{1994,
	doi = {10.1111/j.1464-5491.1994.tb00297.x},
	url = {http://dx.doi.org/10.1111/j.1464-5491.1994.tb00297.x},
	year = 1994,
	month = {may},
	publisher = {Wiley-Blackwell},
	volume = {11},
	number = {4},
	pages = {418--423},
	title = {Measuring the Outcomes of Diabetes Care},
	journal = {Diabetic Medicine}
}
@article{1992,
	doi = {10.1001/jama.268.10.1292},
	url = {http://dx.doi.org/10.1001/jama.268.10.1292},
	year = 1992,
	month = {sep},
	publisher = {American Medical Association ($\\lbrace$AMA$\\rbrace$)},
	volume = {268},
	number = {10},
	pages = {1292--1300},
	title = {Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. $\\lbrace$ETDRS$\\rbrace$ Investigators},
	journal = {$\\lbrace$JAMA$\\rbrace$: The Journal of the American Medical Association}
}
@article{Roffi_2002,
	doi = {10.1016/s1062-1458(02)00618-9},
	url = {http://dx.doi.org/10.1016/s1062-1458(02)00618-9},
	year = 2002,
	month = {may},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {11},
	number = {3},
	pages = {11},
	author = {M. Roffi and D.P. Chew and D. Mukherjee},
	title = {Platelet glycoprotein $\\lbrace$IIb$\\rbrace$/$\\lbrace$IIIa$\\rbrace$ inhibitors reduce mortality in diabetic patients with non{\\textendash}$\\lbrace$ST$\\rbrace$-segment elevation acute coronary syndromes},
	journal = {$\\lbrace$ACC$\\rbrace$ Current Journal Review}
}
@article{2000,
	doi = {10.1016/s1053-0770(00)70021-8},
	url = {http://dx.doi.org/10.1016/s1053-0770(00)70021-8},
	year = 2000,
	month = {aug},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {14},
	number = {4},
	pages = {488},
	title = {Heart Outcomes Prevention Evaluation ($\\lbrace$HOPE$\\rbrace$) Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the $\\lbrace$HOPE$\\rbrace$ study and $\\lbrace$MICRO$\\rbrace$-$\\lbrace$HOPE$\\rbrace$ substudy},
	journal = {Journal of Cardiothoracic and Vascular Anesthesia}
}
@article{Lonn_2003,
	doi = {10.1097/01.hjr.0000106836.977722.cf},
	url = {http://dx.doi.org/10.1097/01.hjr.0000106836.977722.cf},
	year = 2003,
	month = {dec},
	publisher = {Ovid Technologies (Wolters Kluwer Health)},
	volume = {10},
	number = {6},
	pages = {420--428},
	author = {E. Lonn and J. Mathew and J. Pogue and D. Johnstone and K. Danisa and J. Bosch and M. Baird and G. Dagenais and P. Sleight and S. Yusuf},
	title = {Relationship of electrocardiographic left ventricular hypertrophy to mortality and cardiovascular morbidity in high-risk patients},
	journal = {European Journal of Cardiovascular Prevention {\\&} Rehabilitation}
}
@article{Grover_2000,
	doi = {10.1161/01.cir.102.7.722},
	url = {http://dx.doi.org/10.1161/01.cir.102.7.722},
	year = 2000,
	month = {aug},
	publisher = {Ovid Technologies (Wolters Kluwer Health)},
	volume = {102},
	number = {7},
	pages = {722--727},
	author = {S. A. Grover and L. Coupal and H. Zowall and M. Dorais},
	title = {Cost-Effectiveness of Treating Hyperlipidemia in the Presence of Diabetes : Who Should Be Treated?},
	journal = {Circulation}
}
@article{Grover_2001,
	doi = {10.2337/diacare.24.1.45},
	url = {http://dx.doi.org/10.2337/diacare.24.1.45},
	year = 2001,
	month = {jan},
	publisher = {American Diabetes Association},
	volume = {24},
	number = {1},
	pages = {45--50},
	author = {S. A. Grover and L. Coupal and H. Zowall and C. M. Alexander and T. W. Weiss and D. R.J. Gomes},
	title = {How Cost-Effective Is the Treatment of Dyslipidemia in Patients With Diabetes but Without Cardiovascular Disease?},
	journal = {Diabetes Care}
}
@article{Day_1987,
	doi = {10.1136/bmj.294.6587.1590},
	url = {http://dx.doi.org/10.1136/bmj.294.6587.1590},
	year = 1987,
	month = {jun},
	publisher = {$\\lbrace$BMJ$\\rbrace$},
	volume = {294},
	number = {6587},
	pages = {1590--1592},
	author = {J L Day and H Humphreys and H Alban-Davies},
	title = {Problems of comprehensive shared diabetes care.},
	journal = {$\\lbrace$BMJ$\\rbrace$}
}
@article{1994,
	doi = {10.1136/bmj.308.6938.1208},
	url = {http://dx.doi.org/10.1136/bmj.308.6938.1208},
	year = 1994,
	month = {may},
	publisher = {$\\lbrace$BMJ$\\rbrace$},
	volume = {308},
	number = {6938},
	pages = {1208--1212},
	title = {Integrated care for diabetes: clinical, psychosocial, and economic evaluation},
	journal = {$\\lbrace$BMJ$\\rbrace$}
}
@article{Donohoe_2000,
	doi = {10.1046/j.1464-5491.2000.00336.x},
	url = {http://dx.doi.org/10.1046/j.1464-5491.2000.00336.x},
	year = 2000,
	month = {aug},
	publisher = {Wiley-Blackwell},
	volume = {17},
	number = {8},
	pages = {581--587},
	author = {M. E. Donohoe and J. A. Fletton and A. Hook and R. Powell and I. Robinson and J. W. Stead and K. Sweeney and R. Taylor and J. E. Tooke},
	title = {Improving foot care for people with diabetes mellitus - a randomized controlled trial of an integrated care approach},
	journal = {Diabet Med}
}
@article{Newton_1996,
	doi = {10.1111/j.1365-2524.1996.tb00058.x},
	url = {http://dx.doi.org/10.1111/j.1365-2524.1996.tb00058.x},
	year = 1996,
	month = {may},
	publisher = {Wiley-Blackwell},
	volume = {4},
	number = {3},
	pages = {142--149},
	author = {John Newton},
	title = {Patients{\\textquotesingle} involvement in medical audit in general practice},
	journal = {Health {\\&} Social Care in the Community}
}
@article{Carrington_1996,
	doi = {10.1002/(sici)1096-9136(199610)13:10<912::aid-dia258>3.0.co;2-4},
	url = {http://dx.doi.org/10.1002/(sici)1096-9136(199610)13:10<912::aid-dia258>3.0.co;2-4},
	year = 1996,
	month = {oct},
	publisher = {Wiley-Blackwell},
	volume = {13},
	number = {10},
	pages = {912--914},
	author = {A.L. Carrington and H. Connor and A.J.M. Boulton},
	title = {The Diabetic Foot 1996},
	journal = {Diabet. Med.}
}
@article{Fahy_1988,
	doi = {10.1192/pb.12.4.156},
	url = {http://dx.doi.org/10.1192/pb.12.4.156},
	year = 1988,
	month = {apr},
	publisher = {Royal College of Psychiatrists},
	volume = {12},
	number = {4},
	pages = {156--157},
	author = {T. J. Fahy},
	title = {The Presentation of Depression: Current Approaches: Edited by P. Freeling, L. J. Downey and J. C. Malkin (Occasional paper No. 36). London: The Royal College of General Practitioners. 1987. Pp 21. ~4.00, inc. postage (Cheques should be made payable to $\\lbrace$RCGP$\\rbrace$ Enterprises Ltd.)},
	journal = {Psychiatric Bulletin}
}
@article{Hampson_1996,
	doi = {10.1093/fampra/13.3.264},
	url = {http://dx.doi.org/10.1093/fampra/13.3.264},
	year = 1996,
	publisher = {Oxford University Press ($\\lbrace$OUP$\\rbrace$)},
	volume = {13},
	number = {3},
	pages = {264--279},
	author = {JP Hampson and RI Roberts and DA Morgan},
	title = {Shared care: a review of the literature},
	journal = {Fam Pract}
}
@article{Hayes_1984,
	doi = {10.1136/bmj.289.6447.728},
	url = {http://dx.doi.org/10.1136/bmj.289.6447.728},
	year = 1984,
	month = {sep},
	publisher = {$\\lbrace$BMJ$\\rbrace$},
	volume = {289},
	number = {6447},
	pages = {728--730},
	author = {T M Hayes and J Harries},
	title = {Randomised controlled trial of routine hospital clinic care versus routine general practice care for type $\\lbrace$II$\\rbrace$ diabetics.},
	journal = {$\\lbrace$BMJ$\\rbrace$}
}
@article{Mayes_2012,
	doi = {10.1007/s11019-012-9454-0},
	url = {http://dx.doi.org/10.1007/s11019-012-9454-0},
	year = 2012,
	month = {nov},
	publisher = {Springer Science $\\mathplus$ Business Media},
	volume = {16},
	number = {4},
	pages = {691--697},
	author = {Rick Mayes and Blair Armistead},
	title = {Chronic disease, prevention policy, and the future of public health and primary care},
	journal = {Med Health Care and Philos}
}
@article{Hoskins_1993,
	doi = {10.1111/j.1464-5491.1993.tb02001.x},
	url = {http://dx.doi.org/10.1111/j.1464-5491.1993.tb02001.x},
	year = 1993,
	month = {jan},
	publisher = {Wiley-Blackwell},
	volume = {10},
	number = {1},
	pages = {81--86},
	author = {P.L. Hoskins and P.M. Fowler and M. Constantino and J. Forrest and D.K. Yue and J.R. Turtle},
	title = {Sharing the Care of Diabetic Patients between Hospital and General Practitioners: Does it Work?},
	journal = {Diabetic Medicine}
}
@article{Hurwitz_1993,
	doi = {10.1136/bmj.306.6878.624},
	url = {http://dx.doi.org/10.1136/bmj.306.6878.624},
	year = 1993,
	month = {mar},
	publisher = {$\\lbrace$BMJ$\\rbrace$},
	volume = {306},
	number = {6878},
	pages = {624--630},
	author = {B Hurwitz and C Goodman and J Yudkin},
	title = {Prompting the clinical care of non-insulin dependent (type $\\lbrace$II$\\rbrace$) diabetic patients in an inner city area: one model of community care.},
	journal = {$\\lbrace$BMJ$\\rbrace$}
}
@article{Porter_1982,
	doi = {10.1136/bmj.285.6348.1121},
	url = {http://dx.doi.org/10.1136/bmj.285.6348.1121},
	year = 1982,
	month = {oct},
	publisher = {$\\lbrace$BMJ$\\rbrace$},
	volume = {285},
	number = {6348},
	pages = {1121--1121},
	author = {A M Porter},
	title = {Organisation of diabetic care.},
	journal = {$\\lbrace$BMJ$\\rbrace$}
}
@article{Smith_1998,
	doi = {10.2337/diacare.21.6.972},
	url = {http://dx.doi.org/10.2337/diacare.21.6.972},
	year = 1998,
	month = {jun},
	publisher = {American Diabetes Association},
	volume = {21},
	number = {6},
	pages = {972--976},
	author = {S. A. Smith and M. E. Murphy and T. R. Huschka and S. F. Dinneen and C. A. Gorman and B. R. Zimmerman and R. A. Rizza and J. M. Naessens},
	title = {Impact of a diabetes electronic management system on the care of patients seen in a subspecialty diabetes clinic},
	journal = {Diabetes Care}
}
@article{2009,
	doi = {10.1192/pb.bp.109.025262},
	url = {http://dx.doi.org/10.1192/pb.bp.109.025262},
	year = 2009,
	month = {apr},
	publisher = {Royal College of Psychiatrists},
	volume = {33},
	number = {4},
	pages = {157--157},
	title = {Management of patients with physical and psychological problems in primary care (joint report between the Royal College of Psychiatrists and the Royal College of General Practitioners)},
	journal = {Psychiatric Bulletin}
}
@article{Bloomgarden_1987,
	doi = {10.2337/diacare.10.3.263},
	url = {http://dx.doi.org/10.2337/diacare.10.3.263},
	year = 1987,
	month = {may},
	publisher = {American Diabetes Association},
	volume = {10},
	number = {3},
	pages = {263--272},
	author = {Z. T. Bloomgarden and W. Karmally and M. J. Metzger and M. Brothers and C. Nechemias and J. Bookman and D. Faierman and F. Ginsberg-Fellner and E. Rayfield and W. V. Brown},
	title = {Randomized, controlled trial of diabetic patient education: improved knowledge without improved metabolic status},
	journal = {Diabetes Care}
}
@article{Campbell_1996,
	doi = {10.1177/014572179602200412},
	url = {http://dx.doi.org/10.1177/014572179602200412},
	year = 1996,
	month = {jan},
	publisher = {$\\lbrace$SAGE$\\rbrace$ Publications},
	volume = {22},
	number = {4},
	pages = {379--386},
	author = {E. M. Campbell and S. Redman and Pauls. Moffitt and R. W. Sanson-Fisher},
	title = {The Relative Effectiveness of Educational and Behavioral Instruction Programs for Patients With $\\lbrace$NIDDM$\\rbrace$: A Randomized Trial},
	journal = {The Diabetes Educator}
}
@article{Cohen_1983,
	doi = {10.2337/diacare.6.5.499},
	url = {http://dx.doi.org/10.2337/diacare.6.5.499},
	year = 1983,
	month = {sep},
	publisher = {American Diabetes Association},
	volume = {6},
	number = {5},
	pages = {499--500},
	author = {S. J. Cohen},
	title = {Potential barriers to diabetes care},
	journal = {Diabetes Care}
}
@article{Mac_Donald_1974,
	doi = {10.1007/bf01219539},
	url = {http://dx.doi.org/10.1007/bf01219539},
	year = 1974,
	month = {dec},
	publisher = {Springer Science $\\mathplus$ Business Media},
	volume = {10},
	number = {6},
	pages = {767--773},
	author = {M. J. Mac Donald},
	title = {Equal incidence of adult-onset diabetes among ancestors of juvenile diabetics and nondiabetics},
	journal = {Diabetologia}
}
@article{Kruger_1992,
	doi = {10.1177/014572179201800606},
	url = {http://dx.doi.org/10.1177/014572179201800606},
	year = 1992,
	month = {jan},
	publisher = {$\\lbrace$SAGE$\\rbrace$ Publications},
	volume = {18},
	number = {6},
	pages = {487--490},
	author = {S. Kruger and D. Guthrie},
	title = {Foot Care: Knowledge Retention and Self-care Practices},
	journal = {The Diabetes Educator}
}
@article{Hamalainen_1998,
	doi = {10.1177/014572179802400609},
	url = {http://dx.doi.org/10.1177/014572179802400609},
	year = 1998,
	month = {jan},
	publisher = {$\\lbrace$SAGE$\\rbrace$ Publications},
	volume = {24},
	number = {6},
	pages = {734--740},
	author = {H. Hamalainen and T. Ronnemaa and T. Toikka and I. Liukkonen},
	title = {Long-Term Effects of One Year of Intensified Podiatric Activities on Foot-Care Knowledge and Self-Care Habits in Patients With Diabetes},
	journal = {The Diabetes Educator}
}
@article{Litzelman_1993,
	doi = {10.7326/0003-4819-119-1-199307010-00006},
	url = {http://dx.doi.org/10.7326/0003-4819-119-1-199307010-00006},
	year = 1993,
	month = {jul},
	publisher = {American College of Physicians},
	volume = {119},
	number = {1},
	pages = {36},
	author = {Debra K. Litzelman},
	title = {Reduction of Lower Extremity Clinical Abnormalities in Patients with Non-Insulin-Dependent Diabetes Mellitus},
	journal = {Annals of Internal Medicine}
}
@article{Malone_1989,
	doi = {10.1016/0002-9610(89)90183-9},
	url = {http://dx.doi.org/10.1016/0002-9610(89)90183-9},
	year = 1989,
	month = {dec},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {158},
	number = {6},
	pages = {520--524},
	author = {James M. Malone and Martin Snyder and Gary Anderson and Victor M. Bernhard and G.Allen Holloway and Theodore J. Bunt},
	title = {Prevention of amputation by diabetic education},
	journal = {The American Journal of Surgery}
}
@article{Masson_1989,
	doi = {10.1002/pdi.1960060111},
	url = {http://dx.doi.org/10.1002/pdi.1960060111},
	year = 1989,
	month = {jan},
	publisher = {Wiley-Blackwell},
	volume = {6},
	number = {1},
	pages = {22--23},
	author = {E A Masson and Suzanne Angle and Peggy Roseman and C Soper and I Wilson and Marilyn Cotton and A J M Boulton},
	title = {Diabetic foot ulcers {\\textemdash} do patients know how to protect themselves?},
	journal = {Pract. Diab. Int.}
}
@article{Pieber_1995,
	doi = {10.1111/j.1464-5491.1995.tb00491.x},
	url = {http://dx.doi.org/10.1111/j.1464-5491.1995.tb00491.x},
	year = 1995,
	month = {apr},
	publisher = {Wiley-Blackwell},
	volume = {12},
	number = {4},
	pages = {349--354},
	author = {T.R. Pieber and A. Holler and A. Siebenhofer and G.A. Brunner and B. Semlitsch and S. Schattenberg and H. Zapotoczky and W. Rainer and G.J. Krejs},
	title = {Evaluation of a Structured Teaching and Treatment Programme for Type 2 Diabetes in General Practice in a Rural Area of Austria},
	journal = {Diabetic Medicine}
}
@article{Reichard_1993,
	doi = {10.1056/nejm199307293290502},
	url = {http://dx.doi.org/10.1056/nejm199307293290502},
	year = 1993,
	month = {jul},
	publisher = {New England Journal of Medicine ($\\lbrace$NEJM$\\rbrace$/$\\lbrace$MMS$\\rbrace$)},
	volume = {329},
	number = {5},
	pages = {304--309},
	author = {Per Reichard and Bengt-Yngve Nilsson and Urban Rosenqvist},
	title = {The Effect of Long-Term Intensified Insulin Treatment on the Development of Microvascular Complications of Diabetes Mellitus},
	journal = {New England Journal of Medicine}
}
@article{Rettig_1986,
	doi = {10.2337/diacare.9.2.173},
	url = {http://dx.doi.org/10.2337/diacare.9.2.173},
	year = 1986,
	month = {mar},
	publisher = {American Diabetes Association},
	volume = {9},
	number = {2},
	pages = {173--178},
	author = {B. A. Rettig and D. G. Shrauger and R. R. Recker and T. F. Gallagher and H. Wiltse},
	title = {A randomized study of the effects of a home diabetes education program},
	journal = {Diabetes Care}
}
@article{THOMSON_1992,
	doi = {10.1093/ageing/21.5.333},
	url = {http://dx.doi.org/10.1093/ageing/21.5.333},
	year = 1992,
	publisher = {Oxford University Press ($\\lbrace$OUP$\\rbrace$)},
	volume = {21},
	number = {5},
	pages = {333--337},
	author = {FIONA J. THOMSON and EWAN A. MASSON},
	title = {Can Elderly Diabetic Patients Co-operate with Routine Foot Care?},
	journal = {Age Ageing}
}
@article{Abbott_1998,
	doi = {10.2337/diacare.21.7.1071},
	url = {http://dx.doi.org/10.2337/diacare.21.7.1071},
	year = 1998,
	month = {jul},
	publisher = {American Diabetes Association},
	volume = {21},
	number = {7},
	pages = {1071--1075},
	author = {C. A. Abbott and L. Vileikyte and S. Williamson and A. L. Carrington and A. J. Boulton},
	title = {Multicenter study of the incidence of and predictive risk factors for diabetic neuropathic foot ulceration},
	journal = {Diabetes Care}
}
@article{Booth_2000,
	doi = {10.2337/diacare.23.7.984},
	url = {http://dx.doi.org/10.2337/diacare.23.7.984},
	year = 2000,
	month = {jul},
	publisher = {American Diabetes Association},
	volume = {23},
	number = {7},
	pages = {984--988},
	author = {J. Booth and M. J. Young},
	title = {Differences in the performance of commercially available 10-g monofilaments},
	journal = {Diabetes Care}
}
@article{Boulton_1998,
	doi = {10.1002/(sici)1096-9136(199806)15:6<508::aid-dia613>3.3.co;2-c},
	url = {http://dx.doi.org/10.1002/(sici)1096-9136(199806)15:6<508::aid-dia613>3.3.co;2-c},
	year = 1998,
	month = {jun},
	publisher = {Wiley-Blackwell},
	volume = {15},
	number = {6},
	pages = {508--514},
	author = {A.J.M. Boulton and F.A. Gries and J.A. Jervell},
	title = {Guidelines for the diagnosis and outpatient management of diabetic peripheral neuropathy},
	journal = {Diabet. Med.}
}
@article{Edmonds_1999,
	doi = {10.2165/00044011-199917040-00003},
	url = {http://dx.doi.org/10.2165/00044011-199917040-00003},
	year = 1999,
	publisher = {Springer Science $\\mathplus$ Business Media},
	volume = {17},
	number = {4},
	pages = {275--286},
	author = {Michael Edmonds and Andrew Gough and Jose Solovera and Bo Standaert},
	title = {Filgrastim in the Treatment of Infected Diabetic Foot Ulcers},
	journal = {Clinical Drug Investigation}
}
@article{Gaster_1998,
	doi = {10.1001/archinte.158.2.134},
	url = {http://dx.doi.org/10.1001/archinte.158.2.134},
	year = 1998,
	month = {jan},
	publisher = {American Medical Association ($\\lbrace$AMA$\\rbrace$)},
	volume = {158},
	number = {2},
	pages = {134},
	author = {Barak Gaster and Irl B. Hirsch},
	title = {The Effects of Improved Glycemic Control on Complications in Type 2 Diabetes},
	journal = {Archives of Internal Medicine}
}
@article{Klenerman_1996,
	doi = {10.1002/(sici)1096-9136(199606)13:6<561::aid-dia112>3.0.co;2-p},
	url = {http://dx.doi.org/10.1002/(sici)1096-9136(199606)13:6<561::aid-dia112>3.0.co;2-p},
	year = 1996,
	month = {jun},
	publisher = {Wiley-Blackwell},
	volume = {13},
	number = {6},
	pages = {561--563},
	author = {L. Klenerman and C. McCabe and D. Cogley and S. Crerand and P. Laing and M. White},
	title = {Screening for Patients at Risk of Diabetic Foot Ulceration in a General Diabetic Outpatient Clinic},
	journal = {Diabet. Med.}
}
@article{Kumar_1991,
	doi = {10.1016/0168-8227(91)90034-b},
	url = {http://dx.doi.org/10.1016/0168-8227(91)90034-b},
	year = 1991,
	month = {jan},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {13},
	number = {1-2},
	pages = {63--67},
	author = {S. Kumar and D.J.S. Fernando and A. Veves and E.A. Knowles and M.J. Young and A.J.M. Boulton},
	title = {Semmes-Weinstein monofilaments: a simple, effective and inexpensive screening device for identifying diabetic patients at risk of foot ulceration},
	journal = {Diabetes Research and Clinical Practice}
}
@article{Crausaz_1988,
	doi = {10.1111/j.1464-5491.1988.tb01106.x},
	url = {http://dx.doi.org/10.1111/j.1464-5491.1988.tb01106.x},
	year = 1988,
	month = {nov},
	publisher = {Wiley-Blackwell},
	volume = {5},
	number = {8},
	pages = {771--775},
	author = {F. M. Crausaz and S. Clavel and C. Liniger and A. Albeanu and J.-Ph. Assal},
	title = {Additional Factors Associated with Plantar Ulcers in Diabetic Neuropathy},
	journal = {Diabetic Medicine}
}
@article{Liniger_1990,
	doi = {10.1111/j.1464-5491.1990.tb01319.x},
	url = {http://dx.doi.org/10.1111/j.1464-5491.1990.tb01319.x},
	year = 1990,
	month = {dec},
	publisher = {Wiley-Blackwell},
	volume = {7},
	number = {10},
	pages = {859--864},
	author = {C. Liniger and A. Albeanu and D. Bloise and J. Ph. Assal},
	title = {The Tuning Fork Revisited},
	journal = {Diabetic Medicine}
}
@article{Mayfield_1996,
	doi = {10.2337/diacare.19.7.704},
	url = {http://dx.doi.org/10.2337/diacare.19.7.704},
	year = 1996,
	month = {jul},
	publisher = {American Diabetes Association},
	volume = {19},
	number = {7},
	pages = {704--709},
	author = {J. A. Mayfield and G. E. Reiber and R. G. Nelson and T. Greene},
	title = {A foot risk classification system to predict diabetic amputation in Pima Indians},
	journal = {Diabetes Care}
}
@article{Lithner_2000,
	doi = {10.2337/diacare.23.11.1710},
	url = {http://dx.doi.org/10.2337/diacare.23.11.1710},
	year = 2000,
	month = {nov},
	publisher = {American Diabetes Association},
	volume = {23},
	number = {11},
	pages = {1710--1711},
	author = {F. Lithner},
	title = {Venlafaxine in treatment of severe painful peripheral diabetic neuropathy},
	journal = {Diabetes Care}
}
@article{A_N__2002,
	doi = {10.1046/j.1464-5491.2002.00706.x},
	url = {http://dx.doi.org/10.1046/j.1464-5491.2002.00706.x},
	year = 2002,
	month = {may},
	publisher = {Wiley-Blackwell},
	volume = {19},
	number = {5},
	pages = {400--405},
	author = {Paisley A. N. and Abbott C. A. and Van Schie C. H. M. and Boulton A. J. M.},
	title = {A comparison of the Neuropen against standard quantitative sensory-threshold measures for assessing peripheral nerve function},
	journal = {Diabetic Medicine}
}
@article{Pham_2000,
	doi = {10.2337/diacare.23.5.606},
	url = {http://dx.doi.org/10.2337/diacare.23.5.606},
	year = 2000,
	month = {may},
	publisher = {American Diabetes Association},
	volume = {23},
	number = {5},
	pages = {606--611},
	author = {H. Pham and D. G. Armstrong and C. Harvey and L. B. Harkless and J. M. Giurini and A. Veves},
	title = {Screening techniques to identify people at high risk for diabetic foot ulceration: a prospective multicenter trial},
	journal = {Diabetes Care}
}
@article{Rith_Najarian_1992,
	doi = {10.2337/diacare.15.10.1386},
	url = {http://dx.doi.org/10.2337/diacare.15.10.1386},
	year = 1992,
	month = {oct},
	publisher = {American Diabetes Association},
	volume = {15},
	number = {10},
	pages = {1386--1389},
	author = {S. J. Rith-Najarian and T. Stolusky and D. M. Gohdes},
	title = {Identifying diabetic patients at high risk for lower-extremity amputation in a primary health care setting. A prospective evaluation of simple screening criteria},
	journal = {Diabetes Care}
}
@article{Thivolet_1990,
	doi = {10.2337/diacare.13.10.1077},
	url = {http://dx.doi.org/10.2337/diacare.13.10.1077},
	year = 1990,
	month = {oct},
	publisher = {American Diabetes Association},
	volume = {13},
	number = {10},
	pages = {1077--1080},
	author = {C. Thivolet and J. el Farkh and A. Petiot and C. Simonet and J. Tourniaire},
	title = {Measuring vibration sensations with graduated tuning fork. Simple and reliable means to detect diabetic patients at risk of neuropathic foot ulceration},
	journal = {Diabetes Care}
}
@article{UK_Prospective_Diabetes_Study_Group_1998,
	doi = {10.1136/bmj.317.7160.703},
	url = {http://dx.doi.org/10.1136/bmj.317.7160.703},
	year = 1998,
	month = {sep},
	publisher = {$\\lbrace$BMJ$\\rbrace$},
	volume = {317},
	number = {7160},
	pages = {703--713},
	author = {UK Prospective Diabetes Study Group},
	title = {Tight blood pressure control and risk of macrovascular and microvascular complications in type 2~diabetes: $\\lbrace$UKPDS$\\rbrace$ 38},
	journal = {$\\lbrace$BMJ$\\rbrace$}
}
@article{Vileikyte_1997,
	doi = {10.2337/diacare.20.4.623},
	url = {http://dx.doi.org/10.2337/diacare.20.4.623},
	year = 1997,
	month = {apr},
	publisher = {American Diabetes Association},
	volume = {20},
	number = {4},
	pages = {623--626},
	author = {L. Vileikyte and G. Hutchings and S. Hollis and A. J. Boulton},
	title = {The tactile circumferential discriminator. A new, simple screening device to identify diabetic patients at risk of foot ulceration},
	journal = {Diabetes Care}
}
@article{Young_1994,
	doi = {10.2337/diacare.17.6.557},
	url = {http://dx.doi.org/10.2337/diacare.17.6.557},
	year = 1994,
	month = {jun},
	publisher = {American Diabetes Association},
	volume = {17},
	number = {6},
	pages = {557--560},
	author = {M. J. Young and J. L. Breddy and A. Veves and A. J. Boulton},
	title = {The prediction of diabetic neuropathic foot ulceration using vibration perception thresholds. A prospective study},
	journal = {Diabetes Care}
}
@article{Adler_1999,
	doi = {10.2337/diacare.22.7.1029},
	url = {http://dx.doi.org/10.2337/diacare.22.7.1029},
	year = 1999,
	month = {jul},
	publisher = {American Diabetes Association},
	volume = {22},
	number = {7},
	pages = {1029--1035},
	author = {A. I. Adler and E. J. Boyko and J. H. Ahroni and D. G. Smith},
	title = {Lower-extremity amputation in diabetes. The independent effects of peripheral vascular disease, sensory neuropathy, and foot ulcers},
	journal = {Diabetes Care}
}
@article{Benbow_1997,
	doi = {10.1136/bmj.314.7098.1868},
	url = {http://dx.doi.org/10.1136/bmj.314.7098.1868},
	year = 1997,
	month = {jun},
	publisher = {$\\lbrace$BMJ$\\rbrace$},
	volume = {314},
	number = {7098},
	pages = {1868--1868},
	author = {S. J Benbow and A. Walsh and G. V Gill},
	title = {Diabetes in institutionalised elderly people: a forgotten population?},
	journal = {$\\lbrace$BMJ$\\rbrace$}
}
@article{Boyko_1999,
	doi = {10.2337/diacare.22.7.1036},
	url = {http://dx.doi.org/10.2337/diacare.22.7.1036},
	year = 1999,
	month = {jul},
	publisher = {American Diabetes Association},
	volume = {22},
	number = {7},
	pages = {1036--1042},
	author = {E. J. Boyko and J. H. Ahroni and V. Stensel and R. C. Forsberg and D. R. Davignon and D. G. Smith},
	title = {A prospective study of risk factors for diabetic foot ulcer. The Seattle Diabetic Foot Study},
	journal = {Diabetes Care}
}
@article{Caddick_1994,
	doi = {10.1111/j.1464-5491.1994.tb00257.x},
	url = {http://dx.doi.org/10.1111/j.1464-5491.1994.tb00257.x},
	year = 1994,
	month = {dec},
	publisher = {Wiley-Blackwell},
	volume = {11},
	number = {10},
	pages = {981--983},
	author = {S.L. Caddick and M. McKinnon and N. Payne and T.J. Ward and H. Thornton-Jones and J. Kells and J.D. Ward},
	title = {Hospital Admissions and Social Deprivation of Patients with Diabetes Mellitus},
	journal = {Diabetic Medicine}
}
@article{Chaturvedi_1996,
	doi = {10.2337/diacare.19.5.423},
	url = {http://dx.doi.org/10.2337/diacare.19.5.423},
	year = 1996,
	month = {may},
	publisher = {American Diabetes Association},
	volume = {19},
	number = {5},
	pages = {423--430},
	author = {N. Chaturvedi and J. M. Stephenson and J. H. Fuller},
	title = {The relationship between socioeconomic status and diabetes control and complications in the $\\lbrace$EURODIAB$\\rbrace$ $\\lbrace$IDDM$\\rbrace$ Complications Study},
	journal = {Diabetes Care}
}
@article{de_Sonnaville_1997,
	doi = {10.1016/s0168-8227(97)01380-6},
	url = {http://dx.doi.org/10.1016/s0168-8227(97)01380-6},
	year = 1997,
	month = {mar},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {35},
	number = {2-3},
	pages = {149--156},
	author = {J.J.J. de Sonnaville and L.P. Colly and D. Wijkel and R.J. Heine},
	title = {The prevalence and determinants of foot ulceration in type $\\lbrace$II$\\rbrace$ diabetic patients in a primary health care setting},
	journal = {Diabetes Research and Clinical Practice}
}
@article{Dornan_1992,
	doi = {10.1111/j.1464-5491.1992.tb01906.x},
	url = {http://dx.doi.org/10.1111/j.1464-5491.1992.tb01906.x},
	year = 1992,
	month = {nov},
	publisher = {Wiley-Blackwell},
	volume = {9},
	number = {9},
	pages = {860--865},
	author = {T.L. Dornan and G.M. Peck and J.D.C. Dow and R.B. Tattersall},
	title = {A Community Survey of Diabetes in the Elderly},
	journal = {Diabetic Medicine}
}
@article{El_Shazly_1998,
	doi = {10.1016/s1056-8727(97)00001-9},
	url = {http://dx.doi.org/10.1016/s1056-8727(97)00001-9},
	year = 1998,
	month = {jan},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {12},
	number = {1},
	pages = {10--17},
	author = {Medhat El-Shazly and Moataz Abdel-Fattah and Nicola Scorpiglione and Massimo Massi Benedetti and Fabio Capani and Fabrizio Carinci and Quirico Carta and Donatella Cavaliere and Eugenio M. De Feo and Claudio Taboga and Gianni Tognoni and Antonio Nicolucci},
	title = {Risk Factors for Lower Limb Complications in Diabetic Patients},
	journal = {Journal of Diabetes and its Complications}
}
@article{FLETCHER_1996,
	doi = {10.1093/ageing/25.5.349},
	url = {http://dx.doi.org/10.1093/ageing/25.5.349},
	year = 1996,
	publisher = {Oxford University Press ($\\lbrace$OUP$\\rbrace$)},
	volume = {25},
	number = {5},
	pages = {349--352},
	author = {A.K. FLETCHER and J. DOLBEN},
	title = {A Hospital Survey of the Care of Elderly Patients with Diabetes Mellitus},
	journal = {Age Ageing}
}
@article{Frykberg_1998,
	doi = {10.2337/diacare.21.10.1714},
	url = {http://dx.doi.org/10.2337/diacare.21.10.1714},
	year = 1998,
	month = {oct},
	publisher = {American Diabetes Association},
	volume = {21},
	number = {10},
	pages = {1714--1719},
	author = {R. G. Frykberg and L. A. Lavery and H. Pham and C. Harvey and L. Harkless and A. Veves},
	title = {Role of neuropathy and high foot pressures in diabetic foot ulceration},
	journal = {Diabetes Care}
}
@article{G_rlek_1998,
	doi = {10.1055/s-0029-1212006},
	url = {http://dx.doi.org/10.1055/s-0029-1212006},
	year = 1998,
	publisher = {Thieme Publishing Group},
	volume = {106},
	number = {05},
	pages = {404--409},
	author = {A. Grlek and M. Bayraktar and C. Sava{\\c{s}} and O. Gedik},
	title = {Amputation rate in 147 Turkish patients with diabetic foot},
	journal = {Exp Clin Endocrinol Diabetes}
}
@article{Hamalainen_1999,
	doi = {10.1046/j.1365-2796.1999.00523.x},
	url = {http://dx.doi.org/10.1046/j.1365-2796.1999.00523.x},
	year = 1999,
	month = {jul},
	publisher = {Wiley-Blackwell},
	volume = {246},
	number = {1},
	pages = {97--103},
	author = {H. Hamalainen and T. Ronnemaa and J.-P. Halonen and T. Toikka},
	title = {Factors predicting lower extremity amputations in patients with type 1 or type 2 diabetes mellitus: a population-based 7-year follow-up study},
	journal = {J Intern Med}
}
@article{K_stenbauer_2001,
	doi = {10.7547/87507315-91-7-343},
	url = {http://dx.doi.org/10.7547/87507315-91-7-343},
	year = 2001,
	month = {jul},
	publisher = {American Podiatric Medical Association},
	volume = {91},
	number = {7},
	pages = {343--350},
	author = {T. Kstenbauer and S. Sauseng and G. Sokol and M. Auinger and K. Irsigler},
	title = {A Prospective Study of Predictors for Foot Ulceration in Type 2 Diabetes},
	journal = {Journal of the American Podiatric Medical Association}
}
@article{Kumar_1994,
	doi = {10.1111/j.1464-5491.1994.tb00310.x},
	url = {http://dx.doi.org/10.1111/j.1464-5491.1994.tb00310.x},
	year = 1994,
	month = {jun},
	publisher = {Wiley-Blackwell},
	volume = {11},
	number = {5},
	pages = {480--484},
	author = {S. Kumar and H.A. Ashe and L.N. Parnell and D.J.S. Fernando and C. Tsigos and R.J. Young and J.D. Ward and A.J.M. Boulton},
	title = {The Prevalence of Foot Ulceration and its Correlates in Type 2 Diabetic Patients: a Population-based Study},
	journal = {Diabetic Medicine}
}
@article{Lehto_1996,
	doi = {10.2337/diacare.19.6.607},
	url = {http://dx.doi.org/10.2337/diacare.19.6.607},
	year = 1996,
	month = {jun},
	publisher = {American Diabetes Association},
	volume = {19},
	number = {6},
	pages = {607--612},
	author = {S. Lehto and T. Ronnemaa and K. Pyorala and M. Laakso},
	title = {Risk factors predicting lower extremity amputations in patients with $\\lbrace$NIDDM$\\rbrace$},
	journal = {Diabetes Care}
}
@article{Litzelman_1997,
	doi = {10.2337/diacare.20.2.156},
	url = {http://dx.doi.org/10.2337/diacare.20.2.156},
	year = 1997,
	month = {feb},
	publisher = {American Diabetes Association},
	volume = {20},
	number = {2},
	pages = {156--162},
	author = {D. K. Litzelman and D. J. Marriott and F. Vinicor},
	title = {The role of footwear in the prevention of foot lesions in patients with $\\lbrace$NIDDM$\\rbrace$. Conventional wisdom or evidence-based practice?},
	journal = {Diabetes Care}
}
@article{Litzelman_1997,
	doi = {10.2337/diacare.20.8.1273},
	url = {http://dx.doi.org/10.2337/diacare.20.8.1273},
	year = 1997,
	month = {aug},
	publisher = {American Diabetes Association},
	volume = {20},
	number = {8},
	pages = {1273--1278},
	author = {D. K. Litzelman and D. J. Marriott and F. Vinicor},
	title = {Independent physiological predictors of foot lesions in patients with $\\lbrace$NIDDM$\\rbrace$},
	journal = {Diabetes Care}
}
@article{McCabe_1998,
	doi = {10.1002/(sici)1096-9136(199801)15:1<80::aid-dia517>3.0.co;2-k},
	url = {http://dx.doi.org/10.1002/(sici)1096-9136(199801)15:1<80::aid-dia517>3.0.co;2-k},
	year = 1998,
	month = {jan},
	publisher = {Wiley-Blackwell},
	volume = {15},
	number = {1},
	pages = {80--84},
	author = {C.J. McCabe and R.C. Stevenson and A.M. Dolan},
	title = {Evaluation of a diabetic foot screening and protection programme},
	journal = {Diabet. Med.}
}
@article{Murray_1996,
	doi = {10.1002/(sici)1096-9136(199611)13:11<979::aid-dia267>3.3.co;2-1},
	url = {http://dx.doi.org/10.1002/(sici)1096-9136(199611)13:11<979::aid-dia267>3.3.co;2-1},
	year = 1996,
	month = {nov},
	publisher = {Wiley-Blackwell},
	volume = {13},
	number = {11},
	pages = {979--982},
	author = {H.J. Murray and M.J. Young and S. Hollis and A.J.M. Boulton},
	title = {The Association Between Callus Formation, High Pressures and Neuropathy in Diabetic Foot Ulceration},
	journal = {Diabet. Med.}
}
@article{Neil_1989,
	doi = {10.1111/j.1464-5491.1989.tb01237.x},
	url = {http://dx.doi.org/10.1111/j.1464-5491.1989.tb01237.x},
	year = 1989,
	month = {sep},
	publisher = {Wiley-Blackwell},
	volume = {6},
	number = {7},
	pages = {608--613},
	author = {H.A.W. Neil and A.V. Thompson and M. Thorogood and G.H. Fowler and J.I. Mann},
	title = {Diabetes in the Elderly: The Oxford Community Diabetes Study},
	journal = {Diabetic Medicine}
}
@article{Pecoraro_1990,
	doi = {10.2337/diacare.13.5.513},
	url = {http://dx.doi.org/10.2337/diacare.13.5.513},
	year = 1990,
	month = {may},
	publisher = {American Diabetes Association},
	volume = {13},
	number = {5},
	pages = {513--521},
	author = {R. E. Pecoraro and G. E. Reiber and E. M. Burgess},
	title = {Pathways to diabetic limb amputation. Basis for prevention},
	journal = {Diabetes Care}
}
@article{Sriussadaporn_1997,
	doi = {10.1002/(sici)1096-9136(199701)14:1<50::aid-dia292>3.0.co;2-6},
	url = {http://dx.doi.org/10.1002/(sici)1096-9136(199701)14:1<50::aid-dia292>3.0.co;2-6},
	year = 1997,
	month = {jan},
	publisher = {Wiley-Blackwell},
	volume = {14},
	number = {1},
	pages = {50--56},
	author = {S. Sriussadaporn and P. Mekanandha and S. Vannasaeng and W. Nitiyanant and C. Komoltri and S. Ploybutr and P. Yamwong and T. Peerapatdit and A. Vichayanrat},
	title = {Factors Associated with Diabetic Foot Ulceration in Thailand: a Case-control Study},
	journal = {Diabet. Med.}
}
@article{Walters_1992,
	doi = {10.1111/j.1464-5491.1992.tb01796.x},
	url = {http://dx.doi.org/10.1111/j.1464-5491.1992.tb01796.x},
	year = 1992,
	month = {may},
	publisher = {Wiley-Blackwell},
	volume = {9},
	number = {4},
	pages = {354--358},
	author = {D.P. Walters and W. Catling and M.A. Mullee and R.D. Hill},
	title = {The Distribution and Severity of Diabetic Foot Disease: a Community Study with Comparison to a Non-diabetic Group},
	journal = {Diabetic Medicine}
}
@misc{1,
	doi = {10.1037/e616522007-001},
	url = {http://dx.doi.org/10.1037/e616522007-001},
	publisher = {American Psychological Association ($\\lbrace$APA$\\rbrace$)},
	title = {National Service Framework for Mental Health: Modern Standards {\\&} Service Models}
}
@article{Uccioli_1995,
	doi = {10.2337/diacare.18.10.1376},
	url = {http://dx.doi.org/10.2337/diacare.18.10.1376},
	year = 1995,
	month = {oct},
	publisher = {American Diabetes Association},
	volume = {18},
	number = {10},
	pages = {1376--1378},
	author = {L. Uccioli and E. Faglia and G. Monticone and F. Favales and L. Durola and A. Aldeghi and A. Quarantiello and P. Calia and G. Menzinger},
	title = {Manufactured shoes in the prevention of diabetic foot ulcers},
	journal = {Diabetes Care}
}
@article{Colagiuri_1995,
	doi = {10.1016/0168-8227(95)01050-n},
	url = {http://dx.doi.org/10.1016/0168-8227(95)01050-n},
	year = 1995,
	month = {apr},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {28},
	number = {1},
	pages = {29--34},
	author = {S. Colagiuri and L.L. Marsden and V. Naidu and L. Taylor},
	title = {The use of orthotic devices to correct plantar callus in people with diabetes},
	journal = {Diabetes Research and Clinical Practice}
}
@article{Reiber_2002,
	doi = {10.1001/jama.287.19.2552},
	url = {http://dx.doi.org/10.1001/jama.287.19.2552},
	year = 2002,
	month = {may},
	publisher = {American Medical Association ($\\lbrace$AMA$\\rbrace$)},
	volume = {287},
	number = {19},
	pages = {2552},
	author = {Gayle E. Reiber and Douglas G. Smith and Carolyn Wallace and Katrina Sullivan and Shane Hayes and Christy Vath and Matthew L. Maciejewski and Onchee Yu and Patrick J. Heagerty and Joseph LeMaster},
	title = {Effect of Therapeutic Footwear on Foot Reulceration in Patients With Diabetes},
	journal = {$\\lbrace$JAMA$\\rbrace$}
}
@article{Gordin_1985,
	doi = {10.1128/aac.27.4.648},
	url = {http://dx.doi.org/10.1128/aac.27.4.648},
	year = 1985,
	month = {apr},
	publisher = {American Society for Microbiology},
	volume = {27},
	number = {4},
	pages = {648--649},
	author = {F M Gordin and C B Wofsy and J Mills},
	title = {Once-daily ceftriaxone for skin and soft tissue infections.},
	journal = {Antimicrobial Agents and Chemotherapy}
}
@article{Chantelau_1996,
	doi = {10.1002/(sici)1096-9136(199602)13:2<156::aid-dia59>3.0.co;2-u},
	url = {http://dx.doi.org/10.1002/(sici)1096-9136(199602)13:2<156::aid-dia59>3.0.co;2-u},
	year = 1996,
	month = {feb},
	publisher = {Wiley-Blackwell},
	volume = {13},
	number = {2},
	pages = {156--159},
	author = {E. Chantelau and T. Tanudjaja and F. Altenhfer and Z. Ersanli and S. Lacigova and C. Metzger},
	title = {Antibiotic Treatment for Uncomplicated Neuropathic Forefoot Ulcers in Diabetes: a Controlled Trial},
	journal = {Diabet. Med.}
}
@article{File_1983,
	doi = {10.1016/0002-9343(83)90103-1},
	url = {http://dx.doi.org/10.1016/0002-9343(83)90103-1},
	year = 1983,
	month = {aug},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {75},
	number = {2},
	pages = {100--105},
	author = {Thomas M. File and James S. Tan},
	title = {Amdinocillin plus cefoxitin versus cefoxitin alone in therapy of mixed soft tissue infections (including diabetic foot infections)},
	journal = {The American Journal of Medicine}
}
@article{Grayson_1994,
	doi = {10.1093/clinids/18.5.683},
	url = {http://dx.doi.org/10.1093/clinids/18.5.683},
	year = 1994,
	month = {may},
	publisher = {Oxford University Press ($\\lbrace$OUP$\\rbrace$)},
	volume = {18},
	number = {5},
	pages = {683--693},
	author = {M. L. Grayson and G. W. Gibbons and G. M. Habershaw and D. V. Freeman and F. B. Pomposelli and B. I. Rosenblum and E. Levin and A. W. Karchmer},
	title = {Use of Ampicillin/Sulbactam Versus Imipenem/Cilastatin in the Treatment of Limb-Threatening Foot Infections in Diabetic Patients},
	journal = {Clinical Infectious Diseases}
}
@article{Reinhardt_1986,
	doi = {10.1093/clinids/8.supplement_5.s569},
	url = {http://dx.doi.org/10.1093/clinids/8.supplement_5.s569},
	year = 1986,
	month = {nov},
	publisher = {Oxford University Press ($\\lbrace$OUP$\\rbrace$)},
	volume = {8},
	number = {Supplement 5},
	pages = {S569--S575},
	author = {J. F. Reinhardt and L. Johnston and P. Ruane and C. C. Johnson and L. Ingram-drake and K. MacDonald and K. W. Ward and G. Mathisen and W. L. George and S. M. Finegold and M. E. Mulligan},
	title = {A Randomized, Double-Blind Comparison of Sulbactam/Ampicillin and Clindamycin for the Treatment of Aerobic and Aerobic-Anaerobic Infections},
	journal = {Clinical Infectious Diseases}
}
@article{Lipsky_1997,
	doi = {10.1093/clind/24.4.643},
	url = {http://dx.doi.org/10.1093/clind/24.4.643},
	year = 1997,
	month = {apr},
	publisher = {Oxford University Press ($\\lbrace$OUP$\\rbrace$)},
	volume = {24},
	number = {4},
	pages = {643--648},
	author = {B. A. Lipsky and P. D. Baker and G. C. Landon and R. Fernau},
	title = {Antibiotic Therapy for Diabetic Foot Infections: Comparison of Two Parenteral-to-Oral Regimens},
	journal = {Clinical Infectious Diseases}
}
@article{Lipsky_1990,
	doi = {10.1001/archinte.150.4.790},
	url = {http://dx.doi.org/10.1001/archinte.150.4.790},
	year = 1990,
	month = {apr},
	publisher = {American Medical Association ($\\lbrace$AMA$\\rbrace$)},
	volume = {150},
	number = {4},
	pages = {790--797},
	author = {B. A. Lipsky},
	title = {Outpatient management of uncomplicated lower-extremity infections in diabetic patients},
	journal = {Archives of Internal Medicine}
}
@article{Tan_1993,
	doi = {10.1128/aac.37.8.1580},
	url = {http://dx.doi.org/10.1128/aac.37.8.1580},
	year = 1993,
	month = {aug},
	publisher = {American Society for Microbiology},
	volume = {37},
	number = {8},
	pages = {1580--1586},
	author = {J S Tan and R M Wishnow and D A Talan and F P Duncanson and C W Norden},
	title = {Treatment of hospitalized patients with complicated skin and skin structure infections: double-blind, randomized, multicenter study of piperacillin-tazobactam versus ticarcillin-clavulanate. The Piperacillin/Tazobactam Skin and Skin Structure Study Group.},
	journal = {Antimicrobial Agents and Chemotherapy}
}
@article{Boyko_1996,
	doi = {10.1002/(sici)1096-9136(199611)13:11<967::aid-dia266>3.0.co;2-k},
	url = {http://dx.doi.org/10.1002/(sici)1096-9136(199611)13:11<967::aid-dia266>3.0.co;2-k},
	year = 1996,
	month = {nov},
	publisher = {Wiley-Blackwell},
	volume = {13},
	number = {11},
	pages = {967--972},
	author = {E.J. Boyko and J.H. Ahroni and D.G. Smith and D. Davignon},
	title = {Increased Mortality Associated with Diabetic Foot Ulcer},
	journal = {Diabet. Med.}
}
@article{Apelqvist_1995,
	doi = {10.1111/j.1464-5491.1995.tb00442.x},
	url = {http://dx.doi.org/10.1111/j.1464-5491.1995.tb00442.x},
	year = 1995,
	month = {feb},
	publisher = {Wiley-Blackwell},
	volume = {12},
	number = {2},
	pages = {123--128},
	author = {J. Apelqvist and G. Ragnarson-Tennvall and J. Larsson},
	title = {Topical Treatment of Diabetic Foot Ulcers: an Economic Analysis of Treatment Alternatives and Strategies},
	journal = {Diabetic Medicine}
}
@article{Blackman_1994,
	doi = {10.2337/diacare.17.4.322},
	url = {http://dx.doi.org/10.2337/diacare.17.4.322},
	year = 1994,
	month = {apr},
	publisher = {American Diabetes Association},
	volume = {17},
	number = {4},
	pages = {322--325},
	author = {J. D. Blackman and D. Senseng and L. Quinn and T. Mazzone},
	title = {Clinical evaluation of a semipermeable polymeric membrane dressing for the treatment of chronic diabetic foot ulcers},
	journal = {Diabetes Care}
}
@article{Kamaratos_2012,
	doi = {10.1111/j.1742-481x.2012.01082.x},
	url = {http://dx.doi.org/10.1111/j.1742-481x.2012.01082.x},
	year = 2012,
	month = {sep},
	publisher = {Wiley-Blackwell},
	volume = {11},
	number = {3},
	pages = {259--263},
	author = {Alexandros V. Kamaratos and Konstantinos N. Tzirogiannis and Stella A. Iraklianou and Georgios I. Panoutsopoulos and Ilias E. Kanellos and Andreas I. Melidonis},
	title = {Manuka honey-impregnated dressings in the treatment of neuropathic diabetic foot ulcers},
	journal = {Int Wound J}
}
@article{Edmonds_2006,
	doi = {10.2165/00003495-200666070-00003},
	url = {http://dx.doi.org/10.2165/00003495-200666070-00003},
	year = 2006,
	publisher = {Springer Science $\\mathplus$ Business Media},
	volume = {66},
	number = {7},
	pages = {913--929},
	author = {Michael Edmonds},
	title = {Diabetic Foot Ulcers},
	journal = {Drugs}
}
@article{1996,
	doi = {10.1002/pdi.1960130417},
	url = {http://dx.doi.org/10.1002/pdi.1960130417},
	year = 1996,
	month = {jul},
	publisher = {Wiley-Blackwell},
	volume = {13},
	number = {4},
	pages = {134--139},
	title = {Education, prevention, change. Highlights for diabetes professionals fron the 56th Annual Meeting and Scientific Sessions of the American Diabetes Association 8{\\textendash}11 June 1996, San Francisco, $\\lbrace$USA$\\rbrace$},
	journal = {Pract. Diab. Int.}
}
@article{Veves_1995,
	doi = {10.1111/j.1464-5491.1995.tb00546.x},
	url = {http://dx.doi.org/10.1111/j.1464-5491.1995.tb00546.x},
	year = 1995,
	month = {jul},
	publisher = {Wiley-Blackwell},
	volume = {12},
	number = {7},
	pages = {585--589},
	author = {A. Veves and M.R. Sarnow and J.M. Giurini and B.I. Rosenblum and T.E. Lyons and J.S. Chrzan and G.M. Habershaw},
	title = {Differences in Joint Mobility and Foot Pressures Between Black and White Diabetic Patients},
	journal = {Diabetic Medicine}
}
@article{Edmonds_1997,
	doi = {10.1002/(sici)1096-9136(199712)14:12<1010::aid-dia549>3.0.co;2-n},
	url = {http://dx.doi.org/10.1002/(sici)1096-9136(199712)14:12<1010::aid-dia549>3.0.co;2-n},
	year = 1997,
	month = {dec},
	publisher = {Wiley-Blackwell},
	volume = {14},
	number = {12},
	pages = {1010--1011},
	author = {M E Edmonds and AV Foster and M McColgan},
	title = {`Dermagraft': a new treatment for diabetic foot ulcers},
	journal = {Diabet. Med.}
}
@article{MOYER_1895,
	doi = {10.1001/jama.1895.02430120008002a},
	url = {http://dx.doi.org/10.1001/jama.1895.02430120008002a},
	year = 1895,
	month = {mar},
	publisher = {American Medical Association ($\\lbrace$AMA$\\rbrace$)},
	volume = {$\\lbrace$XXIV$\\rbrace$},
	number = {12},
	pages = {432},
	author = {HAROLD N. MOYER},
	title = {$\\lbrace$TABETIC$\\rbrace$ $\\lbrace$FOOT$\\rbrace$ $\\lbrace$WITH$\\rbrace$ $\\lbrace$PERFORATING$\\rbrace$ $\\lbrace$ULCER$\\rbrace$. ($\\lbrace$MAL$\\rbrace$ $\\lbrace$PERFORANT$\\rbrace$ $\\lbrace$DU$\\rbrace$ $\\lbrace$PIED$\\rbrace$.)},
	journal = {Journal of the American Medical Association}
}
@article{Margolis_2000,
	doi = {10.1001/archderm.136.12.1531},
	url = {http://dx.doi.org/10.1001/archderm.136.12.1531},
	year = 2000,
	month = {dec},
	publisher = {American Medical Association ($\\lbrace$AMA$\\rbrace$)},
	volume = {136},
	number = {12},
	author = {David J. Margolis and Jonathan Kantor and Jill Santanna and Brian L. Strom and Jesse A. Berlin},
	title = {Risk Factors for Delayed Healing of Neuropathic Diabetic Foot Ulcers},
	journal = {Arch Dermatol}
}
@article{Mulder_1994,
	doi = {10.1046/j.1524-475x.1994.20406.x},
	url = {http://dx.doi.org/10.1046/j.1524-475x.1994.20406.x},
	year = 1994,
	month = {oct},
	publisher = {Wiley-Blackwell},
	volume = {2},
	number = {4},
	pages = {259--269},
	author = {Gerit D. Mulder and Leonard M. Patt and Lee Sanders and Julio Rosenstock and Morton I. Altman and Marie E. Hanley and Gordon W. Duncan},
	title = {Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper},
	journal = {Wound Repair Regen}
}
@article{Muthukumarasamy_1991,
	doi = {10.2337/diacare.14.10.909},
	url = {http://dx.doi.org/10.2337/diacare.14.10.909},
	year = 1991,
	month = {oct},
	publisher = {American Diabetes Association},
	volume = {14},
	number = {10},
	pages = {909--911},
	author = {M. G. Muthukumarasamy and G. Sivakumar and G. Manoharan},
	title = {Topical phenytoin in diabetic foot ulcers},
	journal = {Diabetes Care}
}
@article{Piaggesi_2001,
	doi = {10.1046/j.1464-5491.2001.00466.x},
	url = {http://dx.doi.org/10.1046/j.1464-5491.2001.00466.x},
	year = 2001,
	month = {apr},
	publisher = {Wiley-Blackwell},
	volume = {18},
	number = {4},
	pages = {320--324},
	author = {A. Piaggesi and F. Baccetti and L. Rizzo and M. Romanelli and R. Navalesi and L. Benzi},
	title = {Sodium carboxyl-methyl-cellulose dressings in the management of deep ulcerations of diabetic foot},
	journal = {Diabet Med}
}
@article{Sandison_2008,
	doi = {10.1136/ebn.11.4.116},
	url = {http://dx.doi.org/10.1136/ebn.11.4.116},
	year = 2008,
	month = {oct},
	publisher = {$\\lbrace$BMJ$\\rbrace$},
	volume = {11},
	number = {4},
	pages = {116--116},
	author = {S. Sandison},
	title = {Negative pressure wound therapy promoted healing of diabetic foot ulcers more than advanced moist wound therapy},
	journal = {Evidence-Based Nursing}
}
@article{Veves_2002,
	doi = {10.1001/archsurg.137.7.822},
	url = {http://dx.doi.org/10.1001/archsurg.137.7.822},
	year = 2002,
	month = {jul},
	publisher = {American Medical Association ($\\lbrace$AMA$\\rbrace$)},
	volume = {137},
	number = {7},
	pages = {822},
	author = {Aristidis Veves},
	title = {A Randomized, Controlled Trial of Promogran (a Collagen/Oxidized Regenerated Cellulose Dressing) vs Standard Treatment in the Management of Diabetic Foot Ulcers},
	journal = {Arch Surg}
}
@article{Armstrong_2000,
	doi = {10.1001/archsurg.135.12.1405},
	url = {http://dx.doi.org/10.1001/archsurg.135.12.1405},
	year = 2000,
	month = {dec},
	publisher = {American Medical Association ($\\lbrace$AMA$\\rbrace$)},
	volume = {135},
	number = {12},
	pages = {1405},
	author = {David G. Armstrong},
	title = {Improvement in Healing With Aggressive Edema Reduction After Debridement of Foot Infection in Persons With Diabetes},
	journal = {Arch Surg}
}
@article{Armstrong_2001,
	doi = {10.2337/diacare.24.6.1019},
	url = {http://dx.doi.org/10.2337/diacare.24.6.1019},
	year = 2001,
	month = {jun},
	publisher = {American Diabetes Association},
	volume = {24},
	number = {6},
	pages = {1019--1022},
	author = {D. G. Armstrong and H. C. Nguyen and L. A. Lavery and C. H.M. van Schie and A. J.M. Boulton and L. B. Harkless},
	title = {Off-Loading the Diabetic Foot Wound: A randomized clinical trial},
	journal = {Diabetes Care}
}
@article{Caravaggi_2000,
	doi = {10.2337/diacare.23.12.1746},
	url = {http://dx.doi.org/10.2337/diacare.23.12.1746},
	year = 2000,
	month = {dec},
	publisher = {American Diabetes Association},
	volume = {23},
	number = {12},
	pages = {1746--1751},
	author = {C. Caravaggi and E. Faglia and R. De Giglio and M. Mantero and A. Quarantiello and E. Sommariva and M. Gino and C. Pritelli and A. Morabito},
	title = {Effectiveness and safety of a nonremovable fiberglass off-bearing cast versus a therapeutic shoe in the treatment of neuropathic foot ulcers: a randomized study},
	journal = {Diabetes Care}
}
@article{Mueller_1989,
	doi = {10.2337/diacare.12.6.384},
	url = {http://dx.doi.org/10.2337/diacare.12.6.384},
	year = 1989,
	month = {jun},
	publisher = {American Diabetes Association},
	volume = {12},
	number = {6},
	pages = {384--388},
	author = {M. J. Mueller and J. E. Diamond and D. R. Sinacore and A. Delitto and V. P. Blair and D. A. Drury and S. J. Rose},
	title = {Total contact casting in treatment of diabetic plantar ulcers. Controlled clinical trial},
	journal = {Diabetes Care}
}
@article{van_Schie_2000,
	doi = {10.2337/diacare.23.5.634},
	url = {http://dx.doi.org/10.2337/diacare.23.5.634},
	year = 2000,
	month = {may},
	publisher = {American Diabetes Association},
	volume = {23},
	number = {5},
	pages = {634--638},
	author = {C. H. van Schie and A. Whalley and L. Vileikyte and T. Wignall and S. Hollis and A. J. Boulton},
	title = {Efficacy of injected liquid silicone in the diabetic foot to reduce risk factors for ulceration: a randomized double-blind placebo-controlled trial},
	journal = {Diabetes Care}
}
@article{Gentzkow_1996,
	doi = {10.2337/diacare.19.4.350},
	url = {http://dx.doi.org/10.2337/diacare.19.4.350},
	year = 1996,
	month = {apr},
	publisher = {American Diabetes Association},
	volume = {19},
	number = {4},
	pages = {350--354},
	author = {G. D. Gentzkow and S. D. Iwasaki and K. S. Hershon and M. Mengel and J. J. Prendergast and J. J. Ricotta and D. P. Steed and S. Lipkin},
	title = {Use of dermagraft, a cultured human dermis, to treat diabetic foot ulcers},
	journal = {Diabetes Care}
}
@article{Naughton_2008,
	doi = {10.1111/j.1525-1594.1997.tb00476.x},
	url = {http://dx.doi.org/10.1111/j.1525-1594.1997.tb00476.x},
	year = 2008,
	month = {nov},
	publisher = {Wiley-Blackwell},
	volume = {21},
	number = {11},
	pages = {1203--1210},
	author = {Gail Naughton and Jonathan Mansbridge and Gary Gentzkow},
	title = {A Metabolically Active Human Dermal Replacement for the Treatment of Diabetic Foot Ulcers},
	journal = {Artificial Organs}
}
@article{Veves_2001,
	doi = {10.2337/diacare.24.2.290},
	url = {http://dx.doi.org/10.2337/diacare.24.2.290},
	year = 2001,
	month = {feb},
	publisher = {American Diabetes Association},
	volume = {24},
	number = {2},
	pages = {290--295},
	author = {A. Veves and V. Falanga and D. G. Armstrong and M. L. Sabolinski},
	title = {Graftskin, a Human Skin Equivalent, Is Effective in the Management of Noninfected Neuropathic Diabetic Foot Ulcers: A prospective randomized multicenter clinical trial},
	journal = {Diabetes Care}
}
@article{Faglia_1996,
	doi = {10.2337/diacare.19.12.1338},
	url = {http://dx.doi.org/10.2337/diacare.19.12.1338},
	year = 1996,
	month = {dec},
	publisher = {American Diabetes Association},
	volume = {19},
	number = {12},
	pages = {1338--1343},
	author = {E. Faglia and F. Favales and A. Aldeghi and P. Calia and A. Quarantiello and G. Oriani and M. Michael and P. Campagnoli and A. Morabito},
	title = {Adjunctive systemic hyperbaric oxygen therapy in treatment of severe prevalently ischemic diabetic foot ulcer. A randomized study},
	journal = {Diabetes Care}
}
@article{Bishop_2012,
	doi = {10.1111/j.1742-481x.2012.01034.x},
	url = {http://dx.doi.org/10.1111/j.1742-481x.2012.01034.x},
	year = 2012,
	month = {jul},
	publisher = {Wiley-Blackwell},
	volume = {11},
	number = {1},
	pages = {28--34},
	author = {Alexandra J Bishop and Elizabeth Mudge},
	title = {Diabetic foot ulcers treated with hyperbaric oxygen therapy: a review of the literature},
	journal = {International Wound Journal}
}
@article{Leslie_1988,
	doi = {10.2337/diacare.11.2.111},
	url = {http://dx.doi.org/10.2337/diacare.11.2.111},
	year = 1988,
	month = {feb},
	publisher = {American Diabetes Association},
	volume = {11},
	number = {2},
	pages = {111--115},
	author = {C. A. Leslie and F. L. Sapico and V. J. Ginunas and R. H. Adkins},
	title = {Randomized controlled trial of topical hyperbaric oxygen for treatment of diabetic foot ulcers},
	journal = {Diabetes Care}
}
@article{Apelqvist_1989,
	doi = {10.1111/j.1464-5491.1989.tb01221.x},
	url = {http://dx.doi.org/10.1111/j.1464-5491.1989.tb01221.x},
	year = 1989,
	month = {aug},
	publisher = {Wiley-Blackwell},
	volume = {6},
	number = {6},
	pages = {526--530},
	author = {Jan Apelqvist and C.-D. Agardh and J. Castenfors and J. Larsson and A. Stenstrm},
	title = {Wound Classification is More Important Than Site of Ulceration in the Outcome of Diabetic Foot Ulcers},
	journal = {Diabetic Medicine}
}
@article{Cecilia_Matilla_2013,
	doi = {10.7547/1030024},
	url = {http://dx.doi.org/10.7547/1030024},
	year = 2013,
	month = {jan},
	publisher = {American Podiatric Medical Association},
	volume = {103},
	number = {1},
	pages = {24--31},
	author = {Almudena Cecilia-Matilla and Jos{\\'{e}} Luis L{\\'{a}}zaro-Mart{\\'{\\i}}nez and Javier Arag{\\'{o}}n-S{\\'{a}}nchez and Esther Garc{\\'{\\i}}a-Morales and Yolanda Garc{\\'{\\i}}a-{\\'{A}}lvarez and Juan Vicente Beneit-Montesinos},
	title = {Histopathologic Characteristics of Bone Infection Complicating Foot Ulcers in Diabetic Patients},
	journal = {Journal of the American Podiatric Medical Association}
}
@article{Janssen_1989,
	doi = {10.1016/s0190-9622(89)70153-5},
	url = {http://dx.doi.org/10.1016/s0190-9622(89)70153-5},
	year = 1989,
	month = {jul},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {21},
	number = {1},
	pages = {85--90},
	author = {Paul A.J. Janssen and Herwig Janssen and Geert Cauwenbergh and Piet De Doncker and Karel De Beule and Paul Lewi and Hubert F. Tytgat and Charles M. Lapi{\\`{e}}re},
	title = {Use of topical ketanserin in the treatment of skin ulcers: A double-blind study},
	journal = {Journal of the American Academy of Dermatology}
}
@article{Steed_1992,
	doi = {10.2337/diacare.15.11.1598},
	url = {http://dx.doi.org/10.2337/diacare.15.11.1598},
	year = 1992,
	month = {nov},
	publisher = {American Diabetes Association},
	volume = {15},
	number = {11},
	pages = {1598--1604},
	author = {D. L. Steed and J. B. Goslen and G. A. Holloway and J. M. Malone and T. J. Bunt and M. W. Webster},
	title = {Randomized prospective double-blind trial in healing chronic diabetic foot ulcers. $\\lbrace$CT$\\rbrace$-102 activated platelet supernatant, topical versus placebo},
	journal = {Diabetes Care}
}
@article{Richard_1995,
	doi = {10.2337/diacare.18.1.64},
	url = {http://dx.doi.org/10.2337/diacare.18.1.64},
	year = 1995,
	month = {jan},
	publisher = {American Diabetes Association},
	volume = {18},
	number = {1},
	pages = {64--69},
	author = {J. L. Richard and C. Parer-Richard and J. P. Daures and S. Clouet and D. Vannereau and J. Bringer and M. Rodier and C. Jacob and M. Comte-Bardonnet},
	title = {Effect of topical basic fibroblast growth factor on the healing of chronic diabetic neuropathic ulcer of the foot. A pilot, randomized, double-blind, placebo-controlled study},
	journal = {Diabetes Care}
}
@article{Steed_1995,
	doi = {10.1016/s0741-5214(95)70245-8},
	url = {http://dx.doi.org/10.1016/s0741-5214(95)70245-8},
	year = 1995,
	month = {jan},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {21},
	number = {1},
	pages = {71--81},
	author = {David L. Steed and the Diabetic Ulcer Study Group},
	title = {Clinical evaluation of recombinant human platelet {\\textendash} derived growth factor for the treatment of lower extremity diabetic ulcers},
	journal = {Journal of Vascular Surgery}
}
@article{Steed_1992,
	doi = {10.2337/diacare.15.11.1598},
	url = {http://dx.doi.org/10.2337/diacare.15.11.1598},
	year = 1992,
	month = {nov},
	publisher = {American Diabetes Association},
	volume = {15},
	number = {11},
	pages = {1598--1604},
	author = {D. L. Steed and J. B. Goslen and G. A. Holloway and J. M. Malone and T. J. Bunt and M. W. Webster},
	title = {Randomized prospective double-blind trial in healing chronic diabetic foot ulcers. $\\lbrace$CT$\\rbrace$-102 activated platelet supernatant, topical versus placebo},
	journal = {Diabetes Care}
}
@article{Steed_1995,
	doi = {10.2337/diacare.18.1.39},
	url = {http://dx.doi.org/10.2337/diacare.18.1.39},
	year = 1995,
	month = {jan},
	publisher = {American Diabetes Association},
	volume = {18},
	number = {1},
	pages = {39--46},
	author = {D. L. Steed and J. J. Ricotta and J. J. Prendergast and R. J. Kaplan and M. W. Webster and J. B. McGill and S. L. Schwartz},
	title = {Promotion and acceleration of diabetic ulcer healing by arginine-glycine-aspartic acid ($\\lbrace$RGD$\\rbrace$) peptide matrix. $\\lbrace$RGD$\\rbrace$ Study Group},
	journal = {Diabetes Care}
}
@article{Wieman_1998,
	doi = {10.2337/diacare.21.5.822},
	url = {http://dx.doi.org/10.2337/diacare.21.5.822},
	year = 1998,
	month = {may},
	publisher = {American Diabetes Association},
	volume = {21},
	number = {5},
	pages = {822--827},
	author = {T. J. Wieman and J. M. Smiell and Y. Su},
	title = {Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-$\\lbrace$BB$\\rbrace$ (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase $\\lbrace$III$\\rbrace$ randomized placebo-controlled double-blind study},
	journal = {Diabetes Care}
}
@article{Greaves_2004,
	doi = {10.1093/fampra/cmh113},
	url = {http://dx.doi.org/10.1093/fampra/cmh113},
	year = 2004,
	month = {feb},
	publisher = {Oxford University Press ($\\lbrace$OUP$\\rbrace$)},
	volume = {21},
	number = {1},
	pages = {57--62},
	author = {C. Greaves},
	title = {A simple pragmatic system for detecting new cases of type 2 diabetes and impaired fasting glycaemia in primary care},
	journal = {Family Practice}
}
@article{Klein_Woolthuis_2007,
	doi = {10.1093/fampra/cmm018},
	url = {http://dx.doi.org/10.1093/fampra/cmm018},
	year = 2007,
	month = {may},
	publisher = {Oxford University Press ($\\lbrace$OUP$\\rbrace$)},
	volume = {24},
	number = {3},
	pages = {230--236},
	author = {E. P Klein Woolthuis and W. J. de Grauw and W. H. van Gerwen and H. J. van den Hoogen and E. H van de Lisdonk and J. F. Metsemakers and C. van Weel},
	title = {Identifying people at risk for undiagnosed type 2 diabetes using the $\\lbrace$GP$\\rbrace${\\textquotesingle}s electronic medical record},
	journal = {Family Practice}
}
@article{Thomas_2006,
	doi = {10.1001/archinte.166.6.682},
	url = {http://dx.doi.org/10.1001/archinte.166.6.682},
	year = 2006,
	month = {mar},
	publisher = {American Medical Association ($\\lbrace$AMA$\\rbrace$)},
	volume = {166},
	number = {6},
	pages = {682},
	author = {Claudia Thomas and Elina Hyppnen and Chris Power},
	title = {Type 2 Diabetes Mellitus in Midlife Estimated From the Cambridge Risk Score and Body Mass Index},
	journal = {Archives of Internal Medicine}
}
@article{Heldgaard_2006,
	doi = {10.1111/j.1464-5491.2006.01929.x},
	url = {http://dx.doi.org/10.1111/j.1464-5491.2006.01929.x},
	year = 2006,
	month = {sep},
	publisher = {Wiley-Blackwell},
	volume = {23},
	number = {9},
	pages = {996--1002},
	author = {P. E. Heldgaard and S. J. Griffin},
	title = {Routinely collected general practice data aids identification of people with hyperglycaemia and metabolic syndrome},
	journal = {Diabetic Medicine}
}
@article{Saaristo_2005,
	doi = {10.3132/dvdr.2005.011},
	url = {http://dx.doi.org/10.3132/dvdr.2005.011},
	year = 2005,
	publisher = {$\\lbrace$SAGE$\\rbrace$ Publications},
	volume = {2},
	number = {2},
	pages = {67},
	author = {Timo Saaristo and Markku Peltonen and Jaana Lindstrom and Liisa Saarikoski and Jouko Sundvall and Johan Gunnar Eriksson and Jaakko Tuomilehto},
	title = {Cross-sectional evaluation of the Finnish Diabetes Risk Score: a tool to identify undetected type 2 diabetes, abnormal glucose tolerance and metabolic syndrome.},
	journal = {Diabetes {\\&} vascular disease research : official journal of the International Society of Diabetes and Vascular Disease}
}
@article{Franciosi_2005,
	doi = {10.2337/diacare.28.5.1187},
	url = {http://dx.doi.org/10.2337/diacare.28.5.1187},
	year = 2005,
	month = {may},
	publisher = {American Diabetes Association},
	volume = {28},
	number = {5},
	pages = {1187--1194},
	author = {M. Franciosi and G. De Berardis and M. C.E. Rossi and M. Sacco and M. Belfiglio and F. Pellegrini and G. Tognoni and M. Valentini and A. Nicolucci},
	title = {Use of the Diabetes Risk Score for Opportunistic Screening of Undiagnosed Diabetes and Impaired Glucose Tolerance: The $\\lbrace$IGLOO$\\rbrace$ (Impaired Glucose Tolerance and Long-Term Outcomes Observational) study},
	journal = {Diabetes Care}
}
@article{Schwarz_2009,
	doi = {10.1210/jc.2007-2427},
	url = {http://dx.doi.org/10.1210/jc.2007-2427},
	year = 2009,
	month = {mar},
	publisher = {The Endocrine Society},
	volume = {94},
	number = {3},
	pages = {920--926},
	author = {Peter E. H. Schwarz and Jiang Li and Manja Reimann and Alta E. Schutte and Antje Bergmann and Markolf Hanefeld and Stefan R. Bornstein and Jan Schulze and Jaakko Tuomilehto and Jaana Lindstrm},
	title = {The Finnish Diabetes Risk Score Is Associated with Insulin Resistance and Progression towards Type 2 Diabetes},
	journal = {The Journal of Clinical Endocrinology {\\&} Metabolism}
}
@article{Gray_2010,
	doi = {10.1111/j.1464-5491.2010.03037.x},
	url = {http://dx.doi.org/10.1111/j.1464-5491.2010.03037.x},
	year = 2010,
	month = {may},
	publisher = {Wiley-Blackwell},
	volume = {27},
	number = {8},
	pages = {887--895},
	author = {L. J. Gray and N. A. Taub and K. Khunti and E. Gardiner and S. Hiles and D. R. Webb and B. T. Srinivasan and M. J. Davies},
	title = {The Leicester Risk Assessment score for detecting undiagnosed Type 2 diabetes and impaired glucose regulation for use in a multiethnic $\\lbrace$UK$\\rbrace$ setting},
	journal = {Diabetic Medicine}
}
@article{Guerrero_Romero_2006,
	doi = {10.1016/j.arcmed.2005.05.010},
	url = {http://dx.doi.org/10.1016/j.arcmed.2005.05.010},
	year = 2006,
	month = {jan},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {37},
	number = {1},
	pages = {140--144},
	author = {Fernando Guerrero-Romero and Martha Rodr{\\'{\\i}}guez-Mor{\\'{a}}n},
	title = {Lowered Criterion for Normal Fasting Plasma Glucose: Impact on the Detection of Impaired Glucose Tolerance and Metabolic Syndrome},
	journal = {Archives of Medical Research}
}
@article{Mannucci_2003,
	doi = {10.1007/s00592-003-0109-8},
	url = {http://dx.doi.org/10.1007/s00592-003-0109-8},
	year = 2003,
	month = {dec},
	publisher = {Springer Science $\\mathplus$ Business Media},
	volume = {40},
	number = {4},
	pages = {181--186},
	author = {E. Mannucci and A. Ognibene and I. Sposato and M. Brogi and G. Gallori and G. Bardini and F. Cremasco and G. Messeri and C. M. Rotella},
	title = {Fasting plasma glucose and glycated haemoglobin in the screening of diabetes and impaired glucose tolerance},
	journal = {Acta Diabetologica}
}
@article{L_ders_2005,
	doi = {10.1111/j.1742-1241.2005.00518.x},
	url = {http://dx.doi.org/10.1111/j.1742-1241.2005.00518.x},
	year = 2005,
	month = {apr},
	publisher = {Wiley-Blackwell},
	volume = {59},
	number = {6},
	pages = {632--638},
	author = {S. Lders and F. Hammersen and A. Kulschewski and U. Venneklaas and C. Zchner and A. Gansz and M. Schnieders and E. Pfarr and C. D. Sturm and W. D. Paar and J. Schrader},
	title = {Diagnosis of impaired glucose tolerance in hypertensive patients in daily clinical practice},
	journal = {International Journal of Clinical Practice}
}
@article{Mohan_2010,
	doi = {10.2337/dc09-1694},
	url = {http://dx.doi.org/10.2337/dc09-1694},
	year = 2010,
	month = {mar},
	publisher = {American Diabetes Association},
	volume = {33},
	number = {3},
	pages = {515--519},
	author = {V. Mohan and V. Vijayachandrika and K. Gokulakrishnan and R. M. Anjana and A. Ganesan and M. B. Weber and K. M. V. Narayan},
	title = {A1C Cut Points to Define Various Glucose Intolerance Groups in Asian Indians},
	journal = {Diabetes Care}
}
@article{Mostafa_2010,
	doi = {10.1016/j.diabres.2010.06.008},
	url = {http://dx.doi.org/10.1016/j.diabres.2010.06.008},
	year = 2010,
	month = {oct},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {90},
	number = {1},
	pages = {100--108},
	author = {Samiul A. Mostafa and Kamlesh Khunti and Balasubramanian Thiagarajan Srinivasan and David Webb and Laura J. Gray and Melanie J. Davies},
	title = {The potential impact and optimal cut-points of using glycated haemoglobin, $\\lbrace$HbA$\\rbrace$1c, to detect people with impaired glucose regulation in a $\\lbrace$UK$\\rbrace$ multi-ethnic cohort},
	journal = {Diabetes Research and Clinical Practice}
}
@article{Zhou_2009,
	doi = {10.1111/j.1464-5491.2009.02831.x},
	url = {http://dx.doi.org/10.1111/j.1464-5491.2009.02831.x},
	year = 2009,
	month = {dec},
	publisher = {Wiley-Blackwell},
	volume = {26},
	number = {12},
	pages = {1262--1268},
	author = {X. H. Zhou and L. N. Ji and Y. Y. Luo and X. Y. Zhang and X. Y. Han and Q. Qiao},
	title = { Performance of $\\lbrace$HbA$\\rbrace$ 1c for detecting newly diagnosed diabetes and pre-diabetes in Chinese communities living in Beijing },
	journal = {Diabetic Medicine}
}
@article{Herdzik_2002,
	doi = {10.1007/s005920200007},
	url = {http://dx.doi.org/10.1007/s005920200007},
	year = 2002,
	month = {apr},
	publisher = {Springer Science $\\mathplus$ Business Media},
	volume = {39},
	number = {1},
	pages = {15--22},
	author = {E. Herdzik and K. Safranow and K. Ciechanowski},
	title = {Diagnostic value of fasting capillary glucose, fructosamine and glycosylated haemoglobin in detecting diabetes and other glucose tolerance abnormalities compared to oral glucose tolerance test},
	journal = {Acta Diabetologica}
}
@article{Hu_2009,
	doi = {10.1007/s00592-009-0143-2},
	url = {http://dx.doi.org/10.1007/s00592-009-0143-2},
	year = 2009,
	month = {sep},
	publisher = {Springer Science $\\mathplus$ Business Media},
	volume = {47},
	number = {3},
	pages = {231--236},
	author = {Yaomin Hu and Wei Liu and Yawen Chen and Ming Zhang and Lihua Wang and Huan Zhou and Peihong Wu and Xiangyu Teng and Ying Dong and Jia wen Zhou and Hua Xu and Jun Zheng and Shengxian Li and Tao Tao and Yumei Hu and Yun Jia},
	title = {Combined use of fasting plasma glucose and glycated hemoglobin A1c in the screening of diabetes and impaired glucose tolerance},
	journal = {Acta Diabetol}
}
@article{Simmons_2005,
	doi = {10.1111/j.1464-5491.2004.01378.x},
	url = {http://dx.doi.org/10.1111/j.1464-5491.2004.01378.x},
	year = 2005,
	month = {feb},
	publisher = {Wiley-Blackwell},
	volume = {22},
	number = {2},
	pages = {207--212},
	author = {D. Simmons and C. F. Thompson and M. M. Engelgau},
	title = {Controlling the diabetes epidemic: how should we screen for undiagnosed diabetes and dysglycaemia?},
	journal = {Diabet Med}
}
@article{Gomyo_2004,
	doi = {10.1016/j.diabres.2003.10.019},
	url = {http://dx.doi.org/10.1016/j.diabres.2003.10.019},
	year = 2004,
	month = {may},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {64},
	number = {2},
	pages = {129--136},
	author = {Mioko Gomyo and Naoki Sakane and Isao Kamae and Shigeaki Sato and Ken-ichi Suzuki and Makoto Tominaga and Shoji Kawazu and Hideyo Yoshinaga and Kazuyo Tsushita and Juichi Sato and Yuzo Sato and Satoru Tsujii and Toshihide Yoshida and Yutaka Seino and Takeshi Usui and Kishio Nanjo and Mari Hirata and Kazuhiko Kotani and Arimasa Hososako and Yutaka Kiyohara and Hideshi Kuzuya},
	title = {Effects of sex, age and $\\lbrace$BMI$\\rbrace$ on screening tests for impaired glucose tolerance},
	journal = {Diabetes Research and Clinical Practice}
}
@article{Saydah_2002,
	doi = {10.2337/diacare.25.11.1940},
	url = {http://dx.doi.org/10.2337/diacare.25.11.1940},
	year = 2002,
	month = {nov},
	publisher = {American Diabetes Association},
	volume = {25},
	number = {11},
	pages = {1940--1945},
	author = {S. H. Saydah and D. Byrd-Holt and M. I. Harris},
	title = {Projected Impact of Implementing the Results of the Diabetes Prevention Program in the U.S. Population},
	journal = {Diabetes Care}
}
@article{Colagiuri_2004,
	doi = {10.2337/diacare.27.2.367},
	url = {http://dx.doi.org/10.2337/diacare.27.2.367},
	year = 2004,
	month = {feb},
	publisher = {American Diabetes Association},
	volume = {27},
	number = {2},
	pages = {367--371},
	author = {S. Colagiuri and Z. Hussain and P. Zimmet and A. Cameron and J. Shaw},
	title = {Screening for Type 2 Diabetes and Impaired Glucose Metabolism: The Australian experience},
	journal = {Diabetes Care}
}
@article{Khatibi_2007,
	doi = {10.1080/13697130701377265},
	url = {http://dx.doi.org/10.1080/13697130701377265},
	year = 2007,
	month = {jan},
	publisher = {Informa $\\lbrace$UK$\\rbrace$ Limited},
	volume = {10},
	number = {5},
	pages = {386--392},
	author = {A. Khatibi and C.-D. Agardh and Y. A. Shakir and C. Nerbrand and P. Nyberg and J. Lidfeldt and G. Samsioe},
	title = {Could androgens protect middle-aged women from cardiovascular events? A population-based study of Swedish women: The Women{\\textquotesingle}s Health in the Lund Area ($\\lbrace$WHILA$\\rbrace$) Study},
	journal = {Climacteric}
}
@article{Rolka_2001,
	doi = {10.2337/diacare.24.11.1899},
	url = {http://dx.doi.org/10.2337/diacare.24.11.1899},
	year = 2001,
	month = {nov},
	publisher = {American Diabetes Association},
	volume = {24},
	number = {11},
	pages = {1899--1903},
	author = {D. B. Rolka and K. M. V. Narayan and T. J. Thompson and D. Goldman and J. Lindenmayer and K. Alich and D. Bacall and E. M. Benjamin and B. Lamb and D. O. Stuart and M. M. Engelgau},
	title = {Performance of Recommended Screening Tests for Undiagnosed Diabetes and Dysglycemia},
	journal = {Diabetes Care}
}
@article{Glumer_2004,
	doi = {10.2337/diacare.27.3.727},
	url = {http://dx.doi.org/10.2337/diacare.27.3.727},
	year = 2004,
	month = {mar},
	publisher = {American Diabetes Association},
	volume = {27},
	number = {3},
	pages = {727--733},
	author = {C. Glumer and B. Carstensen and A. Sandbaek and T. Lauritzen and T. Jorgensen and K. Borch-Johnsen},
	title = {A Danish Diabetes Risk Score for Targeted Screening: The Inter99 study},
	journal = {Diabetes Care}
}
@article{Phillips_2009,
	doi = {10.1007/s00125-009-1407-7},
	url = {http://dx.doi.org/10.1007/s00125-009-1407-7},
	year = 2009,
	month = {jun},
	publisher = {Springer Science $\\mathplus$ Business Media},
	volume = {52},
	number = {9},
	pages = {1798--1807},
	author = {L. S. Phillips and D. C. Ziemer and P. Kolm and W. S. Weintraub and V. Vaccarino and M. K. Rhee and R. Chatterjee and K. M. V. Narayan and D. D. Koch},
	title = {Glucose challenge test screening for prediabetes and undiagnosed diabetes},
	journal = {Diabetologia}
}
@article{Rush_2008,
	doi = {10.1111/j.1464-5491.2008.02526.x},
	url = {http://dx.doi.org/10.1111/j.1464-5491.2008.02526.x},
	year = 2008,
	month = {aug},
	publisher = {Wiley-Blackwell},
	volume = {25},
	number = {9},
	pages = {1070--1075},
	author = {E. Rush and N. Crook and D. Simmons},
	title = {Point-of-care testing as a tool for screening for diabetes and pre-diabetes},
	journal = {Diabetic Medicine}
}
@article{Somannavar_2008,
	doi = {10.2337/dc08-0403},
	url = {http://dx.doi.org/10.2337/dc08-0403},
	year = 2008,
	month = {dec},
	publisher = {American Diabetes Association},
	volume = {32},
	number = {4},
	pages = {641--643},
	author = {S. Somannavar and A. Ganesan and M. Deepa and M. Datta and V. Mohan},
	title = {Random Capillary Blood Glucose Cut Points for Diabetes and Pre-Diabetes Derived From Community-Based Opportunistic Screening in India},
	journal = {Diabetes Care}
}
@article{Zhou_2009,
	doi = {10.2337/dc09-1410},
	url = {http://dx.doi.org/10.2337/dc09-1410},
	year = 2009,
	month = {dec},
	publisher = {American Diabetes Association},
	volume = {33},
	number = {3},
	pages = {545--550},
	author = {X. Zhou and Z. Pang and W. Gao and S. Wang and L. Zhang and F. Ning and Q. Qiao},
	title = {Performance of an A1C and Fasting Capillary Blood Glucose Test for Screening Newly Diagnosed Diabetes and Pre-Diabetes Defined by an Oral Glucose Tolerance Test in Qingdao, China},
	journal = {Diabetes Care}
}
@article{Li_2005,
	doi = {10.1038/sj.ejcn.1602089},
	url = {http://dx.doi.org/10.1038/sj.ejcn.1602089},
	year = 2005,
	month = {mar},
	publisher = {Nature Publishing Group},
	volume = {59},
	number = {3},
	pages = {411--418},
	author = {Z Li and K Hong and P Saltsman and S DeShields and M Bellman and G Thames and Y Liu and H-J Wang and R Elashoff and D Heber},
	title = {Long-term efficacy of soy-based meal replacements vs an individualized diet plan in obese type $\\lbrace$II$\\rbrace$ $\\lbrace$DM$\\rbrace$ patients: relative effects on weight loss, metabolic parameters, and C-reactive protein},
	journal = {Eur J Clin Nutr}
}
@article{Redmon_2003,
	doi = {10.2337/diacare.26.9.2505},
	url = {http://dx.doi.org/10.2337/diacare.26.9.2505},
	year = 2003,
	month = {sep},
	publisher = {American Diabetes Association},
	volume = {26},
	number = {9},
	pages = {2505--2511},
	author = {J. B. Redmon and S. K. Raatz and K. P. Reck and J. E. Swanson and C. A. Kwong and Q. Fan and W. Thomas and J. P. Bantle},
	title = {One-Year Outcome of a Combination of Weight Loss Therapies for Subjects With Type 2 Diabetes: A randomized trial},
	journal = {Diabetes Care}
}
@article{Daly_2006,
	doi = {10.1111/j.1464-5491.2005.01760.x},
	url = {http://dx.doi.org/10.1111/j.1464-5491.2005.01760.x},
	year = 2006,
	month = {jan},
	publisher = {Wiley-Blackwell},
	volume = {23},
	number = {1},
	pages = {15--20},
	author = {M. E. Daly and R. Paisey and R. Paisey and B. A. Millward and C. Eccles and K. Williams and S. Hammersley and K. M. MacLeod and T. J. Gale},
	title = {Short-term effects of severe dietary carbohydrate-restriction advice in Type 2 diabetes-a randomized controlled trial},
	journal = {Diabet Med}
}
@article{Barnard_2006,
	doi = {10.2337/dc06-0606},
	url = {http://dx.doi.org/10.2337/dc06-0606},
	year = 2006,
	month = {aug},
	publisher = {American Diabetes Association},
	volume = {29},
	number = {8},
	pages = {1777--1783},
	author = {N. D. Barnard},
	title = {A Low-Fat Vegan Diet Improves Glycemic Control and Cardiovascular Risk Factors in a Randomized Clinical Trial in Individuals With Type 2 Diabetes},
	journal = {Diabetes Care}
}
@article{van_Strien_2007,
	doi = {10.1037/0278-6133.26.1.105},
	url = {http://dx.doi.org/10.1037/0278-6133.26.1.105},
	year = 2007,
	publisher = {American Psychological Association ($\\lbrace$APA$\\rbrace$)},
	volume = {26},
	number = {1},
	pages = {105--112},
	author = {Tatjana van Strien and Floris A. van de Laar and Jan F. J. van Leeuwe and Peter L. B. J. Lucassen and Henk J. M. van den Hoogen and Guy E. H. M. Rutten and Chris van Weel},
	title = {The dieting dilemma in patients with newly diagnosed type 2 diabetes: Does dietary restraint predict weight gain 4 years after diagnosis?},
	journal = {Health Psychology}
}
@article{2006,
	doi = {10.1016/j.jdiacomp.2005.09.003},
	url = {http://dx.doi.org/10.1016/j.jdiacomp.2005.09.003},
	year = 2006,
	month = {nov},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {20},
	number = {6},
	pages = {361--366},
	title = {Diabetes Nutrition and Complications Trial: adherence to the $\\lbrace$ADA$\\rbrace$ nutritional recommendations, targets of metabolic control, and onset of diabetes complications. A 7-year, prospective, population-based, observational multicenter study},
	journal = {Journal of Diabetes and its Complications}
}
@article{Stratton_2000,
	doi = {10.1136/bmj.321.7258.405},
	url = {http://dx.doi.org/10.1136/bmj.321.7258.405},
	year = 2000,
	month = {aug},
	publisher = {$\\lbrace$BMJ$\\rbrace$},
	volume = {321},
	number = {7258},
	pages = {405--412},
	author = {I. M Stratton},
	title = {Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes ($\\lbrace$UKPDS$\\rbrace$ 35): prospective observational study},
	journal = {$\\lbrace$BMJ$\\rbrace$}
}
@article{Selvin_2004,
	doi = {10.7326/0003-4819-141-6-200409210-00007},
	url = {http://dx.doi.org/10.7326/0003-4819-141-6-200409210-00007},
	year = 2004,
	month = {sep},
	publisher = {American College of Physicians},
	volume = {141},
	number = {6},
	pages = {421},
	author = {Elizabeth Selvin},
	title = {Meta-Analysis: Glycosylated Hemoglobin and Cardiovascular Disease in Diabetes Mellitus},
	journal = {Annals of Internal Medicine}
}
@article{Gerstein_2006,
	doi = {10.1007/s00125-005-0116-0},
	url = {http://dx.doi.org/10.1007/s00125-005-0116-0},
	year = 2006,
	month = {jan},
	publisher = {Springer Science $\\mathplus$ Business Media},
	volume = {49},
	number = {3},
	pages = {613--614},
	author = {H. C. Gerstein},
	title = {Reply to comment on: Gerstein $\\lbrace$HC$\\rbrace$, Pogue J, Mann $\\lbrace$JFE$\\rbrace$ et al. (2005) The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the $\\lbrace$HOPE$\\rbrace$ study: a prospective epidemiological analysis. Diabetologia 48:1749{\\textendash}1755},
	journal = {Diabetologia}
}
@article{Iribarren_2001,
	doi = {10.1161/01.cir.103.22.2668},
	url = {http://dx.doi.org/10.1161/01.cir.103.22.2668},
	year = 2001,
	month = {jun},
	publisher = {Ovid Technologies (Wolters Kluwer Health)},
	volume = {103},
	number = {22},
	pages = {2668--2673},
	author = {C. Iribarren and A. J. Karter and A. S. Go and A. Ferrara and J. Y. Liu and S. Sidney and J. V. Selby},
	title = {Glycemic Control and Heart Failure Among Adult Patients With Diabetes},
	journal = {Circulation}
}
@article{Jr__2005,
	doi = {10.1185/030079904x20286},
	url = {http://dx.doi.org/10.1185/030079904x20286},
	year = 2005,
	month = {feb},
	publisher = {Informa Healthcare},
	volume = {21},
	number = {2},
	pages = {173--183},
	author = {Jesus N. Sarol Jr. and Nemencio A. Nicodemus Jr. and Kathryn M. Tan and Maritess B. Grava},
	title = {Self-monitoring of blood glucose as part of a multi-component therapy among non-insulin requiring type 2 diabetes patients: a meta-analysis (1966{\\textendash}2004){\\ast}},
	journal = {Curr Med Res Opin}
}
@article{Moreland_2006,
	doi = {10.1001/archinte.166.6.689},
	url = {http://dx.doi.org/10.1001/archinte.166.6.689},
	year = 2006,
	month = {mar},
	publisher = {American Medical Association ($\\lbrace$AMA$\\rbrace$)},
	volume = {166},
	number = {6},
	pages = {689},
	author = {Elaine C. Moreland and Lisa K. Volkening and Margaret T. Lawlor and Karen A. Chalmers and Barbara J. Anderson and Lori M. B. Laffel},
	title = {Use of a Blood Glucose Monitoring Manual to Enhance Monitoring Adherence in Adults With Diabetes},
	journal = {Archives of Internal Medicine}
}
@article{Siebolds_2006,
	doi = {10.1016/j.pec.2005.06.013},
	url = {http://dx.doi.org/10.1016/j.pec.2005.06.013},
	year = 2006,
	month = {jul},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {62},
	number = {1},
	pages = {104--110},
	author = {Marcus Siebolds and Oliver Gaedeke and Ulrich Schwedes},
	title = {Self-monitoring of blood glucose{\\textemdash}Psychological aspects relevant to changes in $\\lbrace$HbA$\\rbrace$1c in type 2 diabetic patients treated with diet or diet plus oral antidiabetic medication},
	journal = {Patient Education and Counseling}
}
@article{Wen_2004,
	doi = {10.1016/s1098-3015(10)62431-x},
	url = {http://dx.doi.org/10.1016/s1098-3015(10)62431-x},
	year = 2004,
	month = {may},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {7},
	number = {3},
	pages = {338},
	author = {L Wen and M Parchman and W Linn and S Lee},
	title = {$\\lbrace$PDB$\\rbrace$5 $\\lbrace$SELF$\\rbrace$-$\\lbrace$MONITORING$\\rbrace$ $\\lbrace$OF$\\rbrace$ $\\lbrace$BLOOD$\\rbrace$ $\\lbrace$GLUCOSE$\\rbrace$ $\\lbrace$AMONG$\\rbrace$ $\\lbrace$VETERANS$\\rbrace$ $\\lbrace$WITH$\\rbrace$ $\\lbrace$DIABETES$\\rbrace$ $\\lbrace$MANAGED$\\rbrace$ $\\lbrace$ON$\\rbrace$ $\\lbrace$ORAL$\\rbrace$ $\\lbrace$THERAPY$\\rbrace$},
	journal = {Value in Health}
}
@article{Martin_2006,
	doi = {10.1007/s00125-006-0286-4},
	url = {http://dx.doi.org/10.1007/s00125-006-0286-4},
	year = 2006,
	month = {may},
	publisher = {Springer Science $\\mathplus$ Business Media},
	volume = {49},
	number = {7},
	pages = {1704--1705},
	author = {S. Martin and L. Heinemann and W. A. Scherbaum and H. Kolb},
	title = {Reply to comment on: Martin S, Schneider B, Heinemann L et al (2006) Self-monitoring of blood glucose in type 2 diabetes and long-term outcome: an epidemiological cohort study. Diabetologia 49:271{\\textendash}278},
	journal = {Diabetologia}
}
@article{Karter_2006,
	doi = {10.2337/dc06-2073},
	url = {http://dx.doi.org/10.2337/dc06-2073},
	year = 2006,
	month = {aug},
	publisher = {American Diabetes Association},
	volume = {29},
	number = {8},
	pages = {1757--1763},
	author = {A. J. Karter},
	title = {Longitudinal Study of New and Prevalent Use of Self-Monitoring of Blood Glucose},
	journal = {Diabetes Care}
}
@article{Davis_2007,
	doi = {10.2337/dc06-1992},
	url = {http://dx.doi.org/10.2337/dc06-1992},
	year = 2007,
	month = {jan},
	publisher = {American Diabetes Association},
	volume = {30},
	number = {1},
	pages = {184--185},
	author = {W. A. Davis and D. G. Bruce and T. M.E. Davis},
	title = {Is Self-Monitoring of Blood Glucose Appropriate for All Type 2 Diabetic Patients? The Fremantle Diabetes Study: Response to Kolb et al.},
	journal = {Diabetes Care}
}
@article{Lawton_2004,
	doi = {10.1111/j.1464-5491.2004.01286.x},
	url = {http://dx.doi.org/10.1111/j.1464-5491.2004.01286.x},
	year = 2004,
	month = {aug},
	publisher = {Wiley-Blackwell},
	volume = {21},
	number = {9},
	pages = {1045--1048},
	author = {J. Lawton and E. Peel and M. Douglas and O. Parry},
	title = {`Urine testing is a waste of time': newly diagnosed Type~2 diabetes patients' perceptions of self-monitoring},
	journal = {Diabetic Medicine}
}
@article{Peel_2007,
	doi = {10.1136/bmj.39302.444572.de},
	url = {http://dx.doi.org/10.1136/bmj.39302.444572.de},
	year = 2007,
	month = {sep},
	publisher = {$\\lbrace$BMJ$\\rbrace$},
	volume = {335},
	number = {7618},
	pages = {493--493},
	author = {E. Peel and M. Douglas and J. Lawton},
	title = {Self monitoring of blood glucose in type 2 diabetes: longitudinal qualitative study of patients{\\textquotesingle} perspectives},
	journal = {$\\lbrace$BMJ$\\rbrace$}
}
@article{Schernthaner_2004,
	doi = {10.1210/jc.2003-030861},
	url = {http://dx.doi.org/10.1210/jc.2003-030861},
	year = 2004,
	month = {dec},
	publisher = {The Endocrine Society},
	volume = {89},
	number = {12},
	pages = {6068--6076},
	author = {G. Schernthaner and D. R. Matthews and B. Charbonnel and M. Hanefeld and P. Brunetti},
	title = { Efficacy and Safety of Pioglitazone Versus Metformin in Patients with Type 2 Diabetes Mellitus: A Double-Blind, Randomized Trial },
	journal = {The Journal of Clinical Endocrinology {\\&} Metabolism}
}
@article{Marre_2002,
	doi = {10.1046/j.1463-1326.2002.00196.x},
	url = {http://dx.doi.org/10.1046/j.1463-1326.2002.00196.x},
	year = 2002,
	month = {may},
	publisher = {Wiley-Blackwell},
	volume = {4},
	number = {3},
	pages = {177--186},
	author = {M. Marre and L. Van Gaal and K-H. Usadel and M. Ball and I. Whatmough and C. Guitard},
	title = {Nateglinide improves glycaemic control when added to metformin monotherapy: results of a randomized trial with type 2 diabetes patients},
	journal = {Diabetes Obes Metab}
}
@article{Fujioka_2003,
	doi = {10.1016/s0149-2918(03)80093-0},
	url = {http://dx.doi.org/10.1016/s0149-2918(03)80093-0},
	year = 2003,
	month = {feb},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {25},
	number = {2},
	pages = {515--529},
	author = {Ken Fujioka and Miranda Pans and Steven Joyal},
	title = {Glycemic control in patients with type 2 diabetes mellitus switched from twice-daily immediate-release metformin to a once-daily extended-release formulation},
	journal = {Clinical Therapeutics}
}
@article{Bailey_2005,
	doi = {10.1016/j.clinthera.2005.10.012},
	url = {http://dx.doi.org/10.1016/j.clinthera.2005.10.012},
	year = 2005,
	month = {oct},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {27},
	number = {10},
	pages = {1548--1561},
	author = {Clifford J. Bailey and Alfredas Bagdonas and Josip Rubes and Stephen O. McMorn and Jill Donaldson and Nandita Biswas and Murray W. Stewart},
	title = {Rosiglitazone/metformin fixed-dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: A 24-week, multicenter, randomized, double-blind, parallel-group study},
	journal = {Clinical Therapeutics}
}
@article{Kvapil_2006,
	doi = {10.1111/j.1463-1326.2005.00492.x},
	url = {http://dx.doi.org/10.1111/j.1463-1326.2005.00492.x},
	year = 2006,
	month = {jan},
	publisher = {Wiley-Blackwell},
	volume = {8},
	number = {1},
	pages = {39--48},
	author = {M. Kvapil and A. Swatko and C. Hilberg and M. Shestakova},
	title = {Biphasic insulin aspart 30 plus metformin: an effective combination in type 2 diabetes},
	journal = {Diabetes Obes Metab}
}
@article{Fujioka_2005,
	doi = {10.1111/j.1463-1326.2004.00369.x},
	url = {http://dx.doi.org/10.1111/j.1463-1326.2004.00369.x},
	year = 2005,
	month = {jan},
	publisher = {Wiley-Blackwell},
	volume = {7},
	number = {1},
	pages = {28--39},
	author = {K. Fujioka and R. L. Brazg and I. Raz and S. Bruce and S. Joyal and R. Swanink and M. Pans},
	title = {Efficacy, dose-response relationship and safety of once-daily extended-release metformin ($\\lbrace$GlucophageR$\\rbrace$ $\\lbrace$XR$\\rbrace$) in type 2 diabetic patients with inadequate glycaemic control despite prior treatment with diet and exercise: results from two double-blind, placebo-controlled studies},
	journal = {Diabetes Obes Metab}
}
@article{Blonde_2004,
	doi = {10.1185/030079904125003278},
	url = {http://dx.doi.org/10.1185/030079904125003278},
	year = 2004,
	month = {apr},
	publisher = {Informa Healthcare},
	volume = {20},
	number = {4},
	pages = {565--572},
	author = {Lawrence Blonde and George E. Dailey and Serge A. Jabbour and Charles A. Reasner and Donna J. Mills},
	title = {Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study},
	journal = {Curr Med Res Opin}
}
@article{Cryer_2005,
	doi = {10.2337/diacare.28.3.539},
	url = {http://dx.doi.org/10.2337/diacare.28.3.539},
	year = 2005,
	month = {mar},
	publisher = {American Diabetes Association},
	volume = {28},
	number = {3},
	pages = {539--543},
	author = {D. R. Cryer and S. P. Nicholas and D. H. Henry and D. J. Mills and B. V. Stadel},
	title = {Comparative Outcomes Study of Metformin Intervention Versus Conventional Approach The $\\lbrace$COSMIC$\\rbrace$ Approach Study},
	journal = {Diabetes Care}
}
@article{Papa_2006,
	doi = {10.2337/dc05-2495},
	url = {http://dx.doi.org/10.2337/dc05-2495},
	year = 2006,
	month = {aug},
	publisher = {American Diabetes Association},
	volume = {29},
	number = {8},
	pages = {1918--1920},
	author = {G. Papa},
	title = {Safety of Type 2 Diabetes Treatment With Repaglinide Compared With Glibenclamide in Elderly People: A randomized, open-label, two-period, cross-over trial},
	journal = {Diabetes Care}
}
@article{Saloranta_2002,
	doi = {10.1210/jc.2002-020068},
	url = {http://dx.doi.org/10.1210/jc.2002-020068},
	year = 2002,
	month = {sep},
	publisher = {The Endocrine Society},
	volume = {87},
	number = {9},
	pages = {4171--4176},
	author = {Carola Saloranta and Kenneth Hershon and Michele Ball and Sheila Dickinson and David Holmes},
	title = {Efficacy and Safety of Nateglinide in Type 2 Diabetic Patients with Modest Fasting Hyperglycemia},
	journal = {The Journal of Clinical Endocrinology {\\&} Metabolism}
}
@article{Bengel_2005,
	doi = {10.1111/j.1464-5491.2004.01371.x},
	url = {http://dx.doi.org/10.1111/j.1464-5491.2004.01371.x},
	year = 2005,
	month = {feb},
	publisher = {Wiley-Blackwell},
	volume = {22},
	number = {2},
	pages = {158--163},
	author = {F. M. Bengel and C. Abletshauser and J. Neverve and O. Schnell and S. G. Nekolla and E. Standl and M. Schwaiger},
	title = {Effects of nateglinide on myocardial microvascular reactivity in Type 2 diabetes mellitus - a randomized study using positron emission tomography},
	journal = {Diabet Med}
}
@article{Rosenstock_2004,
	doi = {10.2337/diacare.27.6.1265},
	url = {http://dx.doi.org/10.2337/diacare.27.6.1265},
	year = 2004,
	month = {jun},
	publisher = {American Diabetes Association},
	volume = {27},
	number = {6},
	pages = {1265--1270},
	author = {J. Rosenstock and D. R. Hassman and R. D. Madder and S. A. Brazinsky and J. Farrell and N. Khutoryansky and P. M. Hale},
	title = {Repaglinide Versus Nateglinide Monotherapy: A randomized, multicenter study},
	journal = {Diabetes Care}
}
@article{Derosa_2003,
	doi = {10.1016/s0149-2918(03)80090-5},
	url = {http://dx.doi.org/10.1016/s0149-2918(03)80090-5},
	year = 2003,
	month = {feb},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {25},
	number = {2},
	pages = {472--484},
	author = {Giuseppe Derosa and Amedeo Mugellini and Leonardina Ciccarelli and Giuseppe Crescenzi and Roberto Fogari},
	title = {Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: A one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors},
	journal = {Clinical Therapeutics}
}
@article{Madsbad_2001,
	doi = {10.1046/j.1464-5491.2001.00490.x},
	url = {http://dx.doi.org/10.1046/j.1464-5491.2001.00490.x},
	year = 2001,
	month = {may},
	publisher = {Wiley-Blackwell},
	volume = {18},
	number = {5},
	pages = {395--401},
	author = {S. Madsbad and B. Kilhovd and I. Lager and P. Mustajoki and A. Dejgaard},
	title = {Comparison between repaglinide and glipizide in Type 2 diabetes mellitus: a 1-year multicentre study},
	journal = {Diabet Med}
}
@article{Schernthaner_2004,
	doi = {10.1111/j.1365-2362.2004.01381.x},
	url = {http://dx.doi.org/10.1111/j.1365-2362.2004.01381.x},
	year = 2004,
	month = {aug},
	publisher = {Wiley-Blackwell},
	volume = {34},
	number = {8},
	pages = {535--542},
	author = {G. Schernthaner and A. Grimaldi and U. Di Mario and J. Drzewoski and P. Kempler and M. Kvapil and A. Novials and R. Rottiers and G. E. H. M. Rutten and K. M. Shaw},
	title = {$\\lbrace$GUIDE$\\rbrace$ study: double-blind comparison of once-daily gliclazide $\\lbrace$MR$\\rbrace$ and glimepiride in type 2 diabetic patients},
	journal = {European Journal of Clinical Investigation}
}
@article{Dashora_2007,
	doi = {10.1111/j.1464-5491.2007.02094.x},
	url = {http://dx.doi.org/10.1111/j.1464-5491.2007.02094.x},
	year = 2007,
	month = {apr},
	publisher = {Wiley-Blackwell},
	volume = {24},
	number = {4},
	pages = {344--349},
	author = {U. K. Dashora and L. Sibal and S. G. Ashwell and P. D. Home},
	title = {Insulin glargine in combination with nateglinide in people with Type~2 diabetes: a randomized placebo-controlled trial},
	journal = {Diabetic Medicine}
}
@article{Charpentier_2001,
	doi = {10.1046/j.1464-5491.2001.00582.x},
	url = {http://dx.doi.org/10.1046/j.1464-5491.2001.00582.x},
	year = 2001,
	month = {oct},
	publisher = {Wiley-Blackwell},
	volume = {18},
	number = {10},
	pages = {828--834},
	author = {G. Charpentier and F. Fleury and M. Kabir and L. Vaur and S. Halimi},
	title = {Improved glycaemic control by addition of glimepiride to metformin monotherapy in Type 2 diabetic patients},
	journal = {Diabetic Medicine}
}
@article{Esposito_2004,
	doi = {10.1161/01.cir.0000134501.57864.66},
	url = {http://dx.doi.org/10.1161/01.cir.0000134501.57864.66},
	year = 2004,
	month = {jul},
	publisher = {Ovid Technologies (Wolters Kluwer Health)},
	volume = {110},
	number = {2},
	pages = {214--219},
	author = {K. Esposito},
	title = {Regression of Carotid Atherosclerosis by Control of Postprandial Hyperglycemia in Type 2 Diabetes Mellitus},
	journal = {Circulation}
}
@article{Ristic_2006,
	doi = {10.1111/j.1464-5491.2006.01914.x},
	url = {http://dx.doi.org/10.1111/j.1464-5491.2006.01914.x},
	year = 2006,
	month = {jul},
	publisher = {Wiley-Blackwell},
	volume = {23},
	number = {7},
	pages = {757--762},
	author = {S. Ristic and C. Collober-Maugeais and E. Pecher and F. Cressier},
	title = {Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with Type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone},
	journal = {Diabetic Medicine}
}
@article{Lu_2006,
	doi = {10.1111/j.1463-1326.2005.00501.x},
	url = {http://dx.doi.org/10.1111/j.1463-1326.2005.00501.x},
	year = 2006,
	month = {mar},
	publisher = {Wiley-Blackwell},
	volume = {8},
	number = {2},
	pages = {184--191},
	author = {C.-H. Lu and C.-C. Chang and L.-M. Chuang and C. Y. Wang and Y. D. Jiang and H. P. Wu},
	title = {Double-blind, randomized, multicentre study of the efficacy and safety of gliclazide-modified release in the treatment of Chinese type 2 diabetic patients},
	journal = {Diabetes Obes Metab}
}
@article{Forst_2003,
	doi = {10.1055/s-2003-39237},
	url = {http://dx.doi.org/10.1055/s-2003-39237},
	year = 2003,
	month = {apr},
	publisher = {Thieme Publishing Group},
	volume = {111},
	number = {2},
	pages = {97--103},
	author = {T. Forst and J. W. Eriksson and H.-J. Strotmann and S. Bai and R. Brunelle and K. S. Gulliya and S. Gack and U. Gudat},
	title = {Metabolic Effects of Mealtime Insulin Lispro in Comparison to Glibenclamide in Early Type 2 Diabetes},
	journal = {Experimental and Clinical Endocrinology {\\&} Diabetes}
}
@article{Rabinstein_2007,
	doi = {10.1016/s0513-5117(08)70014-0},
	url = {http://dx.doi.org/10.1016/s0513-5117(08)70014-0},
	year = 2007,
	month = {jan},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {2007},
	pages = {23--24},
	author = {A.A. Rabinstein},
	title = {Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm ($\\lbrace$ASCOT$\\rbrace$-$\\lbrace$BPLA$\\rbrace$): a multicentre randomised controlled trial},
	journal = {Yearbook of Neurology and Neurosurgery}
}
@article{Gray_2000,
	doi = {10.1136/bmj.320.7246.1373},
	url = {http://dx.doi.org/10.1136/bmj.320.7246.1373},
	year = 2000,
	month = {may},
	publisher = {$\\lbrace$BMJ$\\rbrace$},
	volume = {320},
	number = {7246},
	pages = {1373--1378},
	author = {A. Gray},
	title = {Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial ($\\lbrace$UKPDS$\\rbrace$ 41)},
	journal = {$\\lbrace$BMJ$\\rbrace$}
}
@article{Rosenthal_2002,
	doi = {10.2165/00044011-200222100-00006},
	url = {http://dx.doi.org/10.2165/00044011-200222100-00006},
	year = 2002,
	publisher = {Springer Science $\\mathplus$ Business Media},
	volume = {22},
	number = {10},
	pages = {695--701},
	author = {Julian H. Rosenthal and Herbert Mauersberger},
	title = {Effects on Blood Pressure of the ??-Glucosidase Inhibitor Acarbose Compared with the Insulin Enhancer Glibenclamide in Patients with Hypertension and Type 2 Diabetes Mellitus},
	journal = {Clinical Drug Investigation}
}
@article{Rosenthal_2002,
	doi = {10.2165/00044011-200222100-00006},
	url = {http://dx.doi.org/10.2165/00044011-200222100-00006},
	year = 2002,
	publisher = {Springer Science $\\mathplus$ Business Media},
	volume = {22},
	number = {10},
	pages = {695--701},
	author = {Julian H. Rosenthal and Herbert Mauersberger},
	title = {Effects on Blood Pressure of the ??-Glucosidase Inhibitor Acarbose Compared with the Insulin Enhancer Glibenclamide in Patients with Hypertension and Type 2 Diabetes Mellitus},
	journal = {Clinical Drug Investigation}
}
@article{Rosenthal_2002,
	doi = {10.2165/00044011-200222100-00006},
	url = {http://dx.doi.org/10.2165/00044011-200222100-00006},
	year = 2002,
	publisher = {Springer Science $\\mathplus$ Business Media},
	volume = {22},
	number = {10},
	pages = {695--701},
	author = {Julian H. Rosenthal and Herbert Mauersberger},
	title = {Effects on Blood Pressure of the ??-Glucosidase Inhibitor Acarbose Compared with the Insulin Enhancer Glibenclamide in Patients with Hypertension and Type 2 Diabetes Mellitus},
	journal = {Clinical Drug Investigation}
}
@article{Rosenthal_2002,
	doi = {10.2165/00044011-200222100-00006},
	url = {http://dx.doi.org/10.2165/00044011-200222100-00006},
	year = 2002,
	publisher = {Springer Science $\\mathplus$ Business Media},
	volume = {22},
	number = {10},
	pages = {695--701},
	author = {Julian H. Rosenthal and Herbert Mauersberger},
	title = {Effects on Blood Pressure of the ??-Glucosidase Inhibitor Acarbose Compared with the Insulin Enhancer Glibenclamide in Patients with Hypertension and Type 2 Diabetes Mellitus},
	journal = {Clinical Drug Investigation}
}
@article{Rosenthal_2002,
	doi = {10.2165/00044011-200222100-00006},
	url = {http://dx.doi.org/10.2165/00044011-200222100-00006},
	year = 2002,
	publisher = {Springer Science $\\mathplus$ Business Media},
	volume = {22},
	number = {10},
	pages = {695--701},
	author = {Julian H. Rosenthal and Herbert Mauersberger},
	title = {Effects on Blood Pressure of the ??-Glucosidase Inhibitor Acarbose Compared with the Insulin Enhancer Glibenclamide in Patients with Hypertension and Type 2 Diabetes Mellitus},
	journal = {Clinical Drug Investigation}
}
@article{Rosenthal_2002,
	doi = {10.2165/00044011-200222100-00006},
	url = {http://dx.doi.org/10.2165/00044011-200222100-00006},
	year = 2002,
	publisher = {Springer Science $\\mathplus$ Business Media},
	volume = {22},
	number = {10},
	pages = {695--701},
	author = {Julian H. Rosenthal and Herbert Mauersberger},
	title = {Effects on Blood Pressure of the ??-Glucosidase Inhibitor Acarbose Compared with the Insulin Enhancer Glibenclamide in Patients with Hypertension and Type 2 Diabetes Mellitus},
	journal = {Clinical Drug Investigation}
}
@article{Rosenthal_2002,
	doi = {10.2165/00044011-200222100-00006},
	url = {http://dx.doi.org/10.2165/00044011-200222100-00006},
	year = 2002,
	publisher = {Springer Science $\\mathplus$ Business Media},
	volume = {22},
	number = {10},
	pages = {695--701},
	author = {Julian H. Rosenthal and Herbert Mauersberger},
	title = {Effects on Blood Pressure of the ??-Glucosidase Inhibitor Acarbose Compared with the Insulin Enhancer Glibenclamide in Patients with Hypertension and Type 2 Diabetes Mellitus},
	journal = {Clinical Drug Investigation}
}
@article{UK_Prospective_Diabetes_Study_Group_1998,
	doi = {10.1136/bmj.317.7160.703},
	url = {http://dx.doi.org/10.1136/bmj.317.7160.703},
	year = 1998,
	month = {sep},
	publisher = {$\\lbrace$BMJ$\\rbrace$},
	volume = {317},
	number = {7160},
	pages = {703--713},
	author = {UK Prospective Diabetes Study Group},
	title = {Tight blood pressure control and risk of macrovascular and microvascular complications in type 2~diabetes: $\\lbrace$UKPDS$\\rbrace$ 38},
	journal = {$\\lbrace$BMJ$\\rbrace$}
}
@article{Berl_2005,
	doi = {10.1681/asn.2004090763},
	url = {http://dx.doi.org/10.1681/asn.2004090763},
	year = 2005,
	month = {apr},
	publisher = {American Society of Nephrology ($\\lbrace$ASN$\\rbrace$)},
	volume = {16},
	number = {7},
	pages = {2170--2179},
	author = {T. Berl},
	title = {Impact of Achieved Blood Pressure on Cardiovascular Outcomes in the Irbesartan Diabetic Nephropathy Trial},
	journal = {Journal of the American Society of Nephrology}
}
@article{2004,
	doi = {10.1001/archopht.122.11.1631},
	url = {http://dx.doi.org/10.1001/archopht.122.11.1631},
	year = 2004,
	month = {nov},
	publisher = {American Medical Association ($\\lbrace$AMA$\\rbrace$)},
	volume = {122},
	number = {11},
	pages = {1631},
	title = {Risks of Progression of Retinopathy and Vision Loss Related to $\\lbrace$TightBlood$\\rbrace$ Pressure Control in Type 2 Diabetes Mellitus},
	journal = {Archives of Ophthalmology}
}
@article{ESTACIO_2006,
	doi = {10.1016/j.amjhyper.2006.05.011},
	url = {http://dx.doi.org/10.1016/j.amjhyper.2006.05.011},
	year = 2006,
	month = {dec},
	publisher = {Oxford University Press ($\\lbrace$OUP$\\rbrace$)},
	volume = {19},
	number = {12},
	pages = {1241--1248},
	author = {R ESTACIO and J COLL and Z TRAN and R SCHRIER},
	title = {Effect of Intensive Blood Pressure Control With Valsartan on Urinary Albumin Excretion in Normotensive Patients With Type 2 Diabetes},
	journal = {American Journal of Hypertension}
}
@article{Bakris_2003,
	doi = {10.1001/archinte.163.13.1555},
	url = {http://dx.doi.org/10.1001/archinte.163.13.1555},
	year = 2003,
	month = {jul},
	publisher = {American Medical Association ($\\lbrace$AMA$\\rbrace$)},
	volume = {163},
	number = {13},
	pages = {1555},
	author = {George L. Bakris},
	title = {Effects of Blood Pressure Level on Progression of Diabetic Nephropathy$\\less$subtitle$\\greater$Results From the $\\lbrace$RENAAL$\\rbrace$ Study$\\less$/subtitle$\\greater$},
	journal = {Archives of Internal Medicine}
}
@article{Asakura_2005,
	doi = {10.1089/dia.2005.7.620},
	url = {http://dx.doi.org/10.1089/dia.2005.7.620},
	year = 2005,
	month = {aug},
	publisher = {Mary Ann Liebert Inc},
	volume = {7},
	number = {4},
	pages = {620--626},
	author = {Toshinari Asakura and Hiroaki Seino},
	title = {Assessment of Dose Selection Attributes with Audible Notification in Insulin Pen Devices},
	journal = {Diabetes Technology {\\&} Therapeutics}
}
@article{Pohl_2005,
	doi = {10.1681/asn.2004110919},
	url = {http://dx.doi.org/10.1681/asn.2004110919},
	year = 2005,
	month = {aug},
	publisher = {American Society of Nephrology ($\\lbrace$ASN$\\rbrace$)},
	volume = {16},
	number = {10},
	pages = {3027--3037},
	author = {M. A. Pohl},
	title = {Independent and Additive Impact of Blood Pressure Control and Angiotensin $\\lbrace$II$\\rbrace$ Receptor Blockade on Renal Outcomes in the Irbesartan Diabetic Nephropathy Trial: Clinical Implications and Limitations},
	journal = {Journal of the American Society of Nephrology}
}
@article{SIBAL_2006,
	doi = {10.1196/annals.1372.036},
	url = {http://dx.doi.org/10.1196/annals.1372.036},
	year = 2006,
	month = {nov},
	publisher = {Wiley-Blackwell},
	volume = {1084},
	number = {1},
	pages = {304--318},
	author = {L. SIBAL and H. N. LAW and J. GEBBIE and P. HOME},
	title = {Cardiovascular Risk Factors Predicting the Development of Distal Symmetrical Polyneuropathy in People with Type 1 Diabetes: A 9-Year Follow-up Study},
	journal = {Annals of the New York Academy of Sciences}
}
@article{Sengul_2006,
	doi = {10.1016/j.diabres.2005.06.010},
	url = {http://dx.doi.org/10.1016/j.diabres.2005.06.010},
	year = 2006,
	month = {feb},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {71},
	number = {2},
	pages = {210--219},
	author = {Ahmet M. Sengul and Yksel Altuntas and Ak{\\i}n Krkl and Levent Ayd{\\i}n},
	title = {Beneficial effect of lisinopril plus telmisartan in patients with type 2 diabetes, microalbuminuria and hypertension},
	journal = {Diabetes Research and Clinical Practice}
}
@article{Schrier_2002,
	doi = {10.1046/j.1523-1755.2002.00213.x},
	url = {http://dx.doi.org/10.1046/j.1523-1755.2002.00213.x},
	year = 2002,
	month = {mar},
	publisher = {Nature Publishing Group},
	volume = {61},
	number = {3},
	pages = {1086--1097},
	author = {Robert W. Schrier and Raymond O. Estacio and Anne Esler and Philip Mehler},
	title = {Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes},
	journal = {Kidney International}
}
@article{2005,
	doi = {10.1001/archinte.165.12.1410},
	url = {http://dx.doi.org/10.1001/archinte.165.12.1410},
	year = 2005,
	month = {jun},
	publisher = {American Medical Association ($\\lbrace$AMA$\\rbrace$)},
	volume = {165},
	number = {12},
	pages = {1410},
	title = {Effects of Different Blood Pressure{\\textendash}Lowering Regimens on Major Cardiovascular Events in Individuals With and Without Diabetes Mellitus},
	journal = {Archives of Internal Medicine}
}
@article{Casas_2005,
	doi = {10.1016/s0140-6736(05)67814-2},
	url = {http://dx.doi.org/10.1016/s0140-6736(05)67814-2},
	year = 2005,
	month = {dec},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {366},
	number = {9502},
	pages = {2026--2033},
	author = {Juan P Casas and Weiliang Chua and Stavros Loukogeorgakis and Patrick Vallance and Liam Smeeth and Aroon D Hingorani and Raymond J MacAllister},
	title = {Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis},
	journal = {The Lancet}
}
@article{Hadjadj_2008,
	doi = {10.2337/dc08-1229},
	url = {http://dx.doi.org/10.2337/dc08-1229},
	year = 2008,
	month = {jun},
	publisher = {American Diabetes Association},
	volume = {31},
	number = {10},
	pages = {e79--e79},
	author = {S. Hadjadj and R. Roussel and M. Marre},
	title = {Prognostic Value of the Insertion/Deletion Polymorphism of the $\\lbrace$ACE$\\rbrace$ Gene in Type 2 Diabetic Subjects: Results From the Non-Insulin-Dependent Diabetes, Hypertension, Microalbuminuria or Proteinuria, Cardiovascular Events, and Ramipril ($\\lbrace$DIABHYCAR$\\rbrace$), Diabete de type 2, Nephropathie et Genetique ($\\lbrace$DIAB$\\rbrace$2NEPHROGENE), and Survie, Diabete de type 2 et Genetique ($\\lbrace$SURDIAGENE$\\rbrace$) Studies: Response to Ng et al.},
	journal = {Diabetes Care}
}
@article{Mann_2003,
	doi = {10.1097/01.asn.0000051594.21922.99},
	url = {http://dx.doi.org/10.1097/01.asn.0000051594.21922.99},
	year = 2003,
	month = {mar},
	publisher = {American Society of Nephrology ($\\lbrace$ASN$\\rbrace$)},
	volume = {14},
	number = {3},
	pages = {641--647},
	author = {J. F. E. Mann},
	title = {Development of Renal Disease in People at High Cardiovascular Risk: Results of the $\\lbrace$HOPE$\\rbrace$ Randomized Study},
	journal = {Journal of the American Society of Nephrology}
}
@article{Barnett_2004,
	doi = {10.1056/nejmoa042274},
	url = {http://dx.doi.org/10.1056/nejmoa042274},
	year = 2004,
	month = {nov},
	publisher = {New England Journal of Medicine ($\\lbrace$NEJM$\\rbrace$/$\\lbrace$MMS$\\rbrace$)},
	volume = {351},
	number = {19},
	pages = {1952--1961},
	author = {Anthony H. Barnett and Stephen C. Bain and Paul Bouter and Bengt Karlberg and Sten Madsbad and Jak Jervell and Jukka Mustonen},
	title = {Angiotensin-Receptor Blockade versus Converting{\\textendash}Enzyme Inhibition in Type 2 Diabetes and Nephropathy},
	journal = {New England Journal of Medicine}
}
@article{Ruggenenti_2006,
	doi = {10.1681/asn.2006060560},
	url = {http://dx.doi.org/10.1681/asn.2006060560},
	year = 2006,
	month = {nov},
	publisher = {American Society of Nephrology ($\\lbrace$ASN$\\rbrace$)},
	volume = {17},
	number = {12},
	pages = {3472--3481},
	author = {P. Ruggenenti and A. Perna and M. Ganeva and B. Ene-Iordache and G. Remuzzi},
	title = {Impact of Blood Pressure Control and Angiotensin-Converting Enzyme Inhibitor Therapy on New-Onset Microalbuminuria in Type 2 Diabetes: A Post Hoc Analysis of the $\\lbrace$BENEDICT$\\rbrace$ Trial},
	journal = {Journal of the American Society of Nephrology}
}
@article{Torffvit_2002,
	doi = {10.1055/s-2002-19964},
	url = {http://dx.doi.org/10.1055/s-2002-19964},
	year = 2002,
	month = {jan},
	publisher = {Thieme Publishing Group},
	volume = {34},
	number = {1},
	pages = {32--35},
	author = {O. Torffvit and C.-D. Agardh},
	title = {A Blood Pressure Cut-Off Level Identified for Renal Failure, but not for Macrovascular Complications in Type 2 Diabetes: A 10-year Observation Study},
	journal = {Hormone and Metabolic Research}
}
@article{2005,
	doi = {10.1161/circulationaha.105.548461},
	url = {http://dx.doi.org/10.1161/circulationaha.105.548461},
	year = 2005,
	month = {aug},
	publisher = {Ovid Technologies (Wolters Kluwer Health)},
	volume = {112},
	number = {9},
	pages = {1339--1346},
	title = {Long-Term Effects of Ramipril on Cardiovascular Events and on Diabetes: Results of the $\\lbrace$HOPE$\\rbrace$ Study Extension},
	journal = {Circulation}
}
@article{Fogari_2002,
	doi = {10.1016/s0895-7061(02)03017-0},
	url = {http://dx.doi.org/10.1016/s0895-7061(02)03017-0},
	year = 2002,
	month = {dec},
	publisher = {Oxford University Press ($\\lbrace$OUP$\\rbrace$)},
	volume = {15},
	number = {12},
	pages = {1042--1049},
	author = {R Fogari},
	title = {Effects of amlodipine fosinopril combination on microalbuminuria in hypertensive type 2 diabetic patients},
	journal = {American Journal of Hypertension}
}
@article{Mann_2003,
	doi = {10.1016/j.ajkd.2003.07.015},
	url = {http://dx.doi.org/10.1016/j.ajkd.2003.07.015},
	year = 2003,
	month = {nov},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {42},
	number = {5},
	pages = {936--942},
	author = {Johannes F.E. Mann and Hertzel C. Gerstein and Qi-Long Yi and Jrg Franke and Eva M. Lonn and Byron J. Hoogwerf and Andrew Rashkow and Salim Yusuf},
	title = {Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation ($\\lbrace$HOPE$\\rbrace$) randomized study},
	journal = {American Journal of Kidney Diseases}
}
@article{Bakris_2005,
	doi = {10.1016/j.accreview.2004.12.136},
	url = {http://dx.doi.org/10.1016/j.accreview.2004.12.136},
	year = 2005,
	month = {feb},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {14},
	number = {2},
	pages = {20},
	author = {G.L. Bakris and V. Fonseca and R.L. Katholi},
	title = {Metabolic effects of carvedilol vs. metoprolol in patients with type 2 diabetes mellitus and hypertension: A randomized controlled trial},
	journal = {$\\lbrace$ACC$\\rbrace$ Current Journal Review}
}
@article{Palmer_2004,
	doi = {10.1038/sj.jhh.1001729},
	url = {http://dx.doi.org/10.1038/sj.jhh.1001729},
	year = 2004,
	month = {apr},
	publisher = {Nature Publishing Group},
	volume = {18},
	number = {10},
	pages = {733--738},
	author = {A J Palmer and L Annemans and S Roze and M Lamotte and R A Rodby and R W Bilous},
	title = {An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial ($\\lbrace$IDNT$\\rbrace$) in a $\\lbrace$UK$\\rbrace$ setting},
	journal = {J Hum Hypertens}
}
@article{Derosa_2004,
	doi = {10.1016/s0149-2918(04)80049-3},
	url = {http://dx.doi.org/10.1016/s0149-2918(04)80049-3},
	year = 2004,
	month = {aug},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {26},
	number = {8},
	pages = {1228--1236},
	author = {Giuseppe Derosa and Arrigo F.G. Cicero and Gianandrea Bertone and Mario N. Piccinni and Elena Fogari and Leonardina Ciccarelli and Roberto Fogari},
	title = {Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension: a 12-month, randomized, double-blind study},
	journal = {Clinical Therapeutics}
}
@article{Derosa_2005,
	doi = {10.1097/01.fjc.0000161403.91456.39},
	url = {http://dx.doi.org/10.1097/01.fjc.0000161403.91456.39},
	year = 2005,
	publisher = {Ovid Technologies (Wolters Kluwer Health)},
	volume = {45},
	number = {6},
	pages = {599--604},
	author = {Giuseppe Derosa and Arrigo F. G Cicero and Antonio Gaddi and Amedeo Mugellini and Leonardina Ciccarelli and Roberto Fogari},
	title = {Effects of Doxazosin and Irbesartan on Blood Pressure and Metabolic Control in Patients with Type 2 Diabetes and Hypertension},
	journal = {Journal of Cardiovascular Pharmacology}
}
@article{Viberti_2002,
	doi = {10.1161/01.cir.0000024416.33113.0a},
	url = {http://dx.doi.org/10.1161/01.cir.0000024416.33113.0a},
	year = 2002,
	month = {jul},
	publisher = {Ovid Technologies (Wolters Kluwer Health)},
	volume = {106},
	number = {6},
	pages = {672--678},
	author = {G. Viberti and N. M. Wheeldon},
	title = {Microalbuminuria Reduction With Valsartan in Patients With Type 2 Diabetes Mellitus: A Blood Pressure-Independent Effect},
	journal = {Circulation}
}
@article{Remuzzi_2004,
	doi = {10.1097/01.asn.0000146423.71226.0c},
	url = {http://dx.doi.org/10.1097/01.asn.0000146423.71226.0c},
	year = 2004,
	month = {dec},
	publisher = {American Society of Nephrology ($\\lbrace$ASN$\\rbrace$)},
	volume = {15},
	number = {12},
	pages = {3117--3125},
	author = {G. Remuzzi},
	title = {Continuum of Renoprotection with Losartan at All Stages of Type 2 Diabetic Nephropathy: A Post Hoc Analysis of the $\\lbrace$RENAAL$\\rbrace$ Trial Results},
	journal = {Journal of the American Society of Nephrology}
}
@article{Andersen_2003,
	doi = {10.2337/diacare.26.12.3296},
	url = {http://dx.doi.org/10.2337/diacare.26.12.3296},
	year = 2003,
	month = {dec},
	publisher = {American Diabetes Association},
	volume = {26},
	number = {12},
	pages = {3296--3302},
	author = {S. Andersen and J. Brochner-Mortensen and H.-H. Parving},
	title = {Kidney Function During and After Withdrawal of Long-Term Irbesartan Treatment in Patients With Type 2 Diabetes and Microalbuminuria},
	journal = {Diabetes Care}
}
@article{Holzgreve_2003,
	doi = {10.1016/s0895-7061(03)00062-1},
	url = {http://dx.doi.org/10.1016/s0895-7061(03)00062-1},
	year = 2003,
	month = {may},
	publisher = {Oxford University Press ($\\lbrace$OUP$\\rbrace$)},
	volume = {16},
	number = {5},
	pages = {381--386},
	author = {H Holzgreve},
	title = {Antihypertensive therapy with verapamil $\\lbrace$SR$\\rbrace$ plus trandolapril versus atenolol plus chlorthalidone on glycemic control},
	journal = {American Journal of Hypertension}
}
@article{Fern_ndez_2001,
	doi = {10.1038/sj.jhh.1001279},
	url = {http://dx.doi.org/10.1038/sj.jhh.1001279},
	year = 2001,
	month = {dec},
	publisher = {Nature Publishing Group},
	volume = {15},
	number = {12},
	pages = {849--856},
	author = {R Fern{\\'{a}}ndez and J G Puig and J C Rodr{\\'{\\i}}guez-P{\\'{e}}rez and J Garrido and J Redon},
	title = {Effect of two antihypertensive combinations on metabolic control in type-2 diabetic hypertensive patients with albuminuria: a randomised, double-blind study},
	journal = {J Hum Hypertens}
}
@article{Appel_2003,
	doi = {10.2337/diacare.26.5.1402},
	url = {http://dx.doi.org/10.2337/diacare.26.5.1402},
	year = 2003,
	month = {may},
	publisher = {American Diabetes Association},
	volume = {26},
	number = {5},
	pages = {1402--1407},
	author = {G. B. Appel and J. Radhakrishnan and M. M. Avram and R. A. DeFronzo and F. Escobar-Jimenez and M.M. Campos and E. Burgess and D. A. Hille and T. Z. Dickson and S. Shahinfar and B. M. Brenner},
	title = {Analysis of Metabolic Parameters as Predictors of Risk in the $\\lbrace$RENAAL$\\rbrace$ Study},
	journal = {Diabetes Care}
}
@article{Whelton_2005,
	doi = {10.1001/archinte.165.12.1401},
	url = {http://dx.doi.org/10.1001/archinte.165.12.1401},
	year = 2005,
	month = {jun},
	publisher = {American Medical Association ($\\lbrace$AMA$\\rbrace$)},
	volume = {165},
	number = {12},
	pages = {1401},
	author = {Paul K. Whelton},
	title = {Clinical Outcomes in Antihypertensive Treatment of Type 2 Diabetes, Impaired Fasting Glucose Concentration, and Normoglycemia},
	journal = {Archives of Internal Medicine}
}
@article{Gray_2001,
	doi = {10.1046/j.1464-5491.2001.00485.x},
	url = {http://dx.doi.org/10.1046/j.1464-5491.2001.00485.x},
	year = 2001,
	month = {jun},
	publisher = {Wiley-Blackwell},
	volume = {18},
	number = {6},
	pages = {438--444},
	author = {A. Gray and P. Clarke and M. Raikou and A. Adler and R. Stevens and A. Neil and C. Cull and I. Stratton and R. Holman},
	title = {An economic evaluation of atenolol vs. captopril in patients with Type 2 diabetes ($\\lbrace$UKPDS$\\rbrace$ 54)},
	journal = {Diabetic Medicine}
}
@article{Palmer_2004,
	doi = {10.1038/sj.jhh.1001729},
	url = {http://dx.doi.org/10.1038/sj.jhh.1001729},
	year = 2004,
	month = {apr},
	publisher = {Nature Publishing Group},
	volume = {18},
	number = {10},
	pages = {733--738},
	author = {A J Palmer and L Annemans and S Roze and M Lamotte and R A Rodby and R W Bilous},
	title = {An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial ($\\lbrace$IDNT$\\rbrace$) in a $\\lbrace$UK$\\rbrace$ setting},
	journal = {J Hum Hypertens}
}
@article{Rodby_2003,
	doi = {10.1016/s0149-2918(03)80208-4},
	url = {http://dx.doi.org/10.1016/s0149-2918(03)80208-4},
	year = 2003,
	month = {jul},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {25},
	number = {7},
	pages = {2102--2119},
	author = {Roger A. Rodby and Chion-Fang Chiou and Jeff Borenstein and Allison Smitten and Nishan Sengupta and Andrew J. Palmer and St{\\'{e}}phane Roze and Lieven Annemans and Teresa A. Simon and Roland S. Chen and Edmund J. Lewis},
	title = {The cost-effectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy},
	journal = {Clinical Therapeutics}
}
@article{Lindholm_2002,
	doi = {10.1016/s1062-1458(02)00776-6},
	url = {http://dx.doi.org/10.1016/s1062-1458(02)00776-6},
	year = 2002,
	month = {sep},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {11},
	number = {5},
	pages = {26},
	author = {L.H. Lindholm and H. Ibsen and B. Dahof},
	title = {Cardiovascular morbidity and mortality in patients with diabetes in the losartan intervention for endpoint reduction in hypertension study ($\\lbrace$LIFE$\\rbrace$): a randomised trial against atenolol},
	journal = {$\\lbrace$ACC$\\rbrace$ Current Journal Review}
}
@article{Lewis_2001,
	doi = {10.1056/nejmoa011303},
	url = {http://dx.doi.org/10.1056/nejmoa011303},
	year = 2001,
	month = {sep},
	publisher = {New England Journal of Medicine ($\\lbrace$NEJM$\\rbrace$/$\\lbrace$MMS$\\rbrace$)},
	volume = {345},
	number = {12},
	pages = {851--860},
	author = {Edmund J. Lewis and Lawrence G. Hunsicker and William R. Clarke and Tomas Berl and Marc A. Pohl and Julia B. Lewis and Eberhard Ritz and Robert C. Atkins and Richard Rohde and Itamar Raz},
	title = {Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes},
	journal = {New England Journal of Medicine}
}
@article{Zanchetti_2006,
	doi = {10.1097/01.hjh.0000249692.96488.46},
	url = {http://dx.doi.org/10.1097/01.hjh.0000249692.96488.46},
	year = 2006,
	month = {nov},
	publisher = {Ovid Technologies (Wolters Kluwer Health)},
	volume = {24},
	number = {11},
	pages = {2163--2168},
	author = {Alberto Zanchetti and Stevo Julius and Sverre Kjeldsen and Gordon T McInnes and Tsushung Hua and Michael Weber and John H Laragh and Francis Plat and Edouard Battegay and Cesar Calvo-Vargas and Andrzej Cie{\\'{s}}li{\\'{n}}ski and Jean Paul Degaute and Nicolaas J Holwerda and Janna Kobalava and Ole Lederballe Pedersen and Faustinus P Rudyatmoko and Kostas C Siamopoulos and yvind Strset},
	title = {Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the $\\lbrace$VALUE$\\rbrace$ trial},
	journal = {Journal of Hypertension}
}
@article{Pepine_2004,
	doi = {10.1016/j.accreview.2003.12.023},
	url = {http://dx.doi.org/10.1016/j.accreview.2003.12.023},
	year = 2004,
	month = {feb},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {13},
	number = {2},
	pages = {19--20},
	author = {C.J. Pepine and E.M. Handberg and R.M. Cooper-DeHoff},
	title = {A calcium antagonist vs. a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease: the international verapamil-trandolapril study ($\\lbrace$INVEST$\\rbrace$): a randomized controlled trial},
	journal = {$\\lbrace$ACC$\\rbrace$ Current Journal Review}
}
@article{Eddy_2003,
	doi = {10.2337/diacare.26.11.3102},
	url = {http://dx.doi.org/10.2337/diacare.26.11.3102},
	year = 2003,
	month = {nov},
	publisher = {American Diabetes Association},
	volume = {26},
	number = {11},
	pages = {3102--3110},
	author = {D. M. Eddy and L. Schlessinger},
	title = {Validation of the Archimedes Diabetes Model},
	journal = {Diabetes Care}
}
@article{Coleman_2007,
	doi = {10.2337/dc06-1358},
	url = {http://dx.doi.org/10.2337/dc06-1358},
	year = 2007,
	month = {feb},
	publisher = {American Diabetes Association},
	volume = {30},
	number = {5},
	pages = {1292--1293},
	author = {R. L. Coleman and R. J. Stevens and R. Retnakaran and R. R. Holman},
	title = {Framingham, $\\lbrace$SCORE$\\rbrace$, and $\\lbrace$DECODE$\\rbrace$ Risk Equations Do Not Provide Reliable Cardiovascular Risk Estimates in Type 2 Diabetes},
	journal = {Diabetes Care}
}
@misc{De_Backer,
	doi = {10.3410/f.8264.465658},
	url = {http://dx.doi.org/10.3410/f.8264.465658},
	publisher = {Faculty of 1000, Ltd.},
	author = {Guy De Backer},
	title = {Faculty of 1000 evaluation for Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.}
}
@article{Vijan_2004,
	doi = {10.7326/0003-4819-140-8-200404200-00013},
	url = {http://dx.doi.org/10.7326/0003-4819-140-8-200404200-00013},
	year = 2004,
	month = {apr},
	publisher = {American College of Physicians},
	volume = {140},
	number = {8},
	pages = {650},
	author = {Sandeep Vijan},
	title = {Pharmacologic Lipid-Lowering Therapy in Type 2 Diabetes Mellitus: Background Paper for the American College of Physicians},
	journal = {Annals of Internal Medicine}
}
@article{Shepherd_2006,
	doi = {10.2337/dc05-2465},
	url = {http://dx.doi.org/10.2337/dc05-2465},
	year = 2006,
	month = {jun},
	publisher = {American Diabetes Association},
	volume = {29},
	number = {6},
	pages = {1220--1226},
	author = {J. Shepherd},
	title = {Effect of Lowering $\\lbrace$LDL$\\rbrace$ Cholesterol Substantially Below Currently Recommended Levels in Patients With Coronary Heart Disease and Diabetes: The Treating to New Targets ($\\lbrace$TNT$\\rbrace$) study},
	journal = {Diabetes Care}
}
@article{Poulter_2005,
	doi = {10.2337/diacare.28.10.2595a},
	url = {http://dx.doi.org/10.2337/diacare.28.10.2595a},
	year = 2005,
	month = {oct},
	publisher = {American Diabetes Association},
	volume = {28},
	number = {10},
	pages = {2595a--2596a},
	author = {N. R. Poulter and P. S. Sever and B. Dahlof and H. Wedel},
	title = {Reduction in Cardiovascular Events With Atorvastatin in 2,532 Patients With Type 2 Diabetes: Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm ($\\lbrace$ASCOT$\\rbrace$-$\\lbrace$LLA$\\rbrace$)},
	journal = {Diabetes Care}
}
@article{van_Venrooij_2002,
	doi = {10.2337/diacare.25.7.1211},
	url = {http://dx.doi.org/10.2337/diacare.25.7.1211},
	year = 2002,
	month = {jul},
	publisher = {American Diabetes Association},
	volume = {25},
	number = {7},
	pages = {1211--1216},
	author = {F. V. van Venrooij and M. A. van de Ree and M. L. Bots and R. P. Stolk and M. V. Huisman and J. D. Banga},
	title = {Aggressive Lipid Lowering Does Not Improve Endothelial Function in Type 2 Diabetes: The Diabetes Atorvastatin Lipid Intervention ($\\lbrace$DALI$\\rbrace$) Study: a randomized, double-blind, placebo-controlled trial},
	journal = {Diabetes Care}
}
@article{Colhoun_2005,
	doi = {10.1007/s00125-005-0029-y},
	url = {http://dx.doi.org/10.1007/s00125-005-0029-y},
	year = 2005,
	month = {nov},
	publisher = {Springer Science $\\mathplus$ Business Media},
	volume = {48},
	number = {12},
	pages = {2482--2485},
	author = {H. M. Colhoun and D. J. Betteridge and P. N. Durrington and G. A. Hitman and H. A. W. Neil and S. J. Livingstone and M. J. Thomason and J. H. Fuller},
	title = {Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study ($\\lbrace$CARDS$\\rbrace$)},
	journal = {Diabetologia}
}
@article{Miller_2004,
	doi = {10.1185/030079904125004105},
	url = {http://dx.doi.org/10.1185/030079904125004105},
	year = 2004,
	month = {jul},
	publisher = {Informa Healthcare},
	volume = {20},
	number = {7},
	pages = {1087--1094},
	author = {Michael Miller and Adrian Dobs and Zhong Yuan and Wendy P. Battisti and Hannah Borisute and Joanne Palmisano},
	title = {Effectiveness of simvastatin therapy in raising $\\lbrace$HDL$\\rbrace$-C in patients with type 2 diabetes and low $\\lbrace$HDL$\\rbrace$-C},
	journal = {Curr Med Res Opin}
}
@article{Berne_2005,
	doi = {10.1111/j.1368-504x.2005.0538c.x},
	url = {http://dx.doi.org/10.1111/j.1368-504x.2005.0538c.x},
	year = 2005,
	month = {jun},
	publisher = {Wiley-Blackwell},
	volume = {59},
	number = {s148},
	pages = {3--13},
	author = {C. Berne and A. Siewert-Delle},
	title = {Effects of rosuvastatin and atorvastatin on $\\lbrace$LDL$\\rbrace$-C, and apolipoproteins A-I and B in patients with type 2 diabetes: results of the $\\lbrace$URANUS$\\rbrace$ study},
	journal = {Int J Clinical Practice}
}
@article{Frishman_2007,
	doi = {10.1016/s0084-3873(08)70201-3},
	url = {http://dx.doi.org/10.1016/s0084-3873(08)70201-3},
	year = 2007,
	month = {jan},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {2007},
	pages = {309--311},
	author = {W.H. Frishman},
	title = {Effects of longterm fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the $\\lbrace$FIELD$\\rbrace$ study): randomised controlled trial},
	journal = {Yearbook of Medicine}
}
@article{Muhlestein_2006,
	doi = {10.1016/j.jacc.2006.05.009},
	url = {http://dx.doi.org/10.1016/j.jacc.2006.05.009},
	year = 2006,
	month = {jul},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {48},
	number = {2},
	pages = {396--401},
	author = {Joseph B. Muhlestein and Heidi T. May and Jonathan R. Jensen and Benjamin D. Horne and Richard B. Lanman and Farangis Lavasani and Robert L. Wolfert and Robert R. Pearson and H. Daniel Yannicelli and Jeffrey L. Anderson},
	title = {The Reduction of Inflammatory Biomarkers by Statin, Fibrate, and Combination Therapy Among Diabetic Patients With Mixed Dyslipidemia},
	journal = {Journal of the American College of Cardiology}
}
@article{Athyros_2002,
	doi = {10.2337/diacare.25.7.1198},
	url = {http://dx.doi.org/10.2337/diacare.25.7.1198},
	year = 2002,
	month = {jul},
	publisher = {American Diabetes Association},
	volume = {25},
	number = {7},
	pages = {1198--1202},
	author = {V. G. Athyros and A. A. Papageorgiou and V. V. Athyrou and D. S. Demitriadis and A. G. Kontopoulos},
	title = {Atorvastatin and Micronized Fenofibrate Alone and in Combination in Type 2 Diabetes With Combined Hyperlipidemia},
	journal = {Diabetes Care}
}
@article{DEROSA_2004,
	doi = {10.1016/j.clinthera.2004.10.008},
	url = {http://dx.doi.org/10.1016/j.clinthera.2004.10.008},
	year = 2004,
	month = {oct},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {26},
	number = {10},
	pages = {1599--1607},
	author = {G DEROSA and A CICERO and G BERTONE and M PICCINNI and L CICCARELLI and D ROGGERI},
	title = {Comparison of fluvastatin $\\mathplus$ fenofibrate combination therapyand fluvastatin monotherapy in the treatment of combined hyperlipidemia,type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial},
	journal = {Clinical Therapeutics}
}
@article{Durrington_2004,
	doi = {10.1016/j.diabres.2003.11.012},
	url = {http://dx.doi.org/10.1016/j.diabres.2003.11.012},
	year = 2004,
	month = {may},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {64},
	number = {2},
	pages = {137--151},
	author = {Paul N. Durrington and Jaakko Tuomilehto and Andreas Hamann and David Kallend and Karen Smith},
	title = {Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia},
	journal = {Diabetes Research and Clinical Practice}
}
@article{Rubins_2002,
	doi = {10.1001/archinte.162.22.2597},
	url = {http://dx.doi.org/10.1001/archinte.162.22.2597},
	year = 2002,
	month = {dec},
	publisher = {American Medical Association ($\\lbrace$AMA$\\rbrace$)},
	volume = {162},
	number = {22},
	pages = {2597},
	author = {Hanna Bloomfield Rubins},
	title = {Diabetes, Plasma Insulin, and Cardiovascular Disease},
	journal = {Archives of Internal Medicine}
}
@article{_hrvall_1995,
	doi = {10.1016/0026-0495(95)90267-8},
	url = {http://dx.doi.org/10.1016/0026-0495(95)90267-8},
	year = 1995,
	month = {feb},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {44},
	number = {2},
	pages = {212--217},
	author = {Margareta hrvall and Hans Lithell and Jan Johansson and Bengt Vessby},
	title = {A comparison between the effects of gemfibrozil and simvastatin on insulin sensitivity in patients with non{\\textemdash}Insulin-dependent diabetes mellitus and hyperlipoproteinemia},
	journal = {Metabolism}
}
@article{Schweitzer_2002,
	doi = {10.1016/s0021-9150(01)00700-6},
	url = {http://dx.doi.org/10.1016/s0021-9150(01)00700-6},
	year = 2002,
	month = {may},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {162},
	number = {1},
	pages = {201--210},
	author = {Morris Schweitzer and Daniel Tessier and William D Vlahos and Lawrence Leiter and Jean Paul Collet and Matthew J McQueen and Laurent Harvey and Petar Alaupovic},
	title = {A comparison of pravastatin and gemfibrozil in the treatment of dyslipoproteinemia in patients with non-insulin-dependent diabetes mellitus},
	journal = {Atherosclerosis}
}
@article{W_gner_2003,
	doi = {10.1210/jc.2003-030153},
	url = {http://dx.doi.org/10.1210/jc.2003-030153},
	year = 2003,
	month = {jul},
	publisher = {The Endocrine Society},
	volume = {88},
	number = {7},
	pages = {3212--3217},
	author = {Ana M. Wgner and Oscar Jorba and Rosa Bonet and Jordi Ord{\\'{o}}{\\~{n}}ez-Llanos and Antonio P{\\'{e}}rez},
	title = {Efficacy of Atorvastatin and Gemfibrozil, Alone and in Low Dose Combination, in the Treatment of Diabetic Dyslipidemia},
	journal = {The Journal of Clinical Endocrinology {\\&} Metabolism}
}
@article{Elam_2000,
	doi = {10.1001/jama.284.10.1263},
	url = {http://dx.doi.org/10.1001/jama.284.10.1263},
	year = 2000,
	month = {sep},
	publisher = {American Medical Association ($\\lbrace$AMA$\\rbrace$)},
	volume = {284},
	number = {10},
	pages = {1263},
	author = {Marshall B. Elam and Donald B. Hunninghake and Kathryn B. Davis and Rekha Garg and Craig Johnson and Debra Egan and John B. Kostis and David S. Sheps and Eliot A. Brinton and  for the ADMIT Investigators},
	title = {Effect of Niacin on Lipid and Lipoprotein Levels and Glycemic Control in Patients With Diabetes and Peripheral Arterial Disease},
	journal = {$\\lbrace$JAMA$\\rbrace$}
}
@article{Grundy_2002,
	doi = {10.1001/archinte.162.14.1568},
	url = {http://dx.doi.org/10.1001/archinte.162.14.1568},
	year = 2002,
	month = {jul},
	publisher = {American Medical Association ($\\lbrace$AMA$\\rbrace$)},
	volume = {162},
	number = {14},
	pages = {1568},
	author = {Scott M. Grundy},
	title = {Efficacy, Safety, and Tolerability of Once-Daily Niacin for the Treatment of Dyslipidemia Associated With Type 2 Diabetes$\\less$subtitle$\\greater$Results of the Assessment of Diabetes Control and Evaluation of the Efficacy of Niaspan Trial$\\less$/subtitle$\\greater$},
	journal = {Archives of Internal Medicine}
}
@article{Garg_1990,
	doi = {10.1001/jama.1990.03450060069031},
	url = {http://dx.doi.org/10.1001/jama.1990.03450060069031},
	year = 1990,
	month = {aug},
	publisher = {American Medical Association ($\\lbrace$AMA$\\rbrace$)},
	volume = {264},
	number = {6},
	pages = {723},
	author = {Abhimanyu Garg},
	title = {Nicotinic Acid as Therapy for Dyslipidemia in Non{\\textemdash}Insulin-Dependent Diabetes Mellitus},
	journal = {$\\lbrace$JAMA$\\rbrace$: The Journal of the American Medical Association}
}
@article{Tsalamandris_1994,
	doi = {10.1177/174182679400100308},
	url = {http://dx.doi.org/10.1177/174182679400100308},
	year = 1994,
	month = {oct},
	publisher = {$\\lbrace$SAGE$\\rbrace$ Publications},
	volume = {1},
	number = {3},
	pages = {231--239},
	author = {C. Tsalamandris and S. Panagiotopoulos and A. Sinha and M. E. Cooper and G. Jerums},
	title = {Complementary Effects of Pravastatin and Nicotinic Acid in the Treatment of Combined Hyperlipidaemia in Diabetic and Non-Diabetic Patients},
	journal = {European Journal of Cardiovascular Prevention {\\&} Rehabilitation}
}
@article{Bhise_2005,
	doi = {10.1007/bf02867393},
	url = {http://dx.doi.org/10.1007/bf02867393},
	year = 2005,
	month = {jul},
	publisher = {Springer Science $\\mathplus$ Business Media},
	volume = {20},
	number = {2},
	pages = {4--9},
	author = {A. Bhise and P. V. Krishnan and R. Aggarwal and M. Gaiha and J. Bhattacharjee},
	title = {Effect of low-dose omega-3 fatty acids substitution on blood pressure, hyperinsulinemia and dyslipidemia in Indians with essential hypertension: A pilot study},
	journal = {Indian J Clin Biochem}
}
@article{Woodman_2003,
	doi = {10.1016/s0021-9150(02)00307-6},
	url = {http://dx.doi.org/10.1016/s0021-9150(02)00307-6},
	year = 2003,
	month = {jan},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {166},
	number = {1},
	pages = {85--93},
	author = {Richard J Woodman and Trevor A Mori and Valerie Burke and Ian B Puddey and Anne Barden and Gerald F Watts and Lawrence J Beilin},
	title = {Effects of purified eicosapentaenoic acid and docosahexaenoic acid on platelet, fibrinolytic and vascular function in hypertensive type 2 diabetic patients},
	journal = {Atherosclerosis}
}
@article{Pedersen_2003,
	doi = {10.1038/sj.ejcn.1601602},
	url = {http://dx.doi.org/10.1038/sj.ejcn.1601602},
	year = 2003,
	month = {may},
	publisher = {Nature Publishing Group},
	volume = {57},
	number = {5},
	pages = {713--720},
	author = {H Pedersen and M Petersen and A Major-Pedersen and T Jensen and N S Nielsen and S T Lauridsen and P Marckmann},
	title = {Influence of fish oil supplementation on in vivo and in vitro oxidation resistance of low-density lipoprotein in type 2 diabetes},
	journal = {Eur J Clin Nutr}
}
@article{Petersen_2002,
	doi = {10.2337/diacare.25.10.1704},
	url = {http://dx.doi.org/10.2337/diacare.25.10.1704},
	year = 2002,
	month = {oct},
	publisher = {American Diabetes Association},
	volume = {25},
	number = {10},
	pages = {1704--1708},
	author = {M. Petersen and H. Pedersen and A. Major-Pedersen and T. Jensen and P. Marckmann},
	title = {Effect of Fish Oil Versus Corn Oil Supplementation on $\\lbrace$LDL$\\rbrace$ and $\\lbrace$HDL$\\rbrace$ Subclasses in Type 2 Diabetic Patients},
	journal = {Diabetes Care}
}
@article{Dunstan_1997,
	doi = {10.2337/diacare.20.6.913},
	url = {http://dx.doi.org/10.2337/diacare.20.6.913},
	year = 1997,
	month = {jun},
	publisher = {American Diabetes Association},
	volume = {20},
	number = {6},
	pages = {913--921},
	author = {D. W. Dunstan and T. A. Mori and I. B. Puddey and L. J. Beilin and V. Burke and A. R. Morton and K. G. Stanton},
	title = {The independent and combined effects of aerobic exercise and dietary fish intake on serum lipids and glycemic control in $\\lbrace$NIDDM$\\rbrace$. A randomized controlled study},
	journal = {Diabetes Care}
}
@article{Hartweg_2006,
	doi = {10.1007/s00125-006-0486-y},
	url = {http://dx.doi.org/10.1007/s00125-006-0486-y},
	year = 2006,
	month = {nov},
	publisher = {Springer Science $\\mathplus$ Business Media},
	volume = {50},
	number = {2},
	pages = {250--258},
	author = {J. Hartweg and A. J. Farmer and R. R. Holman and H. A. W. Neil},
	title = {Meta-analysis of the effects of n-3 polyunsaturated fatty acids on haematological and thrombogenic factors in type 2 diabetes},
	journal = {Diabetologia}
}
@article{Khajehdehi_2002,
	doi = {10.1080/003655902753679454},
	url = {http://dx.doi.org/10.1080/003655902753679454},
	year = 2002,
	month = {apr},
	publisher = {Informa $\\lbrace$UK$\\rbrace$ Limited},
	volume = {36},
	number = {2},
	pages = {145--148},
	author = {P. Khajehdehi and J. Roozbeh and H. Mostafavi},
	title = {A Comparative Randomized and Placebo-controlled Short-term Trial of Aspirin and Dipyridamole for Overt Type-2 Diabetic Nephropathy},
	journal = {Scandinavian Journal of Urology and Nephrology}
}
@article{Sacco_2003,
	doi = {10.2337/diacare.26.12.3264},
	url = {http://dx.doi.org/10.2337/diacare.26.12.3264},
	year = 2003,
	month = {dec},
	publisher = {American Diabetes Association},
	volume = {26},
	number = {12},
	pages = {3264--3272},
	author = {M. Sacco and F. Pellegrini and M. C. Roncaglioni and F. Avanzini and G. Tognoni and A. Nicolucci},
	title = {Primary Prevention of Cardiovascular Events With Low-Dose Aspirin and Vitamin E in Type 2 Diabetic Patients: Results of the Primary Prevention Project ($\\lbrace$PPP$\\rbrace$) trial},
	journal = {Diabetes Care}
}
@article{2001,
	doi = {10.1056/nejmoa010746},
	url = {http://dx.doi.org/10.1056/nejmoa010746},
	year = 2001,
	month = {aug},
	publisher = {New England Journal of Medicine ($\\lbrace$NEJM$\\rbrace$/$\\lbrace$MMS$\\rbrace$)},
	volume = {345},
	number = {7},
	pages = {494--502},
	title = {Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without $\\lbrace$ST$\\rbrace$-Segment Elevation},
	journal = {New England Journal of Medicine}
}
@article{Bhatt_2002,
	doi = {10.1016/s0002-9149(02)02567-5},
	url = {http://dx.doi.org/10.1016/s0002-9149(02)02567-5},
	year = 2002,
	month = {sep},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {90},
	number = {6},
	pages = {625--628},
	author = {Deepak L Bhatt and Steven P Marso and Alan T Hirsch and Peter A Ringleb and Werner Hacke and Eric J Topol},
	title = {Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus},
	journal = {The American Journal of Cardiology}
}
@article{Bhatt_2006,
	doi = {10.1056/nejmoa060989},
	url = {http://dx.doi.org/10.1056/nejmoa060989},
	year = 2006,
	month = {apr},
	publisher = {New England Journal of Medicine ($\\lbrace$NEJM$\\rbrace$/$\\lbrace$MMS$\\rbrace$)},
	volume = {354},
	number = {16},
	pages = {1706--1717},
	author = {Deepak L. Bhatt and Keith A.A. Fox and Werner Hacke and Peter B. Berger and Henry R. Black and William E. Boden and Patrice Cacoub and Eric A. Cohen and Mark A. Creager and J. Donald Easton and Marcus D. Flather and Steven M. Haffner and Christian W. Hamm and Graeme J. Hankey and S. Claiborne Johnston and Koon-Hou Mak and Jean-Louis Mas and Gilles Montalescot and Thomas A. Pearson and P. Gabriel Steg and Steven R. Steinhubl and Michael A. Weber and Danielle M. Brennan and Liz Fabry-Ribaudo and Joan Booth and Eric J. Topol},
	title = {Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events},
	journal = {New England Journal of Medicine}
}
@article{Steinhubl_2002,
	doi = {10.1001/jama.288.19.2411},
	url = {http://dx.doi.org/10.1001/jama.288.19.2411},
	year = 2002,
	month = {nov},
	publisher = {American Medical Association ($\\lbrace$AMA$\\rbrace$)},
	volume = {288},
	number = {19},
	pages = {2411},
	author = {Steven R. Steinhubl and Peter B. Berger and J. Tift Mann III and Edward T. A. Fry and Augustin DeLago and Charles Wilmer and Eric J. Topol and  for the CREDO Investigators},
	title = {Early and Sustained Dual Oral Antiplatelet Therapy Following Percutaneous Coronary Intervention},
	journal = {$\\lbrace$JAMA$\\rbrace$}
}
@article{Diener_2004,
	doi = {10.1016/s0140-6736(04)16721-4},
	url = {http://dx.doi.org/10.1016/s0140-6736(04)16721-4},
	year = 2004,
	month = {jul},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {364},
	number = {9431},
	pages = {331--337},
	author = {Hans-Christoph Diener and Julien Bogousslavsky and Lawrence M Brass and Claudio Cimminiello and Laszlo Csiba and Markku Kaste and Didier Leys and Jordi Matias-Guiu and Hans-Jrgen Rupprecht},
	title = {Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients ($\\lbrace$MATCH$\\rbrace$): randomised, double-blind, placebo-controlled trial},
	journal = {The Lancet}
}
@article{Rigalleau_2006,
	doi = {10.1016/s1262-3636(07)70247-1},
	url = {http://dx.doi.org/10.1016/s1262-3636(07)70247-1},
	year = 2006,
	month = {feb},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {32},
	number = {1},
	pages = {56--62},
	author = {V Rigalleau and C Lasseur and C Perlemoine and N Barthe and C Raffaitin and R de la Faille and C Combe and H Gin},
	title = {A simplified Cockcroft-Gault formula to improve the prediction of the glomerular filtration rate in diabetic patients},
	journal = {Diabetes {\\&} Metabolism}
}
@article{Garc_a_lvarez_de_Sierra_2007,
	doi = {10.1016/s0214-9168(07)74206-7},
	url = {http://dx.doi.org/10.1016/s0214-9168(07)74206-7},
	year = 2007,
	month = {oct},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {19},
	number = {5},
	pages = {247--251},
	author = {Beatriz Garc{\\'{\\i}}a {\\'{A}}lvarez de Sierra and Jes{\\'{u}}s Millan Nu{\\~{n}}ez-Cort{\\'{e}}s},
	title = {Tratamiento de la dislipemia en la diabetes mellitus tipo 2},
	journal = {Cl{\\'{\\i}}nica e Investigaci{\\'{o}}n en Arteriosclerosis}
}
@article{Parikh_2004,
	doi = {10.1093/ndt/gfh300},
	url = {http://dx.doi.org/10.1093/ndt/gfh300},
	year = 2004,
	month = {may},
	publisher = {Oxford University Press ($\\lbrace$OUP$\\rbrace$)},
	volume = {19},
	number = {7},
	pages = {1881--1885},
	author = {C. R. Parikh and M. J. Fischer and R. Estacio and R. W. Schrier},
	title = {Rapid microalbuminuria screening in type 2 diabetes mellitus: simplified approach with Micral test strips and specific gravity},
	journal = {Nephrology Dialysis Transplantation}
}
@article{Saha_2014,
	doi = {10.4103/2320-8775.126509},
	url = {http://dx.doi.org/10.4103/2320-8775.126509},
	year = 2014,
	publisher = {Medknow},
	volume = {2},
	number = {1},
	pages = {33},
	author = {Arnab Saha and Kaushik Saha and Sanatan Banerjee and Santanu Ghosh and Salim Mallick},
	title = {A case of lung adenocarcinoma with idiopathic pulmonary fibrosis},
	journal = {The Journal of Association of Chest Physicians}
}
@article{Baskar_2006,
	doi = {10.1111/j.1464-5491.2006.01954.x},
	url = {http://dx.doi.org/10.1111/j.1464-5491.2006.01954.x},
	year = 2006,
	month = {oct},
	publisher = {Wiley-Blackwell},
	volume = {23},
	number = {10},
	pages = {1057--1060},
	author = {V. Baskar and H. Venugopal and M. R. Holland and B. M. Singh},
	title = {Clinical utility of estimated glomerular filtration rates in predicting renal risk in a district diabetes population},
	journal = {Diabetic Medicine}
}
@article{Middleton_2005,
	doi = {10.1093/ndt/gfi163},
	url = {http://dx.doi.org/10.1093/ndt/gfi163},
	year = 2005,
	month = {oct},
	publisher = {Oxford University Press ($\\lbrace$OUP$\\rbrace$)},
	volume = {21},
	number = {1},
	pages = {88--92},
	author = {R. J. Middleton and R. N. Foley and J. Hegarty and C. M. Cheung and P. McElduff and J. M. Gibson and P. A. Kalra and D. J. O{\\textquotesingle}Donoghue and J. P. New},
	title = {The unrecognized prevalence of chronic kidney disease in diabetes},
	journal = {Nephrology Dialysis Transplantation}
}
@article{MacIsaac_2004,
	doi = {10.2337/diacare.27.1.195},
	url = {http://dx.doi.org/10.2337/diacare.27.1.195},
	year = 2004,
	month = {jan},
	publisher = {American Diabetes Association},
	volume = {27},
	number = {1},
	pages = {195--200},
	author = {R. J. MacIsaac and C. Tsalamandris and S. Panagiotopoulos and T. J. Smith and K. J. McNeil and G. Jerums},
	title = {Nonalbuminuric Renal Insufficiency in Type 2 Diabetes},
	journal = {Diabetes Care}
}
@article{Janssens_1990,
	doi = {10.1056/nejm199004123221502},
	url = {http://dx.doi.org/10.1056/nejm199004123221502},
	year = 1990,
	month = {apr},
	publisher = {New England Journal of Medicine ($\\lbrace$NEJM$\\rbrace$/$\\lbrace$MMS$\\rbrace$)},
	volume = {322},
	number = {15},
	pages = {1028--1031},
	author = {J. Janssens and T.L. Peeters and G. Vantrappen and J. Tack and J.L. Urbain and M. De Roo and E. Muls and R. Bouillon},
	title = {Improvement of Gastric Emptying in Diabetic Gastroparesis by Erythromycin},
	journal = {New England Journal of Medicine}
}
@article{McCallum_1983,
	doi = {10.2337/diacare.6.5.463},
	url = {http://dx.doi.org/10.2337/diacare.6.5.463},
	year = 1983,
	month = {sep},
	publisher = {American Diabetes Association},
	volume = {6},
	number = {5},
	pages = {463--467},
	author = {R. W. McCallum and D. A. Ricci and H. Rakatansky and J. Behar and J. B. Rhodes and G. Salen and J. Deren and A. Ippoliti and H. W. Olsen and K. Falchuk and al. et},
	title = {A multicenter placebo-controlled clinical trial of oral metoclopramide in diabetic gastroparesis},
	journal = {Diabetes Care}
}
@article{Ricci_1985,
	doi = {10.1097/00004836-198502000-00003},
	url = {http://dx.doi.org/10.1097/00004836-198502000-00003},
	year = 1985,
	month = {feb},
	publisher = {Ovid Technologies (Wolters Kluwer Health)},
	volume = {7},
	number = {1},
	pages = {25--32},
	author = {Dominick A. Ricci and Melvin B. Saltzman and Christopher Meyer and Cynthia Callachan and Richard W. McCallum},
	title = {Effect of Metoclopramide in Diabetic Gastroparesis},
	journal = {Journal of Clinical Gastroenterology}
}
@article{Farup_1998,
	doi = {10.2337/diacare.21.10.1699},
	url = {http://dx.doi.org/10.2337/diacare.21.10.1699},
	year = 1998,
	month = {oct},
	publisher = {American Diabetes Association},
	volume = {21},
	number = {10},
	pages = {1699--1706},
	author = {C. E. Farup and N. K. Leidy and M. Murray and G. R. Williams and L. Helbers and E. M. Quigley},
	title = {Effect of domperidone on the health-related quality of life of patients with symptoms of diabetic gastroparesis},
	journal = {Diabetes Care}
}
@article{Erbas_1993,
	doi = {10.2337/diacare.16.11.1511},
	url = {http://dx.doi.org/10.2337/diacare.16.11.1511},
	year = 1993,
	month = {nov},
	publisher = {American Diabetes Association},
	volume = {16},
	number = {11},
	pages = {1511--1514},
	author = {T. Erbas and E. Varoglu and B. Erbas and G. Tastekin and S. Akalin},
	title = {Comparison of metoclopramide and erythromycin in the treatment of diabetic gastroparesis},
	journal = {Diabetes Care}
}
@article{Hasamnis_2012,
	doi = {10.4103/2249-4855.104018},
	url = {http://dx.doi.org/10.4103/2249-4855.104018},
	year = 2012,
	publisher = {Medknow},
	volume = {2},
	number = {1},
	pages = {47},
	author = {AmeyaA Hasamnis},
	title = {Dapagliflozin: A new drug for treatment of type 2 diabetes mellitus},
	journal = {J Acad Med Sci}
}
@article{Review_Editor_2007,
	doi = {10.3833/pdr.v2007i80.388},
	url = {http://dx.doi.org/10.3833/pdr.v2007i80.388},
	year = 2007,
	month = {feb},
	publisher = {$\\lbrace$PharmaVentures$\\rbrace$},
	volume = {2007},
	number = {80},
	author = {Business Review Editor},
	title = {When Giants Meet: Bristol-Myers Squibb and $\\lbrace$AstraZeneca$\\rbrace$ Form Alliance for Diabetes Drug},
	journal = {$\\lbrace$PharmaDeals$\\rbrace$ Review}
}
@article{Al_Mrayat_2013,
	doi = {10.1002/pdi.1779},
	url = {http://dx.doi.org/10.1002/pdi.1779},
	year = 2013,
	month = {jul},
	publisher = {Wiley-Blackwell},
	volume = {30},
	number = {6},
	pages = {218--220},
	author = {Ma{\\textquotesingle}en Al-Mrayat and Monica Vloemans},
	title = {Dapagliflozin: $\\lbrace$NICE$\\rbrace$ guidance for use in combination therapy for the treatment of type 2 diabetes},
	journal = {Practical Diabetes}
}
@article{Hermansen_2007,
	doi = {10.1111/j.1463-1326.2007.00744.x},
	url = {http://dx.doi.org/10.1111/j.1463-1326.2007.00744.x},
	year = 2007,
	month = {sep},
	publisher = {Wiley-Blackwell},
	volume = {9},
	number = {5},
	pages = {733--745},
	author = {K. Hermansen and M. Kipnes and E. Luo and D. Fanurik and H. Khatami and P. Stein},
	title = {Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin},
	journal = {Diabetes Obes Metab}
}
@article{Nauck_2007,
	doi = {10.1111/j.1463-1326.2006.00704.x},
	url = {http://dx.doi.org/10.1111/j.1463-1326.2006.00704.x},
	year = 2007,
	month = {mar},
	publisher = {Wiley-Blackwell},
	volume = {9},
	number = {2},
	pages = {194--205},
	author = {M. A. Nauck and G. Meininger and D. Sheng and L. Terranella and P. P. Stein},
	title = {Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial},
	journal = {Diabetes Obes Metab}
}
@article{Bolli_2007,
	doi = {10.1111/j.1463-1326.2007.00820.x},
	url = {http://dx.doi.org/10.1111/j.1463-1326.2007.00820.x},
	year = 2007,
	month = {nov},
	publisher = {Wiley-Blackwell},
	volume = {0},
	number = {0},
	pages = {071127144208007--???},
	author = {G. Bolli and F. Dotta and E. Rochotte and S. E. Cohen},
	title = {Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study},
	journal = {Diabetes Obes Metab}
}
@article{Scott_2008,
	doi = {10.1111/j.1463-1326.2007.00839.x},
	url = {http://dx.doi.org/10.1111/j.1463-1326.2007.00839.x},
	year = 2008,
	month = {oct},
	publisher = {Wiley-Blackwell},
	volume = {10},
	number = {10},
	pages = {959--969},
	author = {R. Scott and T. Loeys and M. J. Davies and S. S. Engel},
	title = {Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes{\\ast}},
	journal = {Diabetes, Obesity and Metabolism}
}
@article{Asnani_2006,
	doi = {10.1089/met.2006.4.179},
	url = {http://dx.doi.org/10.1089/met.2006.4.179},
	year = 2006,
	month = {sep},
	publisher = {Mary Ann Liebert Inc},
	volume = {4},
	number = {3},
	pages = {179--184},
	author = {Sunil Asnani and Biju Kunhiraman and Ali Jawa and Donald Akers and David Lumpkin and Vivian Fonseca},
	title = {Pioglitazone Restores Endothelial Function in Patients with Type 2 Diabetes Treated with Insulin},
	journal = {Metabolic Syndrome and Related Disorders}
}
@article{Berhanu_2007,
	doi = {10.1111/j.1463-1326.2006.00633.x},
	url = {http://dx.doi.org/10.1111/j.1463-1326.2006.00633.x},
	year = 2007,
	month = {jul},
	publisher = {Wiley-Blackwell},
	volume = {9},
	number = {4},
	pages = {512--520},
	author = {P. Berhanu and A. Perez and S. Yu},
	title = {Effect of pioglitazone in combination with insulin therapy on glycaemic control, insulin dose requirement and lipid profile in patients with type 2 diabetes previously poorly controlled with combination therapy},
	journal = {Diabetes Obes Metab}
}
@article{Fernandez_2007,
	doi = {10.2337/dc07-0711},
	url = {http://dx.doi.org/10.2337/dc07-0711},
	year = 2007,
	month = {oct},
	publisher = {American Diabetes Association},
	volume = {31},
	number = {1},
	pages = {121--127},
	author = {M. Fernandez and C. Triplitt and E. Wajcberg and A. A. Sriwijilkamol and N. Musi and K. Cusi and R. DeFronzo and E. Cersosimo},
	title = {Addition of Pioglitazone and Ramipril to Intensive Insulin Therapy in Type 2 Diabetic Patients Improves Vascular Dysfunction by Different Mechanisms},
	journal = {Diabetes Care}
}
@article{MATTOO_2005,
	doi = {10.1016/j.clinthera.2005.05.005},
	url = {http://dx.doi.org/10.1016/j.clinthera.2005.05.005},
	year = 2005,
	month = {may},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {27},
	number = {5},
	pages = {554--567},
	author = {V MATTOO and D ECKLAND and M WIDEL and S DURAN and C FAJARDO and J STRAND and D KNIGHT and L GROSSMAN and D OAKLEY and M TAN},
	title = {Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: Results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study},
	journal = {Clinical Therapeutics}
}
@article{Raz_2005,
	doi = {10.1016/j.clinthera.2005.09.001},
	url = {http://dx.doi.org/10.1016/j.clinthera.2005.09.001},
	year = 2005,
	month = {sep},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {27},
	number = {9},
	pages = {1432--1443},
	author = {Itamar Raz and Stephen Stranks and Robert Filipczak and Pankaj Joshi and Benedikte Lertoft and Jacob Rastam and Chun-Chung Chow and Joseph Shaban},
	title = {Efficacy and safety of biphasic insulin aspart 30 combined with pioglitazone in type 2 diabetes poorly controlled on glibenclamide (glyburide) monotherapy or combination therapy: An 18-week, randomized, open-label study},
	journal = {Clinical Therapeutics}
}
@article{Rosenstock_2006,
	doi = {10.1016/j.clinthera.2006.10.007},
	url = {http://dx.doi.org/10.1016/j.clinthera.2006.10.007},
	year = 2006,
	month = {oct},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {28},
	number = {10},
	pages = {1556--1568},
	author = {Julio Rosenstock and Ronald Brazg and Paula J. Andryuk and Kaifeng Lu and Peter Stein},
	title = {Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study},
	journal = {Clinical Therapeutics}
}
@article{IGAKI_2005,
	doi = {10.2169/internalmedicine.44.832},
	url = {http://dx.doi.org/10.2169/internalmedicine.44.832},
	year = 2005,
	publisher = {Japanese Society of Internal Medicine},
	volume = {44},
	number = {8},
	pages = {832--837},
	author = {Naoya IGAKI and Maki TANAKA and Takeo GOTO},
	title = {Markedly Improved Glycemic Control and Enhanced Insulin Sensitivity in a Patient with Type 2 Diabetes Complicated by a Suprasellar Tumor Treated with Pioglitazone and Metformin},
	journal = {Intern. Med.}
}
@article{Shah_2011,
	doi = {10.1111/j.1463-1326.2011.01370.x},
	url = {http://dx.doi.org/10.1111/j.1463-1326.2011.01370.x},
	year = 2011,
	month = {jun},
	publisher = {Wiley-Blackwell},
	volume = {13},
	number = {6},
	pages = {505--510},
	author = {P. K. Shah and S. Mudaliar and A. R. Chang and V. Aroda and M. Andre and P. Burke and R. R. Henry},
	title = {Effects of intensive insulin therapy alone and in combination with pioglitazone on body weight, composition, distribution and liver fat content in patients with type 2 diabetes},
	journal = {Diabetes, Obesity and Metabolism}
}
@article{Diamond_2007,
	doi = {10.7326/0003-4819-147-8-200710160-00182},
	url = {http://dx.doi.org/10.7326/0003-4819-147-8-200710160-00182},
	year = 2007,
	month = {oct},
	publisher = {American College of Physicians},
	volume = {147},
	number = {8},
	pages = {578},
	author = {George A. Diamond},
	title = {Uncertain Effects of Rosiglitazone on the Risk for Myocardial Infarction and Cardiovascular Death},
	journal = {Annals of Internal Medicine}
}
@article{Lago_2007,
	doi = {10.1016/s0140-6736(07)61514-1},
	url = {http://dx.doi.org/10.1016/s0140-6736(07)61514-1},
	year = 2007,
	month = {sep},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {370},
	number = {9593},
	pages = {1129--1136},
	author = {Rodrigo M Lago and Premranjan P Singh and Richard W Nesto},
	title = {Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials},
	journal = {The Lancet}
}
@article{Nissen_2007,
	doi = {10.1056/nejmoa072761},
	url = {http://dx.doi.org/10.1056/nejmoa072761},
	year = 2007,
	month = {jun},
	publisher = {New England Journal of Medicine ($\\lbrace$NEJM$\\rbrace$/$\\lbrace$MMS$\\rbrace$)},
	volume = {356},
	number = {24},
	pages = {2457--2471},
	author = {Steven E. Nissen and Kathy Wolski},
	title = {Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes},
	journal = {New England Journal of Medicine}
}
@article{Psaty_2007,
	doi = {10.1056/nejme078116},
	url = {http://dx.doi.org/10.1056/nejme078116},
	year = 2007,
	month = {jul},
	publisher = {New England Journal of Medicine ($\\lbrace$NEJM$\\rbrace$/$\\lbrace$MMS$\\rbrace$)},
	volume = {357},
	number = {1},
	pages = {67--69},
	author = {Bruce M. Psaty and Curt D. Furberg},
	title = {The Record on Rosiglitazone and the Risk of Myocardial Infarction},
	journal = {New England Journal of Medicine}
}
@article{Singh_2007,
	doi = {10.1001/jama.298.10.1189},
	url = {http://dx.doi.org/10.1001/jama.298.10.1189},
	year = 2007,
	month = {sep},
	publisher = {American Medical Association ($\\lbrace$AMA$\\rbrace$)},
	volume = {298},
	number = {10},
	pages = {1189},
	author = {Sonal Singh and Yoon K. Loke and Curt D. Furberg},
	title = {Long-term Risk of Cardiovascular Events With Rosiglitazone},
	journal = {$\\lbrace$JAMA$\\rbrace$}
}
@article{Doggrell_2006,
	doi = {10.1517/14656566.7.1.109},
	url = {http://dx.doi.org/10.1517/14656566.7.1.109},
	year = 2006,
	month = {jan},
	publisher = {Informa Healthcare},
	volume = {7},
	number = {1},
	pages = {109--112},
	author = {Sheila A Doggrell},
	title = {Is exenatide advancing the treatment of Type 2 diabetes?},
	journal = {Expert Opinion on Pharmacotherapy}
}
@article{Zinman_2007,
	doi = {10.7326/0003-4819-146-7-200704030-00003},
	url = {http://dx.doi.org/10.7326/0003-4819-146-7-200704030-00003},
	year = 2007,
	month = {apr},
	publisher = {American College of Physicians},
	volume = {146},
	number = {7},
	pages = {477},
	author = {Bernard Zinman},
	title = {The Effect of Adding Exenatide to a Thiazolidinedione in Suboptimally Controlled Type 2 Diabetes},
	journal = {Annals of Internal Medicine}
}
@article{Doggrell_2006,
	doi = {10.1517/14656566.7.1.109},
	url = {http://dx.doi.org/10.1517/14656566.7.1.109},
	year = 2006,
	month = {jan},
	publisher = {Informa Healthcare},
	volume = {7},
	number = {1},
	pages = {109--112},
	author = {Sheila A Doggrell},
	title = {Is exenatide advancing the treatment of Type 2 diabetes?},
	journal = {Expert Opinion on Pharmacotherapy}
}
@article{Heine_2005,
	doi = {10.7326/0003-4819-143-8-200510180-00006},
	url = {http://dx.doi.org/10.7326/0003-4819-143-8-200510180-00006},
	year = 2005,
	month = {oct},
	publisher = {American College of Physicians},
	volume = {143},
	number = {8},
	pages = {559},
	author = {Robert J. Heine},
	title = {Exenatide versus Insulin Glargine in Patients with Suboptimally Controlled Type 2 Diabetes},
	journal = {Annals of Internal Medicine}
}
@article{Home_2007,
	doi = {10.1007/s00125-007-0653-9},
	url = {http://dx.doi.org/10.1007/s00125-007-0653-9},
	year = 2007,
	month = {mar},
	publisher = {Springer Science $\\mathplus$ Business Media},
	volume = {50},
	number = {7},
	pages = {1561--1562},
	author = {P. D. Home},
	title = {Comment on: Nauck $\\lbrace$MA$\\rbrace$, Duran S, Kim D et al (2007) A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 50:259{\\textendash}267},
	journal = {Diabetologia}
}
@article{Secnik_2005,
	doi = {10.1016/s1098-3015(10)67625-5},
	url = {http://dx.doi.org/10.1016/s1098-3015(10)67625-5},
	year = 2005,
	month = {nov},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {8},
	number = {6},
	pages = {A155--A156},
	author = {K Secnik and C Hayes and L Matza and S Kim and A Oglesby and N Yurgin and R Brodows and K Malley},
	title = {$\\lbrace$PDB$\\rbrace$5 $\\lbrace$IMPROVED$\\rbrace$ $\\lbrace$TREATMENT$\\rbrace$ $\\lbrace$SATISFACTION$\\rbrace$ $\\lbrace$IN$\\rbrace$ $\\lbrace$PATIENTS$\\rbrace$ $\\lbrace$WITH$\\rbrace$ $\\lbrace$TYPE$\\rbrace$-2 $\\lbrace$DIABETES$\\rbrace$ $\\lbrace$TREATED$\\rbrace$ $\\lbrace$WITH$\\rbrace$ $\\lbrace$EXENATIDE$\\rbrace$ $\\lbrace$OR$\\rbrace$ $\\lbrace$INSULIN$\\rbrace$ $\\lbrace$GLARGINE$\\rbrace$},
	journal = {Value in Health}
}
@article{Davis_2007,
	doi = {10.2337/dc06-2532},
	url = {http://dx.doi.org/10.2337/dc06-2532},
	year = 2007,
	month = {aug},
	publisher = {American Diabetes Association},
	volume = {30},
	number = {11},
	pages = {2767--2772},
	author = {S. N. Davis and D. Johns and D. Maggs and H. Xu and J. H. Northrup and R. G. Brodows},
	title = {Exploring the Substitution of Exenatide for Insulin in Patients With Type 2 Diabetes Treated With Insulin in Combination With Oral Antidiabetes Agents},
	journal = {Diabetes Care}
}
@article{Secnik_2005,
	doi = {10.1016/s1098-3015(10)67625-5},
	url = {http://dx.doi.org/10.1016/s1098-3015(10)67625-5},
	year = 2005,
	month = {nov},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {8},
	number = {6},
	pages = {A155--A156},
	author = {K Secnik and C Hayes and L Matza and S Kim and A Oglesby and N Yurgin and R Brodows and K Malley},
	title = {$\\lbrace$PDB$\\rbrace$5 $\\lbrace$IMPROVED$\\rbrace$ $\\lbrace$TREATMENT$\\rbrace$ $\\lbrace$SATISFACTION$\\rbrace$ $\\lbrace$IN$\\rbrace$ $\\lbrace$PATIENTS$\\rbrace$ $\\lbrace$WITH$\\rbrace$ $\\lbrace$TYPE$\\rbrace$-2 $\\lbrace$DIABETES$\\rbrace$ $\\lbrace$TREATED$\\rbrace$ $\\lbrace$WITH$\\rbrace$ $\\lbrace$EXENATIDE$\\rbrace$ $\\lbrace$OR$\\rbrace$ $\\lbrace$INSULIN$\\rbrace$ $\\lbrace$GLARGINE$\\rbrace$},
	journal = {Value in Health}
}
@article{Leahy_2006,
	doi = {10.1016/s0084-3741(08)70288-9},
	url = {http://dx.doi.org/10.1016/s0084-3741(08)70288-9},
	year = 2006,
	month = {jan},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {2006},
	pages = {65--67},
	author = {J.L. Leahy},
	title = {Systematic Review and Meta-analysis of Short-Acting Insulin Analogues in Patients With Diabetes Mellitus},
	journal = {Yearbook of Endocrinology}
}
@article{Wang_2003,
	doi = {10.1016/s0149-2918(03)80156-x},
	url = {http://dx.doi.org/10.1016/s0149-2918(03)80156-x},
	year = 2003,
	month = {jun},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {25},
	number = {6},
	pages = {1541--1577},
	author = {Fei Wang and Jana M. Carabino and Cunegundo M. Vergara},
	title = {Insulin glargine: A systematic review of a long-acting insulin analogue},
	journal = {Clinical Therapeutics}
}
@article{Monta_ana_2008,
	doi = {10.1111/j.1464-5491.2008.02483.x},
	url = {http://dx.doi.org/10.1111/j.1464-5491.2008.02483.x},
	year = 2008,
	month = {aug},
	publisher = {Wiley-Blackwell},
	volume = {25},
	number = {8},
	pages = {916--923},
	author = {C. Fajardo Monta{\\~{n}}ana and C. Hern{\\'{a}}ndez Herrero and M. Rivas Fern{\\'{a}}ndez},
	title = { Less weight gain and hypoglycaemia with once-daily insulin detemir than $\\lbrace$NPH$\\rbrace$ insulin in intensification of insulin therapy in overweight Type~2 diabetes patients-The $\\lbrace$PREDICTIVE$\\rbrace${\\texttrademark} $\\lbrace$BMI$\\rbrace$ clinical trial 1 },
	journal = {Diabetic Medicine}
}
@article{Pan_2007,
	doi = {10.1016/j.diabres.2006.08.012},
	url = {http://dx.doi.org/10.1016/j.diabres.2006.08.012},
	year = 2007,
	month = {apr},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {76},
	number = {1},
	pages = {111--118},
	author = {Chang-Yu Pan and Patrick Sinnassamy and Kab-Do Chung and Kwang-Won Kim},
	title = {Insulin glargine versus $\\lbrace$NPH$\\rbrace$ insulin therapy in Asian Type 2 diabetes patients},
	journal = {Diabetes Research and Clinical Practice}
}
@article{Philis_Tsimikas_2006,
	doi = {10.1016/j.clinthera.2006.10.020},
	url = {http://dx.doi.org/10.1016/j.clinthera.2006.10.020},
	year = 2006,
	month = {oct},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {28},
	number = {10},
	pages = {1569--1581},
	author = {Athena Philis-Tsimikas and Guillaume Charpentier and Per Clauson and Gabriela Martinez Ravn and Victor Lawrence Roberts and Birger Thorsteinsson},
	title = {Comparison of once-daily insulin detemir with $\\lbrace$NPH$\\rbrace$ insulin added to a regimen of oral antidiabetic drugs in poorly Controlled Type 2 Diabetes},
	journal = {Clinical Therapeutics}
}
@article{Rosenstock_2008,
	doi = {10.1007/s00125-007-0911-x},
	url = {http://dx.doi.org/10.1007/s00125-007-0911-x},
	year = 2008,
	month = {jan},
	publisher = {Springer Science $\\mathplus$ Business Media},
	volume = {51},
	number = {3},
	pages = {408--416},
	author = {J. Rosenstock and M. Davies and P. D. Home and J. Larsen and C. Koenen and G. Schernthaner},
	title = {A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes},
	journal = {Diabetologia}
}
@article{Agrawal_2009,
	doi = {10.1016/j.diabres.2008.12.018},
	url = {http://dx.doi.org/10.1016/j.diabres.2008.12.018},
	year = 2009,
	month = {mar},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {83},
	number = {3},
	pages = {371--378},
	author = {R.P. Agrawal and Jitender Goswami and Shreyans Jain and D.K. Kochar},
	title = {Management of diabetic neuropathy by sodium valproate and glyceryl trinitrate spray: A prospective double-blind randomized placebo-controlled study},
	journal = {Diabetes Research and Clinical Practice}
}
@article{Arbaiza_2007,
	doi = {10.2165/00044011-200727010-00007},
	url = {http://dx.doi.org/10.2165/00044011-200727010-00007},
	year = 2007,
	publisher = {Springer Science $\\mathplus$ Business Media},
	volume = {27},
	number = {1},
	pages = {75--83},
	author = {Daniel Arbaiza and Oscar Vidal},
	title = {Tramadol in the Treatment of Neuropathic Cancer Pain},
	journal = {Clinical Drug Investigation}
}
@article{Arezzo_2008,
	doi = {10.1186/1471-2377-8-33},
	url = {http://dx.doi.org/10.1186/1471-2377-8-33},
	year = 2008,
	publisher = {Springer Science $\\mathplus$ Business Media},
	volume = {8},
	number = {1},
	pages = {33},
	author = {Joseph C Arezzo and Julio Rosenstock and Linda LaMoreaux and Lynne Pauer},
	title = {Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: A double-blind placebo-controlled trial},
	journal = {$\\lbrace$BMC$\\rbrace$ Neurology}
}
@article{Backonja_1998,
	doi = {10.1001/jama.280.21.1831},
	url = {http://dx.doi.org/10.1001/jama.280.21.1831},
	year = 1998,
	month = {dec},
	publisher = {American Medical Association ($\\lbrace$AMA$\\rbrace$)},
	volume = {280},
	number = {21},
	pages = {1831},
	author = {Miroslav Backonja},
	title = {Gabapentin for the Symptomatic Treatment of Painful Neuropathy in Patients With Diabetes Mellitus$\\less$$\\lbrace$SUBTITLE$\\rbrace$$\\greater$A Randomized Controlled Trial$\\less$/$\\lbrace$SUBTITLE$\\rbrace$$\\greater$},
	journal = {$\\lbrace$JAMA$\\rbrace$}
}
@article{Backonja_2008,
	doi = {10.1016/s1474-4422(08)70228-x},
	url = {http://dx.doi.org/10.1016/s1474-4422(08)70228-x},
	year = 2008,
	month = {dec},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {7},
	number = {12},
	pages = {1106--1112},
	author = {Miroslav Backonja and Mark S Wallace and E Richard Blonsky and Barry J Cutler and Philip Malan and Richard Rauck and Jeffrey Tobias},
	title = {$\\lbrace$NGX$\\rbrace$-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study},
	journal = {The Lancet Neurology}
}
@article{Bansal_2009,
	doi = {10.1111/j.1464-5491.2009.02806.x},
	url = {http://dx.doi.org/10.1111/j.1464-5491.2009.02806.x},
	year = 2009,
	month = {oct},
	publisher = {Wiley-Blackwell},
	volume = {26},
	number = {10},
	pages = {1019--1026},
	author = {D. Bansal and A. Bhansali and D. Hota and A. Chakrabarti and P. Dutta},
	title = {Amitriptyline vs. pregabalin in painful diabetic neuropathy: a randomized double blind clinical trial},
	journal = {Diabetic Medicine}
}
@article{Beniczky_2005,
	doi = {10.1007/s00702-005-0300-x},
	url = {http://dx.doi.org/10.1007/s00702-005-0300-x},
	year = 2005,
	month = {jun},
	publisher = {Springer Science $\\mathplus$ Business Media},
	volume = {112},
	number = {6},
	pages = {735--749},
	author = {S. Beniczky and J. Tajti and E. T{\\'{\\i}}mea Varga and L. V{\\'{e}}csei},
	title = {Evidence-based pharmacological treatment of neuropathic pain syndromes},
	journal = {Journal of Neural Transmission}
}
@article{Bernstein_1989,
	doi = {10.1016/s0190-9622(89)70171-7},
	url = {http://dx.doi.org/10.1016/s0190-9622(89)70171-7},
	year = 1989,
	month = {aug},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {21},
	number = {2},
	pages = {265--270},
	author = {Joel E. Bernstein and Neil J. Korman and David R. Bickers and Mark V. Dahl and Lawrence E. Millikan},
	title = {Topical capsaicin treatment of chronic postherpetic neuralgia},
	journal = {Journal of the American Academy of Dermatology}
}
@article{Beydoun_2006,
	doi = {10.1111/j.1600-0404.2006.00631.x},
	url = {http://dx.doi.org/10.1111/j.1600-0404.2006.00631.x},
	year = 2006,
	month = {jun},
	publisher = {Wiley-Blackwell},
	volume = {113},
	number = {6},
	pages = {395--404},
	author = {A. Beydoun and A. Shaibani and M. Hopwood and Y. Wan},
	title = {Oxcarbazepine in painful diabetic neuropathy: results of a dose-ranging study},
	journal = {Acta Neurol Scand}
}
@article{1991,
	doi = {10.1001/archinte.151.11.2225},
	url = {http://dx.doi.org/10.1001/archinte.151.11.2225},
	year = 1991,
	month = {nov},
	publisher = {American Medical Association ($\\lbrace$AMA$\\rbrace$)},
	volume = {151},
	number = {11},
	pages = {2225--2229},
	title = {Treatment of painful diabetic neuropathy with topical capsaicin. A multicenter, double-blind, vehicle-controlled study. The Capsaicin Study Group},
	journal = {Archives of Internal Medicine}
}
@article{Bone_2002,
	doi = {10.1097/00115550-200209000-00007},
	url = {http://dx.doi.org/10.1097/00115550-200209000-00007},
	year = 2002,
	publisher = {Ovid Technologies (Wolters Kluwer Health)},
	volume = {27},
	number = {5},
	pages = {481--486},
	author = {Margaret Bone and Peter Critchley and Donal J. Buggy},
	title = {Gabapentin in Postamputation Phantom Limb Pain},
	journal = {Regional Anesthesia and Pain Medicine}
}
@article{Bouhassira_2008,
	doi = {10.1016/j.pain.2007.08.013},
	url = {http://dx.doi.org/10.1016/j.pain.2007.08.013},
	year = 2008,
	month = {jun},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {136},
	number = {3},
	pages = {380--387},
	author = {Didier Bouhassira and Michel Lant{\\'{e}}ri-Minet and Nadine Attal and Bernard Laurent and Chantal Touboul},
	title = {Prevalence of chronic pain with neuropathic characteristics in the general population},
	journal = {$\\lbrace$PAIN$\\rbrace$}
}
@article{Boureau_2003,
	doi = {10.1016/s0304-3959(03)00020-4},
	url = {http://dx.doi.org/10.1016/s0304-3959(03)00020-4},
	year = 2003,
	month = {jul},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {104},
	number = {1-2},
	pages = {323--331},
	author = {Francois Boureau and Pascale Legallicier and Marmar Kabir-Ahmadi},
	title = {Tramadol in post-herpetic neuralgia: a randomized, double-blind, placebo-controlled trial},
	journal = {Pain}
}
@article{Bowsher_1997,
	doi = {10.1016/s0885-3924(97)00077-8},
	url = {http://dx.doi.org/10.1016/s0885-3924(97)00077-8},
	year = 1997,
	month = {jun},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {13},
	number = {6},
	pages = {327--331},
	author = {David Bowsher},
	title = {The effects of pre-emptive treatment ofpostherpetic neuralgia with amitriptyline: A randomized, double-blind, placebo-controlled trial},
	journal = {Journal of Pain and Symptom Management}
}
@article{BREUER_2007,
	doi = {10.1016/j.clinthera.2007.09.023},
	url = {http://dx.doi.org/10.1016/j.clinthera.2007.09.023},
	year = 2007,
	month = {sep},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {29},
	number = {9},
	pages = {2022--2030},
	author = {B BREUER and M PAPPAGALLO and H KNOTKOVA and N GULEYUPOGLU and S WALLENSTEIN and R PORTENOY},
	title = {A randomized, double-blind, placebo-controlled, two-period, crossover, pilot trial of lamotrigine in patients with central pain due to multiple sclerosis},
	journal = {Clinical Therapeutics}
}
@article{Cardenas_2002,
	doi = {10.1016/s0304-3959(01)00483-3},
	url = {http://dx.doi.org/10.1016/s0304-3959(01)00483-3},
	year = 2002,
	month = {apr},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {96},
	number = {3},
	pages = {365--373},
	author = {Diana D Cardenas and Catherine A Warms and Judith A Turner and Helen Marshall and Marvin M Brooke and John D Loeser},
	title = {Efficacy of amitriptyline for relief of pain in spinal cord injury: results of a randomized controlled trial},
	journal = {Pain}
}
@article{Chandra_2006,
	doi = {10.5414/cpp44358},
	url = {http://dx.doi.org/10.5414/cpp44358},
	year = 2006,
	publisher = {Dustri-Verlgag Dr. Karl Feistle},
	volume = {44},
	number = {08},
	pages = {358--363},
	author = {K. Chandra and N. Shafiq and P. Pandhi and S. Gupta and S. Malhotra},
	title = {Gabapentin versus nortriptyline in post-herpetic neuralgia patients: a randomized, double-blind clinical trial  The $\\lbrace$GONIP$\\rbrace$ Trial},
	journal = {Int. Journal of Clinical Pharmacology and Therapeutics}
}
@article{Cheville_2009,
	doi = {10.1007/s00520-008-0542-x},
	url = {http://dx.doi.org/10.1007/s00520-008-0542-x},
	year = 2009,
	month = {jan},
	publisher = {Springer Science $\\mathplus$ Business Media},
	volume = {17},
	number = {4},
	pages = {451--460},
	author = {Andrea L. Cheville and Jeff A. Sloan and Donald W. Northfelt and Anand P. Jillella and Gilbert Y. Wong and James D. Bearden III and Heshan Liu and Paul L. Schaefer and Benjamin T. Marchello and Bradley J. Christensen and Charles L. Loprinzi},
	title = {Use of a lidocaine patch in the management of postsurgical neuropathic pain in patients with cancer: a phase $\\lbrace$III$\\rbrace$ double-blind crossover study (N01CB)},
	journal = {Supportive Care in Cancer}
}
@article{Clifford_2012,
	doi = {10.1097/qai.0b013e31823e31f7},
	url = {http://dx.doi.org/10.1097/qai.0b013e31823e31f7},
	year = 2012,
	publisher = {Ovid Technologies (Wolters Kluwer Health)},
	volume = {59},
	number = {2},
	pages = {126--133},
	author = {David B. Clifford and David M. Simpson and Stephen Brown and Graeme Moyle and Bruce J. Brew and Brian Conway and Jeffrey K. Tobias and Geertrui F. Vanhove},
	title = {A Randomized, Double-Blind, Controlled Study of $\\lbrace$NGX$\\rbrace$-4010, a Capsaicin 8{\\%} Dermal Patch, for the Treatment of Painful $\\lbrace$HIV$\\rbrace$-Associated Distal Sensory Polyneuropathy},
	journal = {$\\lbrace$JAIDS$\\rbrace$ Journal of Acquired Immune Deficiency Syndromes}
}
@article{Davidoff_1987,
	doi = {10.1016/0304-3959(87)91032-3},
	url = {http://dx.doi.org/10.1016/0304-3959(87)91032-3},
	year = 1987,
	month = {may},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {29},
	number = {2},
	pages = {151--161},
	author = {Gary Davidoff and Mary Guarracini and Elliot Roth and James Sliwa and Gary Yarkony},
	title = {Trazodone hydrochloride in the treatment of dysesthetic pain in traumatic myelopathy: a randomized, double-blind, placebo-controlled study},
	journal = {Pain}
}
@article{Dieleman_2008,
	doi = {10.1016/j.pain.2008.03.002},
	url = {http://dx.doi.org/10.1016/j.pain.2008.03.002},
	year = 2008,
	month = {jul},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {137},
	number = {3},
	pages = {681--688},
	author = {Jeanne P. Dieleman and Joost Kerklaan and Frank J.P.M. Huygen and Paul A.D. Bouma and Miriam C.J.M. Sturkenboom},
	title = {Incidence rates and treatment of neuropathic pain conditions in the general population},
	journal = {Pain}
}
@article{Dogra_2005,
	doi = {10.1016/j.ejpain.2004.11.006},
	url = {http://dx.doi.org/10.1016/j.ejpain.2004.11.006},
	year = 2005,
	month = {oct},
	publisher = {Wiley-Blackwell},
	volume = {9},
	number = {5},
	pages = {543--543},
	author = {Sunil Dogra and Said Beydoun and Jennifer Mazzola and Margaret Hopwood and Ying Wan},
	title = {Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo-controlled study},
	journal = {European Journal of Pain}
}
@article{1992,
	doi = {10.2337/diacare.15.2.159},
	url = {http://dx.doi.org/10.2337/diacare.15.2.159},
	year = 1992,
	month = {feb},
	publisher = {American Diabetes Association},
	volume = {15},
	number = {2},
	pages = {159--165},
	title = {Effect of treatment with capsaicin on daily activities of patients with painful diabetic neuropathy. Capsaicin Study Group},
	journal = {Diabetes Care}
}
@article{Dworkin_2005,
	doi = {10.1016/j.pain.2004.09.012},
	url = {http://dx.doi.org/10.1016/j.pain.2004.09.012},
	year = 2005,
	month = {jan},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {113},
	number = {1-2},
	pages = {9--19},
	author = {Robert H. Dworkin and Dennis C. Turk and John T. Farrar and Jennifer A. Haythornthwaite and Mark P. Jensen and Nathaniel P. Katz and Robert D. Kerns and Gerold Stucki and Robert R. Allen and Nicholas Bellamy and Daniel B. Carr and Julie Chandler and Penney Cowan and Raymond Dionne and Bradley S. Galer and Sharon Hertz and Alejandro R. Jadad and Lynn D. Kramer and Donald C. Manning and Susan Martin and Cynthia G. McCormick and Michael P. McDermott and Patrick McGrath and Steve Quessy and Bob A. Rappaport and Wendye Robbins and James P. Robinson and Margaret Rothman and Mike A. Royal and Lee Simon and Joseph W. Stauffer and Wendy Stein and Jane Tollett and Joachim Wernicke and James Witter},
	title = {Core outcome measures for chronic pain clinical trials: $\\lbrace$IMMPACT$\\rbrace$ recommendations},
	journal = {Pain}
}
@article{Dworkin_2003,
	doi = {10.1212/01.wnl.0000055433.55136.55},
	url = {http://dx.doi.org/10.1212/01.wnl.0000055433.55136.55},
	year = 2003,
	month = {apr},
	publisher = {Ovid Technologies (Wolters Kluwer Health)},
	volume = {60},
	number = {8},
	pages = {1274--1283},
	author = {R.H. Dworkin and A.E. Corbin and J.P. Young and U. Sharma and L. LaMoreaux and H. Bockbrader and E.A. Garofalo and R.M. Poole},
	title = {Pregabalin for the treatment of postherpetic neuralgia: A randomized, placebo-controlled trial},
	journal = {Neurology}
}
@article{Eisenberg_2001,
	doi = {10.1212/wnl.57.3.505},
	url = {http://dx.doi.org/10.1212/wnl.57.3.505},
	year = 2001,
	month = {aug},
	publisher = {Ovid Technologies (Wolters Kluwer Health)},
	volume = {57},
	number = {3},
	pages = {505--509},
	author = {E. Eisenberg and Y. Lurie and C. Braker and D. Daoud and A. Ishay},
	title = {Lamotrigine reduces painful diabetic neuropathy: A randomized, controlled study},
	journal = {Neurology}
}
@article{Falah_2011,
	doi = {10.1002/j.1532-2149.2011.00073.x},
	url = {http://dx.doi.org/10.1002/j.1532-2149.2011.00073.x},
	year = 2011,
	month = {dec},
	publisher = {Wiley-Blackwell},
	volume = {16},
	number = {6},
	pages = {860--869},
	author = {M. Falah and C. Madsen and J.V. Holbech and S.H. Sindrup},
	title = {A randomized, placebo-controlled trial of levetiracetam in central pain in multiple sclerosis},
	journal = {European Journal of Pain}
}
@article{Finnerup_2002,
	doi = {10.1016/s0304-3959(01)00484-5},
	url = {http://dx.doi.org/10.1016/s0304-3959(01)00484-5},
	year = 2002,
	month = {apr},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {96},
	number = {3},
	pages = {375--383},
	author = {Nanna B. Finnerup and S{\\o}ren H. Sindrup and Flemming W. Bach and Inger Lauge Johannesen and Troels S. Jensen},
	title = {Lamotrigine in spinal cord injury pain: a randomized controlled trial},
	journal = {Pain}
}
@article{Finnerup_2009,
	doi = {10.1038/sc.2009.55},
	url = {http://dx.doi.org/10.1038/sc.2009.55},
	year = 2009,
	month = {dec},
	publisher = {Nature Publishing Group},
	volume = {47},
	number = {12},
	pages = {861--867},
	author = {N B Finnerup and J Grydeh{\\o}j and J Bing and I L Johannesen and F Biering-S{\\o}rensen and S H Sindrup and T S Jensen},
	title = {Levetiracetam in spinal cord injury pain: a randomized controlled trial},
	journal = {Spinal Cord}
}
@article{Freynhagen_2005,
	doi = {10.1016/j.pain.2005.02.032},
	url = {http://dx.doi.org/10.1016/j.pain.2005.02.032},
	year = 2005,
	month = {jun},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {115},
	number = {3},
	pages = {254--263},
	author = {Rainer Freynhagen and Krzysztof Strojek and Teresa Griesing and Ed Whalen and Michael Balkenohl},
	title = {Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens},
	journal = {Pain}
}
@article{Zhao_2011,
	doi = {10.1185/03007995.2011.554807},
	url = {http://dx.doi.org/10.1185/03007995.2011.554807},
	year = 2011,
	month = {apr},
	publisher = {Informa Healthcare},
	volume = {27},
	number = {4},
	pages = {785--792},
	author = {Yang Zhao and Peter Sun and Peter Watson},
	title = {Medication adherence and healthcare costs among patients with diabetic peripheral neuropathic pain initiating duloxetine versus pregabalin},
	journal = {Curr Med Res Opin}
}
@article{Gilron_2009,
	doi = {10.1016/s0140-6736(09)61081-3},
	url = {http://dx.doi.org/10.1016/s0140-6736(09)61081-3},
	year = 2009,
	month = {oct},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {374},
	number = {9697},
	pages = {1252--1261},
	author = {Ian Gilron and Joan M Bailey and Dongsheng Tu and Ronald R Holden and Alan C Jackson and Robyn L Houlden},
	title = {Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial},
	journal = {The Lancet}
}
@article{Gimbel_2003,
	doi = {10.1212/01.wnl.0000057720.36503.2c},
	url = {http://dx.doi.org/10.1212/01.wnl.0000057720.36503.2c},
	year = 2003,
	month = {mar},
	publisher = {Ovid Technologies (Wolters Kluwer Health)},
	volume = {60},
	number = {6},
	pages = {927--934},
	author = {J. S. Gimbel and P. Richards and R. K. Portenoy},
	title = {Controlled-release oxycodone for pain in diabetic neuropathy: A randomized controlled trial},
	journal = {Neurology}
}
@article{Goldstein_2005,
	doi = {10.1016/j.pain.2005.03.029},
	url = {http://dx.doi.org/10.1016/j.pain.2005.03.029},
	year = 2005,
	month = {jul},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {116},
	number = {1-2},
	pages = {109--118},
	author = {David J. Goldstein and Yili Lu and Michael J. Detke and Thomas C. Lee and Smriti Iyengar},
	title = {Duloxetine vs. placebo in patients with painful diabetic neuropathy},
	journal = {Pain}
}
@article{Gordh_2008,
	doi = {10.1016/j.pain.2007.12.011},
	url = {http://dx.doi.org/10.1016/j.pain.2007.12.011},
	year = 2008,
	month = {aug},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {138},
	number = {2},
	pages = {255--266},
	author = {Torsten E. Gordh and Audun Stubhaug and Troels S. Jensen and Staffan Arn{\\`{e}}r and Bjrn Biber and Jrgen Boivie and Clas Mannheimer and Jarkko Kalliomki and Eija Kalso},
	title = {Gabapentin in traumatic nerve injury pain: A randomized, double-blind, placebo-controlled, cross-over, multi-center study},
	journal = {$\\lbrace$PAIN$\\rbrace$}
}
@article{Graff_Radford_2000,
	doi = {10.1097/00002508-200009000-00002},
	url = {http://dx.doi.org/10.1097/00002508-200009000-00002},
	year = 2000,
	publisher = {Ovid Technologies (Wolters Kluwer Health)},
	volume = {16},
	number = {3},
	pages = {188--192},
	author = {Steven B. Graff-Radford and Leon R. Shaw and Bruce N. Naliboff},
	title = {Amitriptyline and Fluphenazine in the Treatment of Postherpetic Neuralgia},
	journal = {The Clinical Journal of Pain}
}
@article{Grosskopf_2006,
	doi = {10.1111/j.1600-0404.2005.00559.x},
	url = {http://dx.doi.org/10.1111/j.1600-0404.2005.00559.x},
	year = 2006,
	month = {sep},
	publisher = {Wiley-Blackwell},
	volume = {114},
	number = {3},
	pages = {177--180},
	author = {J. Grosskopf and J. Mazzola and Y. Wan and M. Hopwood},
	title = {A randomized, placebo-controlled study of oxcarbazepine in painful diabetic neuropathy},
	journal = {Acta Neurol Scand}
}
@article{Guan_2011,
	doi = {10.1016/j.clinthera.2011.02.007},
	url = {http://dx.doi.org/10.1016/j.clinthera.2011.02.007},
	year = 2011,
	month = {feb},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {33},
	number = {2},
	pages = {159--166},
	author = {Yuzhou Guan and Xinsheng Ding and Yan Cheng and Dongsheng Fan and Lan Tan and Yongjun Wang and Zhongxin Zhao and Zhen Hong and Dong Zhou and Xiaoping Pan and Shengdi Chen and Andrew Martin and Haiyun Tang and Liying Cui},
	title = {Efficacy of Pregabalin for Peripheral Neuropathic Pain: Results of an 8-Week, Flexible-Dose, Double-Blind, Placebo-Controlled Study Conducted in China},
	journal = {Clinical Therapeutics}
}
@article{Hahn_2004,
	doi = {10.1007/s00415-004-0529-6},
	url = {http://dx.doi.org/10.1007/s00415-004-0529-6},
	year = 2004,
	month = {oct},
	publisher = {Springer Science $\\mathplus$ Business Media},
	volume = {251},
	number = {10},
	pages = {1260--1266},
	author = {K. Hahn and G. Arendt and J. S. Braun and H.-J Giesen and I. W. Husstedt and M. Maschke and M. E. Straube and E. Schielke},
	title = {A placebo-controlled trial of gabapentin for painful $\\lbrace$HIV$\\rbrace$-associated sensory neuropathies},
	journal = {J Neurol}
}
@article{Hanna_2008,
	doi = {10.1016/j.ejpain.2007.12.010},
	url = {http://dx.doi.org/10.1016/j.ejpain.2007.12.010},
	year = 2008,
	month = {aug},
	publisher = {Wiley-Blackwell},
	volume = {12},
	number = {6},
	pages = {804--813},
	author = {Magdi Hanna and Cathy O{\\textquotesingle}Brien and Margaret C. Wilson},
	title = {Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients},
	journal = {European Journal of Pain}
}
@article{Harati_1998,
	doi = {10.1212/wnl.50.6.1842},
	url = {http://dx.doi.org/10.1212/wnl.50.6.1842},
	year = 1998,
	month = {jun},
	publisher = {Ovid Technologies (Wolters Kluwer Health)},
	volume = {50},
	number = {6},
	pages = {1842--1846},
	author = {Y. Harati and C. Gooch and M. Swenson and S. Edelman and D. Greene and P. Raskin and P. Donofrio and D. Cornblath and R. Sachdeo and C. O. Siu and M. Kamin},
	title = {Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy},
	journal = {Neurology}
}
@article{Holbech_2010,
	doi = {10.1016/s1754-3207(10)70494-6},
	url = {http://dx.doi.org/10.1016/s1754-3207(10)70494-6},
	year = 2010,
	month = {apr},
	publisher = {Wiley-Blackwell},
	volume = {4},
	number = {S1},
	pages = {138--138},
	author = {J.V. Holbech and M. Otto and F.W. Bach and T.S. Jensen and S.H. Sindrup},
	title = {489 $\\lbrace$THE$\\rbrace$ $\\lbrace$ANTICONVULSANT$\\rbrace$ $\\lbrace$LEVETIRACETAM$\\rbrace$ $\\lbrace$FOR$\\rbrace$ $\\lbrace$THE$\\rbrace$ $\\lbrace$TREATMENT$\\rbrace$ $\\lbrace$OF$\\rbrace$ $\\lbrace$PAIN$\\rbrace$ $\\lbrace$IN$\\rbrace$ $\\lbrace$POLYNEUROPATHY$\\rbrace$. A $\\lbrace$RANDOMIZED$\\rbrace$, $\\lbrace$PLACEBO$\\rbrace$-$\\lbrace$CONTROLLED$\\rbrace$, $\\lbrace$CROSS$\\rbrace$-$\\lbrace$OVER$\\rbrace$ $\\lbrace$TRIAL$\\rbrace$},
	journal = {European Journal of Pain Supplements}
}
@article{Huse_2001,
	doi = {10.1016/s0304-3959(00)00385-7},
	url = {http://dx.doi.org/10.1016/s0304-3959(00)00385-7},
	year = 2001,
	month = {feb},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {90},
	number = {1-2},
	pages = {47--55},
	author = {Ellena Huse and Wolfgang Larbig and Herta Flor and Niels Birbaumer},
	title = {The effect of opioids on phantom limb pain and cortical reorganization},
	journal = {Pain}
}
@article{Ruskin_1999,
	doi = {10.1097/00000542-199905000-00051},
	url = {http://dx.doi.org/10.1097/00000542-199905000-00051},
	year = 1999,
	publisher = {Ovid Technologies (Wolters Kluwer Health)},
	volume = {90},
	number = {5},
	pages = {1498},
	author = {Keith J. Ruskin},
	title = {The International Association for the Study of Pain ($\\lbrace$IASP$\\rbrace$)},
	journal = {Anesthesiology}
}
@article{Irving_2011,
	doi = {10.1111/j.1526-4637.2010.01004.x},
	url = {http://dx.doi.org/10.1111/j.1526-4637.2010.01004.x},
	year = 2011,
	month = {jan},
	publisher = {Wiley-Blackwell},
	volume = {12},
	number = {1},
	pages = {99--109},
	author = {Gordon A. Irving and Miroslav M. Backonja and Edwin Dunteman and E. Richard Blonsky and Geertrui F. Vanhove and Shiao-Ping Lu and Jeffrey Tobias},
	title = {A Multicenter, Randomized, Double-Blind, Controlled Study of $\\lbrace$NGX$\\rbrace$-4010, a High-Concentration Capsaicin Patch, for the Treatment of Postherpetic Neuralgia},
	journal = {Pain Medicine}
}
@article{Jensen_2006,
	doi = {10.3132/dvdr.2006.013},
	url = {http://dx.doi.org/10.3132/dvdr.2006.013},
	year = 2006,
	publisher = {$\\lbrace$SAGE$\\rbrace$ Publications},
	volume = {3},
	number = {2},
	pages = {108},
	author = {Troels S Jensen and Misha-Miroslav Backonja and Sergio Hernandez Jimenez and Solomon Tesfaye and Paul Valensi and Dan Ziegler},
	title = {New perspectives on the management of diabetic peripheral neuropathic pain.},
	journal = {Diabetes {\\&} vascular disease research : official journal of the International Society of Diabetes and Vascular Disease}
}
@article{Jung_2004,
	doi = {10.1212/01.wnl.0000123261.00004.29},
	url = {http://dx.doi.org/10.1212/01.wnl.0000123261.00004.29},
	year = 2004,
	month = {may},
	publisher = {Ovid Technologies (Wolters Kluwer Health)},
	volume = {62},
	number = {9},
	pages = {1545--1551},
	author = {B. F. Jung and R. W. Johnson and D. R.J. Griffin and R. H. Dworkin},
	title = {Risk factors for postherpetic neuralgia in patients with herpes zoster},
	journal = {Neurology}
}
@article{Eija_1996,
	doi = {10.1016/0304-3959(95)00138-7},
	url = {http://dx.doi.org/10.1016/0304-3959(95)00138-7},
	year = 1996,
	month = {feb},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {64},
	number = {2},
	pages = {293--302},
	author = {kalso Eija and Tasmuth Tiina and Neuvonen Pertti J},
	title = {Amitriptyline effectively relieves neuropathic pain following treatment of breast cancer},
	journal = {Pain}
}
@article{Kautio_2008,
	doi = {10.1016/j.jpainsymman.2007.02.043},
	url = {http://dx.doi.org/10.1016/j.jpainsymman.2007.02.043},
	year = 2008,
	month = {jan},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {35},
	number = {1},
	pages = {31--39},
	author = {Anna-Liisa Kautio and Maija Haanp and Tiina Saarto and Eija Kalso},
	title = {Amitriptyline in the Treatment of Chemotherapy-Induced Neuropathic Symptoms},
	journal = {Journal of Pain and Symptom Management}
}
@article{Kehlet_2006,
	doi = {10.1016/s0140-6736(06)68700-x},
	url = {http://dx.doi.org/10.1016/s0140-6736(06)68700-x},
	year = 2006,
	month = {may},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {367},
	number = {9522},
	pages = {1618--1625},
	author = {Henrik Kehlet and Troels S Jensen and Clifford J Woolf},
	title = {Persistent postsurgical pain: risk factors and prevention},
	journal = {The Lancet}
}
@article{Khoromi_2005,
	doi = {10.1016/j.jpain.2005.08.002},
	url = {http://dx.doi.org/10.1016/j.jpain.2005.08.002},
	year = 2005,
	month = {dec},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {6},
	number = {12},
	pages = {829--836},
	author = {Suzan Khoromi and Athos Patsalides and Suzan Parada and Vesta Salehi and Jennifer M. Meegan and Mitchell B. Max},
	title = {Topiramate in Chronic Lumbar Radicular Pain},
	journal = {The Journal of Pain}
}
@article{KHOROMI_2007,
	doi = {10.1016/j.pain.2006.10.029},
	url = {http://dx.doi.org/10.1016/j.pain.2006.10.029},
	year = 2007,
	month = {jul},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {130},
	number = {1-2},
	pages = {66--75},
	author = {S KHOROMI and L CUI and L NACKERS and M MAX},
	title = {Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain},
	journal = {Pain}
}
@article{Kieburtz_1998,
	doi = {10.1212/wnl.51.6.1682},
	url = {http://dx.doi.org/10.1212/wnl.51.6.1682},
	year = 1998,
	month = {dec},
	publisher = {Ovid Technologies (Wolters Kluwer Health)},
	volume = {51},
	number = {6},
	pages = {1682--1688},
	author = {K. Kieburtz and D. Simpson and C. Yiannoutsos and M. B. Max and C. D. Hall and R. J. Ellis and C. M. Marra and R. McKendall and E. Singer and G. J. Dal Pan and D. B. Clifford and T. Tucker and B. Cohen},
	title = {A randomized trial of amitriptyline and mexiletine for painful neuropathy in $\\lbrace$HIV$\\rbrace$ infection},
	journal = {Neurology}
}
@article{Kim_2011,
	doi = {10.1016/j.pain.2010.12.023},
	url = {http://dx.doi.org/10.1016/j.pain.2010.12.023},
	year = 2011,
	month = {may},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {152},
	number = {5},
	pages = {1018--1023},
	author = {Jong S. Kim and Guy Bashford and T. Kevin Murphy and Andrew Martin and Vardit Dror and Raymond Cheung},
	title = {Safety and efficacy of pregabalin in patients with central post-stroke pain},
	journal = {$\\lbrace$PAIN$\\rbrace$}
}
@article{Kochar_2004,
	doi = {10.1093/qjmed/hci005},
	url = {http://dx.doi.org/10.1093/qjmed/hci005},
	year = 2004,
	month = {dec},
	publisher = {Oxford University Press ($\\lbrace$OUP$\\rbrace$)},
	volume = {98},
	number = {1},
	pages = {29--34},
	author = {D.K. Kochar and P. Garg and R.A. Bumb and S.K. Kochar and R.D. Mehta and R. Beniwal and N. Rawat},
	title = {Divalproex sodium in the management of post-herpetic neuralgia: a randomized double-blind placebo-controlled study},
	journal = {$\\lbrace$QJM$\\rbrace$}
}
@article{Kochar_2002,
	doi = {10.1034/j.1600-0404.2002.01229.x},
	url = {http://dx.doi.org/10.1034/j.1600-0404.2002.01229.x},
	year = 2002,
	month = {nov},
	publisher = {Wiley-Blackwell},
	volume = {106},
	number = {5},
	pages = {248--252},
	author = {D. K. Kochar and N. Jain and R. P. Agarwal and T. Srivastava and P. Agarwal and S. Gupta},
	title = {Sodium valproate in the management of painful neuropathy in type 2 diabetes - a randomized placebo controlled study},
	journal = {Acta Neurol Scand}
}
@article{Kochar_2003,
	doi = {10.1093/qjmed/hch007},
	url = {http://dx.doi.org/10.1093/qjmed/hch007},
	year = 2003,
	month = {dec},
	publisher = {Oxford University Press ($\\lbrace$OUP$\\rbrace$)},
	volume = {97},
	number = {1},
	pages = {33--38},
	author = {D.K. Kochar and N. Rawat and R.P. Agrawal and A. Vyas and R. Beniwal and S.K. Kochar and P. Garg},
	title = {Sodium valproate for painful diabetic neuropathy: a randomized double-blind placebo-controlled study},
	journal = {$\\lbrace$QJM$\\rbrace$}
}
@article{Leijon_1989,
	doi = {10.1016/0304-3959(89)90108-5},
	url = {http://dx.doi.org/10.1016/0304-3959(89)90108-5},
	year = 1989,
	month = {jan},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {36},
	number = {1},
	pages = {27--36},
	author = {G. Leijon and J. Boivie},
	title = {Central post-stroke pain {\\textemdash} a controlled trial of amitriptyline and carbamazepine},
	journal = {Pain}
}
@article{Lesser_2004,
	doi = {10.1212/01.wnl.0000145767.36287.a1},
	url = {http://dx.doi.org/10.1212/01.wnl.0000145767.36287.a1},
	year = 2004,
	month = {dec},
	publisher = {Ovid Technologies (Wolters Kluwer Health)},
	volume = {63},
	number = {11},
	pages = {2104--2110},
	author = {H. Lesser and U. Sharma and L. LaMoreaux and R. M. Poole},
	title = {Pregabalin relieves symptoms of painful diabetic neuropathy: A randomized controlled trial},
	journal = {Neurology}
}
@article{Levendo_lu_2004,
	doi = {10.1097/01.brs.0000112068.16108.3a},
	url = {http://dx.doi.org/10.1097/01.brs.0000112068.16108.3a},
	year = 2004,
	month = {apr},
	publisher = {Ovid Technologies (Wolters Kluwer Health)},
	volume = {29},
	number = {7},
	pages = {743--751},
	author = {Funda Levendo{\\u{g}}lu and Cemile . {\\u{g}}n and nder zerbil and Tun{\\c{c}} C. {\\u{g}}n and Hatice U{\\u{g}}urlu},
	title = {Gabapentin Is a First Line Drug for the Treatment of Neuropathic Pain in Spinal Cord Injury},
	journal = {Spine}
}
@article{Low_1995,
	doi = {10.1016/0304-3959(94)00261-c},
	url = {http://dx.doi.org/10.1016/0304-3959(94)00261-c},
	year = 1995,
	month = {aug},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {62},
	number = {2},
	pages = {163--168},
	author = {Phillip A. Low and Tonette L. Opfer-Gehrking and Peter J. Dyck and William J. Litchy and Peter C. O{\\textquotesingle}Brien},
	title = {Double-blind, placebo-controlled study of the application of capsaicin cream in chronic distal painful polyneuropathy},
	journal = {Pain}
}
@article{Eisenberg_2001,
	doi = {10.1212/wnl.57.3.505},
	url = {http://dx.doi.org/10.1212/wnl.57.3.505},
	year = 2001,
	month = {aug},
	publisher = {Ovid Technologies (Wolters Kluwer Health)},
	volume = {57},
	number = {3},
	pages = {505--509},
	author = {E. Eisenberg and Y. Lurie and C. Braker and D. Daoud and A. Ishay},
	title = {Lamotrigine reduces painful diabetic neuropathy: A randomized, controlled study},
	journal = {Neurology}
}
@article{Max_1988,
	doi = {10.1212/wnl.38.9.1427},
	url = {http://dx.doi.org/10.1212/wnl.38.9.1427},
	year = 1988,
	month = {sep},
	publisher = {Ovid Technologies (Wolters Kluwer Health)},
	volume = {38},
	number = {9},
	pages = {1427--1427},
	author = {M. B. Max and S. C. Schafer and M. Culnane and B. Smoller and R. Dubner and R. H. Gracely},
	title = {Amitriptyline, but not lorazepam, relieves postherpetic neuralgia},
	journal = {Neurology}
}
@article{Chong_2006,
	doi = {10.1016/j.biopha.2006.06.016},
	url = {http://dx.doi.org/10.1016/j.biopha.2006.06.016},
	year = 2006,
	month = {aug},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {60},
	number = {7},
	pages = {318--322},
	author = {M.S. Chong and B. Brandner},
	title = {Neuropathic agents and~pain. New strategies},
	journal = {Biomedicine {\\&} Pharmacotherapy}
}
@article{McCleane_1999,
	doi = {10.1016/s0304-3959(99)00095-0},
	url = {http://dx.doi.org/10.1016/s0304-3959(99)00095-0},
	year = 1999,
	month = {oct},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {83},
	number = {1},
	pages = {105--107},
	author = {Gary McCleane},
	title = {200 mg daily of lamotrigine has no analgesic effect in neuropathic pain: a randomised, double-blind, placebo controlled trial},
	journal = {$\\lbrace$PAIN$\\rbrace$}
}
@article{McCleane_2001,
	doi = {10.1046/j.1365-2125.2000.00200.x},
	url = {http://dx.doi.org/10.1046/j.1365-2125.2000.00200.x},
	year = 2001,
	month = {dec},
	publisher = {Wiley-Blackwell},
	volume = {49},
	number = {6},
	pages = {574--579},
	author = {Gary McCleane},
	title = {Topical application of doxepin hydrochloride, capsaicin and a combination of both produces analgesia in chronic human neuropathic pain: a randomized, double-blind, placebo-controlled study},
	journal = {British Journal of Clinical Pharmacology}
}
@article{Mikkelsen_2004,
	doi = {10.1213/01.ane.0000115147.14626.c5},
	url = {http://dx.doi.org/10.1213/01.ane.0000115147.14626.c5},
	year = 2004,
	month = {jul},
	publisher = {Ovid Technologies (Wolters Kluwer Health)},
	volume = {99},
	number = {1},
	pages = {146--151},
	author = {Trine Mikkelsen and Mads U. Werner and Birgit Lassen and Henrik Kehlet},
	title = {Pain and Sensory Dysfunction 6 to 12 Months After Inguinal Herniotomy},
	journal = {Anesthesia {\\&} Analgesia}
}
@article{Mishra_2011,
	doi = {10.1177/1049909111412539},
	url = {http://dx.doi.org/10.1177/1049909111412539},
	year = 2011,
	month = {jul},
	publisher = {$\\lbrace$SAGE$\\rbrace$ Publications},
	volume = {29},
	number = {3},
	pages = {177--182},
	author = {S. Mishra and S. Bhatnagar and G. N. Goyal and S. P. S. Rana and S. P. Upadhya},
	title = {A Comparative Efficacy of Amitriptyline, Gabapentin, and Pregabalin in Neuropathic Cancer Pain: A Prospective Randomized Double-Blind Placebo-Controlled Study},
	journal = {American Journal of Hospice and Palliative Medicine}
}
@article{Moon_2010,
	doi = {10.1016/j.clinthera.2011.01.014},
	url = {http://dx.doi.org/10.1016/j.clinthera.2011.01.014},
	year = 2010,
	month = {dec},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {32},
	number = {14},
	pages = {2370--2385},
	author = {Dong Eon Moon and Doo Ik Lee and Sang Chul Lee and Sun Ok Song and Duck Mi Yoon and Myung Ha Yoon and Hae Kyu Kim and Youn Woo Lee and Chan Kim and Pyung Bok Lee},
	title = {Efficacy and Tolerability of Pregabalin Using a Flexible, Optimized Dose Schedule in Korean Patients With Peripheral Neuropathic Pain: A 10-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study},
	journal = {Clinical Therapeutics}
}
@article{Moore_2005,
	doi = {10.1016/j.pain.2005.05.001},
	url = {http://dx.doi.org/10.1016/j.pain.2005.05.001},
	year = 2005,
	month = {aug},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {116},
	number = {3},
	pages = {322--331},
	author = {R.A. Moore and J.E. Edwards and H.J. McQuay},
	title = {Acute pain: individual patient meta-analysis shows the impact of different ways of analysing and presenting results},
	journal = {Pain}
}
@article{Morello_1999,
	doi = {10.1001/archinte.159.16.1931},
	url = {http://dx.doi.org/10.1001/archinte.159.16.1931},
	year = 1999,
	month = {sep},
	publisher = {American Medical Association ($\\lbrace$AMA$\\rbrace$)},
	volume = {159},
	number = {16},
	pages = {1931},
	author = {Candis M. Morello and Susan G. Leckband and Carol P. Stoner and David F. Moorhouse and Gregory A. Sahagian},
	title = {Randomized Double-blind Study Comparing the Efficacy of Gabapentin With Amitriptyline on Diabetic Peripheral Neuropathy Pain},
	journal = {Archives of Internal Medicine}
}
@article{Norrbrink_2009,
	doi = {10.1097/ajp.0b013e31818a744d},
	url = {http://dx.doi.org/10.1097/ajp.0b013e31818a744d},
	year = 2009,
	publisher = {Ovid Technologies (Wolters Kluwer Health)},
	volume = {25},
	number = {3},
	pages = {177--184},
	author = {Cecilia Norrbrink and Thomas Lundeberg},
	title = {Tramadol in Neuropathic Pain After Spinal Cord Injury},
	journal = {The Clinical Journal of Pain}
}
@article{Nurmikko_2007,
	doi = {10.1016/j.pain.2007.08.028},
	url = {http://dx.doi.org/10.1016/j.pain.2007.08.028},
	year = 2007,
	month = {dec},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {133},
	number = {1-3},
	pages = {210--220},
	author = {Turo J. Nurmikko and Mick G. Serpell and Barbara Hoggart and Peter J. Toomey and Bart J. Morlion and Derek Haines},
	title = {Sativex successfully treats neuropathic pain characterised by allodynia: A randomised, double-blind, placebo-controlled clinical trial},
	journal = {$\\lbrace$PAIN$\\rbrace$}
}
@article{Otto_2008,
	doi = {10.1016/j.pain.2008.04.012},
	url = {http://dx.doi.org/10.1016/j.pain.2008.04.012},
	year = 2008,
	month = {oct},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {139},
	number = {2},
	pages = {275--283},
	author = {Marit Otto and Flemming W. Bach and Troels S. Jensen and Kim Br{\\o}sen and S{\\o}ren H. Sindrup},
	title = {Escitalopram in painful polyneuropathy: A randomized, placebo-controlled, cross-over trial},
	journal = {$\\lbrace$PAIN$\\rbrace$}
}
@article{Paice_2000,
	doi = {10.1016/s0885-3924(99)00139-6},
	url = {http://dx.doi.org/10.1016/s0885-3924(99)00139-6},
	year = 2000,
	month = {jan},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {19},
	number = {1},
	pages = {45--52},
	author = {Judith A Paice and Carol Estwing Ferrans and Felissa R Lashley and Susan Shott and Vida Vizgirda and David Pitrak},
	title = {Topical Capsaicin in the Management of $\\lbrace$HIV$\\rbrace$-Associated Peripheral Neuropathy},
	journal = {Journal of Pain and Symptom Management}
}
@article{Rao_2007,
	doi = {10.1002/cncr.23008},
	url = {http://dx.doi.org/10.1002/cncr.23008},
	year = 2007,
	publisher = {Wiley-Blackwell},
	volume = {110},
	number = {9},
	pages = {2110--2118},
	author = {Ravi D. Rao and John C. Michalak and Jeff A. Sloan and Charles L. Loprinzi and Gamini S. Soori and Daniel A. Nikcevich and David O. Warner and Paul Novotny and Leila A. Kutteh and Gilbert Y. Wong},
	title = {Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy},
	journal = {Cancer}
}
@article{Rao_2008,
	doi = {10.1002/cncr.23482},
	url = {http://dx.doi.org/10.1002/cncr.23482},
	year = 2008,
	month = {jun},
	publisher = {Wiley-Blackwell},
	volume = {112},
	number = {12},
	pages = {2802--2808},
	author = {Ravi D. Rao and Patrick J. Flynn and Jeff A. Sloan and Gilbert Y. Wong and Paul Novotny and David B. Johnson and Howard M. Gross and Samer I. Renno and Mohammed Nashawaty and Charles L. Loprinzi},
	title = {Efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy},
	journal = {Cancer}
}
@article{Raskin_2005,
	doi = {10.1111/j.1526-4637.2005.00061.x},
	url = {http://dx.doi.org/10.1111/j.1526-4637.2005.00061.x},
	year = 2005,
	month = {sep},
	publisher = {Wiley-Blackwell},
	volume = {6},
	number = {5},
	pages = {346--356},
	author = {Joel Raskin and Yili L. Pritchett and Fujun Wang and Deborah N. D{\\textquotesingle}Souza and Amy L. Waninger and Smriti Iyengar and Joachim F. Wernicke},
	title = {A Double-Blind, Randomized Multicenter Trial Comparing Duloxetine with Placebo in the Management of Diabetic Peripheral Neuropathic Pain},
	journal = {Pain Medicine}
}
@article{Raskin_2004,
	doi = {10.1212/01.wnl.0000137341.89781.14},
	url = {http://dx.doi.org/10.1212/01.wnl.0000137341.89781.14},
	year = 2004,
	month = {sep},
	publisher = {Ovid Technologies (Wolters Kluwer Health)},
	volume = {63},
	number = {5},
	pages = {865--873},
	author = {P. Raskin and P. D. Donofrio and N. R. Rosenthal and D. J. Hewitt and D. M. Jordan and J. Xiang and A. I. Vinik},
	title = {Topiramate vs placebo in painful diabetic neuropathy: Analgesic and metabolic effects},
	journal = {Neurology}
}
@article{Rauck_2007,
	doi = {10.1097/01.ajp.0000210957.39621.b2},
	url = {http://dx.doi.org/10.1097/01.ajp.0000210957.39621.b2},
	year = 2007,
	publisher = {Ovid Technologies (Wolters Kluwer Health)},
	volume = {23},
	number = {2},
	pages = {150--158},
	author = {Richard L. Rauck and Aziz Shaibani and Victor Biton and Jeff Simpson and Brigitte Koch},
	title = {Lacosamide in Painful Diabetic Peripheral Neuropathy},
	journal = {The Clinical Journal of Pain}
}
@article{Revicki_1998,
	doi = {10.1016/s0165-0327(97)00117-1},
	url = {http://dx.doi.org/10.1016/s0165-0327(97)00117-1},
	year = 1998,
	month = {feb},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {48},
	number = {1},
	pages = {25--36},
	author = {D Revicki},
	title = {Patient-assigned health state utilities for depression-related outcomes: differences by depression severity and antidepressant medications},
	journal = {Journal of Affective Disorders}
}
@article{Rice_2001,
	doi = {10.1016/s0304-3959(01)00407-9},
	url = {http://dx.doi.org/10.1016/s0304-3959(01)00407-9},
	year = 2001,
	month = {nov},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {94},
	number = {2},
	pages = {215--224},
	author = {A.S.C. Rice and S. Maton},
	title = {Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study},
	journal = {$\\lbrace$PAIN$\\rbrace$}
}
@article{RICHTER_2005,
	doi = {10.1016/j.jpain.2004.12.007},
	url = {http://dx.doi.org/10.1016/j.jpain.2004.12.007},
	year = 2005,
	month = {apr},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {6},
	number = {4},
	pages = {253--260},
	author = {R RICHTER and R PORTENOY and U SHARMA and L LAMOREAUX and H BOCKBRADER and L KNAPP},
	title = {Relief of painful diabetic peripheral neuropathy with pregabalin: A randomized, placebo-controlled trial},
	journal = {The Journal of Pain}
}
@article{Rintala_2007,
	doi = {10.1016/j.apmr.2007.07.038},
	url = {http://dx.doi.org/10.1016/j.apmr.2007.07.038},
	year = 2007,
	month = {dec},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {88},
	number = {12},
	pages = {1547--1560},
	author = {Diana H. Rintala and Sally Ann Holmes and Daisy Courtade and Richard Neil Fiess and Luz Viviana Tastard and Paul G. Loubser},
	title = {Comparison of the Effectiveness of Amitriptyline and Gabapentin on Chronic Neuropathic Pain in Persons With Spinal Cord Injury},
	journal = {Archives of Physical Medicine and Rehabilitation}
}
@article{Robinson_2004,
	doi = {10.1016/s0003-9993(03)00476-3},
	url = {http://dx.doi.org/10.1016/s0003-9993(03)00476-3},
	year = 2004,
	month = {jan},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {85},
	number = {1},
	pages = {1--6},
	author = {Lawrence R Robinson and Joseph M Czerniecki and Dawn M Ehde and W.Thomas Edwards and David A Judish and Myron L Goldberg and Kellye M Campbell and Douglas G Smith and Mark P Jensen},
	title = {Trial of amitriptyline for relief of pain in amputees: results of a randomized controlled study},
	journal = {Archives of Physical Medicine and Rehabilitation}
}
@article{Rog_2005,
	doi = {10.1212/01.wnl.0000176753.45410.8b},
	url = {http://dx.doi.org/10.1212/01.wnl.0000176753.45410.8b},
	year = 2005,
	month = {sep},
	publisher = {Ovid Technologies (Wolters Kluwer Health)},
	volume = {65},
	number = {6},
	pages = {812--819},
	author = {D. J. Rog and T. J. Nurmikko and T. Friede and C. A. Young},
	title = {Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis},
	journal = {Neurology}
}
@article{ROSENSTOCK_2004,
	doi = {10.1016/j.pain.2004.05.001},
	url = {http://dx.doi.org/10.1016/j.pain.2004.05.001},
	year = 2004,
	month = {aug},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {110},
	number = {3},
	pages = {628--638},
	author = {J ROSENSTOCK},
	title = {Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial{\\ast}1},
	journal = {Pain}
}
@article{Rossi_2009,
	doi = {10.1111/j.1468-1331.2008.02496.x},
	url = {http://dx.doi.org/10.1111/j.1468-1331.2008.02496.x},
	year = 2009,
	month = {mar},
	publisher = {Wiley-Blackwell},
	volume = {16},
	number = {3},
	pages = {360--366},
	author = {S. Rossi and G. Mataluni and C. Codec{\\`{a}} and S. Fiore and F. Buttari and A. Musella and M. Castelli and G. Bernardi and D. Centonze},
	title = {Effects of levetiracetam on chronic pain in multiple sclerosis: results of a pilot, randomized, placebo-controlled study},
	journal = {European Journal of Neurology}
}
@article{Rowbotham_1998,
	doi = {10.1001/jama.280.21.1837},
	url = {http://dx.doi.org/10.1001/jama.280.21.1837},
	year = 1998,
	month = {dec},
	publisher = {American Medical Association ($\\lbrace$AMA$\\rbrace$)},
	volume = {280},
	number = {21},
	pages = {1837},
	author = {Michael Rowbotham},
	title = {Gabapentin for the Treatment of Postherpetic Neuralgia$\\less$$\\lbrace$SUBTITLE$\\rbrace$$\\greater$A Randomized Controlled Trial$\\less$/$\\lbrace$SUBTITLE$\\rbrace$$\\greater$},
	journal = {$\\lbrace$JAMA$\\rbrace$}
}
@article{Rowbotham_2004,
	doi = {10.1016/j.pain.2004.05.010},
	url = {http://dx.doi.org/10.1016/j.pain.2004.05.010},
	year = 2004,
	month = {aug},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {110},
	number = {3},
	pages = {697--706},
	author = {Michael C Rowbotham and Veeraindar Goli and Nadia R Kunz and Dean Lei},
	title = {Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study},
	journal = {Pain}
}
@article{Sabatowski_2004,
	doi = {10.1016/j.pain.2004.01.001},
	url = {http://dx.doi.org/10.1016/j.pain.2004.01.001},
	year = 2004,
	month = {may},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {109},
	number = {1-2},
	pages = {26--35},
	author = {R Sabatowski},
	title = {Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial},
	journal = {Pain}
}
@article{Satoh_2010,
	doi = {10.1111/j.1464-5491.2010.03152.x},
	url = {http://dx.doi.org/10.1111/j.1464-5491.2010.03152.x},
	year = 2010,
	month = {dec},
	publisher = {Wiley-Blackwell},
	volume = {28},
	number = {1},
	pages = {109--116},
	author = {J. Satoh and S. Yagihashi and M. Baba and M. Suzuki and A. Arakawa and T. Yoshiyama and S. Shoji},
	title = {Efficacy and safety of pregabalin for treating neuropathic pain associated with diabetic peripheral neuropathy: a 14 week, randomized, double-blind, placebo-controlled trial},
	journal = {Diabetic Medicine}
}
@article{Scheffler_1991,
	doi = {10.7547/87507315-81-6-288},
	url = {http://dx.doi.org/10.7547/87507315-81-6-288},
	year = 1991,
	month = {jun},
	publisher = {American Podiatric Medical Association},
	volume = {81},
	number = {6},
	pages = {288--293},
	author = {NM Scheffler and PL Sheitel and MN Lipton},
	title = {Treatment of painful diabetic neuropathy with capsaicin 0.075{\\%}},
	journal = {Journal of the American Podiatric Medical Association}
}
@article{Schmader_2002,
	doi = {10.1097/00002508-200211000-00002},
	url = {http://dx.doi.org/10.1097/00002508-200211000-00002},
	year = 2002,
	month = {nov},
	publisher = {Ovid Technologies (Wolters Kluwer Health)},
	volume = {18},
	number = {6},
	pages = {350--354},
	author = {Kenneth E. Schmader},
	title = {Epidemiology and Impact on Quality of Life of Postherpetic Neuralgia and Painful Diabetic Neuropathy},
	journal = {The Clinical Journal of Pain}
}
@article{Selvarajah_2009,
	doi = {10.2337/dc09-1029},
	url = {http://dx.doi.org/10.2337/dc09-1029},
	year = 2009,
	month = {oct},
	publisher = {American Diabetes Association},
	volume = {33},
	number = {1},
	pages = {128--130},
	author = {D. Selvarajah and R. Gandhi and C. J. Emery and S. Tesfaye},
	title = {Randomized Placebo-Controlled Double-Blind Clinical Trial of Cannabis-Based Medicinal Product (Sativex) in Painful Diabetic Neuropathy: Depression is a major confounding factor},
	journal = {Diabetes Care}
}
@article{Shaibani_2009,
	doi = {10.1016/j.jpain.2009.01.322},
	url = {http://dx.doi.org/10.1016/j.jpain.2009.01.322},
	year = 2009,
	month = {aug},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {10},
	number = {8},
	pages = {818--828},
	author = {Aziz Shaibani and Salah Fares and Jean-Louis Selam and Armen Arslanian and Jeffrey Simpson and David Sen and Sabine Bongardt},
	title = {Lacosamide in Painful Diabetic Neuropathy: An 18-Week Double-Blind Placebo-Controlled Trial},
	journal = {The Journal of Pain}
}
@article{Shipton_2008,
	doi = {10.1111/j.1445-2197.2008.04569.x},
	url = {http://dx.doi.org/10.1111/j.1445-2197.2008.04569.x},
	year = 2008,
	month = {jul},
	publisher = {Wiley-Blackwell},
	volume = {78},
	number = {7},
	pages = {548--555},
	author = {Edward Shipton},
	title = {$\\lbrace$POST$\\rbrace$-$\\lbrace$SURGICAL$\\rbrace$ $\\lbrace$NEUROPATHIC$\\rbrace$ $\\lbrace$PAIN$\\rbrace$},
	journal = {$\\lbrace$ANZ$\\rbrace$ J Surg}
}
@article{Siddall_2006,
	doi = {10.1212/01.wnl.0000244422.45278.ff},
	url = {http://dx.doi.org/10.1212/01.wnl.0000244422.45278.ff},
	year = 2006,
	month = {nov},
	publisher = {Ovid Technologies (Wolters Kluwer Health)},
	volume = {67},
	number = {10},
	pages = {1792--1800},
	author = {P. J. Siddall and M. J. Cousins and A. Otte and T. Griesing and R. Chambers and T. K. Murphy},
	title = {Pregabalin in central neuropathic pain associated with spinal cord injury: A placebo-controlled trial},
	journal = {Neurology}
}
@article{Simpson_2001,
	doi = {10.1097/00131402-200112000-00002},
	url = {http://dx.doi.org/10.1097/00131402-200112000-00002},
	year = 2001,
	publisher = {Ovid Technologies (Wolters Kluwer Health)},
	volume = {3},
	number = {2},
	pages = {53--62},
	author = {David A. Simpson},
	title = {Gabapentin and Venlafaxine for the Treatment of Painful Diabetic Neuropathy},
	journal = {Journal of Clinical Neuromuscular Disease}
}
@article{Simpson_2000,
	doi = {10.1212/wnl.54.11.2115},
	url = {http://dx.doi.org/10.1212/wnl.54.11.2115},
	year = 2000,
	month = {jun},
	publisher = {Ovid Technologies (Wolters Kluwer Health)},
	volume = {54},
	number = {11},
	pages = {2115--2119},
	author = {D. M. Simpson and R. Olney and J. C. McArthur and A. Khan and J. Godbold and K. Ebel-Frommer},
	title = {A placebo-controlled trial of lamotrigine for painful $\\lbrace$HIV$\\rbrace$-associated neuropathy},
	journal = {Neurology}
}
@article{Simpson_2003,
	doi = {10.1212/01.wnl.0000063304.88470.d9},
	url = {http://dx.doi.org/10.1212/01.wnl.0000063304.88470.d9},
	year = 2003,
	month = {may},
	publisher = {Ovid Technologies (Wolters Kluwer Health)},
	volume = {60},
	number = {9},
	pages = {1508--1514},
	author = {D. M. Simpson and J. C. McArthur and R. Olney and D. Clifford and Y. So and D. Ross and B. J. Baird and P. Barrett and A. E. Hammer},
	title = {Lamotrigine for $\\lbrace$HIV$\\rbrace$-associated painful sensory neuropathies: A placebo-controlled trial},
	journal = {Neurology}
}
@article{Simpson_2008,
	doi = {10.1212/01.wnl.0000314647.35825.9c},
	url = {http://dx.doi.org/10.1212/01.wnl.0000314647.35825.9c},
	year = 2008,
	month = {jun},
	publisher = {Ovid Technologies (Wolters Kluwer Health)},
	volume = {70},
	number = {24},
	pages = {2305--2313},
	author = {D. M. Simpson and S. Brown and J. Tobias},
	title = {Controlled trial of high-concentration capsaicin patch for treatment of painful $\\lbrace$HIV$\\rbrace$ neuropathy},
	journal = {Neurology}
}
@article{Simpson_2010,
	doi = {10.1212/wnl.0b013e3181ccc6ef},
	url = {http://dx.doi.org/10.1212/wnl.0b013e3181ccc6ef},
	year = 2010,
	month = {feb},
	publisher = {Ovid Technologies (Wolters Kluwer Health)},
	volume = {74},
	number = {5},
	pages = {413--420},
	author = {D. M. Simpson and G. Schifitto and D. B. Clifford and T. K. Murphy and E. Durso-De Cruz and P. Glue and E. Whalen and B. Emir and G. N. Scott and R. Freeman},
	title = {Pregabalin for painful $\\lbrace$HIV$\\rbrace$ neuropathy: A randomized, double-blind, placebo-controlled trial},
	journal = {Neurology}
}
@article{Sindrup_1999,
	doi = {10.1016/s0304-3959(99)00079-2},
	url = {http://dx.doi.org/10.1016/s0304-3959(99)00079-2},
	year = 1999,
	month = {oct},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {83},
	number = {1},
	pages = {85--90},
	author = {S{\\o}ren H Sindrup and Grethe Andersen and Claus Madsen and Torben Smith and Kim Br{\\o}sen and Troels S Jensen},
	title = {Tramadol relieves pain and allodynia in polyneuropathy: a randomised, double-blind, controlled trial},
	journal = {$\\lbrace$PAIN$\\rbrace$}
}
@article{Sindrup_2003,
	doi = {10.1212/01.wnl.0000058749.49264.bd},
	url = {http://dx.doi.org/10.1212/01.wnl.0000058749.49264.bd},
	year = 2003,
	month = {apr},
	publisher = {Ovid Technologies (Wolters Kluwer Health)},
	volume = {60},
	number = {8},
	pages = {1284--1289},
	author = {S. H. Sindrup and F. W. Bach and C. Madsen and L. F. Gram and T. S. Jensen},
	title = {Venlafaxine versus imipramine in painful polyneuropathy: A randomized, controlled trial},
	journal = {Neurology}
}
@article{Smith_2012,
	doi = {10.1186/1471-2377-12-29},
	url = {http://dx.doi.org/10.1186/1471-2377-12-29},
	year = 2012,
	publisher = {Springer Science $\\mathplus$ Business Media},
	volume = {12},
	number = {1},
	pages = {29},
	author = {Blair H Smith and Nicola Torrance and Janice A Ferguson and Michael I Bennett and Michael G Serpell and Kate M Dunn},
	title = {Towards a definition of refractory neuropathic pain for epidemiological research. An international Delphi survey of experts},
	journal = {$\\lbrace$BMC$\\rbrace$ Neurology}
}
@incollection{Smith,
	doi = {10.1093/acprof:oso/9780199235766.003.0018},
	url = {http://dx.doi.org/10.1093/acprof:oso/9780199235766.003.0018},
	publisher = {Oxford University Press},
	pages = {209--234},
	author = {Blair H. Smith and Nicola Torrance},
	title = {Neuropathic pain},
	booktitle = {Chronic Pain Epidemiology}
}
@article{Smith_2005,
	doi = {10.1682/jrrd.2005.05.0082},
	url = {http://dx.doi.org/10.1682/jrrd.2005.05.0082},
	year = 2005,
	publisher = {Journal of Rehabilitation Research {\\&} Development},
	volume = {42},
	number = {5},
	pages = {645},
	author = {Douglas G. Smith and Dawn M. Ehde and Marisol A. Hanley and Kellye M. Campbell and Mark P. Jensen and Amy J. Hoffman and Asaad B. Awan and Joseph M. Czerniecki and Lawrence R. Robinson},
	title = {Efficacy of gabapentin in treating chronic phantom limb and residual limb pain},
	journal = {The Journal of Rehabilitation Research and Development}
}
@article{Stacey_2008,
	doi = {10.1016/j.jpain.2008.05.014},
	url = {http://dx.doi.org/10.1016/j.jpain.2008.05.014},
	year = 2008,
	month = {nov},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {9},
	number = {11},
	pages = {1006--1017},
	author = {Brett R. Stacey and Jeannette A. Barrett and Ed Whalen and Kem F. Phillips and Michael C. Rowbotham},
	title = {Pregabalin for Postherpetic Neuralgia: Placebo-Controlled Trial of Fixed and Flexible Dosing Regimens on Allodynia and Time to Onset of Pain Relief},
	journal = {The Journal of Pain}
}
@article{Tandan_1992,
	doi = {10.2337/diacare.15.1.8},
	url = {http://dx.doi.org/10.2337/diacare.15.1.8},
	year = 1992,
	month = {jan},
	publisher = {American Diabetes Association},
	volume = {15},
	number = {1},
	pages = {8--14},
	author = {R. Tandan and G. A. Lewis and P. B. Krusinski and G. B. Badger and T. J. Fries},
	title = {Topical capsaicin in painful diabetic neuropathy. Controlled study with long-term follow-up},
	journal = {Diabetes Care}
}
@article{Tasmuth_2002,
	doi = {10.1053/eujp.2001.0266},
	url = {http://dx.doi.org/10.1053/eujp.2001.0266},
	year = 2002,
	month = {jan},
	publisher = {Wiley-Blackwell},
	volume = {6},
	number = {1},
	pages = {17--24},
	author = {Tiina Tasmuth and Brita Hrtel and Eija Kalso},
	title = {Venlafaxine in neuropathic pain following treatment of breast cancer},
	journal = {European Journal of Pain}
}
@article{Thienel_2004,
	doi = {10.1111/j.1600-0404.2004.00338.x},
	url = {http://dx.doi.org/10.1111/j.1600-0404.2004.00338.x},
	year = 2004,
	month = {oct},
	publisher = {Wiley-Blackwell},
	volume = {110},
	number = {4},
	pages = {221--231},
	author = {U. Thienel and W. Neto and S. K. Schwabe and U. Vijapurkar},
	title = {Topiramate in painful diabetic polyneuropathy: findings from three double-blind placebo-controlled trials},
	journal = {Acta Neurol Scand}
}
@article{T_lle_2008,
	doi = {10.1016/j.ejpain.2007.05.003},
	url = {http://dx.doi.org/10.1016/j.ejpain.2007.05.003},
	year = 2008,
	month = {feb},
	publisher = {Wiley-Blackwell},
	volume = {12},
	number = {2},
	pages = {203--213},
	author = {Thomas Tlle and Rainer Freynhagen and Mark Versavel and Uwe Trostmann and James P. Young},
	title = {Pregabalin for relief of neuropathic pain associated with diabetic neuropathy: A randomized, double-blind study},
	journal = {European Journal of Pain}
}
@article{Torrance_2006,
	doi = {10.1016/j.jpain.2005.11.008},
	url = {http://dx.doi.org/10.1016/j.jpain.2005.11.008},
	year = 2006,
	month = {apr},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {7},
	number = {4},
	pages = {281--289},
	author = {Nicola Torrance and Blair H. Smith and Michael I. Bennett and Amanda J. Lee},
	title = {The Epidemiology of Chronic Pain of Predominantly Neuropathic Origin. Results From a General Population Survey},
	journal = {The Journal of Pain}
}
@article{van_Seventer_2006,
	doi = {10.1185/030079906x80404},
	url = {http://dx.doi.org/10.1185/030079906x80404},
	year = 2006,
	month = {feb},
	publisher = {Informa Healthcare},
	volume = {22},
	number = {2},
	pages = {375--384},
	author = {Robert van Seventer and Hilary A. Feister and James P. Young and Malcolm Stoker and Mark Versavel and Laurence Rigaudy},
	title = {Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: a 13-week, randomized trial},
	journal = {Curr Med Res Opin}
}
@article{Vestergaard_2001,
	doi = {10.1212/wnl.56.2.184},
	url = {http://dx.doi.org/10.1212/wnl.56.2.184},
	year = 2001,
	month = {jan},
	publisher = {Ovid Technologies (Wolters Kluwer Health)},
	volume = {56},
	number = {2},
	pages = {184--190},
	author = {K. Vestergaard and G. Andersen and H. Gottrup and B.T. Kristensen and T.S. Jensen},
	title = {Lamotrigine for central poststroke pain: A randomized controlled trial},
	journal = {Neurology}
}
@article{Vinik_2007,
	doi = {10.1016/j.pain.2006.09.040},
	url = {http://dx.doi.org/10.1016/j.pain.2006.09.040},
	year = 2007,
	month = {mar},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {128},
	number = {1-2},
	pages = {169--179},
	author = {Aaron I. Vinik and Michael Tuchman and Beth Safirstein and Clinton Corder and Louis Kirby and Kerri Wilks and Steve Quessy and David Blum and Joanne Grainger and Jonathan White and Marianne Silver},
	title = {Lamotrigine for treatment of pain associated with diabetic neuropathy: Results of two randomized, double-blind, placebo-controlled studies},
	journal = {Pain}
}
@article{Vranken_2008,
	doi = {10.1016/j.pain.2007.06.033},
	url = {http://dx.doi.org/10.1016/j.pain.2007.06.033},
	year = 2008,
	month = {may},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {136},
	number = {1-2},
	pages = {150--157},
	author = {J.H. Vranken and M.G.W. Dijkgraaf and M.R. Kruis and M.H. van der Vegt and M.W. Hollmann and M. Heesen},
	title = {Pregabalin in patients with central neuropathic pain: A randomized, double-blind, placebo-controlled trial of a flexible-dose regimen},
	journal = {$\\lbrace$PAIN$\\rbrace$}
}
@article{Vranken_2011,
	doi = {10.1016/j.pain.2010.09.005},
	url = {http://dx.doi.org/10.1016/j.pain.2010.09.005},
	year = 2011,
	month = {feb},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {152},
	number = {2},
	pages = {267--273},
	author = {J.H. Vranken and M.W. Hollmann and M.H. van der Vegt and M.R. Kruis and M. Heesen and K. Vos and A.J. Pijl and M.G.W. Dijkgraaf},
	title = {Duloxetine in patients with central neuropathic pain caused by spinal cord injury or stroke: A randomized, double-blind, placebo-controlled trial},
	journal = {$\\lbrace$PAIN$\\rbrace$}
}
@article{Vrethem_1997,
	doi = {10.1097/00002508-199712000-00009},
	url = {http://dx.doi.org/10.1097/00002508-199712000-00009},
	year = 1997,
	month = {dec},
	publisher = {Ovid Technologies (Wolters Kluwer Health)},
	volume = {13},
	number = {4},
	pages = {313--323},
	author = {Magnus Vrethem and Jrgen Boivie and Hans Arnqvist and Helen Holmgren and Torbjrn Lindstrm and Lars-H{\\aa}kan Thorell},
	title = {A Comparison of Amitriptyline and Maprotiline in the Treatment of Painful Polyneuropathy in Diabetics and Nondiabetics},
	journal = {The Clinical Journal of Pain}
}
@article{Wade_2004,
	doi = {10.1191/1352458504ms1082oa},
	url = {http://dx.doi.org/10.1191/1352458504ms1082oa},
	year = 2004,
	month = {aug},
	publisher = {Cambridge University Press ($\\lbrace$CUP$\\rbrace$)},
	volume = {10},
	number = {4},
	pages = {434--441},
	author = {Derick T Wade and Petra Makela and Philip Robson and Heather House and Cynthia Bateman},
	title = {Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients},
	journal = {Multiple Sclerosis}
}
@article{Watson_1992,
	doi = {10.1016/0304-3959(92)90223-x},
	url = {http://dx.doi.org/10.1016/0304-3959(92)90223-x},
	year = 1992,
	month = {dec},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {51},
	number = {3},
	pages = {375--379},
	author = {C.Peter N. Watson and Ramon J. Evans},
	title = {The postmastectomy pain syndrome and topical capsaicin: a randomized trial},
	journal = {Pain}
}
@article{N_WATSON_1994,
	doi = {10.1097/00132586-199404000-00039},
	url = {http://dx.doi.org/10.1097/00132586-199404000-00039},
	year = 1994,
	month = {apr},
	publisher = {Ovid Technologies (Wolters Kluwer Health)},
	volume = {38},
	number = {2},
	pages = {100},
	author = {C. PETER N. WATSON and KENNETH L. TYLER and DAVID R. BICKERS and LARRY E. MILLIKAN and SHARON SMITH and EDWARD COLEMAN},
	title = {A Randomized Vehicle-Controlled Trial of Topical Capsaicin in the Treatment of Postherpetic Neuralgia},
	journal = {Survey of Anesthesiology}
}
@article{Watson_1998,
	doi = {10.1212/wnl.51.4.1166},
	url = {http://dx.doi.org/10.1212/wnl.51.4.1166},
	year = 1998,
	month = {oct},
	publisher = {Ovid Technologies (Wolters Kluwer Health)},
	volume = {51},
	number = {4},
	pages = {1166--1171},
	author = {C. P. N. Watson and L. Vernich and M. Chipman and K. Reed},
	title = {Nortriptyline versus amitriptyline in postherpetic neuralgia: A randomized trial},
	journal = {Neurology}
}
@article{Webster_2010,
	doi = {10.1186/1471-2377-10-92},
	url = {http://dx.doi.org/10.1186/1471-2377-10-92},
	year = 2010,
	publisher = {Springer Science $\\mathplus$ Business Media},
	volume = {10},
	number = {1},
	pages = {92},
	author = {Lynn R Webster and Marvin Tark and Richard Rauck and Jeffrey K Tobias and Geertrui F Vanhove},
	title = {Effect of duration of postherpetic neuralgia on efficacy analyses in a multicenter, randomized, controlled study of $\\lbrace$NGX$\\rbrace$-4010, an 8{\\%} capsaicin patch evaluated for the treatment of postherpetic neuralgia},
	journal = {$\\lbrace$BMC$\\rbrace$ Neurology}
}
@article{Webster_2010,
	doi = {10.1016/j.jpain.2010.01.270},
	url = {http://dx.doi.org/10.1016/j.jpain.2010.01.270},
	year = 2010,
	month = {oct},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {11},
	number = {10},
	pages = {972--982},
	author = {Lynn R. Webster and T. Philip Malan and Michael M. Tuchman and Martin D. Mollen and Jeffrey K. Tobias and Geertrui F. Vanhove},
	title = {A Multicenter, Randomized, Double-Blind, Controlled Dose Finding Study of $\\lbrace$NGX$\\rbrace$-4010, a High-Concentration Capsaicin Patch, for the Treatment of Postherpetic Neuralgia},
	journal = {The Journal of Pain}
}
@article{Wernicke_2006,
	doi = {10.1212/01.wnl.0000240225.04000.1a},
	url = {http://dx.doi.org/10.1212/01.wnl.0000240225.04000.1a},
	year = 2006,
	month = {oct},
	publisher = {Ovid Technologies (Wolters Kluwer Health)},
	volume = {67},
	number = {8},
	pages = {1411--1420},
	author = {J. F. Wernicke and Y. L. Pritchett and D. N. D{\\textquotesingle}Souza and A. Waninger and P. Tran and S. Iyengar and J. Raskin},
	title = {A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain},
	journal = {Neurology}
}
@article{Xie_2013,
	doi = {10.1007/s40266-013-0062-3},
	url = {http://dx.doi.org/10.1007/s40266-013-0062-3},
	year = 2013,
	month = {feb},
	publisher = {Springer Science $\\mathplus$ Business Media},
	volume = {30},
	number = {5},
	pages = {277--284},
	author = {Feng Xie and Pimwara Tanvejsilp and Kaitryn Campbell and Kathryn Gaebel},
	title = {Cost-Effectiveness of Pharmaceutical Management for Osteoarthritis Pain},
	journal = {Drugs Aging}
}
@article{Close_2007,
	doi = {10.1016/j.transproceed.2006.10.014},
	url = {http://dx.doi.org/10.1016/j.transproceed.2006.10.014},
	year = 2007,
	month = {jan},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {39},
	number = {1},
	pages = {179--182},
	author = {N. Close and R. Alejandro and B. Hering and M. Appel},
	title = {Second Annual Analysis of the Collaborative Islet Transplant Registry},
	journal = {Transplantation Proceedings}
}
@article{Shapiro_2006,
	doi = {10.1056/nejmoa061267},
	url = {http://dx.doi.org/10.1056/nejmoa061267},
	year = 2006,
	month = {sep},
	publisher = {New England Journal of Medicine ($\\lbrace$NEJM$\\rbrace$/$\\lbrace$MMS$\\rbrace$)},
	volume = {355},
	number = {13},
	pages = {1318--1330},
	author = {A.M. James Shapiro and Camillo Ricordi and Bernhard J. Hering and Hugh Auchincloss and Robert Lindblad and R. Paul Robertson and Antonio Secchi and Mathias D. Brendel and Thierry Berney and Daniel C. Brennan and Enrico Cagliero and Rodolfo Alejandro and Edmond A. Ryan and Barbara DiMercurio and Philippe Morel and Kenneth S. Polonsky and Jo-Anna Reems and Reinhard G. Bretzel and Federico Bertuzzi and Tatiana Froud and Raja Kandaswamy and David E.R. Sutherland and George Eisenbarth and Miriam Segal and Jutta Preiksaitis and Gregory S. Korbutt and Franca B. Barton and Lisa Viviano and Vicki Seyfert-Margolis and Jeffrey Bluestone and Jonathan R.T. Lakey},
	title = {International Trial of the Edmonton Protocol for Islet Transplantation},
	journal = {New England Journal of Medicine}
}
@article{Toso_2007,
	doi = {10.1097/01.tp.0000280550.01028.89},
	url = {http://dx.doi.org/10.1097/01.tp.0000280550.01028.89},
	year = 2007,
	month = {sep},
	publisher = {Ovid Technologies (Wolters Kluwer Health)},
	volume = {84},
	number = {5},
	pages = {664--666},
	author = {Christian Toso and A M. James Shapiro and Samantha Bowker and Parastoo Dinyari and Breay Paty and Edmond A. Ryan and Peter Senior and Jeffrey A. Johnson},
	title = {Quality of Life After Islet Transplant: Impact of the Number of Islet Infusions and Metabolic Outcome},
	journal = {Transplantation}
}
@article{Ryan_2005,
	doi = {10.2337/diabetes.54.7.2060},
	url = {http://dx.doi.org/10.2337/diabetes.54.7.2060},
	year = 2005,
	month = {jun},
	publisher = {American Diabetes Association},
	volume = {54},
	number = {7},
	pages = {2060--2069},
	author = {E. A. Ryan and B. W. Paty and P. A. Senior and D. Bigam and E. Alfadhli and N. M. Kneteman and J. R.T. Lakey and A.M. J. Shapiro},
	title = {Five-Year Follow-Up After Clinical Islet Transplantation},
	journal = {Diabetes}
}
@article{Bucher_2004,
	doi = {10.1016/j.transproceed.2004.04.022},
	url = {http://dx.doi.org/10.1016/j.transproceed.2004.04.022},
	year = 2004,
	month = {may},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {36},
	number = {4},
	pages = {1119--1120},
	author = {P Bucher and Z Mathe and D Bosco and C Becker and L Kessler and M Greget and P.Y Benhamou and A Andres and J Oberholzer and L Buhler and Ph Morel and T Berney},
	title = {Morbidity associated with intraportal islet transplantation},
	journal = {Transplantation Proceedings}
}
@article{Barshes_2006,
	doi = {10.1111/j.1600-6143.2006.01564.x},
	url = {http://dx.doi.org/10.1111/j.1600-6143.2006.01564.x},
	year = 2006,
	month = {dec},
	publisher = {Wiley-Blackwell},
	volume = {6},
	number = {12},
	pages = {3037--3037},
	author = {N. R. Barshes and E. E. Agee and T. Zgabay and F. C. Brunicardi and J. A. Goss and M. E. DeBakey},
	title = {West Nile Virus Encephalopathy Following Pancreatic Islet Transplantation},
	journal = {Am J Transplant}
}
@article{D_ndar_2004,
	doi = {10.1080/14017430410032325},
	url = {http://dx.doi.org/10.1080/14017430410032325},
	year = 2004,
	month = {jan},
	publisher = {Informa $\\lbrace$UK$\\rbrace$ Limited},
	volume = {38},
	number = {4},
	pages = {200--210},
	author = {Yenal Dndar and Ruaraidh Hill and Ameet Bakhai and Rumona Dickson and Tom Walley},
	title = {Angioplasty and stents in coronary artery disease: a systematic review and meta-analysis},
	journal = {Scand Cardiovasc J}
}
@article{2003,
	doi = {10.1111/1467-6338.00163},
	url = {http://dx.doi.org/10.1111/1467-6338.00163},
	year = 2003,
	month = {jul},
	publisher = {Wiley-Blackwell},
	volume = {44},
	number = {13},
	pages = {1--8},
	title = {Africa Confidential. Volume 44 Number 13. Published 27 June 2003},
	journal = {Africa Confidential}
}
@article{2003,
	doi = {10.3152/147154603781766293},
	url = {http://dx.doi.org/10.3152/147154603781766293},
	year = 2003,
	month = {sep},
	publisher = {Informa $\\lbrace$UK$\\rbrace$ Limited},
	volume = {21},
	number = {3},
	pages = {231--250},
	title = {Principles and guidelines for social impact assessment in the $\\lbrace$USA$\\rbrace$ : The Interorganizational Committee on Principles and Guidelines for Social Impact Assessment},
	journal = {Impact Assessment and Project Appraisal}
}
@article{Chu_2012,
	doi = {10.1111/j.1440-1746.2011.06999.x},
	url = {http://dx.doi.org/10.1111/j.1440-1746.2011.06999.x},
	year = 2012,
	month = {may},
	publisher = {Wiley-Blackwell},
	volume = {27},
	number = {6},
	pages = {1017--1026},
	author = {Huikuan Chu and Zhiyue Lin and Likun Zhong and Richard W McCallum and Xiaohua Hou},
	title = {Treatment of high-frequency gastric electrical stimulation for gastroparesis},
	journal = {Journal of Gastroenterology and Hepatology}
}
@article{O_grady_2009,
	doi = {10.1111/j.1445-2197.2009.04920_21.x},
	url = {http://dx.doi.org/10.1111/j.1445-2197.2009.04920_21.x},
	year = 2009,
	month = {may},
	publisher = {Wiley-Blackwell},
	volume = {79},
	pages = {A43--A43},
	author = {G. O'grady and J. U. Egbuji and P. Du and L. K. Cheng and A. J. Pullan and J. A. Windsor},
	title = {$\\lbrace$HP$\\rbrace$21P{\\textquestiondown}{\\textonehalf}$\\lbrace$HIGH$\\rbrace$-$\\lbrace$FREQUENCY$\\rbrace$ $\\lbrace$GASTRIC$\\rbrace$ $\\lbrace$ELECTRICAL$\\rbrace$ $\\lbrace$STIMULATION$\\rbrace$ $\\lbrace$FOR$\\rbrace$ $\\lbrace$THE$\\rbrace$ $\\lbrace$TREATMENT$\\rbrace$ $\\lbrace$OF$\\rbrace$ $\\lbrace$GASTROPARESIS$\\rbrace$: A $\\lbrace$META$\\rbrace$-$\\lbrace$ANALYSIS$\\rbrace$},
	journal = {$\\lbrace$ANZ$\\rbrace$ Journal of Surgery}
}
@article{McCallum_2013,
	doi = {10.1111/nmo.12185},
	url = {http://dx.doi.org/10.1111/nmo.12185},
	year = 2013,
	month = {jul},
	publisher = {Wiley-Blackwell},
	pages = {n/a--n/a},
	author = {R. W. McCallum and I. Sarosiek and H. P. Parkman and W. Snape and F. Brody and J. Wo and T. Nowak},
	title = {Gastric electrical stimulation with Enterra therapy improves symptoms of idiopathic gastroparesis},
	journal = {Neurogastroenterol. Motil.}
}
@article{McCallum_2010,
	doi = {10.1016/j.cgh.2010.05.020},
	url = {http://dx.doi.org/10.1016/j.cgh.2010.05.020},
	year = 2010,
	month = {nov},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {8},
	number = {11},
	pages = {947--954.e1},
	author = {Richard W. McCallum and William Snape and Fredrick Brody and John Wo and Henry P. Parkman and Thomas Nowak},
	title = {Gastric Electrical Stimulation With Enterra Therapy Improves Symptoms From Diabetic Gastroparesis in a Prospective Study},
	journal = {Clinical Gastroenterology and Hepatology}
}
@article{Zehetner_2012,
	doi = {10.1007/s00464-012-2407-0},
	url = {http://dx.doi.org/10.1007/s00464-012-2407-0},
	year = 2012,
	month = {jun},
	publisher = {Springer Science $\\mathplus$ Business Media},
	volume = {27},
	number = {1},
	pages = {61--66},
	author = {Joerg Zehetner and Farrokh Ravari and Shahin Ayazi and Afshin Skibba and Ali Darehzereshki and Diana Pelipad and Rodney J. Mason and Namir Katkhouda and John C. Lipham},
	title = {Minimally invasive surgical approach for the treatment of gastroparesis},
	journal = {Surg Endosc}
}
@article{O_Loughlin_2013,
	doi = {10.1016/j.surge.2012.10.006},
	url = {http://dx.doi.org/10.1016/j.surge.2012.10.006},
	year = 2013,
	month = {jun},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {11},
	number = {3},
	pages = {134--140},
	author = {P.M. O{\\textquotesingle}Loughlin and A.D. Gilliam and F. Shaban and J.S. Varma},
	title = {Pre-operative gastric emptying time correlates with clinical response to gastric electrical stimulation in the treatment of~gastroparesis},
	journal = {The Surgeon}
}
@article{McCallum_2011,
	doi = {10.1016/j.cgh.2010.12.013},
	url = {http://dx.doi.org/10.1016/j.cgh.2010.12.013},
	year = 2011,
	month = {apr},
	publisher = {Elsevier $\\lbrace$BV$\\rbrace$},
	volume = {9},
	number = {4},
	pages = {314--319.e1},
	author = {Richard W. McCallum and Zhiyue Lin and Jameson Forster and Katherine Roeser and Qingjiang Hou and Irene Sarosiek},
	title = {Gastric Electrical Stimulation Improves Outcomes of Patients With Gastroparesis for up to 10 Years},
	journal = {Clinical Gastroenterology and Hepatology}
}
@article{Keller_2013,
	doi = {10.1007/s11605-013-2147-z},
	url = {http://dx.doi.org/10.1007/s11605-013-2147-z},
	year = 2013,
	month = {jan},
	publisher = {Springer Science $\\mathplus$ Business Media},
	volume = {17},
	number = {4},
	pages = {620--626},
	author = {Deborah S. Keller and Henry P. Parkman and Daniel O. Boucek and Abhinav Sankineni and John E. Meilahn and John P. Gaughan and Sean Harbison},
	title = {Surgical Outcomes After Gastric Electric Stimulator Placement for Refractory Gastroparesis},
	journal = {J Gastrointest Surg}
}
""";
                                                                                                     <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-Citations.tex>;
                                                                                                     <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                     <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-Citations.tex-0000000000000000000000000000000000000000>;
                                                                                                     <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-introduction-Introduction.md-beb4f86b155e8a94e230a0036d627b612f3c6192> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                               <http://www.w3.org/ns/prov#Entity>;
                                                                                                                             <http://www.w3.org/2011/content#chars> """# Type 1 Diabetes
""";
                                                                                                                             <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-introduction-Introduction.md>;
                                                                                                                             <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                             <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-introduction-Introduction.md-ca2458a6779cddbaeb0e986365ad85b7a7a9b38d>;
                                                                                                                             <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-0abe8d2ab751f38d5506ebd6005c45d3ab743e8b>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-introduction-Introduction.md-ca2458a6779cddbaeb0e986365ad85b7a7a9b38d> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                               <http://www.w3.org/ns/prov#Entity>;
                                                                                                                             <http://www.w3.org/2011/content#chars> """# Type 1 Diabetes

Diabetes is a group of disorders with a number of features in common, of which raised blood sugar is the most evident. This guideline is concerned only with type 1 diabetes, a condition that aetiologically is a pure hormone-deficiency disease. However, because hormone replacement with insulin therapy is sub-optimal, acute and long-term complications are endemic despite the implementation of lifestyle and other disease management measures.

""";
                                                                                                                             <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-introduction-Introduction.md>;
                                                                                                                             <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                             <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-introduction-Introduction.md-beb4f86b155e8a94e230a0036d627b612f3c6192>;
                                                                                                                             <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1-CG15AdultES153.md-27dac4afbd0bf4b54a0354ad5f007f02103527d1> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                                <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES153
The Scottish intercollegiate guidelines 174 identify specific risk factors for arterial disease as cigarette smoking, dyslipidaemia, hypertension, hyperglycaemia, obesity and micro- albuminuria



[@Linden_2011]
""";
                                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1-CG15AdultES153.md>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1-CG15AdultES153.md-33d74e9276eaab2c493e773aaf3f629b5ff3afe0>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1-CG15AdultES154.md-f2d4fdca9e2ffe1d275c0ce4c35499c2e87d0eb2> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                                <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES154
The guideline 174 re ports on non-randomised studies showing that smoking is an independent arterial risk factor in people with diabetes. Additional observational studies reported dyslip- idaemia. An increased concentration of LDL cholesterol or total cholesterol has also been identified as an independent risk factor for arterial morbidity and mortality and each 1.0 mmol/l re duction of LDL cholesterol represents a 36% reduction in risk of arterial disease



[@Linden_2011]
""";
                                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1-CG15AdultES154.md>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1-CG15AdultES154.md-90bad61318669917ee03b9efc50c72564b723ac6>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1-CG15AdultES155.md-ecb08b4a3155197c26f19d10f31502b98400d9fb> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                                <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES155
Two controlled but not randomised studies reported within the guideline 174 demonstrated the positive relationship between hypertension and risk of arterial death, with a progressive increase in risk with rising systolic pressure. Each 10 mmHg reduction in systolic pressure is associated with a 15% (95% CI: 1218) reduction in risk of arterial death over 10 years



[@Linden_2011]
""";
                                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1-CG15AdultES155.md>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1-CG15AdultES155.md-271787833318fcfc6172fa0d946b4ca681086930>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1-CG15AdultES156.md-7cfa5bff40f4474fc22ccc7da2f88a84ffa23d42> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                                <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES156
The link between glycaemia and arterial morbidity and mortality was also reported in two studies reviewed in the SIGN guidelines. 174 In o ne study each 1% reduction in HbA 1c was associated with a 21% (95% CI: 1527) reduction in the risk of diabetes-related death and a 14% reduction for myocardial infarction over 10 years



[@Linden_2011]
""";
                                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1-CG15AdultES156.md>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1-CG15AdultES156.md-9c5c21908d1b0aed308ed2ce48e1a34b4af8313e>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1-CG15AdultES157.md-3a01b9b3d48cbbceecd6d7ffafa725894709a2a2> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                                <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES157
Ev idence for the other risk factors is sparse. In the SIGN guidelines, 174 no studies were identified for linking obesity as an indepen dent risk factor in established diabetes. One observational study reported microalbuminuria as an independent marker associated with doubling in arterial risk, however, there is ins ufficient evidence to determine whether reducing albumin excretion rate specifically reduces arterial morbidity or mortality



[@Linden_2011]
""";
                                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1-CG15AdultES157.md>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1-CG15AdultES157.md-9351c6ade903bda6c77e4c2c61b0f2098cff5893>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1-CG15AdultES158.md-19fba74abbeca08dc15a326ca45c044a3da67215> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                                <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES158
A meta-analysis 175 aimed at defining risk factors for arterial disease from studies in people with diabetes, showed that, adjusted for age, both total mortality and death from all vascular causes increased significantly with total cholesterol level and systolic blood pressure, and decreased w ith percentage of women. Duration of diabetes and mean HbA 1c we re not considered to be associated with mortality. However, this meta-analysis did not contain a critical appraisal of included studies or details of approaches used to ensure study quality before inclusions and should therefore not be used as the basis for clinical recommendations



[@Kanters_1999]
""";
                                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1-CG15AdultES158.md>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1-CG15AdultES158.md-052dd267128c8f667957b6b4ce99455e06c3adca>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1-CG15AdultES159.md-8f5f7c12cac45c283ad6c390a83366ef3b5a2aed> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                                <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES159
One systematic review 176 e xamined 67 studies, addressing both screening for primary detection of arterial risk factors and treatment of lipid abnormalities in asymptomatic people both with and without diabetes. Reliability and effectiveness of each screening strategy for identifying lipid disorders was investigated, and showed that total cholesterol measurements generally have good reliability, with an analytic variability of less than or equal to 3% and a mean total biologic variability of the order of 6%. A total cholesterol level within 10% of the true value can be determined with two separate measurements, which do not differ significantly between fasting or non-fasting venous blood 



[@Pignone_2001]
""";
                                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1-CG15AdultES159.md>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1-CG15AdultES159.md-9e82af853e32bb6dc69f7e9197e32db638d556fd>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1-CG15AdultES160.md-18226035b6205cf9cbc30b1b870b782d6d62bf8e> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                                <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES160
Ev idence within this systematic review 176 for HDL cholesterol showed a higher analytical (6%) and biological (7.5%) variation than total cholesterol, however, two or three values were re quired to estimate true HDL cholesterol levels to within 10 to 15%. Variations were also found between non-fasting and fasting blood samples as HDL cholesterol is 5%10% lower in the non-fasting state, suggesting that non-fasting measurement may slightly overestimate coronary heart disease risk, but not enough to make accuracy of screening unacceptable



[@Pignone_2001]
""";
                                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1-CG15AdultES160.md>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1-CG15AdultES160.md-23365cf732424245ba3bf1052bc20a5d4792f7ca>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1-CG15AdultES161.md-ca7c1404b3857b3f369cac8a4c7fe592129fd363> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                                <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES161
A dditional studies within this systematic review 176 co nsidered triglyceride screening. Values measured varied by 20%30% between fasting and non-fasting states. LDL cholesterol is calculated from total and HDL cholesterol and triglycerides measurements and application of the Friedewald equation. However, this equation has been found to be inaccurate at triglyceride levels greater than or equal to 4.5 mmol/l when special techniques must be employed (eg ultracentrifugation)



[@Pignone_2001]
""";
                                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1-CG15AdultES161.md>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1-CG15AdultES161.md-be0df232b26e65ceb253719059c5988240ae9643>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1-CG15AdultES162.md-851fe06475472d5694b09e712d061b8bd9bd8c0b> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                                <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES162
Also considered in this systematic review 176 was the comparable accuracy of total and HDL c holesterol from capillary blood samples. These were found to be less reliable without proper attention to calibration and proper testing techniques. One study found that a Framingham- based coronary risk model was the best predictor of IHD mortality. Guidelines reported in the re vi ew concluded that the LDL:HDL cholesterol and the total:HDL cholesterol ratios performed equally well in determining arterial outcomes, and the least accurate screening test was that of measuring total cholesterol alone



[@Pignone_2001]
""";
                                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1-CG15AdultES162.md>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1-CG15AdultES162.md-99281921815349147051027d3adc54d9871026ee>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1-CG15AdultES163.md-d019d7c6d2409f4fc3467ceaca023b86f9b4c14f> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                                <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES163
Other studies included in this review 176 assessing characteristics of the screening tests showed that non-fasting total cholesterol alone is the easiest to perform for the patient and provider. T otal:HDL cholesterol ratio is easy for patients to obtain and for providers to interpret and performs equally accurately as the LDL:HDL cholesterol ratio strategy. However, one study in the review demonstrated that risk-based algorithms which directly incorporate age, other risk factors and measures of total and HDL cholesterol are the most accurate approach to screening. These processes are difficult to access and so supplemental tables, such as the Sheffield table, can improve the feasibility of a risk-based strategy



[@Pignone_2001]
""";
                                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1-CG15AdultES163.md>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1-CG15AdultES163.md-2c7b540d288bf029c8dad815b6d8af96fcb375f0>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1-CG15AdultES164.md-fffdd65c1d0dd2ff53242a921d26e3e64cee8488> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                                <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES164
There was no evidence from this systematic review 176 to inform the question of appropriate frequency of screening. National guidelines reco mmend a five-year interval for people with previous normal results and more freque nt screening in those with borderline values



[@Pignone_2001]
""";
                                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1-CG15AdultES164.md>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1-CG15AdultES164.md-d72bed8e6ff9bde897738cca7b0890a8cb76d24c>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1-CG15AdultES165.md-3bcf7ece0d2412814e4765b8065770a00d23b7a6> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                                <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES165
One study 177 co mparing the Sheffield tables to the computer-calculated Framingham equation re v ealed a low sensitivity and specificity for the Sheffield tables (35% (95% CI 28 to 42) and 98% (95% CI 97 to 99) respectively). The old tab les only included patients with systolic blood pressure <160 mmHg, and cholesterol greater than 5.5 mmol/l. Adopting these exclusion criteria led to a substantial reduction in the number of patients eligible for screening without improving detection of risk assessment



[@Bayly_1999]
""";
                                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1-CG15AdultES165.md>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1-CG15AdultES165.md-c3f889eed8f56f5bf0289e3a77e4dd37c757a591>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1-CG15AdultES166.md-9ba51b2147a8a9e21146e56dfea81499d3e10a33> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                                <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES166
A nother evaluation 178 studied all seven guidelines against the calculated Framingham equation in 906 people with diabetes, showing Modified Sheffield tables have higher sensitivity (95% vs 37%) with a slight reduction in specificity (90% vs 97%) compared with the original tables, w ith a slightly better positive predictive value than the original version (80% vs 71%). The Joint Br itish tables have good specificity (99%), but lo w sensitivity (77%) but the tables perform well at the lower CHD risk of greater than or equal to 15% over 10 years (specificity 92%, sensitivity 96%). Canadian tables perform poorly at the = 30% risk, and only slightly better at the greater than or equal to 15% level of risk (specificity 100%, sensitivity 5%, and 85% and 98%, r espectively). The Framingham categorical tables have a lower specificity (83%) for the identification of high-risk individuals (although risk is greater than or equal to 27% not greater than or equal to 30%) and this deteriorates for identification of those at = 15% risk (specificity 77%). New Zealand tables had a sensitivity of 69% and specificity of 88% at a greater than or equal to 20% level of risk, at the = 10% level of risk, specificity deteriorates to 58%. The Joint Eu ro pean tables have a sensitivity of 89% for risk levels greater than or equal to 20% but specificity of only 71%. This means that one in four patients would be incorrectly identified as having a risk above the 20% threshold



[@Bayly_1999]
""";
                                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1-CG15AdultES166.md>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1-CG15AdultES166.md-bada22c1f04305718e915fb0400cc238223442f8>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1-CG15AdultES167.md-7e67e90ebe31a285cfcc3aa7959232363d3a2214> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                                <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES167
A further study from the same investigators 179 assessed the PROCAM program against that of the Framingham equation. Only 56% of the study populat ion were eligible for evaluation with PROCAM. This evaluation also systematically underestimates risk in comparison with the Fr amingham equation at low levels of absolute risk but overestimates at higher risk levels



[@Game_2001]
""";
                                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1-CG15AdultES167.md>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1-CG15AdultES167.md-86ade6b08c1e7c18251fd0b9b644741738d6e460>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1-CG15AdultES168.md-b7bb313f1dc7826619700d3ee93288a12e504451> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                                <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES168
The sensitivity and specificity of various risk pr ediction tables and charts was also investigated in one comparative study. 180 Co mpared to the Framingham equation the Sheffield tables had a low sensitivity (40% eligible for cholesterol lowering treatment would be identified), but with high specificity and thus low false positive rates. The New Zealand tables had similar sensitivities and specificities to the Sheffield tables, but a 10% level of risk prediction of five- y ear arterial disease risk threshold specificity is significantly lower than the Sheffield tables. The Eu ro pean tables have better sensitivity than Sheffield and New Zealand tables but specificity is significantly worse than other risk assessment levels leading to an equally low sensitivity. The joint British Societies table has significantly better specificities at greater than or equal to 15% and greater than or equal to 30% 10-year CHD risk than the modified Sheffield tables. Sensitivity is generally low, but high at the 15% 10-year CHD/10% five-year CVD risk level. Canadian tables are not reliable at greater than or equal to 30% risk but are comparable with the modified Sheffield tables at 154% risk threshold. The Framingham equation had the best performance with sensitivity and specificity comparable to that of the modified Sheffield and joint British Society methods, respectively



[@Jones_2001]
""";
                                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1-CG15AdultES168.md>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1-CG15AdultES168.md-1b9c8af6718003f994818a013881ea6a3599729c>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1-Discussion.md-b16cde6ab1d98b68e054aac0b160558920cc0d0a> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                              <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                            <http://www.w3.org/2011/content#chars> """The group recognised the very considerable difficulties in reaching conclusions from the ev idence in this area. Very little direct information pertaining to people with Type 1 diabetes can be ascertained, whilst the importance of the issue is emphasised by the very high early arterial disease (CVD) risk run by people with Type 1 diabetes. Nevertheless certain sub-groups are known to be at particularly high risk (people with raised albumin excretion rate (micro- albuminuria)), while others combine Type 1 diabetes with combinations of classic risk factors ty pical of the metabolic syndrome and known to be predictors of high arterial risk in people w ith Type 2 diabetes and indeed non-diabetic po pulations. A further group of people will co mbine Type 1 diabetes with a single arterial risk factor or risk marker, while yet others will have Type 1 diabetes but appear low risk otherwise. Ac co r dingly the important factors for surveillance are urinary albumin excretion (most important), other classical risk factors including full lipid profile, and risk markers such as age, family history and some ethnic groups. In accordance with the principle of unified organisation of care, monitoring of these factors annually is to be recommended, but it was recognised that in low risk individuals technology might become capable of programming longer review intervals for serum lipids. The group recognised that different ways of using information from a full lipid profile (calculated LDL and HDL separately, calculation of total: HDL cholesterol ratio, calculation of non-HDL cholesterol) are in use. While the group preferred the first of these as not mixing lipid abnormalities of different pathogenesis, and being a better route to using the treatments for different lipid disorders rationally, it was recog nised that there was not good evidence to suggest supporting one approach over the others. The group could find no confidence in any risk table, engine or equation when applied to people with Type 1 diabetes.
""";
                                                                                                                                            <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1-Discussion.md>;
                                                                                                                                            <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                            <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1-Discussion.md-a476bce947631691a38e11bbb193fad509871e9c>;
                                                                                                                                            <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1-Recommendation.md-fcde5b21d1b635e72404a00b76ddbbab35c4f5d7> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                                <http://www.w3.org/2011/content#chars> """Arterial risk factors should be assessed annually
Arterial risk factors should be assessed annually, and the assessment should include:

*   albumin excretion rate

*   smoking

*   blood glucose control

*   blood pressure

*   full lipid profile (including HDL and LDL cholesterol and triglycerides)

*   age

*   family history of arterial disease (CVD)

*   abdominal adiposity.
'


""";
                                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1-Recommendation.md>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1-Recommendation.md-787d7e0cfb1106a49812759a54ea391c88d9b786>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1.md-e721bfd1f0e0f10089e551a77d3e714b580dd8b4> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                   <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                 <http://www.w3.org/2011/content#chars> """Arterial risk factors should be assessed annually, and the assessment should include:
? albumin excretion rate
? smoking
? blood glucose control
? blood pressure
? full lipid profile (including HDL and LDL cholesterol and triglycerides)
? age
? family history of arterial disease (CVD)
? abdominal adiposity.
'

---
 nice.evidencegrade: C
""";
                                                                                                                                 <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1.md>;
                                                                                                                                 <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                 <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.1.md-0000000000000000000000000000000000000000>;
                                                                                                                                 <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.2.md-27fe712b5ffb1ec85b7006b96d67287dc54a1728> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                   <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                 <http://www.w3.org/2011/content#chars> """Arterial risk tables, equations or engines for calculation of arterial risk should not be used because they underestimate risk in adults with Type 1 diabetes.
'

---
 nice.evidencegrade: DS
""";
                                                                                                                                 <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.2.md>;
                                                                                                                                 <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                 <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.2.md-0000000000000000000000000000000000000000>;
                                                                                                                                 <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.3.md-a09b86a7215459f59901ca27e87a9ade6d4c86dd> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                   <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                 <http://www.w3.org/2011/content#chars> """Adults with raised albumin excretion rate (microalbuminuria), or two or more features of the metabolic syndrome (see Table 4), should be managed as the highest risk category (as though they had Type 2 diabetes or declared arterial disease).
'

---
 nice.evidencegrade: D
""";
                                                                                                                                 <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.3.md>;
                                                                                                                                 <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                 <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.3.md-0000000000000000000000000000000000000000>;
                                                                                                                                 <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.4.md-71d793dec4b7e35e23232b9d0fc768658b6ad003> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                   <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                 <http://www.w3.org/2011/content#chars> """Adults with Type 1 diabetes who are not in the highest risk category but who have other arterial risk factors (increasing age over 35 years, family history of premature heart disease, of ethnic group with high risk or with more severe abnormalities of blood lipids or blood pressure) should be managed as a moderately high risk group.
'

---
 nice.evidencegrade: D
""";
                                                                                                                                 <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.4.md>;
                                                                                                                                 <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                 <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.4.md-0000000000000000000000000000000000000000>;
                                                                                                                                 <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.5.md-096124c41550975b3130ccb9b7d31b093b058a44> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                   <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                 <http://www.w3.org/2011/content#chars> """Where there is no evidence of additional arterial risk, the management of lipids and blood pressure should follow normal procedures for the non-diabetes population, using appropriate clinical guidelines.
'

---
 nice.evidencegrade: D
""";
                                                                                                                                 <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.5.md>;
                                                                                                                                 <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                 <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.1.5.md-0000000000000000000000000000000000000000>;
                                                                                                                                 <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES169.md-3a1111ebf6904052d80dd389201ce74ba4d10bf0> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                                <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES169
The Scottish intercollegiate guidelines 174 identify a role for lipid-lowering drugs in reducing ischaemic heart disease events but not all cause mortality in people with no known arterial disease, compared with placebo



[@Linden_2011]
""";
                                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES169.md>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES169.md-af7054bd9033c4db3a07828f64fffdb5d7d480c9>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES170.md-2e2bc10e1c24c8f33e9013afd1c264d513a8c034> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                                <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES170
SIGN guidelines on lipids 181 and the prevention of ischaemic heart disease detail studies targeted at people with Type 2 diabetes. However, secondary prevention trials of lipids reported 77 Feature Women Men Blood pressure average (mmHg) >135/80 >135/80 Waist circumference (m) (use 0.10m lower >0.90 >1.00 figures for people of South Asian extraction) Serum HDL cholesterol (mmol/l) <1.2 <1.0 Serum triglycerides (mmol/l) >1.8 >1.8 Raised albumin exrection rate is not included because in Type 1 diabetes it is a marker of developing nephropathy and nephropathy alone is associated with extreme risk of ischaemic heart disease. Glucose intolerance cannot be assessed in adults with Type 1 diabetes, but higher insulin doses in adults >20 years (>1.0 U/kg/day) suggest insulin insensitivity. Table 4 Features of the metabolic syndrome suggesting high arterial risk in people with Type 1 diabetes in the guideline have shown significant reduction in arterial disease in both Type 1 and Type 2 diabetes. These guidelines recommend the loss of weight, reduction of intake of saturated fat, increased consumption of fruit and vegetables, regular exercise and the introduction of lipid- lowering drug treatment for primary prevention of arterial problems in high-risk people with diabetes. The guidelines also report a study raising concern about underestimating diabetic ischaemic heart disease risk, particularly in people with Type 1 diabetes 



[@Miller_2002]
""";
                                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES170.md>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES170.md-43d87ea06f0f2a07e31da2d96d64fa4e4d82fc3a>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES171.md-cef96ee3235c462a608f269b9686b496a4c8591a> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                                <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES171
The SIGN guidelines 174 re port on a number of therapeutic studies. The CARE study demonstrated a significant reduction in coronary events with pravastatin vs placebo, although the magnitude of effect was lower than in the 4S study. The LIPID study also showed a trend to re duction in recurrent coronary events but numbers of people with diabetes in this study were to o low to demonstrate statistical significance. The VA-HIT study showed significant secondary prevention of coronary events in men with diabetes aged less than 74 years, taking a fibrate (gemfibrozil) for a mean follow-up of 5.1 years



[@Linden_2011]
""";
                                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES171.md>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES171.md-5a229fe5cbf8f355a4cc7421e20aa7629787438e>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES172.md-6cc8912b78f6a5e43ca46b7d5ec34e0aff4ffbdb> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                                <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES172
Three randomised controlled trials 182184 re ported on the positive effect of pravastatin on arterial outcomes in people with diabetes. One study 182 re ported a significant change in total and LDL cholesterol, HDL cholesterol and triglycerides vs placebo. After 24 weeks the reduction in total cholesterol from baseline was 22%, LDL cholesterol 26%, and triglycerides decreased by 2%, accompanied by an increase in HDL cholesterol of 14%. Pravastatin was well tolerated throughout the study



[@Rustemeijer_1997]

[@Raskin_1995]

[@Goldberg_1998]
""";
                                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES172.md>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES172.md-3393738306285289167e161a73c79d9f6a780201>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES173.md-a148bdc92ffb7c6b86abf8ab560fbe332f8ddad8> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                                <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES173
Similar results were seen in the further two trials. One study 183 reported re ductions in LDL c holesterol and VLDL cholesterol of 30% and 13% respectively with pravastatin compared with placebo and significant increases in HDL cholesterol at eight and 16 weeks. The final study 184 was in a majority of sulfonylurea treated people with Type 2 diabetes, and pravastatin reduced t otal and LDL cholesterol by 19% and 27% in the diabetes group. Compared with placebo pravastatin caused a 13% decrease in triglycerides and a 4% increase HDL cholesterol in people w ith diabetes. Results were similar to those in people without diabetes, and were unaffected by adjustment for age and sex 



[@Raskin_1995]

[@Goldberg_1998]
""";
                                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES173.md>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES173.md-0c97ae07955127655f3c8d32a2919ee3791a7519>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES174.md-5bdd7cf3418db347824486833f53a9bc00695cce> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                                <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES174
The SIGN management of arterial disease in diabetes guidelines 174 cite results from the Scandinavian Simvastan study, which contained 204 people with diabetes (of a study population of 4,444), and demonstrated that cholesterol-lowering therapy was highly effective co mpared with placebo in those undergoing revascularisation procedures, especially in those w ith diabetes (risk reduction 55% v s 32% in non-diabetes)



[@Linden_2011]
""";
                                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES174.md>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES174.md-9d4ae025fa670f41323168d38b439a387ed29de7>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES175.md-03451b1d5ed8aba03e3195d6dfb38935fea31243> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                                <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES175
Two RCTs reported the effect of simvastatin in people with diabetes. Total and LDL cholesterol levels and the ratio between LDL and HDL cholesterol were decreased following treatment in one study 185 of 25 people with diabetes, whereas no difference was seen following placebo, no between group comparison was made. The second study, containing 26 people with Type 1 diabetes 186 also reported a significant reduction in the plasma concentrations of total c holesterol, LDL cholesterol and apolipoprotein B after 12 weeks simvastatin treatment, wh ereas no changes were observed after placebo treatment



[@Sweany_1995]

[@Hommel_1992]
""";
                                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES175.md>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES175.md-7a78a9715f93fe80802870ed16af40ef3ffce2a7>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES176.md-eca207fa58dca49a3b7144965bc90b1ab3ef149b> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                                <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES176
One study reported the effect of bezafibrate on arterial outcomes in 36 people with Type 1 diabetes. 187 However, there are some potential methodological limitations in this study, which does not make this evidence a reliable basis for a clinical recommendation



[@Winocour_1990]
""";
                                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES176.md>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES176.md-fa28ed481fb9598e75062218fc6d1421e10635e4>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES177.md-aa8e1e9877fac96dc0d23cfc638160fdd2d10491> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                                <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES177
The SIGN guidelines 174 re port uncertainty about the role of aspirin in primary prevention. Citing the HOT study (a randomised controlled trial) and the further reduction in arterial risk in well-controlled hypertensive patients with diabetes, they note the importance of balancing this reduction against the risk of bleeding



[@Linden_2011]
""";
                                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES177.md>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES177.md-ed56f33807117451629fa6dffa018c3e5ead2f13>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES178.md-dff4ad7ad8ff2103f892540969a71ba415113e5c> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                                <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES178
The North of England guidelines 188 on aspirin for the secondary prophylaxis of vascular disease in primary care reported a pooled risk ratio by combining he meta-analysis of the Antiplatelet Co llaborative Group with trials published after 1990 to establish the impact of antiplatelet therapy on subsequent myocardial infarction (MI), stroke and vascular death. This provided strong evidence for a general protective effect of aspirin as antiplatelet therapy in patients at r aised vascular risk. Few studies were found containing comparisons of aspirin and alternative antiplatelet agents to enable comparison of their relative effectiveness



[@1994]
""";
                                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES178.md>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES178.md-8deedb4d44a3c28987f31626b14e1d136aaae5f2>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES179.md-67b407b74519128d2ebe082d4fa2a948e9adfc45> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                                <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES179
Fo r evidence relating specifically to people with diabetes the North of England guidelines 188 identified eight trials contributing to an overall estimate of risk difference for arterial morbidity of 1.2% with aspirin compared to placebo or other antiplatelet agent. These trials were homogeneous with a pooled incidence rate differen ce (by random effects model) of a 0.3% re duction in the risk of MI, stroke or vascular death from antiplatelet therapy for one year. This is not a statistically significant difference, and in summary authors state that aspirin given to patients with diabetes appears to have a small and statistically uncertain effect upon the risk of ex periencing a subsequent vascular event. They also suggest that the similar relative risk for MI, stroke and vascular death found in diabetes trials and other trials of patients at raised vascular r isk, indicates that patients with diabetes alongside other indications of vascular risk are likely to benefit from routine aspirin therapy 



[@1994]
""";
                                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES179.md>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES179.md-80cad4c113e3987bff21974a002bf963c67f93c1>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES180.md-b27a282914ce4fb4e06d8676244d98cff78eb6f0> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                                <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES180
Am erican Diabetes Association guidelines 76 indicate that meta-analysis and large-scale co llaborative trials in men and women with diabetes support the view that low-dose aspirin therapy should be prescribed as a secondary prevention strategy if no contraindications exist. The guidelines also point to substantial evidence suggesting that low-dose aspirin therapy should be used as a primary prevention strategy in men and women with diabetes who are at a high risk for arterial events. The meta-analysis of 145 prospective controlled trials of antiplatelet therapy by the Antiplatelet Tr ialists Group reported in the ADA guidelines 76 showed a trend toward increased risk re ductions with doses of aspirin = 325 mg/day, but the difference was not statistically significant. An estimated 3812 vascular events per 1,000 patients with Type 1 diabetes would have been prevented if they were treated with aspirin as a secondary prevention strategy



[@2003]
""";
                                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES180.md>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES180.md-b43408a877dae01de1f1a200c02c8d1566e71dc7>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES181.md-7f064931e04e87f01a5c3f2c6f41b796d795b28b> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                                <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES181
The ADA guidelines 76 also reported on the HOT study, which showed a reduction in arterial ev ents following aspirin therapy compared to placebo of 15% and a 36% reduction in my ocardial infarction. This study also showed that fatal bleeding including intracerebral bleeding were equal in aspirin and control groups, whereas non-fatal minor bleeding episodes we re more frequent in patients receiving aspirin. The US Physicians Health study reported in the same guideline compared aspirin (325 mg/day) with placebo in male physicians (without diabetes), resulting in a 44% risk reduction in MI among the treated group. In a subgroup of people with diabetes there was a reduction in MI from 10% to 4% yielding a relative risk of 0.39 for men with diabetes randomised to aspirin therapy



[@2003]
""";
                                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES181.md>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES181.md-b3fb900c65b07c330055b94aa0b6816bfe25795a>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES182.md-a3979c3d173b3131842ac00f904b905eb34f6cac> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                                <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES182
The ADA guidelines 76 also addressed the safety of aspirin use and reported several prospective r andomised studies in which a trend for an increase in haemorrhagic stroke followed aspirin therapy, although this has not reached statistical significance



[@2003]
""";
                                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES182.md>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES182.md-1dcc8275384fb84ce9ab47b459b56642c4ad7cf1>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES183.md-92bc16e63796cfc543f331a823a0f3a032477eb7> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                                <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES183
Co ntraindications reported 76 include allergy, bleeding tendency, anticoagulant therapy, recent gastrointestinal bleeding and c linically active hepatic disease



[@2003]
""";
                                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES183.md>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES183.md-83693020ed7e83cd5d516eb0a2edcb9f21687ca8>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES184.md-6ef37141afbb2b89792bd6aedb52643da332deed> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                                <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES184
Re lative risk of MI reported by the ETDRS group 189 in which roughly 48% of men and women w ith diabetes had a history of arterial disease was lowered significantly in the first five years in those randomised to aspirin therapy



[@1992]
""";
                                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES184.md>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES184.md-b0ce74dec2bafc8590abd6ea5a330b0a1aa28b8d>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES185.md-3066f75c104e7ba4bb5eab8e4ef957fc364498b8> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                                <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES185
In the management of people with diabetes and new or established vascular disease, the SIGN guidelines 174 re fer to a meta-analysis of platelet inhibitor therapy demonstrating a 31% re duction in non-fatal reinfarction, a 42% reduction in non-fatal stroke and a 13% reduction in arterial mortality



[@Linden_2011]
""";
                                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES185.md>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES185.md-924bba2d9f0d478e02cac7f552e24fbebc4dc167>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES186.md-1d5b3d356cde73b07f3f750295c78295496ec007> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                                <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES186
One meta-analysis 190 of six randomised, double-blind, placebo-controlled trials showed a significant pooled reduction in mortality following treatment with platelet glycoprotein inhibitors. The most marked benefit was seen in patients undergoing percutaneous coronary intervention. A significant reduction in composite death or MI at 30 days was also seen following treatment in people with diabetes. However, potential methodological limitations of the trials included would not permit this analysis to be used as a evidence base to inform re co mmendations in this area



[@Roffi_2002]
""";
                                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES186.md>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES186.md-b6e9c7aa62c1e361fde8b48242c298be52f69d6b>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES187.md-1c696ab67942026196a9102d249ca1174d6345e9> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                                <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES187
Also reported in the SIGN guideline 174 is a sub-study analysis of a large RCT demonstrating that addition of clopidogrel to aspirin over 312 months reduces the risk of fatal or non-fatal MI or stroke by 20% in patients with a past history of coronary heart disease presenting with acute coronary syndromes (without electrocardiographic ST elevation). This risk reduction was however associated with an additional risk of bleeding



[@Linden_2011]
""";
                                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES187.md>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES187.md-10f78d43a3c7b3059452791b2cc591a87f1ee8fa>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES188.md-7914c13da269a04f664930bef9325acc86f3e2bc> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                                <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES188
The ADA guidelines 76 also report from the CAPRIE study which showed that clopidogrel was slightly more effective than aspirin in reducing the combined risk of stroke, MI or vascular death in people with and without diabetes (effect sizes not stated)



[@2003]
""";
                                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES188.md>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES188.md-bacbdc089f09dda848c68359f4a652e6eb282117>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES189.md-e42cf1e85d28e9294a661f7c94f3a89838434d75> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                                <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES189
One randomised controlled study reviewed in the ADA guideline 76 showed that thrombolytic therapy reduced mortality after acute MI in subjects with diabetes by = 42% with no increase in r isk of bleeding or stroke, and should not be withheld due to concern about retinal haemorrhage in patients with retinopathy. This study also demonstrated that the indications and co ntraindications for thrombolysis in patients with diabetes are the same as those without



[@2003]
""";
                                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES189.md>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES189.md-5fb00ff61c7119a5b0b0f742ca596a2bfc7ed210>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES190.md-408c941e66f6be7af8a6052bafd445b9582faa24> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                                <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES190
The SIGN guideline 174 re ports on the results of the beta-blocker adrenergic pooling project study, which demonstrated that diabetes is not a contraindication to the use of beta-blockers, and that these reduce mortality, sudden cardiac death and re-infarction when given after acute MI. The guideline also cites the 1995 Collaborative Group on ACE inhibitor trials meta-analysis of nearly 100,000 patients which showed that receiving therapy with an ACE inhibitor within 36 hours of acute MI for = 4 weeks, reduced mortality post MI. The majority of benefits occurred within the first few days when mortality was highest, benefiting patients at a higher r isk to a greater absolute extent



[@Linden_2011]
""";
                                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES190.md>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES190.md-8d01ca3552898f8cd4d68eafc6646cc1f2ac05d9>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES191.md-cfdea43f9914ef1bcab5ebe1e26b338e7ce0dc67> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                                <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES191
Three large trials (AIRE, SAVE and TRACE studies) 174 also reviewed within the SIGN guideline have shown consistent reductions in mortality when ACE inhibitor therapy is given to people after acute MI with clinical evidence of heart failure or a reduced ejection fraction. A fourth study (SOLVD) demonstrated an absolute risk reduction for mortality of 4.5% in patients with diabetes and chronic heart failure given an ACE inhibitor compared to placebo over a mean follow-up of 4.5 years



[@Linden_2011]
""";
                                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES191.md>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES191.md-820ed2273cf2ed92cacc35ef083dd430ddbcf83f>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES192.md-f8807be2147799694a132111d667f117160e6192> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                                <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES192
A predefined subgroup analysis of 3,577 people over 55 with diabetes (the majority of whom had Type 2 diabetes) in the large multinational HOPE randomised controlled trial 191 showed the effect of ramipril on arterial outcomes in people with diabetes. The rate of combined primary outcome of MI, stroke or arterial death was significantly lower in the ramipril groups than in those receiving placebo. Total mortality was reduced by 24%. Adjustment for changes in systolic and diastolic blood pressures did not change the magnitude of the effect



[@2000]
""";
                                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES192.md>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES192.md-82f5aee612c57043ab9caab05b35a804ecf523d9>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES193.md-5b6c577e7c1a48cbe0f3aab275111cb8eeab93f2> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                                <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES193
Other results from the HOPE study 192 in which patients aged over 55 years, with and without diabetes, who were randomised to receive 400 IU vitamin E for an average follow-up of 4.5 years, showed no effect of antioxidant over placebo. Primary outcomes of MI, stroke or arterial death, or secondary outcomes of hospitalisations for angina or heart failure, were similar following tr eatment with vitamin E and placebo. No differences were observed in the frequency of outcomes in people with diabetes in the two treatment groups



[@Lonn_2003]
""";
                                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES193.md>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES193.md-a15f7265bcb583ff7b4eb3324a39b125ee55bcd4>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES194.md-1f0c6d62590398f24914419f3f7e605bdbcf0a1b> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                                <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES194
SIGN guidelines 174 state that clinical presentation of stroke in people with diabetes is similar to that in people without diabetes. There is little eviden ce specific to people with diabetes let alone specific to Type 1 diabetes, suggesting that the management of stroke should be similar to that in people without diabetes



[@Linden_2011]
""";
                                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES194.md>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES194.md-67a08406dcbacf37abac7f983dab781e8d653420>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES195.md-4609564722562dc9b0b1a9d95ca994d14d82c11f> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                                <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES195
W hilst economic analyses have been conducted on trials of lipid-lowering agents, no evaluation has specifically considered Type 1 diabetes. Three papers were identified within the health economic literature dealing with mixed diabetic populations. 35052 An economic analysis 350 of simvastatin using the 4S trial data suggests that it would provide cost-effective mortality re duction in the UK amongst a similar population. A second cost-effectiveness paper 351 also suggests that the simvastatin may be cost-effective in the UK for those aged 40 to 70 years with elevated cholesterol even if they have not been diagnosed with arterial disease. A third paper based outside the UK suggests that the benefits of simvastatin to diabetics with elevated lipid levels and arterial disease outweigh the benefit to those with elevated lipid levels and no prior arterial disease. 352



[@Grover_2000]

[@Grover_2001]
""";
                                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES195.md>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-CG15AdultES195.md-c8f57f12010ecdeadf6bfdf20d89c7b4f168307a>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-Discussion.md-686dffe806efa0756f878b1bdb1b2756b9667b60> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                              <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                            <http://www.w3.org/2011/content#chars> """The data on arterial risk management in people with Type 1 diabetes are few, though it is noted that studies in people with and without Type 2 diabetes point to clinically effective interventions for those groups. In the absence of quantitative risk assessment and noting the economic evidence placed before the group it seemed clear that interventions in people with Ty pe 1 diabetes must be recommended considering their semi-quantitative arterial disease risk: high, moderate or no risk. Given the high arterial risk of many people with Type 1 diabetes, smoking was considered to be particularly disadvantageous.
""";
                                                                                                                                            <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-Discussion.md>;
                                                                                                                                            <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                            <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-Discussion.md-527a0ed686d68e1a8111bd7b4cabd39a18a88a8b>;
                                                                                                                                            <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-Recommendation.md-3c04667a9427acb41218787e7aa4995b167008fc> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                                <http://www.w3.org/2011/content#chars> """advice on smoking cessation
Adults with Type 1 diabetes who smoke should be given advice on smoking cessation and use of smoking cessation services, including NICE guidance-recommended therapies. The messages should be reinforced in continuing smokers yearly if pre-contemplative of stopping, and at all clinical contacts if there is a prospect of their stopping.
'


""";
                                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-Recommendation.md>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-Recommendation.md-c5f53202ef6edfeb4c8c6785a941d8d4457da213>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-b93cb04c455c7c905afbe9bfb41261a2e18254b5>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-Recommendation.md-c5f53202ef6edfeb4c8c6785a941d8d4457da213> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                                <http://www.w3.org/2011/content#chars> """## Advice on smoking cessation
Adults with Type 1 diabetes who smoke should be given advice on smoking cessation and use of smoking cessation services, including NICE guidance-recommended therapies. The messages should be reinforced in continuing smokers yearly if pre-contemplative of stopping, and at all clinical contacts if there is a prospect of their stopping.


""";
                                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-Recommendation.md>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.1-Recommendation.md-ee4990eb7c63ee9cb1ac7c9fbcb9f996aa754dc0>;
                                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.2.md-b27427f6b03f40589da3450df0d4cf5996628c6b> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                   <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                 <http://www.w3.org/2011/content#chars> """Young adult non-smokers should be advised never to start smoking.
'

---
 nice.evidencegrade: D
""";
                                                                                                                                 <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.2.md>;
                                                                                                                                 <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                 <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.2.md-0000000000000000000000000000000000000000>;
                                                                                                                                 <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.3.md-1b1a490b05932b38795be778517ad12b626dc87e> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                   <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                 <http://www.w3.org/2011/content#chars> """Aspirin therapy (75 mg daily) should be recommended in adults in the highest and moderately-high risk categories
'

---
 nice.evidencegrade: B
""";
                                                                                                                                 <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.3.md>;
                                                                                                                                 <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                 <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.3.md-0000000000000000000000000000000000000000>;
                                                                                                                                 <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.4.md-5243f85cf07647b74caa1d6873a85509cd42df39> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                   <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                 <http://www.w3.org/2011/content#chars> """A standard dose of a statin should be recommended for adults in the highest risk and moderately-high risk groups. Therapy should not be stopped if alanine aminotransferase (ALT) is raised to less than three times the upper limit of reference range
'

---
 nice.evidencegrade: B
""";
                                                                                                                                 <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.4.md>;
                                                                                                                                 <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                 <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.4.md-0000000000000000000000000000000000000000>;
                                                                                                                                 <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.5.md-50fc1c91478d6a0e41ac974b67181de6d92294f2> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                   <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                 <http://www.w3.org/2011/content#chars> """If several statins are not tolerated, fibrates and other lipid-lowering drugs should be considered as indicated according to assessed arterial risk status
'

---
 nice.evidencegrade: D
""";
                                                                                                                                 <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.5.md>;
                                                                                                                                 <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                 <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.5.md-0000000000000000000000000000000000000000>;
                                                                                                                                 <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.6.md-7aaf01fe2ca5fd74b488419699808115a7f48cca> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                   <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                 <http://www.w3.org/2011/content#chars> """Fibrates should be recommended for adults with hypertriglyceridaemia according to local lipid-lowering guidelines, and arterial disease risk status.
'

---
 nice.evidencegrade: D
""";
                                                                                                                                 <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.6.md>;
                                                                                                                                 <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                 <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.6.md-0000000000000000000000000000000000000000>;
                                                                                                                                 <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.7.md-b0aa6be5dfe87c8aaf9148519a56f705a1c7dd78> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                   <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                 <http://www.w3.org/2011/content#chars> """Responses to therapy should be monitored by assessment of lipid profile. If the response is unsatisfactory, the following causes should be considered: non-concordance, inappropriate drug choice and the need for combination therapy
'

---
 nice.evidencegrade: D
""";
                                                                                                                                 <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.7.md>;
                                                                                                                                 <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                 <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.7.md-0000000000000000000000000000000000000000>;
                                                                                                                                 <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.8.md-9db206b2a0c173a44cf936dd45c1a888ad56f852> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                   <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                 <http://www.w3.org/2011/content#chars> """Adults who have had myocardial infarction or stroke should be managed intensively, according to relevant non-diabetes guidelines. In the presence of angina or other ischaemic heart disease,  -adrenergic blockers should be considered (for use of insulin in these circumstances, see R165.) 
'

---
 nice.evidencegrade: D
""";
                                                                                                                                 <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.8.md>;
                                                                                                                                 <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                 <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.10.2.8.md-0000000000000000000000000000000000000000>;
                                                                                                                                 <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.6.1.1-CG15AdultES1.md-68a9e4beeaa295d3f094ac34ccdf6a820d56d676> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                               <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                             <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES1
Diagnosis, in regard of types of diabetes, is generally not addressed by the WHO report.8
That report notes that children present with severe symptoms, and that diagnosis is simply confirmed by blood glucose measurement (advice that may be regarded as dated) 



[@Alberti_1998]
""";
                                                                                                                                             <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.6.1.1-CG15AdultES1.md>;
                                                                                                                                             <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                             <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.6.1.1-CG15AdultES1.md-31cb98e70dae963535ae849c71770d770aa7c89b>;
                                                                                                                                             <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.6.1.1-CG16AdultES2.md-6515ba8bf12cd3c2c63812d0ada0401076ae93e6> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                               <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                             <http://www.w3.org/2011/content#chars> """### Evidence Statement CG16AdultES2
WHO otherwise concentrates mainly on the situation pertaining to Type 2 diabetes, in doing
so noting (by reference to the 1985 report) the lack of need for challenge testing when plasma
glucose levels are high in the absence of other metabolic stress, and are confirmed by a second
laboratory measurement or classic symptoms.


""";
                                                                                                                                             <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.6.1.1-CG16AdultES2.md>;
                                                                                                                                             <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                             <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.6.1.1-CG16AdultES2.md-0da2cece54990a68045bfe1d769ddb1829d7b0a4>;
                                                                                                                                             <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.6.1.1-Discussion.md-5639bb51438d74840c5a1eb63e81cdb103f72815> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                             <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                           <http://www.w3.org/2011/content#chars> """The group endorsed the commentary discussed above, and concluded that simple
recommendations were all that were required. Although in this condition diagnosis of diabetes is rarely in doubt, errors do arise in attribution of diabetes type on occasions, and this is known to result in negative consequences including failure to anticipate ketoacidosis or unnecessary insulin therapy. Accordingly the group felt that cautionary recommendations were in order. The group noted that formal evidence of the utility of tests to distinguish type of diabetes by auto-immune markers or measures of islet B-cell function was not positive, and that these tests were not routinely performed. The group were keen to reiterate the importance of laboratory glucose estimation in line with WHO recommendations to avoid the very rare misdiagnoses with lifelong consequences. The25 role of symptoms and of HbA1c estimation were seen as useful but only supportive, as both lack absolute specificity.
""";
                                                                                                                                           <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.6.1.1-Discussion.md>;
                                                                                                                                           <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                           <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.6.1.1-Discussion.md-c201a4b371b9e031181beb226703b0f18fb109db>;
                                                                                                                                           <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.6.1.1-Recommendation.md-6996df0b7886af052727d1b20b189ac40affc574> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """Confirming diabetes
Diabetes should be confirmed by a single diagnostic laboratory glucose measurement in the presence of classical symptoms, or by a further laboratory glucose measurement. The diagnosis may be supported by a raised HbA1c
'


""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.6.1.1-Recommendation.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.6.1.1-Recommendation.md-3bd52862698df4376bbbe8ccf9ddaeb5394e26e0>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.6.1.2.md-6ddc6d0fe69ee0038ab39970663df447a0d21112> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> """Where diabetes is diagnosed, but Type 2 diabetes suspected, the diagnosis of Type 1 diabetes should be considered if:
?ketonuria is detected, or
?weight loss is marked, or
?the person does not have features of the metabolic syndrome or other contributing
illness.
'

---
 nice.evidencegrade: D
""";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.6.1.2.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.6.1.2.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.6.1.3.md-7a987b0a9f80c144aba5274849f6bf2e14193352> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> """When diabetes is diagnosed in a younger person, the possibility that the diabetes is not Type 1 diabetes should be considered if they are obese or have a family history of diabetes, particularly if they are of non-white ethnicity. 
'

---
 nice.evidencegrade: D
""";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.6.1.3.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.6.1.3.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.6.1.4.md-d102e4cfa138106b8ee46433e8a7673323b50a69> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> """Tests to detect specific auto-antibodies or to measure C-peptide deficiency should not be regularly used to confirm the diagnosis of Type 1 diabetes. Their use should be considered if predicting the rate of decline of islet B-cell function would be useful in discriminating Type 1 from Type 2 diabetes. 
'

---
 nice.evidencegrade: D
""";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.6.1.4.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.6.1.4.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.1-CG15AdultES10.md-c1d9be6de7bdb90d705e249c684fabf1377f16c9> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES10
Most papers in this area are descriptive, and there is inevitable overlap with deployment of multidisciplinary teams and provision of diabetes information and foot care. Using historical controls a study37 suggests improved blood glucose control, while another non-randomised study suggests improved survival (presumably mainly in people with Type 2 diabetes)



[@Day_1992]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.1-CG15AdultES10.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.1-CG15AdultES10.md-8af2e9b78e14907fc451fb396ba339a9351bc91f>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.1-CG15AdultES11.md-bc688a32f82ac2e73fb99646d1ab11550de5c7b4> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES11
Although papers were ascertained addressing these areas,3844 the papers were descriptive with no useful analysis of patient-related outcomes



[@Bridgford_2001]

[@Davis_2001]

[@Engelbrecht_1994]

[@Engelbrecht_1996]

[@Engelbrecht_1996]

[@Engelbrecht_2006]

[@Gupta_2014]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.1-CG15AdultES11.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.1-CG15AdultES11.md-f3c0cee930bf626b1cfe69fdc87486cf7038abc8>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.1-CG15AdultES12.md-20fc74793561c4d42bf704351d84b8e69ad99e7d> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES12
A number of descriptive papers were identified,4548 suggesting such approaches can be feasible and have utility, but not demonstrating comparative advantage to traditional approaches



[@Chiarelli_1998]

[@Gorman_1996]

[@Kucher_1990]

[@Smith_1998]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.1-CG15AdultES12.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.1-CG15AdultES12.md-9ae855b55203a99fe6d3e400ef9294d559d671ee>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.1-CG15AdultES13.md-0d8a002493d1feaaf0fc07d76342414d1900a286> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES13
However when such records were used to send judgemental letters to people with diabetes,49 randomising sites of care, intermediate outcomes were significantly improved (probably mainly in people with Type 2 diabetes)



[@Chaudhry_2007]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.1-CG15AdultES13.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.1-CG15AdultES13.md-29db02fcff6039083d08c8a5883b226444a43572>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.1-CG15AdultES14.md-d95b955a4245ff5bece50fc80613d6cb6eaddc97> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES14
A number of approaches to medical care without direct patient contact are described in the literature. One RCT of a telecare system for insulin50 provided equivalent control at reduced cost, while another study12 using nurses resulted in improved blood glucose control



[@EVANS_2000]

[@Biermann_2002]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.1-CG15AdultES14.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.1-CG15AdultES14.md-89207360a3be1dd955481f7b4763b3941a484e1c>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.1-CG15AdultES15.md-4668a0eda8d9aa07eedb01155675cd92afd27133> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES15
In more rural and remote situations telemedicine can similarly provide apparent time and cost savings where images of foot problems51 and eye photographs52 need to be reviewed by specialists



[@McGill_2000]

[@Cummings_2001]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.1-CG15AdultES15.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.1-CG15AdultES15.md-ae935add07fe06135240cd8df7717903f127d171>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.1-CG15AdultES16.md-31e997fc7ec6163de5a01152de8c29ffa604cacc> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES16
Three papers using historical controls or randomised controls address the value of multidisciplinary teams with a specialist interest in diabetes management in the care of inpatients on non-diabetes wards.5355 Reduced length of inpatient stay is consistently reported. One study suggests improved glucose control.55 One study, also using historical controls, addresses length of stay in a developing country in newly-diagnosed people with
diabetes, showing much reduced stays with multidisciplinary team input



[@Levetan_1995]

[@Levetan_1995]

[@Koproski_1997]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.1-CG15AdultES16.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.1-CG15AdultES16.md-c089ef105ffe335a2fd9fad4463c763072cdd153>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.1-CG15AdultES17.md-bbf7429d51144faf08612be6ca1bf525efc39a6d> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES17
No literature on the deployment or impact of diabetes guidelines was identified.


""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.1-CG15AdultES17.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.1-CG15AdultES17.md-16c2e236d569a204547eda91cc0579768ea04180>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.1-CG15AdultES18.md-0b4024d7f286febb2f3ffa2c319d40194f5619be> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES18
Two potentially useful papers consider the type of treatment facility used to deliver care to those with Type 1 diabetes.334,335 One German study334 found that the treatment facility (polyclinics, specialist clinics or general practitioners) makes no difference to diabetes-specific knowledge when this was controlled for age, sex and education. One UK study335 found no difference between hospital- and general practice-based care on a range of outcome measures for metabolic control, satisfaction with treatment or beliefs about diabetic control for a mixed
diabetic population. Some differences were observed in the surveillance for complications, with more frequent testing in integrated care. Whilst costly, it is worth noting that fewer patients defaulted from general practice-based care than conventional care. Avoided complications may offset the increased cost of general practice-based care, although this cannot be established on the basis of this study. One UK-based study297 suggested that the provision of a hospital-based diabetes specialist nurse lowered the cost per patient admission without producing a significant difference in readmission, quality of life or patient satisfaction.



[@Rose_2000]

[@1994]

[@Davies_2001]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.1-CG15AdultES18.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.1-CG15AdultES18.md-d17bcddf47b41c5e3acde77c77ca8f7217976dba>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.1-CG15AdultES4.md-41e1b698fd85a523d929ad9ef003d9cd1f4ac5a3> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                               <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                             <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES4
A nurse specialist approach has been justified by a number of before-and-after studies and case series with such input1317



[@Hearnshaw_2001]

[@Batista_2010]

[@Larsson_1995]

[@Brink]

[@Yokoyama_2001]
""";
                                                                                                                                             <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.1-CG15AdultES4.md>;
                                                                                                                                             <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                             <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.1-CG15AdultES4.md-6fdd70216357df85b4793428f30a02cb430492c8>;
                                                                                                                                             <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.1-CG15AdultES5.md-1da365cc3c8342a21c708f6eb3feee931bdf27f2> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                               <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                             <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES5
A number of studies of variable quality address the impact of inclusion of podiatrists compared to normal care within what is then usually called a diabetes foot care team. These studies included one RCT showing more patient knowledge and less callosities at one year, and a controlled study18 (it is unclear whether that study is randomised) showing less foot ulceration



[@Dargis_1999]
""";
                                                                                                                                             <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.1-CG15AdultES5.md>;
                                                                                                                                             <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                             <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.1-CG15AdultES5.md-4af45ff7848c1ced6b201aecc475f5253df1e89c>;
                                                                                                                                             <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.1-CG15AdultES6.md-636048ca30f97172963e94aaedf3c79dbc458240> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                               <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                             <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES6
A number of historically-controlled or descriptive studies support this approach, mainly reporting on patient preference outcomes15,1921



[@Larsson_1995]

[@Cox_1995]

[@APELQVIST_1994]

[@Frykberg_1997]
""";
                                                                                                                                             <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.1-CG15AdultES6.md>;
                                                                                                                                             <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                             <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.1-CG15AdultES6.md-3e825bf6e9a587c687ce675b2481c37513638e20>;
                                                                                                                                             <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.1-CG15AdultES7.md-3cf289baa1ad5dc9da21f52a579e42fa97c899dd> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                               <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                             <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES7
No RCTs address the concept of integrated annual review. Newly-implemented structured annual review has been subject to a descriptive review,22 suggesting improved satisfaction with care and improved patient motivation. Few full-length descriptions of the review process are available,23 most references being editorials and letters



[@Riazi_2000]

[@1992]
""";
                                                                                                                                             <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.1-CG15AdultES7.md>;
                                                                                                                                             <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                             <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.1-CG15AdultES7.md-3d4b87b9973ca1b255e10ce38adb38c3b87c0905>;
                                                                                                                                             <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.1-CG15AdultES8.md-dbab5dc237586cd37086788d05d6cba7c21ca8a5> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                               <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                             <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES8
The current guideline suggests annual surveillance of a number of potentially developing late complications (as do all other guidelines for the most complications). The International Diabetes Federations European guideline recommends integration of these activities into one patient visit.24 Annual review is also the basis of many quality control structures proposed for diabetes care,25 including (implicitly) that of the UK Audit Commission



[@1998]

[@Grabert_2002]
""";
                                                                                                                                             <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.1-CG15AdultES8.md>;
                                                                                                                                             <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                             <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.1-CG15AdultES8.md-8369e2b0e0ba253eac38947542ad09c54f1a9f4d>;
                                                                                                                                             <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.1-CG15AdultES9.md-3954325a4a615cc4088b6c557e954c0349214450> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                               <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                             <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES9
A series of descriptive papers appear to demonstrate the feasibility of establishing populationbased and clinic-based diabetes registers, with varying densities of information.2636 A system of database-driven recall for complications surveillance is implicit in the recommendations for annual complications surveillance of this and published guidelines. Issues of data security and confidentiality are not reported to have proved to be problematic obstructions to the deployment
of diabetes registers



[@Azzopardi_1995]

[@Burnett_1992]

[@Burnett_1993]

[@Unkown_date]

[@Comino_2013]

[@Howitt_1993]

[@Kelly_1998]

[@Taylor_2010]

[@Edelman_2001]

[@Kopelman_1995]

[@Vaughan_1996]
""";
                                                                                                                                             <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.1-CG15AdultES9.md>;
                                                                                                                                             <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                             <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.1-CG15AdultES9.md-780a8138f5093600c848b548eacbb986fb3bd9f0>;
                                                                                                                                             <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.1-CG17AdultES3.md-1d84360487f1d47a2d22e16eb85da527123ca3bc> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                               <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                             <http://www.w3.org/2011/content#chars> """### Evidence Statement CG17AdultES3
The Diabetes Control and Complications Trial (DCCT),9 and smaller RCTs using improved management to judge the effect on patient outcomes, used multidisciplinary team input (in particular from specialist nurses and dietitians) as part of an integrated package to improve metabolic intermediate outcomes. A Cochrane review10 of diabetes specialist nurse input identified six heterogeneous studies unsuitable for meta-analysis, and found little evidence of longer-term impact on intermediate outcomes. An RCT11 of the impact of structured team care as compared to usual care showed improved satisfaction and blood glucose control at six months. An RCT12 of the use of diabetes specialist nurses to adjust insulin doses over the telephone showed improved blood glucose control.


""";
                                                                                                                                             <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.1-CG17AdultES3.md>;
                                                                                                                                             <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                             <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.1-CG17AdultES3.md-6ac1157ea1850361ae87e1bac8a7d464eadd6f2e>;
                                                                                                                                             <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.1-Discussion.md-96925e06119c33575335d63fb810d561d67bbeb5> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                             <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                           <http://www.w3.org/2011/content#chars> """The group endorsed the approaches suggested by the evidence, but noted that attempts to implement some of the recommendations in the past had been inhibited by funding difficulties.This however was not felt to be a barrier to reiterating the health gains to be obtained. It was noted that recent publications (beyond the cut-off date of the searches) supported some of the recommendations further, including those relating to specialist nurses. The UKs national service framework for diabetes was noted to have endorsed diabetes registers. The group recognised the lack of any kind of formal evidence relating to walk-in, telephone-request and out-of-hours services.
""";
                                                                                                                                           <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.1-Discussion.md>;
                                                                                                                                           <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                           <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.1-Discussion.md-6dee04b0b6a9a1c7af013a974fc13449afe85b6d>;
                                                                                                                                           <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.1-Recommendation.md-ddb8903e74fe9943dba7c60c8e15c9746e044418> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """Multidisciplinary teams provide advice
Advice to adults with Type 1 diabetes should be provided by a range of professionals with skills in diabetes care working together in a coordinated approach. A common environment (diabetes centre) is an important resource in allowing a diabetes multidisciplinary team to work and communicate efficiently while providing consistent advice.
'


""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.1-Recommendation.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.1-Recommendation.md-7c6043a4b735c65cb3ad389b818854e679c97d1e>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.2.md-eccfdc33dd1603d6218fce673b253bdc44034c13> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> """Open access services should be provided on a walk-in and telephone-request basis during working hours to adults with Type 1 diabetes, and a helpline staffed by people with specific diabetes expertise should be provided on a 24-hour basis. Adults with diabetes should be provided with contact information for these services.
'

---
 nice.evidencegrade: C
""";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.2.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.2.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.3.md-6a736900f7171560a46f466141ea50186a60ef6e> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> """Each adult with type 1 diabetes should be managed as  an individual, rather than as a member of any cultural, economic or health-affected group. Attention should be paid to the recommendations given elsewhere in this guideline with respect to the cultural preferences of individual adults with type 1 diabetes.
'

---
 nice.evidencegrade: D
""";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.3.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.3.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.4.md-fcfb25056847520c93d96be919c7885c61c95a32> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> """An individual care plan should be set up and reviewed annually, modified according to changes in wishes, circumstances and medical findings, and the details recorded. The plan should include aspects of:
? diabetes education including nutritional advice (see section 6.1, Education
programmes for adults with Type 1 diabetes and 6.3, Dietary management)
? insulin therapy (see section 7.3, Insulin regimens and 7.4, Insulin delivery)
? self-monitoring (see section 6.2, Self-monitoring of blood glucose)
? arterial risk factor surveillance and management (see chapter 8, Arterial risk control)
? late complications surveillance and management (see sections on late complications)
? means and frequency of communication with the professional care team
? follow-up consultations including next annual review.
'

---
 nice.evidencegrade: D
""";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.4.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.4.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.5.md-f0545e5fd6b04e723ce922388aa1a6670b512742> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> """Population, practice-based and clinic diabetes registers (as specified by the national service framework) should be used to assist programmed recall for annual review and assessment of complications and vascular risk.
'

---
 nice.evidencegrade: D
""";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.5.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.5.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.6.md-57854a49b1ec0df15651b61c064ca124ec0f8d18> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> """Conventional technology (telephones), or newer technologies for high-density data transmission of images, should be used to improve process and outcomes.
'

---
 nice.evidencegrade: A
""";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.6.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.6.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.7.md-f70e761c21bae0df84df9e62bcea5a2e0ebf543f> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> """The multidisciplinary team approach should be available to inpatients with Type 1 diabetes, regardless of the reason for admission (see section 13.3, Inpatient management).
'

---
 nice.evidencegrade: D
""";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.7.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.1.7.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.2.1-#Set.md%23-8fb3f6db8b1cd10c35592943657bc12bdf18908b> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                          <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                        <http://www.w3.org/2011/content#chars> """## Topic CG15AdultS3
As having Type 1 diabetes can have a major impact on lifestyle and self-esteem, it would appear
that support groups could have a role in providing for some needs outside the professional
environment and even separately from immediate carers. The range of such potential input is
large and might stretch from simply fulfilling a need for belonging, through to helping with
diabetes-related financial problems (such as insurance), and even providing a further source of
diabetes-related information. Coping with diabetes, or any other condition, is influenced not only by psychological characteristics of the individual but also by social relationships (eg support and communication byhealthcare team, family and friends). Informal interpersonal variables, such as social resources and support, have been found to be associated with better diabetes self-management,56 7 family environment,58 60 and marital interaction.61  A medical condition is only one aspect that affects the make-up of an individual s personal identity, and for some may be perceived as a minor factor compared to their environmental and social circumstances.  A  support group  is defined in this guideline as a group of people with Type 1 diabetes that comes together to provide support to themselves and others in their locality. Members are usually unpaid and many will be supported under the auspices of national (or local) voluntary organisations. Support groups have become commonplace throughout health and social care. Patients and carers may choose to contact or be involved with support groups to gain information and support to benefit their own needs, or with a wider altruistic aim of helping other people within the local community. It was not possible to find specific research
identifying patient and carer preferences for support groups, or indeed to identify specific groups or types of people who may benefit more than others. Some people attend meetings of groups regularly whilst other individuals are reassured by being aware of a group s existence and the opportunity to contact the group at a later date if problems arise and/or support is required. Preferences are dependent on what stage people are at in their lives and what information is taken (or needs to be taken) on board. 
""";
                                                                                                                                        <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.2.1-#Set.md%23>;
                                                                                                                                        <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                        <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.2.1-#Set.md%23-0000000000000000000000000000000000000000>;
                                                                                                                                        <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.2.1-CG15AdultES19.md-a12a6e538be0f70126c1f2f4d406ff3bc0a6428c> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES19
The Diabetes Attitudes, Wishes and Needs (DAWN) questionnaire study 62 highlighted that emotional support, along with family support, was a key factor in how well people with diabetes manage their condition, with support networks being considered at least as important as the medication they take in helping them manage their diabetes. Interim results also indicate that people who do not have access to a community of support, especially the young or elderly living alone, may be less likely to be concordant with their medication regimes, putting them at risk of inadequate control of their diabetes



[@2002]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.2.1-CG15AdultES19.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.2.1-CG15AdultES19.md-048b2f7c6e5e6d9188ad265c531c89210bc2a8ba>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.2.1-CG15AdultES20.md-2f13ba411c939eed671e9e1bb4469732f520117e> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES20
There are still significant numbers of people emerging from the confirmation of a diagnosis who are underinformed and unsupported. 63 Qualitative research of various designs examining the views and experiences of people with diabetes and carers has identified that many perceived benefits exist from meeting other people with diabetes. It has helped many to overcome the feelings of isolation and is seen as an opportunity to talk to others going through the same experience 64



[@2008]

[@Greenwood_2003]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.2.1-CG15AdultES20.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.2.1-CG15AdultES20.md-670404aedc33f5b0cade74444de72af849a66f8e>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.2.1-CG15AdultES21.md-0af0e8c38217c7a3a94de145bbed31bf7ce6498b> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES21
R esearch evaluating the effectiveness of support groups for patients and carers, across n umerous conditions and groups (not necessarily diabetes), has shown specific benefits including: 

*   psychological and emotional benefits 65 including lower pain perception and improved ability to cope with stress 63,667 

*    reduction of carers burdens and stresses 689 

*    improvement in quality of life 7071 

*    improved self-care through health promotion strategies which have been helpful in smoking cessation and management of chronic conditions 723 

*    improved access to health service provision 74 

*    reduced isolation, overcoming depression and loss of self-esteem 64 

*    better understanding of conditions, symptoms and healthcare systems through education and information. 67



[@Jessup_2001]

[@Knight_1993]

[@Toseland_1992]

[@Labrecque_1992]

[@Ostwald_1999]

[@Hanestad_1993]

[@Maxwell_1992]

[@Fisher_1998]

[@Morris_1998]

[@Tomlinson_1992]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.2.1-CG15AdultES21.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.2.1-CG15AdultES21.md-d9883e552e9f1d2919c191032644c16ed748ab61>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.2.1-CG15AdultES22.md-d7cf8b2fb44a4efd88675f89008877039612af20> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES22
The Diabetes UK network of support groups recorded 175,426 members in July 2003, with
around 7% under the age of 20 years and around 30% aged 70 years or over. Around 40% had paid for annual adult membership, 50% had a reduced rate membership (including children), and 10% had chosen life membership. The Diabetes UK Careline is, at the time of writing, one of the busiest sources of information for all people with Type 1 diabetes in the UK. In 2002, Careline were contacted 40,747 times (81% telephone, 13% e-mail, 6% post).  The five most frequent topics of enquiry recorded were:
67a

*   diet

*   insulin

*   medicines other than insulin

*   new diagnosis

*   travel. 


""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.2.1-CG15AdultES22.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.2.1-CG15AdultES22.md-b8dfaea87a14a1829c3a512da897c66b307dd16d>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.2.1-Discussion.md-9f33b4748bfb95407c7ca78484635cd3538cd883> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                             <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                           <http://www.w3.org/2011/content#chars> """-
""";
                                                                                                                                           <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.2.1-Discussion.md>;
                                                                                                                                           <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                           <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.2.1-Discussion.md-b425ae4a5e2e896946a4b270fcbdcbeafbc7b866>;
                                                                                                                                           <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.2.1-Recommendation.md-81ae768bdad13371835459836a4708e95559d71b> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """Support groups
At the time of diagnosis and periodically thereafter, adults with Type 1 diabetes should be offered up-to-date information on the existence of and means of contacting diabetes support groups (local and national) and the benefits of membership.
'


""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.2.1-Recommendation.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.2.1-Recommendation.md-c60f0aac4b66bc2491fafc37d1588245d3aad96a>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-b93cb04c455c7c905afbe9bfb41261a2e18254b5>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.2.1-Recommendation.md-c60f0aac4b66bc2491fafc37d1588245d3aad96a> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """## Support groups
At the time of diagnosis and periodically thereafter, adults with Type 1 diabetes should be offered up-to-date information on the existence of and means of contacting diabetes support groups (local and national) and the benefits of membership.



""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.2.1-Recommendation.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.2.1-Recommendation.md-24bea069a2344a29164a38aa54d3720d28331ad6>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.2.1-Set.md-e9128c752c9f2211a0858764c5e592d9a337c0a5> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                      <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                    <http://www.w3.org/2011/content#chars> """## Topic CG15AdultS3
As having Type 1 diabetes can have a major impact on lifestyle and self-esteem, it would appear
that support groups could have a role in providing for some needs outside the professional
environment and even separately from immediate carers. The range of such potential input is
large and might stretch from simply fulfilling a need for belonging, through to helping with
diabetes-related financial problems (such as insurance), and even providing a further source of
diabetes-related information. Coping with diabetes, or any other condition, is influenced not only by psychological characteristics of the individual but also by social relationships (eg support and communication byhealthcare team, family and friends). Informal interpersonal variables, such as social resources and support, have been found to be associated with better diabetes self-management,567 family environment,5860 and marital interaction.61  A medical condition is only one aspect that affects the make-up of an individuals personal identity, and for some may be perceived as a minor factor compared to their environmental and social circumstances.  A support group is defined in this guideline as a group of people with Type 1 diabetes that comes together to provide support to themselves and others in their locality. Members are usually unpaid and many will be supported under the auspices of national (or local) voluntary organisations. Support groups have become commonplace throughout health and social care. Patients and carers may choose to contact or be involved with support groups to gain information and support to benefit their own needs, or with a wider altruistic aim of helping other people within the local community. It was not possible to find specific research
identifying patient and carer preferences for support groups, or indeed to identify specific groups or types of people who may benefit more than others. Some people attend meetings of groups regularly whilst other individuals are reassured by being aware of a groups existence and the opportunity to contact the group at a later date if problems arise and/or support is required. Preferences are dependent on what stage people are at in their lives and what information is taken (or needs to be taken) on board. 
""";
                                                                                                                                    <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.2.1-Set.md>;
                                                                                                                                    <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                    <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.7.2.1-Set.md-8fb3f6db8b1cd10c35592943657bc12bdf18908b>;
                                                                                                                                    <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-332a35d1000ad9f48052b739c045858dc0b18841>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.1-CG15AdultES23.md-4b38f5f704f196681cd49c1621ed4702818a8899> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES23
There were no trials located in newly-diagnosed people with Type 1 diabetes specifically, or co ncerned with the initial content of educatio n. The American Diabetes Association (ADA) guidelines 76 suggest that as part of initial visit people should be referred to a diabetes educator if education is not provided by the physician or practice staff, but content of this education is not defined 



[@2003]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.1-CG15AdultES23.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.1-CG15AdultES23.md-148c4f4d1ca75f4a44f9338dbbae3679c20b3e89>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.1-CG15AdultES24.md-59f08ee6175f076451d7424af991b982985a051d> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES24
One small randomised controlled trial 77 co mparing the efficacy of classroom teaching of diabetes skills, compared to individualised learning, found that classroom teaching led to a gr eater level of awareness about diabetes self-care. However, there was no significant difference in terms of the level of use of self-care practices. Furthermore, the two education techniques provided no different outcome of levels of technical skill in self-care. However this study made no analysis of comparability of study groups at baseline and was not blinded 



[@Street_1993]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.1-CG15AdultES24.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.1-CG15AdultES24.md-5c437a967fb1db7d4ccd263e4cd0318ffae1d913>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.1-CG15AdultES25.md-c0391ac8b8080581a011f9a468a6d9d3d81bba77> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES25
One randomised controlled study compared two interactive computer schemes to reinforce an educational video. The first gave additional f eedback and information on the correct answers, the second only the correct answers. 78 Pe ople with diabetes in the interactive group scored significantly better in a follow-up test of diabetes knowledge than those following the standard scheme. There were no significant differences in use r ratings for the two software packages, but the people in the additional feedback group had a better diabetes knowledge at baseline, so the re sults may be biased by this confounding factor



[@RICCOMINI_2002]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.1-CG15AdultES25.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.1-CG15AdultES25.md-8d1e680a154d6b96854b27f310e582fbc70e25b1>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.1-CG15AdultES26.md-30284b2c3f501060aa0c8def0b9fb924fae539f3> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES26
An update of the US standards for diabetes self-management education79 based on a literature review covered the organisation of diabetes self-management education, its content and provision. A multiprofessional task force encompassing all the major interested stakeholders agreed the following standards.

*  Education and information-giving will involve the interaction of the individual with diabetes with a multifaceted education instructional team, which may include a behaviourist, exercise physiologist, ophthalmologist, optometrist, pharmacist, physician,podiatrist, registered dietitian, registered nurse, other healthcare professionals, and paraprofessionals.

*  Instructors will obtain regular continuing education in the areas of diabetes management,behavioural interventions, teaching and learning skills and counselling skills.

*  Assessed needs of the individual will determine which of the following content areas are delivered:
describing the diabetes disease process and treatment options
incorporating appropriate nutritional management
incorporating physical activity into lifestyle
utilising medications (if applicable) for therapeutic effectiveness
monitoring blood glucose and urine ketones (where appropriate) and using results to improve control
preventing, detecting and treating acute complications
preventing (through risk reduction behaviour), detecting and treating chroniccomplications
goal-setting to promote health, and problem-solving for daily living
integrating psychosocial adjustment to daily life
promoting preconception care, management during pregnancy and gestational diabetes management (if applicable).

*  An individualised assessment, development of an education plan and periodic reassessment between participant and instructor will direct the selection of appropriate educational materials and interventions.

*  The assessment includes relevant medical history, cultural influences, health beliefs and attitudes, diabetes knowledge, self-management skills and behaviours, readiness to learn,cognitive ability, physical limitations, family support and financial status.

*  There shall be documentation of the individuals assessment, education plan,intervention, evaluation and follow-up in the permanent confidential education record.



[@Mensing_2000]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.1-CG15AdultES26.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.1-CG15AdultES26.md-6915e4c2b3a82061cdad9baa16da0e40c46c0c9c>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.1-CG15AdultES27.md-a94a06f3263fd381e60eb66c2513262110750e39> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES27
Within an overall review of patient education models for diabetes (not type-specific) one health technology assessment80 reviewing four controlled trials of a range of education programmes including items of self-management, self-monitoring, diet and the effects of insulin and exercise, taught by a variety of staff or self-taught, and as an initial intense course or as ongoing programmes, reported a variety of positive outcomes compared to normal care. This review found that one study had demonstrated improvements over 10 years in diabetic control, in ter ms of reduced HbA 1c levels. In another study, an intensive five-day training course was found to be effective in reducing HbA 1c levels. In one study there was no difference in blood gl ucose control with education compared to usual care, while there were no between-group co mparisons made in another other study. Education was also shown to improve blood pressure. There is limited evidence to suggest a reduced rate of ketoacidosis and reduced hospitalisation. However, there was no evidence to indicate that education can reduce body mass index. There is some data to suggest increased incidence of hypoglycaemic episodes. Long-term outcomes of retinopathy or neuro pathy were not found to be significantly affected by education, but there is some limited evidence to suggest nephropathy incidence is improved, although rates were low. Unsurprisingly, diabetes knowledge was significantly improved with education, although this was not true of quality of life. Overall the included trials were of moderate methodological rigour. Three of the trials included were investigating education in the context of intensification of treatment compared to normal care, and it is difficult to be sure that the benefits reported are directl y attributable to the education aspect of the intervention.


""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.1-CG15AdultES27.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.1-CG15AdultES27.md-429945e4a438dc0219b73582d87375f280131be2>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.1-CG15AdultES28.md-e7e941a9e29cf7ddc7a281e05dd942d09906da4a> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES28
Metabolic control and quality of life were not found to be significantly affected by a structured outpatient programme of education led by a nurse, dietitian and other people with diabetes over four weeks in a large randomised trial as compared to conventional care81



[@Weerdt_1991]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.1-CG15AdultES28.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.1-CG15AdultES28.md-5e2b1f9ba97c774ae8a1cdda9bf0d85899c12c52>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.1-CG15AdultES29.md-b103d6b2b037c2472f83a43a88a2d7a97e95b8e1> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES29
A medium-sized randomised controlled trial 82 of a monthly education programme at which different aspects of diabetes treatment and technical skills were considered found that after one year of education HbA 1c levels were reduced compared with normal clinical care in people w ith Type 1 diabetes. However, age differences between the control and intervention groups at baseline mean that this study is possibly methodologically limited



[@Lennon_1990]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.1-CG15AdultES29.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.1-CG15AdultES29.md-fa7e9bdc6e1c18d51c945b4518de8d999def6ab2>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.1-CG15AdultES30.md-51c41577f27e6a7e56a02de53347fe6665f71a5f> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES30
A nother moderate-sized systematic review of eight trials encompassing over 3,000 patients with either Type 1 or Type 2 diabetes, 83 found that intensive vs brief education on foot care provided a significant decrease in incidence of foot ulcers, and in one trial amputations, but no difference in the same outcomes over seven years in another study. This is despite three trials reporting successful uptake of messages regarding foot care behaviour. Another trial reported in this re vi ew found that an intensive educational inter ve ntion including both people with diabetes and doctors improved the prevalence of serious foot lesions compared to usual care, although the composite outcome of all foot lesions and amputations was not significantly improved. Au thors of the review noted methodological limitations of the included studies, and outcome re porting times varied between individual trials



[@Valk_2002]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.1-CG15AdultES30.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.1-CG15AdultES30.md-9f94a1121a269531da0b68db226f79c7d4de5a11>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.1-CG15AdultES31.md-938b783740545dff974a3ea37bc04823bbb4835d> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES31
Ev aluation, in a large systematic review, 84 of a range of diabetes self-management education (DSME) programmes compared to normal routine levels in populations of people with diabetes found that interventions based in community gathering places were able to reduce blood glycated haemoglobin (GHb) and fasting blood glucose levels. There is some evidence that they can also improve diabetes knowledge and improve physical activity (minutes of walking). Other trials reviewed that were based in the home setting  half of which included c hildren or adolescents  showed a significant decrease in GHb after DSME, and a borderline 6 Education programmes and self-care beneficial effect on weight for people undergoing DSME as compared to conventional care. Specific analysis in patients with Type 1 diabetes found no significant change in diabetes knowledge with such programmes



[@NORRIS_2002]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.1-CG15AdultES31.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.1-CG15AdultES31.md-67e3ead181b23a208cc57628d2c2c5d2aabd6d81>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.1-CG15AdultES32.md-59009a7adaf27acf7023566d2a399b0fcf15db99> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES32
A small randomised controlled trial 12 in people with Type 1 diabetes found that an intervention wh ereby patients received regular telephone contact with a diabetes nurse to alter insulin re g imen decreased HbA 1c ov er six months compared to usual care. This difference was not found to be affected by age, sex or type of diabetes



[@EVANS_2000]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.1-CG15AdultES32.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.1-CG15AdultES32.md-cb8fdabea6b42786f736754f23a9574dc07fd956>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.1-CG15AdultES33.md-480578fcec3b1669004c7d54454df188a2c12790> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES33
There are no systematic reviews and few prospective randomised studies that report on methods to improve concordance in self-management in people with Type 1 diabetes. One small unblinded study, 85 w hich was methodologically limited owing to high drop-out rates and inequalities in patient characteristics at baseline, found that an intervention of a self-taught study programme to improve self-control behaviour was able to demonstrate improved adherence to goals of self-monitoring of blood glucose level over 12 weeks. The intervention included a wide range of educational and behavioural choice items, and the relative effectiveness of any of these is hard to define. The methodological limitations of the study w ould not form a rigorous basis for recommending such an approach



[@Jones_1990]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.1-CG15AdultES33.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.1-CG15AdultES33.md-49f5780713684cec05d689ab1bbef07af52528d5>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.1-CG15AdultES34.md-e35d8c604edf73e4ce1736f4694720e804c9af40> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES34
A similar intervention among adolescents (mean age 18 years) in India enrolled in a prospective r andomised trial, 86 w ith an intervention of 15 hours of individualised learning over three months comprising both behavioural and cognitive strategies based on an operant learning model, found improved adherence on a composite three-item scale, compared to usual care. This improved adherence was mirrored in significantly improved blood glucose level compared to pe ople in the control group. However, this study had a small sample size and was unblinded, and it was not possible to determine whether benefits persist after the cessation of the intervention



[@Sudhir_2003]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.1-CG15AdultES34.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.1-CG15AdultES34.md-4af50fa099306540dd7378b560e7bbff92a6ce6c>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.1-CG15AdultES35.md-77d59950f041564b1682447c8a7f64048bd81cb5> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES35
One small- to medium-sized randomised trial of a specialist education programme delivered to people with Type 1 diabetes by a team of physicians, dietitians and specialist nurses found there to be no statistically significant differences in diabetes knowledge or adherence to dietary advice co mpared to a control group who received conventional diabetes education. Both groups improved in both measures immediately after the completion of the education intervention but then knowledge and adherence fell away with time. This trial was sited in Finland and there may be differences in content of conventional diabetes education compared to that of the UK care setting 87



[@Korhonen_1983]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.1-CG15AdultES35.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.1-CG15AdultES35.md-9bf8d01062eebf3a318835c65285889f76dc7909>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.1-CG15AdultES36.md-16e1fd68a8ea168ce529acf3373c302236d0e7f9> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES36
There were no significant differences in adherence to glucose self-monitoring or in blood gl ucose levels reported at six months between two interventions with novel glucose monitoring devices and control with a standard device from a medium-sized multicentre randomised Type 1 diabetes in adults: national clinical guideline for diagnosis and management tr ial. 88 The trial included a population of people with Type 1 diabetes who had had the co ndition for an average of 14 years. The study was blinded between the two novel monitoring machines, but the people in the control group would have been aware that they were not re ce iv ing the intervention as they continued to use their usual machine. To evaluate adherence all patients were asked to keep diaries of self-monitoring behaviour and this may have stimulated greater adherence even in the control group than under normal everyday self- monitoring conditions



[@Davis_2007]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.1-CG15AdultES36.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.1-CG15AdultES36.md-dd2b5784792c3166c9c941891ab80a6f2fa89e08>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.1-CG15AdultES37.md-8d60cc027f8ec51f7b437a5b32ceefbc5cec59d8> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES37
A ssessing the cost-effectiveness of patient education is complicated by the fact that patient education is rarely assessed in isolation. Recent NICE guidance 338 into patient education models considered the health economic evidence for interventions in terms of self-care, quality of life and the long-term complications of diabetes. Interventions improving knowledge of diabetes were excluded from consideration, as improved knowledge of diabetes does not necessarily affect subsequent outcomes.  The NICE appraisal found only two published health economic papers suitable for assessing patient education. 339,340 Of these, only one 339 included Type 1 diabetes patients, and this established cost-effectiveness ratios for altering food habits.



[@Bryant_2007]

[@Glasgow_1997]

[@Kaplan_1987]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.1-CG15AdultES37.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.1-CG15AdultES37.md-0fb67d398a34fe68384a55d7d1839011b14e6eee>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.1-Discussion.md-35006751c398975ccc2a76d2f9d54e88bbd124c7> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                             <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                           <http://www.w3.org/2011/content#chars> """The group noted that patient education was a necessary and logical part of most aspects of diabetes self-care, and that self-care was a social, health and economic necessity in the manage- ment of the condition. Specific recommendations related to aspects of care such as self- monitoring, insulin therapy, foot care and nutrition were thought best presented in the individual sections of this guideline. The group noted inap propriateness of the classical clinical trial model when just one feature of an integrated pac kage was varied, and one of many possible outputs monitored as primary outcome. There is also the difficulty of, and lack of funding for, the larger, longer-term trials used for pharmaceutical interventions. Equally, the central role of education in achieving success in blood glucose control and health outcomes (DCCT and other key studies) c ould not be ignored. Such information suggested that educational interventions were likely to be c ost-effective, but it was impossible to make compar ative judgements of different education models, a conclusion seemingly also reached by the NICE Appraisal Committee on the basis of a re port from the University of Southamptons health technology assessment unit. Is sues of information overload at the stressful time of diagnosis, the size of the longer-term educational needs of individuals, the diversity of individual needs, and the retention of the information needed to make informed choices, and the groups experience of these in practice, served to guide recommendations broadly in line with those of Diabetes UK and the International Diabetes Federation (Europe).
""";
                                                                                                                                           <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.1-Discussion.md>;
                                                                                                                                           <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                           <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.1-Discussion.md-5945a19a54c384fccc58f92ea4b23b998c50224b>;
                                                                                                                                           <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.1-Recommendation.md-05a34446b931bfa82ef19894b2a11bca9b8fb17f> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """## Structured diabetes education
A programme of structured diabetes education covering all major aspects of diabetes self-care and the reasons for it should be made available to all adults with Type 1 diabetes in the months after diagnosis, and periodically thereafter according to agreed need following yearly assessment



""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.1-Recommendation.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.1-Recommendation.md-54191d297f642445c4db80a8d6cec2eb8059e4e5>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.1-Recommendation.md-cb19b9915de9ede21d8cd5f459e7e3a9f0c2e96b> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """Structured diabetes education
A programme of structured diabetes education covering all major aspects of diabetes self-care and the reasons for it should be made available to all adults with Type 1 diabetes in the months after diagnosis, and periodically thereafter according to agreed need following yearly assessment.
'


""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.1-Recommendation.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.1-Recommendation.md-05a34446b931bfa82ef19894b2a11bca9b8fb17f>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-b93cb04c455c7c905afbe9bfb41261a2e18254b5>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.2.md-5d12662d186cef24a9a69b747b7e27d2aca4b410> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> """Education programmes for adults with Type 1 diabetes should be flexible so that they can be adapted to specific educational, social and cultural needs. These needs should be integrated with individual health needs as dictated by the impact of diabetes and other re levant health conditions on the individual.
'

---
 nice.evidencegrade: D
""";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.2.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.2.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.3.md-ba19f42add4f273a54a159ee9d995bc5265af9d2> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> """Education programmes for adults with Type 1 diabetes should be designed and delivered by members of the multidisciplinary diabetes team in accordance with the principles of adult education
'

---
 nice.evidencegrade: D
""";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.3.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.3.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.4.md-e48876af6a00a803d48178e7b500c88a5f73a509> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> """Education programmes for adults with Type 1 diabetes should include modules designed to empower adults to participate in their own healthcare through:
? enabling them to make judgements and choices about how they effect that care
? obtaining appropriate input from the professionals available to advise them.
'

---
 nice.evidencegrade: D
""";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.4.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.4.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.5.md-82d31a6746626616ee1b8d19146b7c8a535a3f57> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> """Pr ofessionals engaged in the delivery of diabetes care should consider incorporating educational interchange at all opportunities when in contact with a person with Ty pe 1 diabetes. The professional should have the skills and training to make best use of such time.
'

---
 nice.evidencegrade: D
""";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.5.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.5.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.6.md-0d3182f01560da26290a77417aa47ae0ba1b648d> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> """More formal review of self-care and needs should be made annually in all adults with Type 1 diabetes, and the agenda addressed each year should vary according to the priorities agreed between the healthcare professional and the person with Type 1 diabetes. 
'

---
 nice.evidencegrade: D
""";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.6.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.1.6.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.1-CG15AdultES38.md-bf55232725aba7cec8a49c6e243f92fd20917a56> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES38
Pa pe rs contained within a systematic review 89 suggest that the evidence on issues of observer tr aining, interdevice variability, the effects of long-term use and patient acceptability have not been adequately addressed



[@Coster_2000]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.1-CG15AdultES38.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.1-CG15AdultES38.md-edcc86181b8ad13492027f03410eeacdcb73560c>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.1-CG15AdultES39.md-09fda9808d4c3cd370e82f9ff29e335dff3b96eb> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES39
One study within the systematic review 89 co mparing self-reported readings against a memory meter showed that inaccuracies in readings were common. This was due to rounding of values, omission of outlying values and reporting of re sults when no test had been performed. These findings were confirmed in another reviewed study of 14 people who recorded lower blood gl ucose values in logbook records than meter memories



[@Coster_2000]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.1-CG15AdultES39.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.1-CG15AdultES39.md-2f446b021bc2207b56b28dba2954b0e5db148198>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.1-CG15AdultES40.md-95fd46fa0c20e39f0f6156f83f7aa51a114e0cc7> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES40
Reported within the systematic review, one trial 89 suggested that patients needed to be informed of the memory capacity of their meters to improve accuracy. A further study reported in the review argued that the true diurnal variability in glycaemia in people with Type 1 diabetes is too great to be measured, even when self-monitoring of blood glucose (SMBG) is repeated seven times daily



[@Coster_2000]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.1-CG15AdultES40.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.1-CG15AdultES40.md-0d75b0f87bff3dfc1b529b1299b88eb284b0cacd>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.1-CG15AdultES41.md-5016f943358f0de79c58066158e416e5231c5a52> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES41
Pa tient factors (as described below) were shown to have an impact (both positive and negative) on the reliability of monitoring in five studies. 89 Re liability can be improved through proper training of patients, and was shown in sub-group analysis to be equally as good in older pe ople, and people with visual impairments (on co ndition that extensive instruction has been provided). One study concluded that impairment of colour vision affects the ability to interpret self-monitoring with visually read strips, suggesting that all patients should be screened for colour vision before self-monitoring begins




[@Coster_2000]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.1-CG15AdultES41.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.1-CG15AdultES41.md-c278060adae84031c8f2ac3cafa621b90da1e176>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.1-CG15AdultES42.md-87da028587df8928d5e32d69ec3196d6958bd2ec> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES42
Four trials contained within a systematic review 89 failed to show with sufficient power a demonstrated effect of SMBG on blood glucose control 



[@Coster_2000]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.1-CG15AdultES42.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.1-CG15AdultES42.md-45ecda10c4296f791b49ac272aa2452c5d1097f3>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.1-CG15AdultES43.md-81d9b0c2186f658dfc26accf7a09892dad60f0a7> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES43
Two trials comparing urine and blood testing showed no clinical difference in the two tests89



[@Coster_2000]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.1-CG15AdultES43.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.1-CG15AdultES43.md-4944202baa4e0381de42bcdc6bb2e40013cd6cdb>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.1-CG15AdultES44.md-1188462a1a5004556da803d53d5c9ced420970c2> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES44
A systematic review 89 reported on patient preferences for different monitoring techniques. One trial reported patients preferring blood testing, or a combination of blood and urine testing,compared to urine testing alone. No preference was stated for visual strips or strips with meters



[@Coster_2000]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.1-CG15AdultES44.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.1-CG15AdultES44.md-f1266cfa92c633d28c14002937b77c65a6cb3620>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.1-CG15AdultES45.md-72131b6a886b7c9b510992f47a1680c2f9328a95> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES45
One methodologically-limited crossover study 90 co mparing blood glucose meters with visual t est strips showed patients found the two techniques equally convenient to use, although overall more patients preferred the blood glucose meter.  Preferences were based on: accuracy, confidence in test result, no judgement by patient,inability to cheat with result and use of the built in timer



[@Brown_1986]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.1-CG15AdultES45.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.1-CG15AdultES45.md-8219ad38ce9db36c305e6398f69a4f833f5eb495>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.1-CG15AdultES46.md-bc595d419d1e699f1c55d549d1fa4934ccb99c91> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES46
One methodologically-limited comparative study 91 showed that fructosamine self-test results co rr elated well with laboratory test with very low bias. Imprecision of the self-test was higher than the laboratory test, but could still identify patients with good vs poor glycaemic control



[@Edelman_2000]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.1-CG15AdultES46.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.1-CG15AdultES46.md-5028b5c56bb0e9821ace05dd57e41d2bff6ddd0a>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.1-CG15AdultES47.md-b84495a51778747500445aa8667f1388f4186522> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES47
A further methodologically-limited diagnostic study 92 in people with Type 2 diabetes showed self-testing of fructosamine to be comparable in accuracy to laboratory fructosamine and GHb values 



[@Cefalu_1999]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.1-CG15AdultES47.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.1-CG15AdultES47.md-7bf35a0991015036f16d56511d7ce1df8b7a2b51>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.1-CG15AdultES48.md-fbc4ac615e9aa6378110870f74aa8a2cca248fd4> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES48
One trial with 25 patients 93 showed no significant difference in glucose control or patient practice based on frequency of testing. The authors stated that they are unable to identify any optimal frequency for blood glucose self-monitoring in typical diabetic population. There is little or no relationship between the frequency of blood glucose monitoring, the frequency of insulin dose adjustments and the level of metabolic control



[@Gordon_1991]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.1-CG15AdultES48.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.1-CG15AdultES48.md-6f3d9dd49d1a2a2cee3c26dcd749b808a97a0e1d>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.1-CG15AdultES49.md-09e26aa8497f5acd5110c9a0dfdd2c0b53a314bf> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES49
A study of the preferences of 18 patients within a systematic review 89 reported a pr eference for t esting four times daily twice weekly, or four times daily once a week, compared to twice daily ev ery day of the week



[@Coster_2000]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.1-CG15AdultES49.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.1-CG15AdultES49.md-5ae76ae82b30accaf0096f6fe8df3815ebaea176>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.1-CG15AdultES50.md-252df9c75a42b66a0dac4258bd768afa3f099806> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES50
One study from a systematic review reported fasting plasma glucose to be less useful as an accurate mode of monitoring in insulin-treated people with diabetes than in other people 89



[@Coster_2000]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.1-CG15AdultES50.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.1-CG15AdultES50.md-37b1e49c57ab484b1f97d092df3c8965ac2014ff>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.1-CG15AdultES51.md-de6c679fa757cf3c7c5f5618e52ed45651e57f00> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES51
The DCCT included self-monitoring of blood glucose as part of intensive treatment. Self-monitoring is only likely to have an effect on blood glucose control when used to inform the management of diabetes. As such, it is not feasible to analyse its cost-effectiveness in isolation from the requirements of subsequent management strategies.  A recent HTA report 89 identifies one paper considering the cost-effectiveness of blood or urine glucose monitoring against conventional dietary control amongst those with Type 1 diabetes. 341 This paper is based on Russian conditions and also includes education in the intervention technologies. The GDG felt that differences in international healthcare systems mean little weight could be placed on its assertions that no significant difference exists between blood and urine glucose monitoring



[@Coster_2000]

[@Starostina_1994]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.1-CG15AdultES51.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.1-CG15AdultES51.md-9f38efdc62d8120078e7d5535e319f0c8410797f>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.1-Discussion.md-addfa614caa44f7a38e03ae1e455b5d8d7a9dbbe> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                             <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                           <http://www.w3.org/2011/content#chars> """Self-monitoring does not, in itself, appear to improve blood glucose control. However, the gr oup noted that it was an essential component of the markedly improved blood glucose control with improved outcomes demonstrated in the landmark DCCT study, and indeed in the other smaller studies of blood glucose control and complications. Indeed it was difficult for members of the group to conceive how modern flexible insulin dosage regimens could be adopted without it. However, the technique is not easy, painless or convenient, and as a result no one system is found appropriate for use by all individuals. Improved technical facility could be identified from clinical experience. Nevertheless appropriate training and quality of skills re vi ew is agreed as necessary and normal practice. Different individuals are noted to use this te c hnology with different frequencies and for different needs according to personal preferences. Given the nature of the technology it is rarely abused. A newer approach, using smaller blood samples from non-finger-prick sites, was not judged to have adequate evidence of reliability, particularly in the situation of hypoglycaemia, to allow a general recommendation.
""";
                                                                                                                                           <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.1-Discussion.md>;
                                                                                                                                           <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                           <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.1-Discussion.md-e429c4c6bb30260cef48d6aeef846280bf5d8b3e>;
                                                                                                                                           <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.1-Recommendation.md-dd2990201fde11a267ed20e38417383b4469bf81> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """Self-monitoring of blood glucose levels
Self-monitoring of blood glucose levels should be used as part of an integrated package that includes appropriate insulin regimens and education to help choice and achievement of optimal diabetes outcomes.
'


""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.1-Recommendation.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.1-Recommendation.md-607b925c919af800d1f271b1cf5c81c72bf0ca27>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.2.md-79badfca49ac920e5e387b2a8df88e1631827756> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> """Self-monitoring skills should be taught close to the time of diagnosis and initiation of insulin therapy. 
'

---
 nice.evidencegrade: D
""";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.2.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.2.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.3.md-4b2f3de44bac36bc9ddaae173893d67fb1b20eb0> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> """Self-monitoring results should be interpreted in the light of clinically significant life events. 
'

---
 nice.evidencegrade: D
""";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.3.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.3.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.4.md-76e362abeef4847fee1c6ba1e0f15b9c10b0df8f> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> """Self-monitoring should be performed using meters and strips chosen by adults with Type 1 diabetes to suit their needs, and usually with low blood requirements, fast analysis times and integral memories. 
'

---
 nice.evidencegrade: D
""";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.4.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.4.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.5.md-97f971720af6a3b89f800540172466d221318be2> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> """Structured assessment of self-monitoring skills, the quality and use made of the results obtained and the equipment used should be made annually. Self-monitoring skills should be reviewed as part of annual review or, more frequently, according to need and reinforced where appropriate. 
'

---
 nice.evidencegrade: D
""";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.5.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.5.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.6.md-038696679052075700f91955d9b006b84dcdc15e> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> """Adults with Type 1 diabetes should be advised that the optimal frequency of self-monitoring will depend on:
? the characteristics of their blood glucose control
? the insulin treatment regimen
? personal preference in using the results to achieve the desired lifestyle. 
'

---
 nice.evidencegrade: D
""";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.6.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.6.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.7.md-a765cab6049ecb28f355cbe483844a8cff221380> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> """Adults with Type 1 diabetes should be advised that the optimal targets for short-term glycaemic control are:
? a pre-prandial blood glucose level of 4.07.0 mmol/l and
? a post-prandial blood glucose level of less than 9.0 mmol/l. 
Note: These values are different to those given in the recommendations for children and young people with Type 1 diabetes because of clinical differences between these two age groups.
'

---
 nice.evidencegrade: D
""";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.7.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.7.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.8.md-ba01f88bc7a2191a23b4d2326ef89e7f81150b19> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> """Monitoring using sites other than the finger tips (often the forearm, using meters that require small volumes of blood and devices to obtain those small volumes) cannot be recommended as a routine alternative to conventional self-blood glucose monitoring.
'

---
 nice.evidencegrade: D
""";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.8.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.2.8.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.1-CG15AdultES52.md-d77fb107b703ef06f581be83f6c2e86fad092ede> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES52
F our small randomised controlled trials 9497 we re identified examining different diet regimens in people with Type 1 diabetes. One randomised controlled study 94 found that a high fibre diet (50 g/day) for 24 weeks compared to a low fibre diet (15 g/day) improved blood glucose profile, and number of hypoglycaemic events, although HbA 1c , cholesterol, body weight and insulin dose were not affected



[@Giacco_2000]

[@HANSEN_1999]

[@Chantelau_1992]

[@McCulloch_1985]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.1-CG15AdultES52.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.1-CG15AdultES52.md-2bcd1a27790ab3784b4cdee9297fdebf713e83ee>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.1-CG15AdultES53.md-3b5fc5429e075a9559838d5accb4e0decb82bfdb> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES53
A high carbohydrate, high fibre and low fat diet, compared to conventional low carbohydrate diet, taught by a dietitian in an unblinded randomised controlled trial 97 was seen at 12 months to improve HbA 1c



[@McCulloch_1985]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.1-CG15AdultES53.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.1-CG15AdultES53.md-61512d955160c634e159c1826cb3135b4ee52fbf>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.1-CG15AdultES54.md-608b68de52d4159aacffc6d203d73188512d5e22> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES54
The addition of vitamin E to the normal diet has been shown to provide no benefit in terms of c holesterol level, HbA 1c , body mass index (BMI), insulin dose or blood pressure over a 12-month period 96



[@Chantelau_1992]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.1-CG15AdultES54.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.1-CG15AdultES54.md-5f5f686733b0321984561c42fc094eb28bf0d6a5>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.1-CG15AdultES55.md-69064e304b2789eacb45e3890eef048c46bb3b0d> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES55
There were significant improvements in glomerular filtration rate, and a decline in albuminuria after four weeks of a low protein diet compared to a normal protein diet in a randomised prospective trial in people with overt diabetic nephropathy. 95 Outcomes of urinary sodium ex cretion, blood pressure, BMI and HbA 1c we re not significantly different between the diets 



[@HANSEN_1999]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.1-CG15AdultES55.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.1-CG15AdultES55.md-3e9ccaabc659287ec5c3a8e5684cf348db9448c2>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.1-CG15AdultES56.md-be37f61fa27cf5010dca8ee3b18aea1bf67db92e> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES56
Canadian clinical practice guidelines 98 re co mmend that all people with diabetes on fixed-dose insulin regimen should have an individualised meal and activity plan developed. Two studies showed that patients should be taught how to adjust insulin dosage, diet and physical activity in response to blood glucose levels to reduce incidence of hypoglycaemia



[@Lau_2007]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.1-CG15AdultES56.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.1-CG15AdultES56.md-3e4ee96bc9ef779617046ef0a356f36b1b9a52a5>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.1-CG15AdultES57.md-403c50f81f2b73669c9a10e654a32685aa07e992> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES57
A medium-sized randomised controlled trial 99 of a five-day outpatient programme to enable patients to replace insulin by matching it to desired carbohydrate intake amongst adults with Ty pe 1 diabetes found that the intervention improved HbA 1c com pared to a control of normal care to six months. Positive effects were also seen in weighted quality of life and total well-being. There was no effect on incidence of severe hypoglycaemia, weight or total cholesterol. This trial enrolled people with poorly-controlled diabetes



[@DAFNE_Study_Group_2002]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.1-CG15AdultES57.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.1-CG15AdultES57.md-ec486e4cc2ac8b81c01fc99e5e46a06ed8098fcf>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.1-CG15AdultES58.md-49e0a5e208ef41c5720451eeb92b9346fb198e5f> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES58
A similar small trial 96 in which intensified insulin plus simplified diet was compared to co nv entional therapy and diet found HbA 1c to be significantly reduced, although there was no differences between the study groups for outcomes of body weight, BMI, cholesterol or triglyce rides



[@Chantelau_1992]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.1-CG15AdultES58.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.1-CG15AdultES58.md-96f367395349aa79c8f1e2bd5424551ca3554e06>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.1-CG15AdultES59.md-10f4321edbaf1efd042a6dab13c833d07096b065> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES59
A large cohort study 100 comparing degree of liberalisation of diet away from a specific co ntrolled diet after a treatment and teaching programme with estimation of carbohydrate intake and subsequent insulin self-adjustme nt found that there was no significant relationship between BMI and degree of diet liberalisation. In addition there was no relationship with HbA1c level or severe hypoglycaemia. However there was a relationship between liberalised diet and higher cholesterol levels, and an inverse relationship with tendency to monitor blood gl ucose more than three times a day



[@M_HLHAUSER_1995]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.1-CG15AdultES59.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.1-CG15AdultES59.md-9af27653a52f5d6e833af324fa8ee77249e9c8ca>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.1-CG15AdultES60.md-9956dce7fe846c5658518b1a1ba13a86ea05d01f> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES60
The recent evidence-based guidelines for nutrition principles developed by the ADA, 76 provide a broad overview of research in the area of improved diabetes care for people with Type 1 diabetes through beneficial nutritional therapies. There are recommendations based on well- performed RCTs showing significant effectiveness of interventions for areas such as carbohydrates, dietary fat, energy balance and obesity, nutritional therapy for the treatment or prevention of acute complications, and hypertension. Recommendations in other key areas are based on cohort or uncontrolled studies 



[@2003]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.1-CG15AdultES60.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.1-CG15AdultES60.md-c2adde3a1fd7e79502a573d05630b66acd6f1aed>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.1-CG15AdultES61.md-c01496a0b917df6c09140de09890f6604fddf956> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES61
The recent NICE Technology Appraisal 101 into patient education models ( www.nice. org.uk/cat.asp
*  c=68326 ) recommends dose adjustment for normal eating (DAFNE), and the intensified treatment required by DAFNE, as cost effective.



[@Blinkhorn_2003]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.1-CG15AdultES61.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.1-CG15AdultES61.md-d1667e74f70f74c37ac1f2e6d5b38f3f88851b02>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.1-Discussion.md-0e85609fcf9c6f49a5165cda146ae074bdefee3a> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                             <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                           <http://www.w3.org/2011/content#chars> """The group was impressed by the systematic approach to nutritional recommendations published by the ADA, 76 and the consistency of that approach with the new recommendations from Diabetes UK. 107 Co nsideration of the existing guidelines in the area did not lead the group to any divergent recommendations on nutrition. Furthermore, recent NICE guidance on education models for people with Type 1 diabet es had particularly addressed the relevance of one programme for mealtime insulin dose ad justment (DAFNE) and, after due discussion of some of the issues surrounding that study including the health economic issues, it was felt inappropriate to recommend modification of any of the appraisals conclusions. Accordingly the recommendations agreed by the group are mainly those of emphasis and approach appropriate to people with Type 1 diabetes, but reflecting both management of blood glucose ex cursions and arterial risk
""";
                                                                                                                                           <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.1-Discussion.md>;
                                                                                                                                           <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                           <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.1-Discussion.md-2dbf59e0a5e82bc171ad90e2bb404860eafd6014>;
                                                                                                                                           <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.1-Recommendation.md-b9eec3096fc2bad6747c8125d41efeda752e8cd3> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """Offer nutritional information at time of diagnosis
Nutritional information sensitive to personal needs and culture should be offered from the time of diagnosis of Type 1 diabetes.
'


""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.1-Recommendation.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.1-Recommendation.md-3b064871e371ae815e7f331820fa661d1ccad4b7>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.2.md-f422663bb4f6d1d7f09b6c325697b11a766ab239> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> """Nutritional information should be offered individually and as part of a diabetes education programme (see Patient Education recommendations in this chapter (R12-17). Information should include advice from professionals with specific and approved training and continuing accredited education in delivering nutritional advice to people with health conditions. Opportunities to receive nutritional advice should be offered at intervals agreed between adults with Type 1 diabetes and their advising professionals.
'

---
 nice.evidencegrade: D
""";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.2.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.2.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.3.md-ad39598d43a812915ee0532cd5f0dc2c38934fab> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> """The hyperglycaemic effects of different foods a person with Type 1 diabetes wishes to eat should be discussed in the context of the insulin preparations chosen to match those food choices. 
'

---
 nice.evidencegrade: A
""";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.3.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.3.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.4.md-0551e45941824f8e345508a29811e4622cb8c643> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> """Programmes should be available to adults with Type 1 diabetes to enable them to make:
? optimal choices about the variety of foods they wish to consume
? insulin dose changes appropriate to reduce glucose excursions when taking different quantities of those foods.
'

---
 nice.evidencegrade: A
""";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.4.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.4.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.5.md-7024a369367895bb71a7d1f664798fd970827e43> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> """The choice of content, timing and amount of snacks between meals or at bedtime available to the person with Type 1 diabetes should be agreed on the basis of informed discussion about the extent and duration of the effects of consumption of different food types and the insulin preparations available to match them. Those choices should be modified on the basis of discussion of the results of self-monitoring tests.
'

---
 nice.evidencegrade: D
""";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.5.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.5.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.6.md-e6b824793a559aee65f62b56c01081102062b683> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> """Information should also be made available on:
? effects of different alcohol-containing drinks on blood glucose excursions and calorie intake
? use of high calorie and high sugar treats
? use of foods of high glycaemic index
'

---
 nice.evidencegrade: D
""";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.6.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.6.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.7.md-ecb0617d28db3c45d680061036cf52703110c538> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> """In formation about the benefits of healthy eating in reducing arterial risk should be made available as part of dietary education in the period after diagnosis, and according to need and interest at intervals thereafter. This should include information about low gl yc aemic index foods, fruit and vegetables, and types and amounts of fat, and ways of making the appropriate nutritional changes.
'

---
 nice.evidencegrade: D
""";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.7.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.7.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.8.md-e853d97658ceb066bb8d356a9099b1d4d8a7268b> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> """Nutritional recommendations to individuals should be modified to take account of associated features of diabetes, including:
? excess weight and obesity
? underweight
? eating disorders
? raised blood pressure
? renal failure
'

---
 nice.evidencegrade: D
""";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.8.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.8.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.9.md-35c2c235b60d752978fd785fb6a86a5bff6f1869> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> """All healthcare professionals providing advice on the management of Type 1 diabetes should be aware of appropriate nutritional advice on common topics of concern and interest to adults living with Type 1 diabetes, and should be prepared to seek advice from colleagues with more specialised knowledge. Suggested common topics include:
? glycaemic index of specific foods
? body weight, energy balance and obesity management
? cultural and religious diets, feasts and fasts
? foods sold as diabetic
? sweeteners
? dietary fibre intake
? protein intake
? vitamin and mineral supplements
? alcohol
? matching carbohydrate, insulin and physical activity
? salt intake in hypertension
? co-morbidities including nephropathy and renal failure, coeliac disease, cystic fibrosis or eating disorders
? use of peer support groups.
'

---
 nice.evidencegrade: D
""";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.9.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.3.9.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.4.1-CG15AdultES62.md-88dd608001c56557ab68bf98ab4904da7e634d06> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES62
One small randomised controlled trial 102 was identified that assessed the effect of a 16-week aerobic exercise programme on fitness and lipid profile in young men with Type 1 diabetes. There were significant differences in VO 2max and serum total cholesterol compared to no tr aining. There were no significant changes in outcomes of HbA 1c and plasma glucose. The study was not blinded due to the nature of the intervention



[@LAAKSONEN_2000]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.4.1-CG15AdultES62.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.4.1-CG15AdultES62.md-8ca5fee9623ff1e3aab24fd911d7393895f001d4>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.4.1-CG15AdultES63.md-baab09623413d34e0955fc0c50b3bfdc96467698> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES63
A small cross-sectional study 103 ev aluating the effect of three months of individualised aerobic ex ercise in altering blood pressure and lipid profile found that HbA 1c , fructosamine and total blood glucose did not change significantly from baseline levels. The design of the study would not represent a sound basis for supporting a recommendation for advocating exercise as therapy



[@Ligtenberg_1999]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.4.1-CG15AdultES63.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.4.1-CG15AdultES63.md-998078787bc705e7a590aedf262c22ec3662b3f2>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.4.1-CG15AdultES64.md-b196bab3966e7b3a35621bcec96992e8c183e610> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES64
Another study with a similar intervention 102 found that four months of aerobic training provided no changes in terms of HbA 1c or total cholesterol, although there were benefits of ex ercise compared to control in terms of peak oxygen uptake



[@LAAKSONEN_2000]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.4.1-CG15AdultES64.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.4.1-CG15AdultES64.md-69129ff0274cd8f18152f138925ec35d8e3ceed0>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.4.1-CG15AdultES65.md-edd2bbeac59b16906eb7a676a76d6bd477132a05> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES65
A prospective non-randomised study 104 w ith a before and after design found that steady-state plasma glucose was significantly decreased compared to baseline as was plasma insulin with supervised exercise program (at least 135 minutes/week) for three months compared to no ex ercise. Also cholesterol decreased significantly, however there were no reported significant c hanges in fasting blood glucose, HbA 1c and microalbuminuria



[@Lehmann_1997]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.4.1-CG15AdultES65.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.4.1-CG15AdultES65.md-563a278891cf170e95fa8eb8750624eb8b0ec0ff>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.4.1-CG15AdultES66.md-c24bb5c7c04a5d7386ab02ea8caf48b33dd99d25> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES66
A medium-sized randomised controlled trial 105 of intensive advice and lifestyle programme w ith specified diet and exercise prescriptions compared to conventional care found that HbA 1c decreased from baseline measurements significantly over six months in the control group but re mained relatively stable in the intervention group, but no between-group comparison was made. Also, HDL cholesterol and triglycerides were not significantly different between groups at any phase of the study. However exercise sessions were not standardised in the study and a lack of blinding limited the validity of the trial



[@Perry_1997]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.4.1-CG15AdultES66.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.4.1-CG15AdultES66.md-5be11648c7479eebdb97b59a808d773a002a97bb>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.4.1-CG15AdultES67.md-9eb49341c956484fe0af28c8cd1811b70c870429> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES67
A small before and after study 106 found that an intervention of 10 hours of education and physical training three or four times a week produced no metabolic response at three months w ith fasting plasma glucose levels and serum cholesterol not changing significantly. Without blinding or randomisation this evidence is not sufficient to support the use of a mixed education and exercise intervention for people with Type 1 diabetes



[@Schneider_1992]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.4.1-CG15AdultES67.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.4.1-CG15AdultES67.md-1b3f4e9843ea96a11f3fdaab6e813f82ebbef45d>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.4.1-CG15AdultES68.md-92a53bdfd35c52c4e135c9ec16a7a3f76c369907> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES68
A non-randomised prospective controlled study 103 to assess whether exercise is related to better diabetes control was reviewed. There was no significant correlation between the exercise ex pe nditure and HbA 1c in all Type 1 diabetes patients, nor was there any relationship to the frequency of mild hypoglycaemic events



[@Ligtenberg_1999]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.4.1-CG15AdultES68.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.4.1-CG15AdultES68.md-ff937beda6d239fa77a3b8e55eb725d865a30c3b>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.4.1-CG15AdultES69.md-fddd8a561ba78a1c32958957e33f5e2ae956fd57> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES69
The ADA 76 guidelines present recommendations based on a good evidence-based review. They recommend that a thorough evaluation be undertaken of patients before exercise is initiated. General recommendations for how to exercise safely include:

*   metabolic control before activity

*   blood glucose monitoring before and after physical activity

*   food intake to be considered with added carbohydrate as necessary



[@2003]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.4.1-CG15AdultES69.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.4.1-CG15AdultES69.md-085797b3b6b4590ab459429ff4d7d133955fb083>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.4.1-Discussion.md-fcdffd325dc4d19a62f750046bc1e466c6092343> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                             <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                           <http://www.w3.org/2011/content#chars> """The group noted that the evidence for an improved arterial risk profile in people with Type 1 diabetes was consistent with that for other diabetic and non-diabetic people. Evidence of a co nsistent effect in improving blood glucose control was absent, although by analogy with people with Type 2 diabetes the overweight/insulin-resistant person might benefit from an ex ercise programme as part of a lifestyle improvement initiative. Some people will undertake significant exercise by choice and would benefit from support in so doing.
""";
                                                                                                                                           <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.4.1-Discussion.md>;
                                                                                                                                           <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                           <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.4.1-Discussion.md-e7a41c41f91859edf10ed72a7c0f709575dd906c>;
                                                                                                                                           <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.4.1-Recommendation.md-bf59615212af8708e65e9177441f3eebb1d86951> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """Advise that physical activity can reduce enhanced arterial risk
Adults with Type 1 diabetes should be advised that physical activity can reduce their enhanced arterial risk in the medium and longer term. 
'


""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.4.1-Recommendation.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.4.1-Recommendation.md-cf64599a0a5eb483a2d0c32508c5a1be79baff1e>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.4.2.md-53458d0d5490b1c85dd2aaed363517ed812b0ab9> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> """Adults with Type 1 diabetes who choose to integrate increased physical activity into a more healthy lifestyle should be offered information about:
? appropriate intensity and frequency of physical activity
? role of self-monitoring of changed insulin and/or nutritional needs
? effect of activity on blood glucose levels (a fall is likely) when insulin levels are adequate
? effect of exercise on blood glucose levels when hyperglycaemic and hypoinsulinaemic (risk of worsening of hyperglycaemia and ketonaemia)
? appropriate adjustments of insulin dosage and/or nutritional intake for exercise and post-exercise periods, and the next 24 hours
? interactions of exercise and alcohol
? further contacts and sources of information.
'

---
 nice.evidencegrade: D
""";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.4.2.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.8.4.2.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES70.md-f3a1dc6e99268e1b737f9ac825cee96e85ddd6ab> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES70
A Diabetes UK consensus statement recommended that only HbA 1c should be used in the monitoring of blood glucose control. Other studies reported within a systematic review 89 have shown discrepancies in the classification of patients between HbA 1c and HbA 1 assays



[@Coster_2000]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES70.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES70.md-9e77b8985c8ec74ef896b7013947dcf8f8431d69>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES71.md-dac75f2e570afa20f64957e35be778379a69f2d5> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES71
Tw o studies in a systematic review 89 showed high inter-individual variability for GHb assays in non-diabetic and in diabetic subjects with stable or variable control. One of these studies suggested an association between clinical control and sampling interval



[@Coster_2000]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES71.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES71.md-2b788b01dbbd29f43fff5e538d30a954808adb99>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES72.md-ec6eb503049d1522288b858d3421df02de0babd1> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES72
The same systematic review 89 re ported on randomised controlled trial evidence supporting the use of GHb measurements, in particular results cited from the DCCT demonstrated the usefulness of these assays in contributing to improved long-term blood glucose control and a re duction in morbidity



[@Coster_2000]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES72.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES72.md-76a5216f20d7b148bd8d955aa18c5484a03d8ea9>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES73.md-6a5adfba2c0c968dffd34e2255d368fa70f56fd2> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES73
A Danish systematic review 108 re ported that HbA 1c values allowed clinicians to identify patients with poor glycaemic control, concluding that GHb is the most clinically appropriate t est of long-term glycaemia and should be used in routine management of Type 1 diabetes



[@Larsen_1989]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES73.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES73.md-282f0a3773855dfa92a80e7a5a659eb16b2be6b6>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES74.md-a06f8fcba321b58d2c0f80a6ee5527c214bc1e91> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES74
One study within a systematic review 89 recommended that no more than six GHb assays were necessary in a given year 



[@Coster_2000]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES74.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES74.md-f4d33c748e7d32f80e9b604cb5f38b377cfd7a2d>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES75.md-4ce04d10460984b3337b0eb07371dcbec9b958c3> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES75
ADA recommendations 76 advise GHb measurements are performed in accordance with clinical judgements. ADA consensus recommends GHb testing at least twice a year in patients with stable glycaemic control who are meeting treatment goals. Testing should be more frequent (quarterly) in patients whose therapy has changed or who are not meeting glycaemic control targets



[@2003]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES75.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES75.md-5d5f7d857471025e162d714776ff6fdea5a8a4a6>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES76.md-d494797a2e3d1e1d66e628308e9deee52fd96384> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES76
One study within a systematic review 89 re ported fructosamine testing as able to detect shorter or more recent fluctuations in blood glucose compared to GHb. Fructosamine testing does not have the problems of standardisation associated with GHb, thus results are comparable between laboratories



[@Coster_2000]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES76.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES76.md-9d0e829c83b1895000da0e7153a85740e7474227>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES77.md-a8702b9ef95c2b540586595fa0356f7482978f4c> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES77
Two studies within a systematic review 89 described a high correlation between fructosamine and HbA 1c , however later studies debated this claim. One study suggested that although fructosamine correlates with HbA 1c , the value of HbA 1c in an individual cannot routinely be inferred with reliability from the level of fructosamine



[@Coster_2000]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES77.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES77.md-61bfd377def74c5a49d9f59d1bce82644a32592f>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES78.md-9011600731aee6d49222af96f1f4273c79a95159> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES78
Two studies contained within a systematic review, 89 in patients with renal failure and elderly Ty pe 2 diabetes patients with liver cirrhosis and nephrotic syndrome, suggest the influence of ch ro nic conditions rather than metabolic control on fructosamine levels is the source of unreliability in test result. The systematic review co ncludes that more evidence is needed to r esolve these issues



[@Coster_2000]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES78.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES78.md-2bf03134ac5df3080c60cd0bc272528d0a680f6c>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES79.md-57d7df8f49b4935c85ab0423060d9d52579995c7> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES79
One correlation study within a review 89 showed no significant correlation between HbA 1c and fructosamine results over a six month follow-up



[@Coster_2000]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES79.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES79.md-46a6cbbfe3746a191d72a988f825cbdcb2254d71>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES80.md-5f7b80a9ff3233d18df834417d7c1e101e895bae> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES80
ADA recommendations 76 state that assays of glycated serum protein would have to be performed on a monthly basis to gather the same information as measured in GHb three to four times per year



[@2003]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES80.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES80.md-b8825afa044794830245a358f239654c1febc651>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES81.md-36bdc79f1154c1eb70f3f1ecc6575c31327c9b44> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES81
A systematic review 89 urges caution in using fructosamine testing, in light of the fact that fructosamine values can be improved by increased concordance a week or two before testing



[@Coster_2000]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES81.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES81.md-81784c50b039c8cdc47110919975e40445707dba>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES82.md-ff9d6c03c0502bc9bfdbeabc79cb64febed25410> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES82
A nother study found that fasting blood glucose level (FBG) and serum fructosamine are not as useful as HbA 1c for monitoring diabetic control, but are additional extras for assessing control ov er short and long periods 89



[@Coster_2000]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES82.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES82.md-cf81ffbce2a639b802a0c091be7761e47e2aa00e>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES83.md-14f5b3434507e97bacb08fa30490b52782d2f6b1> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES83
Three observational studies 109111 co mpared continuous glucose monitoring systems (CGMS) w ith SMBG. Studies demonstrated good correlation of CGMS with plasma and capillary measures of blood glucose over a range of blood glucose values. Error grid analysis showed the majority of readings fell within a clinically acceptable margin of error across all studies



[@Gross_2000]

[@Gross_2000]

[@Maran_2002]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES83.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES83.md-a08ad8ea751e2e788def64e0666d3fec9e2a28db>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES84.md-5221344f8dd774cf5e5eb8a27095de20b2227d16> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES84
One study 111 re ported acceptable level of comfort with CGMS. However, none of these studies address viable outcomes of glycaemic control or long-term use. Study methodology is not clearly reported



[@Maran_2002]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES84.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES84.md-97eb2c1f43883e013f690d3b07108c4fdeb06991>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES85.md-de47a69dc005cd87a3690f321cafc5053a4da4a8> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES85
One controlled trial within a systematic review 112 demonstrated that near patient testing led to an increase in management changes for patients with poor glucose control. Near patient testing for HbA 1c improved the process of care of patients



[@Bernstein_2002]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES85.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES85.md-17f66fb1ae813aebdb33322c7c8d6acb01d47721>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES86.md-2ece7d68927a20c05d5b8fd0c0c8bbb32bafa859> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES86
In the same review, 112 questionnaires recording patient satisfaction of near patient testing co ncluded that the introduction of near patient testing for HbA 1c improves the likelihood of monitoring and discussion of glycaemic control at patient visits. Patients reported that this was important to them and resulted in greater satisfaction with the test information provided



[@Bernstein_2002]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES86.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES86.md-bd7c8f152536a2a2c7cb2a406a1b239ebc667845>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES87.md-5d38d8a8064bd9beffd9cf8c75ab64759c830ad5> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES87
W ithin the health technology assessment, 112 a retrospective cohort study showed that, after allowing for confounding factors, mean HbA 1c level was lower following near patient testing and the immediate availability of results. In order to precisely quantify the effect of the testing system on HbA 1c level, further, prospective studies are required



[@Bernstein_2002]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES87.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES87.md-cb9c6bfdd6ae2ce2e9d1fb87af05b287b2dad523>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES88.md-e95b6971cd479ab8cd8da1dc5dfa7fa7b38165b2> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES88
A systematic review 89 re ported four studies on the effectiveness of benchtop analysers co mpared with traditional laboratory methods. Two studies showed comparable results between the two techniques when operated by non-medical personnel. One study found that the benchtop analyser, although reliable, tended to slightly underestimate HbA 1c , compared w ith high performance liquid chromatography (HPLC)



[@Coster_2000]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES88.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES88.md-9967a814a7db3be74c43412ea932303016b5d6fb>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES89.md-1a8466b4c8093041f20c05a0d385cf4002ffe14a> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES89
An HTA report 112 produced cost estimates for near patient testing conducted by a laboratory or nurse against conventional testing. However, little data was available on the effects of near patient testing on clinical or quality of life outcomes. For health economics to provide guidance in this area, the long-term effects of different types of clinical monitoring on glycaemic control and subsequent complications must be known. A recent HTA report 89 re co mmended further research into the cost-effectiveness of near patient t esting for diabetes, FBG and fructosamine testing. No other paper in the health economics searches specifically addressed the issue of clinical monitoring



[@Bernstein_2002]

[@Coster_2000]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES89.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-CG15AdultES89.md-26d669e7b84c28374af409fd9e2e12e7915b3006>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-Discussion.md-ae280274c679a3adf7e6ad34aa5923d343964e17> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                             <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                           <http://www.w3.org/2011/content#chars> """The group endorsed the utility of having a frame of reference against which people with diabetes and the professionals advising them could assess risk and risk threshold for micro- and macro-vascular disease in terms of blood glucose control. This was a core component of intensification of therapy in studies showing improved long-term outcomes. HbA 1c is the only measure for which quantitative information linking glucose control to complications is av ailable, and then only when standardised to the assay used in the DCCT study. Near patient t esting was felt to be a core component of making optimal and relevant use of HbA 1c re sults. Co ntinuous glucose monitoring systems were considered to not yet have established their usefulness beyond problem-solving in the occasional person with recurrent blood glucose co ntrol problems at the same time of day.
""";
                                                                                                                                           <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-Discussion.md>;
                                                                                                                                           <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                           <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-Discussion.md-d3d6b79aaccd7ce03b36f7692024cc2af54bfebd>;
                                                                                                                                           <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-Recommendation.md-ad6ecfb58583910ada1234823c0aaf320f16d36b> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """Clinical monitoring of blood glucose levels
Clinical monitoring of blood glucose levels by high precision DCCT-aligned methods of haemoglobin A 1c (HbA 1c ) should be performed every two to six months depending on: 

*   achieved level of blood glucose control 

*   stability of blood glucose control 

*   change in insulin dose or regimen
'


""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-Recommendation.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1-Recommendation.md-72a619b29b0f51b6d3b5a847bb60a229d436c340>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1.md-0c4528420ec760c97ce7eb4109a47caefece7fa1> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> """Clinical monitoring of blood glucose levels by high precision DCCT-aligned methods of haemoglobin A 1c (HbA 1c ) should be performed every two to six months depending on: 
? achieved level of blood glucose control 
? stability of blood glucose control 
? change in insulin dose or regimen
'

---
 nice.evidencegrade: D
""";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.1.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.2.md-64463cd69fda0a320e741e2576dda1444e475bba> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> """Site-of-care measurement, or measurement before clinical consultation, should be provided.
'

---
 nice.evidencegrade: D
""";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.2.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.2.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.3.md-5f9cdac9527b4855cddf495a4466506a902ebb79> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> """HbA1c results should be communicated to the person with Type 1 diabetes after each measurement. The term A1c can be used for simplicity.
'

---
 nice.evidencegrade: D
""";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.3.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.3.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.4.md-98761389e214ae7e17242d4b1be379b59267127c> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> """Total glycated haemoglobin (GHb) estimation, or assessment of glucose profiles, should be used where haemoglobinopathy or haemoglobin turnover invalidate HbA1c measurement.
'

---
 nice.evidencegrade: A
""";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.4.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.4.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.5.md-dfb28b39a004f34e0dfceb3e49a60b3e6004c1f4> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> """Fructosamine should not be used as a routine substitute for HbA1c estimation. 
'

---
 nice.evidencegrade: A
""";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.5.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.5.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.6.md-ace058969ef92544ca15bf1ea9c9128e2849954f> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> """Continuous glucose monitoring systems have a role in the assessment of glucose profiles in adults with consistent glucose control problems on insulin therapy, notably:
? repeated hyper- or hypoglycaemia at the same time of day
? hypoglycaemia unawareness, unresponsive to conventional insulin dose adjustment. 
'

---
 nice.evidencegrade: A
""";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.6.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.1.6.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-CG15AdultES100.md-e93cc18eb69a1ac1e4f0505d23e4450a6d6d1dd7> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES100
One study (1989) 120 studied HbA 1 and retinopathy incidence long term in Belfast. While some clear relationships were established the data showing no proliferative retinopathy below an HbA 1 of 10.0% (HbA 1c 8.5%) are compromised by very small numbers, and only interquartile r anges are given for non-proliferative retinopathy



[@MCCANCE_1989]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-CG15AdultES100.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-CG15AdultES100.md-b80ceac82e461b09b9d0cde60022d2e17ceea228>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-CG15AdultES101.md-8280d795491f45b80569eeca12af40662d4a82cb> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES101
Ne ither the Oslo nor Stockholm studies of control and complications in Type 1 diabetes 121 give useful data on targets and thresholds, beyond showing that people with lower levels on average do better



[@Reichard_1993]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-CG15AdultES101.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-CG15AdultES101.md-babac9142265a9f6292567659aa117f954058fa3>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-CG15AdultES102.md-eb662e5442f539ef6aa1fb72fdf48c01ebaa7fe0> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES102
A non-randomised controlled study 122 looked prospectively at glycated Hb and micro- albuminuria risk in people with Type 1 diabetes attending their clinic. Their data did suggest a threshold effect (small and unchanging incidence below threshold, sharp rise above), at 7.98.5% HbA 1c (the authors chose to centre on 8.1%)



[@Krolewski_1995]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-CG15AdultES102.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-CG15AdultES102.md-4cf84bd697fd1d050a08b5b2229d83208e551c82>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-CG15AdultES103.md-b0df520bcd349d65a02b6081804e207bbe88aed2> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES103
A non-randomised controlled study 123 looked at how glycated Hb measurement related to OG TT re sults, performing a meta-analysis on 18 studies. Unfortunately most of these were published before any kind of GHb standardisation, rendering the results uninterpretable



[@Peters_1996]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-CG15AdultES103.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-CG15AdultES103.md-aeac11535631c8e03adf81253c6032f58f19e6d8>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-CG15AdultES104.md-ec91b26d082c61277926325bf5138093b9a434dd> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES104
A further cohort study 124 looked in more detail at GHb, fasting and 2h glucose as diagnostic methods (and thus mainly Type 2 diabetes), using retinopathy and nephropathy as outcome measures. It may be noted that the Wisconsin data suggested that the microvascular/glucose co ntrol relationships were the same in Type 1 and Type 2 diabetes. The data presentations are strongly reminiscent of previous work, 122 w ith low and unchanging incidence of microvascular disease up to an inflection point, then sharply rising rates. The thresholds for fasting glucose appear to be somewhere above 6.8 mmol/l (consistent with older OGTT data), and HbA 1c somewhere above 7.4% (and below 9.1%)



[@Krolewski_1995]

[@1994]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-CG15AdultES104.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-CG15AdultES104.md-b1a6a8d476954090c0ea7c480e92952bc25d3553>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-CG15AdultES105.md-518cc8a1e1a2c23ddd8626357df014684e0ee56c> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES105
Tw o non-randomised controlled studies 116,125 re port the relationship between HbA 1c and self- monitored pre- and post-prandial glucose levels. The reports are consistent and can be related to D CCT-harmonised assays. It must be noted that these studies used pre-determined, self- monitored profiles taken from memory meters, and cannot easily be translated into patient- selected estimations, or only pre-prandial monitoring. They also omit the effects of night-time gl ucose profiles between bedtime and pre-breakfast readings. These data give the most robust ev idence of the relationship between HbA 1c and the toxic glucose concentrations which actually cause the microvascular damage



[@Rohlfing_2002]

[@Nathan_1984]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-CG15AdultES105.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-CG15AdultES105.md-4e354002624eaaebd52fefdd32adb1211faf4470>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-CG15AdultES90.md-9042dc856af813ec35e94839d2cd4ae60957586d> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES90
In 1989, the European NIDDM Policy Group (Type 2 diabetes) suggested HbA 1 was good <8.5%, acceptable 8.59.5%, poor >9.5% (equivalent to HbA 1c of <6.9, 6.97.7, >7.7%). No ev idence for these limits was given, and it was not clear whether the intent was for micro- or macrovascular protection or both. However, the need to individualise by life expectancy was acknowledged 114



[@Alberti_1988]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-CG15AdultES90.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-CG15AdultES90.md-d972bbacec9d66c4c5d99c925055e4f7976a1d3d>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-CG15AdultES91.md-95df3bdf77c83abf1c43a2fbf7f6513163a35248> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES91
In 1993, the above guidelines were revised to HbA 1c <6.5%, 6.57.5%, and >7.5%. The European IDDM Policy Group (Type 1 diabetes) (WHO, IDF, St Vincent) met concurrently and agreed these, but using the terminology good, borderline and poor to describe the groups. These pre- D CCT recommendations are not justified in the text 115



[@Group_1999]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-CG15AdultES91.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-CG15AdultES91.md-617a5476fdf9948755973fc2877f06f7a619be0f>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-CG15AdultES92.md-d649c548b166e9152d623fc821255311dd6bf072> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES92
In 1998, the European Diabetes Policy Group revised its terminology to assessment levels, giving advice on how to use assessment levels to set targets for individuals. These were, for HbA 1c : adequate 6.27.5%, inadequate >7.5%. However the relation of this 7.5% to glucose levels was then revised to equivalent to a self-monitored pre-prandial level of 6.5 mmol/l and post-prandial 9.0 mmol/l. These post-DCCT recommendations are not justified in the text 115



[@Group_1999]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-CG15AdultES92.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-CG15AdultES92.md-832090298d8a5d117072d8d4403c06581861556d>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-CG15AdultES93.md-3483e0115677090c5501121f9ec0da19b773f060> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES93
The NICE Type 2 diabetes guidelines therefore recommended 6.5% to 7.5% as ideal targets, individualised by balance of macrovascular (tend to 6.5%) and microvascular (7.5%) risk



[@Boynton_1998]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-CG15AdultES93.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-CG15AdultES93.md-126e47eb3971b5947821e0669da454f3114f0717>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-CG15AdultES94.md-ea537cff418d792480fa89d30a91937aa226a65a> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES94
The ADA has republished its recommendations yearly. 76 These choose a glycaemic goal of HbA 1c <7.0% for adults (type of diabetes not specified), equating this to pre-prandial <7.2 mmol/l and peak post-prandial <10.0 mmol/l. However, a table in the same paper suggests that an HbA 1c of 7.0% equates to mean self-monitored plasma glucose of 9.5 mmol/l 116



[@2003]

[@Rohlfing_2002]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-CG15AdultES94.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-CG15AdultES94.md-5bf7e42b61d5cfee96058abd51fb35c72573a070>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-CG15AdultES95.md-9f45a218d203dba2baded3fc995b3315f7364072> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES95
Ho we ve r in the same issue (January 2003), 76 the ADA notes in a chapter on Implications of the D CCT that the level of glucose control to be sought under ideal circumstances is an HbA 1c of around 7.2% (average glucose 8.6 mmol/l). This argument is based on that achieved in the D CCT, and is thus not theoretically justified



[@2003]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-CG15AdultES95.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-CG15AdultES95.md-9c33e78b98ebe7de2869707229e9311144f569a1>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-CG15AdultES96.md-a0e84af4895230aaaf80e10e80ef27d30d8b15d6> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES96
The microvascular risk threshold is what determines the diagnostic threshold for diabetes. In theory, oral glucose tolerance test (OGTT) findings should give some guidance as to this threshold. Unfortunately these are mainly based on non-physiological glucose load findings, and set a top limit of risk for 2h post-prandial levels. Fasting levels have been set as a microvascular threshold of 7.0 mmol/l (based on epidemiological equivalence with 2h OGTT levels), which would map to a DCCT-harmonised HbA 1c of about 7.7%


""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-CG15AdultES96.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-CG15AdultES96.md-90adb7615ff38aa055a84af4ceeeda5a740e56f9>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-CG15AdultES97.md-d7580d495e42b0c2ac8af798e61dc408d76f85a1> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES97
The DCCT data has never been satisfactorily analysed with a view to answering this question. A graph in the original main paper 117 suggests a curvilinear relationship between control and complications, giving the conclusion that lower is always better (ignoring the hypoglycaemia issue for this purpose), down at least to the levels measured in the study (5.5%). This conclusion is called into question because:

*   it is based on study averages, and even people at lower levels over nine years may have been at high levels at times

*   it takes no account of pre-trial levels

*   incident retinopathy is counted only in a forward (worsening) direction, which makes no allowance for false negative retinopathy at baseline

*   worsening retinopathy is known to occur in the first two years after improvement of blood glucose control, and this is not discounted



[@1993]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-CG15AdultES97.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-CG15AdultES97.md-f5b212ef386ba94d7844ce38d856c2cc42222001>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-CG15AdultES98.md-791f45352351c3a781693cea38dfa7585fb1c653> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES98
Fu r ther analysis was published in 1995. 118 Un fortunately, this is mostly in the form of a series of fitted curves without the data on which they are based. Curves of risk vs time suggest that r etinopathy progression in the intensively managed group did not increase with time with a mean HbA 1c of 8.0%, and increased little at this level in the conventionally managed group w ith time



[@1995]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-CG15AdultES98.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-CG15AdultES98.md-c7fa0bf2db28bc7b51be48903c38cd5ba3bcb16b>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-CG15AdultES99.md-0f5f3a2d5df77a3891af64a40453d7e984e2f901> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES99
R eanalysis of the published DCCT curve 118 suggests no worsening of retinopathy rates from normal levels until HbA 1c >8.0%; the low rates (2% per 100 patient years) below that may be artefact for the reasons given above. The UKPDS (epidemiological analysis, Type 2 diabetes, microvascular disease) suffers much the same problems. 119 A similar level is found for r etinopathy of 2% per 100 patient years at an HbA 1c of 7.5% and of 1% per 100 patient years at a level of 6.5% 



[@1995]

[@Stratton_2001]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-CG15AdultES99.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-CG15AdultES99.md-be1e385f92c06b422cd16d7b26a8f1bc7f4326b5>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-Discussion.md-163f66fded565801f9f79ca5670677e0647fd545> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                             <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                           <http://www.w3.org/2011/content#chars> """There must be a threshold for glucose control and the development of microvascular co mplications, or non-diabetic people would get complications. Indeed, this threshold must be we ll above the normal range as people with impaired glucose tolerance (IGT) do not (by definition) get microvascular complications. As people with IGT have HbA 1c levels of up to 7.0%, this by itself sets a lower limit of microvascular risk. The microvascular thresholds of HbA 1c 7.5% set around 10 years ago have stood the test of all data published since. If anything the DCCT, Krolewski and McCance data suggest a figure closer to 8.0%. Re co mmendations from the ADA (7.0%) and American College of Endocrinologists (6.5%) are not specific to type of diabetes; data does suggest macrovascular protection is gained by lowering blood glucose levels into the normal range, and the NICE (inherited) guidelines for Ty pe 2 diabetes go for HbA 1c 6.5% in these higher arterial risk individuals. Some people with Type 1 diabetes are at higher arterial risk, notably those with developing nephropathy. This can be identified by increased albumin excretion rate. The presence of features of the metabolic syndrome will also predict higher arterial risk. It may be appropriate to co nsider tighter targets for glucose control (if feasible) in people in these categories. Ho we ve r, these levels are better considered as assessment levels , to be used in setting realistic targets for the individual. Major diabetes services in Europe currently only get about 20% of people with Type 1 diabetes into the sub-7.5% bracket. UK composite data (UKDIABS) shows some services doing better, but this may only represent non-standardised GHb estimation. That current technologies of diabetes care markedly limited the proportion of people on insulin w ho were able to manage themselves to ideal levels was not seen as a bar to setting such assessment levels. It was noted that arterial risk would be likely to have a different relationship in this regard from microvascular risk, and that for the former there was little direct information available for people with Type 1 diabetes, but that the understandings gained in Ty pe 2 diabetes and people without diabetes gave strong guidance in this respect. It was felt that as the assessment of the evidence available pointed to target definition in the same range as other published guidelines, and in particular the NICE inherited guidelines for Type 2 diabetes, there was practical utility for practice of care in having matching recommendations. Lastly the problem of hypoglycaemia in limiting was what achievable in any individual should be addressed within any recommendations, to assuage inappropriate attempts to achieve tight co ntrol and counter impressions of failure if targets are not attained.
""";
                                                                                                                                           <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-Discussion.md>;
                                                                                                                                           <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                           <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-Discussion.md-0a18f03dd4f590d15363e3d7ac683bafc3ae1bca>;
                                                                                                                                           <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-Recommendation.md-beae9f3a86f482307cf4adc249322ff6b4a4efeb> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """Maintaining a DCCT-harmonised HbA 1c below 7.5%
Adults with Type 1 diabetes should be advised that maintaining a DCCT-harmonised HbA 1c below 7.5% is likely to minimise their risk of developing diabetic eye, kidney or nerve damage in the longer term.
'


""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-Recommendation.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-Recommendation.md-ea26d6f570c811c96c2fcdda0bddd980cdc11d0a>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-Set.md-731eec0e60c032d7217b9e3904b70018b34c0763> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                      <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                    <http://www.w3.org/2011/content#chars> """## Topic CG15AdultS11
The DCCT, and a number of smaller studies which are potentially underpowered, 113 suggest that more intensive management of people with Type 1 diabetes (by themselves, with advice) re duces the rate of development of microvascular complications over a period of years. The primary metabolic improvement in the DCCT was lowering of blood glucose level, and this was the measure used in that study to drive the intensification of therapy. This suggests that using measures of blood glucose control in the routine management of therapy in people with Type 1 diabetes is well founded. A question then arises as to what level of blood glucose control people with diabetes should ch oose to strive for. A closely related question is what level(s) of glucose control should be used in assessing the performance of diabetes services.  Targets  have been criticised by some as not giving flexibility for individuals with particular problems (eg hypoglycaemia) to be content with higher HbA 1c levels, which allows some longer-term risk for a gain in current well-being. It is clearly useful to be able to identify those in whom newer and more expensive technologies could be tried in an attempt to reduce microvascular risk, and to distinguish them from those who already achieve safe (or safer) levels on their current therapy. People with diabetes need information on what blood glucose level they need to attain if they wish to minimise vascular risk.
""";
                                                                                                                                    <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-Set.md>;
                                                                                                                                    <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                    <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-Set.md-0f373cbd0dde5bd3938d5a8c47c14a1ed0e2ac64>;
                                                                                                                                    <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-Set.md-9e64a871c32fcc5492cf962f22ed902b9dbd9a8b> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                      <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                    <http://www.w3.org/2011/content#chars> """## Topic CG15AdultS11
The DCCT, and a number of smaller studies which are potentially underpowered, 113 suggest that more intensive management of people with Type 1 diabetes (by themselves, with advice) re duces the rate of development of microvascular complications over a period of years. The primary metabolic improvement in the DCCT was lowering of blood glucose level, and this was the measure used in that study to drive the intensification of therapy. This suggests that using measures of blood glucose control in the routine management of therapy in people with Type 1 diabetes is well founded. A question then arises as to what level of blood glucose control people with diabetes should ch oose to strive for. A closely related question is what level(s) of glucose control should be used in assessing the performance of diabetes services. T argets have been criticised by some as not giving flexibility for individuals with particular problems (eg hypoglycaemia) to be content with higher HbA 1c levels, which allows some longer-term risk for a gain in current well-being. It is clearly useful to be able to identify those in whom newer and more expensive technologies could be tried in an attempt to reduce microvascular risk, and to distinguish them from those who already achieve safe (or safer) levels on their current therapy. People with diabetes need information on what blood glucose level they need to attain if they wish to minimise vascular risk.
""";
                                                                                                                                    <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-Set.md>;
                                                                                                                                    <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                    <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.1-Set.md-731eec0e60c032d7217b9e3904b70018b34c0763>;
                                                                                                                                    <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-332a35d1000ad9f48052b739c045858dc0b18841>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.2.md-f0948706fb3e67d4e1bd69b7d129aa1b9c94c4f5> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> """Adults with Type 1 diabetes who want to achieve an HbA 1c down to, or towards, 7.5% should be given all appropriate support in their efforts to do so.
'

---
 nice.evidencegrade: D
""";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.2.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.2.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.3.md-a1b13e4e1057be18f96dc53a57415b933ee9a0d6> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> """Where there is evidence of increased arterial risk (identified by a raised albumin excretion rate, features of the metabolic syndrome, or other arterial risk factors) people w ith Type 1 diabetes should be advised that approaching lower HbA 1c levels (for e xample 6.5% or lower) may be of benefit to them. Support should be given to approaching this target if so wished.
'

---
 nice.evidencegrade: NICE
""";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.3.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.3.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.4.md-16f8ad55780b3533095190559385b1408f499dfc> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> """Where target HbA 1c levels are not reached in the individual, adults with Type 1 diabetes should be advised that any improvement is beneficial in the medium and long term, and that greater improvements towards the target level lead to greater absolute gains.
'

---
 nice.evidencegrade: B
""";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.4.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.4.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.5.md-c7bed5231d139d139141579408330728206b33ba> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> """Undetected hypoglycaemia and an attendant risk of unexpected disabling hypoglycaemia or of hypoglycaemia unawareness should be suspected in adults with Type 1 diabetes who have:
? lower HbA1c levels, in particular levels in or approaching the normal reference range (DCCT harmonised <6.1%)
? HbA1c levels lower than expected from self-monitoring results.
'

---
 nice.evidencegrade: D
""";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.5.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.5.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.6.md-87e6a4d80df8ae2a1d9721e9be72a3995b9e11ce> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> """Where experience or risk of hypoglycaemia is significant to an individual, or the effort needed to achieve target levels severely curtails other quality of life despite optimal use of current diabetes technologies, tighter blood glucose control should not be pursued without balanced discussion of the advantages and disadvantages.
'

---
 nice.evidencegrade: D
""";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.6.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.2.6.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES106.md-0d3d9c75f6e8d0c4d8620ed4d4ed4ad767c22720> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES106
In sulin with the molecular structure of human and animal insulins is currently available. Ev idence from the majority of studies 1268 re ports no significant differences in hypoglycaemic episodes and glycaemic control between the insulin of human and animal chemical structures



[@Richter_2002]

[@George_1997]

[@Karlson_1994]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES106.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES106.md-a311661f3ac743620c04ee1633b86b7668503fb6>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES107.md-a616eaf435983c4a9f0917feba1606b4fd910011> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES107
Co nv entional two-dose insulin regimens may re sult in a high frequency of nocturnal hy poglycaemia. Intensified three-dose insulin regimens improve glycaemic control, but often do not improve morning blood glucose 129



[@Egger_1997]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES107.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES107.md-be8e9f2c444f41e98e805c1efa4b838446a61ea9>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES108.md-92bb5c82e9aa7caaead6890dfd84a7ca06e46d2e> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES108
Co ntinuous subcutaneous insulin infusion (CSII) improves nocturnal and morning glycaemic co ntrol compared with multiple daily injection (MDI) regimens. With multiple injection re g imens the morning injection must not be delaye d. Total and bolus insulin doses required are lower with CSII compared with MDI 130



[@Haakens_1989]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES108.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES108.md-31d7d9ba84fcf91e591d2a94d93cde15233c033a>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES109.md-ae4681460b46c6273ff6a7e1ce72d4ee3d400b0c> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES109
Mo r tality from acute metabolic causes (ketoacidosis) was reported as significantly increased w ith intensified treatment; odds ratio 7.20 (pumps) 1.13 (multiple daily injection). 129 The pump data is however based on early pump technologies



[@Egger_1997]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES109.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES109.md-fe482a2eb3f3a9c9e64395b28b8409084f2d870d>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES110.md-7d59cddec3398d32974583898034289ef5776be8> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES110
S imilar glycaemic control results from either lente or isophane (NPH) insulin when used as basal insulin for multiple injection regimens toge ther with a short-acting insulin preparation before meals 131



[@Tunbridge_1989]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES110.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES110.md-28f018047bbd5c94c47d4a72e8897305e9c96674>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES111.md-5b0f3e465d7ebf97861c344b58aa4fba45b8c663> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES111
On the balance of effectiveness and cost-effectiveness evidence, insulin glargine, which has a peakless action profile, is also recommended as a long-acting preparation for people with Ty pe 1 diabetes; 132 some studies in this review show significantly lower fasting blood glucose w ith insulin glargine than isophane (NPH) insulin and others suggest that people on insulin g largine may experience fewer hypoglycaemic ev ents than people receiving once-daily isophane (NPH) insulin 132



[@_NA__2008]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES111.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES111.md-5e273d36ca99a6a7c746c2b460c053b0761923fe>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES112.md-3e29b76969b2fb1035208859e7ac00c06f4f2a3a> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES112
Ev idence from a large multicentred study suggests that people commonl y inject insulin closer to mealtime than the recommended 30 minutes. Due to slow absorption and delayed action, the use of unmodified (soluble) human insulin as pre-meal dose results in high and variable post-breakfast blood glucose concentrations, which together with the incidence of later hy poglycaemia suggests that this regimen does not give satisfactory post-prandial blood glucose contr ol in many patients 133



[@Vignati_1997]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES112.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES112.md-82ab296e7518b4092ec5576b2e867f3b9baf2b29>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES113.md-293876a3602fa72974f8382302dc0cd1664c6116> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES113
Rapid acting insulin analogues allow injection close r to mealtimes due to their pharmacokinetic profile 1346



[@Nielsen_1995]

[@Lindholm_1999]

[@Sindaco_1998]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES113.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES113.md-a18e0122da1715e31b29c642b7d0f7d62d6f1b71>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES114.md-4f9d95e1c3cf1e302442d2d44e8e3e9f5faaa2c2> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES114
A meta-analysis 137 and several open-label trials 133,138145 show that insulin lispro is more effective than unmodified (soluble) human insulin in improving post-prandial glucose co ntrol, without an increase in the rate of hypoglycaemic episodes



[@Vignati_1997]

[@Davey_1997]

[@Lalli_1999]

[@Anderson_1997]

[@Pf_tzner_1996]

[@Renner_1999]

[@Ebeling_1997]

[@Roach_1999]

[@Group_2000]

[@Roach_1999]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES114.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES114.md-5e3692741ebb6c2f8b31e0a8eff08b46ee883526>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES115.md-568b68622ecdb19976b9654e467071f36c112b09> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES115
Two studies 1467 show reduced frequency of nocturnal hypoglycaemia 148 with insulin lispro compared to unmodified (soluble) human insulin 



[@Holleman_1997]

[@Ahmed_1998]

[@Brunelle_1998]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES115.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES115.md-81c9603802b1e927ded24508c13495c02be67af2>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES116.md-50a59f1e15c381a9df7e96ba5f211bc4b37785fb> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES116
Two studies 1489 show reduced frequency of severe hypoglycaemia with insulin lispro co mpared to unmodified (soluble) human insulin



[@Brunelle_1998]

[@Battista_1995]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES116.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES116.md-c3bd4dcc33252933d6d5488b4dd966fd780a77f2>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES117.md-37e44a83d533e8b1866791f06cd8a474d86a6795> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES117
Pa tients perceive an improvement in their well-being and quality of life with rapid-acting insulin analogues due to flexibility of inject ion times and less frequent hypoglycaemic reactions 128,141,146



[@Karlson_1994]

[@Renner_1999]

[@Holleman_1997]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES117.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES117.md-64a0e072d8cd82ee20a9716e9a3a4c80129b6946>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES118.md-f25f8d5fdf5d480f78f048651c30e907b402b09a> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES118
The effects of insulin lispro on HbA 1c levels (overall glycaemic control) have not been firmly established. 133,137,149 The long-term safety profile is as yet unknown



[@Vignati_1997]

[@Davey_1997]

[@Battista_1995]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES118.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES118.md-d082bd021eed822a5449bbdef1c2e6c5bd3d891f>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES119.md-03826d5ffb3fe76259f7ddc5ced193d76f6cca30> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES119
Two multicentre randomised studies 14950 and one RCT 135 showed insulin aspart to improve post-prandial glucose control more effectively than unmodified (soluble) human insulin, without an increase in the rate of hypoglycaemic episodes. Fewer major hypoglycaemic episodes were observed



[@Lindholm_1999]

[@Battista_1995]

[@Home_1998]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES119.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES119.md-bfe4ae75b54032a3eac0f1eb091d613c20e74e21>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES120.md-7f25a5463ad1d801b5d4d752d3cd1f6ac27611ff> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES120
A before-and-after study has shown that a lower dose of mealtime insulin can be taken along w ith an increase in basal dose, with no increase in hypoglycaemic episodes when insulin lispro is used as a replacement for human insulin as mealtime injection therapy 142



[@Ebeling_1997]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES120.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES120.md-ab0d5a308de49b17f0164cad042e17e3c3548544>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES121.md-1c5dc1664f9f9c2b0da22f31910e158b9dbec995> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES121
Tw o randomised trials have shown that it is possible to replace mealtime unmodified (soluble) h uman insulin with insulin lispro or insulin aspart without detriment to glycaemic control if care is taken to replace basal insulin delivery more physiologically 1512



[@Zinman_1999]

[@Hermansen_2001]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES121.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES121.md-15a81aa8e6c05e68514697665b80099994c926d0>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES122.md-06c5c531cb9badd97d801d385c2f4a6e4f510eab> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES122
A multi-arm randomised trial found that a dding a few units of isophane (NPH) insulin to insulin lispro at each meal, in combination with bedtime NPH insulin improves blood glucose co ncentrations compared to an unmodified (soluble) human insulin regimen in a multidose reg imen 136



[@Sindaco_1998]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES122.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES122.md-1a630124d7483feb54d8993fb8bb2f9d29ede2e6>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES123.md-7c649d323a0decf12ec99846eb4ae8ec3f1793ab> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES123
Splitting the evening administration of insulin to short-acting insulin at dinner and isophane (NPH) insulin at bedtime has a number of advantages over mixed administration of short- acting insulin and isophane (NPH) at dinner. Compared with the mixed mealtime regimen, the ev ening split regimen reduced by more than 60% the risk of nocturnal hypoglycaemia; 1534 improved long-term control of blood glucose levels, decreased variability of blood glucose levels in fasting state and led to improvement in preserved hormonal, symptom and cognitive function responses to hypoglycaemia



[@Stades_2002]

[@Fanelli_2002]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES123.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES123.md-535c2ebf0a4aee4358defab7b840d3ceaae4bfb3>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES124.md-aa0902d8b9b5dfb57642202e4c3853e32f575190> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES124
Wh en basal insulin replacement is by either continuous subcutaneous insulin infusion (CSII) or multiple daily administrations of isophane (NPH) insulin, the long term administration of lispro at mealtime reduces HbA 1c ; 130 however, compared with multiple daily injections, patients using continuous subcutaneous administration of insulin (mainly those using older systems) have been at a significantly higher risk of ketoacidosis



[@Haakens_1989]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES124.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES124.md-fdc3fc3ecfdb8171ed97b4d4726660048dff4540>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES125.md-abe5b5726d0b43f509668526b57e6706289a4b1d> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES125
Fr equency of hypoglycaemic reactions was found to be similar on patient-mixed and premixed insulins. 143,155 One randomised controlled trial showed premixed preparations of insulin analogues to be well suited for those who wish to limit the number of daily injections; 155 83% of people expressed a preference for premixed insulins throughout the trial



[@Roach_1999]

[@Dunbar_1994]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES125.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES125.md-73c7eb8dd93a9e1cbdda2ca28bb72c23cda3e2d1>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES126.md-2b616ab6f419fa88e983e4cc0126d12f27ad1aa4> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES126
Fe w studies have addressed the needs of people with diabetes with suboptimal glucose control, and none of suitable design from the evidence hierarchy were found for review. In a group of people with Type 1 diabetes with poor glucose control, the introduction of more intensive insulin regimens may lead to high loss to follow-up. 156 Po or outcome appears to be due to the people refusing the constraints of multiple daily injections, effective blood glucose self-monitoring and regular clinic visits at short time intervals. It was suggested that people should be given clear and concise information on tr eatment goals and the ways in which these goals are to be attained as well as an explanation of the advantages and disadvantages



[@Swinnen_2009]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES126.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES126.md-042aa5df19f4ee89110ae26f6896d96619c25ff1>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES127.md-6989671a175b34e0a1d3369a253153d462092dad> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES127
F our randomised controlled trials, two large parallel groups, 1578 and two small crossover designs 15960 we re identified that examined the use of acarbose in conjunction with insulin therapy compared to insulin and placebo in each case, in people with Type 1 diabetes. A m ulticentred study 157 w ith variable doses titrated up to 300 mg three times a day for 24 weeks, found a significant reduction in HbA 1c levels with acarbose compared to placebo, and decreases in fasting and post-prandial glucose levels to two hours. There were no differences between gr oups for daily insulin dose or hypoglycaemic ev ents, although adverse events of abdominal pain, diarrhoea and flatulence were more common with acarbose. This led to more frequent tr eatment discontinuation in the acarbose group than the placebo group. A similar Italian tr ial 158 w ith up to 100 mg acarbose three times daily for 24 weeks found no difference in HbA 1c levels, daily insulin dose, fasting glycaemia and total cholesterol. However, a significant decrease was found in two-hour post-prandial plasma glucose level, and HDL cholesterol levels were lower in people on acarbose than placebo. Again minor adverse events were more common in the acarbose group, but hypoglycaemic episodes were similar in both groups. Although care was taken not to alter baseline insulin doses, this could be adjusted if glucose levels exceeded 11.1 mmol/l or reduced with hypoglycaemic episodes



[@Hollander_1997]

[@Riccardi_1999]

[@Viviani_1988]

[@Marena_1991]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES127.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES127.md-cdd968e48c3ba8e9a964f2e1071d7f177cdee66b>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES128.md-5582fc2597be125890972fee4c8938baf9e6ac71> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES128
The two crossover trials with 100 mg acarbose three times a day over relatively short time periods did not assess requirement for wash ou t periods (although analysis in one found no effect of treatment order) and did not account for study withdrawals. One study found a benefit in terms of HbA 1c w ith acarbose, 160 while the other found no significant differences between gr oups. 159 Po te ntial methodological limitations of these trials would not permit them to be used as an evidence base to inform recommendations in this area



[@Viviani_1988]

[@Marena_1991]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES128.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES128.md-91bb54421795050d3c5086ff9fa23dc62f781366>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES129.md-38911f13432df85dfe2ffe6f269617094d960dda> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES129
Tw o small randomised controlled trials investigat ed the use of glibenclamide (called glyburide as the trials were conducted in the USA) in the therapy for Type 1 diabetics. A study using 5 mg gl yburide (orally) for 12 weeks compared to placebo after a 12-week open-label insulin stabilisation run-in period 161 found fasting blood glucose declined significantly at 12 weeks from baseline, although no comparison was made between groups. No differences were found in daily insulin dose or glycated haemoglobin le ve ls at any stage of the study. A randomised study without comparison between groups at baseline with 5 mg glyburide daily for 24 weeks co mpared to placebo 162 found no differences in plasma C-peptide levels between groups, nor difference in plasma glucose concentrations at any time point. Although HbA 1c levels were re ported to have changed more from baseline in the glyburide treated group at six weeks, potential methodological limitations of these trials would not permit them to be used as an ev idence base to inform recommendations in this area



[@Tzefos_2010]

[@NATHAN_1988]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES129.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES129.md-398caca6ce0d7f27203a179bb5ce89a846f929cc>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES130.md-49344d9405aea1d5f02cce4ada93332fb23ccdc6> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES130
Co mparison of 15 mg of glibenclamide daily with placebo in addition to insulin therapy in a small sample of people with Type 1 diabetes in a randomised double-blind crossover study 163 found mean blood glucose level, HbA 1c and blood glucose variability to be significantly lower w ith the intervention among people who retained endogenous insulin production. No such differences were found in a subgroup who were C-peptide negative. Although the study had a medium-term intervention period of three months, it did not provide analysis of the cohort as a whole for glibenclamide vs placebo and thus cannot be used for recommendations given the small sample sizes of the subgroups, and the inherent difficulties of extrapolating such findings to a wider population



[@Burke_1984]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES130.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES130.md-a6ce2dfb57f08af8b4028beacc9348effe9c0658>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES131.md-8ac2a234e054bec35c36939d90b7641e235a3a14> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES131
A reduced insulin requirement at 18 months was found in patients given 80 mg gliclazide twice a day compared to placebo in a small sample in a long-term study. 164 Although glycated haemoglobin both fasting and one hour post-breakfast were found to be very similar in both gr oups, the gliclazide group had C-peptide levels significantly higher than people on placebo for the same test times of the day, at six-monthly assessment points to 18 months. This study only applies to people with retained endogenous insulin secretion, and thus not the ov erwhelming majority of people with Type 1 diabetes



[@Fallucca_1996]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES131.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES131.md-7927c5e72c7cdd7ea03eeea8d200cdeb9a301cac>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES132.md-2e24961203613fda57fe28f750316e5444e0ac08> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES132
A medium-sized randomised controlled study found that the addition of metformin to an insulin regimen provided by CSII was able to reduce the total IR required by the person with Ty pe 1 diabetes (including reduced basal therapy) as compared to placebo over a period of six months. This was achieved without significant change to HbA 1c or increased incidence of hy poglycaemia


""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES132.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES132.md-06c4523df2890a8e33675e499440613d60e51447>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES133.md-a5faf900a078acbfeaa1bd6aa5a2a40eaef19f3f> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES133
The health economic searches produced no studies giving guidance on appropriate insulin re g imens for those newly-diagnosed with Type 1 diabetes or for the management and prevention of hypoglycaemia, with the exception of the NICE appraisal of insulin glargine. The health economic searches found no published papers dealing with insulin glargine or NPH insulin. A recent NICE technology appraisal 132 re co mmended insulin glargine as a long-acting preparation for people with Type 1 diabet es alongside insulin NPH. The crucial issue for the c ost-effectiveness of insulin glargine is the amount of utility associated with reducing the fear of hypoglycaemia. Tw o cost-benefit studies were identified that considered the role of insulin lispro. 342,380 Ne ither paper was based in the UK (Canada, Australia), and both suggest that the willingness to pay for insulin lispro will outweigh its additional cost. The cost-effectiveness of lispro is unclear and is likely to be most favourable amongst those who require increased flexibility in setting mealtimes, or those for whom mealtimes are often unpredictable. The issue of the cost-effectiveness of intensive insulin therapy is complicated by a shortage of unconfounded data. The DCCT showed that a series of interventions including intensive insulin therapy reduces the rate of diabetic complications and increases life expectancy amongst an unrepresentative sample of adults and adolescents with Type 1 diabetes. Because of the co mplexity of this intervention, health economic analysis of the DCCT data has typically assumed that these reductions are primarily due to intensive insulin regimens. The health economic searches found three models designed to find the cost-effectiveness of intensive treatment, 3434,381 of which two attempted to form QALYs. The health utility values in each of the studies are poor: in one study 343 non-preference-based values are used; in another 381 only a very small sample was used to find health utilities. Both studies considered only a small number of health states and both suggest that intensive therapy is cost-effective.  Tw o models analysed intensive treatment in cost-per-life-year terms, and differed in their re sults. One study 343 produced a cost-per-life-year figure of US$28,661 at 1994 prices, whilst another 344 found a figure several times larger. Neither study used UK costs. Note that as several diabetic complications will affect quality of life but will not significantly shorten life expectancy, the cost-per-QALY figure may be lower than the corresponding cost-per-life-year figure. Two c ost analyses also suggest that the DCCT cost estimates may be overestimates. 3456 Few inferences can be drawn because these studies are limited but it appears likely that intensive tr eatment, including intensive insulin regimens, will be cost-effective.


""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES133.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-CG15AdultES133.md-dd15b1880bc7faaf2ff6236e162eabdf14531a29>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-Discussion.md-1b9604fd4a63e94595e0acc331b5f6fabc57a02a> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                             <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                           <http://www.w3.org/2011/content#chars> """It was noted that Type 1 diabetes is a hormone deficiency disease. The problems faced by people w ith the condition (injections, hypoglycaemia, hyperglycaemia, consequences of capricious co ntrol, late complications) were noted to be solely a function of the poor state of insulin re placement therapy. The group noted that the use of insulin injections in people with Type 1 diabetes is not RCT- based and never could be. It was also noted that, prior to the introduction of short- and long- acting insulin analogues, the use of insulin regimens based on a combination in various forms of unmodified (soluble) human insulin befo re meals and human isophane (NPH) insulin for basal supply had become widespread, and that, the analogues aside, there was no evidence to ch allenge that conventional practice. Long-acting analogues, or rather insulin glargine, are co ve re d by NICE appraisal guidance, and this recommends their availability for use in people w ith Type 1 diabetes. Rapid-acting insulin analogues are supported by an evidence base for less hy poglycaemia at night and at some other times, reduced hyperglycaemic excursions after meals and small improvements in HbA 1c , suggesting that these too should have an increasing r ole in people with Type 1 diabetes. The group was aware that the evidence for combining the advantages of rapid- and long-acting insulin analogues was evolving as the knowledge base to use these technologies improves. This co mbination would be particularly suitable to matching with active mealtime insulin dose adjustment (AMIDA, see dietary recommendations in 6.3). Some recent NICE technology appraisals provided a health economic basis for supporting this regimen, should appropriate improvements in HbA 1c be demonstrated. Accordingly the recommendations were drafted to allow choice of human or combined analogue regimens including from the time of diagnosis. The group noted the potential usefulness of the new insulins in some special situations, including religious feasts and fasts, and shift work. A need to address insulin starters and people who wished for smaller numbers of injections was identified. A need to caution against using newer, more expensive insulins in people with control problems without proper assessment of underlying causes was felt appropriate. The NICE appraisal of insulin pumps (effectively an insulin regimen rather than a device) was noted, and no elaboration felt to be needed on that. The group found the evidence for the general recommendation of any glucose-lowering drug in combination with insulin to be unconvincing. While there may be a small gain in overall gl ucose control evidenced inconsistently in the acarbose studies, the size of this gain, the prevalence of intolerance, and the suggestion of increased hypoglycaemia, together were taken as indicating that no recommendation for the general use of this drug in this context could be made.  The use of metformin and insulin sensitisers in people with Type 1 diabetes and the metabolic syndrome has not been adequately investigated. The group was aware of the concern that arterial complications in people with Type 1 diabetes we re associated with features of the metabolic syndrome as seen in Type 2 diabetes, and that there was evidence of benefit in people with Type 2 diabetes for some drugs, notably metformin (UKPDS study) and PPAR- 
*   agonists (see NICE guidance). While not endorsing the general use of such drugs in people with Type 1 diabetes and features of the metabolic syndrome (see section 8.2, Arterial disease management), the group noted that further investigation might support the high a priori likelihood of benefit in this high-risk situation.
""";
                                                                                                                                           <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-Discussion.md>;
                                                                                                                                           <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                           <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-Discussion.md-4142f9935bc7e1965653da8ab99445e61762f685>;
                                                                                                                                           <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-Recommendation.md-6210c6bce5a836eff53ebe0ee503624c9c906d42> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """Access to insulin
Adults with Type 1 diabetes should have access to the types (preparation and species) of insulin they find allow them optimal well-being.
'


""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-Recommendation.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.1-Recommendation.md-e62f19b26dac9256f579320980a539c42312c3dd>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.10.md-342a29190553c2fd163b48fc5129b98a38145fd7> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                   <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                 <http://www.w3.org/2011/content#chars> """Adults whose nutritional and physical activity patterns vary considerably from day-to-day, for vocational or recreational reasons, may need careful and detailed review of their self-monitoring and insulin injection regimen(s). This should include all the appropriate preparations (see R557) and consideration of unusual patterns and combinations
'

---
 nice.evidencegrade: D
""";
                                                                                                                                 <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.10.md>;
                                                                                                                                 <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                 <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.10.md-0000000000000000000000000000000000000000>;
                                                                                                                                 <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.11.md-0f5fe64b0f0bfcc7267d6e0745dbacd1e74c89e0> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                   <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                 <http://www.w3.org/2011/content#chars> """For adults undergoing periods of fasting or sleep following eating (such as during religious feasts and fasts or after night-shift work), a rapid-acting insulin analogue before the meal (provided the meal is not prolonged) should be considered.
'

---
 nice.evidencegrade: D
""";
                                                                                                                                 <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.11.md>;
                                                                                                                                 <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                 <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.11.md-0000000000000000000000000000000000000000>;
                                                                                                                                 <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.12.md-648c398b96afd4cd72f096c6fe1a09a642e832d7> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                   <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                 <http://www.w3.org/2011/content#chars> """For adults with erratic and unpredictable blood glucose control (hyper- and hypoglycaemia at no consistent times), rather than a change in a previously optimised insulin regimen, the following should be considered:
? resuspension of insulin and injection technique
? injection sites
? self-monitoring skills
? knowledge and self-management skills
? nature of lifestyle
? psychological and psychosocial difficulties
? possible organic causes such as gastroparesis. 
'

---
 nice.evidencegrade: D
""";
                                                                                                                                 <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.12.md>;
                                                                                                                                 <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                 <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.12.md-0000000000000000000000000000000000000000>;
                                                                                                                                 <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.13.md-163c7e9f2ca96754ade485d4da37d4c836ccd114> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                   <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                 <http://www.w3.org/2011/content#chars> """Continuous subcutaneous insulin infusion (insulin pump therapy) is recommended as an option for people with Type 1 diabetes provided that:
? multiple-dose insulin therapy (including, where appropriate, the use of insuling largine) has failed;* and
? those receiving the treatment have the commitment and competence to use the therapy effectively.
'

---
 nice.evidencegrade: NICE
""";
                                                                                                                                 <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.13.md>;
                                                                                                                                 <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                 <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.13.md-0000000000000000000000000000000000000000>;
                                                                                                                                 <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.14.md-568a7e0e088ed0a936ab9e388d431fa6c8b18ec1> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                   <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                 <http://www.w3.org/2011/content#chars> """Partial insulin replacement to achieve blood glucose control targets (basal insulin only, or just some mealtime insulin) should be consider ed for adults starting insulin therapy, until such time as islet B-cell deficiency progresses further.
'

---
 nice.evidencegrade: D
""";
                                                                                                                                 <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.14.md>;
                                                                                                                                 <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                 <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.14.md-0000000000000000000000000000000000000000>;
                                                                                                                                 <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.15.md-0104ff4661006cafe633334728738653fa111985> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                   <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                 <http://www.w3.org/2011/content#chars> """Clear guidelines and protocols (sick day rules) should be given to all adults with Type 1 diabetes to assist them in adjusting insulin doses appropriately during intercurrent illness.
'

---
 nice.evidencegrade: D
""";
                                                                                                                                 <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.15.md>;
                                                                                                                                 <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                 <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.15.md-0000000000000000000000000000000000000000>;
                                                                                                                                 <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.16.md-4fe370ebd7f2c7569155df70ccc0b965eadc5960> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                   <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                 <http://www.w3.org/2011/content#chars> """Oral glucose-lowering drugs should generally not be used in the management of adults with Type 1 diabetes.
'

---
 nice.evidencegrade: D
""";
                                                                                                                                 <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.16.md>;
                                                                                                                                 <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                 <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.16.md-0000000000000000000000000000000000000000>;
                                                                                                                                 <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.2.md-ecb35a5bd83b309aba0def6159eb0c1653e5e072> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> """Cultural preferences need to be discussed and respected in agreeing the insulin regimen for a person with Type 1 diabetes
'

---
 nice.evidencegrade: D
""";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.2.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.2.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.3.md-f9cd7f7580f1e560349bd919b1690b88451460b4> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> """M ultiple insulin injection regimens, in adults who prefer them, should be used as part of an integrated package of which education, food and skills training should be integral parts.
'

---
 nice.evidencegrade: A
""";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.3.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.3.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.4.md-9aa179771a2db7f7862fa930b0a3230287ec61c3> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> """Appropriate self-monitoring and education should be used as part of an integrated package to help achieve optimal diabetes outcomes.
'

---
 nice.evidencegrade: D
""";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.4.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.4.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.5.md-3d0c0e4e8a42dfa6fd59270ea5770bf67c987a27> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> """Mealtime insulin injections should be provided by injection of unmodified (soluble) insulin or rapid-acting insulin analogues before main meals.
'

---
 nice.evidencegrade: D
""";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.5.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.5.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.6.md-ed1d2a48b0647863e0a043ee45a0e639dc01a772> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> """Rapid-acting insulin analogues should be used as an alternative to mealtime unmodified insulin:
? where nocturnal or late inter-prandial hypoglycaemia is a problem
? in those in whom they allow equivalent blood glucose control without use of snacks between meals and this is needed or desired. 
'

---
 nice.evidencegrade: A
""";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.6.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.6.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.7.md-345d6f822dd279e679db04d12db1d6a063fac52c> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> """Basal insulin supply (including nocturnal insulin supply) should be provided by the use of isophane (NPH) insulin or long-acting insulin analogues (insulin glargine). Is ophane (NPH) insulin should be given at bedtime. If rapid-acting insulin analogues are given at mealtimes or the midday insulin dose is small or lacking, the need to give isophane (NPH) insulin twice daily (or more often) should be considered.
'

---
 nice.evidencegrade: D
""";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.7.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.7.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.8.md-e7da9ab1956fc762cdb68e203625aa100d2262ff> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> """Long-acting insulin analogues (insulin glargine) should be used when:
? nocturnal hypoglycaemia is a problem on isophane (NPH) insulin
? morning hyperglycaemia on isophane (NPH) insulin results in difficult daytime blood glucose control
? rapid-acting insulin analogues are used for mealtime blood glucose control.
'

---
 nice.evidencegrade: D
""";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.8.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.8.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.9.md-ac4450fe75b773b5d67bab97e96024e33bb510d7> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> """Twice-daily insulin regimens should be used by those adults who consider number of daily injections an important issue in quality of life:
? biphasic insulin preparations (pre-mixes) are often the preparations of choice in this circumstance
? biphasic rapid-acting insulin analogue pre-mixes may give an advantage to those prone to hypoglycaemia at night.
Such twice daily regimens may also help:
? those who find adherence to their agreed lunchtime insulin injection difficult
? adults with learning difficulties who may require assistance from others. 
'

---
 nice.evidencegrade: D
""";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.9.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.3.9.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.4.1-CG15AdultES134.md-e28105a7ef27937498328c751b8aaf72e0943c34> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES134
NICE guidance 165 co ncluded that, compared to optimised MDI therapy, CSII results in a modest but worthwhile improvement in GHb and quality of life (by allowing greater flexibility of lifestyle), and reduction of other problems such as hypoglycaemia and rising blood glucose levels at the end of the night. In routine practi c e, patients who go on to pumps are carefully selected, and to a large degree self-select ed. Overall, insulin pumps appear to be a useful advance for patients having particular problems, rather than a dramatic breakthrough in therapy, and would probably be used only in a small percentage of patients



[@Al_Mrayat_2009]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.4.1-CG15AdultES134.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.4.1-CG15AdultES134.md-3a66e93c4eb6116c0d2c52a62d5f09202b0f1a2a>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.4.1-CG15AdultES135.md-536c7e784794e5b8b2e074b73726e0aba07c5e47> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES135
One randomised trial 166 of medium sample size compared a multiple injection regimen from a pen injector with conventional treatment with twice-daily syringe injection. No significant differ- ences were seen in GHb values, blood glucose values or hypoglycaemic episodes. Patient satisfac- tion with pen injectors was high and most patients opted to continue on this delivery system following termination of the trial. However, this study has some methodological limitations



[@Murray_1988]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.4.1-CG15AdultES135.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.4.1-CG15AdultES135.md-4d6c7dbb3f8d3cd205422c170d7229d82642d316>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.4.1-CG15AdultES136.md-e6c5c3f5e50082d1fa23ce5d9e9f10dcc42af3b2> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES136
One randomised crossover trial 167 co mpared two types of insulin regimen injected in the abdomen with the same regimen injected in the thigh. Regular insulin injections in the abdomen resulted in significantly lower post-prandial plasma glucose values, peak plasma gl ucose and increment in plasma glucose compared to time periods following injection in the thigh. Significantly higher serum free insulin values were also seen following abdominal injection of regular insulin, compared with injections administered at the thigh. No differences we re re co rd ed between injections at either site following injections containing both isophane (NPH) and unmodified (soluble) insulin



[@Bantle_1993]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.4.1-CG15AdultES136.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.4.1-CG15AdultES136.md-b57ac16fb94a5a866d6c6623b3043badef7dc735>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.4.1-CG15AdultES137.md-e3053e024daa9e824c75b5058ad6856ffcefbd23> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES137
One prospective study 168 co mparing the absorption of insulin injected superficially and deep subcutaneously at the fat-muscle boundary showed no significant difference between the two te c hniques. A sub-group of 10 participants showed no difference in overall serum free insulin or plasma glucose values following superficial and deep subcutaneous injection



[@Meijer_1990]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.4.1-CG15AdultES137.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.4.1-CG15AdultES137.md-552a8d8c656e3ec0d9a572adcc87d22548e35d13>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.4.1-CG15AdultES138.md-bb7ba83a63f9930f6af3e6d25f8c43460fac2ef4> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES138
One study 169 re ported benefits associated with injection through clothing, compared with co nv entional injection practice with skin preparat ion over a 20-week trial period. This study had some methodological limitations



[@Fleming_1997]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.4.1-CG15AdultES138.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.4.1-CG15AdultES138.md-93c168e5b7dbeca33b16ecf900b1c8fb4acca9ea>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.4.1-CG15AdultES139.md-b3c1a7ffe3072b073fbc1a3b96bfdbb059424108> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES139
The health economic searches produced three published papers 3479 co nsidering the use of insulin pens. None of the three papers compare their benefits (patient satisfaction, or improved HbA 1c ) against their costs.



[@Graff_1998]

[@H_rnquist_1995]

[@H_rnquist_1990]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.4.1-CG15AdultES139.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.4.1-CG15AdultES139.md-14b6a1138903e26297f9746daf7172ec252b6fad>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.4.1-Discussion.md-21ba304ee2be8ef06740120751a56887a321be0f> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                             <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                           <http://www.w3.org/2011/content#chars> """In sulin injection pens were noted to be the overwhelming norm in the UK for insulin delivery for reasons of convenience, ease of teaching and portability. Some devices with particular design characteristics can be used by people with disabilities, where otherwise a third party w ould have to give injections. The desirability and often cost-effectiveness of this was noted. In jection into deep subcutaneous fat, and on the basis of many studies into the tissues of the abdominal wall for mealtime unmodified human insulin, are generally advised and logically based. However the needs and beliefs of individuals in giving their own insulin were felt to be of importance. Simple logic also leads to the conclusion that rotation of injection sites should be within one region rather than between regions. Group members (both clinicians and people w ith diabetes) expressed a widespread experience of repeated self-injection with the same needle without problems arising. The group considered the utility of recommending advice on cleanliness for those who choose to re-use needles, but noted the regulatory position from the Me dicines and Healthcare Products Regulatory Agency (MHRA, formerly the Medical Devices Ag ency) in the bulletin DB2000(04). Consequently, the guideline cannot make such a re co mmendation. Other common sense issues included provision for sharps disposal, and ch eck on the condition of injection sites annually or if blood glucose control problems worsen.
""";
                                                                                                                                           <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.4.1-Discussion.md>;
                                                                                                                                           <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                           <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.4.1-Discussion.md-c5172aff92f436d4493d5e3e14b50c7c125b47d3>;
                                                                                                                                           <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.4.1-Recommendation.md-1aae91d9b48948a2c72513f2d870d2285c584413> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """access to insulin injection delivery device
Adults with Type 1 diabetes who inject insulin should have access to the insulin injection delivery device they find allows them optimal well-being, often using one or more types of insulin injection pen.
'


""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.4.1-Recommendation.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.4.1-Recommendation.md-e6e92dcbfbf13ac08f38320e29d5906ca885b398>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.4.1.md-d5bc5cf38bf4d7dd902e1d112235ef8781c69e64> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> """Adults with Type 1 diabetes who inject insulin should have access to the insulin injection delivery device they find allows them optimal well-being, often using one or more types of insulin injection pen.
'

---
 nice.evidencegrade: D
""";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.4.1.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.4.1.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.4.2.md-b9bb5737dc77a525e30419bf7bc665ac516490ad> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> """Adults with Type 1 diabetes who have special visual or psychological needs should be provided with injection devices or needle-free systems that they can use independently for accurate dosing
'

---
 nice.evidencegrade: D
""";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.4.2.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.4.2.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.4.3.md-c27f5e10a34f3f1c56275998cb5d9fee6bf7eb78> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> """Insulin injection should be made into the deep subcutaneous fat. To achieve this, needles of a length appropriate to the individual should be made available.
'

---
 nice.evidencegrade: D
""";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.4.3.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.4.3.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.4.4.md-bd7b2a367064ac2301dfce5cc2685959c3cc725a> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> """Adults with Type 1 diabetes should be informed that the abdominal wall is the therapeutic choice for mealtime insulin injections
'

---
 nice.evidencegrade: D
""";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.4.4.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.4.4.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.4.5.md-6140251524d53ba1ff8d01648bc65cccbe2dc8bc> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> """Adults with Type 1 diabetes should be informed that extended-acting suspension insulin (for example isophane (NPH) insulin) may give a longer profile of action when injected into the subcutaneous tissue of the thigh rather than the arm or abdominal wall.
'

---
 nice.evidencegrade: D
""";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.4.5.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.4.5.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.4.6.md-d7429dbfbc61eea01aa5c5495b35282b2bbe2cfc> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> """Adults with Type 1 diabetes should be recommended to use one anatomical area for the injections given at the same time of day, but to move the precise injection site around in the whole of the available skin within that area.
'

---
 nice.evidencegrade: D
""";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.4.6.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.4.6.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.4.7.md-0827ed4609f3e46490aece4ceaabe9681e64e02c> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> """Adults with Type 1 diabetes should be provided with suitable containers for the collection of used needles. Arrangements should be available for the suitable disposal of these containers.
'

---
 nice.evidencegrade: D
""";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.4.7.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.4.7.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.4.8.md-cd63c36485b047dddc61da4f5e47677951fe34ce> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> """Injection site condition should be checked annually, and if new problems with blood glucose control occur.
'

---
 nice.evidencegrade: D
""";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.4.8.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.4.8.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.1-CG15AdultES140.md-3fbad1caca271d0d96521360e55c8fee8933dd3d> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES140
Canadian clinical practice guidelines 98 re ported four studies supporting the use of 15 g glucose (monosaccharide) (orally) for the treatment of moderate hypoglycaemia. Two studies within the guidelines explored a 20 g oral glucose dose for recovery of blood glucose levels. Recovery was slower following treatment with milk and orange juice. The use of glucose gel also delivered slower recovery in the latter study and required swallowing to have a significant effect. A further study showed no support for buccal administration of glucose



[@Lau_2007]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.1-CG15AdultES140.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.1-CG15AdultES140.md-ad9af70b33efb1657f0f5543442f3685d690ed8a>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.1-CG15AdultES141.md-64f7126d2bebc2f7ba66179e08856778fd76353d> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES141
One study within the Canadian guidelines 98 re ported on the special needs of people taking alpha-glycosidase inhibitors when treating hypoglycaemia, recommending the use of glucose (dextrose) tablets, or milk or honey if these are unavailable



[@Lau_2007]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.1-CG15AdultES141.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.1-CG15AdultES141.md-8b6449e951b0d2ae049d1800ea9da1718d664c43>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.1-CG15AdultES142.md-c37b8a60d4a974fe0649b66727bda0ef687b9354> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES142
A bedtime snack may be needed to avoid nocturnal hypoglycaemia. Two studies from a systematic review 98 showed prepared cornstarch snack bars have some benefit in overnight re duction of hypoglycaemia, but the number of events were not significantly reduced



[@Lau_2007]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.1-CG15AdultES142.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.1-CG15AdultES142.md-0919de41d4574702ed6afd85cc8d43935e8484ea>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.1-CG15AdultES143.md-ce1bc024edb80a9b8f12fd5b92db308fa284defb> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES143
Canadian clinical practice guidelines 98 re port one paper on the link between incidence of prior hy poglycaemic episodes and worsening in the defect of the hormonal responses to hy poglycaemia, leading to a reduction in the self-detection of hypoglycaemia. Eight papers re port the benefits of strict avoidance of hypoglycaemia in improving recognition of severe hy poglycaemia or the responses of counter-regulatory hormones



[@Lau_2007]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.1-CG15AdultES143.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.1-CG15AdultES143.md-50e9bbc4b7cd7938a98d599c837cb10e973e082b>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.1-CG15AdultES144.md-7d0545064b2015ce157988b8e8b0a04a2993e626> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES144
A randomised controlled study 170 co mpared blood glucose awareness training (BGAT) with no tr aining on the increased hypoglycaemia after initiation of more intensive diabetes management. The counter-regulatory hormone epinephrine (adrenaline) response was not impaired following BGAT despite an increase in frequency of hypoglycaemia induced by intensive diabetes management. No difference was seen in awareness of the symptoms of hy poglycaemia following BGAT, compared with controls, although BGAT does lead to a better detection of low blood glucose levels in people starting intensive diabetes management



[@Kinsley_1999]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.1-CG15AdultES144.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.1-CG15AdultES144.md-1f990b580199f06ec6dba12f38f093452f853097>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.1-CG15AdultES145.md-3db9c2fa76180857c7a439b1397db550cf72df8e> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES145
An observational study 171 co mpared blood glucose sensitivity and prediction accuracy in inpatients before and after blood glucose awareness training, showed no additional effect on the improvement of HbA 1c . The decrease in HbA 1c was not however accompanied by a change in the accuracy of blood glucose estimation or sensitivit y of recognition of low blood glucose levels



[@Fritsche_1998]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.1-CG15AdultES145.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.1-CG15AdultES145.md-315d2f86e7eec10a9227b25997dbf315ad6a1f42>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.1-CG15AdultES146.md-fc640e870a8b6b37411b10b081eabe55a86e8afa> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES146
Canadian clinical practice guidelines 98 cite five studies demonstrating a positive effect of BGAT on accurate detection and treatment of hypoglycaemia, and allowing reduced-awareness subjects to detect a greater percentage of low blood glucose levels. These BGAT programmes involve instruction in interpretation of physical symptoms and instruction on food, exercise, insulin dosage and action, and the impact of time of day and last blood glucose measurements on estimations of blood glucose



[@Lau_2007]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.1-CG15AdultES146.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.1-CG15AdultES146.md-c1c6736c8e55fd3bd07648ddea0b903db0f7da20>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.1-CG15AdultES147.md-f736540408427b57cd45da5d8548889bfe8bdd10> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES147
Evidence on the impact of hypoglycaemia on cognitive function is not clear. Two prospective studies reported within the Canadian guidelines 98 did not find association between intensive diabetes management and cognitive function. However, six retrospective studies found subjects w ith recurrent hypoglycaemia performed more poorly in a range of intellectual tests



[@Lau_2007]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.1-CG15AdultES147.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.1-CG15AdultES147.md-18bbdbd39ff03cbbe45f12aae18e9b1282c8a807>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.1-CG15AdultES148.md-1383722f649cca2ab3903c3e92136ee040b32b77> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES148
Tw o randomised studies compared the use of glucagon and dextrose in the treatment of severe hy poglycaemia. One study 172 co mpared intramuscular administration of 1 mg glucagon with 50 ml 50% IV dextrose in people with hypoglycaemic coma. A second study 173 co mpared intravenous administration of 1 mg glucagon vs 50 ml 50% dextrose in people with hypo- gl yc aemic coma. Both studies showed a significantly slower recovery to a normal level of co nsciousness in the glucagon treated group



[@Patrick_1990]

[@Collier_1987]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.1-CG15AdultES148.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.1-CG15AdultES148.md-a096af1d8f27acb29da857046a0afef1dc9d7d13>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.1-CG15AdultES149.md-63211a4512b13fd5ba0691063a89b3203dba91cf> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES149
Two glucagon-treated patients in each study (7% and 4% respectively) and two dextrose-treated patients in the second study (4%) required additional administration of 12.5 g IV dextrose following failing to recover consciousness after 15 minutes. In the first study average duration of hypoglycaemic coma was not different between the two treatment groups


""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.1-CG15AdultES149.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.1-CG15AdultES149.md-1d797c6d17dfbe9ed79df552fb18aed5af6646f4>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.1-CG15AdultES150.md-16694b09c470dd368235bed596bdebd767900fe1> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES150
No co rr elation was seen between time taken to recovery of consciousness and initial plasma gl ucose concentration or duration of hypoglycaemia in either of the studies. Side effects were similar among the treatment groups


""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.1-CG15AdultES150.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.1-CG15AdultES150.md-12a7daa24b97a3b43d54eb67c09e6fc1b7cec015>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.1-CG15AdultES151.md-feddd341998ba7d7f869c2e8a228e69273ef16ec> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES151
These two small studies suggest that intravenous glucose gives a clinically non-significant advantage over intramuscular glucagon in time to recovery of consciousness in people with Type 1 diabetes in hypoglycaemic coma


""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.1-CG15AdultES151.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.1-CG15AdultES151.md-7f9937d25a7817e0e8ff44b86e5b0c5142065fd6>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.1-CG15AdultES152.md-30c9fe2d37839a7f8adaf7cb6c9f47cb62c895da> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """### Evidence Statement CG15AdultES152
No health economic evidence on the prevention or management of hypoglycaemia was identified in the literature review.


""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.1-CG15AdultES152.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.1-CG15AdultES152.md-439042ca4091ed00be6f9f95df86bc4221392fe5>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.1-Discussion.md-391914d9d80b512779e4d2a70884c12a294e8e5e> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                             <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                           <http://www.w3.org/2011/content#chars> """The group noted this was an area of considerable importance to people with Type 1 diabetes, but that prevention of hypoglycaemia was considered appropriately under insulin therapy re co mmendations, and secondarily under education and lifestyle issues. The group noted issues re lated to absorption and ingestion of free carbohydrate in people with decreased conscious level. They were concerned that recurrent hypoglycaemia was properly considered in a medical co ntext, and not simply attributed to lifestyle problems secondary to insulin therapy. Hy poglycaemia unawareness was also noted to be an important issue, and be partially reversible and capable of useful management, as now is nocturnal hypoglycaemia (it was noted that the re co mmendations on insulin therapy and clinical monitoring addressed other aspects of such management). No useful hard evidence was available for cognitive decline occurring in people w ith Type 1 diabetes, but the possibility of recurrent severe hypoglycaemia being a contributory factor was felt worth mentioning. The group noted that the ease and safety of administration of glucagon compared to IV glucose (risk of extravasation) meant that in most situations it was the treatment of choice. While it was re co g nised that there were groups of people to whom the identified studies do not apply (starvation, alcohol toxic), and that these people would not be expected to respond well to gl ucagon, it was agreed that the best means of detecting this was by absence of a response to gl ucagon at 10 minutes. Safe follow-up management after either therapy should include oral carbohydrate and awareness of risk of relapse. Users of glucagon injections need appropriate education and training.
""";
                                                                                                                                           <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.1-Discussion.md>;
                                                                                                                                           <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                           <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.1-Discussion.md-ff2545f0e8bdf20c0d331b3fbd1fa83f3fd636b3>;
                                                                                                                                           <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.1-Recommendation.md-df27bdcd536e68f8a45d181515beda9afc45c087> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """management of hypoglycaemic symptoms
Adults with Type 1 diabetes should be informed that any available glucose/sucrose containing fluid is suitable for the management of hypoglycaemic symptoms or signs in people who are able to swallow. Glucose containing tablets or gels are also suitable for those able to dissolve or disperse these in the mouth and swallow the products. 
'


""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.1-Recommendation.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.1-Recommendation.md-e650c5fb794b051fbb90aed8bb42cfd17b43478b>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.1.md-7b3db7f72c8398c7281e0c3e9acb2c365ae57672> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> """Adults with Type 1 diabetes should be informed that any available glucose/sucrose containing fluid is suitable for the management of hypoglycaemic symptoms or signs in people who are able to swallow. Glucose containing tablets or gels are also suitable for those able to dissolve or disperse these in the mouth and swallow the products. 
'

---
 nice.evidencegrade: A
""";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.1.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.1.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.10.md-679b8f79b9c755bab5c2da1878a0cdb386eb1e39> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                   <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                 <http://www.w3.org/2011/content#chars> """Where early cognitive decline occurs in adults on long-term insulin therapy, normal investigations should be supplemented by co nsideration or investigation of possible brain damage due to overt or covert hypoglycaemia, and the need to ameliorate this.
'

---
 nice.evidencegrade: D
""";
                                                                                                                                 <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.10.md>;
                                                                                                                                 <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                 <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.10.md-0000000000000000000000000000000000000000>;
                                                                                                                                 <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.2.md-0f78174d6895369073aa6045bc3acc6dab1f5be8> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> """When a more rapid-acting form of glucose is required, purer glucose-containing solutions should be given.
'

---
 nice.evidencegrade: D
""";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.2.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.2.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.3.md-5e4ffa4752ce7f736b26ad2920ad04e6006168f5> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> """Adults with decreased level of consciousness due to hypoglycaemia who are unable to take oral treatment safely should be:
? given intramuscular glucagon by a trained user (intravenous glucose may be used by professionals skilled in obtaining intravenous access)
? monitored for response at 10 minutes, and then given intravenous glucose if the level of consciousness is not improving significantly
? then given oral carbohydrate when it is safe to administer it, and placed under continued observation by a third party who has been warned of the risk of relapse. 
'

---
 nice.evidencegrade: D
""";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.3.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.3.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.4.md-416ea7ef3d0cd18cde4a8cac5cfda0a0a91bb59c> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> """Adults with Type 1 diabetes should be informed that some hypoglycaemic episodes are an inevitable consequence of insulin therapy in most people using any insulin regimen, and that it is advisable that they should use a regimen that avoids or reduces the frequency of hypoglycaemic episodes while maintaining as optimal a level of blood gl ucose control as is feasible. Advice to assist in obtaining the best such balance from any insulin regimen should be available to all adults with Type 1 diabetes. (see section 7.2, Insulin regimens and 7.2, Insulin delivery)
'

---
 nice.evidencegrade: B
""";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.4.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.4.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.5.md-da76c84b4411e2d3434540ccf2092f8fb784949b> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> """When hypoglycaemia becomes unusually problematic or of increased frequency,review should be made of the following possibly contributory causes:
? inappropriate insulin regimens (incorrect dose distributions and insulin types)
? meal and activity patterns including alcohol
? injection technique and skills including insulin resuspension
? injection site problems
? possible organic causes including gastroparesis
? changes in insulin sensitivity (the latter including drugs affecting the renin- angiotensin system and renal failure)
? psychological problems
? previous physical activity
? lack of appropriate knowledge and skills for self-management. 
'

---
 nice.evidencegrade: D
""";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.5.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.5.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.6.md-52ae4ffd31db2d111de0c8a8314e39ede13a43f3> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> """Hypoglycaemia unawareness should be assumed to be secondary to undetected periods of hypoglycaemia (<3.5 mmol/l, often for extended periods, commonly at night) until these are excluded by appropriate monitoring techniques. If present, such periods of hypoglycaemia should be ameliorated.
'

---
 nice.evidencegrade: D
""";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.6.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.6.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.7.md-828aa3d1efc8447c1e23ef625ce67f86691055e4> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> """Specific education on the detection and management of hypoglycaemia in adults with problems of hypoglycaemia awareness should be offered.
'

---
 nice.evidencegrade: D
""";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.7.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.7.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.8.md-20719eda23cf93bb661f2d31e1949751bffa5f01> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> """Nocturnal hypoglycaemia (symptomatic or detected on monitoring) should be managed by:
? reviewing knowledge and self-management skills
? reviewing current insulin regimen and evening eating habits and previous physical activity
? choosing an insulin type and regimen with less propensity to induce low glucose levels in the night hours, such as:
 isophane (NPH) insulin at bedtime
 rapid-acting analogue with the evening meal
 long-acting insulin analogues (insulin glargine)
 insulin pump
'

---
 nice.evidencegrade: D
""";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.8.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.8.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.9.md-de4814315d4cec2a0e7c0a29a021ce11d2930e92> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> """Adults with Type 1 diabetes should be informed that late post-prandial hypoglycaemia may be managed by appropriate inter-prandial snacks, or the use of rapid-acting insulin analogues before meals
'

---
 nice.evidencegrade: D
""";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.9.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R1.9.5.9.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R__-Discussion.md-8f1b1a58755bce41d402d42b55bdeb69a27f016b> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                        <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                      <http://www.w3.org/2011/content#chars> """The group were aware of a systematic review designed to detect issues of relevance (rather than trials of interventions) and identified papers concerning differences in incidence, attitudes to complications, degree of response to education programmes, blood glucose control, religious fasting and feasting, and hospitalisation. The group noted that cultural and genetic issues affected diabetes healthcare delivery in the areas of:

*   patient education and self-care

*   nutritional advice

*   insulin therapy (including religious feasts and fasts)

*   arterial risk

*   blood pressure management

*   hospitalisation. Insome areas there was overlap with social/deprivation issues. The groups recommendations address cultural/religious issues in the appropriate sections of this guideline, emphasising the
primacy of the individual in this regard. 
""";
                                                                                                                                      <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R__-Discussion.md>;
                                                                                                                                      <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                      <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R__-Discussion.md-20225b2f6580b909a35f58e6405225815ae66124>;
                                                                                                                                      <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R__-Recommendation.md-a4d5571fab8b3709eeb79dc48d17f90f65280b2f> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                            <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                          <http://www.w3.org/2011/content#chars> """Manage as an individual
Each adult with Type 1 diabetes should be managed as an individual, rather than as a member of any cultural, economic or health-affected group. Attention should be paid to the recommendations given elsewhere in this guideline with respect to the cultural preferences of individual adults with Type 1 diabetes
'


""";
                                                                                                                                          <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R__-Recommendation.md>;
                                                                                                                                          <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                          <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-recommendations-CG15R__-Recommendation.md-22e8f269979df0e68389cfde116d8e4dd18730fc>;
                                                                                                                                          <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-3200de357fd8b0347972d6ab73bfe71bff03d230>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS10-statements-CG15AdultES83.md-5d332540f4b892be122d65d187e9e07e1166ce3f> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """Three observational studies 109111 co mpared continuous glucose monitoring systems (CGMS) w ith SMBG. Studies demonstrated good correlation of CGMS with plasma and capillary measures of blood glucose over a range of blood glucose values. Error grid analysis showed the majority of readings fell within a clinically acceptable margin of error across all studies
---
 nice.evidencecategory: III
[@Gross_2000]
[@Gross_2000]
[@Maran_2002]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS10-statements-CG15AdultES83.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS10-statements-CG15AdultES83.md-0000000000000000000000000000000000000000>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS11-statements-CG15AdultES90.md-286d0569bac20f3b24015b7f41c9504789425767> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """In 1989, the European NIDDM Policy Group (Type 2 diabetes) suggested HbA 1 was good <8.5%, acceptable 8.59.5%, poor >9.5% (equivalent to HbA 1c of <6.9, 6.97.7, >7.7%). No ev idence for these limits was given, and it was not clear whether the intent was for micro- or macrovascular protection or both. However, the need to individualise by life expectancy was acknowledged 114
---
 nice.evidencecategory: IV
[@Alberti_1988]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS11-statements-CG15AdultES90.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS11-statements-CG15AdultES90.md-0000000000000000000000000000000000000000>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS11-statements-CG15AdultES91.md-f9587c9c1a41dc5c84ba7fe8626e41a1b7348ab2> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """In 1993, the above guidelines were revised to HbA 1c <6.5%, 6.57.5%, and >7.5%. The European IDDM Policy Group (Type 1 diabetes) (WHO, IDF, St Vincent) met concurrently and agreed these, but using the terminology good, borderline and poor to describe the groups. These pre- D CCT recommendations are not justified in the text 115
---
 nice.evidencecategory: IV
[@Group_1999]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS11-statements-CG15AdultES91.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS11-statements-CG15AdultES91.md-0000000000000000000000000000000000000000>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS11-statements-CG15AdultES92.md-d48c87aebe05d87eff40ba1052eaa6b9c149d58a> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """In 1998, the European Diabetes Policy Group revised its terminology to assessment levels, giving advice on how to use assessment levels to set targets for individuals. These were, for HbA 1c : adequate 6.27.5%, inadequate >7.5%. However the relation of this 7.5% to glucose levels was then revised to equivalent to a self-monitored pre-prandial level of 6.5 mmol/l and post-prandial 9.0 mmol/l. These post-DCCT recommendations are not justified in the text 115
---
 nice.evidencecategory: III
[@Group_1999]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS11-statements-CG15AdultES92.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS11-statements-CG15AdultES92.md-0000000000000000000000000000000000000000>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS11-statements-CG15AdultES94.md-2b815839478a743d2925ab40549bec89d554a371> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """The ADA has republished its recommendations yearly. 76 These choose a glycaemic goal of HbA 1c <7.0% for adults (type of diabetes not specified), equating this to pre-prandial <7.2 mmol/l and peak post-prandial <10.0 mmol/l. However, a table in the same paper suggests that an HbA 1c of 7.0% equates to mean self-monitored plasma glucose of 9.5 mmol/l 116
---
 nice.evidencecategory: IV
[@2003]
[@Rohlfing_2002]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS11-statements-CG15AdultES94.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS11-statements-CG15AdultES94.md-0000000000000000000000000000000000000000>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS11-statements-CG15AdultES95.md-11f1323c3f561319e4a627adfe10657eb1ab409e> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """Ho we ve r in the same issue (January 2003), 76 the ADA notes in a chapter on Implications of the D CCT that the level of glucose control to be sought under ideal circumstances is an HbA 1c of around 7.2% (average glucose 8.6 mmol/l). This argument is based on that achieved in the D CCT, and is thus not theoretically justified
---
 nice.evidencecategory: IV
[@2003]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS11-statements-CG15AdultES95.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS11-statements-CG15AdultES95.md-0000000000000000000000000000000000000000>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS11-statements-CG15AdultES97.md-36264f1555ab5e466240e49ec5b99559742af003> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """The DCCT data has never been satisfactorily analysed with a view to answering this question. A graph in the original main paper 117 suggests a curvilinear relationship between control and complications, giving the conclusion that lower is always better (ignoring the hypoglycaemia issue for this purpose), down at least to the levels measured in the study (5.5%). This conclusion is called into question because:
? it is based on study averages, and even people at lower levels over nine years may have been at high levels at times
? it takes no account of pre-trial levels
? incident retinopathy is counted only in a forward (worsening) direction, which makes no allowance for false negative retinopathy at baseline
? worsening retinopathy is known to occur in the first two years after improvement of blood glucose control, and this is not discounted
---
 nice.evidencecategory: IIa
[@1993]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS11-statements-CG15AdultES97.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS11-statements-CG15AdultES97.md-0000000000000000000000000000000000000000>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS11-statements-CG15AdultES99.md-d3732c603fb6e115ce0d28909508218488b28afd> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                              <http://www.w3.org/2011/content#chars> """R eanalysis of the published DCCT curve 118 suggests no worsening of retinopathy rates from normal levels until HbA 1c >8.0%; the low rates (2% per 100 patient years) below that may be artefact for the reasons given above. The UKPDS (epidemiological analysis, Type 2 diabetes, microvascular disease) suffers much the same problems. 119 A similar level is found for r etinopathy of 2% per 100 patient years at an HbA 1c of 7.5% and of 1% per 100 patient years at a level of 6.5% 
---
 nice.evidencecategory: III
[@1995]
[@Stratton_2001]
""";
                                                                                                                                              <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS11-statements-CG15AdultES99.md>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS11-statements-CG15AdultES99.md-0000000000000000000000000000000000000000>;
                                                                                                                                              <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS12-statements-CG15AdultES106.md-badd0371e8a3aaef09f8219dc34e80a15463b42a> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """In sulin with the molecular structure of human and animal insulins is currently available. Ev idence from the majority of studies 1268 re ports no significant differences in hypoglycaemic episodes and glycaemic control between the insulin of human and animal chemical structures
---
 nice.evidencecategory: Ia
[@Richter_2002]
[@George_1997]
[@Karlson_1994]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS12-statements-CG15AdultES106.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS12-statements-CG15AdultES106.md-0000000000000000000000000000000000000000>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS12-statements-CG15AdultES112.md-2a2d77f5f2d926659a7b5c2c317d5cbe69454cf7> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """Ev idence from a large multicentred study suggests that people commonl y inject insulin closer to mealtime than the recommended 30 minutes. Due to slow absorption and delayed action, the use of unmodified (soluble) human insulin as pre-meal dose results in high and variable post-breakfast blood glucose concentrations, which together with the incidence of later hy poglycaemia suggests that this regimen does not give satisfactory post-prandial blood glucose contr ol in many patients 133
---
 nice.evidencecategory: Ib
[@Vignati_1997]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS12-statements-CG15AdultES112.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS12-statements-CG15AdultES112.md-0000000000000000000000000000000000000000>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS12-statements-CG15AdultES115.md-6dfac822c01eca46e1290f243fd0397c158429da> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """Two studies 1467 show reduced frequency of nocturnal hypoglycaemia 148 with insulin lispro compared to unmodified (soluble) human insulin 
---
 nice.evidencecategory: Ib
[@Holleman_1997]
[@Ahmed_1998]
[@Brunelle_1998]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS12-statements-CG15AdultES115.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS12-statements-CG15AdultES115.md-0000000000000000000000000000000000000000>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS12-statements-CG15AdultES116.md-dbe59b3c5ad20efc595e5c87e78405d2efe438bf> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """Two studies 1489 show reduced frequency of severe hypoglycaemia with insulin lispro co mpared to unmodified (soluble) human insulin
---
 nice.evidencecategory: Ia
[@Brunelle_1998]
[@Battista_1995]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS12-statements-CG15AdultES116.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS12-statements-CG15AdultES116.md-0000000000000000000000000000000000000000>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS12-statements-CG15AdultES119.md-a96aa4a679752bc93871bb35f598e4b32541666a> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """Two multicentre randomised studies 14950 and one RCT 135 showed insulin aspart to improve post-prandial glucose control more effectively than unmodified (soluble) human insulin, without an increase in the rate of hypoglycaemic episodes. Fewer major hypoglycaemic episodes were observed
---
 nice.evidencecategory: Ia
[@Lindholm_1999]
[@Battista_1995]
[@Home_1998]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS12-statements-CG15AdultES119.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS12-statements-CG15AdultES119.md-0000000000000000000000000000000000000000>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS12-statements-CG15AdultES121.md-48fbb83803ab76b4ca1aea38fa6d65d94c0c6abf> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """Tw o randomised trials have shown that it is possible to replace mealtime unmodified (soluble) h uman insulin with insulin lispro or insulin aspart without detriment to glycaemic control if care is taken to replace basal insulin delivery more physiologically 1512
---
 nice.evidencecategory: Ib
[@Zinman_1999]
[@Hermansen_2001]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS12-statements-CG15AdultES121.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS12-statements-CG15AdultES121.md-0000000000000000000000000000000000000000>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS12-statements-CG15AdultES122.md-622f670e35bab82f6ceb1137eca499115d6e4451> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """A multi-arm randomised trial found that a dding a few units of isophane (NPH) insulin to insulin lispro at each meal, in combination with bedtime NPH insulin improves blood glucose co ncentrations compared to an unmodified (soluble) human insulin regimen in a multidose reg imen 136
---
 nice.evidencecategory: Ib
[@Sindaco_1998]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS12-statements-CG15AdultES122.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS12-statements-CG15AdultES122.md-0000000000000000000000000000000000000000>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS12-statements-CG15AdultES127.md-09beb32c0e059b0e17e38aae6b2adaddfdf691ca> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """F our randomised controlled trials, two large parallel groups, 1578 and two small crossover designs 15960 we re identified that examined the use of acarbose in conjunction with insulin therapy compared to insulin and placebo in each case, in people with Type 1 diabetes. A m ulticentred study 157 w ith variable doses titrated up to 300 mg three times a day for 24 weeks, found a significant reduction in HbA 1c levels with acarbose compared to placebo, and decreases in fasting and post-prandial glucose levels to two hours. There were no differences between gr oups for daily insulin dose or hypoglycaemic ev ents, although adverse events of abdominal pain, diarrhoea and flatulence were more common with acarbose. This led to more frequent tr eatment discontinuation in the acarbose group than the placebo group. A similar Italian tr ial 158 w ith up to 100 mg acarbose three times daily for 24 weeks found no difference in HbA 1c levels, daily insulin dose, fasting glycaemia and total cholesterol. However, a significant decrease was found in two-hour post-prandial plasma glucose level, and HDL cholesterol levels were lower in people on acarbose than placebo. Again minor adverse events were more common in the acarbose group, but hypoglycaemic episodes were similar in both groups. Although care was taken not to alter baseline insulin doses, this could be adjusted if glucose levels exceeded 11.1 mmol/l or reduced with hypoglycaemic episodes
---
 nice.evidencecategory: Ib
[@Hollander_1997]
[@Riccardi_1999]
[@Viviani_1988]
[@Marena_1991]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS12-statements-CG15AdultES127.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS12-statements-CG15AdultES127.md-0000000000000000000000000000000000000000>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS12-statements-CG15AdultES128.md-344a31e954c67bcd4b0b9d9fb446429b7ab06324> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """The two crossover trials with 100 mg acarbose three times a day over relatively short time periods did not assess requirement for wash ou t periods (although analysis in one found no effect of treatment order) and did not account for study withdrawals. One study found a benefit in terms of HbA 1c w ith acarbose, 160 while the other found no significant differences between gr oups. 159 Po te ntial methodological limitations of these trials would not permit them to be used as an evidence base to inform recommendations in this area
---
 nice.evidencecategory: Ib
[@Viviani_1988]
[@Marena_1991]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS12-statements-CG15AdultES128.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS12-statements-CG15AdultES128.md-0000000000000000000000000000000000000000>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS12-statements-CG15AdultES129.md-e45d452f36783110199d3aa003f4b2dd33d59967> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """Tw o small randomised controlled trials investigat ed the use of glibenclamide (called glyburide as the trials were conducted in the USA) in the therapy for Type 1 diabetics. A study using 5 mg gl yburide (orally) for 12 weeks compared to placebo after a 12-week open-label insulin stabilisation run-in period 161 found fasting blood glucose declined significantly at 12 weeks from baseline, although no comparison was made between groups. No differences were found in daily insulin dose or glycated haemoglobin le ve ls at any stage of the study. A randomised study without comparison between groups at baseline with 5 mg glyburide daily for 24 weeks co mpared to placebo 162 found no differences in plasma C-peptide levels between groups, nor difference in plasma glucose concentrations at any time point. Although HbA 1c levels were re ported to have changed more from baseline in the glyburide treated group at six weeks, potential methodological limitations of these trials would not permit them to be used as an ev idence base to inform recommendations in this area
---
 nice.evidencecategory: Ib
[@Tzefos_2010]
[@NATHAN_1988]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS12-statements-CG15AdultES129.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS12-statements-CG15AdultES129.md-0000000000000000000000000000000000000000>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS12-statements-CG15AdultES130.md-9c0e650b7331adbd502fc9cc2eff5e43731bbd0f> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """Co mparison of 15 mg of glibenclamide daily with placebo in addition to insulin therapy in a small sample of people with Type 1 diabetes in a randomised double-blind crossover study 163 found mean blood glucose level, HbA 1c and blood glucose variability to be significantly lower w ith the intervention among people who retained endogenous insulin production. No such differences were found in a subgroup who were C-peptide negative. Although the study had a medium-term intervention period of three months, it did not provide analysis of the cohort as a whole for glibenclamide vs placebo and thus cannot be used for recommendations given the small sample sizes of the subgroups, and the inherent difficulties of extrapolating such findings to a wider population
---
 nice.evidencecategory: Ib
[@Burke_1984]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS12-statements-CG15AdultES130.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS12-statements-CG15AdultES130.md-0000000000000000000000000000000000000000>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS12-statements-CG15AdultES131.md-9ac14387e915a0db67cde6e49fed1ca983045c29> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """A reduced insulin requirement at 18 months was found in patients given 80 mg gliclazide twice a day compared to placebo in a small sample in a long-term study. 164 Although glycated haemoglobin both fasting and one hour post-breakfast were found to be very similar in both gr oups, the gliclazide group had C-peptide levels significantly higher than people on placebo for the same test times of the day, at six-monthly assessment points to 18 months. This study only applies to people with retained endogenous insulin secretion, and thus not the ov erwhelming majority of people with Type 1 diabetes
---
 nice.evidencecategory: Ib
[@Fallucca_1996]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS12-statements-CG15AdultES131.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS12-statements-CG15AdultES131.md-0000000000000000000000000000000000000000>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS12-statements-CG15AdultES132.md-43044804a0b1d7ddc7faa7dd700d431c9dde50e8> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """A medium-sized randomised controlled study found that the addition of metformin to an insulin regimen provided by CSII was able to reduce the total IR required by the person with Ty pe 1 diabetes (including reduced basal therapy) as compared to placebo over a period of six months. This was achieved without significant change to HbA 1c or increased incidence of hy poglycaemia
---
 nice.evidencecategory: Ib
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS12-statements-CG15AdultES132.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS12-statements-CG15AdultES132.md-0000000000000000000000000000000000000000>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS13-Discussion.md-a2da057674070d6170699dfb766181c3e26c40ab> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> "In sulin injection pens were noted to be the overwhelming norm in the UK for insulin delivery for reasons of convenience, ease of teaching and portability. Some devices with particular design characteristics can be used by people with disabilities, where otherwise a third party w ould have to give injections. The desirability and often cost-effectiveness of this was noted. In jection into deep subcutaneous fat, and on the basis of many studies into the tissues of the abdominal wall for mealtime unmodified human insulin, are generally advised and logically based. However the needs and beliefs of individuals in giving their own insulin were felt to be of importance. Simple logic also leads to the conclusion that rotation of injection sites should be within one region rather than between regions. Group members (both clinicians and people w ith diabetes) expressed a widespread experience of repeated self-injection with the same needle without problems arising. The group considered the utility of recommending advice on cleanliness for those who choose to re-use needles, but noted the regulatory position from the Me dicines and Healthcare Products Regulatory Agency (MHRA, formerly the Medical Devices Ag ency) in the bulletin DB2000(04). Consequently, the guideline cannot make such a re co mmendation. Other common sense issues included provision for sharps disposal, and ch eck on the condition of injection sites annually or if blood glucose control problems worsen.";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS13-Discussion.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS13-Discussion.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS13-statements-CG15AdultES134.md-b71d852a0fcd851555282446f864c3b42602d927> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """NICE guidance 165 co ncluded that, compared to optimised MDI therapy, CSII results in a modest but worthwhile improvement in GHb and quality of life (by allowing greater flexibility of lifestyle), and reduction of other problems such as hypoglycaemia and rising blood glucose levels at the end of the night. In routine practi c e, patients who go on to pumps are carefully selected, and to a large degree self-select ed. Overall, insulin pumps appear to be a useful advance for patients having particular problems, rather than a dramatic breakthrough in therapy, and would probably be used only in a small percentage of patients
---
 nice.evidencecategory: NICE
[@Al_Mrayat_2009]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS13-statements-CG15AdultES134.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS13-statements-CG15AdultES134.md-0000000000000000000000000000000000000000>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS13-statements-CG15AdultES135.md-332d559e498efea955140e7e02c26c0459fe2119> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """One randomised trial 166 of medium sample size compared a multiple injection regimen from a pen injector with conventional treatment with twice-daily syringe injection. No significant differ- ences were seen in GHb values, blood glucose values or hypoglycaemic episodes. Patient satisfac- tion with pen injectors was high and most patients opted to continue on this delivery system following termination of the trial. However, this study has some methodological limitations
---
 nice.evidencecategory: Ib
[@Murray_1988]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS13-statements-CG15AdultES135.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS13-statements-CG15AdultES135.md-0000000000000000000000000000000000000000>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS13-statements-CG15AdultES136.md-a4f23f7a7e8298376c130b60b11f8c7a9d5b9fa4> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """One randomised crossover trial 167 co mpared two types of insulin regimen injected in the abdomen with the same regimen injected in the thigh. Regular insulin injections in the abdomen resulted in significantly lower post-prandial plasma glucose values, peak plasma gl ucose and increment in plasma glucose compared to time periods following injection in the thigh. Significantly higher serum free insulin values were also seen following abdominal injection of regular insulin, compared with injections administered at the thigh. No differences we re re co rd ed between injections at either site following injections containing both isophane (NPH) and unmodified (soluble) insulin
---
 nice.evidencecategory: Ib
[@Bantle_1993]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS13-statements-CG15AdultES136.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS13-statements-CG15AdultES136.md-0000000000000000000000000000000000000000>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS13-statements-CG15AdultES137.md-d5f5ffb6f01dac04e41427b7344f6080249a59ae> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """One prospective study 168 co mparing the absorption of insulin injected superficially and deep subcutaneously at the fat-muscle boundary showed no significant difference between the two te c hniques. A sub-group of 10 participants showed no difference in overall serum free insulin or plasma glucose values following superficial and deep subcutaneous injection
---
 nice.evidencecategory: IIa
[@Meijer_1990]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS13-statements-CG15AdultES137.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS13-statements-CG15AdultES137.md-0000000000000000000000000000000000000000>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS13-statements-CG15AdultES138.md-3077da5781657b7837a1c186ce41abac334155d6> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """One study 169 re ported benefits associated with injection through clothing, compared with co nv entional injection practice with skin preparat ion over a 20-week trial period. This study had some methodological limitations
---
 nice.evidencecategory: Ib
[@Fleming_1997]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS13-statements-CG15AdultES138.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS13-statements-CG15AdultES138.md-0000000000000000000000000000000000000000>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS13-statements-CG15AdultES139.md-f1f1e736273c9823a573ebacc0abfdf8534cf400> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """The health economic searches produced three published papers 3479 co nsidering the use of insulin pens. None of the three papers compare their benefits (patient satisfaction, or improved HbA 1c ) against their costs.
---
 nice.evidencecategory: -
[@Graff_1998]
[@H_rnquist_1995]
[@H_rnquist_1990]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS13-statements-CG15AdultES139.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS13-statements-CG15AdultES139.md-0000000000000000000000000000000000000000>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS14-Discussion.md-e25b8ac94c3f2a25783ed5a44d4a02cb0cca085d> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> "The group noted this was an area of considerable importance to people with Type 1 diabetes, but that prevention of hypoglycaemia was considered appropriately under insulin therapy re co mmendations, and secondarily under education and lifestyle issues. The group noted issues re lated to absorption and ingestion of free carbohydrate in people with decreased conscious level. They were concerned that recurrent hypoglycaemia was properly considered in a medical co ntext, and not simply attributed to lifestyle problems secondary to insulin therapy. Hy poglycaemia unawareness was also noted to be an important issue, and be partially reversible and capable of useful management, as now is nocturnal hypoglycaemia (it was noted that the re co mmendations on insulin therapy and clinical monitoring addressed other aspects of such management). No useful hard evidence was available for cognitive decline occurring in people w ith Type 1 diabetes, but the possibility of recurrent severe hypoglycaemia being a contributory factor was felt worth mentioning. The group noted that the ease and safety of administration of glucagon compared to IV glucose (risk of extravasation) meant that in most situations it was the treatment of choice. While it was re co g nised that there were groups of people to whom the identified studies do not apply (starvation, alcohol toxic), and that these people would not be expected to respond well to gl ucagon, it was agreed that the best means of detecting this was by absence of a response to gl ucagon at 10 minutes. Safe follow-up management after either therapy should include oral carbohydrate and awareness of risk of relapse. Users of glucagon injections need appropriate education and training.";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS14-Discussion.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS14-Discussion.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS14-statements-CG15AdultES140.md-5717bda0fe4c31fae22f4218e6fd2fb09e658370> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """Canadian clinical practice guidelines 98 re ported four studies supporting the use of 15 g glucose (monosaccharide) (orally) for the treatment of moderate hypoglycaemia. Two studies within the guidelines explored a 20 g oral glucose dose for recovery of blood glucose levels. Recovery was slower following treatment with milk and orange juice. The use of glucose gel also delivered slower recovery in the latter study and required swallowing to have a significant effect. A further study showed no support for buccal administration of glucose
---
 nice.evidencecategory: Ia
[@Lau_2007]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS14-statements-CG15AdultES140.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS14-statements-CG15AdultES140.md-0000000000000000000000000000000000000000>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS14-statements-CG15AdultES141.md-30c94a2c1db93e99f3725652b478f45a8f7df0b3> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """One study within the Canadian guidelines 98 re ported on the special needs of people taking alpha-glycosidase inhibitors when treating hypoglycaemia, recommending the use of glucose (dextrose) tablets, or milk or honey if these are unavailable
---
 nice.evidencecategory: IV
[@Lau_2007]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS14-statements-CG15AdultES141.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS14-statements-CG15AdultES141.md-0000000000000000000000000000000000000000>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS14-statements-CG15AdultES142.md-69e5e4e0b9ae6d4064ee97fb156611cb660220a7> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """A bedtime snack may be needed to avoid nocturnal hypoglycaemia. Two studies from a systematic review 98 showed prepared cornstarch snack bars have some benefit in overnight re duction of hypoglycaemia, but the number of events were not significantly reduced
---
 nice.evidencecategory: Ia
[@Lau_2007]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS14-statements-CG15AdultES142.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS14-statements-CG15AdultES142.md-0000000000000000000000000000000000000000>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS14-statements-CG15AdultES143.md-f779682d8071b7e89744252e5a877cbb564b156e> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """Canadian clinical practice guidelines 98 re port one paper on the link between incidence of prior hy poglycaemic episodes and worsening in the defect of the hormonal responses to hy poglycaemia, leading to a reduction in the self-detection of hypoglycaemia. Eight papers re port the benefits of strict avoidance of hypoglycaemia in improving recognition of severe hy poglycaemia or the responses of counter-regulatory hormones
---
 nice.evidencecategory: Ia
[@Lau_2007]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS14-statements-CG15AdultES143.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS14-statements-CG15AdultES143.md-0000000000000000000000000000000000000000>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS14-statements-CG15AdultES144.md-adedfb08004b0eeb1e617fb33b971e08179dd814> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """A randomised controlled study 170 co mpared blood glucose awareness training (BGAT) with no tr aining on the increased hypoglycaemia after initiation of more intensive diabetes management. The counter-regulatory hormone epinephrine (adrenaline) response was not impaired following BGAT despite an increase in frequency of hypoglycaemia induced by intensive diabetes management. No difference was seen in awareness of the symptoms of hy poglycaemia following BGAT, compared with controls, although BGAT does lead to a better detection of low blood glucose levels in people starting intensive diabetes management
---
 nice.evidencecategory: Ib
[@Kinsley_1999]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS14-statements-CG15AdultES144.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS14-statements-CG15AdultES144.md-0000000000000000000000000000000000000000>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS14-statements-CG15AdultES145.md-dda34d1b6714d7dcc3685bb3318f9bf1af38554f> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """An observational study 171 co mpared blood glucose sensitivity and prediction accuracy in inpatients before and after blood glucose awareness training, showed no additional effect on the improvement of HbA 1c . The decrease in HbA 1c was not however accompanied by a change in the accuracy of blood glucose estimation or sensitivit y of recognition of low blood glucose levels
---
 nice.evidencecategory: IIa
[@Fritsche_1998]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS14-statements-CG15AdultES145.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS14-statements-CG15AdultES145.md-0000000000000000000000000000000000000000>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS14-statements-CG15AdultES146.md-45c5aded02e8aea61a8ee733b9a348e09790fe88> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """Canadian clinical practice guidelines 98 cite five studies demonstrating a positive effect of BGAT on accurate detection and treatment of hypoglycaemia, and allowing reduced-awareness subjects to detect a greater percentage of low blood glucose levels. These BGAT programmes involve instruction in interpretation of physical symptoms and instruction on food, exercise, insulin dosage and action, and the impact of time of day and last blood glucose measurements on estimations of blood glucose
---
 nice.evidencecategory: Ia
[@Lau_2007]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS14-statements-CG15AdultES146.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS14-statements-CG15AdultES146.md-0000000000000000000000000000000000000000>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS14-statements-CG15AdultES147.md-fce31b50b372ec1b12d411ae278e64e99102774f> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """Evidence on the impact of hypoglycaemia on cognitive function is not clear. Two prospective studies reported within the Canadian guidelines 98 did not find association between intensive diabetes management and cognitive function. However, six retrospective studies found subjects w ith recurrent hypoglycaemia performed more poorly in a range of intellectual tests
---
 nice.evidencecategory: IIa
[@Lau_2007]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS14-statements-CG15AdultES147.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS14-statements-CG15AdultES147.md-0000000000000000000000000000000000000000>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS14-statements-CG15AdultES148.md-7df4af9c9d6fe11124303b62494dce522d44b836> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """Tw o randomised studies compared the use of glucagon and dextrose in the treatment of severe hy poglycaemia. One study 172 co mpared intramuscular administration of 1 mg glucagon with 50 ml 50% IV dextrose in people with hypoglycaemic coma. A second study 173 co mpared intravenous administration of 1 mg glucagon vs 50 ml 50% dextrose in people with hypo- gl yc aemic coma. Both studies showed a significantly slower recovery to a normal level of co nsciousness in the glucagon treated group
---
 nice.evidencecategory: Ib
[@Patrick_1990]
[@Collier_1987]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS14-statements-CG15AdultES148.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS14-statements-CG15AdultES148.md-0000000000000000000000000000000000000000>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS14-statements-CG15AdultES149.md-b418bb5b60695da97bc07fd73699f10b6d60cc9c> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """Two glucagon-treated patients in each study (7% and 4% respectively) and two dextrose-treated patients in the second study (4%) required additional administration of 12.5 g IV dextrose following failing to recover consciousness after 15 minutes. In the first study average duration of hypoglycaemic coma was not different between the two treatment groups
---
 nice.evidencecategory: Ib
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS14-statements-CG15AdultES149.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS14-statements-CG15AdultES149.md-0000000000000000000000000000000000000000>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS14-statements-CG15AdultES150.md-7da755b32e3c0b7e9d77019b877c4d34c1044ebe> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """No co rr elation was seen between time taken to recovery of consciousness and initial plasma gl ucose concentration or duration of hypoglycaemia in either of the studies. Side effects were similar among the treatment groups
---
 nice.evidencecategory: Ib
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS14-statements-CG15AdultES150.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS14-statements-CG15AdultES150.md-0000000000000000000000000000000000000000>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS14-statements-CG15AdultES151.md-0ffc9cd4cd1687ddd780111b0171bac093d3a395> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """These two small studies suggest that intravenous glucose gives a clinically non-significant advantage over intramuscular glucagon in time to recovery of consciousness in people with Type 1 diabetes in hypoglycaemic coma
---
 nice.evidencecategory: Ib
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS14-statements-CG15AdultES151.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS14-statements-CG15AdultES151.md-0000000000000000000000000000000000000000>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS14-statements-CG15AdultES152.md-74dbbb2719c45e3975cb54c43be5a9ff2081b442> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """No health economic evidence on the prevention or management of hypoglycaemia was identified in the literature review.
---
 nice.evidencecategory: -
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS14-statements-CG15AdultES152.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS14-statements-CG15AdultES152.md-0000000000000000000000000000000000000000>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS15-statements-CG15AdultES156.md-fcd04126707991f3dfef2bb602c0f81f6f59fb78> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """The link between glycaemia and arterial morbidity and mortality was also reported in two studies reviewed in the SIGN guidelines. 174 In o ne study each 1% reduction in HbA 1c was associated with a 21% (95% CI: 1527) reduction in the risk of diabetes-related death and a 14% reduction for myocardial infarction over 10 years
---
 nice.evidencecategory: IIa
[@Linden_2011]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS15-statements-CG15AdultES156.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS15-statements-CG15AdultES156.md-0000000000000000000000000000000000000000>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS15-statements-CG15AdultES161.md-afac68967daf0daa6c6e5cf09bbd444f7f62ae5c> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """A dditional studies within this systematic review 176 co nsidered triglyceride screening. Values measured varied by 20%30% between fasting and non-fasting states. LDL cholesterol is calculated from total and HDL cholesterol and triglycerides measurements and application of the Friedewald equation. However, this equation has been found to be inaccurate at triglyceride levels greater than or equal to 4.5 mmol/l when special techniques must be employed (eg ultracentrifugation)
---
 nice.evidencecategory: III
[@Pignone_2001]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS15-statements-CG15AdultES161.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS15-statements-CG15AdultES161.md-0000000000000000000000000000000000000000>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS16-statements-CG15AdultES172.md-9601c86e8e9dcb1a9a421bda2931590cc2ce786e> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """Three randomised controlled trials 182184 re ported on the positive effect of pravastatin on arterial outcomes in people with diabetes. One study 182 re ported a significant change in total and LDL cholesterol, HDL cholesterol and triglycerides vs placebo. After 24 weeks the reduction in total cholesterol from baseline was 22%, LDL cholesterol 26%, and triglycerides decreased by 2%, accompanied by an increase in HDL cholesterol of 14%. Pravastatin was well tolerated throughout the study
---
 nice.evidencecategory: Ib
[@Rustemeijer_1997]
[@Raskin_1995]
[@Goldberg_1998]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS16-statements-CG15AdultES172.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS16-statements-CG15AdultES172.md-0000000000000000000000000000000000000000>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS16-statements-CG15AdultES187.md-68a4b662c26e4f6a6361754b33a9fdb4383ea00d> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """Also reported in the SIGN guideline 174 is a sub-study analysis of a large RCT demonstrating that addition of clopidogrel to aspirin over 312 months reduces the risk of fatal or non-fatal MI or stroke by 20% in patients with a past history of coronary heart disease presenting with acute coronary syndromes (without electrocardiographic ST elevation). This risk reduction was however associated with an additional risk of bleeding
---
 nice.evidencecategory: Ia
[@Linden_2011]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS16-statements-CG15AdultES187.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS16-statements-CG15AdultES187.md-0000000000000000000000000000000000000000>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS16-statements-CG15AdultES195.md-9f74a5c1c975733affcb6037a26067bc20b514fb> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                               <http://www.w3.org/2011/content#chars> """W hilst economic analyses have been conducted on trials of lipid-lowering agents, no evaluation has specifically considered Type 1 diabetes. Three papers were identified within the health economic literature dealing with mixed diabetic populations. 35052 An economic analysis 350 of simvastatin using the 4S trial data suggests that it would provide cost-effective mortality re duction in the UK amongst a similar population. A second cost-effectiveness paper 351 also suggests that the simvastatin may be cost-effective in the UK for those aged 40 to 70 years with elevated cholesterol even if they have not been diagnosed with arterial disease. A third paper based outside the UK suggests that the benefits of simvastatin to diabetics with elevated lipid levels and arterial disease outweigh the benefit to those with elevated lipid levels and no prior arterial disease. 352
---
 nice.evidencecategory: -
[@Grover_2000]
[@Grover_2001]
""";
                                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS16-statements-CG15AdultES195.md>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS16-statements-CG15AdultES195.md-0000000000000000000000000000000000000000>;
                                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS17-Discussion.md-e69de29bb2d1d6434b8b29ae775ad8c2e48c5391> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> "";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS17-Discussion.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS17-Discussion.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS18-Discussion.md-e69de29bb2d1d6434b8b29ae775ad8c2e48c5391> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> "";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS18-Discussion.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS18-Discussion.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS19-Discussion.md-e69de29bb2d1d6434b8b29ae775ad8c2e48c5391> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> "";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS19-Discussion.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS19-Discussion.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS2-statements-CG15AdultES12.md-56019fb0812b63fbd0a42e7bfd7217c61e184d6c> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                               <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                             <http://www.w3.org/2011/content#chars> """A number of descriptive papers were identified,4548 suggesting such approaches can be feasible and have utility, but not demonstrating comparative advantage to traditional approaches
---
 nice.evidencecategory: IV
[@Chiarelli_1998]
[@Gorman_1996]
[@Kucher_1990]
[@Smith_1998]
""";
                                                                                                                                             <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS2-statements-CG15AdultES12.md>;
                                                                                                                                             <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                             <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS2-statements-CG15AdultES12.md-0000000000000000000000000000000000000000>;
                                                                                                                                             <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS2-statements-CG15AdultES17.md-c2d0681a0f81279d43f0fe8b624f51a7715d2722> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                               <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                             <http://www.w3.org/2011/content#chars> """No literature on the deployment or impact of diabetes guidelines was identified.
---
 nice.evidencecategory: -
""";
                                                                                                                                             <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS2-statements-CG15AdultES17.md>;
                                                                                                                                             <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                             <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS2-statements-CG15AdultES17.md-0000000000000000000000000000000000000000>;
                                                                                                                                             <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS2-statements-CG15AdultES8.md-9793742c64b5c328bf8e3b7edce6c22b23b29794> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                              <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                            <http://www.w3.org/2011/content#chars> """The current guideline suggests annual surveillance of a number of potentially developing late complications (as do all other guidelines for the most complications). The International Diabetes Federations European guideline recommends integration of these activities into one patient visit.24 Annual review is also the basis of many quality control structures proposed for diabetes care,25 including (implicitly) that of the UK Audit Commission
---
 nice.evidencecategory: IV
[@1998]
[@Grabert_2002]
""";
                                                                                                                                            <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS2-statements-CG15AdultES8.md>;
                                                                                                                                            <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                            <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS2-statements-CG15AdultES8.md-0000000000000000000000000000000000000000>;
                                                                                                                                            <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS20-Discussion.md-e69de29bb2d1d6434b8b29ae775ad8c2e48c5391> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> "";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS20-Discussion.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS20-Discussion.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS21-Discussion.md-e69de29bb2d1d6434b8b29ae775ad8c2e48c5391> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> "";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS21-Discussion.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS21-Discussion.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS22-Discussion.md-e69de29bb2d1d6434b8b29ae775ad8c2e48c5391> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> "";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS22-Discussion.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS22-Discussion.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS23-Discussion.md-e69de29bb2d1d6434b8b29ae775ad8c2e48c5391> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> "";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS23-Discussion.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS23-Discussion.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS24-Discussion.md-e69de29bb2d1d6434b8b29ae775ad8c2e48c5391> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> "";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS24-Discussion.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS24-Discussion.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS25-Discussion.md-e69de29bb2d1d6434b8b29ae775ad8c2e48c5391> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> "";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS25-Discussion.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS25-Discussion.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS26-Discussion.md-e69de29bb2d1d6434b8b29ae775ad8c2e48c5391> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> "";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS26-Discussion.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS26-Discussion.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS27-Discussion.md-e69de29bb2d1d6434b8b29ae775ad8c2e48c5391> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> "";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS27-Discussion.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS27-Discussion.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS28-Discussion.md-e69de29bb2d1d6434b8b29ae775ad8c2e48c5391> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> "";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS28-Discussion.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS28-Discussion.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS29-Discussion.md-e69de29bb2d1d6434b8b29ae775ad8c2e48c5391> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> "";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS29-Discussion.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS29-Discussion.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS3-Discussion.md-3cf20d57b0b8258463711cedd592007b0b5cdfe8> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                               <http://www.w3.org/2011/content#chars> "-";
                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS3-Discussion.md>;
                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS3-Discussion.md-0000000000000000000000000000000000000000>;
                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS30-Discussion.md-e69de29bb2d1d6434b8b29ae775ad8c2e48c5391> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> "";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS30-Discussion.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS30-Discussion.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS31-Discussion.md-e69de29bb2d1d6434b8b29ae775ad8c2e48c5391> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> "";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS31-Discussion.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS31-Discussion.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS32-Discussion.md-e69de29bb2d1d6434b8b29ae775ad8c2e48c5391> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> "";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS32-Discussion.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS32-Discussion.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS33-Discussion.md-e69de29bb2d1d6434b8b29ae775ad8c2e48c5391> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                <http://www.w3.org/2011/content#chars> "";
                                                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS33-Discussion.md>;
                                                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS33-Discussion.md-0000000000000000000000000000000000000000>;
                                                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS4-Discussion.md-3cf20d57b0b8258463711cedd592007b0b5cdfe8> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                               <http://www.w3.org/2011/content#chars> "-";
                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS4-Discussion.md>;
                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS4-Discussion.md-0000000000000000000000000000000000000000>;
                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS5-statements-CG15AdultES26.md-18accec4d2fda88d0e511c4c57de9b273a80f5a8> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                               <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                             <http://www.w3.org/2011/content#chars> """An update of the US standards for diabetes self-management education79 based on a literature review covered the organisation of diabetes self-management education, its content and provision. A multiprofessional task force encompassing all the major interested stakeholders agreed the following standards.
?Education and information-giving will involve the interaction of the individual with diabetes with a multifaceted education instructional team, which may include a behaviourist, exercise physiologist, ophthalmologist, optometrist, pharmacist, physician,podiatrist, registered dietitian, registered nurse, other healthcare professionals, and paraprofessionals.
?Instructors will obtain regular continuing education in the areas of diabetes management,behavioural interventions, teaching and learning skills and counselling skills.
?Assessed needs of the individual will determine which of the following content areas are delivered:
describing the diabetes disease process and treatment options
incorporating appropriate nutritional management
incorporating physical activity into lifestyle
utilising medications (if applicable) for therapeutic effectiveness
monitoring blood glucose and urine ketones (where appropriate) and using results to improve control
preventing, detecting and treating acute complications
preventing (through risk reduction behaviour), detecting and treating chroniccomplications
goal-setting to promote health, and problem-solving for daily living
integrating psychosocial adjustment to daily life
promoting preconception care, management during pregnancy and gestational diabetes management (if applicable).
?An individualised assessment, development of an education plan and periodic reassessment between participant and instructor will direct the selection of appropriate educational materials and interventions.
?The assessment includes relevant medical history, cultural influences, health beliefs and attitudes, diabetes knowledge, self-management skills and behaviours, readiness to learn,cognitive ability, physical limitations, family support and financial status.
?There shall be documentation of the individuals assessment, education plan,intervention, evaluation and follow-up in the permanent confidential education record.
---
 nice.evidencecategory: IV
[@Mensing_2000]
""";
                                                                                                                                             <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS5-statements-CG15AdultES26.md>;
                                                                                                                                             <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                             <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS5-statements-CG15AdultES26.md-0000000000000000000000000000000000000000>;
                                                                                                                                             <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS6-statements-CG15AdultES51.md-243b24af86841770042c9ca11ab94b599c5fe03a> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                               <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                             <http://www.w3.org/2011/content#chars> """The DCCT included self-monitoring of blood glucose as part of intensive treatment. Self-monitoring is only likely to have an effect on blood glucose control when used to inform the management of diabetes. As such, it is not feasible to analyse its cost-effectiveness in isolation from the requirements of subsequent management strategies.  A recent HTA report 89 identifies one paper considering the cost-effectiveness of blood or urine glucose monitoring against conventional dietary control amongst those with Type 1 diabetes. 341 This paper is based on Russian conditions and also includes education in the intervention technologies. The GDG felt that differences in international healthcare systems mean little weight could be placed on its assertions that no significant difference exists between blood and urine glucose monitoring
---
 nice.evidencecategory: -
[@Coster_2000]
[@Starostina_1994]
""";
                                                                                                                                             <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS6-statements-CG15AdultES51.md>;
                                                                                                                                             <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                             <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS6-statements-CG15AdultES51.md-0000000000000000000000000000000000000000>;
                                                                                                                                             <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS7-statements-CG15AdultES52.md-315c69a3940b08bba2602d041eb598e276708224> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                               <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                             <http://www.w3.org/2011/content#chars> """F our small randomised controlled trials 9497 we re identified examining different diet regimens in people with Type 1 diabetes. One randomised controlled study 94 found that a high fibre diet (50 g/day) for 24 weeks compared to a low fibre diet (15 g/day) improved blood glucose profile, and number of hypoglycaemic events, although HbA 1c , cholesterol, body weight and insulin dose were not affected
---
 nice.evidencecategory: Ib
[@Giacco_2000]
[@HANSEN_1999]
[@Chantelau_1992]
[@McCulloch_1985]
""";
                                                                                                                                             <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS7-statements-CG15AdultES52.md>;
                                                                                                                                             <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                             <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS7-statements-CG15AdultES52.md-0000000000000000000000000000000000000000>;
                                                                                                                                             <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS7-statements-CG15AdultES61.md-2fca3b4084e419e275246f1a69a4358d15868594> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                               <http://www.w3.org/ns/prov#Entity>;
                                                                                                                                             <http://www.w3.org/2011/content#chars> """The recent NICE Technology Appraisal 101 into patient education models ( www.nice. org.uk/cat.asp?c=68326 ) recommends dose adjustment for normal eating (DAFNE), and the intensified treatment required by DAFNE, as cost effective.
---
 nice.evidencecategory: -
[@Blinkhorn_2003]
""";
                                                                                                                                             <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS7-statements-CG15AdultES61.md>;
                                                                                                                                             <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                                             <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS7-statements-CG15AdultES61.md-0000000000000000000000000000000000000000>;
                                                                                                                                             <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS9-Discussion.md-b3e58141dfa0afd78fc8742fda533479d00023b4> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                                                 <http://www.w3.org/ns/prov#Entity>;
                                                                                                                               <http://www.w3.org/2011/content#chars> """The group were aware of a systematic review designed to detect issues of relevance (rather than trials of interventions) and identified papers concerning differences in incidence, attitudes to complications, degree of response to education programmes, blood glucose control, religious fasting and feasting, and hospitalisation. The group noted that cultural and genetic issues affected diabetes healthcare delivery in the areas of:
? patient education and self-care
? nutritional advice
? insulin therapy (including religious feasts and fasts)
? arterial risk
? blood pressure management
? hospitalisation. Insome areas there was overlap with social/deprivation issues. The groups recommendations address cultural/religious issues in the appropriate sections of this guideline, emphasising the
primacy of the individual in this regard. """;
                                                                                                                               <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS9-Discussion.md>;
                                                                                                                               <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                                               <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-src-pandoc-CG15-chapters-sets-CG15AdultS9-Discussion.md-0000000000000000000000000000000000000000>;
                                                                                                                               <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
<http://nice.org.uk/vcs/file-templates-latex.template-cc964ae12b2b47be075dd37485ebbda2623473a6> a <http://www.w3.org/2011/content#ContentAsText>,
                                                                                                  <http://www.w3.org/ns/prov#Entity>;
                                                                                                <http://www.w3.org/2011/content#chars> """\\documentclass[11pt,article,oneside]{memoir}
\\usepackage[minion]{org-preamble-pdflatex}
\\input{vc}

$if(listings)$
\\usepackage{listings}
$endif$
$if(lhs)$
\\lstnewenvironment{code}{\\lstset{language=r,basicstyle=\\small\\ttfamily}}{}
$endif$
$if(highlighting-macros)$
$highlighting-macros$
$endif$
$if(verbatim-in-note)$
\\usepackage{fancyvrb}
$endif$
$if(tables)$
\\usepackage{longtable}
$endif$

$if(graphics)$
\\usepackage{graphicx}
% We will generate all images so they have a width \\maxwidth. This means
% that they will get their normal width if they fit onto the page, but
% are scaled down if they would overflow the margins.
\\makeatletter
\\def\\maxwidth{\\ifdim\\Gin@nat@width>\\linewidth\\linewidth
\\else\\Gin@nat@width\\fi}
\\makeatother
\\let\\Oldincludegraphics\\includegraphics
\\renewcommand{\\includegraphics}[1]{\\Oldincludegraphics[width=\\maxwidth]{#1}}
$endif$

$if(title)$
\\title{\\bigskip \\bigskip $title$}
$endif$ 

%\\author{$for(author)$$author$$sep$\\\\$endfor$}

\\author{$for(author)$\\Large $author.name$\\vspace{0.05in} \\newline\\normalsize\\emph{$author.affiliation$} \\newline\\footnotesize \\url{$author.email$}\\vspace*{0.2in}\\newline $sep$ \\and $endfor$}

%\\author{$for(author)$$author.name$ ($author.affiliation$)$sep$ \\and $endfor$}

\\date{}

\\begin{document}  
\\setkeys{Gin}{width=1\\textwidth} 	
%\\setromanfont[Mapping=tex-text,Numbers=OldStyle]{Minion Pro} 
%\\setsansfont[Mapping=tex-text]{Minion Pro} 
%\\setmonofont[Mapping=tex-text,Scale=0.8]{Pragmata}
\\chapterstyle{article-4} 
\\pagestyle{kjh}

\\published{$date$. Incomplete Draft. Please do not cite without permission.}

$if(title)$
\\maketitle
$endif$

$if(toc)$
{
\\hypersetup{linkcolor=black}
\\setcounter{tocdepth}{$toc-depth$}
\\tableofcontents
}
$endif$

$if(abstract)$

\\begin{abstract}

\\noindent $abstract$

\\end{abstract}

$endif$

$body$

$if(natbib)$
$if(biblio-files)$
$if(biblio-title)$
$if(book-class)$
\\renewcommand\\bibname{Bibliography}
$else$
\\renewcommand\\refname{References}
$endif$
$endif$

\\bibliography{$biblio-files$}

$endif$
$endif$
$if(biblatex)$
\\printbibliography$if(biblio-title)$[title=References]$endif$

$endif$
$for(include-after)$
$include-after$

$endfor$
\\end{document}""";
                                                                                                <http://www.w3.org/ns/prov#specializationOf> <http://nice.org.uk/vcs/file-templates-latex.template>;
                                                                                                <http://www.w3.org/ns/prov#wasAttributedTo> <http://nice.org.uk/identity/git-username-Ryan-Roberts>;
                                                                                                <http://www.w3.org/ns/prov#wasDerivedFrom> <http://nice.org.uk/vcs/file-templates-latex.template-1a62c0c83968d0afc96d4dd2cc89305467c13023>;
                                                                                                <http://www.w3.org/ns/prov#wasGeneratedBy> <http://nice.org.uk/vcs/commit-fe9a574373e43b2e412140c94001110ef797e963>.
